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Abstract 
 
A subset of familial and sporadic pituitary adenomas is due to germline mutations in the aryl 
hydrocarbon receptor interacting protein gene (AIP). A systematic follow-up of cases and 
families with AIP mutation (AIPmut)-associated pituitary adenomas is lacking. The product of 
this novel tumour suppressor gene is a ubiquitously expressed co-chaperone of the heat shock 
proteins HSPA8 and HSP90, but besides of pituitary adenomas, there is no clear association of 
AIPmuts to other neoplasms. The molecular processes leading to pituitary tumorigenesis in the 
presence of AIPmuts and the mechanism for tissue-specific tumour suppressor function are 
unclear.  
  
This research work describes the clinical features of AIPmut positive familial and sporadic 
pituitary adenomas in a large international cohort of patients, aiming to increase the knowledge 
about this condition and focusing on the screening-led detection of pituitary adenomas. To 
define the repertoire of interactions of AIP in the pituitary gland and to determine which 
interactions are lost by AIP mutants, a proteomic screening for molecular partners of AIP in a 
pituitary cell line was conducted. The stability of a panel of missense AIP mutant proteins and 
the mechanism of protein degradation were evaluated in half-life studies, and the relationship 
between protein stability and phenotype was analysed.  
 
A number of novel features of AIPmut positive pituitary disease were identified, drawing 
attention to the high percentage of positive clinical screening of the apparently unaffected 
AIPmut carriers. The AIP tumour suppressor function is apparently mediated by its interaction 
with molecular chaperones, perhaps modifying their affinity for specific client proteins. AIP could 
exert an additional anti-tumorigenic action by regulating cytoskeletal organisation. AIP is 
processed via ubiquitination and proteasomal degradation, probably mediated by the FBXO3-
containing SKP1-CUL1-F-BOX protein complex E3 ubiquitin-ligase. Enhanced proteasomal 
degradation conferred shorter half-life to most of the AIP mutants tested, with implications for 
the clinical presentation. 
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MAX  MYC associated factor X gene 
MEG3 Maternally expressed 3 (non-protein coding) gene  
MEM  Minimum essential medium  
MEN1 Multiple endocrine neoplasia type 1 
MEN1 Multiple endocrine neoplasia type 1 gene 
MEN4 Multiple endocrine neoplasia type 4 
MERTK  MER proto-oncogene, tyrosine kinase gene 
MES  2-(N-Morpholino)ethanesulfonic acid (MES) 
MGMT O-6-methylguanine-DNA methyltransferase 
min  Minute(s) 
miRNAs  MicroRNAs  
MLL  Mixed lineage leukaemia protein  
MLPA  Multiplex ligation-dependent probe amplification 
MRI  Magnetic resonance images 
mRNA  Messenger RNA 
MS  Mass spectrometry  
MSHR  Melanocyte-stimulating hormone receptor 
MT-CYB Mitochondrially encoded cytochrome b gene 
mtDNA  Mitochondrial DNA 
MT-ND1 Mitochondrially encoded NADH dehydrogenase 1 gene 
MT-ND2 Mitochondrially encoded NADH dehydrogenase 2 gene 
MT-ND3 Mitochondrially encoded NADH dehydrogenase 3 gene 
MT-ND4 Mitochondrially encoded NADH dehydrogenase 4 gene 
MT-ND5  Mitochondrially encoded NADH dehydrogenase 5 gene 
MT-RNR2 Mitochondrially encoded 16S RNA gene 
MT-TM Mitochondrially encoded tRNA methionine gene 
MT-TI  Mitochondrially encoded tRNA isoleucine gene 
MT-TL2 Mitochondrially encoded tRNA leucine 2 (CUN) gene 
MT-TV  Mitochondrially encoded tRNA valine gene 
MT-TW Mitochondrially encoded tRNA tryptophan gene 
MYC  V-myc avian myelocytomatosis viral oncogene homolog gene 
m/z  Mass-to-charge ratio 
N-terminal Amino-terminal 
NADSYN1 Glutamine-dependent NAD(+) synthetase 
NAME Nevi, atrial myxomas and ephelides  
NEAA  Non-essential amino acids 
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NEDD8 Neural precursor cell expressed developmentally down-regulated protein 8  
NEFL  Neurofilament, light polypeptide 
NESP55 Neuroendocrine secretory protein 55 isoform NESP55  
NEUROD1 Neuronal differentiation 1 
NF1  Neurofibromin 1 gene 
NFκB  Nuclear factor kappa B 
NFPA   Non-functioning pituitary adenoma 
NHLBI EVS National Heart, Lung, and Blood Institute Exome Variant Server 
NKX3-1  Homeobox protein Nkx-3.1 
NLS   Nuclear localization signal  
NMD   Nonsense-mediated mRNA decay  
NME1 Nucleoside diphosphate kinase 1  
NOTCH2  Neurogenic locus notch homolog protein 2  
NOTCH3 Neurogenic locus notch homolog protein 3 
NR3C1 Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) gene 
NR3C2 Mineralocorticoid receptor  
OGTT Oral glucose tolerance test 
ODC1  Ornithine decarboxylase 1 gene 
ORF   Open reading frame 
P  P value 
PAGE Polyacrylamide gel electrophoresis 
PAP   Pituitary adenoma predisposition  
PAX6  Paired box protein Pax-6  
PBS  Phosphate buffered saline 
PCA   Protein-fragment complementation assay 
PCR  Polymerase chain reaction 
PDE2A  cGMP-dependent 3',5'-cyclic phosphodiesterase 2A 
PDE4A cAMP-specific 3',5'-cyclic phosphodiesterase 4A 
PERK  PKR-like ER kinase 
PHD   Prolyl-hydroxylase 
PHPT  Primary hyperparathyroidism 
PIK3CA Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha gene 
PIT1  Pituitary-specific positive transcription factor 1  
PITX1 Pituitary homeobox 1  
PITX2 Pituitary homeobox 2  
PKA   Protein kinase A 
PL-MS Proximity label-mass spectrometry 
PLAGL1  Pleiomorphic adenoma gene-like 1 gene 
POU3F4 POU domain, class 3, transcription factor 4 
PP  Precocious puberty  
PPB  Pleuropulmonary blastoma 
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PPARA Peroxisome proliferator-activated receptor alpha 
PPARG  Peroxisome proliferator-activated receptor gamma 
PPIase  Peptidylprolyl cis-trans isomerase  
PPNAD  Primary pigmented nodular adrenal dysplasia  
PPP6R2 Serine/threonine-protein phosphatase 6 regulatory subunit 2 
PRKACA Protein kinase A catalytic subunit alpha 
PRKACA Protein kinase A catalytic subunit alpha gene 
PRKAR1A Protein kinase A regulatory type I subunit alpha 
PRKAR1A Protein kinase A regulatory type I subunit alpha gene 
PRKCD Protein kinase C delta gene 
PRL  Prolactin 
PROP1  Homeobox protein prophet of Pit-1 
ptd-FGFR4 Pituitary tumour-derived fibroblast growth factor receptor 4 
PTEN  Phosphatase and tensin homolog gene 
PTGES3 Prostaglandin E synthase 3 
PTH   Parathyroid hormone 
PTHrp  Parathyroid hormone-related protein 
PTN  Pleiotrophin gene 
PTTG1 Pituitary tumour-transforming 1 gene 
PTTG1IP  Pituitary tumour-transforming 1 interacting protein gene 
qMS  Quantitative mass spectrometry 
RARS Arginyl-tRNA synthetase 
RB1  Retinoblastoma 1 gene 
RBMX RNA binding motif protein, X-linked gene 
RBR   RING-between-RING 
RC  Reconstituted complex  
RET   Rearranged during transfection tyrosine-kinase receptor 
RET  Rearranged during transfection protooncogene 
RHBDD3  Rhomboid domain containing 3 gene 
RING  Really interesting new gene 
RISC   RNA-induced silencing complex 
RNA  Ribonucleic acid 
RNase Ribonuclease 
RPA2  Replication protein A 32 kDa 
RPS12 40S ribosomal protein S12 
RPS14 40S ribosomal protein S14 
RPS20 40S ribosomal protein S20 
RPS21 40S ribosomal protein S21 
RPS28 40S ribosomal protein S28 
rRNA  Ribosomal RNA 
RT  Room temperature  
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SCF   SKP1-CUL1-F-BOX protein complex 
SDH  Succinate dehydrogenase 
SDHA SDH complex subunit A, flavoprotein (Fp) 
SDHA SDH complex, subunit A, flavoprotein (Fp) gene 
SDHAF2 SDH complex assembly factor 2  
SDHAF2 SDH complex assembly factor 2 gene 
SDHB SDH complex, subunit B, iron sulphur (Ip) 
SDHB SDH complex, subunit B, iron sulphur (Ip) gene 
SDHC SDH complex, subunit C, integral membrane protein, 15k Da 
SDHC SDH complex, subunit C, integral membrane protein, 15k Da gene 
SDHD  SDH complex, subunit D, integral membrane protein 
SDHD  SDH complex, subunit D, integral membrane protein gene 
SDHx  Subunits A, B, C and D of the SDH mitochondrial complex II genes 
SDS  Sodium dodecyl sulfate 
sec  Second(s) 
SF1   Steroidogenic factor 1 
SHC1  Src homology 2 domain containing transforming protein 1 gene 
SHH   Sonic hedgehog 
SILAC  Stable isotope labelling by amino acids in cell culture  
siRNAs  Small interfering RNAs  
SIX6  Homeobox protein SIX6 
SKP1  S-phase kinase-associated protein 1  
SMAD2 SMAD family member 2 
SMAD3 SMAD family member 3 
SMARCA4   SWI/SNF related, matrix associated, actin dependent regulator of chromatin, 
subfamily a, member 4 gene 
SNP  Single nucleotide polymorphism 
SOD1  Superoxide dismutase 1, soluble 
SOS1/2 Son of sevenless homologs 1/2 (Drosophila) 
SOX2  SRY (sex determining region Y)-box  
SOX5  SRY (sex determining region Y)-box gene 
SRF   C-fos serum response element-binding transcription factor gene 
SS  Somatostatin 
SSA  Somatostatin analogue(s) 
SSTR  Somatostatin receptor 
SSTR2 Somatostatin receptor 2 gene 
STI1  Stress-induced phosphoprotein 1 
SUGT1 Suppressor of G2 allele of SKP1 homolog 
SUMO Small ubiquitin-like modifier  
TAE  Tris-Acetate EDTA 
TAP  Tandem affinity purification 
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TBX19 T-box 19 
TCDD  2, 3, 7, 8-tetrachloro-p-dioxin  
TCEP  Tris(2-carboxyethyl)phosphine hydrochloride 
TCTP  Translationally-controlled tumour protein 
TE  Trypsin-EDTA 
TEAB  Triethylammonium bicarbonate  
TEV  Tobacco etch virus 
TGF-β  Transforming growth factor beta 
THRB  Thyroid hormone receptor beta  
THRB  Thyroid hormone receptor beta gene 
TMEM127 Transmembrane protein 127 gene 
TMT  Tandem mass tagging, tandem mass tags 
TNNI3K TNNI3 interacting kinase 
TOMM20 Mitochondrial import receptor subunit TOM20 homolog 
TP53  Tumour protein p53 
TP53  Tumour protein p53 gene 
TPD52 Tumour protein D52 gene   
TPR  Tetratricopeptide repeat 
TRH  Thyrotropin-releasing hormone 
tRNA   Transfer RNA 
TSH  Thyroid stimulating hormone 
TUBB  Tubulin beta chain 
TUBB2A  Tubulin, beta-2A chain 
TUBB4B Tubulin, beta-4B chain 
UBA1  Ubiquitin-like modifier-activating enzyme 1  
UBA6  Ubiquitin-like modifier-activating enzyme 6 
UBC   Polyubiquitin C 
UPR   Unfolded protein response 
UPS  Ubiquitin-proteasome system 
UQ  Ubiquinone 
USP8  Ubiquitin specific peptidase 8 gene 
USP19 Ubiquitin specific peptidase 19 
UTR  Untranslated region 
VAPA  VAMP (vesicle-associated membrane protein)-associated protein A, 33 kDa 
VDR  Vitamin D receptor 
VHL  Von Hippel-Lindau tumour suppressor, E3 ubiquitin protein ligase gene 
WB  Western blot  
WEE1 WEE1 G2 checkpoint kinase gene 
WIF1  WNT inhibitory factor 1 gene 
WISP2 WNT1-inducible signalling pathway protein 2 
WNT   Wingless-type MMTV integration site family protein 
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WNT   Wingless-type MMTV integration site family gene 
WNT4 Protein Wnt-4  
WNT5A Protein Wnt-5a  
WT  Wild type  
X-Gal  5-bromo-4-chloro-3-indolyl-beta-D-galacto-pyranoside 
X-LAG  X-linked acrogigantism   
XAP2  X-associated protein 2 
XLαs  Protein GNAS isoform XLas  
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Justification 
 
Pituitary adenomas are common tumours originated in the adenohypophysis.
1
 Even though 
these neoplasms are almost always histologically benign, they can cause considerable 
morbidity due to excessive hormonal secretion, and/or compression and local invasion of 
important surrounding structures.
2
     
 
Most of the pituitary adenomas occur sporadically, and only around 4-5% of the cases are 
estimated to occur in a familial setting, either isolated or as part of endocrine tumour 
syndromes.
3
 However, the proportion of pituitary adenomas that could potentially be inherited 
may be higher,
4
 and this is especially true for some subsets of patients. For example, genetic 
forms of pituitary adenomas (both hereditary and non-hereditary) are more common within 
young patients;
5
 in fact, up to 20% of the children with a hormone-secreting pituitary adenoma 
have a germline mutation in a known predisposing gene.
6;7
 
 
Despite their relative rarity, familial pituitary tumours represent a very important group of 
conditions with a heterogeneous genetic background and a widely variable phenotype within 
affected families. A better understanding of the causative genes and the pathogenic 
mechanisms of this particular group of tumours is needed to improve the diagnosis and 
management of these patients, leading to a better prognosis.  
 
Familial isolated pituitary adenoma (FIPA) is defined as the occurrence of pituitary adenomas in 
two or more members of the same family, in the absence of other clinical features. Around 20% 
of the cases of FIPA are due to mutations in the aryl-hydrocarbon receptor interacting protein 
gene (AIP).
8-11
 Germline AIP mutations (AIPmuts) also play an important role in a subset of 
sporadically diagnosed
7;12;13
 pituitary adenomas and in somatotropinomas resistant to the 
treatment with somatostatin analogues (SSA).
14
 In general, pituitary adenomas associated with 
AIPmuts tend to arise at a young age, and to be large, aggressive, and relatively resistant to the 
treatment with SSA. However, the phenotype is variable and the clinical picture remains 
incompletely described, due to the rarity of these cases. This research work describes in detail 
the characteristic clinical features of AIPmut positive FIPA and sporadic pituitary adenomas in a 
large cohort of patients, which should be useful to increase the knowledge about this condition 
and to guide the genetic screening of these groups of patients. A successful outcome of genetic 
testing for disease-causative genes is the possibility of detecting the condition in a subclinical 
stage; therefore, information about the clinical screening and follow-up of AIPmut positive 
unaffected carriers and the prospective diagnosis of pituitary adenomas in these individuals is 
also provided. 
 
A tumour suppressor function of AIP is supported by in vitro and in vivo models of pituitary 
tumorigenesis, and an abnormal or deficient protein is supposed to account for the phenotype of 
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pituitary adenomas. Nevertheless, while individuals with AIPmuts develop only pituitary 
adenomas, AIP is a ubiquitously expressed protein and the reason for its tissue-specific 
tumorigenic effect is currently unknown. AIP has multiple interacting partners,
15
 but none of 
them is known to exert a pituitary-specific function; therefore, the exact molecular mechanism 
for the development of pituitary adenomas in AIPmut positive individuals remains unveiled. In 
addition, AIP expression in somatotropinomas is a marker of responsiveness to the treatment 
with SSA in somatotropinomas;
16;17
 therefore, AIP seems to also play a role in acromegaly not 
related to AIPmuts. A better understanding of the molecular basis of AIPmut-related pituitary 
adenomas could lead to the implementation of disease-specific protocols of treatment, with an 
expectedly better clinical outcome. Also, a detailed description of the molecular pathways in 
which AIP is involved could reveal potential drug targets for acromegaly treatment. In addition, 
the protein stability of missense AIP mutants has been studied, as a means to determine the 
effect of clinically relevant AIPmuts on the protein structure and function. 
 
 In summary, this research work is expected to increase the knowledge about the clinical 
features of AIPmut-related FIPA and sporadic pituitary adenomas, to provide guidance for 
AIPmut screening in patients and for the follow-up of apparently unaffected AIPmut positive 
carriers, to elucidate the molecular partners of AIP in the pituitary gland and to explain the 
pathogenic mechanism of missense AIPmuts. This work should also provide evidence about the 
effect of missense AIPmuts on protein stability, which could be a good method to determine 
pathogenicity. 
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General aims 
 
- To confirm and extend the description of the genotype and phenotype of patients with 
AIPmut-related familial and simplex pituitary adenomas in a large cohort of pituitary 
adenoma patients, providing a comparison with AIPmut negative cases, and to perform 
a systematic follow-up of families to identify and characterise AIPmut positive carriers. 
 
- To identify the molecular partners of AIP in the pituitary gland using a proteomic 
approach and to analyse the potential role of AIP in the pathways that drive pituitary 
tumorigenesis. 
 
- To analyse the mechanism and speed of protein turnover of wild type (WT) AIP and AIP 
missense variants, and to correlate the protein half-life with the phenotype, using 
protein stability as an indicator of loss-of-function (LOF). 
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Chapter 1: General overview 
 
The pituitary gland 
Functional Macroscopic and Microscopic Anatomy 
The pituitary gland coordinates the function and structural integrity of multiple endocrine glands, 
such as the thyroid, adrenals and gonads. Pituitary hormones also exert effects on other target 
tissues, including the cartilage and breast.
18
 The term pituitary is derived from the Greek ptuo 
and the Latin pituita, ‘phlegm’, which refers to its nasopharyngeal origin.
18
 The pituitary is 
located within the sella turcica, a recess of the sphenoid bone in the middle cranial fossa, above 
the sphenoid sinus,
19
 and it is covered by the diaphragma sellae, a dural recess separating it 
from the suprasellar cistern (located superiorly), which is traversed by the pituitary stalk, a 
structure connecting the gland with the hypothalamic median eminence.
18;19
 The optic chiasm is 
located anteriorly to the pituitary stalk (infundibulum).
20
 Lateral to the pituitary gland are the 
cavernous sinuses, containing the internal carotid arteries, sympathetic fibres and the cranial 
nerves III, IV, V (ophthalmic and maxillary branches) and VI.
19
 Anteriorly, the pituitary is flanked 
by the tuberculum sellae (the anterior part of the sella turcica) and the anterior clinoid 
processes, and posteriorly, by the dorsum sellae with the posterior clinoid processes.
21
 An adult 
pituitary gland weights 400-900 mg and measures 13 mm transversally, 6-9 mm vertically and 9 
mm anteroposteriorly,
18
 though a physiological increase in size occurs during puberty and 
pregnancy.
22
  
 
The pituitary gland is composed of an anterior lobe (adenohypophysis), comprising two thirds of 
the total volume of the gland, and a posterior lobe (neurohypophysis).
21
 The anterior lobe is 
subdivided in three components, pars distalis (pars glandularis), pars intermedia and pars 
tuberalis (pars infundibularis), being the first the biggest one (80% of the volume of the 
adenohypophysis) and the responsible for the secretion of adenohypophysial hormones.
19;20
 
The pars intermedia is located between the pars distalis and the posterior pituitary, and 
corresponds to the intermediate lobe found in other species, though it is vestigial in humans.
19
 
The pars tuberalis extends upwards, surrounding the infundibular stalk.  
 
The anterior pituitary is an endocrine tissue, composed of nests or cords of cuboidal cells, 
surrounded by venous sinusoids with a fenestrate epithelium, which collects the secretory 
products of the gland.
19
 The classical histopathological description classified the cells of the 
anterior pituitary in three groups, according to their appearance in haematoxylin-eosin (H&E)-
stained specimens: chromophobes, acidophils and basophils.
21
 The use of 
immunohistochemistry (IHC) techniques allowed a more detailed classification, based on the 
secretory products of the cells, and currently, five different hormone-producing cell lineages are 
distinguished in the anterior pituitary.
21
 Fifty percent of the cells are somatotrophs (producing 
somatotrophin or growth hormone [GH]), 10-30% are lactotrophs (producing prolactin [PRL]), 
15-20% correspond to corticotrophs (producing adrenocorticotropic hormone [ACTH]), 10-15% 
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are gonadotrophs (producing luteinising [LH] and follicle-stimulating [FSH] hormones), and the 
less abundant cells are thyrotrophs (producing thyroid stimulating hormone [TSH], representing 
only 3-5% of all the cells).
22
 Some cells do not stain with the antibodies to any of the anterior 
pituitary hormones, but they show secretory granules under electron microscopy; these cells are 
usually chromophobes.
21
  
 
The anterior pituitary is frequently divided in three morphological areas, with different cellular 
composition: two lateral wings and a median wedge. Most of the somatotrophs are located in 
the lateral wings, but they also occupy a narrow posterolateral area, and they can be found 
scattered in the median wedge.
23
 Lactotrophs are evenly scattered on the pars distalis, but they 
predominate in the posterolateral rim of the lateral wings.
23
 Corticotrophs cluster in the central 
wedge, but they are also scattered in the lateral wings. Gonadotrophs can be found evenly 
distributed in the pars distalis and they are the main component of the pars tuberalis.
20
 
Thyrotrophs are mainly located in the anterior median wedge, with a few of them extending to 
the lateral wings and the pars tuberalis.
20;23
 
 
The endocrine cells in the anterior pituitary are surrounded by non-endocrine, agranular cells 
known as folliculostellate cells, comprising 5-10% of the total pituitary cells.
20
 Folliculostellate 
cells comprise an immunophenotypically heterogeneous population, playing an important role in 
controlling the behaviour of the surrounding cells, by the formation of a complex tridimensional 
network involved in the integration of the pituitary autocrine and paracrine loops, and as 
scavengers engulfing degenerated cells.
24;25
 These star-shaped cells stain positive for S100 
protein and/or glial fibrillary acidic protein, suggesting an astrocyte- or microglia-like origin,
26
 but 
they can also express interleukin-6 and the major histocompatibility complex antigen type II 
(dendritic cell immunophenotype) and/or keratin (epithelial-like cells),
24
 as well as other growth 
factors and cytokines, such as leukaemia inhibitory factor, basic fibroblastic growth factor, 
vascular endothelial cell growth factor and follistatin.
25
 Other non-endocrine cells in the anterior 
pituitary are the granule-free, follicular cells
27
 and large epithelial cells with strong cytoplasmic 
positivity for mitochondrial protein and cytochrome oxidase, corresponding to oncocytes.
28
 The 
pars intermedia is not structurally distinct in the human pituitary, and the proopiomelanocortin-
producing cells, supposedly originated from this area, are found scattered throughout the pars 
distalis.
29
  
 
The posterior pituitary comprises the pars nervosa, the infundibular stalk, the hypothalamic 
median eminence and a structure at the base of the hypothalamus denominated tuber 
cinereum.
20
 The pars nervosa is an extension of the ventral diencephalon (the embryological 
structure that forms the hypothalamus), formed by axons projecting from hypothalamic 
magnocellular neurons from the supraoptic and paraventricular nuclei, that secrete oxytocin and 
arginine-vassopressin,
30
 surrounded by pituicytes.
21
 
 
28 
 
The function of the anterior pituitary is regulated by the secretion of multiple hormones and 
factors produced mainly by neurons located in the medial hypothalamus.
20
 The medial 
eminence, containing axons from the periventricular, paraventricular and arcuate nuclei, is the 
principal structure linking the function of the hypothalamus and the pituitary gland.
20
 This 
structure lies outside the blood-brain barrier, allowing the release of hypophysiotropic hormones 
and factors into a specialised hypophysial portal system, which irrigates the pars distalis with 
venous blood through the long portal veins.
19;20
 The portal capillary plexus in the median 
eminence is irrigated by the superior hypophysial artery, a branch of the internal carotid. The 
pars distalis also receives venous blood from the posterior pituitary through the short portal 
vessels.
19
 Other hypophysiotropic factors are not transported by the portal system, but released 
locally by axons originated from other structures of the central nervous system.
20
  
 
The feedback regulation of the hypothalamus by peripheral humoral factors seems to occur via 
transcytosis through glial and endothelial cells in the blood-brain barrier, permeable capillaries 
that reach the cerebrospinal fluid and through bidirectional fenestrated capillaries.
20
 The main 
factors involved in the hypothalamic-pituitary crosstalk are the neurohypophysial hormones 
(arginine-vasopressin and oxytocin) and the hypophysiotropic hormones, including: 
corticotropin-releasing hormone (CRH), cortistatin, ghrelin, gonadotropin-releasing hormone 
(GnRH), GH-releasing hormone (GHRH), somatostatin (SS), thyrotropin-releasing hormone 
(TRH) and urocortin.
20;31-33
 Additionally, the anterior pituitary synthesises non-classical peptides, 
growth factors, cytokines, binding proteins and neurotransmitters, important for the 
autocrine/paracrine control of its own hormonal secretion and for the control of growth and cell 
proliferation under specific physiological conditions.
19
  
 
The venous drainage from the anterior pituitary is carried out by the adenohypophysial veins, 
and the posterior pituitary is drained by the adenohypophysial veins. Both systems anastomose 
forming the confluent pituitary veins and end at the cavernous sinus. The posterior pituitary is 
irrigated by branches of the inferior hypophysial arteries.
19
  
 
Embryology 
The human hypothalamus-pituitary axis is established by the 20 weeks of gestation.
21
 The 
anterior pituitary derives from the Rathke’s pouch, an evagination of the oral ectoderm at the 
level of the oropharynx, evident by the third week of gestation.
34
 During development, the 
anterior pituitary remains in close contact with the primordium of the ventral hypothalamus (the 
ventral diencephalon, derived from neuroectoderm); this relationship is critical for the 
differentiation of the pituitary endocrine cells.
35
  
 
Most of the knowledge about pituitary embryogenesis proceeds from studies in murine models, 
but these data can be extrapolated to the human embryo. The earliest transcription factor 
implicated in the development of the pituitary primordium is homeobox expressed in embryonic 
stem cells 1 (HESX1).
34
 Other early transcription factors expressed by the primordium include 
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pituitary homeobox (PITX) 1 and 2, transcription factor SOX-2 (SOX2), LIM/homeobox protein 
Lhx (LHX) 3 and 4, homeobox protein SIX6 (SIX6), beta-catenin (CTNNB1), zinc finger protein 
GLI (GLI) 1 and 3 and neurogenic locus notch homolog protein (NOTCH) 2 and 3.
35
 Sequential 
phases of signalling events are implicated in the terminal differentiation of the pituitary cells. 
First, the bone morphogenetic protein (BMP) 4 signal (together with protein Wnt-5a [WNT5A] 
and fibroblast growth factor [FGF] 8), arising from the ventral diencephalon, induces organ 
commitment in the anterior pituitary.
36
 Then, BMP2 expression appears in a region of oral 
ectoderm in which sonic hedgehog (SHH), which is initially uniformly expressed, selectively 
disappears. This ventral BMP2 signal and the dorsal FGF8 expression create opposing activity 
gradients, inducing overlapping patterns of specific transcription factors, favouring cell lineage 
specification. The main dorsally-expressed transcription factors are homeobox protein Nkx-3.1 
(NKX3-1), SIX3, paired box protein Pax-6 (PAX6), and homeobox protein prophet of Pit-1 
(PROP1).  
 
Before the appearance of the ventral cells, pituitary-specific positive transcription factor 1 
(POU1F1, also known as PIT1) leads to somatotroph, lactotroph, and thyrotroph development, 
while the steroidogenic factor 1 (SF1) is selectively expressed in the gonadotrophs. Attenuation 
of the BMP2 signal leads to terminal ventral cell differentiation, which is dependent on the 
transcription factors insulin gene enhancer protein-1 (ISL1), POU domain, class 3, transcription 
factor 4 (POU3F4), forkhead box protein L2 (FOXL2) and endothelial transcription factor GATA-
2 (GATA2). The ventral to dorsal gradient induces GATA2 in the developing gonadotrophs and 
thyrotrophs, and in the gonadotrophs, this transcription factor stops PIT1 expression, favouring 
the appearance of SF1, FOXL2 and ISL1.
34
 The absence of GATA2 dorsally is critical for 
differentiation of PIT1-positive cells to somatotrophs and lactotrophs. Protein Wnt-4 (WNT4) 
expression is needed for the expansion of the ventral pituitary cell types, and PAX6 attenuates 
the ventral signals directing thyrotroph and gonadotroph cell lineages.
34;36
 Once these 
differentiation events are completed, the gonadotrophs, thyrotrophs, somatotrophs, and 
lactotrophs display a ventral-to-dorsal location, respectively.
36
 However, the adequate 
morphogenesis and differentiation of the pituitary primordium is not completely explained by 
these gradients, and it depends also on the relationship between cellular responsiveness and 
concentration/time of exposure of individual opposing extracellular factors.
35
 
 
The posterior lobe derives from the neural crest as an evagination of the floor of the third 
ventricle, and its sides fuse to form the neural stalk, while its superior portion forms a recess in 
the floor of the third ventricle, the median eminence.
21
 The primordium of the posterior lobe 
migrates downward and is encapsulated together with the ascending cells of the Rathke’s 
pouch; its development is completed by the end of the first trimester and by then vasopressin 
and oxytocin can already be detected in the tissue.
37
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Pituitary adenomas 
Definition 
Pituitary adenomas (ICD 8272/0) are common, benign tumours from epithelial origin, arising 
from and composed of adenohypophysial cells,
38-40
 that can express and secrete hormones 
autonomously or behave functionally silent.
18
 As specified by the World Health Organisation 
2004 histological classification of pituitary tumours, primary tumours from a non-
adenohypophysial origin, as well as metastatic lesions can also affect the pituitary gland.
39
 
 
Pituitary adenomas are classically defined as monoclonal tumours, caused by de novo somatic 
mutations in a single cell.
41-43
 Nevertheless, more than one abnormal clone can exist in a 
pituitary adenoma, either synchronically or asynchronically, with the potential of producing 
oligoclonal or polyclonal proliferation.
44
 Although it is improbable that hypothalamic products, 
such as hypophysiotropic hormones or growth factors could initiate pituitary transformation, they 
could certainly facilitate the proliferation of a cell already containing a tumorigenic mutation.
45
 
The intrapituitary microenvironment could also contribute to pituitary adenoma development 
through dysregulated growth factor signalling, angiogenic stimuli such as hypoxia and the 
presence of progenitor mesenchymal cells.
46-48
 
 
Even though pituitary adenomas are considered as benign tumours, their behaviour is highly 
variable, ranging from slowly growing intrasellar masses to rapidly growing tumours with 
macroscopically evident extrasellar extension and invasion.
38;40
 In fact, around 30 to 45% of 
pituitary adenomas invade the cavernous or sphenoid sinus, and some of them display features 
or aggressiveness.
49
 The clinical presentation of pituitary adenomas is also variable, including 
signs and symptoms derived from local compression (visual impairment, headache, intracranial 
hypertension, damage to cranial nerves) and/or clinical syndromes derived from hypersecretion 
of one or more pituitary hormones (acromegaly, gigantism, amenorrhoea-galactorrhoea, 
Cushing’s disease and hyperthyroidism).
38
 However, many tumours remain subclinical and are 
only detected incidentally (pituitary incidentalomas), either during imaging studies performed for 
other reasons, or as autopsy findings.
50
 Pituitary carcinomas (ICD 8272/3), defined as tumours 
of adenohypophysial cells displaying distant metastases, are extremely rare.
39;39
  
 
Clinical and histopathological classifications 
Different classifications can be applied to pituitary adenomas. Clinically, they can be divided in 
hormonally active or functioning adenomas and non-functioning pituitary adenomas (NFPAs), 
the former representing approximately two thirds of the clinically diagnosed pituitary 
adenomas.
51
 Based on their size, pituitary adenomas can be defined as microadenomas, 
measuring <10 mm in their largest diameter, or macroadenomas, with maximum diameter ≥10 
mm.
38
 Tumours with a maximum diameter ≥40 mm are considered giant adenomas.
39
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Classification systems based on image studies are important for the preoperatory evaluation of 
pituitary adenomas. Hardy’s classification (based on radiographic images) divides pituitary 
adenomas in four grades, according to their size and local extension: grade I: microadenomas, 
minimally alter the appearance of the sella; grade II: macroadenomas, enlarge the sella or 
exhibit suprasellar extension, but no destruction of bony structures; grade III: invasive 
adenomas, locally erode the sella and show suprasellar outgrowth; grade IV: strongly invasive 
adenomas, destroying adjacent bony structures, with suprasellar outgrowth and invasion of 
bone, hypothalamus and cavernous sinus.
52
 Modified versions of Hardy’s classification are also 
frequently used.  
 
Knosp’s classification takes into consideration the degree of invasion of the cavernous sinus in 
magnetic resonance images (MRI): grade 0, no cavernous sinus involvement; grade 1, tumour 
surpassing the medial tangent (between the medial aspects of the intra and supracavernous 
internal carotid artery [ICA]), but not the intercarotid line (between the cross-sectional centres of 
the intra and supracavernous ICA); grade 2, extension beyond the intercarotid line, not 
surpassing the tangent on the lateral aspects of the intra and supracavernous ICA; grade 3A, 
tumour extension lateral to the lateral tangent of the intra and supracavernous ICA into the 
superior cavernous sinus compartment; grade 3B, tumour extension lateral to the lateral tangent 
of the intra and supracavernous ICA into the inferior cavernous sinus compartment; grade 4, 
total encasement of the intracavernous carotid artery.
53;54
   
 
According to their degree of invasiveness, pituitary adenomas are classified as intrapituitary 
(confined within the gland), intrasellar (confined to the sella turcica, with no erosion of bony 
structures), diffuse (large and expansive, fill the sella turcica without bone erosion), or invasive 
(erode the sella, spread into neighbouring tissues).
38
 Pituitary adenomas can display expansive 
growth (for example, suprasellar extension), when an interface is conserved between the 
tumour and the surrounding tissues, or invasive growth, when there is involvement of other 
tissues (dura, bone, nerves, vessels, etc.).
39;55
 However, microscopic invasion, found in 35-
46%
56;57
 of the cases, is not considered a feature of aggressiveness.
39
 
 
The World Health Organisation 2004 classification divides pituitary adenomas into the 
categories of typical adenomas, atypical adenomas and pituitary carcinomas, but the more 
detailed histological subclassification of these tumours is based on their IHC profile, considering 
also the cell lineage of origin and the main transcription factors expressed in each case,
39
 as 
summarised in Table 1. Besides this classification, most of the pituitary adenomas are positive 
for synaptophysin, and in a lower degree, to chromogranin A (CgA) and/or low molecular weight 
keratins, such as cytokeratin (Ck).
39
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Table 1. Clinicopathological classification of pituitary adenomas
39;47;58-61 
Transcription factors 
(cell lineage) 
Cell of origin Tumour type and variants* 
Frequency  
(% of total)† 
IHC profile Usual clinical presentation 
Invasive  
(% of total)† 
PIT1 family (GH-PRL-TSH) 
 
Lactotroph 
Lactotroph adenoma (prolactinoma) 
PIT1, ER, GH repressor Densely granulated lactotroph adenoma 0.3 PRL, Golgi pattern Hypogonadism and/or 
galactorrhoea 
50 
PIT1, ER, GH repressor Sparsely granulated lactotroph adenoma 8.9 PRL diffuse cytoplasmic, α-GSU NA 
PIT1, ER Acidophil stem cell adenoma   PRL, GH, fibrous bodies Hypogonadism and acromegaly NA 
 
Somatotroph 
Somatotroph adenoma (somatotropinoma) 
PIT1 
Densely granulated somatotroph 
adenoma 
9.2 GH, α-GSU, Ck, CgA Acromegaly, very rarely silent 52 
PIT1 
Sparsely granulated somatotroph 
adenoma 
6.3 GH, fibrous bodies, α-GSU, Ck, CgA 
Acromegaly or gigantism, very 
rarely silent 
NA 
PIT1, ER, GH repressor Mixed GH and PRL (bicellular) 5.2 GH, PRL, α-GSU, β-TSH Hypogonadism and acromegaly 31 
PIT1, ER Mammosomatotroph adenoma 1.1 GH, PRL, α-GSU, β-TSH Acromegaly or gigantism NA 
PIT1, TEF, GATA-2 Thyrotroph Thyrotroph adenoma (thyrotropinoma) 1.5 β-TSH, α-GSU Hyperthyroidism 100 
PIT1, ER, TEF, GATA-2 
PIT1 positive 
cells 
Plurihormonal adenoma NA GH, PRL, β-TSH, α-GSU Variable 52 
ACTH family 
 
Corticotroph 
Corticotroph adenoma (corticotropinoma) 
TBX19 
Densely granulated corticotroph 
adenoma 
7.2 ACTH, β-endorphin, β-LPH, Ck, CgA 
Cushing's disease, Nelson's 
syndrome or silent (silent 
corticotropinoma type 1) 
NA 
TBX19 
Sparsely granulated corticotroph 
adenoma 
7.9 ACTH, β-endorphin, β-LPH, Ck, CgA 
Cushing's disease, Nelson's 
syndrome or silent (silent 
corticotropinoma type 2) 
NA 
TBX19 Crooke cell adenoma 0.03 ACTH, β-endorphin, β-LPH, Ck, CgA Silent, possibly Cushing's disease 85 
Gonadotroph family 
SF-1, ER, GATA-2 
Gonadotroph 
Gonadotroph adenoma 
(gonadotropinoma) 
25.2 β-FSH, β-LH, α-GSU, CgA  
Silent or pituitary failure/mass 
effect. Rarely, gonadal 
hyperfunction 
95 
SF-1 Null-cell adenoma 19.8 
CgA, negative for hormones, or 
scattered cells positive for β-FSH, β-
LH, β-TSH or α-GSU 
Silent or pituitary failure/mass 
effect 
42 
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Transcription factors 
(cell lineage) 
Cell of origin Tumour type and variants* 
Frequency  
(% of total)† 
IHC profile Usual clinical presentation 
Invasive  
(% of total)† 
SF-1 
Null-cell adenoma, oncocytic variant 
(oncocytoma) 
5.8 
CgA, negative for hormones, or 
scattered cells positive for β-FSH, β-
LH, β-TSH or α-GSU 
Silent or pituitary failure/mass 
effect 
NA 
Unclassified adenomas 
Unknown 
PIT1 negative 
cells? 
Unusual plurihormonal adenoma  1.3 
GH, PRL and TSH, usually together. 
Occasionally, FSH and LH, rarely 
ACTH 
 Silent or pituitary failure/mass 
effect (silent adenoma subtype 3), 
often acromegaly and/or 
hyperprolactinaemia 
60 
NA: not available. α-GSU: glycoprotein hormone subunit alpha.  
* Names in parentheses are commonly used in the literature, and for practical reasons, they will be used in this text.  
† As presented in 
59
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It is important to keep in mind that tumours of any pituitary cell origin can also behave clinically 
as NFPAs, being the cell type only determined after IHC analysis. However, regardless of their 
clinical presentation with no hormonal excess, most of them express one or more anterior 
pituitary hormones with IHC analysis, and they are therefore termed silent adenomas. This 
presentation is apparently due to the production of hormones with no biological activity, or 
maybe due to a defect in the secretion mechanism. A small number of NFPAs, termed as null 
cell adenomas, are immunonegative for all the adenohypophysial hormones, though they are 
considered of gonadotroph origin, as most of them express LH and/or FSH messenger RNA 
(mRNA).
47;62
 Finally, oncocytic tumours display a unique pattern characterised by a remarkable 
abundance of mitochondria (up to 50%), obscuring other organelles.
38
 In around two thirds of 
the oncocytic pituitary adenomas, the phenotype is explained by somatic mutations in the 
mitochondrial DNA (mtDNA), affecting members of the respiratory complexes I and III, mtDNA 
promoters, and mitochondrial ribosomal RNA (rRNA) and transfer RNA (tRNA): MT-CYB, MT-
ND1, MT-ND2, MT-ND3, MT-ND4, MT-ND5, H (heavy)-strand promoter PH1, L (light)-strand 
promoter PL, MT-RNR2, MT-TL2, MT-TM, MT-TI, MT-TW and MT-TV genes.
63;64
   
 
Morphological features suggestive of an aggressive behaviour can be found in some pituitary 
adenomas, including invasive growth, elevated mitotic index, Ki-67 labelling index ≥3% and 
extensive nuclear staining for TP53 by IHC. Tumours with these characteristics, in the absence 
of metastases, are termed atypical pituitary adenomas (ICD 8272/1),
39
 accounting for 2.7-15% 
of all the pituitary tumours.
55
 Aggressive pituitary adenomas are tumours with atypical 
histological features, plus an aggressive clinical behaviour (reduced response to treatment, 
rapid growth and recurrence). Pituitary carcinomas (0.2% of all the operated pituitary tumours) 
may also exhibit features of aggressiveness and/or signs of malignancy (cellular/nuclear 
pleomorphism, nuclear hyperchromatism, increased nuclear/cytoplasmic ratio, mitotic figures, 
foci of necrosis, and invasive spread) but these features are not universal, and the diagnosis of 
pituitary carcinoma is only established in the presence of craniospinal or systemic 
metastases.
38;39
 A recently proposed clinicopathological classification of pituitary adenomas 
takes into consideration the tumour size, IHC, invasiveness and proliferation, making it useful 
for prognosis. It divides the pituitary adenomas in five grades: 1a, non-invasive tumour; 1b, non-
invasive and proliferative tumour; 2a, invasive tumour; 2b, invasive and proliferative tumour; and 
3, metastatic tumour.
65
 
 
Epidemiology 
Considered the most common lesions affecting the sellar region, pituitary adenomas account for 
approximately 10-15% of all the intracranial tumours, based on surgical series, and 3-24% 
based on unselected autopsies,
38
 representing the third most common intracranial tumour type, 
after meningiomas and gliomas
40
. Pituitary adenomas are common, but defining their exact 
prevalence among the general population is not easy, due to their variable clinical features and 
the high proportion of cases with no clinical manifestations. A metaanalysis reported a 
prevalence of pituitary adenomas of 14.4% in autopsy studies and 22.5% in radiological studies, 
35 
 
resulting in an overall estimated prevalence of 16.7%.
1
 Clinically-relevant adenomas diagnosed 
due to symptoms are significantly less common, but recent data show a higher prevalence than 
previously suspected. When considering data from population based studies, the prevalence of 
pituitary adenomas varies between 1:1471 and 1:1064.
66-70
 
 
The frequency of pituitary adenomas increases with age: while more than 30% of the people in 
the sixth decade of life carry an undiagnosed tumour, only 3.5-8.5% of all the pituitary 
adenomas are detected before the age of 20 years, and they are extremely rare before the age 
of 9 years.
71;72
 The frequency of prolactinomas peaks between the second and fifth decades of 
life, and NFPAs usually present between the fourth and eighth decades of life, while the rest of 
the pituitary adenoma types do not have a specific distribution among age groups.
73
 
Prolactinomas are the most common pituitary adenomas (39%), followed by NFPAs, 
somatotropinomas and adrenocorticotropinomas, while thyrotropinomas are infrequent.
73
 Before 
the age of 50, pituitary adenomas are more frequent in females, but they are more common in 
males during the sixth decade of life.
74
 Prolactinomas, adrenocorticotropinomas and 
thyrotropinomas are more common in females, while NFPAs and somatotropinomas are more 
common in males; however, in older age groups, the differences in gender distribution are lost, 
except for NFPAs.
73
  
 
Most pituitary adenomas present as sporadic tumours, but it has classically been considered 
that 4-5% of all the pituitary adenoma cases occur in a family setting, either isolated or as part 
of an endocrine tumour syndrome.
3
 In a recent survey-based study conducted in a tertiary 
hospital centre, 7% of the pituitary patients referred a family history of pituitary adenomas.
75
 
Nevertheless, a registry-based study demonstrated that first degree relatives of pituitary 
adenoma patients have a relative risk of 2.8 of carrying themselves a pituitary adenoma
4
 and, 
therefore, the frequency of familial cases could be underestimated. The proportion of inherited 
cases is higher among young patients; indeed, up to 20% of the children with a hormone-
secreting pituitary adenoma have a germline mutation in a known predisposing gene.
6;7
  
 
Genetic causes of pituitary adenomas 
It is usually accepted that most of the pituitary adenomas arise as a result of multiple somatic 
mutations, but in some cases they are due to mosaic mutations (very rarely) or germline 
mutations. Pituitary adenomas due to germline mutations are considered potentially inheritable 
even in the absence of a second case in the same family, due to the possibility of transmitting 
the mutated predisposing gene from one to the next generation. The main genetic causes of 
pituitary adenomas are summarised in Figure 1. 
 
Somatic alterations 
The current evidence suggests that multiple somatic genetic mutations and/or epimutations 
conferring growth advantage to a single somatic pituitary cell give rise to clonal expansion and, 
36 
 
eventually, to a pituitary adenoma.
42
 Alterations in the expression (by diverse mechanisms) of 
various genes involved in cell cycle and apoptosis regulation, as well as growth factors and their 
receptors, are common findings in pituitary adenomas.
2
 However, it is not clear whether these 
alterations represent primary tumorigenic events, or if they occur as a consequence of other 
molecular abnormalities,
2;47
 although the inactivation or overexpression of various cell cycle 
regulators is sufficient for the development of pituitary tumours in murine models.
47;76
 This 
environment of genomic instability facilitates the accumulation of multiple mutations, but those 
affecting classical tumour suppressor genes (e.g. TP53, RB1) or oncogenes (e.g. BRAF, HRAS, 
MYC), which are generic findings in cancer, are rarely implicated in the pathogenesis of pituitary 
adenomas (and in other endocrine tumours), being found only in cases of atypical adenomas 
and pituitary carcinomas.
2;77-79
 The best known genes involved in pituitary tumorigenesis are 
listed in Table 2. 
 
GNAS1 mutations: the gsp oncogene 
Signalling pathways involving the accumulation of intracellular cyclic adenosine monophosphate 
(cAMP) play crucial roles in multiple endocrine tissues, as many hormone receptors are, indeed, 
heptahelical transmembrane G protein coupled receptors (GPCRs). The production of cAMP by 
adenylyl cyclase (AC) is regulated by heterotrimeric guanine nucleotide-binding proteins (G 
proteins) conformed by three different subunits, α, β and γ. When the associated GPCR is 
inactive, stimulatory G protein subunit alpha (Gsα) is found in complex with Gsβ and γ, and 
bound to guanosine diphosphate (GDP).
80
 After GPCR activation following ligand binding, Gsα 
dissociates from the other Gs subunits and exchanges GDP for guanosine triphosphate (GTP), 
with subsequent activation of effector proteins, such as ACs.
80;81
 Due to its intrinsic GTP 
hydrolase (GTPase) activity, Gsα can deactivate itself by hydrolysing GTP to GDP, preventing 
the continued activation of the downstream signalling pathway.
82
  
 
The GNAS1 gene complex, located at 20q13.32, displays a complicated genomic imprinting, 
generating multiple alternative products from the paternal and maternal alleles, driven by the 
activation of alternative promoters (four sense and one antisense), differently imprinted.
83;84
 The 
ubiquitously expressed Gsα subunit of Gs protein is the best known product codified by GNAS1. 
Gsα is transcribed from the exons 1-13 of GNAS1, originating four alternatively spliced products 
(two long, Gsα-1 and -2, and two short, Gsα-3 and -4), that might have variable biological 
roles.
85
 Exons 2-13 are common to the other GNAS1 products, NESP55 and XLαs. The 
expression of Gsα directed by an alternative promoter located just upstream the exon 1 is 
biallellic; however, GNAS1 is imprinted in a promoter-specific fashion.
86
 An alternative promoter 
located ~49kb upstream of exon 1 is methylated on the paternal allele, so the gene expression 
depends on the maternal allele.
83;84
 This promoter drives the expression of the human 
homologue of the bovine neuroendocrine secretory granule protein gene, NESP55, which has a 
unique exon 1 at this region and shares the exons 2-13 with Gsα and XLαs.
83
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Figure 1. Genetic causes of pituitary adenomas.
8;87-95
 Multiple somatic mutations and abnormalities in the expression of tumour suppressor genes/oncogenes are present in the vast majority of the pituitary 
adenomas, but they could theoretically coexist with germline mutations. The most common somatic mutations in pituitary adenomas are mutation in the USP8 gene in corticotropinomas and the gsp 
oncogene (mutation in GNAS1 codons 201 or 227) in somatotropinomas. The McCune-Albright syndrome (MAS) is a rare clinical entity, comprising the only known cause of mosaic genetic mutations 
causing pituitary disease. Seven clinical syndromes of inherited adenohypophysial tumours are currently known: multiple endocrine neoplasia (MEN) type 1 and type 4, the syndrome of pituitary blastoma 
due to DICER1 mutations, FIPA including X-linked acrogigantism (X-LAG) and AIP mutation (AIPmut)-associated FIPA, Carney complex (CNC, due to mutations in the PRKAR1A gene or to still unknown 
genetic alterations in the 2q16 region) and the syndrome of pituitary adenoma and phaeochromocytoma/paraganglioma (3PAs). See details in text. 
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Table 2: Main genes involved in the pathogenesis of sporadic pituitary adenomas (modified from 
2
) 
Gene name  
(other names) 
Location 
(Chr) 
Function Molecular abnormality in pituitary adenomas References 
Tumour suppressor genes 
AIP* 11q13.2 Co-chaperone, regulator of cAMP pathway Decreased expression in invasive somatotropinomas 
16;96
 
BMP4 14q22.2 Regulator of cell differentiation/proliferation in the anterior pituitary Increased expression in prolactinomas 
97
 
CDKN1A (p21
CIP1
) 6p21.2 Cell cycle regulator (G1) 
Decreased expression in NFPAs, increased in functioning adenomas 
(especially somatotropinomas) 
98
 
CDKN1B (p27
KIP1
)* 12p13.1 
Cell cycle regulator (G0/G1). Involved in cell migration, proliferation, 
neuronal differentiation, apoptosis. Tumour suppressor or oncogene 
Decreased expression, especially in recurrent adenomas 
99-107
 
CDKN2A (p16
INK4
) 9p21.3 Cell cycle regulator (G1 and G2) Decreased expression mostly by promoter methylation, mainly in NFPAs 
108-116
 
CDKN2B (p15
INK4B
) 9p21.3 
Cell cycle regulator (G1) 
Decreased expression partly by promoter methylation, homozygous 
deletion 
113;114
 
CDKN2C (p18
INK4C
) 1p32.3 Decreased expression mostly by promoter methylation 
116-118
 
DAPK1 9q21.33 Positive mediator of programmed cell death induced by γ-interferon 
Decreased expression either by promoter methylation or by homozygous 
deletion of the promoter CpG island 
119
 
DKC1 Xq28 Pseudouridine synthase, rRNA modifier and telomerase regulator LOF somatic mutation in one NFPA 
120
 
GADD45B (GADD45-β) 19p13.3 
Regulator of growth and apoptosis 
Decreased expression in gonadotropinomas 
121
 
GADD45G (GADD45-γ) 9q22.2 
Decreased expression mainly due to promoter methylation in NFPAs, 
somatotropinomas and prolactinomas 
122;123
 
MEG3 14q32.3 Long non-coding RNA, induces apoptosis, inhibits cell proliferation Decreased expression in NFPAs 
122;124-128
 
MEN1* 11q13.1 Transcriptional regulator LOF somatic mutations/deletions, reduced expression 
129-133
 
PLAGL1 (ZAC1) 6q24.2 
Transcription factor, role in pituitary development, differentiation, 
maturation and tumorigenesis 
Decreased expression in NFPAs 
134;135
 
RB1 (pRB) 13q14.2 Regulator of entry into cell division 
Decreased expression partly due to promoter methylation in aggressive 
pituitary adenomas 
113;114;136
 
RHBDD3 (PTAG) 22q12.2 Pro-apoptotic mediator Decreased expression partly due to promoter methylation 
137
 
SMARCA4 (Brg1) 19p13.2 
Helicase and ATPase activities. Regulator of gene transcription by 
altering chromatin structure 
Decreased expression, altered subcellular localisation in 
corticotropinomas 
138
 
SSTR2 17q25.1 Heptahelical transmembrane GPCR for SS Decreased expression in resistant somatotropinomas 
139
 
THRB (TRβ) 3p24.2 Nuclear receptor for thyroid hormone LOF somatic mutation and alternatively spliced variant in thyrotropinomas 
140;141
 
TP53 (P53) 17p13.1 
Trans-activator, negatively regulates cell division by controlling the 
expression of genes required for this process 
LOF somatic mutations in atypical corticotropinoma and prolactinoma, 
post-radiotherapy aggressive corticotropinoma, pituitary carcinoma 
142-145
 
WIF1 12q14.3 Inhibitor of WNT proteins Decreased expression by promoter methylation  
146
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Gene name  
(other names) 
Location 
(Chr) 
Function Molecular abnormality in pituitary adenomas References 
Oncogenes 
AKT1 14q32.33 Regulator of cell metabolism, proliferation, survival, growth and 
angiogenesis 
Increased expression, especially in NFPAs 
107
 
AKT2 19q13.2 
BMI1 (BMI-1) 10p12.2 
Component of the polycomb repressive complex 1 (involved in the 
transcriptional repression of various genes) 
Increased expression, genetic amplification 
147-149
 
CCNA1 (cyclin A1) 13q13.3 Cell cycle regulation (G1/S and G2/M) Increased expression, especially in recurrent adenomas 
105;150
 
CCNB1 (cyclin B1) 5q13.2 
Involved in G2-M transition 
Increased expression 
150;151
 
CCNB2 (cyclin B2) 15q22.2 Increased expression, correlating with HMGA1 and HMGA2  
152
 
CCND1 (cyclin D1) 11q13.3 
Promotes progression through the G1-S phase of the cell cycle 
Increased expression, allelic imbalance in aggressive NFPAs and 
somatotropinomas 
146;150;153-155
 
CCNE1 (cyclin E1) 19q12 Increased expression mainly in corticotropinomas 
150;154
 
CREB1 (CREB) 2q33.3 Phosphorylation-dependent transcriptional activator of CREs Constitutive activation by phosphorylation in somatotropinomas 
156
 
EGFR 7p11.2 Transmembrane tyrosine kinase receptor for EGF 
Increased expression in corticotropinomas, less importantly in other 
pituitary adenoma subtypes 
157;158
 
FGFR1 
8p11.23-
p11.22 
Transmembrane tyrosine kinase receptor for FGFs 
Increased expression especially in NFPAs, decreased mRNA expression 
in thyrotropinomas 
159
 
FGFR2 10q26.13 Decreased expression by promoter methylation 
160
 
FGFR4 5q35.2 
Increased expression of a N-terminally truncated cytoplasmic isoform 
(ptd-FGFR4) by alternative transcription initiation 
161
 
FOLR1 (FR) 11q13.4 Mediator of transport of 5-methyltetrahydrofolate into the cells 
Increased expression in NFPAs, decreased in prolactinomas and 
somatotropinomas 
162
 
GNAI2 (Gi2α) 3p21.31 Adenylate cyclase and Ca
++
 influx inhibitor GOF somatic mutations in NFPAs and one corticotropinoma 
163;164
 
GNAS (GNAS1) 20q13.32 Stimulatory Gsα, AC activator 
GOF somatic mutations, loss of imprinting, increased expression in some 
somatotropinomas 
95;163-170
 
HDAC2 6q21 Histone deacetylase Decreased expression in corticotropinomas 
138
 
HMGA1 6p21.31 Various biological functions. Key role in growth and development Overexpression 
152
 
HMGA2 12q14.3 Various biological functions. Key role in growth and development Amplification and overexpression in prolactinomas and NFPAs 
171;172
 
HRAS (Ras) 11p15.5 
GDP/GTP binding protein, regulator of cell division in response to 
growth factor stimulation 
GOF somatic mutations in pituitary carcinomas 
173-176
 
IKZF1 7p12.2 
DNA-binding protein with crucial functions in the hematopoietic 
system and in the development of the immune system 
Dominant-negative truncated isoform (Ik6) 
177
 
LAPTM4B 613296 Required for lysosome homeostasis, acidification and function Increased expression in NFPAs and corticotropinomas 
117
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Gene name  
(other names) 
Location 
(Chr) 
Function Molecular abnormality in pituitary adenomas References 
MAGEA3 Xq28 
Unknown function, but may play a role in embryonal development 
and tumour transformation or progression 
Increased expression by promoter hypomethylation and histone 
acetylation in association with FGFR2 down-regulation 
178
 
MERTK (CMP-tk) 2q13 
Tyrosine kinase receptor, transduces signals from the extracellular 
matrix into the cytoplasm, several ligands 
Increased expression in corticotropinomas, decreased in prolactinomas 
162
 
ODC1 (ODC) 2p25.1 Catalyses decarboxylation of ornithine into putrescine 
Increased expression in somatotropinomas, decreased in 
corticotropinomas 
PIK3CA 3q26.32 
Catalytic subunit of phosphatidylinositol 3-kinase (coordinates cell 
proliferation, survival, migration, vesicle trafficking, degranulation) 
GOF somatic mutations (invasive corticotropinoma, prolactinoma, 
plurihormonal adenomas and NFPAs) and genetic amplification 
176
 
PRKACA (PKCα) 17q24.2 
Kinase involved in growth factor- and hormone-mediated 
transmembrane signalling and cell proliferation 
Increased expression, GOF somatic mutations in invasive NFPAs 
179
 
PTTG1 (PTTG, securin) 5q33.3 Cell cycle regulation and cell senescence Increased expression, especially in corticotropinomas 
117;159;180;181
 
PTTG1IP (PBF) 21q22.3 
Facilitator of nuclear translocation of PTTG1, potentiates 
transcriptional activation of FGF2 by PTTG1 
Increased expression, especially in NFPAs 
159
 
Other genes 
BAG1 9p13.3 Co-chaperone, regulator of HSP70/HSPA8 and PPP1R15A Increased expression in somatotropinomas, prolactinomas, NFPAs 
117
 
COPS5 (JAB1) 8q13.1 
Probable protease subunit of the COP9 signalosome complex 
(involved in various cellular and developmental processes) 
Increased expression in pituitary carcinomas 
106
 
DRD2 (D2R) 11q23.2 Heptahelical transmembrane GPCR for dopamine Decreased expression in resistant prolactinomas 
182
 
FGF2 (bFGF) 4q27-28 Regulator of angiogenesis, cell survival, division and differentiation Increased expression, decreased mRNA in thyrotropinomas 
159
 
GHR 5p13-p12 Heptahelical transmembrane GPCR for GH LOF somatic mutations in somatotropinomas 
183
 
GHRH 20q11.23 Secretagogue for GH Increased expression in somatotropinomas 
184
 
GHRHR 7p14.3 Heptahelical transmembrane GPCR for GHRH Truncated (alternatively spliced) in somatotropinomas 
185
 
NR3C1 (GR, GCR) 5q31.3 Nuclear receptor for glucocorticoids LOF somatic mutation and LOH in corticotropinomas 
186;187
 
MT-CYB 
MT (non-
nuclear) 
Component of the ubiquinol-cytochrome c reductase complex 
(complex III), a respiratory chain that generates an electrochemical 
potential coupled to ATP synthesis 
LOF mutations in oncocytic pituitary adenomas 
64
 
MT-ND1 
Core subunits of the mitochondrial membrane respiratory chain 
NADH dehydrogenase (complex I). This complex transfers electrons 
from NADH to the respiratory chain. The immediate electron 
acceptor seems to be ubiquinone 
63;64
 
MT-ND2 
63
 
MT-ND3 
63
 
MT-ND4 
63;64
 
MT-ND5 
63;64
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Gene name  
(other names) 
Location 
(Chr) 
Function Molecular abnormality in pituitary adenomas References 
H-strand promoter PH1 Predominant promoter of the mtDNA H-strand 
63
 
L-strand promoter PL Predominant promoter of the mtDNA L-strand 
63
 
MT-RNR2 Mitochondrially encoded 16S rRNA 
64
 
MT-TL2 Mitochondrially encoded tRNA leucine 2 (CUN) 
64
 
MT-TM Mitochondrially encoded tRNA methionine 
64
 
MT-TI Mitochondrially encoded tRNA isoleucine 
63
 
MT-TW Mitochondrially encoded tRNA tryptophan 
63
 
MT-TV Mitochondrially encoded tRNA valine 
64
 
PITX2 4q25 Transcription factor, involved in the WNT/DVL/ CTNNB1 pathway Increased expression in NFPAs 188 
POU1F1 (PIT1) 3p11.2 
Transcription factor, regulator of differentiation, expansion and 
survival of different pituitary cell types 
Increased expression in somatotropinomas, prolactinomas and 
thyrotropinomas 
189
 
USP8 (UBPY) 15q21.2 Deubiquitinase for EGFR GOF somatic mutations in corticotropinomas 
94;190
 
ATP: adenosine triphosphate; ATPase: adenosine triphosphatase; CpG island: C-phosphate-G (CpG) island; CREs: cAMP response elements; EGF: epidermal growth factor; EGFR: epidermal growth 
factor receptor; EGFR: epidermal growth factor receptor; GHRHR: GHRH receptor; GOF: gain-of-function; LOH: loss of heterozygosity; ptd-FGFR4: pituitary tumour-derived FGFR4. 
* Germline mutations in these genes are associated to familial pituitary adenomas. 
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NESP55 is a protein expressed in secretory granules of neuroendocrine cells, expressed mainly 
in adrenal medulla, pituitary, and brain).
83
 Loss of NESP55 expression is humans is not 
associated with an obvious phenotype.
85
 There is another promoter ~35kb upstream the 
GNAS1 exon 1 that, opposite to the NESP55 promoter, is methylated on the maternal allele.
86
 
This region contains three exons specific for the amino-terminal end of the protein XLαs: the 
XLαs exon 1 and two more alternative exons (known as A20 and A21) that are included (both or 
only A20) in only a small proportion of XLαs transcripts.
85;86
 These three exons are spliced into 
alternative mRNA species and their expression is paternally-derived.
86
 XLαs expression is 
limited to neuroendocrine tissues and it is apparently not activated by the same type of 
receptors that activate Gsα.
85
 A fourth alternative promoter is located 2.5 kb upstream the Gsα 
exon 1, controlling the expression of an alternative first exon (exon A/B), that splices onto exon 
2.
85;191
 This promoter is methylated exclusively on the maternal allele
85
 and its mRNA encodes a 
truncated form of Gsα.
191
 Finally, a maternally methylated (paternally expressed) region ~3 kb 
upstream the XLαs exon 1 contains a promoter controlling the expression of multiple antisense 
transcripts that include the NESP55 exon and uses multiple splice sites.
84
   
 
GNAS1 mutations associated to pituitary adenomas are always located at the codons 201 or 
227, both of them within the exon 8.
192
 These sites seem to be essential for the GTPase activity 
of Gsα, and LOF mutations at these locations produce a constitutively active Gsα subunit, the 
so called gsp oncogene.
95;193
 Therefore, although the mutation effect is GTPase inactivation, 
these mutations are usually referred as activating, as the final functional consequence is 
constitutive activation of the cAMP signalling pathway.  
 
Heterozygous somatic GNAS1 mutations play a prominent role in the pathogenesis of 
somatotropinomas, where they are present in 4.4-59% of the cases.
194-201
 Somatotropinomas 
harbouring a GNAS1 mutation tend to be smaller,
198;202
 to respond better to the treatment with 
SSA, and to be more often densely granulated somatotropinomas according to some,
203
 but not 
all studies.
204
 These mutations are also present in other types of pituitary adenomas 
(corticotropinomas and NFPAs),
164;205
 though with a lower frequency, as well as in thyroid 
tumours,
206;207
 ovarian and testicular stromal Leydig cell tumours,
208
 in phaeochromocytomas 
(PHAEOs), paragangliomas (PGLs) and parathyroid adenomas in patients with multiple 
endocrine tumours,
207
 and in multiple types of malignant neoplasms (renal clear cell carcinoma, 
pancreatic adenocarcinoma, hepatocellular carcinoma, and colorectal adenocarcinoma).
209
 
Mosaic GNAS1 mutations at the codon 201 are the cause of the McCune-Albright syndrome 
(MAS).
210
 In somatotropinomas, GNAS1 mutations are almost always found in the maternal 
allele because Gsα is normally monoallelically expressed from the maternal allele in the 
pituitary.
168;211
 However, the imprinting pattern is sometimes relaxed both in GNAS1 mutation 
positive and negative tumours, suggesting a role for the biallelic expression of the protein in 
pituitary tumorigenesis.
168
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On the other hand, GNAS1 mutations resulting in LOF of Gsα and, therefore, reduced or non-
existent AC activity, are known as inactivating mutations.
212
 Germline inactivating GNAS1 
mutations produce a variety of inherited syndromes mainly characterised by hormone 
resistance, short stature and/or calcium and phosphate imbalance, including cases with the 
clinical picture of Albright’s hereditary osteodystrophia: pseudohypoparathyroidism (PHP) type 
Ia and Ic, pseudo-pseudohypoparathyroidism and progressive osseous heteroplasia.
209
 
Deletions in neighbouring genes, affecting the methylation pattern of GNAS1 are the cause of 
PHP type Ib.
212
 The specific phenotype present in a patient is given by the parent-of-origin of 
the mutated allele, due to the genetic imprinting present in GNAS1.  
 
The FGFR4 gene 
The fibroblast growth factor receptor (FGFR) signalling pathway is disrupted in multiple types of 
cancer, by diverse mechanisms (somatic mutations, gene amplifications, autocrine ligand 
production). Paracrine signalling through FGFR1 to 4 and other tyrosine-kinase receptors in 
tumoral tissues can act as an additional mitogenic signal, amplifying the initial oncogenic stimuli, 
and a pro-survival effect depending on FGFR activation has been linked to chemotherapy 
resistance.
213
 An N-terminally truncated isoform of FGFR4 with cytoplasmic localisation (in 
contrast with its normal membranous localisation), named pituitary tumour-derived (ptd)-FGFR4, 
is specifically expressed in pituitary adenomas.
214
 The targeted expression of ptd-FGFR4 in a 
murine model induces prolactinomas.
161
 In human pituitary adenomas, the expression of ptd-
FGFR4 correlates with Ki-67, a proliferation marker.
215
  
 
In addition, the FGFR4 gene rs351855 single nucleotide polymorphism (SNP) c.1162G>A, 
(p.G388R), with a MAF of 0.3 in three different databases,
216-218
 is a predictor of progression 
and poor prognosis in a variety of human neoplasms.
219
 This polymorphism increases the 
receptor stability, producing sustained receptor activation in vitro.
220
 A role for rs351855 as a 
facilitator of somatotroph cell tumorigenesis has been recently proposed.
221
 
 
Regulation of gene expression by miRNAs 
Small, non-coding molecules of RNA, known as microRNAs (miRNAs), act as 
posttranscriptional repressors of genetic expression through mRNA cleavage or translational 
repression.
222
 Sequences codifying miRNAs are located throughout the whole genome and 
most of them comprise independent transcriptional units, though a minority of them are part of 
introns in genes, and around one third of the human genes are apparently targets for miRNA 
regulation.
222;223
 Initially transcribed as pri-miRNAs that undergo different cleavage steps, 
mature single-stranded miRNAs are incorporated in the RNA-induced silencing complex (RISC) 
and, in the presence of extensive complementarity between the miRNA and the target 
sequence, the RISC cleaves the mRNA, while if there is incomplete complementarity, it 
represses the mRNA translation.
222
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Given their regulatory functions, in the setting of human neoplasms miRNAs can have either 
oncogenic or tumour suppressor activity, and the expression of multiple miRNAs has been 
found to be altered in different types of cancer, making them potential targets for diagnostic and 
therapeutic strategies.
224
 Although multiple authors have addressed the miRNA expression 
profile in different types of pituitary adenomas and its impact on the clinical behaviour (reviewed 
in
225
), the most recent studies have focused on the regulatory effect of miRNAs on specific 
genes with a known role in pituitary tumorigenesis, and the most relevant results are 
summarised in Table 3. 
 
Table 3: miRNAs regulating genes implicated in pituitary tumorigenesis (modified from
225
) 
miRNA(s) 
Affected 
gene(s) 
Target gene(s) function 
Molecular abnormality in 
pituitary adenomas 
References 
miR-15a and 
miR-16-1 
RARS Arginyl-tRNA synthetase 
Reduced expression in 
somatotropinomas and 
prolactinomas 
226
 
Let-7 HMGA2 See Table 2 
Increased expression in 
adenomas (all types) with low 
HMGA2 levels 
227
 
miR-20a, miR-
128a, miR-516-
3p, miR-93 and 
miR-155 
WEE1 
Tyrosine-kinase specific for 
cyclin B1-complexed CDK1. Acts 
as a negative regulator of entry 
into mitosis (G2 to M transition) 
Increased expression of miR-
20a, miR128a and miR-516-3p in 
NFPAs and of miR-93 and miR-
155 in somatotropinomas and 
NFPAs 
228
 
miR-107 AIP See Table 2 
Increased expression in 
somatotropinomas and NFPAs 
229
 
miR-15, miR-
16, miR26a, 
miR196a2 and 
Let-7a 
HMGA1 
and 
HMGA2 
See Table 2 
Reduced expression in 
somatotropinomas, 
prolactinomas and NFPAs 
230
 
miR34b, miR-
326, miR374b, 
miR-432, miR-
548c-3p, miR-
570, miR-603, 
miR-633 and 
miR-320 
HMGA1, 
HMGA2 
and E2F1 
HMGA1 and 2: see table 2. 
E2F1: trancription 
factor,regulator of cell cycle and 
the action of tumour suppressor 
proteins 
Increased expression of miR-320 
and reduced expression of the 
rest of the studied miRNAs in 
somatotropinomas 
231
 
miR-26b, miR-
26a, miR-212, 
miR-107, miR-
103, miR125b, 
miR-141, miR-
144, miR-164, 
miR-145, miR-
143, miR-15b, 
miR-16, miR-
186, let-7b, let-
7a3, miR-128 
PTEN and 
BMI1 
PTEN: lipid and protein 
phosphatase, tumour 
suppressor, modulator of cell 
cycle progression and cell 
survival.  
BMI1: component of a polycomb 
group multiprotein PRC1-like 
complex, transcriptional regulator 
of many genes throughout 
development 
Increased expression of miR-
26b, miR-26a, miR-212, miR-107 
and miR-103, reduced 
expression of the rest of the 
studied miRNAs in 
somatotropinomas 
149
 
miR-26a PRKCD 
Serine/threonine kinase involved 
in cell proliferation, apoptosis, 
and cell cycle regulation 
Increased expression in 
corticotropinomas 
232
 
miR-23b and 
miR-130b 
HMGA2 
and 
CCNA2 
HMGA2: see table 2. CCNA2: 
cyclin, promoter of cell cycle 
progression (G1/S and G2/M) 
Reduced expression in 
somatotropinomas and NFPAs 
233
 
miR-132, 
miR15a and 
miR-16 
SOX5 
Transcription factor, regulator of 
embryonic development and cell 
fate, and of cell proliferation, 
migration and invasion in 
neoplasms 
Reduced expression in invasive 
pituitary adenomas 
234
 
miR-34a AIP See Table 2 
Increased expression in 
somatotropinomas with low AIP 
levels, inversely correlated with 
response to SSA 
235
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Mosaic mutations 
McCUNE-ALBRIGHT SYNDROME 
Definition and general description 
Originally described in the 1930s (first by McCune
236
 and then by Albright
237
) as the triad of 
polyostotic fibrous dysplasia (FD), dermal café-au-lait spots and precocious puberty (PP), MAS 
is a complex genetic syndrome (OMIM #174800) encompassing also other diseases due to 
endocrine hyperfunction. In accordance with its current definition, the diagnosis of MAS is 
established in the presence of bone FD (monostotic or polyostotic) together with at least one 
manifestation of endocrine hyperfunction and/or café-au-lait spots. Therefore, the original 
clinical triad is known as classic MAS, while the presence of only one or two manifestations is 
known as non-classic MAS. Café-au-lait spots are the commonest component of the syndrome 
(53-95% of patients),
238
 but they are frequently disregarded. In the largest series, composed of 
113 European patients with clinical diagnosis of MAS, the classic triad was present in only 24% 
of patients, one third had two components of the triad and the rest had only one (usually PP).
239
 
MAS is extremely infrequent (prevalence around 1:10
5
-1:10
6
 in the general population), but FD 
(especially the monostotic variant) is much more common.
240
 Albeit there is a gender 
imbalance, with a predominance of female patients
239
 the reason for this is unknown.  
 
Genetics and pathophysiology 
MAS is caused by mutations in the GNAS1 gene
210
 occurring at the postzygotic (i.e. somatic) 
level; therefore, there is no vertical transmission of the mutations and the clinical manifestations 
are widely variable, due to differential affection among body tissues (MAS patients are somatic 
mosaics for GNAS1 mutations).
210;241
 Theoretically, severe MAS cases are related to a 
mutational event at an early developmental stage,
193
 and in agreement with this hypothesis, in 
MAS patients with involvement of several tissues, the same GNAS1 mutation is found in all the 
tissues analysed.
239
 Somatic mosaicism is, apparently, a sine qua non condition of MAS: cells 
bearing the mutation can only survive if they are interspersed with normal cells in the affected 
tissues,
241
 as it has been proved for FD lesions.
242
 GNAS1 mutations causing MAS are never 
inherited, as they are apparently embryonically lethal.
193;241
 
 
Gsα constitutive activation at multiple tissues is the accepted pathogenic basis of MAS, 
whereas there is not a clear contribution of the other GNAS1 products to the clinical features.
210
 
However, Gsα is generally biallelically expressed, as has been shown for human foetal 
tissues
243
 and lymphocytes,
86
 in contrast with the tissue-specificity of clinical manifestations in 
MAS. It has been proposed that tissue-specific genomic imprinting in some organs could 
explain the pattern of MAS clinical features, depending on the origin of the allele bearing the 
GNAS1 mutation.
244
 This hypothesis is supported by the variable phenotypic expression of 
Albright hereditary osteodystrophy (AHO), a disease caused by inactivating GNAS1 mutations, 
depending on the origin of the mutated allele. While maternal inheritance leads to AHO 
associated with pseudohypoparathyroidism, hypocalcaemia, hyperphosphataemia and 
multihormone resistance, paternal inheritance of the mutation results in AHO with 
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pseusopseudohypoparathyroidism, with no other clinical abnormalities.
245
 The imprinting model 
should predict that Gsα is primarily expressed from the maternal allele (with imprinting of the 
paternal allele) in the specific hormone target tissues, explaining the absence of hormone 
resistance when the paternal allele is mutated.
85
 This hypothesis has been proven in the murine 
renal cortex (a target for parathyroid hormone [PTH]), where Gsα expression is primarily from 
the maternal allele,
246
 but not in the foetal renal cortex, where Gsα is biallelically expressed.
247
 It 
is possible that Gsα imprinting exists only in fully mature renal tubules.
244
 
 
In humans, tissue-specific imprinting has been demonstrated in the pituitary, where Gsα is 
exclusively expressed from the maternal allele.
168
 Somatotropinomas (both those with and 
without GNAS1 mutations) often show a relaxation of Gsα monoallelic expression, but retain the 
normal imprinting of NESP55 and XLαs, implying a possible role for loss of Gsα imprinting in 
somatotroph cell tumorigenesis.
168
 In GNAS1 mutation positive somatotropinomas, both 
sporadic and MAS-related, mutations almost always affect the maternal allele, in agreement 
with the pituitary-specific imprinting of this gene.
211
 In thyroid and gonads, the expression of Gsα 
is mainly dependent on the maternal allele, but the paternal contribution is not negligible, 
indicating that genetic imprinting is not necessarily an all-or-nothing phenomenon.
248
 Therefore, 
acromegaly occurs only in those MAS patients with an affected maternal allele, but there is no 
apparent relationship between the origin of the mutated allele and the rest of the MAS 
components,
211
 each individual showing a particular distribution of abnormal cells in the affected 
tissues.  
 
GNAS1 mutations in MAS patients always occur at codon 201 and usually result in the 
substitution of an R residue for an H or a C,
210;239
 or, infrequently, by an S,
249
 G
250
 or L,
85
 but 
mutations at the position 227 have never been found as MAS-causative.
85
 The sensitivity for 
detection of GNAS1 mutations in MAS patients is variable and tissue-dependent. For example, 
Lumbroso et al detected GNAS1 mutations in 43% of 113 patients with clinical diagnosis of 
MAS, but when the samples were obtained from at least one known affected tissue, the 
percentage of positive samples rose to 90%.
239
 While GNAS1 mutations were detected in testis, 
thyroid muscle and endometrium in 100% of the samples analysed, the screening was positive 
in only 21 and 27% of peripheral blood lymphocytes and skin samples, respectively.
239
 Despite 
the use of highly sensitive screening methods,
249
 some samples (around 10%) are negative for 
GNAS1 mutations.
239
 Mutated cells might be confined to specific areas of the affected tissues, 
so it is advisable to screen pathological regions localised by histological studies.
239
 Considering 
the limitations for the genetic analysis, MAS diagnosis is established based on clinical grounds. 
Nevertheless, detection of GNAS1 mutations is especially important in those cases with partial 
or atypical presentation.
239
 
 
Clinical features 
PP is the most common endocrine manifestation of MAS, and despite being more commonly 
diagnosed in females, the incidence of gonadal pathology is equal in patients of both genders 
47 
 
(around 83% of females and 81% of males).
251;252
 PP in the setting of MAS has a peripheral 
(primary) origin, due to autonomous gonadal function, but some patients develop also 
secondary gonadotroph activation (central/secondary PP).
251
 Even though most MAS patients 
have intermittent PP interrupted by long periods of remission, some of them show a fast 
progression, with growth acceleration and premature skeletal maturation, compromising the 
final height,
251;253
 especially if FD coexists. PP in female MAS patients is caused by oestrogen 
production from large ovarian hyperfunctioning cysts.
254
 Males develop benign testicular lesions 
(Leydig cell hyperplasia more commonly, and less frequently Sertoli cell hyperplasia with or 
without macro-orchidism or Sertoli cell intraepithelial neoplasia); malignant testicular lesions and 
adrenal rests are rare.
252
 
 
Current treatment of PP in MAS female patients is based in anti-oestrogens. 
Medroxyprogesterone and ketoconazole might inhibit vaginal bleeding, but have no effect over 
skeletal maturation.
255
 The aromatase inhibitor anastrozole was ineffective for the treatment of 
PP in a group of 28 girls with MAS,
253
 but letrozole slowed down skeletal maturation, and 
decreased vaginal bleeding, without reduction in ovarian volume in nine patients.
254
 In a group 
of 25 girls with MAS, tamoxifen treatment was effective to control menstrual haemorrhages, 
growth speed and skeletal maturation, but increased ovarian and uterine volumes were 
observed.
255
 In patients with associated gonadotroph activation, combined therapy with long-
acting GnRH analogues should be installed.
240
 In cases resistant to medical treatment, surgical 
resection of hyperfunctioning ovarian follicles is an option, but recurrences are frequent.
255
 
Despite the high frequency of gonadal lesions, requiring periodic ultrasonographic surveillance 
and rarely surgical management, only around one fifth of the MAS male patients develop clinical 
signs of PP, requiring GnRH analogue therapy, aromatase inhibition or testosterone receptor 
blockade.
251;252
 
 
Thirty to 50% of MAS patients develop hyperthyroidism, and even more patients bear 
subclinical disease. MAS-related ultrasonographic findings (diffuse heterogeneity, 
hypoechogenic micro and macro nodules and hyperechogenic nodules) are present in 34-54% 
of the patients.
256;257
 Even in the absence of clinical hyperthyroidism, MAS patients show an 
elevated T3/T4 ratio, via increased D1 and D2 deiodinase activity, due to constitutive cAMP 
production.
257
 Treatment with thionamides can be efficient, but these patients almost never have 
spontaneous remission and a definitive treatment (surgery or radioactive iodine) is frequently 
warranted.
240
  
 
Cushing’s syndrome in MAS is infrequent (~7%) and displays variable clinical behaviour, 
ranging from spontaneous resolution to more severe forms requiring adrenalectomy, with 
lethality in ~20% of such cases.
258;259
 Hypercortisolism seems to arise during foetal life, due to 
tonic activity of Gsα in the adrenal cortex, so the diagnosis is usually established in the first 
three months of life.
259;260
 Presenting features include Cushingoid facies, failure to thrive, 
premature delivery and low birth weight, and hepatic and cardiac abnormalities.
259
 These 
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children tend to develop more comorbidities than other MAS patients (3.4 vs 2.9 MAS features), 
and, not infrequently, also neurocognitive disorders.
259
 This endocrinopathy is unique among 
other MAS features because of the possibility of spontaneous resolution: cells bearing the 
GNAS1 mutation are localised in the foetal zone of the adrenal cortex, which physiologically 
suffers complete degeneration by the first year of age.
259
 
 
Renal phosphate wasting occurs in around one half of MAS patients.
261
 Phosphaturia correlates 
with the degree of bone involvement and is associated with proteinuria and amiaciduria; renal 
cAMP is normal.
261
 This feature is explained by the production of the phosphaturic factor 
fibroblast growth factor 23 (FGF23) by the FD lesions.
262
 Treatment is based on the oral 
administration of phosphates at high doses, together with calcitriol or alfacalcidol.
251
 
 
Café-au-lait macules are due to constitutive activity of the melanocyte-stimulating hormone 
receptor (MSHR), with active proliferation of melanocytes and increased melanin production.
238
 
These lesions bear no malignant potential and are not MAS specific: the can be isolated or 
associated with other genetic syndromes.
238
 Café-au-lait macules in MAS are classically 
described as multiple lesions with variable number and size, with irregular borders (coast of 
Maine appearance) and limited to one side of the body, which usually matches the FD 
affection,
85;238
 but morphology and distribution are widely heterogeneous. These lesions are 
present at birth or arise in the first years of life, the most common localisations are back or the 
neck, thorax and gluteus and they grow proportionally to the growth of the patient.
238
 The 
distribution of the lesions follows Blaschko’s lines, reflecting the migration pattern of endodermal 
cells during development.
241
  
 
Although any bone can be involved, skull base and long bones are the most frequently affected 
areas in MAS-associated bone FD. FD is usually unilateral and most often includes more than 
one bone (polyostotic presentation), though some patients develop lesions in only one bone 
(monostotic) or, very rarely, the whole skeleton is affected (panostotic).
263
 FD consists on focal 
lesions composed of bone marrow stromal cells, immature bone tissue spicules, non-
mineralised osteoid and, sometimes, hyaline cartilage islands, expanding from the bone marrow 
cavity to surrounding cortical bone, with peripheral osteoclasts.
85;242
 In the lesions, stromal cells 
start differentiating in the osteogenic lineage but, instead of becoming completely differentiated, 
they proliferate, apparently due to sustained cAMP stimulation, giving place to the lesions.
264
 
Initial manifestations are pain, claudication of an extremity or a pathologic fracture. Plain 
radiographies show cystic or lytic lesions with heterogeneous radioopacity in infants, ground 
glass appearance in children and peripheral sclerosis in adults.
264
  
 
The majority of the FD extension is established between 3-10 years of age and it becomes 
clinically evident around the 5 years of age.
251
 Lesions grow from marrow to cortex and 
epiphyses are usually unaffected; weight-supporting bones might undergo deformation, being 
characteristic the shepherd’s crook femur.
240;264
 In craniofacial bones, protuberances and 
49 
 
asymmetry might compromise cranial nerves, jeopardizing sight and hearing.
264
 Treatment 
includes surgery to install intramedullary prostheses in long bones and to correct craniofacial 
lesions causing cranial nerve compromise, severe pain or disfiguration.
240;263
 Intravenous 
pamidronate is useful as a pain reliever, but has a negligible effect over disease progression.
265
 
Malignant transformation of FD lesions occurs in less than 1% of cases, usually in association 
with GH excess and radiation exposure.
264
 
 
Some other features have been uncommonly reported in MAS patients and are probably related 
to Gsα constitutive activation, including gastrointestinal reflux, gastrointestinal polyps, 
pancreatitis, neonatal cholestasis, sudden death, tachycardia, aortic root dilatation and platelet 
dysfunction.
239;240;251
 Hyperparathyroidism in MAS is secondary to the abnormalities in mineral 
metabolism and not caused by GNAS1 mutations.
240
 A few cases of thyroid and breast cancer 
have been reported in association with MAS, nevertheless, a causality has not been 
established.
251
 
 
Excessive GH production is part of MAS in 20-30% of patients,
266
 but only 33-65% of them 
develop a pituitary adenoma detectable by image studies.
267;268
 Originally described as 
mammosomatotroph hyperplasia,
269
 the current concept is that pituitary involvement in MAS is 
widespread and diffuse, including areas of normal gland, somatotroph hyperplasia, somatotroph 
neoplasia, lactotroph neoplasia and mammosomatotroph neoplasia, being somatotroph 
hyperplasia the predominant pattern.
268
 Each foci of neoplasia or hyperplasia within a single 
pituitary gland contain the same GNAS1 mutation.
268
 In concordance with the histopathological 
picture, 81-92% of the patients present with concomitant hyperprolactinaemia.
266;267
 
Interestingly, the proportion of patients with a positive thyrotropin-releasing hormone (TRH) test 
is much higher (100% in a recent series) in MAS-related acromegaly than in other populations 
of acromegalic patients (50-60%).
267
  
 
One third of the MAS patients with GH excess are diagnosed before the age of 16 years, 
usually due to accelerated growth, with coexistent PP in 57% of them.
266
 Most of the MAS 
patients with acromegaly and gigantism have also FD of the skull base, and around one third of 
them develop visual and/or audition compromise, being more severe in those patients with very 
high GH and insulin-like growth factor-1 (IGF-1) levels.
266;267
 Surgical treatment in these cases 
is precluded by the presence of craniofacial bone lesions, which complicates the surgical 
approaches, as well as by the universal involvement of the anterior pituitary, requiring 
hypophysectomy.
267;268
 There is a consistent response to the treatment with CBG and SSA, 
especially when combined, though the disease control is frequently partial.
267
 Thirty percent of 
the patients can be controlled with SSA alone and 77% with pegvisomant alone.
266
 Combined 
treatment with pegvisomant and radiotherapy achieved total control of the disease in five out of 
six patients in a series of acromegalic SSA-resistant MAS cases.
270
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Inherited pituitary adenomas (germline mutations) 
The inherited conditions that, to date, are known to predispose to pituitary adenomas are 
multiple endocrine neoplasia (MEN) type 1 (MEN1), MEN type 4 (MEN4), pituitary blastomas 
due to DICER1 mutations, Carney complex (CNC), the syndrome of pituitary adenoma and 
PHAEO/PGL and FIPA, including X-linked acrogigantism (X-LAG), AIP mutation associated 
FIPA or FIPA with undetermined genetic cause. Previous data suggests that approximately 
2.7% of all pituitary tumours occur in the context of MEN1
271
 and that FIPA accounts for another 
2.5%.
272
 CNC explains a few hundred cases world-wide,
272
 while MEN4, pituitary adenoma and 
PHAEO/PGL, pituitary blastomas and X-LAG have only been described in a few individuals. 
Though the inheritability of these phenotypes is well known and a genetic basis has been 
established for each of them, the causative gene remains elusive in 5-10% of MEN1 
patients,
273;274
 27% of CNC patients
275
 and 70-85% of FIPA patients.
276
  
 
An important aspect of the study of these rare genetic syndromes is the potential role of the 
causative genes in the more common sporadic pituitary adenomas. Although the expression of 
some of the genes causing familial pituitary adenomas has been found to be altered in pituitary 
adenomas, somatic mutations in these genes are not common events: while somatic mutations 
in MEN1 (the gene causing MEN1) have rarely been identified in pituitary adenomas (see next 
section) and a somatic mutation in PRKAR1A has only been detected in one patient (coexisting 
with a germline deletion in a CNC patient)
277
 no somatic mutations have been described in other 
genes associated to familial pituitary adenomas.
9;278-280
 
 
Multiple endocrine neoplasia 
The occurrence of two or more endocrine tumours in the same patient characterises a 
syndrome of MEN. Currently, four main forms of MEN, all of them autosomal dominant, are 
recognised: MEN1, MEN2A (also referred as MEN2), MEN2B (also referred as MEN3) and 
MEN4 (also referred as MENX),
281
 although only MEN1 and MEN4 include pituitary adenomas 
as part of their presentation. The spectrum of neoplasms associated to DICER1 mutations, 
including pituitary blastoma, can be considered as a novel form of MEN, characterised by a 
predominance of malignant tumours, as opposed to other MEN syndromes. Other uncommon 
forms of MEN are the CNC and the syndrome of pituitary adenoma and PHAEO/PGL. 
 
MULTIPLE ENDOCRINE NEOPLASIA TYPE 1 
Definition and general description 
In 1903 Erdheim reported a case of concomitant pituitary gigantism, and parathyroid tumours in 
one individual, and in 1954,
282
 Wermer wrote the first clinical description of a family with an 
association of pituitary tumours, hypercalcaemia and pancreatic adenomas.
283
 MEN1 (OMIM 
#131100) is a syndrome characterised by the development of tumours mainly in endocrine but 
also non-endocrine organs, with three main components: primary hyperparathyroidism (PHPT), 
entero-pancreatic endocrine tumours and pituitary adenomas.
283;284
 The diagnosis of MEN1 is 
51 
 
established in the presence of two of these features or when one feature is present together 
with a first degree relative with established MEN1 diagnosis.
285
 Other endocrine components of 
the syndrome are foregut carcinoids, non-functioning tumours of the adrenal cortex, and, rarely, 
PHAEOs, while lipomas, facial angiofibromas, collagenomas and ependymomas are non-
endocrine tumours associated to MEN1.
285
  
 
The observation of loss of heterozygosity (LOH) at 11q13 in tumours from MEN1 patients, led to 
the mapping, in 1988,
286
 and later cloning, in 1997,
87;287
 of MEN1. This gene spans 7.2 kb of 
genomic sequence, containing an 1830 base pairs (bp) coding region with ten exons (the first is 
not translated), encoding a 610 amino acid protein, menin.
87
 Heterozygous MEN1 mutations are 
detected in 90-95% of MEN1 patients.
273;274
 Until 2008, 1133 germline and 203 somatic 
mutations had been described: 23% were nonsense, 9% splice-site, 41% frameshift deletions or 
insertions, 6% in-frame deletions or insertions, 20% missense and 1% whole or partial gene 
deletions; mutations are distributed throughout the whole gene, with mutational hotspots in 
exons 2, 3, 9 and 10 and intron 4.
273;288
 More than 10% of the MEN1 mutations arise de novo 
and there is no clear genotype-phenotype association in MEN1 patients.
281
 
 
LOH in 11q13 occurs in around 90% of tumours from MEN1 patients but LOH can also be found 
at this region in 5-50% of sporadic endocrine tumours,
273
 and somatic MEN1 mutations are 
detected in some of the tumours with no LOH,
289
 in line with Knudson’s “two-hit” hypothesis.
290
 
Somatic MEN1 mutations are also common in sporadic parathyroid (9.5-21% of cases)
291-294
 
and pancreatic islet cell tumours (19-44%),
294-299
 but they occur only very rarely (0-3.67%, only 
ten mutations described) in sporadic pituitary tumours.
129-133;300-306
 Seventy five percent of the 
MEN1 mutations result in LOF:
273
 nonsense and frameshift mutations can result either in a 
truncated protein, with loss of important domains such as the nuclear localization signal 
(NLS),
307
 or in a loss of the transcript via nonsense-mediated mRNA decay (NMD).
308;309
 Splice-
site mutations are predicted to lead to unspliced precursor mRNA accumulation, retention of 
incompletely spliced precursors, aberrantly processed mRNA, or short or absent 
transcripts.
273;310
 MEN1 missense mutations affect the functions of menin, reducing its ability to 
interact with other proteins and enhancing its proteolytic degradation.
311;312
 
 
Genetics and pathophysiology 
MEN1 is considered a tumour suppressor gene because heterozygous inactivating mutations 
predispose to neoplasms, Men1 knockout (KO) mice reproduce the human phenotype and the 
majority of MEN1-related tumours display LOH at 11q13.
274;286;289;313-315
 In tumours with no LOH, 
other mechanisms of gene inactivation, such as hypermethylation, mutations of the promoter or 
non-coding regions and miRNAs may occur.
289;316
 By transcriptional regulation, MEN1 produces 
two transcripts: a ubiquitously expressed 2.9 kb transcript with several alternatively spliced 
isoforms, and a 4.2 kb transcript, present in the pancreas and thymus.
287
 Menin is a 67 
kilodaltons (kDa) protein without homology to any other protein,
87;317
 highly conserved within 
species: murine menin shows 97% identity/98% similarity to human menin.
318
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Menin acts as a scaffold protein, regulating genetic expression of multiple genes involved in 
transcriptional regulation, genome stability, cell division and proliferation.
274;281
 Due to three NLS 
domains,
307
 menin is predominantly expressed in the nucleus, though an increased cytoplasmic 
expression has been described after cell division.
319
 Menin expression fluctuates through the 
cell cycle: it is high in quiescent cells, decreases during G1 phase and increases again in S 
phase.
320
 Menin represses the progression of cell cycle and promotes apoptosis; in vitro, its 
overexpression causes apoptosis in murine embryonic fibroblasts.
321
  
 
The tumour suppressor activity of menin is explained by diverse mechanisms:  
− Menin activates the transcription of CDKN1B (encoding the cyclin-dependent kinase 
inhibitor CDKN1B) and CDKN2C (encoding CDKN2C) by recruiting the histone 
methyltransferase mixed lineage leukaemia protein (MLL) to the promoters and coding 
regions of these genes, where MLL catalyses histone H3 lysine 4 methylation.
322
 
Although menin expression does not differ between endocrine and non-endocrine 
organs, MLL, CDKN1B and CDKN2C are predominantly expressed in endocrine organs 
and this expression profile could partially explain the selectivity of tumorigenesis in 
patients with MEN1.
323
 Through interaction with MLL, menin also regulates the 
transcription of homeobox genes, particularly HOXA9, important for cell proliferation, 
differentiation and morphogenesis.
324;325
 In a similar way, menin recruits polycomb 
group proteins to enhance methylation at the pleiotrophin (PTN) gene, silencing the 
expression of this pro-proliferative gene.
325;326
 
− In the normal pituitary, menin interacts with activin, negatively regulating cell 
proliferation and the secretion of PRL, GH and ACTH, through inhibition of PIT1 
expression.
327;328
 
− The transforming growth factor-β (TGF-β) signalling pathway inhibits cell proliferation 
and transcriptional activity through SMAD2 and SMAD3 proteins.
325
 Menin interacts with 
SMAD3 and the loss of this interaction prevents SMAD3 binding to DNA, blocking the 
TGF-β effects.
329
  
− Menin inhibits JunD protooncogene (JUND) and enhances Jun protooncogene (JUN) 
transactivation,
330
 as well as its interaction with members of the nuclear factor kappa B 
(NFκB) family, modulating their transcriptional activity.
331
 These regulatory activities 
seem to be particularly relevant for the MEN1 phenotype, as patients carrying mutations 
affecting the JUND-interacting domain of the protein have a higher risk of death.
332
 
− Menin interacts with the nuclear receptors peroxisome proliferator-activated receptor 
gamma (PPARG)
333
 and the vitamin D receptor (VDR),
334
 enhancing the expression of 
their target genes.  
− The expression of insulin-like growth factor binding protein 2 (IGFBP-2),
335
 insulin-like 
growth factor 2 (IGF-2) and PTH-related protein (PTHrp),
336
 important proliferative 
factors in endocrine tumours, is negatively modulated by menin.  
53 
 
− Menin inhibits transcriptional activity and cell proliferation by the wingless-type MMTV 
integration site family (WNT)/CTNNB1 signalling pathway by binding and translocating 
CTNNB1 out of the nucleus.
337
 
− Menin interacts with the 32 kDa subunit of replication protein A 32 kDa (RPA2)
338
 as 
well as with Fanconi anemia complementation group D2 (FANCD2);
339
 both are proteins 
involved in DNA repair, and through its interaction with the promoter of the human 
telomerase reverse transcriptase (hTERT), menin apparently acts as a repressor of 
telomerase activity.
340
 Other menin interactors are proteins involved in cell division, 
such as non-muscle myosin II-A heavy chain,
341
 glial fibrillary acidic protein and 
vimentin.
342
 
− In pancreatic endocrine cells, menin determines the effects of the K-RAS pathway, by 
blocking K-RAS-dependent proliferation (driven by the RAS/RAF/MEK/ERK signalling 
pathway), while leaving K-RAS inhibitory pathways intact.
79
 
 
In mice, Men1 homozygous deletion is lethal in utero due to multiple developmental delay and 
craniofacial, cardiac, neural and hepatic abnormalities.
273;313;343
 Mice heterozygous for partial 
deletions of Men1 develop a syndrome similar to human MEN1.
313;343
 In a different model, 
heterozygous MEN1 deletion restricted to the pancreas caused hyperplasia, but LOH was 
necessary for progression to a tumour.
314
 
 
Clinical features 
MEN1 has an autosomal dominant pattern of inheritance.
274
 Eighty five percent of the cases are 
familial and 15% are sporadic, but the frequency of MEN1 mutations is apparently not different 
between these two groups.
344
 Female gender slightly predominates (52-57% of patients).
345
 
Within MEN1 patients, pituitary tumours are more common in females, while gastrinomas and 
thymic carcinomas are more common in males.
345
 There is no clear genotype-phenotype 
correlation.
346
 The penetrance of MEN1 is progressive and age and organ-specific,
285
 and the 
clinical presentation during the first decade of life remains infrequent.
347
 Parathyroid adenomas 
are the most constant feature of MEN1, being present in 90-100% of the patients by the age of 
50 years,
285
 and they are usually the first manifestation of the syndrome (72-87% of 
patients).
274;348;349
 These tumours are frequently multiple, and require extensive surgical 
treatment.
285
  
 
Thirty to 80% of MEN1 patients develop entero-pancreatic islet cell tumours.
285
 In the setting of 
MEN1, these tumours are multicentric, hormone-secreting and may become invasive or 
metastatic (especially gastrinomas and glucagonomas).
285;350
 Islet cell tumours are the first 
manifestation of the disease in around 25% of patients,
349
 and arise in any part of the pancreas 
or the duodenal mucosa. The most common subtype is gastrinoma (in 40%-63% of patients), 
causing the Zollinger-Ellison syndrome.
328;348
 Surgery is usually curative for insulinoma, but 
other entero-pancreatic islet cell tumours respond well to medical treatment with proton pump 
inhibitors (gastrinomas) or SSA (other entero-pancreatic tumours).
285
 Carcinoids related to 
54 
 
MEN1 arise in bronchi, thymus and gastric or duodenal mucosa and rarely hypersecrete 
hormones,
285
 but they may cause clinical manifestations due to ectopic GHRH or ACTH 
production.
351
 Metastatic neuroendocrine tumours represent the main MEN1-related cause of 
death.
352;353
  
 
Adrenal cortical tumours are present in 20-40% of MEN1 patients, most often are bilateral, 
hyperplastic and non-functional lesions; adrenal carcinomas are rare.
285
 Up to one third of the 
patients develop lipomas, both cutaneous and visceral.
285
 Multiple facial angiofibromas are 
found in 40-80% of cases.
285
 A PGL has recently been described in a patient with genetically 
confirmed MEN1,
354
 and a possible predisposition for breast cancer among females carrying 
MEN1 mutations has been suggested by an epidemiological study.
355
 
 
Approximately 40% of MEN1 patients develop pituitary adenomas,
344
 and these tumours are the 
first manifestation of MEN1 in around 17% of patients
344
 (ranging from 10 to 25%).
285
 Pituitary 
adenomas in the context of MEN1 arise at a younger age (35.1±14.8 years) than in patients with 
sporadic pituitary adenomas;
344
 the earliest age of presentation reported is five years.
356
 
Prolactinomas predominate (62%), but NFPAs (15%), somatotropinomas (9%), 
corticotropinomas (4%), and rarely thyrotropinomas can also be detected.
344;357
 One case of 
gonadotroph cell carcinoma in an MEN1 patient has been reported.
357
 Ten to 39% of tumours 
secrete more than one hormone, usually PRL/GH.
344;358
 The majority of these tumours are 
macroadenomas (76-85%) and around half of them are invasive.
344;358
 Four percent of patients 
present multiple adenomas.
358
 
 
Pituitary adenomas in MEN1 patients are significantly larger and more invasive than in sporadic 
patients, but the Ki-67 index and the mitotic activity are not different.
358
 Hyperplasia of 
somatotroph or mammosomatotroph cells has been described, but it is not common and in 
some cases is due to an ectopic GHRH-secreting tumour.
358;359
 In an invasive tumour from a 
very young MEN1 patient, overexpression of genes related to tumorigenesis (TPD52, FOS and 
SHC1), and cell growth (GNAS1, FOSB and SRF) as well as loss of e-cadherin function were 
detected.
356
 In general, the response of secretory pituitary adenomas to medical and/or surgical 
treatment is suboptimal; normalisation of hormone secretion is achieved in only 42% of 
patients.
344
 Medical treatment of prolactinomas in MEN1 patients is difficult because they show 
a poor response to dopamine agonists (DA).
344
 
 
Sequence analysis of MEN1 (including both Sanger sequencing and multiplex ligation-
dependent probe amplification [MLPA]) of index cases and their relatives is important in order to 
determine which individuals require follow-up, as well as to identify phenocopies (they are 
present in ~5% of families).
274
 MEN1 mutation carriers and MEN1 patients should have long-
term follow-up, because new components of the syndrome can arise at any age.
285;353
 Annual 
biochemical screening, including calcium, parathyroid hormone, gastrin, fasting glucose, insulin, 
chromogranin-A, glucagon, proinsulin, PRL and IGF-1 is recommended.
285
 Imaging studies 
55 
 
(computed tomography, MRI and, rarely, 
111
In-DTPA octreotide scan) should be performed at 
regular intervals.
285
  
 
MULTIPLE ENDOCRINE NEOPLASIA TYPE 4 
Definition and general description 
The absence of MEN1 mutations in a minority (5-10%) of patients with MEN1 clinical features 
drove a search for additional loci implicated in this phenotype. Homozygous mutations were 
found in Cdkn1b in association with MEN syndrome (termed MENX) showing features of both 
human MEN1 and MEN2, occurring spontaneously in a laboratory rat strain.
89;360
 Following this 
discovery, mutations in the human CDKN1B gene were identified in a small group of patients 
with multiple endocrine tumours typical of MEN1 (but not of MEN2) and other neoplasms, but 
negative for germline mutations in MEN1 or RET (the gene associated with MEN2 
syndrome).
361
 This infrequent MEN1-like syndrome was named MEN4 (OMIM #610755).
346;362
 
CDKN1B, localised at 12p13.1, encodes the cyclin-dependent kinase inhibitor (CDKI) CDKN1B 
(p27
Kip1
).
363
 Since the first report, mutations in CDKN1B have been searched in many patients 
with MEN1 features, negative for MEN1 mutations, but they have rarely been found.
364-367
 Those 
patients might have a different genetic background, not yet identified.  
 
Genetics and pathophysiology 
CDKN1B is a 27 kDa protein, highly conserved (around 90% identity) in human, mouse and 
mink.
368
 It contains 198 amino acids, with an NLS in the C-terminal region.
368
 CDKN1B is a 
tumour suppressor gene:
369
 as a member of the KIP/CIP family of CDKIs, CDKN1B
 
is implicated 
in the regulation of cell cycle progression from G1 to S phase
370
 by binding to and regulating the 
activity of cyclin-dependent kinases (CDKs).
371
 Subcellular localisation of CDKN1B determines 
its functions. In G0 and early G1, CDKN1B expression is maximal and is localised in the 
nucleus, where it binds and inhibits cyclin E/CDK2 complex.
370;372
 In proliferating cells, CDKN1B 
is sequestered in the cytoplasm, with a substantial proportion bound to cyclin D/CDK4 
complex.
370
 As cells progress through phase G1, CDKN1B expression decreases, allowing 
cyclin E/CDK2 and cyclin A/CDK2 to activate the transcription of genes necessary for G1-S 
transition and the initiation of DNA replication.
371;372
 CDKN1B exerts a dual effect over cyclin D, 
which is inhibitory under adverse conditions for replication, while in early G1 to mid-G1 phase it 
promotes cyclin D-CDK4 assembly and nuclear import.
371
 In an additional anti-oncogenic 
activity, CDKN1B binds directly to GRB2, blocking the formation of the GRB2-SOS1/2 complex 
and therefore the activation of the RAS/RAF/MEK/ERK signalling pathway.
373
 
 
CDKN1B is a substrate for tyrosine phosphorylation by the cyclin E/CDK2 complex, which 
triggers ubiquitination (mediated by the SKP1-CUL1-F-BOX protein complex [SCF] E3 ubiquitin 
ligase, containing the F-box protein SKP2) and proteasomal degradation of CDKN1B, although 
other proteins and also miRNAs modulate CDKN1B transcription and proteolysis.
361;362;374
 For 
example, in tumoral cells, cytoplasmic sequestration of CDKN1B (via AKT-dependent 
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phosphorylation on residue T157) inhibits its activity, leading to enhanced tumour 
invasiveness.
361;362
  
 
CDKN1B is a downstream element of the MEN1 signalling pathway, and menin, through its 
interaction with histone methyltransferases, enhances the activity of the CDKN1B promoter.
361
 
Paradoxically, CDKN1B can display oncogenic activity through a CDK-independent mechanism 
in experiments using knock-in mice with a mutant CDKN1B unable to bind CDKs.
375
 
Homozygous Cdkn1b KO mice have increased body size and develop multiorgan hyperplasia, 
retinal dysplasia, ovulatory defects, female sterility and, in 100% of the cases, hyperplasia or 
adenomas of the pituitary pars intermedia, secreting ACTH.
376-378
 In addition, Cdkn1b
-/-
 mice 
also show an increased susceptibility to tumour development after exposure to γ-irradiation and 
N-ethyl-N-nitrosourea, developing lymphomas and adenomas of the liver, intestine, lung and 
pituitary, ovarian granulosa cell tumours, endometrial adenocarcinomas, endometrial polyps, 
angiosarcomas and fibromas, as well as medullary and cortical adrenal tumours.
369
 
Nevertheless, CDKN1B
 
somatic mutations or LOH at its locus have only rarely been described 
in human tumours.
89;361;379;380;380;381
 Decreased CDKN1B expression, either due to heterozygous 
mutations or to changes in extragenic pathways regulating protein levels, is enough for tumour 
development in Cdkn1b
+/-
 mice.
369
 Furthermore, an important reduction in CDKN1B expression 
has been described in multiple human cancers, correlating with aggressive behaviour,
371;382-386
 
as well as in some endocrine malignant and benign tumours (PHAEOs, parathyroid adenomas 
and pancreatic and digestive endocrine tumours).
361;387-389
 
 
Human germline CDKN1B mutations are extremely rare: they explain only 1.5-2.8% of MEN1 
phenotype/MEN1 mutation negative cases,
390;391
 and therefore, only ~0.1-0.2% of all MEN1 
cases. The first CDKN1B germline mutation identified in an MEN4 patient was a nonsense 
mutation that had been previously identified as a somatic change in an adult patient with 
leukaemia.
89;361
 To date, eleven heterozygous CDKN1B germline mutations have been 
described in familial and sporadic patients with MEN1-like phenotype, including two frameshift, 
two nonsense, one non-stop, three missense, two deletions at the 5’ untranslated region (UTR), 
one mutation at the Kozak sequence and one mutation affecting an open reading frame (ORF) 
located at the 5’UTR.
89;390-398
 Additionally, two missense germline CDKN1B mutations have 
been reported in two patients with sporadic PHPT
380
 and two more in two patients with a FIPA-
like phenotype.
399
 However, in the FIPA-like cases, the pathogenic association was unclear, as 
CDKN1B mutations did not segregate with the disease.
399
 The functional effect of these 
mutations on the protein include a reduced protein level,
391;395;396
 reduced mRNA and protein 
levels,
394
 reduced protein stability,
380
 abnormal electrophoretic migration,
399
 loss of molecular 
interactions (with CDK2
392
 and GRB2
391;399
) or cytoplasmic localisation,
89;397
 but for some 
mutations the functional effect remains elusive.
380;390;393
 
57 
 
 
Clinical features 
Five familial and seven sporadic MEN4 patients have been identified so far.
89;390-398
 In two of the 
familial cases not only CDKN1B mutations carriers but clinically affected relatives were 
identified.
89;391
 With this small number of patients, the penetrance, frequency of familial and 
sporadic cases and possible phenotype-genotype correlations cannot be determined at this 
moment. The patients described to date have presented one to four endocrine tumours 
concomitantly; nevertheless, the most common component of the syndrome is parathyroid 
involvement, and the presentation is similar to that of MEN1, with multiple parathyroid 
adenomas. Other benign and malignant tumours described as part of MEN4 are renal 
angiomyolipoma, adrenal non-functional tumour, uterine fibroids, gastrinoma and gastric 
carcinoma, gastro-entero-pancreatic neuroendocrine tumours, non-functioning pancreatic 
endocrine neoplasm, neuroendocrine cervical carcinoma, bronchial carcinoid and papillary 
thyroid carcinoma.
89;390-394;397
 
 
Under physiological conditions, CDKN1B
 
is especially highly expressed in the human pituitary
323
 
in all types of cells except normal corticotroph cells, which show a lower expression.
103
 
Expression of CDKN1B is significantly reduced in all pituitary adenoma types, but the protein is 
practically absent in corticotropinomas and pituitary carcinomas;
103
 however, no somatic 
CDKN1B mutations, nor LOH of 12p13, have been found in corticotropinomas.
102;379
 Only four 
cases of pituitary adenomas have been identified among the eleven CDKN1B mutation positive 
MEN4 patients reported to date, including two cases of acromegaly, one of gigantism, one of 
Cushing’s disease and one NFPA,
89;390;392;395;398
 and two more patients, with diagnoses of 
prolactinoma and acromegaly have been reported with a FIPA phenotype.
399
 Due to the scarcity 
of cases, there is not enough data about the specific clinicopathological features of pituitary 
adenomas in MEN4 cases. 
 
Due to the lack of a specific MEN4 phenotype, it is not possible to establish this diagnosis only 
by clinical data.
367
 Because of the low prevalence of MEN4, screening for CDKN1B mutations in 
patients with MEN1 diagnosis and negative MEN1 mutations is currently not a routine practice. 
However, patients previously considered as MEN1 phenocopies could be tested for CDKN1B 
mutations in a research setting.
367
 
 
OTHER RARE MEN1-LIKE CASES 
A mutation in the CDKN1A (p21
CIP1
) gene was described in two sisters with an MEN1-like 
syndrome of PHPT and microprolactinoma, and mutations in other two genes encoding CDKIs, 
CDKN2B (p14
INK4b
) and CDKN2C (p18
INK4c
) have also been detected in the context of MEN, but 
none of these cases included pituitary tumours as part of the phenotype.
391
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PITUITARY BLASTOMA 
Definition and general description 
Pituitary blastoma is a very rare, aggressive and potentially lethal, apparently congenital 
pituitary tumour, which forms part of the DICER1 syndrome or pleuropulmonary blastoma 
familial tumour and dysplasia syndrome (OMIM #601200), caused by germline mutations in the 
DICER1 gene, a novel genetic association.
400
 In addition to pituitary blastoma, the main 
manifestations of the DICER1 syndrome are pleuropulmonary blastoma (PPB), ovarian sex 
cord-stromal tumours (Sertoli-Leydig cell tumour, juvenile granulosa cell tumour, and 
gynandroblastoma), cystic nephroma (CN) and thyroid gland tumours such as multinodular 
goitre, adenomas, or differentiated thyroid cancer. Other less frequently associated neoplasms 
are ciliary body medulloepithelioma, botryoid-type embryonal rhabdomyosarcoma (ERMS) of 
the cervix or other sites, nasal chondromesenchymal hamartoma, renal sarcoma and 
pineoblastoma, and in very rare cases, Wilms tumour, neuroblastoma, and other childhood 
cancers have been reported.
401;402
 These neoplasms can also present isolated in the presence 
or absence of DICER1 mutations,
401
 and 66% of all the cases of PPB carry a DICER1 germline 
mutation.
403
 
 
The DICER1 syndrome is an autosomal dominant disorder,
402
 with very low penetrance 
(apparently 15% or less).
93;404
 Eighty percent of the mutations in these patients are inherited and 
20% present de novo; around 35% of the DICER1 mutation carriers have a known familial 
history of DICER1-related tumours.
402
 There is a predominance of female patients, perhaps due 
to the occurrence of ovarian and cervical tumours.
404
  
 
A recent study reported thirteen (nine previously published and six unpublished) cases of 
DICER1 syndrome with pituitary blastoma, and nine out of ten infants tested were positive for 
heterozygous DICER1 mutations. Results of the genetic testing were not reported for two 
patients, due to either unavailability or suboptimal DNA quality. Only one of these germline 
mutations occurred de novo. In addition, somatic DICER1 mutations were detected in seven 
cases, and two cases displayed LOH in the tumour, accounting for a total of nine patients with 
somatic alterations; seven of these cases were also positive for germline mutations.
93
 This 
series, together with a recently reported case of isolated pituitary blastoma causing Cushing’s 
disease in a female with DICER1 germline and somatic mutation (and no familial history of 
DICER1-associated neoplasms),
405
 account for a total of 14 genetically screened cases of this 
neoplasm reported to date. 
 
Genetics and pathophysiology 
DICER1 is located at 14q32.13 and contains 27 exons, encoding for a large protein (218.7 
kDa), composed of 1922 amino acids. DICER1 is a multidomain enzyme with three main 
functions in miRNA processing: the processing of pre-miRNAs into mature miRNAs and long 
double stranded RNAs (dsRNAs) into small interfering RNAs (siRNAs); the loading of small 
RNAs onto argonaute (AGO) proteins to programme the RISC (this activity is known as RISC-
59 
 
loading); and the scaffolding of interactions between different proteins implicated in the 
interference RNA (iRNA) mechanisms. In the miRNA biogenesis pathway, DICER1 acts 
downstream its nuclear homologue, the DROSHA protein. The most important functions of 
DICER1 are carried out by its RNaseIIIa and RNaseIIIb domains, located at its C-terminal half, 
which assemble into an intramolecular dimer to create the catalytic core of the enzyme.
404
 
 
In multiple neoplastic tissues (lung, breast, skin, endometrial and ovarian cancer) reduced 
DICER1 levels (and in some cases, also DROSHA levels) are a marker of bad prognosis; 
however, overexpression of DICER1 has been found in prostate cancer metastases, in 
precursor lesions of lung cancers, in some oral cancers and in acute myeloid leukaemia, while 
DROSHA has been found upregulated in advanced stage cervical cancer and aggressive 
oesophageal cancers.
404
 Somatic DICER1 pathogenic variants have been reported, in the 
presence or absence of germline mutations, in patients with PPB,
406-408
 CN,
409;410
 Wilms tumour, 
non-epithelial ovarian tumours,
411
 cervical ERMS,
412
 pituitary blastoma
93
, prostate carcinoma, 
pineoblastoma
413
, differentiated thyroid carcinoma
414
 and testicular germ cell tumour.
415
 Most of 
the somatic mutations detected affect the RNase IIIb catalytic domain (exons 24 and 25), 
specifically affecting the metal-ion binding residues or their adjacent amino acids (positions 
1705, 1709, 1809 or 1813), which are therefore termed “missense hotspots”.
402;404
 The fact that 
the second hit on the WT allele almost always affects one specific region of DICER1 
distinguishes this gene from other tumour suppressors.
404
 
 
The histopathological features of pituitary blastomas include the presence of small blastemal-
like cells, small and larger glandular structures and ill-defined clusters of large epithelial cells.
416
 
Electron microscopy reveals the presence of folliculostellate and secretory, neuroendocrine 
cells. The glandular structures have the ultrastructural characteristics of Rathke’s epithelium, as 
seen in the foetal pituitary.
417
 The mitotic activity is highly variable and there is no evidence of 
normal adenohypohysis.
416;417
 The larger, secretory cells are neuroendocrine cells, 
immunoreactive for synaptophysin, CgA, keratins, ACTH, β-endorphin and CRH, with rare GH 
positive cells.
416
 Stains for other adenohypophysial hormones are negative. Ki-67 and MGMT 
immunoreactivity are variable. Both blastemal and glandular cells express NEUROD1, PIT1 and 
TBX19. 
416
 In summary, the histopathological appearance of pituitary blastomas resembles that 
of the human foetal adenohypophysis, at the age of 10-12 gestational weeks, when 
corticotrophs and somatotrophs are already differentiated, and α-GSU starts to emerge, but 
other cells types are not yet evident.
417
 These findings together with the very early clinical 
presentation of pituitary blastomas, suggest that the development of these and possibly other 
DICER1-associated neoplasms starts in utero. 
 
Clinical features 
The phenotype of the DICER1 syndrome is widely variable, but most of its manifestations occur 
before the age of 40 years. PPB, the most common manifestation, arises during lung 
development or during the neonatal stage, and it is usually diagnosed in infants and children 
60 
 
before the age of six years (median: 12 months, range: 0-546 months).
403;410
 CN usually 
presents before the age of four years, while the age of onset of ovarian sex cord-stromal 
tumours is not well defined.
402;404
 
 
PPB presents in infants with shortness of breath with or without pneumothorax secondary to 
cyst rupture, while ovarian sex cord-stromal tumours present as adnexal masses with or without 
signs of hormone production (PP, menstrual irregularities, or signs of virilisation). CN usually 
presents as a painless enlarging abdominal or flank mass; the finding of bilateral lesions 
strongly suggests DICER1 mutations, and thyroid lesions usually present as palpable 
masses.
402
 Treatment for DICER1-related malignant tumours usually involves surgical resection 
with or without chemotherapy/radiotherapy.
402
 
 
Out of the 14 cases with pituitary blastoma and genetic screening reported to date, ten patients 
were females and four were males.
93;405
 The first manifestation of disease appeared early in 
childhood (median: 12 months, range: 7-24 months), there was no familial history of that or 
other neoplasms and in most of the cases (9/14) pituitary blastoma was the only manifestation 
of the syndrome.
93;405
 More than one DICER1 syndrome-associated neoplasm can coexist in the 
same patient (2/14), in other cases the index patient presents one neoplasm only, but there is 
familial history of other tumours associated to the syndrome (3/14). Cushing’s syndrome and 
ophtalmoplegia were the most common presenting clinical features, but in most of the patients 
where this parameter was available, elevated blood ACTH levels were reported, even in the 
absence of clinical Cushing’s disease. Five out of the 14 infants died within 0-26 months of the 
first surgery; the maximum follow-up period in the rest of the patients is 17.4 years.
93
 Pituitary 
blastoma is an extremely rare neoplasm and it is considered a pathognomonic feature of 
DICER1 syndrome.
93
 
 
Once a germline DICER1 pathogenic variant has been detected in a patient, genetic testing 
should be offered to all the relatives at risk.
404
 For the follow-up of DICER1 mutation carriers, 
The International PPB Registry recommends annual physical examination and targeted review 
of systems, and imaging studies based on the patient’s age and clinical findings, focusing on 
the most common components of the syndrome.
402;418
 
 
CARNEY COMPLEX 
Definition and general description 
In 1985, Carney and collaborators described the clinical features and reported the first series of 
patients with the association of myxomas, spotty skin pigmentation and endocrine 
overactivity.
419
 CNC (OMIM #160980 and %605244) is a syndrome characterised by the 
association of multiple endocrine tumours and cardiocutaneous manifestations.
420
 A few 
patients with some components of the complex were previously described as NAME (nevi, atrial 
myxomas and ephelides, i.e. light-brown dermal macules) or LAMB (lentigines, atrial myxomas 
and blue nevi); currently all these cases are grouped as CNC.
420;421
 Around 70% of the CNC 
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cases occur in a familial setting.
275
 CNC is an infrequent clinical entity, with around 750 cases 
registered to date.
422
 Patients are from diverse ethnicity, distributed through all the continents.
423
  
 
The major diagnostic criteria for CNC are:
421
 
- Spotty skin pigmentation with a typical distribution 
- Myxoma (cutaneous and mucosal) 
- Cardiac myxoma 
- Breast myxomatosis or MRI suggestive image 
- Primary pigmented nodular adrenal dysplasia (PPNAD) or paradoxical positive 
response of urinary glucocorticoids to dexamethasone 
- Acromegaly 
- Large-cell calcifying Sertoli cell tumours (LCCSCT) or characteristic calcification on 
testicular ultrasonography 
- Thyroid carcinoma or multiple hypoechoic thyroid nodules in a young patient 
- Psammomatous melanotic schwannoma 
- Blue nevus or epithelioid blue nevus (multiple) 
- Breast ductal adenoma (multiple) 
- Osteochondromyxoma 
 
The diagnosis of CNC is established if two major criteria are present or in the presence of one 
major criterion plus an inactivating PRKAR1A mutation or a first-degree relative with CNC.
421;423
 
Other less frequently detected clinical manifestations associated to CNC are: intense freckling, 
multiple blue nevus, café-au-lait spots, elevated IGF-1 levels, paradoxical GH response to TRH 
or to an oral glucose tolerance test (OGTT), cardiomyopathy, pilonidal sinus, a history of 
Cushing’s syndrome, acromegaly or sudden death in extended family, multiple skin tags or 
lipomas, colonic polyps, hyperprolactinaemia, a single benign thyroid nodule in a young patient 
or multiple nodules in older patients, and familial history of carcinoma or other benign or 
malignant tumours.
423
 
 
The genetic basis of CNC is heterogeneous, involving at least two loci, as demonstrated by 
linkage analysis.
424
 The CNC1 gene is located at 17q24.2 and encodes the regulatory subunit 1-
alpha of the protein kinase A (PRKAR1A);
88;420
 seventy three percent of CNC patients present 
germline mutations in this gene.
275
 The CNC2 gene, located at 2p16, is still unknown.
425
 This 
locus frequently presents amplification in tumours of CNC patients, including some with known 
mutations in PRKAR1A, and thus it is suspected that an oncogene may be implicated.
426
  
 
Genetics and pathophysiology 
PRKAR1A is 21 kb in length and spans 11 exons, for a coding region of 1143 bp,
346
 encoding a 
protein of 381 amino acids and 42.9 kDa. Protein kinase A (PKA), a main mediator of cAMP 
signalling is a tetramer composed of a dimer of regulatory subunits and a dimer of catalytic 
subunits. When four molecules of cAMP bind to the regulatory subunits, the catalytic subunits 
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are released to phosphorylate serine or threonine residues in their target proteins. There are 
four isoforms of regulatory subunits: Iα, Iβ, IIα and IIβ, which can pair up as homodimers or type 
I or type II heterodimers, composing holoenzyme complexes of PKA with a number of 
combinatorial configurations, including RIα2C2, RIβ2C2, RIIα2C2, RIIβ2C2 and RIαRIβC2. The 
dimer of catalytic subunits can contain different combinations of the three different isoforms: Cα, 
Cβ and Cγ.
427
 Experimental downregulation of PRKAR1A inhibits growth in human cancer cell 
lines, while the overexpression of type I PKA stimulates cell growth and proliferation, via 
interactions with the epidermal growth factor receptor (EGFR).
428
 Tumours in CNC often present 
LOH at 17q22-24, supporting the role or PRKAR1A as a tumour suppressor gene.
88
  
 
More than 120 PRKAR1A mutations have been described to date in CNC patients,
422
 distributed 
throughout the gene, with higher frequency in exons 2, 3, 5, 7 and 8.
275
 Almost 80% of 
PRKAR1A mutations originate a premature stop codon, but truncated proteins are not 
expressed.
275;423;429
 The abnormal mRNA, transcribed from the affected allele, is destroyed by a 
mechanism known as NMD, by which the cells degrade mRNA containing a deleterious, 
premature stop codon mutation prior to its translation.
428
 Loss of expression of PRKAR1A in 
CNC tumours leads to a reduced regulatory activity over PKA, but also to compensatory 
increases in the expression of other PKA subunits.
88
 These alterations derive in an increased 
response of PKA to cAMP, with upregulation of the cAMP signalling pathway.
428
 
 
There is not a clear genotype-phenotype correlation for most of the PRKAR1A mutations in 
CNC,
430
 although the intronic deletion exon 7 IVS del(-7→-2) is related to isolated PPNAD.
431
 
Differences in presentation of molecular defects and clinical features may be due to disease-
modifying genes, located at other loci.
424;430
 In a cohort of CNC patients, variants of the 
phosphodiesterase type 11A gene (PDE11A) showed association with a higher incidence of 
PPNAD and LCCSCT, suggesting that PDE11A can modify the phenotype.
432
 No association 
was found with other components of the complex.   
 
Prkar1a
-/-
 mice are not viable. Lethality occurs during embryogenesis, due to a failure in 
mesoderm-derived structures.
280
 Pituitary-conditional Prkar1a
-/-
 mice develop pituitary 
adenomas with a higher frequency than their littermates. These tumours are sometimes multiple 
and express GH, PRL and TSH.
280
 Prkar1a
+/- 
mice are prone to develop tumours in cAMP-
responsive tissues, such as bone, Schwann cells and thyroid, but not myxomas or pituitary 
adenomas.
433;434
 Prkar1a haploinsufficiency in combination with Tp53 or Rb1 haploinsufficiency 
(Prkar1a
+/-
/Tp53
+/-
 and Prkar1a
+/-
/Rb1
+/-
, respectively) enhances the phenotype generated by 
each gene disruption, suggesting that Prkar1a haploinsufficiency in mice is a generic, but weak 
tumorigenic signal.
433;435
 E2f, a downstream effector of Rb1, mediates the proliferative effects of 
the defective Prkar1a, and E2f activity is regulated by Tp53, providing a link between these 
tumour suppressor genes. 
433;436
 Prkar1a haploinsufficiency causes an increase in cAMP levels, 
leading to increased RAS/RAF/MEK/ERK activity, while complete Prkar1a deficiency causes 
constitutive activation of PKA and immortalisation of mouse embryonic fibroblasts through 
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upregulation of cyclin D1 in vitro.
433
 A murine model with double heterozygosity for Prkar1 and 
the PKA catalytic subunit alpha (Prkar1a
+/-
/Prkaca
+/-
) developed multiple bone lesions, including 
condromas, osteochondrodysplasia and rarely sarcomas.
434
 This effect over bone stromal cells 
was mediated by PKA-II and alternative PKA catalytic subunits.  
 
Multiple elements of the Wnt signalling pathway are overexpressed in different tumours from 
Prkar1a
+/-
, Prkar1a
+/-
/Trp53
+/-
, Prkar1a
+/-
/Rb1
+/-
 and Prkar1a
+/-
/Prkaca
+/-
 mice, suggesting its 
implication in Prkar1a-derived tumorigenesis.
433-435
 A microarray analysis of tumours from three 
different mouse models of Prkar1a haploinsufficiency (Prkar1a
+/-
, Prkar1a
+/-
/Trp53
+/-
 and 
Prkar1a
+/-
/Rb1
+/-
) identified Wnt signalling as the main pathway activated by abnormal cAMP 
signalling, along with the mentioned cell cycle abnormalities.
433
 In human tissue from PPNAD, 
PKA activates the expression of WISP2, a component of the WNT signalling pathway, via 
miRNA regulation.
437
  
 
Twenty percent of CNC patients present PRKAR1A mutations in intronic sequences affecting 
splicing.
275
 At least some of these mutations escape from NMD, leading to expression of the 
truncated protein.
438
 LOH is not a universal finding in CNC tumours,
275
 and in vitro, the 
expression of abnormal PRKAR1A without concomitant loss of the normal allele causes 
increased PKA activity.
438
 The contribution of possible PKA-independent effects due to different 
protein interactions cannot be discarded.
275
 PRKAR1A mutations have not been found in 
sporadic pituitary tumours;
278
 however, low levels of PRKAR1A have been detected in sporadic 
functioning and NFPAs, despite adequate mRNA.
439
 
 
In the pituitary, GHRH requires the cAMP/PKA pathway to stimulate GH synthesis and 
release.
280
 The expression of other hormones is mainly regulated by different pathways, thus 
they are less likely to be affected by PRKAR1A mutations. Pituitary tumorigenesis in the context 
of CNC is a slow-developing process that requires mutation accumulation (“multiple hits”).
440
 
Apparently, in CNC patients, germline mutations cause a predisposition, but other molecular 
events are necessary for pituitary adenoma development.
440
 
 
Clinical features 
CNC is inherited as an autosomal dominant trait.
421
 Penetrance for CNC due to PRKAR1A is 
almost complete for some of the manifestations.
275;441
 Clinical manifestations are variable, even 
within members of the same family. Thirty two percent of the PRKAR1A mutation positive 
patients present as simplex cases, and in more than 85% of them the mutation occurs de 
novo.
275
 
 
Lentiginosis, consisting of 2-10 mm brown to black macules, distributed on the lips, eyelids, 
ears and genital area,
420
 is the most common feature of CNC (70% of patients)
275
 and is present 
in half of the patients before other components of the complex appear.
428
 Lesions can exist at 
birth, but do not acquire their clinical characteristics until puberty.
421
 Half of the patients develop 
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other skin lesions, such as blue, Spitz and compound nevi and café-au-lait spots.
275
 Skin 
myxomas are found in 20% of the patients in eyelids, external ear canal, nipple, oropharynx, 
female genital tract and female pelvis.
275;421
 Twenty percent of female patients present breast 
myxomas,
275
 and also a few cases of breast ductal adenoma have been reported.
421
 Cardiac 
myxomas are detected in 32% of cases.
275
 In the setting of CNC, these tumours occur at any 
age, are multicentric, can be located in any cardiac chamber, tend to recur and can behave 
aggressively, requiring surgical resection to avoid complications such as embolism, strokes and 
cardiac failure.
423
  
 
ACTH-independent Cushing’s syndrome due to PPNAD is the main endocrine manifestation of 
CNC (60% of patients).
275;421
 PPNAD almost always occurs in the context of CNC, but a very 
infrequent sporadic form also exists.
436
 It has a bimodal age distribution: most of cases are 
diagnosed during the second and third decades of life and a minority present at the age of 2-3 
years.
421
 The disease is usually bilateral,
420
 although the adrenal glands do not always show an 
obvious enlargement on imaging studies as nodules can be very small.
420
 Hypercortisolism 
generally progresses subtly over years or follows a cyclic pattern, but the circadian cycle of 
cortisol is completely abolished, sometimes even in periods of inactive disease.
423;442
 Pseudo-
PP or hirsutism can appear.
442
 Diagnosis is better established with the six day Liddle test, 
showing a paradoxical increase in the 24 hours (h) urinary free cortisol and/or 17-
hydroxysteroids.
442;443
 Bilateral adrenalectomy is the treatment of choice, but some patients 
respond to ketoconazole or mitotane.
423;442
 
 
LCCSCT is a common (41% of male patients)
275
 and almost always benign tumour in CNC, 
usually appears in the first decade of life, and most of the times is detected by ultrasonography, 
appearing as microcalcifications.
423
 LCCSCT can rarely lead to gynecomastia and PP, but 
fertility impairment (due to obstruction of seminiferous tubules or inappropriate hormone 
production or aromatisation) is common. Adrenal rests and Leydig cell tumours can exist 
concomitantly with LCCSCT; ovarian cysts and cystadenoma have been found in some 
patients.
423
 Thyroid nodules occur in 25% of patients and usually correspond to non-toxic 
adenomas of follicular type;
275;420;421
 up to 10% of CNC patients with thyroid nodules develop 
thyroid carcinoma (follicular of papillary).
423
 Psammomatous melanotic schwannomas are very 
rare tumours that can arise from any peripheral nerve, usually in the gastrointestinal tract and 
paraspinal sympathetic chain; they are pigmented, multicentric and frequently calcified.
421
 
These tumours are found in 8% of CNC patients
275
 and they are malignant in 10% of the cases, 
metastasizing to lungs, liver or brain.
423
 Osteochondromyxomas of the bone and tetralogy of 
Fallot have been found in some CNC patients and are possible components of the syndrome.
421
 
 
A possible association between CNC and pancreatic neoplasms has recently been proposed. 
There is an unexpectedly high prevalence (2.5%) of pancreatic neoplasms among CNC 
patients, some of them of a very uncommon histological type (acinar cell carcinoma).
444
 Most of 
the analysed cases present LOH at chromosome 17 and loss of PRKAR1A immunostaining.
444
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The main CNC-related cause of death is metastatic cancer (56% of deaths) and pancreatic 
cancer accounts for one third of cancer-related deaths in CNC patients.
275
 
 
Histologically, pituitaries of CNC patients show zones of mammosomatotroph hyperplasia, that 
only occasionally progress to adenomas.
440
 This “pro-acromegalic state” is a common 
characteristic shared by CNC and MAS, a syndrome in which the same molecular pathway is 
disturbed, though at a different level.
445
 By IHC, almost all the somatotropinomas also stain 
positive for PRL and plurihormonal expression is frequent, but positive staining for ACTH has 
not been reported.
280;445
 Microadenomas are much more common than macroadenomas, they 
are frequently multiple, sometimes microscopic and they grow surrounded by hyperplastic 
tissue.
440;445
 Electron microscopy features are highly variable: from mammosomatotroph cells 
with abundant rough endoplasmic reticulum (ER), immature secretory granules and a small 
percentage (1%) of densely granulated cells, to sparsely granulated cells with poorly developed 
ER, and fibrous bodies, or a mixture of both types of cells.
445
 Aggressive pituitary adenomas in 
CNC show genetic instability, whereas cytogenetic abnormalities are absent in hyperplasia or 
microadenomas;
440
 LOH is not always detected.
280
  
 
Clinically evident acromegaly is a relatively infrequent manifestation of CNC: the incidence of 
GH-producing pituitary tumours in CNC is 12%.
275
 Nevertheless, paradoxical GH response to 
TRH or non-suppressible GH during a glucose challenge and/or IGF-1 elevation are present in 
up to 80% of patients, even in the absence of detectable tumours.
421
 Acromegaly in CNC 
patients has a slowly progressive course,
440
 and in some cases it only becomes apparent after 
the patient undergoes bilateral adrenalectomy for Cushing´s syndrome.
362
 Pituitary tumours in 
CNC are almost exclusively GH or GH/PRL-secreting tumours. Around two thirds of CNC 
patients have mild hyperprolactinaemia (generally <100 ng/ml), but there are few cases of frank 
prolactinomas.
280
  
 
Regular screening for the manifestations of the disease is recommended for patients with CNC 
and known carriers of PRKAR1A mutations. Screening for cardiac myxomas by 
echocardiography must start at diagnosis or during the first six months of life, and yearly 
thereafter.
421
 If a cardiac myxoma was excised in the past, echocardiography is necessary 
every six months.
423
 During childhood, screening for other manifestations should be performed 
only by clinical examination, because it is rare to detect endocrine tumours in CNC before the 
second decade of life.
423
 Pubertal staging and growth rate must be monitored.
420
 For post-
pubertal patients the following annual studies are recommended: urinary free cortisol 
determination (plus diurnal cortisol or overnight 1mg dexamethasone test), serum IGF-1 and 
testicular ultrasonography in male patients.
421
 Brain and spine MRI should be obtained at 
diagnosis and repeated only if clinical signs suggest the possibility of a schwannoma.
423
 Pelvic 
ultrasonography in women is recommended at diagnosis and then as needed.
421
 Thyroid 
ultrasonography is indicated at diagnosis and then as clinically indicated.
421
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PHAEOCHROMOCYTOMA/PARAGANGLIOMA AND PITUITARY ADENOMA 
Definition and general description 
Multiple cases reporting the coexistence of pituitary adenoma with a PHAEO or a PGL in the 
same patient can be found in the literature. Different causes explain the coexistence of these 
tumours, and a few example cases for each of them have been published: 1) a PHAEO/PGL-
related gene mutation causing pituitary adenomas, 2) a pituitary adenoma-related gene 
mutation causing PHAEO/PGL, 3) ectopic synthesis of a hypophysiotropic hormone (GHRH or 
CRH) by the PHAEO/PGL and 4) pure coincidence. 
92
  
 
Recently, a cohort of 39 of such cases was screened for germline mutations in genes known to 
cause hereditary PHAEO/PGL (SDHA, SDHAB, SDHAC, SDHAD, SDHAF2, RET, VHL, 
TMEM127, MAX, FH) or pituitary adenomas (MEN1, AIP, CDKN1B), finding that mutations in 
SDHB, SDHC, SDHD, VHL, and MEN1 can cause this phenotype.
92
 Other few cases of the 
recently termed “Three P Association” (3PAs) have been reported in association with germline 
mutations in SDHA,
446
 SDHB,
447-449
 SDHC
450
 and SDHD.
90;449;451-453
 The MEN1 and VHL 
mutation positive patients (one patient positive for each mutation), together with a few 
previously reported cases with mutations in these genes or in RET (causative of MEN2A),
454;455
 
seem to represent variants of the classic phenotypes of MEN1, the Von Hippel-Lindau disease 
and MEN2A respectively, whereas the patients with 3PAs and mutations in the genes encoding 
the subunits A, B, C and D of the succinate dehydrogenase (SDH) mitochondrial complex II 
(SDHx genes) share unique pathological features.  
 
Germline mutations affecting multiple genes have been implicated in the pathogenesis of 
PHAEO/PGL: NF1, RET, VHL, SDHD, SDHC, SDHB, EGLN1, KIF1B, SDHAF2, IDH1, 
TMEM127, SDHA, MAX, HIF2A and FH.
456;457
 Germline SDHB mutations are the most common 
genetic cause of PHAEO/PGL (10.3% of patients), followed by SDHD (8.9%) and RET 
(6.3%).
456
 SDHB mutations are associated to a higher risk of malignancy and poor prognosis, 
and SDHD mutation carriers have a greater frequency of head and neck PGL and multiple 
tumours.
447;456
  
 
Germline mutations in the SDHx genes are the main genetic cause of familial and sporadic 
cases of PHAEO/PGL (SDHA: paragangliomas 5 [OMIM #614165]; SDHB: paragangliomas 4 
[OMIM #115310]; SDHC: paragangliomas 3 [OMIM #605373]; SDHD: paragangliomas 1 [OMIM 
#168000]),
456;458-461
 but besides their association to 3PAs, so far they have not been associated 
to sporadic pituitary adenomas or FIPA.
92;449
 Somatic SDHx mutations can be found in 
PHAEO/PGL (including one case with a germline and a somatic SDHA mutation),
446
 but they 
seem to be extremely rare in pituitary adenomas, as only one positive case has been reported 
so far (double SDHA mutation in a prolactinoma).
462
 Germline SDHx mutations are also 
associated to other clinical entities, such as sporadic gastrointestinal stromal tumours 
(GISTs),
463
 the Carney-Stratakis syndrome,
464;465
 and Cowden and Cowden-like syndrome,
466
 
and they have been detected in other neoplasms, such as multiple cases of renal cell 
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carcinoma,
467
 a single case of adrenal medullary hyperplasia,
468
 a single case of testicular 
seminoma,
469
 two cases of neuroblastoma,
470
 and a few cases of papillary thyroid carcinoma,
453
 
though for the last two tumour types the association remains unclear. In most of these cases 
there was familial or personal history of PHAEO/PGL. SDHA mutations are also associated to 
the mitochondrial complex II deficiency (OMIM #252011, progressive encephalomyopathy with 
variable phenotype, including the Leigh syndrome [OMIM #256000])
471
 and with an autosomal 
recessive form of neonatal dilated cardiomyopathy (OMIM #613642).
472
 
 
Genetics and pathophysiology 
The SDH complex or succinate-coenzyme Q reductase is a heterotetrameric enzyme bound to 
the inner mitochondrial membrane. The catalytic core of the enzyme is composed of two 
hydrophilic proteins, SDHA and SDHB, and two hydrophobic proteins, SDHC and SDHD, 
anchor the complex to the membrane and serve as the ubiquinone site.
473
 In addition, SDHAF2 
is a factor required for the flavination of SDHA and for the assembly of the tetramer.
474
 The SDH 
subunits are encoded by highly conserved nuclear genes (SDHA: 5p15, SDHB: 1p36.1-p35, 
SDHC: 1q23.3, SDHD: 11q23). 
 
SDH is part of the Krebs cycle, catalysing the oxidation of succinate into fumarate. Electrons 
derived from this reaction are transferred to the respiratory chain complex III to reduce oxygen 
and form water, creating an electrochemical gradient across the mitochondrial inner membrane, 
which promotes adenosine triphosphate (ATP) synthesis.
473;474
 Alternatively, electrons can be 
diverted to the ubiquinone pool (UQ pool), providing reducing equivalents necessary to reduce 
superoxide anions (reactive oxygen species) originated either from exogenous sources or as a 
result of the respiratory chain itself. A complete lack of succinate dehydrogenase activity 
hampers the electron flow to both respiratory chain complex III and the UQ pool, resulting in 
major oxidative stress.
473
 
 
Different mechanisms can explain SDHx-associated tumorigenesis. The hypoxia-inducible 
factor (HIF) is a transcription factor composed of HIFα (oxygen-inducible) and HIFβ subunits, 
whose physiological function is the induction of cell adaptation to hypoxic conditions, by 
stimulating neovascularization and glycolysis.
475
 The induction of the hypoxia pathway is the 
cause of the “glycolytic shift”, a feature of tumoral tissues first reported by Otto Warburg in the 
1920s: even in the presence of oxygen, tumoral cells rely on anaerobic ATP production through 
glycolysis.
474
 
 
The oxygen-dependent cytosolic enzymes prolyl-hydroxylases (PHDs) 1, 2 and 3 hydroxylate 
the HIF1α, HIF2α and HIF3α subunits, which are then bound by the von Hippel-Lindau (VHL) 
protein, an E3 ubiquitin-ligase, and driven to polyubiquitination and proteasomal degradation.
475
 
Excessive succinate accumulation, as occurs in the presence of LOF SDHx mutations, inhibits 
the function of the PHDs. In the absence of hydroxylation, HIFα subunits escape degradation, 
translocate to the nucleus and, after dimerising with HIFβ, induce the transcription of target 
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genes such as angiogenic factors and enzymes involved in glucose metabolism and cell 
survival, among others; this mechanism of tumorigenesis is known as “pseudohypoxia”.
475;476
 In 
addition, in the absence of SHD function, reactive oxygen species accumulate and they can 
also inhibit PHDs. Succinate accumulation can also inhibit the function of KDM4D, an α-
ketoglutarate-dependent histone demethylase, which could lead to tumorigenesis via a variety 
of epigenetic changes.
476
 
 
In tumours carrying SDHx mutations, immunostaining for SDHA and SDHB is useful as a 
marker of involvement of the hypoxia pathway, and tumours carrying germline or somatic 
mutations usually display negative or decreased staining, which could be used as a screening 
test to triage genetic testing for SDHx,
462;477
 though this has only been done in a small number 
of pituitary adenomas from SDHB mutation positive patients.
92
  
 
Pituitary adenomas from SDHx mutation positive patients are characterised by focal oncocytic 
changes and by the presence of intracytoplasmic vacuoles (small and multiple or large, 
occupying most of the cytoplasm) in a variable number of cells (50-80%); the origin of these 
vacuoles remains uncertain.
92
 LOH of the mutated SDHx gene in the tumoral tissue has been 
described in some of the cases, but it is not always present. The human phenotype is 
recapitulated by the Sdhb
+/-
 mice, displaying pituitary hyperplasia of lactotroph and, to a minor 
extent, somatotroph cells after the age of 12 months, with blood-filled lakes and cells with large 
mitochondria with abnormal and/or missing cristae, intranuclear inclusions or pseudoinclusions 
and strong HIF1α staining, with a nuclear pattern in some cells, indicating hypoxia pathway 
activation.
449
 
 
Clinical features 
The phenotype can be variable among families with 3PAs: some members present both a 
pituitary adenoma and a PHAEO/PGL while other members harbour only one of the tumours. 
The phenotype of PHAEO/PGL in these patients is similar to that of other patients carrying 
SDHx mutations, usually with bilateral and/or multiple lesions, prone to recur.
449
 
 
Twenty one cases of SDHx mutation positive 3PAs have been described so far.
92;446-453;476
 
Among them, SDHB and SDHD are the genes more frequently affected, with nine cases each, 
followed by SDHC, with two cases. Only one case has tested positive for a mutation in SDHA. 
In addition, an SDHB mutation was reported in a patient with a PHAEO, adrenal cortical 
hyperplasia and an abnormal pituitary MRI, though the pituitary diagnosis was not specified. 
Among the cases with available clinical data, there is a slight predominance of females (nine 
females vs. seven males). Sixteen cases had a familial presentation, and only one case was 
reported to occur in a sporadic setting. In the only two studies that have screened multiple 3PAs 
cases, nine out of twelve families and none of the 22 sporadic cases have tested positive for an 
SDHx mutation;
449
 therefore, the presentation of this entity is almost always familial. However, 
only one of the families included two cases of pituitary adenoma, the rest of them had a single 
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case, while multiple cases of PHAEO/PGL are a more consistent finding among carriers of 
SDHx mutations.  
 
The mean age at diagnosis of a pituitary adenoma was 44±16 years, and only two cases were 
diagnosed before the age of 30 years. The most common diagnosis was prolactinoma (ten 
cases), followed by NFPA (five cases); however, one operated NFPA stained positive for PRL. 
Three patients had somatotropinomas and one had a mammosomatotroph adenoma. Twelve of 
the patients harboured a pituitary adenoma together with a PHAEO/PGL; in one of these 
patients, a GIST was also detected. Five patients had only a pituitary adenoma and a 
PHAEO/PGL was detected in a different family member.  
 
No phenotype-genotype associations can be established at the moment, due to the small 
number of cases, but it is unlikely that some SDHx mutations would lead specifically to 
PHAEO/PGL and others to 3PAs, as among members of a single SDHx mutation positive 
family, some patients present the full 3PAs phenotype while others develop PHEAO/PGL only 
or pituitary adenoma only, in the presence of the same mutation. 
 
Based on the available data and in addition to the current known pathogenic implications for 
SDHx mutations, screening for SDHx genes is suggested in patients with 3PAs phenotype, in 
particular in patients with a familial presentation, as well as in families with cases of pituitary 
adenomas and PHAEO/PGL, even if not in the same individual. Screening for SDHx mutations 
is not recommended in patients with isolated sporadic or familial pituitary adenomas.
449
 Apart of 
the genetic screening and close follow-up of SDHx mutation carriers, and possibly pituitary MRI 
in SDHx mutation positive PHAEO/PGL patients,
446
 no specific indications for treatment or 
clinical screening of these individuals can be suggested as yet, and it would be advisable to 
follow the guidelines established for PHAEO/PGL patients with this genetic background.
456
  
 
Familial isolated pituitary adenoma  
Reports of familial presentation of nonsyndromic acromegaly and gigantism exist in the 
literature since the 18
th
 century, even before the cause of acromegaly was known, but 
unfortunately, the earliest descriptions lack scientific accuracy.
478
 However, by the end of the 
20
th
 century, and after the clinical description and finding of the causative genes for MEN1 and 
CNC, it was clear that a proportion of the pituitary adenomas in the general population, mainly 
somatotropinomas, could be inherited in the absence of other clinical manifestations.  
 
FIPA (FIPA, OMIM #102200) is characterised by the presence of pituitary adenomas in two or 
more members of the same family in the absence of other syndromic clinical features, such as 
those characteristic of MEN1 and MEN4, CNC or tumours related to mutations in the SDHx 
genes. FIPA includes families previously identified as isolated familial somatotropinoma (IFS)
479
 
and pituitary adenoma predisposition (PAP).
8
 FIPA is an autosomal dominant disease, with 
70 
 
incomplete penetrance and variable clinical presentation,
8;480;481
 and it is estimated to account 
for around 2.5% of all the pituitary adenomas.
272
  
 
Patients with known genetic cause represent around one fifth of all the FIPA cases, and include 
two different entities: FIPA associated to mutations in the AIP gene, accounting for the great 
majority of these cases, and patients with very young-onset GH excess and pituitary 
adenoma/hyperplasia due to microduplications in the Xq26.3 region (X-LAG), a novel clinical 
entity whose prevalence has not been determined as yet.
91
 
8;276;482
 
 
Most of the FIPA families are composed of two to five affected members, and there is a first 
degree relationship between the affected members in about 75% of the cases.
482
 
Somatotropinomas and prolactinomas are the most common tumours among FIPA patients 
(75% of the cases), followed non-functioning pituitary adenomas (NFPA) and corticotropinomas, 
but functioning gonadotropinomas and one thyrotropinoma have also been diagnosed.
10;11;272
 
FIPA families can be classified as homogeneous (60% of all the reported families), when 
patients within the same family exhibit the same pituitary tumour type, or heterogeneous (40%), 
when two of more different tumour types are found within a family.
272;482
 Families with only 
somatotropinomas or prolactinomas account for around 90% of all the homogeneous FIPA 
families.
482
 
 
Patients from FIPA kindreds tend to be diagnosed on average four years before pituitary 
adenoma patients presenting in a non-familial setting,
272
 and patients from IFS families are 
diagnosed around one decade earlier compared to MEN1 patients with pituitary adenomas.
483
 In 
IFS families, 70% of the pituitary adenomas are diagnosed before the age of 30 years.
479
 
Pituitary adenomas occurring in the setting of FIPA tend to be more aggressive than those 
presenting as sporadic cases.
482
 Despite its autosomal dominant pattern of inheritance, FIPA 
has a very variable penetrance and the disease is frequently not transmitted to a succeeding 
generation within a kindred.
483
 It is not clear whether this is due to the influence of disease 
modifying genes (very probable), to a reduced reproductive potential among affected individuals 
(unlikely),
483
 or to a combination of both factors. 
 
FIPA WITH UNDETERMINED GENETIC CAUSE 
Definition and general description 
Around 80-85% of the FIPA families do not carry mutations in genes associated to pituitary 
adenomas.
276;482;484;485
 Although the occurrence of two or more pituitary adenomas in the same 
family could be due to mere coincidence, it is possible that some of these cases could represent 
separate clinical entities of inherited pituitary adenomas, caused by still undetermined genetic 
causes.   
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Genetics and pathophysiology 
Initial studies linked IFS to two distant loci: 11q13.1-13.3 and 2p16-12.
479
 The former 
chromosomal region contains the AIP and MEN1 genes; MEN1 mutations were not detected, 
but in these and other families AIPmuts were later discovered.
8;9
 Only 8% of the sporadic 
somatotropinomas with LOH in 11q13 harbour MEN1 mutations,
479
 while the frequency of AIP 
mutations has not been studied in this subset of tumours. Nevertheless, LOH in 11q13 is a 
frequent finding in pituitary adenomas and other endocrine tumours, which can occur in the 
absence of AIP and MEN1 mutations, suggesting the involvement of another gene at this 
chromosomal location in endocrine tumorigenesis.
486
  
 
The second chromosomal region has also been implicated in the pathogenesis of some cases 
of CNC, in the absence of PRKAR1A mutations, but a pituitary adenoma causative gene in this 
region has not been described so far. Other chromosomal regions possibly implicated in FIPA, 
with significant linkage in different studies, are 8q,
8;487
 and regions in chromosomes 4 and 5.
8
 
 
Clinical features 
Even though cases with undetermined genetic cause represent the wide majority of FIPA 
patients, their clinical features have been the less accurately described, perhaps because they 
represent a genetically heterogeneous population.
9
 Homogeneous FIPA families with 
prolactinomas or Cushing’s disease have only been reported to occur in the absence of 
AIPmuts.
482
  
 
These patients are 12 to 16 years older at diagnosis and their tumours are smaller, when 
compared to AIPmut positive patients.
485;488
 Around half of the patients in these families have 
somatotropinomas, compared to three quarters of the patients with this type of tumours among 
AIPmut positive families.
485
 Even though their response to treatment is relatively poor, they 
respond better than AIPmut positive patients.
488
 The disease onset occurs during childhood in 
11% of these families.
485
 
 
X-LINKED ACROGIGANTISM 
Definition and general description 
X-LAG is characterised by childhood onset gigantism, usually manifest by the first year of life in 
previously normal infants, due to a pituitary adenoma or hyperplasia, caused by 
microduplications in Xq26.3.
91
 This is a novel genetic cause of FIPA, although it can also 
present as sporadic disease in patients with nonsyndromic gigantism. Only 18 cases of X-LAG 
have been described so far, five of them occurring in a familial setting and the rest presenting 
as sporadic patients, and only transmission from affected mother to an affected son has been 
observed, while all the unaffected carriers of the duplication are females; therefore, X-LAG is 
considered a genetic disease with X chromosome-linked dominant inheritance pattern.
489
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Genetics and pathophysiology 
The microduplicated regions of Xq26.3 in X-LAG patients encompass the genes CD40LG, 
ARHGEF6, RBMX and GPR101. CD40LG is not expressed in pituitary tumours and ARHGEF6 
and RBMX were found expressed, but not upregulated, while the expression of GPR101 was 
increased by a factor as high as 1000 in the pituitary tumours of individuals with Xq26.3 
microduplications, compared with normal pituitary and tumours from patients who tested 
negative for microduplications. In concordance, protein expression was increased in patients 
with Xq26.3 microduplications.
91
  
 
In addition to the X-LAG cases, none out of 248 sporadic acromegaly patients tested carried 
microduplications at Xq26.13, but 11 of them carried the GPR101 variant c.924G>C 
(p.E308D).
91
 The minor allele frequency (MAF) of this variant is 0.004 according to the Exome 
Aggregation Consortium (ExAC) database,
217
 but MAF is not reported in the 1000 Genomes
218
 
or National Heart, Lung, and Blood Institute Exome Variant Server (NHLBI EVS) databases;
216
 
this variant is a benign change according to in silico predictions. In three cases the variant was 
present in the germline, one of those patients presented also a somatic mutation, and three 
more patients had somatic mutations only.
91
 One more acromegaly patient carrying this variant 
in the germline has recently been reported, for a global frequency of germline and somatic 
mutations of 2.3% (12/511), and one more GPR101 variant, c.1098C>A (p.D366E, MAF not 
reported in 1000 Genomes, ExAC or NHLBI EVS databases), was reported in another sporadic 
acromegaly patient (among 263 tested).
490
 In GH3 cells, overexpression of the p.E308D variant 
significantly increased cell proliferation and GH secretion compared to the WT protein, 
supporting a possible pathogenic role.
91
 
 
GPR101 is composed of one exon, encoding a 508 amino acids and 56.7 kDa GPCR. GPR101 
is a distant relative of the biogenic amine superfamily of GPCRs, expressed mainly in the 
caudate putamen and hypothalamus in the human, and in the hypothalamus, nucleus 
accumbens, amygdala and hippocampus in the mouse, although it was also found in other 
central nervous system structures.
491;492
 Both murine and human GPR101 are coupled to Gs 
proteins, though they remain as orphan receptors.
492
  
 
Notwithstanding the fact that the normal ligand of GPR101 is unknown, overexpression of the 
WT protein and of the two mutants detected in sporadic acromegaly patients resulted in 
increased cAMP signalling in GH3 cells, in the presence and absence of forskolin (an AC 
stimulator),
91
 suggesting that the activation of this receptor in somatotroph cells could have 
similar effects to those of the GHRH receptor (GHRHR) on cell proliferation and GH secretion. 
The histopathological analysis of lesions from X-LAG patients reports mammosomatotroph 
adenomas, with a minority of the cases bearing mammosomatotroph hyperplasia.
91;489
 The IHC 
analysis for the somatostatin receptors (SSTRs) 2, 3, and 5 and AIP is normal and there is 
increased expression of GPR101 and of GHRHR, but no GHRH.
91;489
  
 
73 
 
Clinical features 
Gigantism in X-LAG patients characteristically develops in early childhood, in contrast with other 
forms of nonsyndromic gigantism, where disease onset occurs in adolescence.
91
 Most of X-LAG 
patients are females, in contrast with other forms of pituitary gigantism, where males 
predominate.
489
 Most of these patients have normal height and weight at birth (except one case, 
with length over the 97
th
 percentile at birth), but there is an abrupt acceleration of both 
parameters typically by the first year of life, though it can occur as early as two months of age, 
an always before the age of five years.
91;489
 Many of the X-LAG patients described so far 
developed not only tall stature, but marked acral growth and facial coarsening with 
hypertelorism, as well as other features that resemble those of adult acromegaly patients, 
including interdental separation, hyperhidrosis, skin thickening, sleep apnoea, acanthosis 
nigricans and hyperinsulinaemia. Interestingly, some of these patients develop increased 
appetite, which has not been associated to other forms of gigantism.
489
 In addition to very 
marked hypersomatotropism, these patients display PRL co-secretion and normal or slightly 
elevated GHRH.
91;489
 None of the patients has achieved disease control under treatment with 
SSA and the hyperprolactinaemia has not been controlled with DA; in most of the cases either 
radical surgery or multimodal therapy was necessary.
489
 
 
AIP MUTATION-ASSOCIATED FIPA 
Definition and general description 
AIPmut-associated FIPA is an autosomal dominant disease, with incomplete and highly variable 
penetrance.
8;480;481
 Since the late 1990s, linkage analysis and LOH studies implicated the 11q13 
region in the pathogenesis of FIPA.
479;493-496
 After the study of more families, the implicated 
locus was first narrowed down to 11q13.1-13.3,
479;483
 and later to 11q13.2-13.3,
496
 just next to 
MEN1, but not involving that gene. In 2006, linkage analysis identified a truncating germline 
AIPmut as the cause of several cases of pituitary adenomas (somatotropinomas and 
prolactinomas) in one large Finnish family.
8
 Further studies identified many other novel AIPmuts 
in individuals from FIPA families with gigantism, acromegaly and prolactinomas, and also in 
patients with apparently sporadic pituitary adenomas.
8-11;484
 To date, AIPmut-associated FIPA 
and X-LAG are the two only known genetic causes of FIPA, and also the two only known 
causes of hereditary pituitary gigantism, defined as the occurrence of two or more cases of 
gigantism due to pituitary adenoma or hyperplasia in the same family. 
 
Germline AIPmuts have been identified in around 15-20% of the FIPA cases, with a higher 
prevalence among families with only cases of somatotropinomas, were mutations are found in 
36-50% of the cases.
8;9;11;276;482;484
 Initial studies failed to detect AIPmuts in apparently sporadic 
pituitary adenomas in the general population,
279;497
 but it is currently recognised that, apart from 
FIPA, AIPmuts can also be found in other subsets of patients, including a small percentage (3-
3.6%) of the sporadic pituitary adenomas in the general population,
6;7;12;13;13;276;498
 in SSA-
resistant acromegaly (8%)
14
 and very rare cases of PHPT (two cases described so far).
499
 
Nevertheless, the most prominent pathogenic association of AIPmuts involves pituitary 
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adenomas occurring in young (≤30 years old) people (11.7% of all the patients
498
 and 11.7% of 
those with macroadenomas),
7
 particularly in cases occurring in the paediatric population (20.5% 
of the paediatric patients with functional pituitary adenomas)
7
 and in around half of the cases of 
gigantism.
482;500
 Since the identification of AIP as a FIPA causative gene, 95 pathogenic or likely 
pathogenic mutations have been described among pituitary adenoma patients with familial and 
sporadic presentation (considering unpublished data from our group, part of it included in this 
thesis). Somatic AIPmuts have never been detected. 
 
The pattern of inheritance in AIPmut positive FIPA is autosomal dominant, but the penetrance is 
low and variable, calculated in around 15-33%, which is highly variable among families, as the 
number of affected individuals per family fluctuates between two and eleven.
8;480;482;485
 The 
reason for the variable penetrance is unknown, but it is probable that other loci, not yet 
identified, could contribute to disease presentation.
487
 Due to this incomplete penetrance, the 
phenotype can be absent in one or more generations, and reappear in subsequent generations 
of the same kindred.
501
 
 
Genetics and pathophysiology 
Located in the chromosomal region 11q13.2, just 2.6Mb downstream from MEN1, the AIP gene 
(GenBank: NG_008969.1,
502
 Locus Reference Genomic: LRG_460)
503
 spans six exons, 
encoding a protein of 37 kDa and 330 amino acids, highly conserved among species.
8;10;15
 The 
best known function of AIP is to serve as a co-chaperone of the heat shock protein HSP90, 
forming part of the protein complex that regulates the function of the aryl hydrocarbon receptor 
(AHR).
504
  
 
AIPmuts in pituitary adenoma patients include deletions, insertions, segmental duplications, 
nonsense, missense, splice-site and promoter mutations, as well as large deletions of whole 
exons or the entire gene.
276
 Loss of the C-terminal end of AIP occurs in the majority of the 
mutants, due to stop codons or frameshifts resulting in stop codons. Only one de novo mutation 
has been described, in a single patient.
6
 There are three mutational hot spots in AIP, 
corresponding to C-phosphate-G (CpG) islands: mutation of both members of the c.910-911 
CpG site has been described (c.910C>T [p.R304*] and c.911G>A [p.R304Q]), c.811C>T 
(p.R271W) and c.241C>T (p.R81*).
505
 The missense variants and the in-frame segmental 
duplication mostly affect the tetratricopeptide repeat (TPR) domain or the C-terminal α-helix. 
Approximately 10% of the families that are negative for AIPmuts by conventional methods carry 
large AIP deletions, which are only detectable by MLPA.
276
 A founder effect for certain AIPmuts 
has been described in different populations: Northern Irish (c.910C>G [p.R304*]),
506
 Finnish 
(c.40C>T [p.Q14*]),
8
 Italian (c.910C>G [p.R304*]),
507
 English (c.805-825dup 
[p.F269_H275dup])
508
 and Comoros islander (p.G117Afs*39).
498
  
 
The molecular mechanism explaining the link between AIPmuts and pituitary adenomas 
remains elusive, but a regulatory effect over the cAMP pathway that could affect cell 
75 
 
proliferation and GH secretion in somatotroph cells has been proposed.
509
 More details about 
the normal functions of AIP and its implication in pituitary tumorigenesis are provided in the 
section “Aryl hydrocarbon receptor interacting protein: association to pituitary tumorigenesis”. 
 
Clinical features 
AIPmut positive patients constitute a well defined group among pituitary adenoma cases. 
AIPmut positive FIPA families have more affected individuals (3.2±1.8) than families with no 
AIPmuts (22±0.4).
10
 AIPmut positive tumours are almost always macroadenomas, 
predominantly somatotropinomas, more than a half of them with PRL co-secretion, with disease 
onset during adolescence or young adulthood.
11;485
 In more than a half of the patients, tumours 
are aggressive.
328
 Pituitary adenomas in AIPmut positive patients show a considerably reduced 
response to the treatment with SSA and DA, regarding tumour size and hormone secretion, 
usually requiring multimodal therapy.
7
  
 
The presence of gigantism in one third of AIPmut positive patients with somatotropinomas is 
noteworthy, given the extreme rarity of this condition among sporadic patients.
11
 The frequency 
of gigantism, a disease which is more prevalent in males, could explain the predominance of 
males among AIPmut positive patients in different series.
11
 Also, initial series proposed the 
occurrence of genetic anticipation among AIPmut FIPA families, but the observed earlier 
diagnosis in consequent generations is more likely to be due to patient education regarding the 
symptoms in other family members.
11;276
 
 
Aryl hydrocarbon receptor interacting protein: association to pituitary 
tumorigenesis 
Expression and structure 
The reference AIP mRNA (NM_003977.3)
502
 encodes the isoform 1 of AIP, which is the only 
known translated form of the protein (UniProt: O00170).
510
 The Ensembl database reports three 
predicted alternative transcripts for this gene, two of them predicted to encode proteins
511
 (these 
two also reported in GenBank);
502
 however, the biological relevance of these alternative 
transcripts or their encoded proteins, if they exist, has not been demonstrated as yet. Putative 
phosphorylation sites for AIP have been determined by site-directed mutagenesis and two-
dimensional phosphopeptide mapping analysis in serine residues 43, 53, 131, 132, and 329, but 
loss of any or all of these residues does not significantly affect the ability of AIP to bind AHR 
and to retain it in the cytoplasm, although S53 could be necessary for the nuclear translocation 
of AIP.
512
 Many other putative phosphorylation sites have been reported by mass spectrometry 
(MS) studies, but they have not been experimentally tested.
513
 No other posttranslational 
modifications for this protein are known. The structure and domains of AIP are shown in Figure 
2.  
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Figure 2. Prediction of the tridimensional structure of AIP (two views). Main motifs in the molecule are displayed in 
colours, according to UniProt annotation at 05/05/15: PPIase domain (orange, amino acids 31-121), TPR1 (blue, 179-
212), TPR2 (purple, 231-264), TPR3 (green, 265-298) and C-terminal α-7 helix (red, 300-330).
510
 the image was created 
using the PyMol software (DeLano Scientific LLC), using a prediction generated by the Phyre2 platform
514
 on 04/02/13, 
based on the data available at the RCSB Protein Data Bank (entries: 4AWO, 4B7P, 4AWQ, 4AWP, 1Q18, 2LKN, 4AIF, 
4APO).
515
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Also known as X-associated protein 2 (XAP2),
516
 AHR-activated 9 protein (ARA9)
517
 and 
FK506-binding protein 37.7 (FKBP37.7),
518
 AIP was first described in 1996 as an inhibitor of 
hepatitis B virus X protein-mediated transactivation.
516
 AIP is ubiquitously expressed in human 
and murine tissues, most abundantly in the cardiovascular system, brain, cerebellum, 
diaphragm, kidney, tongue and testis, though it is poorly expressed in the human liver.
516;519
 The 
AIP gene is evolutionarily conserved among species, with orthologues in a variety of organisms, 
from primates (100% of protein identity for G.g.gorilla and P. troglodytes), and rodents (R. 
norvegicus: 94%, M. musculus: 95%) to lower organisms such as D. rerio (66%), D. 
melanogaster (35%) and C. elegans (35%).
511
 AIP expression is predominantly cytoplasmic,
520
 
and there is nuclear expression to a lesser extent.
521
 Sequence homology predicts two different 
domains in AIP: an N-terminal FK506-binding protein (FKBP) or peptidylprolyl cis-trans 
isomerase (PPIase)-like domain and a C-terminal TPR domain, composed of three TPR motifs 
and a final α-helix.
520;522;523
  
 
FKBPs, proteins that bind the fungi-derived immunosuppressant drugs tacrolimus and 
rapamycin, together with cyclophilins, cyclosporine-A binding proteins, are the two largest 
families composing the immunophilin superfamily, with at least 16 paralogs in humans.
524
 
Immunophilins are highly conserved chaperones that can also display PPIase activity, but their 
chaperone function can occur independently of the PPIase effect.
525
 Some immunophilins 
contain a single PPIase domain and others are multidomain proteins with one or more PPIase 
domains in addition to other functional domains. In S. cerevisiae, the deletion of 12 
immunophilins individually or as a group has no effect on physiological parameters (viability at 
various temperatures, arrest and recovery from α-factor pheromones or glycogen, mating, 
sporulation) under basal conditions, but these proteins are required for specific signalling 
events, as for example, growth under starvation-induced stress.
525
 Immunophilins play important 
roles as regulators of protein kinases, protein folding and retrotransport into the ER, among 
others.
525
 Some members of the FBKP family contain a TPR through which they interact with 
HSP90.
526
  
 
Frequently referred as “scaffold proteins”, due to their function as interaction modules and 
multiprotein complex mediators, TPR-containing proteins are abundant in the proteome and 
regulate several biological processes, such as organelle targeting, protein import and vesicle 
fusion.
527
 The TPR motif consists of 3-16 tandem-repeats of 34 amino acids adopting a helix-
turn-helix arrangement, with adjacent TPR motifs packed in parallel, resulting in a unique super-
helix tridimensional structure formed by repeating anti-parallel α-helices.
528
 The degenerate 
consensus sequence of TPRs has no fully invariant positions, but follows a pattern of small and 
large hydrophobic amino acids. Residue type is highly conserved only at positions 8 (A or G), 
20 (A), and 27 (A), while positions 4, 7, 11, and 24 have a preference for large hydrophobic 
amino acids.
527
 Positions with a strong preference for small amino acids are located in places 
where the helices are in close contact, and in fact there is a consistent pairing between large 
and small amino acids, which pack together in a complementary fashion.
527;528
 Therefore, non-
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conservative mutations in these positions are not tolerated and often result in LOF of the 
protein.
528
 The exterior of the super-helix displays amino acid variety and some degree of 
elasticity and has a concave and a convex surface; ligand binding usually occurs via 
hydrophobic pockets on the concave surface.
527
  
 
In the case of TPR-containing co-chaperones, the hydrophobic pockets on the TPR domain that 
bind the methionine and the valine in the MEEVD conserved sequence of the TPR domain of 
HSP90 can be classified depending on their relative position. When both pockets are on the 
same side of the TPR binding surface, as it is the case for the co-chaperone STI1 (also known 
as HOP), the proteins follow a cis-mode of binding (STI1-type). When they are on different 
sides, as it happens for the co-chaperones AIP and CHIP, there is a trans-mode of binding.
523
  
 
The secondary structure of the FKBP domain of AIP (including amino acids 2 to 166), resolved 
by nuclear magnetic resonance (NMR) spectroscopy, resembles a typical FKBP domain with 
five antiparallel β-strands forming a half β-barrel wrapped around a central α-helix.
518;529
 
However, the FKBP domain of AIP has no inherent FK506 binding or PPIase activity, and 
displays two unusual structural elements: an N-terminal α-helix, which additionally stabilises the 
domain, and a long insert connecting the last two β-strands and covering the putative active 
site.
518
 The TPR domain of AIP appears to be similar to those of STI1, CHIP, CYP40, PP5, 
FKBP51, FKBP52 and the aryl hydrocarbon receptor-interacting protein like 1 (AIPL1). The 
crystal structure of this domain shows that residues lining the TPR-binding site are highly 
conserved, and their spatial organisation shows a CHIP-type interaction with HSP90.
523
 
 
Normal function and protein-protein interactions 
There is strong data in the literature to support direct interaction of AIP with two viral proteins, 
Epstein-Barr virus (EBV)-encoded nuclear protein 3 (EBNA3)
530
 and hepatitis B virus X 
protein,
516
 and with a variety of human proteins, such as AHR,
520;531
 HSP90,
520
 
phosphodiesterases 4A (PDE4A)
532
 and 2A (PDE2A),
533
 heat shock cognate 70 (HSPA8, also 
known as HSC70),
534
 baculoviral IAP repeat-containing protein 5 (apoptosis inhibitor survivin, 
BIRC5),
535
 peroxisome proliferator-activated receptor alpha (PPARA),
536
 thyroid hormone 
receptor beta (THRB),
537
 oestrogen receptor (ESR1),
538
 mitochondrial import receptor subunit 
TOM20 homolog (TOMM20),
534
 rearranged during transfection tyrosine-kinase receptor 
(RET)
539
 and guanine nucleotide-binding protein subunit alpha 13 (GNA13);
540
 the most studied 
associations are with AHR and HSP90. Other interacting partners are also reported in the 
BIOGRID database of protein-protein interactions, as part of datasets generated by high 
throughput proteomics studies, with lower levels of evidence to support the interactions, and 
they are not necessarily validated by other methods.
541
 All the known AIP interactions with 
human proteins are summarised in Table 4.  
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Table 4: Proven and putative interacting partners of AIP (human proteins only) 
UniProt 
entry
510
 
Protein name (gene) 
Reported in 
BIOGRID
541
 
Experimental 
method 
References 
P60709  Actin, cytoplasmic 1 (ACTB)* No AC-MS 
542
 
Q9UL18 Argonaute RISC catalytic component 1 (AGO1) Yes 
AC-MS 
543
 
Co-IP 
P35869 Aryl hydrocarbon receptor (AHR) Yes 
Co-IP 
520;544
 
RC 
517;520;522
 
2H 
517;520;545
 
P27540 
Aryl hydrocarbon receptor nuclear translocator 
(ARNT)† 
Yes 
Co-IP 
542
 
RC 
517;546
 
2H 
522
 
O15392 Baculoviral IAP repeat-containing protein 5 (BIRC5) Yes Co-IP 
539
 
Q96HB5 Coiled-coil domain containing protein 120 (CCDC120) Yes AC-MS 
547
 
Q16543 Hsp90 co-chaperone cell division cycle 37 (CDC37) 
Yes AC-L 
548
 
Yes AC-MS 
P50750 Cyclin-dependent kinase 9 (CDK9) Yes AC-MS 
547;549
 
Q9BXN2 C-type lectin domain family 7, member A (CLEC7A) Yes 2H 
550
 
P68400 Casein kinase 2, alpha 1 polypeptide (CSNK2A1) Yes BA 
551
 
Q9NVR5 Protein kintoun (DNAAF2) Yes 
AC-L 
548
 
AC-MS 
P00533 Epidermal growth factor receptor (EGFR) Yes PCA 
552
 
P03372 Oestrogen receptor (ESR1) No Co-IP 
538
 
P41091 
Eukaryotic translation initiation factor 2 subunit 3 
(EIF2G) 
Yes Co-F 
553
 
P50395 Rab GDP dissociation inhibitor beta (GDIB) Yes Co-F 
554
 
Q14344 
Guanine nucleotide-binding protein subunit alpha 13 
(GNA13) 
Yes 
RC 
540
 
2H 
P50148 
Guanine nucleotide-binding protein G(q) subunit alpha 
(GNAQ) 
Yes RC 
540
 
P11142 Heat shock cognate 71 kDa protein (HSPA8)‡ No Co-IP 
534
 
P07900 Heat shock protein HSP 90-alpha (HSP90AA1) Yes 
AC-L 
548
 
AC-MS 
Co-IP 
522;534;555-559
¶ 
RC 
523;560
 
P08238 Heat shock protein HSP 90-beta (HSP90AB1) Yes 
AC-L 
548
 
AC-MS 
P38646 Stress-70 protein, mitochondrial (HSPA9) Yes Co-F 
553
 
Q9Y6K9 NF-kappa-B essential modulator (IKBKG) Yes 2H 
561
 
Q92985 Interferon regulatory factor 7 (IRF7) Yes 
AC-MS 
562
 
RC 
P11279  
Lysosome-associated membrane glycoprotein 1 
(LAMP1) 
Yes Co-F 
553
 
Q6IA69 Glutamine-dependent NAD(+) synthetase (NADSYN1) Yes 
AC-L 
548
 
AC-MS 
P08235 Mineralocorticoid receptor (NR3C2) Yes Co-IP 
559
 
P27815 
cAMP-specific 3',5'-cyclic phosphodiesterase 4A 
(PDE4A) 
No 
2H 
9;532
 
Co-IP 
532
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UniProt 
entry
510
 
Protein name (gene) 
Reported in 
BIOGRID
541
 
Experimental 
method 
References 
O00408 
cGMP-dependent 3',5'-cyclic phosphodiesterase 2A 
(PDE2A) 
No 
2H 
533
 Co-IP 
Co-loc 
Q07869  
Peroxisome proliferator-activated receptor alpha 
(PPARA) 
Yes 
Co-IP 
536
 
RC 
O75170 
Serine/threonine-protein phosphatase 6 regulatory 
subunit 2 (PPP6R2) 
Yes PL-MS 
563
 
Q15185 Prostaglandin E synthase 3 (PTGES3) Yes 
AC-L 
548
 
AC-MS 
Co-IP 
559
 
P07949 
Rearranged during transfection tyrosine-kinase 
receptor (RET) 
Yes 
Co-IP 
539
 
PCA 
P31948 Stress-induced phosphoprotein 1 (STIP1) Yes RC 
560
 
Q9Y2Z0 Suppressor of G2 allele of SKP1 homolog (SUGT1) Yes 
AC-L 
548
 
AC-MS 
Q59H18 TNNI3 interacting kinase (TNNI3K) Yes 2H 
564
 
Q15388 
Mitochondrial import receptor subunit TOM20 homolog 
(TOMM20) 
No RC 
523;534
 
P10828 Thyroid hormone receptor beta (THRB) No 2H 
537
 
P0CG48 Polyubiquitin C (UBC) Yes AC-MS 
565-569
 
O94966 Ubiquitin specific peptidase 19 (USP19) Yes 
AC-L 
548
 
AC-MS 
2H: two-hybrid assay, AC-MS: affinity capture (pull-down)-mass spectrometry, AC-WB: affinity capture-Western blot 
(co-immunoprecipitation), BA: biochemical activity (an interaction is inferred from the biochemical effect of one 
protein upon another), co-F: co-fractionation, co-IP: co-immunoprecipitation, co-loc: co-localisation, PCA: protein-
fragment complementation assay, PL-MS: proximity label-mass spectrometry, RC: reconstituted complex (an 
interaction is detected between two proteins in vitro). Detailed explanation of all the experimental methods: 
http://wiki.thebiogrid.org/doku.php/experimental_systems 
* Contradictive results, a direct interaction between AIP and ACTB was disproven by a different study.
570
 
†Contradictive results, a direct interaction between AIP and ARNT was disproven by different studies.
517;520;555
 
‡ A positive but reduced binding between AIP and HSPA8, compared to CHIP, was found in a different study.
559
 
¶ Some of these experiments did not specify the HSP90 isoform used. HSP90AB1 was assumed, as this is the 
major form of the protein. 
 
The best known function of the AHR is to act as a transcription factor mediating the toxic effects 
(immune, hepatic, cardiac, dermal, teratogenic, endocrine and carcinogenic) of the 
environmental toxin 2, 3, 7, 8-tetrachloro-p-dioxin (TCDD, dioxin).
571;572
 Endogenous AHR 
ligands have also been described, such as indigo, indirubin, equilenin, 2-(1´H-indole-3´-
carbonyl)-thiazole-4-carboxylic acid methyl ester, lipoxin 4A, prostaglandin G2, tryptamine, 
indole acetic acid, 6-formylindolo-carbazole,
90
 bilirubin
573
 and kynurenine.
574
 The physiological 
role of AHR is, apparently, ligand, tissue and species-specific and comprises a wide variety of 
effects, such as regulation of the activity of nuclear receptors, transcription factors and protein 
kinases, modulation of cell cycle, cell adhesion and migration as well as alteration of multiple 
intracellular signalling pathways.
572
 AHR-dependent transcription is regulated by interactions 
with multiple partners, thus AHR integrates signals from diverse ligands and molecular 
pathways.
575
 Although there are some earlier controversial data, more recent studies suggest 
that human AIP (opposed to the murine protein) enhances the rate of nuclear translocation, but 
inhibits the transcriptional effects of AHR.
531;576
 Some data indicate that AIP modulates AHR 
81 
 
levels;
521
 this effect is also apparently tissue-specific
15;577
 and potentially relevant for pituitary 
tumorigenesis.  
 
Ligand-free AHR is localised in the cytoplasm, attached to a heterotetramer composed of a 
dimer of the chaperone HSP90
504;578
 and one unit of each of the co-chaperone proteins 
translationally-controlled tumour protein (TCTP, also known as p23)
579
 and AIP.
517;520;531
 AIP 
binds to both HSP90 and AHR, but HSP90 is required to model AHR to a ligand-binding 
configuration.
556
 The co-chaperone TCTP binds to HSP90, stabilising the complex and 
favouring its nuclear import.
580
 After binding dioxin or other exogenous or endogenous ligands, 
AHR undergoes a conformational change, allowing the nuclear translocation of the protein 
complex.
571
 Interestingly, the human AIP protein translocates to the nucleus together with the 
rest of the complex, while the murine protein remains in the cytoplasm.
576
 In the nucleus, the 
aryl hydrocarbon receptor nuclear translocator (ARNT, also known as HIF1β) binds to ligand-
bound AHR,
571
 dissociating it from the rest of the complex. Thus, the ligand:AHR:ARNT 
complex is able to bind a dioxin-responsive element (also known as xenobiotic or AH-
responsive element), leading to the activation of AHR-responsive genes.
572;581
 AIP interacts with 
AHR through its TPR domain,
521;522
 but the PPIase domain is required for the stability of the 
AHR:HSP90:AIP complex.
546
  
 
HSP90, a highly conserved, essential and very abundant protein (it accounts for 1-2% of 
cytosolic proteins) is a molecular chaperone that interacts with multiple client proteins, including 
transcription factors, protein kinases and enzymes, therefore regulating a wide variety of cellular 
pathways.
526;560
 HSP90 also facilitates, in concert with other chaperones, the folding and 
proteolytic stability of its client proteins, but it can also promote their degradation.
526
 HSP90 
forms complexes with different co-chaperones in a cyclical way: first STI1 binds and inhibits the 
adenosine triphosphatase (ATPase) activity of HSP90, but then STI1 is released and replaced 
by a PPIase and TCTP, in an ATP-dependent reaction.
560
 Interestingly, AIP displays binding 
sites for HSP90 not only at the TPR but also at the PPIase domain, 
518
 but it does not affect the 
ATPase activity of HSP90.
523
 The stoichiometry of the interaction between AIP and HSP90 is 
0.5:1, meaning that one molecule of AIP binds two HSP90 molecules.
523
 
 
Only 13 out of 100-150 different mitochondrial proteins are encoded by mtDNA; therefore, 
mitochondrial proteins synthesised in the cytosol require to be imported into these organelles. 
This process occurs through four different protein systems: presequence translocase-
associated motor, sorting and assembly machinery of the outer membrane, translocase of the 
inner membrane and translocase of the outer membrane.
582
 AIP forms a complex with 
mitochondrial pre-proteins and TOMM20, a member of the translocase of the outer membrane 
system, exerting a chaperone-like activity to supress the aggregation of the substrate 
proteins.
534
 The interaction between TOMM20 and AIP involves the C-terminal EDDVE 
sequence of TOMM20 and the TPR domain of AIP.
523;534
 One of the proteins translocated into 
the mitochondria by the AIP/TOMM20 complex is BIRC5, an anti-apoptotic protein.
534;535;583
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AIP also binds HSPA8, and, according to the proposed model, mitochondrial pre-proteins bound 
to AIP and HSPA8 would be maintained in an unfolded state, until transferred (bound to AIP) 
from HSPA8 to TOMM20, enabling their folding and mitochondrial translocation.
534
 HSPA8 is an 
abundant cytosolic protein with intrinsic ATPase activity, which is part of the HSP70 family of 
molecular chaperones.
584
 The cellular functions of HSPA8 (regulated by multiple co-
chaperones) include the regulation of the dynamics of clathrin-coated vesicles and of the cell 
cycle (through regulation of cyclin D1), as well as protein homeostasis (maturation, folding, 
assembly, degradation) and translocation.
584;585
 The C-terminal IEEVD sequence of HSPA8 is 
assumed to mediate the interaction between this protein and the TPR domain of AIP.
523
 
 
Cyclic nucleotide phosphodiesterases (PDEs) regulate cell signalling by hydrolysing the 
intracellular second messengers cAMP and cyclic guanosine monophosphate (cGMP). PDE4A 
is a member of the PDE4 subfamily of phosphodiesterases, with cAMP-specific hydrolytic 
activity.
586
 AIP directly binds and reversibly inhibits the enzymatic activity of PDE4A5 (the rat 
isoform of the human PDE4A) attenuating the ability of PKA to phosphorylate this protein.
532
 
This interaction involves the C-terminal α-helix of AIP, and probably the N-terminal region of 
PDE4A5.
523;532
 Dysfunction of the cAMP molecular pathway is relevant for somatotroph function 
and loss of the AIP-PDE4A interaction has been demonstrated in vitro for different pathogenic 
missense and nonsense AIPmuts.
9;10
 In addition, a member of the PDE2 subfamily, PDE2A 
(also known as PDE2A3), which is activated by cGMP but hydrolyses both cAMP and cGMP, 
interacts with the TPR domain of AIP through its GAF-B domain (involved also in cGMP 
binding).
533;586
 This interaction inhibits dioxin and cAMP-induced nuclear translocation of AHR, 
attenuating the AHR-dependent gene transcription.
533
 
 
It has also been proposed that AIP could self-associate to form multimers, which could serve as 
a cytoplasmic reservoir of the protein.
587
 However, the stoichiometric analysis of the 
AHR:HSP90:AIP complex has shown a ratio of 1:2:1,
504;578
 and for the HSP90:AIP complex the 
ratio is 2:1.
523
 Therefore, AIP self-association, if existent, is probably not relevant for the 
biological functions of the protein.  
 
AIP functions in the pituitary gland 
In the normal pituitary, AIP is predominantly expressed in somatotroph and lactotroph cells,
9;481
 
where it associates with GH and PRL-containing vesicles.
9
 AIP has been detected in 
corticotropinomas and it is especially abundant in NFPAs, while it is absent in normal 
corticotroph and gonadotroph cells. In addition, in these adenomas AIP is not localised in the 
secretory vesicles but it is found free in the cytoplasm.
9
  
 
A possible function of AIP as a regulator of the cAMP pathway has recently been proposed. 
Under physiological conditions, binding of GHRH to its receptor, activates a stimulatory G 
protein (Gs)-mediated signalling pathway, with cAMP as a central second messenger. The 
cAMP pathway regulates both GH secretion and the proliferation of somatotroph cells, and the 
83 
 
most important regulator of this pathway in the somatotroph cells is the inhibitory G protein (Gi)-
mediated SS signalling pathway. The inhibition of hormone secretion and cell proliferation by 
the SS pathway is the basis of the use of SSA as antitumorigenic drugs in pituitary adenomas 
and other endocrine tumours.   
 
The current notion about AIP function in the pituitary gland is that it exerts an inhibitory effect 
over the cAMP pathway. In GH3 cells (rat somatotropinoma-derived), Aip overexpression 
reduces the cAMP response to forskolin (a drug that produces cAMP accumulation) measured 
by cAMP assay and mRNA expression of downstream members of the pathway, resulting in GH 
secretion. Inversely, also in the presence of forskolin, Aip knockdown (KD) activates the cAMP 
pathway, but this effect is not coupled to increased GH secretion.
588
 it is important to remark 
that these effects are significant under forskolin stimulation, but not in the basal conditions.  
 
In the pituitary gland of a heterozygous Aip KO murine model, AIP deficiency leads to down-
regulation of genes involved in the Gi signalling pathway (mediated by Gα i2 and Gαi3), and as a 
consequence, to cAMP accumulation.
509
 However, Gi impairment is not exactly equal to Gs 
constitutive activity (e.g. the effect of the gsp oncogene), as the regulation of the cAMP pathway 
is complex, involving multiple steps and regulatory proteins. This could explain why the 
accumulation of cAMP does not cause an increased phosphorylation of the mitogen-activated 
protein kinases (MAPKs) 3 and 1 (also known as ERK1 and 2, respectively) and cAMP-
response element binding protein (CREB), cAMP-responsive effectors of the cAMP pathway, in 
AIPmut positive somatotropinomas.
509
  
 
AIP expression in somatotropinoma tissue is a positive predictor of responsiveness to the 
treatment with SSA in sporadic acromegaly patients,
16
 and aggressive somatotropinomas 
display reduced AIP expression.
17;96;481
 In concordance, AIP is upregulated in sporadic 
somatotropinomas with preoperative SSA treatment, compared to patients with no pre-
treatment, and a similar effect has been found in GH3 cells treated with SSA.
589
 The stimulatory 
effect of SSA over AIP expression is independent of the GNAS1 status of the tumour, indicating 
that this response is independent of the activation status of the cAMP pathway,
17
 and it is also 
independent of the expression of the SSTR2, the main receptor for the clinically used SSA 
octreotide and lanreotide.
16
 Nonetheless, AIP immunostaining in pituitary adenomas is not 
predictive of AIPmuts.
590
  
 
The antiproliferative/antisecretory response to SSTR activation is carried out through multiple 
mechanisms; the most prominent ones regarding the somatotroph cell function are: AC 
inhibition, calcium channel inhibition and dephosphorylation of the cAMP effectors MAPK3/1 by 
phosphotyrosine phosphatases.
591
 In addition, in an apparently independent mechanism of 
post-receptor response to SS, AIP overexpression upregulates ZAC1, an anti-proliferative target 
of SS, while AIP KD has an inverse effect.
592
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SSTRs are GPCRs, coupled to different types of G proteins: Gαi1-3, Gαo, Gαq and Gα12. The 
repertoire of G proteins binding each SSTR type seems to be tissue and function-specific. For 
example, Gαo is the specific subunit necessary for the SSTR5 inhibitory effect on GH secretion 
and MAPK3/1 phosphorylation.
593
 The Gαi proteins involved in the somatotroph-specific function 
of SSTR2 have not been described, although Gαi1-3 expression has been demonstrated in all 
types of pituitary adenomas, where they are very infrequently mutated.
509;594
 The SSTR type 
mediating the AIP response in pituitary adenomas remains elusive. The proposed mechanisms 
for the AIP tumour suppressor activity in the somatotroph cells are summarised in Figure 3. 
 
 
 
Figure 3. Summary of the proposed functions of AIP in the somatotroph cell. In response to GHRH, the GHRHR 
activates the cAMP pathway (via PKA) to increase GH expression and secretion and cell proliferation. In contrast, 
binding of SS to its receptors (mainly SSTR2 and 5) elicits multiple signalling cascades to control cell proliferation and 
GH expression and secretion. These effects are predominantly mediated by stimulatory G proteins in the case of 
GHRHR and by inhibitory G proteins for the SSTRs. AIP expression increases in response to SSTR activation, causing 
a rise in ZAC1 levels and therefore reduced cell proliferation and metabolism, although the signalling pathways involved 
in these responses remain elusive. AIP is also involved in controlling the expression and function of the inhibitory G 
protein subunits Gαi2 and Gαi3, but the mediators of these effects have not been elucidated as yet. Gαi2 and Gαi3 exert 
an inhibitory effect over AC, therefore inhibiting the cAMP pathway. The specific GPCR to which these subunits are 
associated in the somatotroph cells is unclear, although the SSTRs are good candidates. The AIP tumour suppressor 
activity could as well involve other signalling cascades, such as the AHR pathway, the HSP90 and HSP70 chaperone 
systems and the mitochondrial function, though this has not been studied in depth. The arrows indicate the direction of 
the signalling pathways, the stop ends indicate inactivation and the dashed lines indicate unknown signalling pathways; 
+, activation; *, molecular interaction with no functional consequence. See references in text. 
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Animal models of AIP deficiency 
The first attempt to produce an Aip KO mouse model led to the discovery that this gene is 
necessary for embryonic development, as Aip
-/- 
mice died in utero due to cardiovascular 
abnormalities (double-outlet right ventricle, ventricular septal defects and pericardial oedema) at 
the embryonic age of 10.5-14.5 days post coitum, while the Aip
+/-
 genotype led to no apparent 
phenotype.
595
 A hypomorphic murine model of Aip deficiency showed a phenotype similar to 
that of the Ahr KO mouse (patent ductus venosus), and the expression levels of Aip correlated 
with the frequency of the malformation, demonstrating that Aip is necessary for Ahr signalling 
during development.
596
 
 
A mouse model with a heterozygous partial deletion of Aip presented pituitary adenoma 
predisposition, developing tumours of the pars distalis since the age of six months, with full 
penetrance by the age of 15 months. As in the human condition, the great majority of these 
mice (88%) developed somatotropinomas or mammosomatotroph adenomas, and a small 
percentage of them had prolactinomas and corticotropinomas; AIP LOH was detected in the 
tissues.
597
 Some of the tumours were invasive, and in mice with GH-secreting adenomas, 
serum Igf-1 levels were elevated. The phenotype of this model differs from the human AIPmut-
associated tumours in two main aspects: in mice, the disease develops in adulthood, in contrast 
with the young-onset of the human tumours, and the penetrance is full later in life, while in 
humans the penetrance remains low.
482
   
 
Hemizygous KO (by partial deletion) of the AIP orthologue CG1847 in a D. melanogaster model 
is lethal, and the phenotype can be rescued by the human WT AIP coding deoxyribonucleic acid 
sequence (CDS), but not by the CDS containing mutations that are disease-causative in 
humans. These results confirm the high degree of conservation of AIP among species and its 
importance of embryonic development in different species. Furthermore, this model has been 
proposed as a functional assay to test the pathogenicity of AIPmuts.
598
  
 
AIP as a pituitary-specific tumour suppressor: questions to be solved 
The role of AIP as a tumour suppressor is supported by the association of multiple LOF 
mutations in this gene with the development of pituitary adenomas, as well as by the presence 
of LOH in 11q13 in pituitary adenomas from AIPmut positive FIPA patients.
9;10;479;496
 
Furthermore, AIP, like most of the tumour suppressor genes, is evolutionarily conserved among 
species,
15
 and its overexpression slows down cell proliferation in vitro,
9
 while AIP KD leads to 
increased cell proliferation.
599
 As occurs with other tumour suppressor genes, AIP plays a role in 
early development: AIP-null mice and fruit flies are not viable.
595;596;598
 
 
Considering that AIP is a tumour suppressor gene with ubiquitous expression, it would be 
expectable to find tumours in different organs in patients with germline AIPmuts. Nevertheless, 
besides pituitary adenomas and a couple of cases of parathyroid adenomas,
499
 no other tumour 
types have been consistently associated to germline AIPmuts. Even more, the screening of a 
86 
 
large series of samples from different types of endocrine and non-endocrine cancer (colorectal, 
breast and prostate), revealed that neither germline nor somatic AIPmuts are associated with 
these neoplasms.
600
 Somatic mutations have not been found in pituitary adenomas either.
9;279
 
Therefore, pituitary tumorigenesis driven by AIPmuts should be explained by a tumour 
suppressor function that is only biologically relevant for the pituitary gland, more specifically, for 
somatotroph cells, but not for other tissues. Overexpression of the mutant AIP p.R304* lacks 
the inhibitory effect of the WT protein over forskolin-stimulated cAMP response,
588
 but if the final 
effect of AIP LOF is upregulation of the cAMP pathway, development of tumours in other cAMP-
responsive tissues, as for example, the adrenal glands, would be expected in AIPmut carriers. 
Whether the AIP regulatory effect over the cAMP pathway is pituitary-specific, remains to be 
proven.  
 
The LOF of AIP can occur through different mechanisms, which are not mutually exclusive. 
Truncating mutations, with partial or total loss of the three TPR repeats and the final α-7 helix 
that constitute the TPR domain of the protein, are expected to lead to unstable or non-existent 
proteins, with lost of molecular interactions,
523
 but the occurrence of NMD is also possible. 
Experimental mutagenesis has proven that mutations affecting the C-terminal α-helix of AIP 
disrupt the interaction between AIP and some of its molecular partners, thus, the lack of function 
of this domain seems to be sufficient for pituitary adenoma predisposition.
523
 A large percentage 
of the patients with AIPmut-related pituitary adenomas bear mutations affecting the C-terminal 
α-7 helix of the protein, and the repertoire of molecular partners binding AIP at this level could 
determine both the mechanism for tumorigenesis as well the pituitary-specific pathogenicity of 
such mutations. Nevertheless, even in the presence of a non-functional protein, it is difficult to 
determine if the loss of a specific interaction could explain the tumorigenic mechanism of 
AIPmuts, as AIP interacts with a large number of independent proteins, including three different 
chaperone systems: HSP90, HSP70 and TOMM20.
523
 
 
AIPmuts, in combination with LOH in the tumour would theoretically lead to complete absence 
of AIP in the tissue, and in fact, in most of the AIPmut positive patients, AIP expression is 
reduced at the level of both mRNA and protein, correlating with invasiveness.
481
 However, 
several questions remain to be answered regarding the “second hit” in AIPmut-associated 
pituitary tumours. On the one hand, LOH is not a universal finding in these tissues,
9;10
 meaning 
that posttranscriptional mechanisms, as for example miR-34a,
235
 could also be implicated, as it 
has been described for MEN1.
316
 On the other hand, the extension of the LOH necessary to 
produce pituitary adenomas in these patients is not clear. In most of the cases the affected 
chromosomal region includes the loci for both AIP and MEN1,
601
 and the combined loss of these 
genes could be relevant for their tumour suppressor effects. For example, combined deletion of 
MEN1 and AIP is essential for the development of hibernomas, a rare type of brown fat 
tumour.
602
 Nevertheless, some AIPmut positive pituitary adenomas display loss of only the AIP 
locus.  
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The comprehensive study of the clinical features of large numbers of cases of AIPmut-
associated pituitary adenomas, in combination with studies assessing the normal molecular 
function of AIP in the pituitary in detail, and determining how AIPmuts can disrupt this function, 
should hopefully contribute to solve these questions. 
  
88 
 
Chapter 2: The clinical and genetic landscape of familial 
isolated and young-onset sporadic pituitary adenomas: 
prospective identification of clinical disease in AIP mutation 
positive family members 
 
Introduction 
FIPA is a heterogeneous condition, encompassing cases with unknown genetic cause and 
patients with mutations in the AIP gene, with distinctive clinical characteristics, as well as the 
patients with the novel entity X-LAG. The phenotype of AIPmut-associated pituitary adenomas 
has been described before,
9-11;484
 but a systematic follow-up of cases and families is lacking, 
due to the relative novelty of this pathogenic association,
8
 the variable disease 
penetrance
10;11;480;506
 and the rarity of this clinical entity. The association of AIPmuts with 
pituitary tumorigenesis is relatively recent,
8
 therefore there are no data available describing the 
clinical behaviour of this entity in the long term. The follow-up of AIPmut positive carriers has 
been described only in one FIPA family,
603
 demonstrating the usefulness of clinical screening for 
early diagnosis and opportune treatment, but this approach has never been applied in a larger 
population. 
 
Screening for AIPmuts is not part of the routine clinical investigations done in pituitary adenoma 
patients in most of the centres, and because most of the case series reported in the literature 
include small numbers of patients, it is unlikely that they have described the whole spectrum of 
the disease. This has also precluded the analysis of other important features, such as possible 
phenotype-genotype associations, the possible influence of disease-modifying genes, 
complications of pituitary adenomas, other associated clinical features, and causes of death in 
this population. Trying to fill gaps in the knowledge about the genetic and clinical features of this 
rare disease, a large cohort of FIPA and simplex (patients with germline mutation and no family 
history) AIPmut positive patients has been studied.  
 
Aims 
General 
- To confirm and extend the description of the genotype and phenotype of patients with 
AIPmut-related familial and simplex pituitary adenomas in a large cohort of pituitary 
adenoma patients, providing a comparison with AIPmut negative cases, and to perform 
a systematic follow-up of families to identify and characterise AIPmut positive carriers. 
 
Specific 
1. To investigate a possible genotype-phenotype association for the AIPmuts detected in 
the study population. 
89 
 
2. To describe and compare the following features between AIPmut positive and negative 
patients from a familial and a simplex cohort: 
a. Frequency of specific diagnoses. 
b. Age at disease onset and at diagnosis. 
c. Tumour size and invasiveness. 
d. IHC. 
e. Apoplexy of the pituitary adenoma. 
3. To calculate the penetrance of pituitary adenomas among members of AIPmut positive 
FIPA families. 
4. To identify differences in the clinical presentation between AIPmut positive and negative 
patients with GH-secreting tumours and in the subset of patients with gigantism. 
5. To investigate the role of two possible disease-modifying genes (GNAS1 and FGFR4) 
on the variable phenotype and penetrance of the disease. 
6. To analyse the results of the clinical screening and follow-up of AIPmut positive 
apparently unaffected individuals and to identify the characteristics of prospectively 
diagnosed AIPmut positive pituitary adenoma cases. 
 
Hypotheses 
1. In AIPmut positive patients, the type (truncating or non-truncating) or localisation (in the 
gene) of the mutation has an effect on the pituitary adenoma phenotype. 
2. AIPmut positive patients have a well-defined phenotype, while AIPmut negative patients 
are a heterogeneous group. 
3. Pituitary adenomas develop and are diagnosed earlier in life in AIPmut positive, 
compared to AIPmut negative patients. 
 
Methods 
Patients and carriers 
Our study population (1725 subjects) was recruited via the collaborative research network of the 
International FIPA Consortium.
604
 Between January 2007 and January 2014, we recruited 
patients from 35 countries from two different groups: either members of FIPA families, defined 
by the presence of pituitary adenomas in two or more members of a family without other 
associated clinical features
8;9;272;484
 (‘familial’ cohort), or sporadically diagnosed pituitary 
adenoma patients with disease onset at ≤30 years of age (‘sporadic’ cohort). As an exception to 
these inclusion criteria, one AIPmut positive >30 years sporadic patient was found thanks to AIP 
screening in the setting of a research study, and the screening of his relatives detected a 
second AIPmut positive pituitary adenoma case; this family was included in the familial cohort. 
The first patient reported in each FIPA family and all the sporadic patients were considered 
‘probands’.  
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Pituitary adenoma patients were grouped into 11 clinical diagnostic categories, as listed in 
Table 5. The diagnoses of acromegaly, acromegaly/prolactinoma, gigantism, gigantism/ 
prolactinoma, and mild acromegaly
605
 were grouped together under the category of ‘GH excess’ 
for some analyses.  
 
Table 5. Definition of the clinical diagnostic categories used in the study 
Diagnosis Criteria 
Cushing’s disease 
Evidence of ACTH-depending hypercortisolaemia with proven pituitary 
adenoma, in accordance to the diagnostic protocol of each institution 
Clinically functioning FSH-
secreting pituitary adenoma 
(FSHoma) 
Raised serum FSH levels for age and gender and evidence of gonadal 
stimulation in a patient with a pituitary adenoma 
GH 
excess 
Acromegaly 
Raised IGF-1 levels and unsuppressed GH during an OGTT, with cut-offs 
according to the protocol of each institution 
Acromegaly/prolactinoma Diagnosis of acromegaly with concurrent hyperprolactinaemia 
Mild acromegaly* 
Mild clinical features attributed to acromegaly, fulfilling the criterion of raised 
IGF-1 levels but not the lack of suppression of GH during an OGTT, or normal 
IGF-1 but lack of suppression of GH during an OGTT
605
 
Gigantism 
Any of the following categories in a patient with a pituitary adenoma: (i) 
abnormally high growth velocity in children or teenagers with abnormal IGF-1 
and OGTT, (ii) height >3SD above the mean height for age, (iii) >2SD over the 
calculated midparental height, using country-specific growth charts when 
possible 
Gigantism/prolactinoma Diagnosis of gigantism with concurrent hyperprolactinaemia 
Clinically non-functioning 
pituitary adenoma (NFPA) 
Pituitary adenoma in the absence of clinical or biochemical evidence of 
pituitary hypersecretion 
Pituitary tumour 
Cases of pituitary tumour where the diagnosis could not be specified, due to 
unavailability of histopathological specimens, clinical and/or biochemical data 
Prolactinoma 
Hyperprolactinaemia in the presence of a pituitary adenoma and unlikely to be 
purely due to a stalk effect, based on either histopathology results or the 
relation between PRL levels and tumour size 
Thyrotropinoma 
Hyperthyrotropinaemia in a patient with a pituitary adenoma, with clinical 
and/or biochemical hyperthyroidism and no other demonstrable causes of 
raised TSH 
* This category is important in our study, as we detected acromegaly via biochemical screening of AIPmut positive 
carriers, often not presented (yet) clinically. 
 
All the patients received treatment and were followed up in accordance with the guidelines and 
clinical criteria of their respective centres. Relevant clinical and family structure data were 
received from clinicians and/or patients, and genetic screening was performed in the families of 
all the AIPmut positive probands, selecting individuals according to their risk of inheriting the 
mutation, based on their position in the family tree, and extending the screening to as many 
generations as possible. In both familial and sporadic cases, other causes of familial pituitary 
adenomas, such as MEN1 and 4, CNC, phaeochromocytoma/paraganglioma and pituitary 
adenoma syndrome and X-linked acrogigantism were ruled out by clinical, biochemical and, in 
some cases, genetic tests, as appropriate. 
 
The study population included a great majority of new cases, but also previously diagnosed 
patients being followed up by the participating centres and a few historical cases, corresponding 
to deceased members of FIPA families. Four AIPmut positive patients (two with diagnosis of 
acromegaly and two with gigantism) died in the post-recruitment period. Three of the deaths 
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were due to cardiovascular causes (stroke, chronic heart failure and acute coronary syndrome), 
while the exact cause of death is unknown in the fourth case, a patient with long-standing 
untreated familial acromegaly.  
 
At the recruitment, relevant clinical and biochemical data were collected at each participating 
centre and all the information was entered into our central database. Data about the follow-up, 
treatments and current status of the patients were prospectively requested and collected from 
the collaborating centres and directly from the patients. Data about the historical cases were 
collected from family members and from hospital archives, when available. With a few 
exceptions, genetic screening results were directly sent to our centre and entered in the 
database. The available data did not allow a comprehensive analysis of the response to specific 
therapeutic modalities.    
 
We identified subjects ‘at risk’ (those with the possibility of inheriting an AIPmut), ‘obligate 
carriers’ (based on their position in family tree, AIPmuts were verified when possible) and 
‘unaffected carriers’. Therefore, in our analysis the term ‘unaffected carrier’ includes all the 
relatives of AIPmut positive patients without clinical manifestations of a pituitary adenoma and 
with either a genetic screening positive for the AIPmut present in the proband or with a position 
in the family tree defining them as ‘obligate carriers’. In addition, the analysis of the family trees 
led to the identification of some affected individuals as ‘predicted AIPmut positive patients’, 
defined as individuals with an established clinical diagnosis of pituitary adenoma in whom the 
genetic screening could not be carried out due to unavailability of a DNA sample, but in whom 
the presence of the mutation was assumed based on both the phenotype and the position in the 
family tree. Therefore, the term ‘AIPmut positive patient’ will refer to both ‘predicted AIPmut 
positive patients’ and ‘AIPmut positive patients’ in whom the presence of the mutation was 
verified. Subjects ‘not at risk’ of inheriting an AIPmut were defined based on their position in the 
family tree. In the sporadic cohort, the AIPmut positive patients with no apparent familial history 
of pituitary disease were also referred as ‘simplex’ cases as they can be considered the first 
case of a potentially hereditary disease. All the patients and family members included agreed to 
take part by providing signed informed consent forms approved by the local Ethics Committee. 
 
Genetic screening 
Pituitary adenoma patients and their apparently unaffected relatives were screened for AIPmuts 
using Sanger sequencing and MLPA. Genomic DNA was obtained from blood (Ilustra DNA 
Extraction Kit BACC2, GE Healthcare, Little Chalfont, UK) or saliva (Oragene-DNA [collection] 
and prepIT-L2P [extraction] kits, DNA Genotek, Ontario, Canada) samples. The detection of the 
AIP gene variants and dosage was performed at the Molecular Genetics Laboratory, Royal 
Devon and Exeter, NHS Foundation Trust for the great majority of the samples, as previously 
described.
9;10
 Although the genetic tests were performed in one of the largest Genetics 
laboratories in the world, with appropriate quality controls, we cannot rule out that mutations 
were not identified in a small number of cases, due to either technical problems or due to 
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location of mutations in areas not analysed (such as intronic regions). The pathogenicity of the 
detected variants was assessed using the Pathogenic Or Not-Pipeline (PON-P) and Alamut 
2.2.1 in silico prediction programs, as well as considering the scientific literature concerning 
clinical and experimental data on the previously reported variants. We have divided the AIP 
variants into 5 classes according to the likelihood of pathogenicity, as recommended by Plon et 
al.:
606
 definitely pathogenic, likely pathogenic, uncertain, unlikely pathogenic and not 
pathogenic. Only those variants considered as definitely or likely pathogenic
606
 were included in 
the study. Additionally, we included one novel intronic variant with no experimental data 
available, for which the prediction software could not exclude pathogenicity. The variants 
described in this paper are listed by their position in the DNA, with the corresponding change at 
the protein level in parentheses, according to the nomenclature guidelines of the Human 
Genome Variation Society (HGVS) version 1.0
607
 and the changes proposed for the version 
2.0.
608
 The nomenclature was verified using the Mutalyzer 2.0.beta-21 software.
609
 The 
positions in the DNA are based on the GRCh37/hg19 assembly of the human genome and the 
human AIP reference sequence (Locus Reference Genomic code LRG_460,
503
 based on 
NG_008969.1 and NM_003977.3). All the unaffected individuals with positive genetic screening 
for AIPmuts were advised to undergo clinical, biochemical and image screening tests for the 
early diagnosis of possible pituitary disease, on an annual basis or as appropriate. The 
recommendations for screening were based on the published experience of our group
610
 and 
others.
482
  
 
Additional genetic tests were performed in subjects with no pituitary adenomas, but with other 
clinical features indicative of such tests (screening for mutations in BRCA1 and 2 and TP53 was 
performed in members of a family with breast cancer, osteosarcoma and a neuroendocrine 
tumour of the colon), as well as and in a randomly selected cohort of AIPmut negative FIPA 
probands, searching for mutations in other genes via direct sequencing and MLPA (BRCA1 and 
2, CDKN1B, MEN1, TP53, PRKAR1A) or via a next-generation sequencing panel (MAX, RET, 
SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEM127, and VHL).
611
 Array comparative genomic 
hybridization analysis was performed in a group of patients with gigantism, and patients positive 
for Xq26 microduplications
91
 were excluded from further analysis.  
 
Disease-modifying genes 
Genomic DNA (gDNA) samples from 98 AIPmut positive patients (55 males/43 females) and 
108 unaffected AIPmut carriers (56 males/52 females) were subjected to polymerase chain 
reaction (PCR), and screened for the FGFR4 p.G388R (rs351855) SNP, using 100 ng of each 
DNA sample and previously described primers: 
612
 
 
FGFR4ex9_F:  5’-GACCGCAGCAGCGCCCGAGGCCAG-3’ 
FGFR4ex9_R2:  5’-AGAGGGAAGCGGGAGAGCTTCTG-3’ 
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The PCR reactions were prepared as described in Protocol 1 and ran in a thermal cycler, using 
the following program: 
 
One cycle: 
95°C 2 minutes (min) 
35 cycles: 
95°C 15 seconds (sec) 
67°C 15 sec 
68°C 20 sec 
One cycle: 
68°C 5 min 
10°C Hold  
 
Ten microliters of each PCR product (168 bp) were resolved in a 3% agarose gel, as presented 
in Figure 4. 
 
 
Figure 4. Example of FGFR4 PCR. Lane 1: DNA ladder (GeneRuler,Life Technologies SM0241), lanes 2-6: samples 
(sample in lane 6 did not amplify), lane 7: empty, lane 8: negative control. Arrow: expected PCR product (168 bp). The 
lower bands appearing in some samples correspond to primer dimers.  
 
In addition, gDNA was extracted from paraffin-embedded somatotropinomas for 23 AIPmut 
positive patients (familial and simplex), ten AIPmut negative FIPA patients and six AIPmut 
negative sporadic patients and cDNA was obtained from 19 frozen somatotropinomas from 
unselected acromegaly cases (control group, 13 males/6 females, age at diagnosis 37-77 
years) as detailed in Protocol 2. All these samples were screened for mutations in the GNAS1 
codons 201 and 227 using 100 ng of each DNA sample and previously described primers for 
gDNA:
613
  
 
GNAS1201_F: 5’- CCAAACTACTCCAGACCTTT-3’ 
GNAS1201_R: 5’- TGGAAGTTGACTTTGTCCAC-3’ 
GNAS1227_F: 5’- ACAGAGATCATGGTTTCTTG-3’ 
GNAS1227_R: 5’- TTAACCAAAGAGAGCAAAGC-3’ 
300bp
200bp
500bp
400bp
100bp
1           2            3           4           5          6           7            8
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The primers used for cDNA were available in the laboratory stocks, and the resulting PCR 
product contains both codons 201 and 227: 
 
GNAS1_F: 5’-CAAGCAGGCTGACTATGTGC-3’ 
GNAS1_R: 5’-ACCACGAAGATGATGGCAGT-3’  
 
The PCR reactions with each pair of primers were prepared as described in Protocol 1 and 
processed in a thermal cycler, using the following program for the three pairs of primers: 
 
One cycle: 
95°C 2 min 
35 cycles: 
95°C 15 sec 
60°C 15 sec 
68°C 20 sec 
One cycle: 
68°C 5 min 
10°C Hold  
 
Ten microliters of each of the PCR products (164 bp for GNAS1 201 PCR, 232 bp for GNAS1 
227 PCR and 189 bp for GNAS1 201 and 227 PCR from cDNA) were resolved in a 3% agarose 
gel, as presented in Figure 5. 
 
 
Figure 5. Examples of PCR for GNAS1 genotyping. a) PCR products for GNAS1 201 and 227 PCR reactions. Lane 1: 
DNA ladder (GeneRuler,Life Technologies SM0241), lane 2: sample amplified for GNAS1 201, lane 3: negative control 
for GNAS1 201, lane 4: empty, lane 5: sample amplified for GNAS1 227, lane 6: negative control for GNAS1 227. Top 
arrow: expected PCR product for GNAS1 227 (232 bp); bottom arrow: expected PCR product for GNAS1 201 (164 bp). 
b) PCR products for GNAS1 PCR reaction from cDNA. Lane 1: DNA ladder (GeneRuler,Life Technologies SM0241), 
lanes 2-12: samples, lane 13: negative control. Arrow: expected PCR product (189 bp) Sample in lane 5 presented non-
specific amplification; the 189bp band was cut and purified before sequencing.  
 
The sequence analysis of the FGFR4 and GNAS1 PCR products was carried out by Sanger 
sequencing (BigDye Terminator v. 3.1 kit in and ABI 3730 capillary sequencer, Applied 
Biosystems, Foster City, CA, USA) at the Genome Centre sequencing facility (Barts and The 
London School of Medicine). The obtained chromatograms were aligned against the GenBank 
300bp
200bp
400bp
100bp
300bp
200bp
500bp
400bp
100bp
a b
1      2      3      4       5      6      7      8      9    10    11    12   131       2       3       4       5       6 
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reference sequences NM_000516.4 (GNAS1 variant 1 mRNA) and NG_012067 (FGFR4 
gDNA). 
 
Statistical analysis 
The qualitative, categorical variables were expressed as percentages and compared using the 
chi-squared test or the Fisher’s exact test, as appropriate. The normal distribution of the 
quantitative variables was verified using the Shapiro-Wilk and the Kolmogorov-Smirnov tests for 
normality. Means and standard deviations were used to report parametric data, and non-
parametric data were expressed as median and interquartile ranges. Parametric data were 
analysed with the unpaired t-test, with a 95% confidence interval, while the Mann-Whitney U 
test was used for the non-parametric data. Statistical significance was considered when the P 
value (P) was <0.05. All the statistical analyses were carried out using the GraphPad Prism 6 
(GraphPad Software Inc.) and Stata 12 (StataCorp LP) statistical software.  
 
Results 
Study population 
 
Table 6. Study population: demographics and general description 
 Familial cohort Sporadic cohort Combined 
Total individuals, no. (%) 1231 (71.4) 494 (28.6) 1725 (100) 
Females, no. (%) 668 (54.3) 250 (50.6) 918 (53.2) 
Current age, median (range, [IQR]) 46.2 (2-97 [32-62]) 35 (3-77 [26-42]) 42.6 (2-97 [29-56]) 
Clinical status, no. (%):    
Affected 502 (40.8) 404 (81.8) 906 (52.5) 
Unaffected 729 (59.2) 90 (18.2) 819 (47.5) 
Affected males, no. (%) 219 (43.6) 203 (50.2) 422 (46.6) 
Affected females, no. (%) 283 (56.4) 201 (49.8) 484 (53.4) 
Diagnoses, no. (%):    
Acromegaly 170 (33.9) 203 (50.2) 373 (41.2) 
Acromegaly/prolactinoma 17 (3.4) 12 (3) 29 (3.2) 
Cushing's disease 24 (4.8) 21 (5.2) 45 (5) 
FSH-secreting adenoma 2 (0.4) 1 (0.2) 3 (0.3) 
Gigantism  44 (8.8) 65 (16.1) 109 (12) 
Gigantism/prolactinoma 1 (0.2) 10 (2.5) 11 (1.2) 
Mild acromegaly 2 (0.4) - 2 (0.2) 
NFPA 91 (18.1) 21 (5.2) 112 (12.4) 
Pituitary tumour 17 (3.4) 2 (0.5) 19 (2.1) 
Prolactinoma 134 (26.7) 67 (16.6) 201 (22.2) 
Thyrotropinoma - 2 (0.5) 2 (0.2) 
GH excess patients, no. (%) 234 (46.6) 290 (71.8) 524 (57.8) 
IQR: interquartile range.  
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The familial cohort was composed of 216 FIPA families, including 156 new families (989 
subjects: 337 patients and 652 unaffected family members) and 60 previously described 
families where 46 new subjects (15 patients and 31 unaffected family members) were added to 
the previously reported 196 individuals (150 patients and 46 unaffected family members, Table 
6).
9;10
  
 
The sporadic cohort originally included 409 pituitary adenoma patients ≤30 years old at disease 
onset, with no known familial history of pituitary adenoma, but five of these patients were 
excluded from further analysis due to harbouring Xq26.3 microduplications. Of the remaining 
404 sporadic patients, six were reported previously.
9
 In addition to the AIPmut screening, a 
subset of AIPmut negative FIPA (n=55) and sporadic (n=45) patients underwent genetic 
screening for other endocrine neoplasia-associated genes (Table 7). All of these tests were 
negative for pathogenic variants. After the genetic screening and follow-up of the patients and 
carriers, 60 individuals in the familial cohort and seven in the sporadic cohort were classified as 
‘not at risk’ of inheriting an AIPmut, and were excluded from further analysis. Twenty three 
individuals initially thought to be unaffected were identified with pituitary abnormalities (see 
details in the ‘Prospective diagnosis’ section).  
 
Table 7. Other genes tested 
 Familial cohort Sporadic cohort 
Combined, 
no. (%)  
AIPmut 
positive, 
no. (%) 
AIPmut 
negative, 
no. (%) 
Total 
familial,          
no. (%) 
AIPmut 
positive, 
no. (%) 
AIPmut 
negative, 
no. (%) 
Total 
sporadic,       
no. (%) 
BRCA1 1 (14.3) 2 (0.7) 3 (1) - - - 3 (0.8) 
BRCA2 1 (14.3) 2 (0.7) 3 (1) - - - 3 (0.8) 
CDKN1B - 20 (6.5) 20 (6.4) - 1 (2.4) 1 (2.4) 21 (5.9) 
GPR101 - - - - 8 (19) 8 (19) 8 (2.2) 
MAX - 23 (7.5) 23 (7.3) - - - 23 (6.5) 
MEN1 3 (42.9) 51 (16.6) 54 (17.2) - 33 (78.6) 33 (78.6) 87 (24.4) 
PRKAR1A - 23 (7.5) 23 (7.3) - - - 23 (6.5) 
RET - 23 (7.5) 23 (7.3) - - - 23 (6.5) 
SDHA - 23 (7.5) 23 (7.3) - - - 23 (6.5) 
SDHAF2 - 23 (7.5) 23 (7.3) - - - 23 (6.5) 
SDHB - 23 (7.5) 23 (7.3) - - - 23 (6.5) 
SDHC - 23 (7.5) 23 (7.3) - - - 23 (6.5) 
SDHD - 25 (8.1) 25 (8) - - - 25 (7) 
TMEM127 - 23 (7.5) 23 (7.3) - - - 23 (6.5) 
TP53 2 (28.6) - 2 (0.6) - - - 2 (0.6) 
VHL - 23 (7.5) 23 (7.3) - - - 23 (6.5) 
Total 7 307 314 0 42 42 712 
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Table 8. Screening for AIP mutations 
  Familial cohort Sporadic cohort Combined 
  
AIPmut 
positive 
familial 
AIPmut 
negative 
familial 
Total familial 
AIPmut 
positive 
simplex 
AIPmut 
negative 
sporadic 
Total 
sporadic 
AIPmut 
positive 
familial and 
simplex 
AIPmut 
negative 
familial and 
sporadic 
Total 
Total number of kindreds, no (%) 
37 (17.1% of 
familial) 
179 (82.9% 
of familial) 
216 (34.8% 
of total) 
34 (8.4% of 
sporadic) 
370 (91.6% 
of sporadic) 
404 (65.2% 
of total) 
71 (11.5% of 
total) 
549 (88.5% 
of total) 
620 (100) 
Total individuals, no. (%): 
475 (38.6% 
of familial) 
756 (61.4% 
of familial) 
1231 (71.4% 
of total) 
82 (16.6% of 
sporadic) 
412 (83.4% 
of sporadic) 
494 (28.6% 
of total) 
557 (32.3% 
of total) 
1168 (67.7% 
of total) 
1725 (100) 
Genetic status, no. (%):          
AIPmut negative patients 3 (0.6) 389 (51.5)* 392 (31.8) - 370 (89.8) 370 (74.9) 3 (0.5) 759 (65) 762 (44.2) 
AIPmut positive tested patients  95 (20) - 95 (7.7) 34 (41.5) - 34 (6.9) 129 (23.2) - 129 (7.5) 
At risk, but not tested 33 (6.9) - 33 (2.7) 8 (9.8) - 8 (1.6) 41 (7.4) - 41 (2.4) 
Not at risk 48 (10.1) 12 (1.6) 60 (4.9) 7 (8.5) - 7 (1.4) 55 (9.9) 12 (1) 67 (3.9) 
Obligate unaffected carriers, not tested 8 (1.7) - 8 (0.6) 2 (2.4) - 2 (0.4) 10 (1.8) - 10 (0.6) 
Predicted AIPmut positive patients 15 (3.2) - 15 (1.2) - - - 15 (2.7) - 15 (0.9) 
Unaffected AIPmut tested carriers 120 (25.3) - 120 (9.7) 16 (19.5) - 16 (3.2) 136 (24.4) - 136 (7.9) 
Unaffected and AIPmut negative 153 (32.2) - 153 (12.4) 15 (18.3) - 15 (3) 168 (30.2) - 168 (9.7) 
Unaffected relatives of AIPmut negative patients - 355 (47) 355 (28.8) - 42 (10.2) 42 (8.5) - 397 (34) 397 (23) 
Summary of AIPmut positive individuals, no. (%):          
Total AIPmut positive patients:† 110 (23.2) - 110 (8.9) 34 (41.5) - 34 (6.9) 144 (25.9) - 144 (8.3) 
Total unaffected AIPmut carriers:‡ 128 (26.9) - 128 (10.4) 18 (22) - 18 (3.6) 146 (26.2) - 146 (8.5) 
* In AIPmut negative FIPA families, 199 patients were tested for AIPmuts, the rest (n=190) were assumed to be negative.                                                                                                                                 
†This is equal to the sum of tested AIPmut positive patients plus the predicted AIPmut positive patients.                                                                                                                                                             
‡ Sum of tested unaffected carriers plus obligate unaffected carriers. 
 
98 
 
Genetic screening results 
Thirty-seven (17.1%) out of 216 FIPA families screened and 34 out of 404 sporadic patients 
(8.4%) were positive for pathogenic or likely pathogenic AIPmuts, accounting for a total of 71 
AIPmut positive kindreds and 144 AIPmut positive patients (76.4% familial and 23.6% simplex, 
Table 8). We also identified 164 AIPmut positive apparently unaffected family members (see 
‘Follow-up and prospective diagnosis’). Samples were not available from family members of 25 
AIPmut positive simplex cases to establish the presence or lack of de novo mutations. We 
identified three pituitary adenoma patients (two with clinically NFPA and one with a 
microprolactinoma) belonging to AIPmut positive FIPA families and being ‘at risk’ of inheriting, 
but not carrying an AIPmut, therefore they were considered as phenocopies.  
 
Thirty-one different AIPmuts (ten not previously reported) were identified in our study 
population: 12 exclusively in familial cases, 12 in simplex cases only and seven in both settings 
(Table 9 and Figure 6). Of the total mutations, 70.8% (22/31) predicted a truncated or missing 
protein, and were termed as ‘truncating AIPmuts’ (Figure 7). There were no exclusive 
associations of specific AIPmuts with particular diagnoses. However, 77.4% of all the mutations 
(24/31) were found in cases of gigantism (with or without prolactin (PRL) co-secretion), being 
this the diagnosis with the highest number of associated AIPmuts. Furthermore, all the 
mutations were found in at least one patient with GH excess, supporting this diagnostic 
category as the most frequent AIPmut pathogenic association. Patients with diagnosis of NFPA 
harboured 29% (9/31) of the AIPmuts found in the study, and 22.6% of them (7/31) were 
detected in prolactinoma cases. As expected based on previous data,
482;614
 the commonest 
mutation in both cohorts was c.910C>T (p.R304*), found in 33.3% of the AIPmut patients and in 
35.9% of all the AIPmut positive individuals (affected plus unaffected carriers).  
 
Table 9. AIP pathogenic or likely pathogenic mutations in familial and simplex cohorts 
Mutation 
(DNA level [protein 
level]) 
Mutation 
type 
Pathogenic 
Location in 
protein 
Familial 
cohort 
(n=238)
*
 
Sporadic 
cohort 
(n=52)
*
 
Combined 
(n=290)
*
 
References 
g.4856_4857CG>AA Promoter Yes
†
 
Not in 
protein           
(5' UTR) 
3 (1.3) - 3 (1) 
9;10;496
 
c.3G>A (p.?) 
Start 
codon 
Likely
†
 N-terminus 2 (0.8) - 2 (0.7) This thesis 
c.40C>T (p.Q14*) Nonsense Yes
†
 N-terminus 2 (0.8) - 2 (0.7) 
8;615;616
 
c.70G>T (p.E24*) Nonsense Yes
†
 N-terminus 9 (3.8) - 9 (3.1) 
9;495
 
c.74_81delins7 
(p.L25Pfs*130) 
Frameshift Yes
†
 
PPIase 
domain 
10 (4.2) - 10 (3.4) 
10;617
 
c.100-
1025_279+357del 
(ex2del) 
(p.A34_K93del) 
Large 
genomic 
deletion 
Yes
†
 
PPIase 
domain 
12 (5) 2 (4) 14 (4.8) 
618
 
c.100-18C>T  Intronic Likely 
Not in 
protein 
(intron 1) 
- 3 (6) 3 (1) 
7;9;14;615
 
c.241C>T (p.R81*) Nonsense Yes
†
 
PPIase 
domain 
12 (5) 4 (8) 16 (5.5) 
9;496;590;619;620
 
c.249G>T Splice site Yes
†
 PPIase 4 (1.7) - 4 (1.4) 
10
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Mutation 
(DNA level [protein 
level]) 
Mutation 
type 
Pathogenic 
Location in 
protein 
Familial 
cohort 
(n=238)
*
 
Sporadic 
cohort 
(n=52)
*
 
Combined 
(n=290)
*
 
References 
(p.G83Afs*15) (cryptic 
splice site) 
domain 
c.338_341dup 
(p.L115Pfs*16) 
Frameshift Yes
†
 
PPIase 
domain 
- 2 (4) 2 (0.7) 
6
 
c.427C>T (p.Q143*) Nonsense Yes
†
 
Between 
PPIase and 
TPR1 
domains 
- 1 (2) 1 (0.3) This thesis 
c.469-2A>G 
(p.E158_Q184del) 
Splice site Likely 
TPR1 
domain 
- 1 (2) 1 (0.3) 
12;13;621
 
c.490C>T (p.Q164*) Nonsense Yes
†
 
Between 
PPIase and 
TPR1 
domains 
3 (1.3) - 3 (1) 
10
 
c.570C>G (p.Y190*) Nonsense Yes
†
 
TPR1 
domain 
9 (3.8) - 9 (3.1) This thesis 
c.662dupC (p.E222*) Nonsense Yes
†
 
Between 
TPR1 and 2 
domains 
3 (1.3) - 3 (1) 
10
 
c.713G>A (p.C238Y) Missense Yes 
TPR2 
domain 
4 (1.7) - 4 (1.4) 
9;495
 
c.783C>G (p.Y261*) Nonsense Yes
†
 
TPR2 
domain 
4 (1.7) - 4 (1.4) 
13;498;622;623
 
c.787+9C>T Intronic Uncertain 
Not in 
protein    
(intron 5) 
- 1 (2) 1 (0.3) This thesis 
c.804C>A (p.Y268*) Nonsense Yes
†
 
TPR3 
domain 
19 (8) 3 (6) 22 (7.6) 
624;625
 
c.805_825dup 
(p.F269_H275dup) 
In-frame 
insertion 
Yes 
TPR3 
domain 
16 (6.7) 2 (4) 18 (6.2) 
9;13;496;626
 
c.807C>T (p.(=)) 
Splice site 
(reduced 
transcript 
level) 
Yes 
TPR3 
domain 
7 (2.9) 4 (8) 11 (3.8) 
7;9;10;12;14;627;6
28
 
c.811C>T (p.R271W) Missense Yes 
TPR3 
domain 
- 1 (2) 1 (0.3) 
7;10;484;629
 
c.816delC 
(p.K273Rfs*30) 
Frameshift Yes
†
 
TPR3 
domain 
- 1 (2) 1 (0.3) This thesis 
c.868A>T (p.K290*) Nonsense Yes
†
 
TPR3 
domain 
- 1 (2) 1 (0.3) This thesis 
c.872_877delTGCTG
G (p.V291_L292del) 
In-frame 
deletion 
Yes 
TPR3 
domain 
- 1 (2) 1 (0.3) This thesis 
c.910C>T (p.R304*) Nonsense Yes
†
 
C-terminal 
α-helix 
88 (37) 16 (31) 104 (35.9) 
7-
10;12;13;484;498;5
06;507;630;631
 
c.911G>A (p.R304Q) Missense Yes 
C-terminal 
α-helix 
20 (8.4) 3 (6) 23 (7.9) 
7;7;9;10;12;13;13;4
98;539;615;632
 
c.967delC 
(p.R323Gfs*39) 
Frameshift Yes
†
 
C-terminal 
α-helix 
- 4 (8) 4 (1.4) This thesis 
c.976_977insC 
(p.G326Afs*?) 
Frameshift Yes
†
 
C-terminal 
α-helix 
- 1 (2) 1 (0.3) This thesis 
c.978dupG 
(p.I327Dfs*?) 
Frameshift Yes
†
 
C-terminal 
α-helix 
- 1 (2) 1 (0.3) This thesis 
c.1-?_993+?del- 
(whole gene deletion) 
Large 
genomic 
deletion 
Yes
†
 
Absence of 
the whole 
protein 
11 (4.6) - 11 (3.8) 
10
 
* 
Number of positive individuals for each mutation, considering the AIPmut positive tested individuals, the obligate 
carriers and the predicted AIPmut patients. 
† 
Truncating mutation. 
PPIase, peptidylprolyl isomerase. 
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Figure 6. AIPmuts detected in the study population and their position on the AIP gene. Shadowed areas indicate the protein domains codified by each region of the gene. Mutations producing a truncated or 
missing protein are shown at the bottom of the scheme, and non-truncating mutations are at the top. Even though we identified variants throughout the whole AIP gene, mutations tended to cluster in the 
genomic regions encoding the TPR domains and the C-terminal α-helix of the protein. Furthermore, the mutations located at the N-terminal extreme and inside the peptidylprolyl isomerase (PPIase) domain 
were essentially truncating mutations, resulting in short and unstable proteins, lacking the TPR domains. 
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Figure 7. AIPmut types and frequency according to age at disease onset in the familial and sporadic cohorts (whole 
study population). a) Number of AIPmuts per mutation type, note the predominance of nonsense mutations. b) The 
probability of finding an AIPmut was higher when testing patients with disease onset during the second decade of life; c) 
in concordance, three quarters of all the AIPmut positive patients had disease onset during the second and third 
decades of life.  
 
We also identified 11 apparently non-pathogenic AIP variants (three of them novel) in our 
population (Table 10). 
 
A multiple regression analysis was performed to determine which clinical features could more 
accurately predict the likelihood of a patient to carry an AIPmut. An age at diagnosis ≥10 and 
<20 years conferred an odds ratio (OR) of 5.8 (P=0.000, 95% CI 3.1-10.8) of having an AIPmut, 
while the OR was 2.8 if the age at diagnosis was ≥20 and <30 years (P=0.000, 95% CI 1.3- 
5.7); thus, an age at diagnosis between 10 and 30 years is the best predictor of AIPmuts. 
Inversely, a diagnosis of prolactinoma resulted in an OR of 0.2 (P=0.000, 95% CI 0.1-0.5).  
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Table 10 AIP non-pathogenic mutations in the familial and simplex cohorts. 
Variant (DNA level 
[protein level]) 
Variant type Pathogenic 
Location 
in protein 
Familial 
cohort
*
 
(N=19) 
Sporadic 
cohort
*
 
(N=37) 
Combined
*
 
(N=56) 
References 
c.47G>A (p.R16H) Missense No N-terminus 0 2 2 
7;12;13;484;600;61
5;633-636
 
c.132C>T (p.(=)) Synonymous No 
PPIase 
domain 
0 3 3 
12;637 
c.144C>T (p.(=)) Synonymous No 
PPIase 
domain 
0 1 1 
632;637-639 
c.516C>T (p.(=)) Synonymous No 
Between 
PPIase and 
TPR1 
domains 
8 13 21 
10;12;279;633;636;
637;639;640 
c.573C>T (p.(=)) Synonymous No 
TPR1 
domain 
0 0 0 This thesis 
c.579G>T (p.(=)) Synonymous No 
TPR1 
domain 
1 0 1 This thesis 
c.682A>C 
(p.K228Q)
 †
 
Missense No 
Between 
TPR1 and 
2 domains 
2 16 18 
12;279;636;637 
c.831C>T (p.(=)) Synonymous Unlikely 
TPR3 
domain 
1 0 1 This thesis 
c.891C>A (p.(=)) Synonymous No 
TPR3 
domain 
0 2 2 
12;637 
C.896C>T 
(p.A299V) 
Missense Unlikely 
TPR3 
domain 
5 0 5 
10;615 
c.906G>A (p.(=)) Synonymous No 
C-terminal 
α-helix 
2 0 2 
615;637 
* 
Number of positive individuals for each mutation, considering the AIPmut positive tested individuals, the obligate 
carriers and the predicted AIPmut patients. 
† 
There is a Q at this position in the AIP reference sequence, but we consider K as the WT amino acid, due to its 
higher prevalence in the population screened so far (Stals K., unpublished data). 
PPIase, peptidylprolyl isomerase. 
 
Genotype-phenotype correlation within the AIPmut positive cohort 
Truncating mutations accounted for 78.9% (15/19) of the AIPmuts found in the familial cohort, 
and for 57.9% (11/19) of those detected in the sporadic cohort. To study a possible difference in 
disease penetrance between truncating and non-truncating mutations, we compared the 
number of affected individuals with truncating AIPmuts in the familial (85/110 [77.3%]) and 
simplex cohorts (21/34 [61.8%]), finding no significant difference, although a trend was 
observed (P=0.0729, analysis included prospectively diagnosed patients). No significant 
differences were found regarding the proportion of GH excess cases, number of patients per 
family, maximum tumoral diameter, frequency of macroadenomas, extrasellar invasion or 
number of treatments received between the patients with truncating and non-truncating 
mutations. However, patients with truncating mutations were significantly younger at disease 
onset (median 16 [IQR 15-25] vs. 22 [IQR 17.3-27.8] years, P=0.0046, Figure 8a) and at 
diagnosis (median 21 [IQR 16-30] vs. 27 [IQR 20.8-37] years, P=0.0028, Figure 8b), and the 
occurrence of paediatric cases was more common in this group (60% [57/95], Figure 8c), 
compared to the patients with non-truncating AIPmuts (33.3% [12/36], P=0.0064). 
 
In concordance with these differences, gigantism accounted for a significantly higher proportion 
of the GH excess cases in the patients with truncating AIPmuts (54.7% [47/86]), compared to 
those with non-truncating AIPmuts (30% [9/30], P=0.0200). As p.R304* was the most common 
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AIPmut in our study population (20 kindreds), we analysed if these patients behaved differently 
to other patients with truncating mutations. We found more affected individuals per family 
(median 4 [IQR 2.5-5]) among families carrying the p.R304* AIPmut, compared to families with 
other AIPmuts (median 2 [IQR 2-3], P=0.0133). When considering all the AIPmut positive 
patients together (familial and sporadic), we found a higher proportion of paediatric patients 
among those with the AIP p.R304* mutation (65.8% [25/38] vs. 46.5% [40/86], P=0.0475).  
 
 
Figure 8. Patients with truncating vs. non-truncating AIPmuts. a) Patients with truncating AIPmuts present with a more 
aggressive phenotype, characterised by an earlier age at onset (P=0.005) and b) at diagnosis (P=0.003). c) This earlier 
disease onset results in a higher frequency of paediatric cases (n [total]= 131); in fact, the majority of the patients with 
truncating mutations present in childhood and adolescence. **, P<0.01.   
 
Clinical and histopathological features 
Gender distribution  
Among the familial patients, there was a significantly different gender distribution of the affected 
individuals between the AIPmut positive and negative subgroups (P=0.0015, Figure 9a), 
showing a predominance of females in the AIPmut negative families. This difference is unlikely 
to be due to a selection bias, as the gender distribution was not significantly different between 
affected and unaffected individuals in the whole study population (P=0.8581), or, in the familial 
cohort, between unaffected AIPmut positive and negative individuals (P=0.4421, Figure 9b), or 
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between AIPmut positive affected and unaffected individuals (P=0.1367). We did not see a 
difference in gender distribution between the AIPmut positive and negative sporadic patients 
either (P=0.1605, Figure 9c). 
 
 
Figure 9. Gender distribution in FIPA families and sporadic patients: a) Gender distribution was different between the 
AIPmut positive and negative FIPA patients, due to a predominance of female patients within the AIPmut negative 
families. b) This difference cannot be explained by a selection bias towards one specific gender, as there were similar 
numbers of males and females within the unaffected family members (excluding ‘not at risk’ individuals) of AIPmut 
positive and negative FIPA families. c) The gender distribution was not significantly different between AIPmut positive 
and negative patients, despite a slight prevalence of males in the AIPmut positive subgroup. ns, not significant, **, 
P<0.01.  
 
Age 
Familial patients 
FIPA AIPmut positive patients were younger at disease onset (Figure 10) compared to AIPmut 
negative FIPA patients. In the AIPmut positive subgroup, the earliest age at onset was three 
years, while in the AIPmut negative families a female patient with Cushing’s disease had the 
earliest disease onset at seven years. Most of the AIPmut positive FIPA patients (71.7% 
[71/99]) developed their pituitary adenomas during the second and third decades of life (10-29 
years), whereas only 39.2% (121/309) of the AIPmut negative FIPA patients had their first 
signs/symptoms of pituitary adenoma during the same stage of life (P<0.0001, Figure 10a and 
b). The age at diagnosis was also significantly different (P<0.0001): 68.2% (75/110) of the 
AIPmut positive FIPA patients were diagnosed at ≤30 years of age, whereas the diagnosis was 
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established in only 36.7% (116/316) of the AIPmut negative patients by that age. The earlier 
disease presentation was also reflected in a much higher frequency of paediatric cases 
(disease onset at ≤18 years of age, Figure 10c) in the AIPmut positive FIPA families, compared 
with the AIPmut negative FIPA families (44.1 vs. 11.8%, P<0.0001). These distributions were 
calculated taking into consideration the prospectively diagnosed AIPmut positive patients; 
however, the statistical analysis results were not significantly different when those patients were 
excluded.  
 
Sporadic patients 
Even though our sporadic cohort included only young-onset pituitary adenoma patients, a 
significant younger age at onset was still found within this young group in the AIPmut positive 
simplex patients in comparison with the AIPmut negative ones (median 16 [IQR 14.8-22.3] vs. 
22 [IQR 16-26] years, P=0.0054, Figure 10d), and there was a higher proportion of paediatric 
cases within the AIPmut positive subgroup (58.8% vs. 35.9%, P=0.0085). Nevertheless, while 
the youngest age at onset in the AIPmut positive simplex patients was nine years, 3% (11/369) 
of the AIPmut negative patients had disease onset before the nine years of age, with a 
minimum age of three years.  
 
Clinical diagnoses 
GH excess patients accounted for 57.8% (524/906) of the total affected individuals in the entire 
cohort: 46.6% (234/502) of the familial and 71.8% (290/404) of the sporadic cases. Patients with 
GH excess, prolactinomas and NFPAs were present in both AIPmut positive and negative 
subgroups, but Cushing’s disease, functioning gonadotropinomas and TSHomas were not 
found in patients bearing AIPmuts.  
 
Familial patients 
We classified the FIPA families as ‘homogeneous’, when all the affected individuals within the 
family had the same diagnosis (GH excess was considered as a single category), or 
‘heterogeneous’, when different diagnoses were found in the same family.
272
 Around one half of 
the families in our cohort were homogeneous FIPA families (families with only one pituitary 
adenoma type) in both the AIPmut positive (48.6%) and negative (52.5%) subgroups (Table 11). 
The most common family type in both subgroups (according to the diagnostic categories found 
in the affected members) was the pure GH excess family, but it was significantly more frequent 
within the AIPmut positive FIPA families (P=0.0249). The most common diagnoses in AIPmut 
positive and negative families were the different categories of GH excess; nevertheless, these 
cases were significantly more frequent in the AIPmut positive subgroup, with at least one case 
of GH excess in 91.9% (34/37) of the AIPmut positive and in 53.1% (95/179) of the AIPmut 
negative FIPA families (P<0.0001, Figure 10e). There was a higher frequency of PRL co-
secretion among the AIPmut positive patients with acromegaly or gigantism, compared to the 
AIPmut negative ones (P=0.0158, Figure 10f). In the AIPmut negative FIPA patients the most 
frequent diagnosis was acromegaly, in 35.3% (137/389) of the patients, with prolactinoma in the 
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second place of frequency (30.9%, 120/389). In sharp contrast to AIPmut positive families, 
where 31% (35/113) of the patients had gigantism, only 2.1% (8/389) of the AIPmut negative 
FIPA patients had this diagnosis. 
 
 
Figure 10. Clinical features in FIPA families and sporadic patients: a) AIPmut positive familial patients were younger at 
disease onset (P<0.0001), b) as most of them developed symptoms after the age of 10 and before the age of 40. c) 
There was a higher frequency of paediatric cases (n [total]=425) in the AIPmut positive FIPA families, compared with 
the AIPmut negative FIPA families. d) In the sporadic group, although all these patients were <30 years at disease 
onset, AIPmut positive individuals were significantly younger at disease onset than the AIPmut negative ones. e) GH 
excess and f) presence of GH and PRL co-secretion were significantly more frequent in AIPmut positive familial 
patients. *, P<0.05, **, P<0.01, ****, P<0.0001.  
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Table 11. Classification of FIPA families by diagnoses 
  
AIPmut 
positive 
AIPmut 
negative 
Total 
Total families, no.: 37 179 216 
Diagnoses:    
Cushing's disease only, no. (%) - 3 (1.7) 3 (1.4) 
Cushing's disease + FSHoma, no. (%) - 1 (0.6) 1 (0.5) 
Cushing's disease + NFPA, no. (%) - 1 (0.6) 1 (0.5) 
Cushing's disease + NFPA + pituitary tumour, no. (%) - 1 (0.6) 1 (0.5) 
Cushing's disease + prolactinoma, no. (%) - 5 (2.8) 5 (2.3) 
FSHoma + prolactinoma, no. (%) - 1 (0.6) 1 (0.5) 
Cushing's disease+ GH excess, no. (%) - 7 (3.9) 7 (3.2) 
GH excess only, no. (%) 16 (43.2) 44 (24.6) 60 (27.8) 
GH excess + NFPA, no. (%) 8 (21.6) 12 (6.7) 20 (9.3) 
GH excess + NFPA + prolactinoma, no. (%) 1 (2.7%) 3 (1.7) 4 (1.9) 
GH excess + pituitary tumour, no. (%) - 5 (2.8) 5 (2.3) 
GH excess + pituitary tumour + prolactinoma, no. (%) - 1 (0.6) 1 (0.5) 
GH excess + prolactinoma, no. (%) 9 (24.3) 30 (16.8) 39 (18.1) 
NFPA only, no. (%) 2 (5.4) 17 (9.5) 19 (8.8) 
NFPA + pituitary tumour, no. (%) - 7 (3.9) 7 (3.2) 
NFPA + prolactinoma, no. (%) 1 (2.7) 10 (5.6) 11 (5.1) 
Pituitary tumour + prolactinoma, no. (%) - 1 (0.6) 1 (0.5) 
 Prolactinoma, no. (%) - 30 (16.8) 30 (13.9) 
* The category "GH excess" includes the following diagnoses: acromegaly, acromegaly/ prolactinoma, gigantism, 
gigantism/ prolactinoma and mild acromegaly. 
FSHoma, FSH secreting adenoma. NFPA, non-functioning pituitary adenoma.  
 
Sporadic patients 
In the sporadic cohort, all the AIPmut positive simplex patients harboured GH-secreting 
adenomas (vs. 69.2% of the AIPmut negative cases), as proven by the clinical diagnosis and 
IHC report. The predominance of GH excess cases in both groups could be due to a selection 
bias, as the previously reported association between AIPmuts and acromegaly/gigantism could 
have influenced the referral of these patients for the study.  
 
Histopathology 
Familial patients 
The IHC analysis of the operated pituitary adenomas confirmed the clinical/biochemical picture 
in the vast majority of the cases, reporting a predominance of somatotropinomas and 
mammosomatotroph adenomas in FIPA patients, more evident in the AIPmut positive subgroup 
(P= 0.0304, Figure 11a and b). There was a unique case of a double adenoma (one tumour 
positive for GH and another one for PRL) and one unusual case of somatotroph hyperplasia in a 
patient with gigantism within the AIPmut positive patients. None of the few AIPmut positive 
clinically NFPA cases were gonadotroph or null cell adenomas. In contrast, in the AIPmut 
negative FIPA families, 48.3% of the NFPAs analysed were reported as gonadotropinomas and 
31% were null cell adenomas (based on negative immunostaining for GH, ACTH, PRL, TSH, LH  
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Figure 11. Histopathological diagnoses in FIPA families and sporadic patients. The distribution of the IHC diagnoses 
was different between AIPmut positive (a) and negative (b) familial patients, though GH positive tumours predominated 
in both subgroups. c) The analysis of the granulation pattern reported sparsely granulated tumours in all the AIPmut 
positive and in 43.8% of the AIPmut negative familial adenomas (P<0.0001). d) AIPmut simplex patients had GH 
positive adenomas (with or without positive PRL staining), while e) the AIPmut negative sporadic patients had a variety 
of other tumour types. PRLoma, prolactinoma; GH/PRLoma, mammosomatotroph adenoma; ns, not significant; ****, 
P<0.0001. 
 
and FSH). There was a similar prevalence of plurihormonal tumours in both subgroups (17.4% 
in the AIPmut positive and 10.5% in the AIPmut negative families, P=0.2763). Seventy five 
percent of all the plurihormonal tumours in both subgroups had positive GH staining. There was 
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a significant difference among the AIPmut positive and negative FIPA patients involving the 
granulation pattern in GH positive adenomas. All the AIPmut positive FIPA patients for whom 
this parameter was available (22/22) had sparsely granulated adenomas, while 43.8% (7/16) of 
the AIPmut negative patients harboured densely granulated adenomas (P<0.0001, Figure 11c); 
this difference could correspond to the response to the treatment with SSA, as suggested by 
previous reports.
202
 We found no difference in the proportion of patients with Ki-67 index 3% 
between the two subgroups (global 28.1%, P=1.0000).  
 
Sporadic patients 
All the AIPmut positive patients with available histopathology results (n=14) had GH positive 
pituitary adenomas by IHC, 28.6% of them (n=4) were mammosomatotroph adenomas (Figure 
11d). In contrast, the AIPmut negative subgroup (n=89) included corticotropinomas (7.9%), null 
cell adenomas (3.4%), plurihormonal tumours (13.5%), prolactinomas (12.4%), 
somatotropinomas (32.6%), mammosomatotroph adenomas (29.2%), as well as a TSHoma 
(1.1%, Figure 11e). In the AIPmut positive subgroup, one third (2/6) of the somatotroph 
adenomas with available cytokeratin staining had a densely granulated pattern and the rest 
were sparsely granulated. The distribution was similar in the AIPmut negative subgroup, where 
31.6% of the GH adenomas presented a densely granulated pattern (6/19) and 68.4% were 
sparsely granulated. Additionally, one AIPmut negative patient had a somatotropinoma with a 
mixed granulation pattern.  
 
Pituitary adenoma size and extension  
Familial patients 
We compared size and extension of pituitary adenomas between AIPmut positive and negative 
FIPA patients (Figure 12), and for this purpose, the prospectively diagnosed AIPmut positive 
patients were excluded from the analysis. Despite macroadenomas being predominant in both 
FIPA patient groups, the AIPmut positive FIPA patients had larger tumours, demonstrated by a 
larger maximum diameter (P=0.0404, Figure 12a) and a higher prevalence of macroadenomas 
(P<0.0001, Figure 12b). The proportion of giant (maximum diameter ≥40 mm) adenomas (6.3% 
in AIPmut positive and 3% in AIPmut negative patients) was not significantly different 
(P=0.1766). There was a higher frequency of extrasellar extension in AIPmut positive FIPA 
patients with pituitary adenomas (P=0.004, Figure 12c). Three of the AIPmut negative, but none 
of the AIPmut positive patients, harboured tumours with extensive invasion (defined as 
involvement of intracranial areas beyond the perisellar region); two of them had 
somatotropinomas and the third one harboured a gonadotropinoma. None of the patients in our 
cohort had evidence of metastases to justify a diagnosis of pituitary carcinoma.  
 
Sporadic patients 
In the sporadic cohort, the maximum diameter of the tumours and the proportion of giant 
adenomas were similar between AIPmut positive and negative sporadic cases (P=0.6965 and 
0.7859, respectively). All the AIPmut positive patients had macroadenomas (29/29) vs. 86.3% 
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(283/328) of the AIPmut negative subgroup, and the presence of extrasellar extension was 
more common in the former group (95% vs. 58.9%, P=0.0011).  
 
Apoplexy of the pituitary adenoma 
Excluding the prospectively diagnosed patients, symptomatic apoplexy of the pituitary adenoma 
occurred in 8.3% of the AIPmut positive cases (9.1% of the familial cases, including three 
families with two cases per family, and 5.9% of the sporadic patients) and in only 1.3% of the 
patients in the AIPmut negative subgroup (P<0.0001) and this difference remained significant 
when only the familial cases were analysed (10.6% of the AIPmut positive vs. 2.3% of the 
AIPmut negative patients, P=0.0002, Figure 12d).  
 
Eight (72.7%) of the AIPmut positive patients with a history of pituitary apoplexy had a diagnosis 
of gigantism, and in three of them (27.2%) apoplexy was the manifestation that led to the 
diagnosis of pituitary disease (Figure 12e). There were no significant differences in the age at 
onset/diagnosis or in the tumoral size between the AIPmut positive patients that developed 
pituitary apoplexy and those who did not have this complication. Out of ten AIPmut negative 
pituitary adenoma patients with a history of apoplexy, six had NFPA, two had acromegaly, one 
had gigantism and the specific diagnosis was unknown in the last patient.  
 
GH excess patients 
With the purpose of analysing a relatively homogeneous population of patients, we compared 
the main clinical features of the AIPmut positive and negative GH excess patients from both 
cohorts, excluding the prospectively diagnosed patients. Similar to the whole study population, 
the GH excess AIPmut positive patients had an earlier disease onset and diagnosis, had 
significantly more apoplexy cases (8.4 vs. 1.2%, P<0.0001) and a higher frequency of sparsely 
granulated tumours (91.7 vs. 57.1%, P=0.0073). In the AIPmut positive subgroup there is a 
preponderance of males (60.7% [65/107]), in contrast with the gender distribution found in 
patients with all the diagnostic categories. PRL co-secretion was more common in AIPmut 
positive patients (14 vs. 5.9%, P=0.0046).  
 
There were no differences in tumour size, frequency of extrasellar extension, or giant tumours, 
though most of the tumours in both subgroups (89.5%) were macroadenomas. There was no 
significant difference in the number of therapeutic modalities employed between the two 
subgroups, but there were fewer patients cured or controlled in the AIPmut negative subgroup 
(41/66 vs. 86/192, P=0.0151). Given that the AIPmut positive patients had a significantly longer 
follow-up duration, we decided to evaluate the current status (i.e. effect of the therapies) only in 
patients with zero to five years of follow-up. In this subset of patients, there was no significant 
difference in the percentage of cured or controlled patients between the AIPmut positive 
(57.1%) and the AIPmut negative (41.7%) subgroups.  
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Figure 12. Tumour size and pituitary apoplexy in FIPA families (excluding prospectively diagnosed AIPmut positive 
patients): AIPmut positive vs. AIPmut negative patients. a) Pituitary adenomas were larger in AIPmut positive familial 
patients (P=0.040), b) what was reflected in a higher frequency of macroadenomas (P=0.0001). c) In concordance with 
this, there was a higher frequency of extrasellar extension within AIPmut positive patients (P=0.004). d) The occurrence 
of symptomatic apoplexy of the pituitary adenoma was significantly more common among the AIPmut positive families, 
occurring in 10.6% of these patients (vs. 2.3% of the AIPmut negative FIPA patients, (P=0.0002), including one 
phenocopy NFPA patient. e) Apoplexy was the first sign of pituitary disease in 4.3% of the AIPmut positive familial 
patients, but only in 1% of the AIPmut negative ones. * P<0.05, **, P<0.01, ***, P<0.001, ****, P<0.0001.   
 
Gigantism 
This study included 120 patients with gigantism, 45 of them, (37.5%) were part of FIPA families 
and 75 (62.5%) presented as sporadic patients. Overall, 46.7% (56/120) of the patients with 
gigantism were AIPmut positive. Males were predominant among AIPmut positive and negative 
patients (global 67.5%), as expected for gigantism cases. Childhood-onset GH excess resulting 
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in gigantism was more prevalent among the AIPmut positive patients (48.3% [56/116]) than GH 
excess with no pathological body height, while the opposite pattern was observed in the AIPmut 
negative subgroup (only 16.7% [64/408] had gigantism, P<0.0001). Sixty percent of the AIPmut 
positive families had at least one patient with gigantism.  
 
 
Figure 13. Characteristics of gigantism cases (familial n=45, sporadic n=75) and penetrance. a) The great majority of 
the gigantism cases occurring in a familial setting were AIPmut positive vs. only one quarter of those cases presenting 
sporadically (P<0.0001). b) In our study population, all the kindreds including more than one case of gigantism carried 
AIPmuts (this graph includes all the AIPmut positive kindreds, FIPA and simplex patients, and the AIPmut negative FIPA 
families). c) Considering only those patients fulfilling the criterion of height ≥3SD over percentile 50, AIPmut positive 
patients were taller at diagnosis than the AIPmut negative ones (P=0.0164); however, d) there was no significant 
difference in height when the comparison was done among patients fulfilling the criterion of >2SD over midparental 
height. e) In average, there were more affected individuals per family in the AIPmut positive families (P<0.0001). ns, not 
significant, * P<0.05, ** P<0.01, ****, P<0.0001. 
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The frequency of AIPmuts was much higher in the gigantism cases occurring in a familial setting 
(Figure 13a), where 82.2% (37/45) of the patients were AIPmut positive, in comparison with the 
sporadic cohort, where AIPmut positive patients accounted for only 25.3% (19/75) of the 
patients (P<0.0001). Familial gigantism, defined as the occurrence of two or more gigantism 
cases due to pituitary adenoma in the same family, occurred only in AIPmut positive FIPA 
families (9/37 families, 24.3%, Figure 13b). Four of these families harboured the p.R304* 
AIPmut, and the AIPmuts g.4856_4857CG>AA, p.Q164*, p.269_H275dup, p.E24* and a whole 
gene deletion accounted for one family each. AIPmut positive gigantism patients were taller 
than their AIPmut negative counterparts if we considered the criterion of height >3SD over 
percentile 50 but not when considering >2SD over midparental height (Figure 13c and d). 
 
There was no difference in the age at diagnosis (global median 18 [IQR 15-23]) between the 
AIPmut positive and negative gigantism subgroups. Differences in the frequency of disease 
onset and diagnosis during the first decade of life did not reach statistical significance (onset: 
AIPmut positive 9.1% vs. AIPmut negative 9.5%; diagnosis: 3.6% vs. 1.6%). There were no 
significant differences in the parameters of tumour size and extension either (maximum 
diameter, frequency of giant adenomas and extrasellar invasion). However, it is worth noting 
that the vast majority of the tumours in both subgroups were macroadenomas (global 91.5%), 
and most of them displayed extrasellar invasion (77.6%). A small percentage of the patients had 
PRL co-secretion at diagnosis (9.2% global, not significantly different between AIPmut positive 
and negative patients). There were no significant differences in the number of treatments 
received or the frequency of controlled patients between the two subgroups. Overall, 43.2% of 
all the patients with gigantism have currently active or only partially controlled disease.  
 
Disease penetrance 
To calculate the penetrance of pituitary adenomas among AIPmut positive families, complete 
data is needed both for phenotype and genotype. Therefore, we have selected three families 
(two with p.R304*, and one with p.A34_K39del mutations) where complete data was available in 
three or more generations for consenting ‘at risk’ individuals. The AIP genotype was known in 
76.6% (range 68.4-94.7%) of the individuals at risk; of them, 16.8% were patients and 83.2% 
were unaffected carriers. The gender distribution was similar between patients and unaffected 
carriers. The mean penetrance in these three families was 28.6% (19-38.1), and it decreased to 
22.7% (18.2-26.7) when 50% of the individuals at risk with unknown genotype were considered 
as unaffected carriers. When the prospectively diagnosed patients were omitted from this 
calculation, the total penetrance of pituitary adenomas was 12.5%, highlighting the importance 
of the follow-up of apparently unaffected carriers for the correct calculation of the disease 
penetrance. 
 
As penetrance cannot be appropriately calculated for AIPmut negative families, we assessed 
the number of affected family members. The AIPmut positive families had more affected 
individuals per family than the AIPmut negative families (P<0.0001, Figure 13e). While 84.9% 
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(152/179) of the AIPmut negative families had only two affected members, 48.6% (18/37) of the 
AIPmut positive families had three or more pituitary adenoma patients per family. The maximum 
number of affected individuals within the same family was eight (six of them prospectively 
diagnosed) in a family carrying the p.R304* AIPmut, and the maximum number of cases of 
gigantism in the same family was five, in a FIPA family with the p.E24* AIPmut.  
 
Disease-modifying genes 
We have studied the role of two possible disease-modifying genes: GNAS1
95
 (somatic) and 
FGFR4 (germline).
221
 GNAS1 mutations were absent in all the studied AIPmut positive 
somatotropinomas (n=23), but were detected in 50% of the AIPmut negative familial 
somatotropinomas (5/10), 16.7% of the AIPmut negative young-onset cases (1/6), and 26.3% of 
the unselected acromegaly cases studied (5/19). All the mutations detected, detailed in Figure 
14, have been previously reported in the literature.  
 
 
Figure 14. GNAS1 mutations detected in the study population. Top panel: mutations in codon 201. Bottom panel: 
mutation in codon 227. All these mutations have previously been reported in the literature. WT sequence is at the top of 
each panel.  
 
Codon 201
CGT (WT)
c.601C>T 
(p.R201C)
c.602G>A 
(p.R201H)
Codon 227
CAG (WT)
c.680A>G 
(Q227R)
c.680A>T 
(Q227L)
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Figure 15. FGFR4 genotyping. Top: chromatogram of a WT individual. Middle: individual heterozygous for the SNP of 
risk. Bottom: individual homozygous for the SNP of risk.  
 
The distribution of the FGFR4 p.G388R SNP conserved the Hardy-Weinberg equilibrium 
(P=0.5509)
641
 and the genotype distribution was similar between patients (n=98) and AIPmut 
carriers (n=108) (P=0.523). The age at onset and at diagnosis, tumour size and frequency of 
extrasellar invasion were not significantly different between the GG (WT) and GR/RR patients.  
 
Extra-pituitary neoplasms in AIPmut positive individuals 
To explore the possibility of a syndromic presentation, we looked for additional neoplasms in the 
affected and unaffected AIPmut positive individuals (n=290). We found a total of ten cases of 
eight different extra-pituitary neoplasms (osteosarcoma, breast cancer, neuroendocrine tumour 
of the colon, GIST, glioma, meningioma, non-Hodgkin’s lymphoma and spinal ependymoma) in 
nine subjects (four patients and five unaffected AIPmut carriers, Table 12), accounting for 3.1% 
of the AIPmut positive individuals studied. AIPmut positive GH excess patients accounted for 
44.4% (4/9) of the individuals with extra-pituitary neoplasms, while the rest were unaffected 
AIPmut positive carriers. We note that the association of these tumours with AIPmuts could be 
coincidental.  
 
Table 12. Extrapituitary neoplasms in AIPmut positive individuals. 
Pituitary diagnosis Cohort Gender AIPmut Extrapituitary neoplasm 
Unaffected Familial Male c.910C>T (p.R304*) 
Osteosarcoma and neuroendocrine 
tumour of the colon† 
Unaffected Familial Female c.910C>T (p.R304*) Breast cancer† 
Unaffected Familial Female c.910C>T (p.R304*) Breast cancer† 
Acromegaly Familial Male 
c.805_825dup 
(p.F269_H275dup) 
GIST 
Acromegaly Familial Male c.241C>T (p.R81*) GIST* 
Unaffected Sporadic Male c.910C>T (p.R304*) Glioma 
Acromegaly Familial Female c.241C>T (p.R81*) Meningioma* 
Gigantism Familial Male c.74_81delins7 (p.L25Pfs*130) Non-Hodgkin’s lymphoma 
Unaffected Familial Female 
c.100-1025_279+357del 
(ex2del) (p.A34_K93del) 
Spinal ependymoma 
* Brother and sister. † Brother and 2 sisters. 
c.1162G/G (WT)
c.1162G/A
c.1162A/A
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An increased risk of malignancy among unselected pituitary adenoma patients has been 
previously reported.
642;643
 We have also found neoplasms within the AIPmut positive individuals 
with no pituitary adenomas, where hormonal excess, especially GH, does not play a role. 
Further analyses are needed to establish whether there is a possible association between 
AIPmuts and these neoplasms. Recently, germline AIPmuts have been associated with three 
cases of parathyroid adenomas (two middle aged women in the setting of non-familial, isolated 
PHPT and a young male with acromegaly).
393;499
 An MEN-1 like phenotype was an exclusion 
criterion in our study, therefore, it was not possible to assess this novel pathogenic association, 
and none of our patients or carriers developed PHPT during the follow-up. 
 
Follow-up and prospective diagnosis 
Out of the 164 originally identified unaffected AIPmut carriers, 160 were available and advised 
to undergo biochemical and clinical screening. Prospective diagnosis of a pituitary adenoma 
was established in 11.3% (18 subjects, 11 males) of the individuals originally considered as 
unaffected AIPmut carriers. Six of the prospectively diagnosed patients had acromegaly (one of 
them with PRL co-secretion), one patient had gigantism, two patients were diagnosed with mild 
acromegaly
605
 and nine patients harboured NFPAs. Out of the 142 individuals remaining as 
apparently unaffected AIPmut carriers, 79 (55.6%) underwent clinical assessment and one or 
more biochemical or imaging tests, while 63 subjects (44.4%) had only clinical evaluation. 
 
The prospective cases were diagnosed at an older age than the rest of the patients (median 30 
[IQR 22.8-39.5] vs. 23 [IQR 16-33] years, P=0.025). At diagnosis, seven of the prospectively 
diagnosed patients were symptomatic (headaches, arthralgias, acral growth, facial changes, 
weight gain or hyperhidrosis). Five of the 18 prospectively diagnosed tumours were 
macroadenomas, in contrast with a predominance of macroadenomas (89.9%, 71/79) in the rest 
of the AIPmut positive FIPA patients (P<0.0001). The maximum diameter was significantly 
smaller for prospective cases (median 5.8 [IQR 4.7-14.4] vs. 16.5 [IQR 10-29] mm, P=0.0002). 
Four of the patients with macroadenomas had surgery and the histopathological study 
confirmed GH or GH/PRL positive adenomas. The fifth macroadenoma was identified in a 68-
year-old male patient with high IGF-1, well-controlled hypertension and diabetes mellitus and no 
other comorbidities or symptoms, who did not want to receive any treatment. In addition, one 
AIPmut negative pituitary adenoma patient, harbouring a 25mm NFPA, was prospectively 
diagnosed as part of an AIPmut positive family (brother of the AIPmut positive proband).  
 
Further seven subjects had abnormalities in their screening tests, but a pituitary disease was 
not confirmed: five individuals had slightly elevated IGF-1 levels for their age/gender, one 
patient displayed acromegaloid features but normal pituitary MRI and biochemistry, and a 17-
year-old female had repeatedly borderline high IGF-1 and incompletely suppressed GH on 
OGTT, but her bulky pituitary gland (11mm in height), normal at this age group, is not changing 
during follow-up and her biochemical results are now within the normal range, after three years 
of follow-up.  
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The global penetrance of pituitary adenomas among the individuals initially considered as 
unaffected AIPmut carriers was 11.3% (18/160). However, the penetrance was higher in the 
group of carriers who underwent biochemical and imaging investigations varying between 18.6 
and 28.1% depending on the depth of screening (Figure 16). Overall, these data suggest that 
approximately 20-25% of the apparently unaffected AIPmut carriers screened with biochemical 
or imaging tests will be identified with a pituitary adenoma at some point in their lives. 
 
 
Figure 16. Penetrance in screened AIPmut positive carriers (n [total]=160). The probability of detecting new cases of 
pituitary adenomas within apparently unaffected AIPmut carriers depends on the clinical assessment and the type of 
complementary biochemical/imaging studies included in the screening protocol (see text). 
 
Clinical screening was not systematically performed in the AIPmut negative FIPA unaffected 
family members. Nevertheless, due to the increased disease awareness given by the existence 
of previous pituitary adenoma cases within their families, four individuals (three females and 
one male) from three different AIPmut negative FIPA families were prospectively diagnosed. 
Three of them harboured NFPAs, but we lack complete information about the fourth patient. The 
mean age at diagnosis in the three NFPA cases was 37 years, and only one patient referred 
symptoms at diagnosis (galactorrhoea, not clearly associated to stalk compression, and 
lethargy). All of them had microadenomas, with a mean diameter of 6.5mm, and did not require 
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any therapeutic intervention other than hormonal replacement in one case. The characteristics 
of these cases resemble those of incidentalomas; however, the occurrence of two prospective 
cases in the same family supports an apparent inherited component.  
 
Discussion 
AIPmuts are prevalent in young-onset GH-excess patients (24%) and FIPA (17.1%), with more 
than double frequency in patients with gigantism (46.7%) in our cohort, in concordance with 
other studies.
7;498;500;644
 However, in contrast to previous reports, in this large and extensively 
studied cohort there was no predominance of male patients among the AIPmut positive familial 
cases, and equal numbers of male and female unaffected carriers were identified. Earlier 
studies
9-11;488
 may have had an ascertainment bias for families with cases of gigantism, a 
disease that is more prevalent in males, at least partly due to the physiologically later puberty 
and therefore later cessation of growth in boys. In addition, we have found some interesting 
clinical features among AIPmut positive patients, which are described in the next paragraphs. 
 
The presence of two different types of pituitary adenomas in the same gland is infrequent (2.3% 
of all the cases and 3.3% of the cases of Cushing’s disease).
645
 Multiple pituitary adenomas 
have been previously described in a few cases of MEN1 and FIPA (not screened for AIPmuts) 
patients.
358;646-649
 Although somatotroph hyperplasia has been described before in the setting of 
AIPmuts,
6;650
 this finding does not seem to be particularly frequent, as in our cohort it was found 
only in one patient with acromegaly and PRL co-secretion.  
 
There was a marked predominance of sparsely granulated GH-secreting adenomas among the 
AIPmut positive patients, compared to the AIPmut negative ones. Patients with sparsely 
granulated tumours are usually younger at diagnosis than those with a densely granulated 
pattern,
651;652
 have increased invasiveness
202;651-653
 and reduced response to the treatment with 
SSA,
202;653
 though the strength of these associations has been variable among different studies. 
The mechanism proposed for this effect in sporadic adenomas implies a reduced expression of 
the SS receptor subtype 2 (SSTR2).
654;655
 Since the expression of the SSTR2 and other SSTR 
subtypes is not reduced in somatotropinomas from AIPmut positive patients, other molecular 
mechanisms must be involved in the association of these mutations with decreased 
responsiveness to SSA and a sparsely granulated pattern, such as ZAC1 activation
589;591
 or an 
impaired inhibitory G protein subunit function in these tumours.
509
 
 
The original description of multiple cases of pituitary adenoma apoplexy in AIPmut positive 
patients
9
 was later confirmed in other studies
10;11;276;603;650;656
 as well as now in this larger cohort. 
Although the prevalence of 8.3% does not seem to be higher than the prevalence reported in  
populations of unselected pituitary adenomas (7.9%),
68
 in the latter study patients were older 
(mean age 60.5 years) and harboured NFPAs, while in our cohort the majority had gigantism 
and the rest, acromegaly or prolactinoma, with a mean age at diagnosis of 23.4 years. Our 
three familial apoplexy families, together with a recently reported family with three apoplexy 
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cases
56
 provide support for the phenotype of young-onset, familial apoplexy in AIPmut positive 
patients. To our knowledge, there are no previously known genetic causes of familial pituitary 
adenoma apoplexy, and this remains an uncommon finding. The mechanism why AIPmut 
positive cases are more prone to apoplexy needs further study. 
 
We have demonstrated that around a quarter of the individuals initially identified as unaffected 
AIPmut carriers who underwent clinical screening tests were diagnosed with pituitary 
abnormalities. Full clinical screening identified 28.1% of the carriers, with fewer tests 
understandably resulting in fewer positive cases. Our data suggest that not all the AIPmut-
associated pituitary adenomas have a rapidly growing, aggressive phenotype. The follow-up of 
these patients allowed us to observe some probably very early cases of acromegaly, where the 
current clinical scenario had not indicated intervention at data closure. We cannot rule out that 
some of the small NFPAs are indeed incidentalomas, similar to those frequently observed in 
AIPmut negative subjects of the general population. 
 
This frequency of prospective diagnosis may justify the clinical screening and, possibly, follow-
up of all the AIPmut positive unaffected carriers. Our data would support the assessment of all 
the newly identified AIPmut carriers (clinical examination/history, PRL and IGF-1, as a minimum, 
up to a full screening, including also an OGTT and contrast-enhanced pituitary MRI). Follow-up 
of the younger family members should continue until at least the 30 years of age, preferably 
annually, with clinical assessment and basal pituitary hormonal levels, leaving stimulation tests 
for cases with suspicion of pituitary disease and a follow-up MRI if necessary.
603;610
 The cost-
effectiveness and the possible psychological burden of this approach will need future study. 
Stopping the follow-up should be considered in older patients, given the low possibility of 
detecting new pituitary adenoma patients in these individuals after the fifth decade of life.
603;610
 
Once a case has been prospectively diagnosed, the treatment and follow-up should proceed as 
for the general population of pituitary adenoma patients, as there are no data to suggest a 
different type of treatment in AIPmut positive patients.
482
  
 
The genetic and clinical screening of AIPmut negative FIPA families is uncertain at this point. 
Baseline screening and follow-up of obligate carriers could be considered, keeping in mind that 
the age of onset is considerably older in these families. Education on possible signs and 
symptoms of family members is a viable option in the routine setting. We expect that the 
identification of further genes implicated in the pathogenesis of FIPA in the next years will allow 
us to tailor these recommendations in accordance with the clinical behaviour of each genetic 
entity.  
 
Patients with GH excess starting before the age of 5 years should be tested for the recently 
identified Xq26.3 chromosomal microduplications.
91
 The genetic screening of other sporadic 
young-onset pituitary adenoma patients with no evidence of other endocrine tumours should be 
focused on AIPmuts in first instance in cases of GH excess (with or without PRL co-secretion) 
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and on MEN1 mutations, especially in cases of prolactinoma,
498
 as this can be the first 
manifestation of MEN1
657
. Whether it would be advisable to continue screening young patients 
with other diagnoses for AIPmuts out of the setting of research studies needs longer follow-up.  
 
To explain the variable clinical phenotype in our AIPmut positive patients, we evaluated the 
possible influence of two disease-modifying genes, GNAS1 and FGFR4. While somatic GNAS1 
mutations are common in unselected somatotropinomas, we have not identified any in 
adenomas from AIPmut positive patients, suggesting that germline AIPmuts and somatic 
GNAS1 mutations are mutually exclusive in somatotropinomas. A previous study in two isolated 
familial acromegaly cases, carrying the AIP c.804C>A (p.Y268*) mutation, reported similar 
results.
624
 GNAS1 mutations have previously been rarely studied in paediatric patients with 
acromegaly and gigantism, and they seem to be an extremely infrequent finding in this age-
group.
658;659
 GNAS1 mutations have rarely been studied in paediatric patients with acromegaly 
and gigantism, and they seem to be an extremely infrequent finding in this age-group.
658;659
 A 
recent study has shown no change in the AIP immunostaining in sporadic somatotropinomas in 
the presence of GNAS1 mutations.
17
 The characteristic phenotype of adenomas containing the 
GNAS1 seems to be in contrast with the typical AIPmut positive tumour phenotype. On the 
other hand, in somatotroph adenomas of AIPmut negative FIPA patients, half of the tested 
samples had GNAS1 mutations. This suggests that in AIPmut negative FIPA, somatic GNAS1 
mutations could exist in a similar frequency as to in unselected somatotropinomas and possibly, 
in addition to a germline predisposing mutation, may play a role in their pathogenesis.  
 
The FGFR4 gene SNP rs351855 (c.1162G>A, p.G388R), with a minor allele frequency of 0.3, is 
a predictor of progression and poor prognosis in a variety of human neoplasms.
219
 A role for 
rs351855 as a facilitator of somatotroph cell tumorigenesis has been recently proposed,
221
 and 
we hypothesised that this variant could increase the penetrance and/or size and extension of 
AIPmut positive pituitary adenomas. The screening for this SNP in our AIPmut positive patients 
failed to show increase in size, extension or apoplexy, even though this association had 
previously been suggested in sporadic acromegaly patients,
221
 and no earlier onset or higher 
penetrance were observed. The lack of association with these two potentially disease-modifying 
genes suggests that AIPmut-related pituitary adenomas are regulated by different pathogenic 
mechanisms than unselected somatotropinomas. 
 
The numerous limitations of our study are fully acknowledged. We chose an arbitrary age cut-off 
(≤ 30 years), in concordance with previous AIP-related publications, but our data shows that 
only 13.2% of the AIPmut positive patients had disease onset after the age of 30 years. Our 
patients were recruited from different genetic backgrounds and this could have influenced the 
disease penetrance and presentation. On the other hand, 19.7% of the AIPmut positive 
kindreds (24.3% of the AIPmut positive patients) belong to a cohort with a founder AIPmut 
(p.R304*), originally from Northern Ireland.
506
 The larger number of subjects screened in these 
families provided a higher number of carriers and chance for detection of affected individuals. 
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Additional genetic traits possibly co-segregating with this founder mutation could modify the 
phenotype and thus introduce a bias into our results. Full genotype and phenotype data were 
not available for all the families; therefore, we limited our penetrance calculations to three large, 
well-characterised families. A better assessment of the prevalence of pituitary apoplexy and 
extrapituitary adenomas in AIPmut positive patients would require a large control group, 
screened ad hoc, which was beyond the scope of this study. Finally, the data about therapeutic 
modalities was limited, hampering the analysis of the response to different treatments.  
 
Conclusions 
The analysis of this large cohort of FIPA patients allowed us establishing a number of novel 
aspects of FIPA. A phenotype-genotype correlation was found with younger onset of disease in 
patients with truncating AIPmuts. We identified a surprisingly high percentage of somatic 
GNAS1 mutations in the AIPmut negative somatotropinomas, and their absence in AIPmut 
positive tumours. The lack of influence of the germline FGFR4 p.G388R variant on disease 
penetrance/severity suggests that currently unknown factors drive penetrance and variable 
phenotype in AIPmut positive pituitary adenomas. The presence of milder, more indolent 
disease in some AIPmut positive subjects has been established. Genetic and clinical screening 
leads to the prospective identification of an unexpectedly high proportion of affected patients in 
the originally apparently unaffected carrier group, resulting in earlier diagnosis and treatment 
and, possibly, better long-term outcome
603
. The recruitment of a large study population with this 
uncommon disease has only been possible thanks to world-wide collaboration. 
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Chapter 3: 
An integral analysis of the panel of molecular partners of 
AIP in the pituitary: the role of AIP in pituitary tumorigenic 
pathways 
 
Introduction 
The mechanism by which AIP LOF disrupts pituitary function has remained elusive ever since 
disease causality was established between AIPmuts and pituitary adenomas. AIP is a co-
chaperone of HSP90 and HSPA8, with a promiscuous repertoire of molecular interactions.
15
 
More functional studies are needed to explain the role of AIPmut in pituitary tumorigenesis, in 
order to determine how the loss of tumour suppression activity occurs and to clarify the 
mechanism for the apparent pituitary specificity of this effect. 
 
The diverse experimental approaches used to describe AIP functions have been focused, in 
most of the cases, on addressing the function of AIP in the AHR signalling pathway in the 
setting of toxicological studies.
521;570;587
 The role of AHR in tumorigenesis is complex, but the 
current hypothesis is that increased AHR expression or activity correlates with tumour 
progression in most human tissues.
660
 AIPmut positive pituitary adenomas show loss of nuclear 
AHR staining, indicating that AIPmut-associated tumorigenesis is very probably not driven via 
increased AHR signalling.
481
 An epidemiological study suggested an association between 
environmental pollution by dioxins and a higher frequency of acromegaly,
661
 and an AHR SNP 
has been described as a possible disease modifier in somatotropinomas.
662
 However, animal 
models of AHR deficiency do not display a pituitary phenotype,
596
 and it is clear from other 
studies that the role of AHR on pituitary tumorigenesis, if existent, is not prominent, neither in 
the setting of AIP LOF,
509
 nor in other types of pituitary adenomas.
663
 
 
Two recent studies reported an apparent regulatory role of AIP in the cAMP pathway,
509;588
 
which could be mediated by activation of GNAI2 and GNAI3.
509
 These results are supported by 
the clinical and experimental observation that AIP expression is enhanced by the treatment with 
drugs activating the SS pathway, the main regulator of cAMP in the pituitary gland. 
Nevertheless, the experimental approaches used to address these questions have been based 
on the study of expression patterns under different conditions, such as AIP KD or KO, 
pharmacological phosphodiesterase blocking or cAMP overactivation, among others.  
Although these techniques have rendered important data regarding the functional changes in 
signalling pathways under those stimuli, they have been unable to determine which specific 
molecular interactions must occur (or stop occurring) for those functional changes to take place. 
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Considering the fact that AIP is a ubiquitously expressed protein, that it is not known to be a 
transcription factor and that AIPmuts are associated to pituitary adenomas only, it is very 
probable that the pituitary specific function of AIP is not due to the protein itself or to its 
expression pattern, but explained by its possible intervention on signalling pathways regulating 
cell proliferation specifically in the pituitary gland. On these bases, the present study has been 
focused on studying the specific repertoire of AIP interacting proteins in the pituitary gland, 
using a proteomic approach. 
 
Aims 
General  
To identify the molecular partners of AIP in the pituitary gland using a proteomic approach and 
to analyse the potential role of AIP in the pathways that drive pituitary tumorigenesis.  
 
Specific 
1. To produce a glutathione-S-transferase (GST)-fused WT AIP and six AIP variants 
(p.E192R, p.C238Y, p.K266A, p.A299V, p.R304* and p.R304Q) using a GST tag-
mediated affinity purification system. 
2. To perform pull-down assays in a somatotropinoma cell line using the purified proteins 
as baits.  
3. To identify relevant AIP interacting proteins in a somatotropinoma cell line through 
quantitative MS (qMS), analysing differences in the repertoire of protein interactions 
among WT AIP and its variants. 
– To determine if the differences in AIP interactions are only due to loss of normal 
interactions or if new interactions are generated by variants. 
4. To validate qMS results through co-immunoprecipitation (co-IP) and co-localisation 
assays. 
5. To analyse the identified AIP interacting proteins using a pathway analysis software.  
– To define if the identified AIP interacting proteins are involved in pathways 
which are relevant for pituitary tumorigenesis.  
6. To explore the role of AIP in pituitary tumorigenic pathways. 
 
Hypotheses 
1. AIP interacts with proteins that regulate the cell cycle in somatotroph cells.  
a. Pathogenic AIP variants lose some of these protein-protein interactions, 
supporting the role of AIP as a tumour suppressor factor. 
2. Variants with a questionable pathogenic effect do not differ to WT AIP in their 
interacting proteins repertoire. 
3. Proteins related to pituitary tumorigenesis interact with some AIP variants but neither 
with other variants, nor with WT AIP.  
a. Those abnormal interactions favour uncontrolled cell proliferation.  
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4. The effect of certain variants is double: disruption of tumour suppressor function and 
enhancement of uncontrolled cell proliferation. 
 
Methods 
Selection of AIP variants  
Six AIP variants were selected for the study, as detailed below. 
 
AIP p.E192R (chr11:67257614-67257615)  
The possibility that AIP could dimerise has been proposed, but remains unproven. If this occurs, 
the residue E192 is expected to be essential for binding another AIP molecule, through its 
interaction with R312 (in silico analysis by C. Prodromou). The variant p.E192R (c.574-
575GA>CG) at AIP exon 4 has never been found in patients, but it is predicted to disrupt the 
hypothetical AIP dimerisation ability.  
 
p.C238Y (rs267606569, Genbank EF643648, chr11:67257854) 
This transition (c.713G>A), located at AIP exon 5, was detected for the first time in a FIPA 
family.
9;495
 This variant is considered a missense mutation, predicted to destabilise the 
packaging of α and β helices of the second TPR motif.
10
 Functional studies have shown a 
reduced ability of AIP p.C238Y to block cell proliferation in vitro,
9
 as well as a complete 
disruption the AIP-PDE4A5 interaction.
10
 All the available information supports its pathogenic 
potential. 
 
p.K266A (chr11:67258267-67258268) 
The residue K266 in AIP is essential for the interaction between AIP and HSP90.
556
 The 
experimental mutation p.K266A (c.796-797AA>GC) at exon 6 disrupts this interaction in vitro, 
though it has never been found in patients.
556
 Loss of HSP90 binding significantly reduces the 
ability of AIP to interact with AHR,
556
 but it is unknown if this affects other signalling pathways. 
We decided to include this mutation as an approach to analyse the importance of HSP90 for 
AIP function.  
 
p.A299V (rs148986773, Genbank EF203235, chr11:67258367) 
This variant is a transition (c.896C>T) at the exon 6 of AIP, first described in a patient with 
sporadic acromegaly.
615
 Although it was initially considered a missense mutation, two 
apparently healthy individuals are compound heterozygotes for p.R304* and p.A299V.
9
 
Furthermore, one FIPA patient has been found to bear p.A299V and a microprolactinoma, so 
the probability of a phenocopy cannot be discarded.
10
 This variant is localised at the beginning 
of the C-terminal α-7 helix of the protein. Functional studies for p.A299V showed only slight 
reduction in PDE4A5 binding in vitro.
10
 This variant in currently not considered pathogenic, 
mainly based on clinical data, but there is not enough experimental evidence to support this.  
 
p.R304* (rs104894195, Genbank AM236344, chr11:67258381) 
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The codon 304 is a mutational hotspot in AIP and p.R304* is the most frequent mutation found 
in AIPmut positive pituitary adenoma patients. This transition (c.910C>T) at AIP exon 6 was 
originally described in a family with IFS.
8
 Since then, p.R304* has been reported in both patients 
(familial and simplex) and apparently healthy carriers. Functional studies for R304* proved 
complete disruption in PDE4A5 binding and loss of the ability of the mutant AIP to block cell 
proliferation in vitro.
9
 This variant is considered a nonsense mutation, resulting in a truncated 
protein, and all the available data support its pathogenic potential. 
 
p.R304Q (rs104894190, Genbank EF203236, chr11:67258382) 
This variant is also a transition (c.911G>A) at AIP codon 304. The p.R304Q variant was first 
found in an apparently sporadic case of Cushing´s disease
615
 and since then it has been 
reported in several FIPA families and simplex patients. This variant is relatively conservative, 
changing a longer side chain, positively charged amino acid, to a slightly shorter, uncharged, 
hydrophilic one at the C-terminal α-7 helix.
10
 Although it does not affect PDE4A5 binding by AIP 
in vitro,
10
 other functional studies are not available and clinical data support the role of p.R304Q 
as a missense pathogenic mutation. Interestingly, the ExAC database reports the presence of 
this variant in homozygosity in two European individuals,
217
 increasing the uncertainty about its 
pathogenic effect. 
 
Generation of plasmids for protein production 
 
 
Figure 17. Plasmid for expression of GST- tagged AIP. The pTHREE-E plasmid is based on the commercial plasmid 
pGEX-6P-1 and confers ampicillin resistance to the transformed bacteria. The CDS cloned into the multiple cloning site, 
in this case AIP, is positioned downstream the CDS of S. japonicum GST, to express a fused GST-AIP protein. The 
expression of the GST-AIP CDS is regulated by the tac promoter. The plasmid constitutively expresses the lacIq 
repressor, which binds and represses the tac promoter (containing a lac operator). When IPTG is supplemented to the 
medium, it binds the lacIq repressor, inactivating it, and thus allowing tac promoter-driven transcription to take 
place.
664;665
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A set of plasmids based on the non-commercial p-THREE-E plasmid (A. Oliver, University of 
Sussex. Figure 17) was generated, carrying the AIP CDS (WT and variants) downstream the S. 
japonicum GST gene. In this plasmid, the transcription of the fused cDNA GST-AIP is under the 
control of the isopropyl-β-thiogalactoside (IPTG)-inducible lac promoter. The plasmids for WT 
AIP and the mutants p.C238Y, p.A299V, p.R304* and p.R304Q and the empty plasmid 
(codifying GST only) were a kind gift of C. Prodromou and collaborators (University of Sussex).  
 
Calcium competent JM109 E.coli (strain pre-existent in the laboratory stocks, prepared as 
described in Protocol 3) were transformed with each of the GST-AIP plasmids, as described in 
Protocol 4, and grown overnight at 37°C. Colonies were selected and inoculated in 10 ml of LB 
broth with 100 µg/ml ampicillin, to be grown overnight at 37°C/250 rpm. One millilitre of each 
culture was used to inoculate 200 ml of LB broth with 100 µg/ml ampicillin to obtain large-scale 
cultures and the remaining volume was used for DNA extraction, as specified in Protocol 5. The 
large-scale cultures were incubated overnight and then centrifuged at 4000rpm for 10 min at 
room temperature (RT). The pellets were stored at -80°C until the sequences of the plasmids 
were confirmed. 
 
To obtain the plasmids for the AIP mutants p.E192R and p.K266A, site-directed mutagenesis of 
the WT plasmid was performed using the QuikChange II XL kit (Agilent Technologies 200521), 
following the manufacturer’s instructions, as detailed in Protocol 6. The mutagenic primers were 
designed using the QuikChange Primer Design tool:
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AIP_E192R_F: 5’- ACCGGTTGTACCGCCGGGGGCATGTGAAGG-3’ 
AIP_E192R_R: 5’-CCTTCACATGCCCCCGGCGGTACAACCGGT-3’ 
AIP_K266A_F: 5’-GTACGACGACAACGTCGCGGCCTACTTCAAGCGG-3’ 
AIP_K266A_R: 5’-CCGCTTGAAGTAGGCCGCGACGTTGTCGTCGTAC-3’ 
 
Colonies of XL10-Gold E.coli transformed with the mutagenised plasmids were selected and 
inoculated in 10 ml of LB broth with 100 µg/ml ampicillin, to be grown overnight at 37°C/250 
rpm. As for the rest of the plasmids, these cultures were used for inoculating large-scale 
cultures and for DNA extraction, and pellets obtained from the large scale cultures were stored 
frozen at -80°C. The plasmids for p.E192R and p.K266A were submitted for Sanger sequencing 
at the Genome Centre sequencing facility (Barts and The London School of Medicine), using 
the following primers: 
 
pGEX-5_F: 5’-CTGGCAAGCCACGTTTGG 
pGEX-5_R: 5’-GGAGCTGCATGTGTCAGAG 
 
The sequences of the rest of the plasmids were obtained from C. Prodromou and collaborators 
(University of Sussex). Once all the sequences had been confirmed, the frozen bacterial pellets 
were used for DNA extraction, as described in Protocol 7. 
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Production and purification of GST-AIP proteins 
To optimise the conditions for protein production, calcium competent protease-negative BL-21 
E. coli (Bioline BIO-85031) were transformed with p.THREE-E-WT_AIP (as described in 
Protocol 4). Two colonies were selected, inoculated in 5 ml of LB broth with 100 µg/ml ampicillin 
and grown at 37°C/250 rpm. Twelve hours later, 1 M IPTG was added to one of the tubes to a 
final concentration of 1 mM, and the incubation was continued at 20, 22 or 28°C. At, 0, 5, 10, 
20, 30 and 40 h after the addition of IPTG, 500 µl samples were taken from each culture, 
pelleted (13000 g for 2 min) and stored at -20°C until the end of the experiment. Finally, the 
bacterial pellets were defrosted, the cells were disrupted in 100 µl of 1X SDS gel loading buffer, 
denatured for 5 min at 100°C and resolved by polyacrylamide gel electrophoresis (PAGE), as 
detailed in Protocol 8. The PAGE gels underwent Coomassie staining (see Protocol 9) and the 
band corresponding to the size of AIP was compared between the IPTG-induced and the non-
induced cultures at each time point for each induction temperature (Figure 18). Based on these 
results, an induction temperature of 20°C was selected, and used for protein production. 
 
 
Figure 18. Optimisation of growth and IPTG induction conditions for protein production. Bacteria transformed with 
pTHREE-E-WT_AIP plasmid were grown for 12 h and then induced with 1 mM IPTG (IPTG) or not induced (NI) at 20°C. 
Samples were taken at 0, 5, 10, 20, 30 and 40 h post-induction. Whole bacterial lysates were resolved in a 10% bis-tris 
polyacrylamide gel and Commassie blue stained. The arrow indicates the location of the expected AIP band (64.8 kDa). 
MWM: molecular weight marker. 
 
Protein production and purification were carried out at the Genome Damage and Stability 
Centre, University of Sussex, following the procedures detailed in Protocol 10. For each of the 
GST-AIP and GST plasmids, calcium competent protease deficient BL21-PLyss E. coli were 
transformed, and all the transformed colonies were collected and used as a starter culture to 
inoculate 3 l of LB broth with 100 µg/ml ampicillin. Bacteria were grown at 37°C/250 rpm until 
OD600 0.6-0.8, then IPTG was added to a final concentration of 1 mM and incubation was 
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continued at 20°C overnight. Bacteria were pelleted and lysed by sonication, and the lysates 
were cleared by centrifugation. Lysates underwent affinity purification using glutathione 
sepharose, and the purified proteins were eluted with a glutathione-containing buffer and 
concentrated. The affinity-purified samples, except the GST protein, underwent gel filtration 
chromatography to eliminate protein aggregates, with reduced biological activity. 
Chromatography fractions were resolved by PAGE and Coomassie blue staining, and the 
fractions containing the expected proteins were pooled, concentrated and frozen for later use 
(Figure 19 and Figure 20). The yield of GST-AIP C238Y was poor and the protein looked 
insufficiently purified, so it was not used in subsequent experiments. GST protein, eluted in 
glutathione-containing buffer, was dialysed against 1 l of 1M NaCl/1M Tris-HCl pH 7.5 overnight 
at 4°C in agitation (10K MWCO Slide-A-Lyzer dialysis cassette [Thermo Scientific 66383]), and 
concentrated; 5% glycerol was added and the sample was frozen for later use. 
 
The identity of the synthetic proteins obtained was verified by Western blot (WB, details in 
Protocol 11), using the following antibodies and concentrations (Figure 21):  
- Primary antibodies: mouse monoclonal anti-AIP/ARA9 antibody (35-2) (Novus 
Biologicals NB100-127) and rabbit polyclonal anti-GST antibody (1-109) (Santa Cruz 
Biotechnologies sc-33613), both 1:1000 (v/v). 
- Secondary antibodies: IRDye® 680 RD Goat anti-Mouse IgM (µ chain specific) (LI-COR 
926-68180) IRDye® 800CW Goat anti-Rabbit IgG (H + L) (LI-COR 926-32211), both 
1:20000 (v/v). 
 
GST pull-down assays 
The experimental procedure was based on a classic protocol
667
 and optimised by varying the 
starting material and washes to obtain a consistent pattern of visible bands in Coomassie blue 
stained polyacrylamide gels. Using the experimental conditions detailed in Protocol 12, six 
different assays were performed, using no bait or GST, GST-WT AIP, GST-AIP K266A, GST-
AIP A299V, GST-AIP R304* and GST-AIP R304Q as bait proteins, respectively. Briefly, cell 
lysates obtained from 12X10
6
 GH3 cells (R.norvegicus somatotropinoma-derived) were pre-
cleaned with glutathione beads, and then incubated for 4 h with 10 µl of each bait protein, pre-
bound to glutathione beads. The beads were washed and eluted in a glutathione-containing 
buffer. The pull-down assay was repeated four times for each bait protein and the eluates of the 
four experiments were pooled together and dialysed against 1X PBS, as reduced glutathione 
and Tris-HCl present in the elution buffer are not compatible with isobaric mass tagging 
reagents. Finally, the samples and the unbound fractions were resolved by PAGE and analysed 
in Coomassie-stained gels (Figure 22). The total protein content of the cleared lysate used for 
each pull-down experiment was ~2 mg. Additionally, samples from all the steps of one of the 
pull-down experiments using GST- WT AIP as bait were analysed by WB to verify the presence 
of HSP90, a known molecular partner of AIP, using the mouse monoclonal HSP 90α/β (F-8) 
antibody (Santa Cruz Biotechnologies sc-13119) at a concentration of 1:1000 (v/v), according to 
Protocol 11 (Figure 23). 
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Figure 19. Gel filtration chromatography 1. WT AIP (a), AIP p.E192R (b) and AIP p.C238Y (C). Collected fractions are 
marked with brackets in the chromatograms, 5 µl of each fraction were resolved in a 4-12% bis-tris gel and Coomassie 
blue stained. Arrow: expected size of GST-AIP. Ladder is in the first lane of each gel, except for the last gel.  
b AIP p.E192R: chromatogram
AIP p.E192R: PAGE of collected fractions
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188 kDa
14 kDa
6 kDa
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a WT AIP: chromatogram WT AIP: PAGE of collected fractions
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c AIP p.C238Y: chromatogram
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Figure 20. Gel filtration chromatography 2. AIP K266A (a), AIP p.A299V (b), AIP p.R304Q (c) and AIP p.R304* (d). 
Collected fractions are marked with brackets in the chromatograms, 5 µl of each fraction were resolved in a 4-12% bis-
tris gel and Coomassie blue stained. Arrow: expected size of GST-AIP. Ladder is in the first lane of each gel. Gel for 
p.K266A includes a sample of the flow-through of the affinity purification (second lane).  
a AIP p.K266A: PAGE of collected fractionsAIP p.K266A: chromatogram
28 kDa
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188 kDa
14 kDa
6 kDa
62 Da
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49 kDa
98 kDa
b AIP p.A299V: chromatogram AIP p.A299V: PAGE of collected fractions
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c AIP p.R304*: PAGE of collected fractionsAIP p.R304*: chromatogram
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62 Da
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d AIP p.R304Q: chromatogram
AIP p.R304Q: PAGE of collected fractions
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62 Da
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49 kDa
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3 kDa
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Figure 21. WB to confirm the identity of the synthetic GST-proteins. Two hundred nanograms of each purified protein 
were resolved in an 4-12% bis-tris polyacrylamide gel and used for WB (see text). The membrane for the anti-GST WB 
is on the left panel, and the membrane for the anti-AIP WB is on the right panel. The arrows mark the position of the 
normal-sized GST-AIP proteins (upper arrow, 64.8 kDa) and the truncated GST-AIP p.R304* protein (lower arrow, 61.5 
kDa). Mass of GST (second lane of the left panel) is 26.8 kDa.  
 
 
 
Figure 22. Pull-down assays. Pull-down experiments were carried out using the final experimental conditions. On the left 
panel, the total pull-down products, eluted in loading buffer, are shown. The arrows mark the position of the normal-
sized GST-AIP proteins (upper arrow, 64.8 kDa) and the truncated GST-AIP p.R304* protein (lower arrow, 61.5 kDa). 
On the right panel, the unbound fractions are presented for comparison. The samples were resolved in a 4-12% bis-tris 
polyacrylamide gel and Commassie blue stained. CL: cleared lysate. 
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Figure 23. Anti-HSP90 WB in pull-down fractions. HSP90 was detected in a sample of cleared lysate (CL, ~15 µg), in an 
eluate from the beads used to pre-clean the lysate (beads PC, ~20 µl), in the unbound fraction (20 µl) and in the pull-
down (total reaction eluted in 20 µl). The samples were resolved in a 4-12% bis-tris polyacrylamide gel and used for 
anti-HSP90 WB (see text). 
 
Tandem mass tagging and quantitative mass spectrometry analysis 
Tandem mass tagging (TMT)
668
 and qMS were carried out at the King’s College London 
Denmark Hill Proteomics Facility. Ten micrograms of each of the six protein eluates obtained 
from the pull-down experiment were labelled with a different TMT tag, and the six samples were 
pooled together after labelling. The pooled sample was loaded in two lanes of a 4-12% bis-tris 
polyacrylamide gel and separated by PAGE. The gel was stained with Coomassie blue and the 
two lanes containing the samples were cut in 15 transversal slices. The samples were then 
lyophilised, rehydrated, destained and trypsin-digested. Finally, the resulting peptides were 
extracted from the gel and stored at -80°C until analysed. The complete method for TMT, in gel 
trypsin digestion and peptide extraction can be found in Protocol 15. 
 
For MS analysis, the samples were separated by liquid chromatography (LC) in a gradient of 
acetonitrile in formic acid. Peptides underwent electrospray ionisation (ESI) using a Z-spray 
source and ion trap MS/MS was conducted using an Orbitrap Velos Pro (Thermo Scientific) 
instrument. The MS/MS analyses were conducted using collision energy profiles that were 
chosen based on the mass-to-charge ratio (m/z) and the charge state of the peptide. The qMS 
data were processed using the Proteome Discoverer version 1.3.0.339 (Thermo Scientific) 
software, obtaining the following number of filtered/unfiltered result items: 
- 102/117 Protein groups 
- 2568/2568 Merged proteins 
- 2377/2377 Peptides 
- 3967/3967 PSM 
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- 6981/6981 Search inputs 
 
The following parameters were applied to generate the spectrum files: 
- Peptide Grouping Options 
 Show peptide groups: True 
 Group peptides by: Mass and Sequence 
- Protein Grouping Options 
 Enable protein grouping: True 
 Consider leucine and isoleucine as equal: True 
 Consider only PSMs with confidence at least: Medium 
 Consider only PSMs with delta Cn better than: 0.15 
 Apply strict maximum parsimony principle: True 
 
Then, spectra were selected using the following filters: 
 Min. Precursor Mass: 700 Da 
 Max. Precursor Mass: 10000 Da 
 Total Intensity Threshold: 100 
 Minimum Peak Count: 8 
 
The peptides’ sequences generated were searched in the UniProt
510
 database using the Mascot 
v.2.2 platform.
669
 The following Mascot search parameters were used:  
- Protein Database: uniprot_sprot 
- Enzyme Name: Trypsin 
- Maximum Missed Cleavage Sites: 3 
- Instrument: ESI-TRAP 
- Taxonomy: all entries 
- Peptide Scoring Options: 
 Peptide Cut Off Score: 10 
 Peptide Without Protein Cut Off Score: 5 
-  Protein Scoring Options: 
- Use MudPIT Scoring: Automatic 
- Protein Relevance Threshold: 20 
- Protein Relevance Factor: 1 
- Tolerances: 
 Precursor Mass Tolerance: 5 ppm 
 Fragment Mass Tolerance: 0.5 Da 
- Dynamic Modifications: deamidated (NQ), oxidation (M), TMT6plex intact labelling (K) 
- Static Modifications: carbamidomethyl (C), TMT6plex intact labelling (Protein N-term) 
- Taxonomy: Rattus norvegicus. 
- Variable modifications: carbamidomethyl (C), Gln->pyro=Glu (N-termQ), oxidation (M), 
TMT6plex (K), TMT6plex (protein N-term) 
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The list of peptides generated was quantitatively analysed by performing a new search which 
omitted the variable modifications TMT6plex [K] and TMT6plex [protein N-term] and adding 
quantitation using the parameter “TMT6plex intact protein labelling”. 
 
Results were filtered using the Percolator function in the platform  
- Maximum Delta Cn: 0.05 
- Decoy Database Search: 
- Target false discovery rate (FDR) (Strict): 0.01 
- Target FDR (Relaxed): 0.05 
- Validation based on: q-value 
 
For reporting the quantifier ions, the following parameters were entered:  
- Quantification Method: TMT 6plex PS (Custom) 
- Peak Integration: 
 Integration Window Tolerance: 20 ppm 
 Integration Method: most confident centroid 
 
All data files were processed through the in-house Perl script Mmunger (King’s College London 
Denmark Hill Proteomics Facility), which extracted the absolute intensity values of the TMT 
reporter ions from the .dat file generated by the Proteome Discoverer platform. CSV files were 
produced and saved, and these results were exported to a Microsoft Excel 97 file for further 
analysis. A manual analysis of the MS fragmentation spectra of all the peptides obtained from 
the Mascot search was performed by the MS Facility staff using the Scaffold (Proteome 
Software) software. Only peptides with the following criteria were considered valid further 
analysis: a Mascot score ≥20 and a valid MS spectrum. The Mascot score is defined as the 
probability that the observed match is a random event, reported as -10*log10 (probability). 
Proteins with three or more assigned peptides were considered as highly probable candidates. 
 
Selection of candidates 
The peptides considered valid were grouped in proteins, and these proteins were listed in 
decreasing order, according to the number of assigned peptides. Those proteins with three or 
more assigned peptides were considered as highly probable candidates. The intensity values 
for each TMT tag were matched to the corresponding AIPmut and GST control used in the pull-
down experiments and labelled as follows: TMT126=GST, TMT127=WT, TMT128=K266A, 
TMT129=A299V, TMT130=R304*, TMT131=R304Q. When a single peptide was reported 
several times, an average of the intensity values was calculated for each tag. For normalisation 
against the negative control, the intensity value obtained for the GST experiment was 
subtracted from the value obtained for WT AIP and each of the mutants. Peptides showing 
intensity values below 0 for all the tags after normalisation were discarded. Then, the 
normalised values for each of the mutants were divided by the normalised value for the WT 
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protein. Those peptides showing significant differences between the intensity values for AIP and 
the pathogenic variant R304* (≥1.5 fold, positive or negative) or present in the WT protein and 
absent in the mutant, or vice versa, were also considered of interest. When none of the peptides 
assigned to one candidate protein was identified in the WT AIP pull-down experiment, or when 
the normalised intensity value for all the peptides assigned to one protein was ≤0, the protein 
was discarded from the list of candidates. The Ingenuity Pathways Analysis platform
670
 was 
used for grouping the identified proteins in signalling pathways. The human homologues of the 
candidates selected were identified using the Blast tool in the UniProt database.
510
 The best 
match was selected in each case, and the rest of the experiments are based on these human 
homologues.  
 
Generation of plasmids for co-immunoprecipitation 
Candidate AIP partners selected from the previous analysis underwent a validation process 
using co-IP and/or co-localisation. For the co-IP experiments, a previously existent plasmid 
containing the Myc tag upstream the WT AIP CDS (pcDNA3.0-Myc-AIP_WT) was co-
transfected in HEK293 cells (human embryo kidney, ECACC 85120602) together with the 
human influenza hemagglutinin (HA) tag-containing plasmid pSF-CMV-NH2-HA-EKT-NcoI 
(Oxford Genetics OG93), in which the CDS of each of the candidate AIP partners was cloned 
downstream the tag. Additionally, a previously existent plasmid containing the Flag tag at the 3’ 
end of the WT AIP CDS (pCI-neo-AIP_WT-Flag) was used for testing the dimerisation of AIP. A 
scheme of these plasmids is shown in Figure 24.  
 
 
Figure 24. Map of the plasmids used in the co-IP experiments. AIP was expressed with an N-terminal Myc (a) and a C-
terminal Flag (b) tags. c) Candidate AIP partners were expressed as N-terminal HA-tagged (as HSPA9 in this example). 
Antibiotics used for colony selection were ampicillin for plasmids a and b, and kanamycin for plasmid c. 
 
a
c
b
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A pcDNA3.0-Myc plasmid carrying the p.R304* AIP mutation (previously existent in the 
laboratory stocks) was also used for some experiments. 
 
Three different strategies were employed for cloning the CDS of AIP candidate partners in the 
pSF-CMV-NH2-HA-EKT-NcoI plasmid, based on the available source of the CDS for each 
candidate partner: cloning from cDNA, subcloning from other plasmids using two restriction 
enzyme sites and creating one restriction enzyme site by PCR and then subcloning using two 
restriction enzyme sites. The procedures used to create each plasmid are presented in Table 
13. Sequences used matched the reference sequence for each mRNA (with some exceptions, 
as detailed in Table 14), and codified the exact proteins reported in the candidate partners list. 
Mutations were corrected by site-directed mutagenesis when necessary.  
 
Cloning from cDNA was used only for the SOD1 plasmid. As shown in Table 13, primers to 
amplify the whole CDS from cDNA were designed using the Primer3 v.4.0.0 software.
671
 Total 
RNA was extracted from HEK293 cells as specified in Protocol 16. One microgram of total RNA 
was reverse transcribed, following the procedure specified in Protocol 18. High-fidelity PCR was 
carried out with 40 ng of cDNA, 3’ A-overhangs were added and the PCR product was 
visualised in an agarose gel, according to Protocol 19. The band containing the expected PCR 
product was cut and DNA was extracted, according to Protocol 20. The purified band was used 
for TA cloning into the plasmid pCR2.1, according to Protocol 21, and calcium competent DH5α 
E.coli were transformed with the whole ligation reaction, according to Protocol 4. Bacteria were 
plated on agar containing 0.1 mM IPTG, 20 µg/ml 5-bromo-4-chloro-3-indolyl-beta-D-galacto-
pyranoside (X-gal) and 100 µg/ml ampicillin for blue-white colony screening. White colonies 
were screened by colony PCR (Protocol 22), using the following primers: 
 
pUC/M13_F: 5´-GTTTTCCCAGTCACGAC-3´ 
pUC/M13_R: 5´-CAGGAAACAGCTATGAC-3´ 
 
Positive colonies were inoculated in 10 ml of LB broth with 100 µg/ml ampicillin, to be grown 
overnight at 37°C/250 rpm, and DNA was extracted from one culture (Protocol 5); the rest of 
them were stored at 4°C. The purified plasmid was sent for sequencing (Genome Centre, Barts 
and The London School of Medicine) using the pUC/M13 primers. 
 
The pCR2.1-SOD1 plasmid was used as a template for high-fidelity PCR (Protocol 19) to add a 
5’ NcoI restriction enzyme site, as specified in Table 13. The PCR product was visualised in an 
agarose gel, cut and purified (Protocol 20), the whole sample volume was digested with NcoI 
and SpeI restriction enzymes, as detailed in Protocol 23. The plasmid of destination (psF-CMV-
NH2-HA-EKT-NcoI) was digested likewise, using the restriction enzymes NcoI and NheI (SpeI 
and NheI create complementary ends), and dephosphorylated (Protocol 23). The digestion 
products were resolved in a 1% agarose gel and the bands were cut and purified, as before. 
Finally, the purified bands were ligated (see Protocol 24).  
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Table 13. Plasmids used for co-immunoprecipitation of candidate AIP partners 
Human 
protein 
CDS origin 
Plasmid of 
destination 
Subcloning method Primers Final plasmid  
AIP 
- 
 
- - - 
pcDNA3.0-Myc-AIP_WT 
(1026 bp) 
AIP 
- 
 
- - - 
pCI-Neo-AIP_WT-Flag 
(1014 bp) 
CBR1 
pDONR221-CBR1                           
(PlasmID 
HsCD00044416 ) 
pSF-CMV-NH2-HA-
EKT-NcoI 
PCR adding a 5' XbaI site, then XbaI 
digestion of PCR product and ligation in 
XbaI-EcoRV- digested plasmid 
CBR1-XbaI_F CCGTTCTAGAATGTCGTCCGGCATCCA                           
pUC/M13_rev CAGGAAACAGCTATGAC 
pSF-CMV-NH2-HA-EKT-
NcoI-CBR1 
DSTN 
pOTB7-DSTN                     
(PlasmID 
HsCD00328071) 
pSF-CMV-NH2-HA-
EKT-NcoI 
PCR adding a 5' NcoI site, then NcoI 
digestion of PCR product and ligation in 
NcoI-EcoRV-digested plasmid 
DSTN-NcoI_F GCGACCATGGCCTCAGGAGTGCAAG                            
pUC/M13_rev CAGGAAACAGCTATGAC 
pSF-CMV-NH2-HA-EKT-
NcoI-DSTN 
EEF1G 
pOTB7-EEF1G                      
(PlasmID 
HsCD00321611) 
pSF-CMV-NH2-HA-
EKT-NcoI 
NcoI-HincII digestion of plasmid of origin 
and ligation in NcoI-EcoRV-digested 
plasmid 
- 
pSF-CMV-NH2-HA-EKT-
NcoI-EEF1G 
FBXO3 
pDONR221-FBXO3                        
(PlasmID 
HsCD00296315) 
pSF-CMV-NH2-HA-
EKT-NcoI 
PCR adding a 5' KpnI site, then KpnI 
digestion of PCR product and ligation in 
KpnI-EcoRV-digested plasmid 
FBX3-KpnI_F CGGGGTACCCCATGGCGGCCATGGAGA                               
pUC/M13_rev CAGGAAACAGCTATGAC 
pSF-CMV-NH2-HA-EKT-
NcoI-FBXO3 
HSPA5 
pDONR221-HSPA5                         
(PlasmID 
HsCD00044236) 
pSF-CMV-NH2-HA-
EKT-NcoI 
PCR adding a 5' KpnI site, then KpnI 
digestion of PCR product and ligation in 
KpnI-EcoRV-digested plasmid 
HSPA5-KpnI_F CTGGGGTACCAGATGAAGCTCTCCCTG                               
pUC/M13_rev CAGGAAACAGCTATGAC 
pSF-CMV-NH2-HA-EKT-
NcoI-HSPA5 
HSPA8 
pGEMT-HSPA8                               
(Paul Chapple's lab) 
pSF-CMV-NH2-HA-
EKT-NcoI 
NcoI-XhoI digestion of both plasmids and 
ligation 
- 
pSF-CMV-NH2-HA-EKT-
NcoI-HSPA8 
HSPA9 
pOTB7-HSPA9                               
(PlasmID 
HsCD00322446) 
pSF-CMV-NH2-HA-
EKT-NcoI 
1. PCR adding a 5' NcoI site, HindIII 
digestion of PCR product (to eliminate 3' 
sequence after stop codon), NcoI 
digestion and ligation in NcoI-EcoRV-
digested plasmid.  
 
2. Site-directed mutagenesis to revert 
p.74Q>R, present in the original plasmid 
Subcloning:                                                                                  
HSPA9-NcoI_F 
CATGCCATGGCAATGATAAGTGCCAGCCGAG                    
pUC/M13_rev CAGGAAACAGCTATGAC  
         
Site-directed mutagenesis:                                                                    
HSPA9-p.74R>Q_F  
CAGTTATGGAAGGTAAACAAGCAAAGGTGCTGGAGAA 
HSPA9-p.72R>Q_R 
TTCTCCAGCACCTTTGCTTGTTTACCTTCCATAACTG 
pSF-CMV-NH2-HA-EKT-
NcoI-HSPA9 
HSP90A 
pGEMT-HSP90A                                
(Paul Chapple's lab) 
pSF-CMV-NH2-HA-
EKT-NcoI 
NcoI-XhoI digestion of both plasmids and 
ligation 
- 
pSF-CMV-NH2-HA-EKT-
NcoI-HSP90A 
HSP90B 
pGEMT-HSP90β                             
(Paul Chapple's lab) 
pSF-CMV-NH2-HA-
EKT-NcoI 
PCR adding a 5'XbaI site, then XbaI-
SpeI digestion of PCR product and 
ligation in XbaI-NheI-digested plasmid 
HSP90β-XbaI_F TGCTCTAGAATGCCTGAGGAAGTGCAC                 
pUC/M13_rev CAGGAAACAGCTATGAC 
pSF-CMV-NH2-HA-EKT-
NcoI-HSP90β 
NEFL 
pDONR221-NEFL                  
(PlasmID 
HsCD00044698) 
pSF-CMV-NH2-HA-
EKT-NcoI 
PCR adding a 5' NcoI site, then NcoI-
EcoRV digestion of PCR product and 
plasmid and ligation 
NEFL-NcoI_F CGGCCATGGCCATGAGTTCCTTCAGC                 
pUC/M13_rev CAGGAAACAGCTATGAC 
pSF-CMV-NH2-HA-EKT-
NcoI-NEFL 
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Human 
protein 
CDS origin 
Plasmid of 
destination 
Subcloning method Primers Final plasmid  
NME1 
pDONR201-NME1                 
(PlasmID 
HsCD00001213) 
pSF-CMV-NH2-HA-
EKT-NcoI 
PCR adding a 5' KpnI site, then KpnI 
digestion of PCR product and ligation in 
KpnI-EcoRV-digested plasmid 
NDKA-KpnI_F CGGGGTACCCCATGGCCAACTGTGAGCG                                                                                              
pDONRE01_R: GTAACATCAGAGATTTTGAGACAC 
pSF-CMV-NH2-HA-EKT-
NcoI-NME1 
SKP1 
pDONR221-SKP1               
(PlasmID 
HsCD00295916) 
pSF-CMV-NH2-HA-
EKT-NcoI 
1. PCR adding a 5' NcoI site, then NcoI 
digestion of PCR product and ligation in 
NcoI-EcoRV-digested plasmid.  
 
2. Site-directed mutagenesis to revert 
c.299T>C(p.L100P), present in the 
original plasmid 
Subcloning: 
SKP1-NcoI_F2 TATGCCATGGCCATGCCTTCAATTAAGTT               
pUC/M13_rev CAGGAAACAGCTATGAC       
 
Site-directed mutagenesis:                                                                   
SKP1_c.299C>T_F 
GAAAGTTGACCAAGGAACACTTTTTGAACTCATTCTGGCTG             
SKP1_c.299C>T_R 
CAGCCAGAATGAGTTCAAAAAGTGTTCCTTGGTCAACTTTC 
pSF-CMV-NH2-HA-EKT-
NcoI-SKP1 
SOD1 
cDNA from HEK293 
cells 
pSF-CMV-NH2-HA-
EKT-NcoI 
PCR from cDNA and TA ligation in 
pCR2.1. PCR adding a 5’ NcoI site, then  
NcoI-SpeI digestion of PCR product and 
ligation in NcoI-NheI-digested plasmid  
Cloning from cDNA: 
SOD1_F: GTTTGCGTCGTAGTCTCCTG 
SOD1_R2: GGGCCTCAGACTACATCCAA 
Subcloning: 
SOD1-NcoI_F: CGAGCCATGGCGACGAAGGCC 
pSF-CMV-NH2-HA-EKT-
NcoI-SOD1 
TUBB 
pDONR221-TUBB               
(PlasmID 
HsCD00043911) 
pSF-CMV-NH2-HA-
EKT-NcoI 
PCR adding a 5'KpnI site, then KpnI 
digestion of PCR product and ligation in 
KpnI-EcoRV-digested plasmid 
TUBB-KpnI_F CGGGGTACCCCATGAGGGAAATCGTGCACA                                                        
pUC/M13_rev CAGGAAACAGCTATGAC 
pSF-CMV-NH2-HA-EKT-
NcoI-TUBB 
TUBB2A 
pDONR221-TUBB2A               
(PlasmID 
HsCD00044406) 
pSF-CMV-NH2-HA-
EKT-NcoI 
PCR adding a 5' KpnI site, then KpnI  
digestion of PCR product and ligation in 
KpnI-EcoRV-digested plasmid 
TUBB2A-KpnI_F GCAGGGTACCCCATGCGCGAGATCG                 
pUC/M13_rev CAGGAAACAGCTATGAC 
pSF-CMV-NH2-HA-EKT-
NcoI-TUBB2A 
VAPA 
pOTB7-VAPA                     
(PlasmID 
HsCD00321764) 
pSF-CMV-NH2-HA-
EKT-NcoI 
PCR adding a 5' KpnI site, then KpnI 
digestion of PCR product and ligation in 
KpnI-EcoRV-digested plasmid 
VAPA-KpnI_F CGGGGTACCCCATGGCGTCCGCCTCAG                
pUC/M13_rev CAGGAAACAGCTATGAC 
pSF-CMV-NH2-HA-EKT-
NcoI-VAPA 
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Table 14. Details of CDS sequences used in HA-tagged expression plasmids 
Protein 
Genbank 
reference 
sequence 
(mRNA) 
Genbank entry name 
CDS 
(bp) 
Amino 
acids 
Notes 
AIP NM_003977.3 Aryl hydrocarbon receptor interacting protein (AIP), transcript variant 1 993 330 
The plasmid carries the changes c.19A>C and c.21A>C, in codon 7 
(AGA to CGC), with no effect on amino acid R7.This plasmid carries 
also the c.682C>A (Q228K) variant, which has been found in the 
majority of the individuals when sequencing AIP (see Chapter 2) 
CBR1 NM_001757.3 Carbonyl reductase [NADPH] 1 isoform 1 834 277 
Termination codon in the plasmid is TAG, instead of TGA in the 
reference sequence 
DSTN NM_006870.3 Destrin (actin depolymerizing factor) (DSTN), transcript variant 1 498 165 - 
EEF1G NM_001404.4 Eukaryotic translation elongation factor 1 gamma (EEF1G) 1314 437 - 
FBXO3 NM_012175.3 F-box protein 3 (FBXO3), transcript variant 1 1416 471 
Termination codon in the plasmid is TGA, instead of TAG in the 
reference sequence 
HSPA5 NM_005347.4 Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5) 1965 654 - 
HSPA8 NM_006597.5 Heat shock 70 kDa protein 8 (HSPA8), transcript variant 1 1941 646 - 
HSPA9 NM_004134.6 Heat shock 70 kDa protein 9 (mortalin) (HSPA9) 2040 679 The plasmid carries c.1933C>T, causing no change on L645 
HSP90A NM_005348.3 
Heat shock protein 90 kDa alpha (cytosolic), class A member 1 
(HSP90AA1), transcript variant 2 
2199 732 - 
HSP90B NM_007355.3 
Heat shock protein 90 kDa alpha (cytosolic), class B member 1 
(HSP90AB1), transcript variant 2 
2175 724 - 
NEFL NM_006158.4 Neurofilament, light polypeptide (NEFL) 1632 543 
Termination codon in the plasmid is TAG, instead of TGA in the 
reference sequence 
NME1 NM_000269.2 NME/NM23 nucleoside diphosphate kinase 1 (NME1), transcript variant 2 459 152 - 
SKP1 NM_170679.2 S-phase kinase-associated protein 1 (SKP1), transcript variant 2 492 163 
Termination codon in the plasmid is TAG, instead of TGA in the 
reference sequence 
SOD1 NM_000454.4 Superoxide dismutase 1, soluble (SOD1) 465 154 - 
TUBB NM_178014.3 Tubulin, beta class I (TUBB), transcript variant 2 1335 444 
Termination codon in the plasmid is TAG, instead of TAA in the 
reference sequence 
TUBB2A NM_001069.2 Tubulin, beta 2A class IIa (TUBB2A) 1338 445 
The plasmid carries c.564T>G, causing no change on S188 
(synonymous variant). Termination codon in the plasmid is TAG, 
instead of TAA in the reference sequence 
VAPA NM_194434.2 
VAMP (vesicle-associated membrane protein)-associated protein A, 33 
kDa (VAPA), transcript variant 2 
750 249 - 
140 
 
The plasmids of origin for HSPA8, HSP90A and HSP90B (pGEMT-HSPA8 and pGEMT-
HSP90A and pGEMT-HSP90B) were kindly donated by P. Chapple (Barts and The London 
School of Medicine). For HSPA8 and HSP90A, the plasmids of origin and destination were 
digested with the restriction enzymes NcoI and XhoI, dephosphorylating the plasmid of 
destination (Protocol 23), and then ligating the gel-extracted fragments (Protocol 24). For 
HSP90B, a forward primer was designed to create a 5’ XbaI restriction site and amplify the CDS 
with pUC/M13_R as a reverse primer (Protocol 19). The gel-extracted PCR product was 
digested with XbaI and Spe I and the plasmid of destination underwent XbaI-NheI digestion and 
dephosphorylation (Protocol 23). The gel-extracted fragments were ligated as above.  
 
To obtain the CDS for the rest of the candidate partners to be tested, a set of plasmids was 
acquired from the PlasmID Repository (DNA Resource Core, Harvard Medical School). Direct 
subcloning with restriction enzymes was done for the plasmid containing the EEF1G CDS 
(pOTB7-EEF1G), by digesting the plasmid of origin with NcoI and HincII and the plasmid of 
destination with NcoI and EcoRV (EcoRV leaves a blunt end, that can be ligated in a cohesive 
end at the 3’ end). The plasmid of destination was dephosphorylated and both digestion 
products were gel-extracted and ligated. For the rest of the plasmids, a forward primer was 
designed to create a 5’ restriction enzyme site suitable for subcloning the CDS contained in 
each plasmid. Primers normally used for sequencing these plasmids were employed as reverse 
primers for CDS amplification. The PCR products were purified, digested and gel-extracted and 
finally ligated in appropriately digested and dephosphorylated pSF-CMV-NH2-HA-EKT-NcoI 
(see Table 13 for details). 
 
For all the inserts subcloned in pSF-CMV-NH2-Ha-EKT-NcoI, the whole ligation reactions were 
used for transforming DH5α E.coli (Protocol 4). Bacteria were plated on 50 µg/ml kanamycin-
containing agar plates and grown overnight at 37°C. Colonies were screened by colony PCR 
(Protocol 22), using the following primers: 
 
CMV_F:  5’- CGCAAATGGGCGGTAGGCGTG-3’ 
R3:  5’- AGCTGAAGGTACGCTGTATC-3’ 
 
Positive colonies were inoculated in 10 ml of LB broth with 50 µg/ml kanamycin and grown 
overnight at 37°C/250 rpm. DNA was extracted from nine millilitres of one of these cultures 
(Protocol 5), and 1 ml was inoculated in 200 ml of LB broth with 50 µg/ml kanamycin to be 
grown overnight at 37°C/250 rpm, pelleted and frozen, awaiting sequence confirmation. The 
rest of the cultures were kept at 4°C. Finally, the plasmids were sent for sequencing using the 
CMV_F and R3 primers (Genome Centre, Barts and The London School of Medicine). DNA 
extraction from the frozen bacterial pellets for all the plasmids (large-scale cultures) was carried 
out once the sequences had been confirmed, as described in Protocol 7. The plasmids pSF-
CMV-NH2-HA-EKT-NcoI-HSPA9 and SKP1 underwent site-directed mutagenesis (Protocol 6) to 
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correct probably damaging changes in the CDS that were present in the plasmids of origin (see 
Table 13 for details). 
 
Co-immunoprecipitation 
For most of the experiments, a total of 20 µg of an equimolar mixture (considering the size of 
the CDS) of plasmids containing AIP and one or more plasmids containing the candidate 
partners were transfected in 10X10
6
 HEK293 cells, plated 24 h before in a T175 flask. The cells 
were harvested one day later by trypsinisation and lysed in 1.5ml of lysis buffer. The crude 
lysates were cleared by centrifugation and then cleaned by incubation with 50 µl of Protein G 
beads. The cleared lysate was divided in three 1.5ml tubes and mixed with 5 µg anti-Myc or 
anti-HA mouse monoclonal antibodies, or mouse anti-IgG, as appropriate. A small volume of 
cleared lysate was reserved for protein quantification and WB. The reactions were incubated for 
1 h at 4°C and then transferred to a tube with 50 µl of protein G beads and incubated overnight 
at 4°C on a rotator. The supernatant was discarded and the beads were washed three times 
with lysis buffer and once with PBS, and finally the samples were denatured and eluted in 30 µl 
of 2X SDS loading buffer at 95°C. The eluates were resolved by PAGE and anti-Myc and anti-
HA WB, including a sample of the cleared lysate (input).  
 
Only those experiments with positive bands for the anti-Myc and anti-HA co-IP in both WBs, and 
negative IgG controls, were considered as real interactions by this method. The general co-IP 
protocol is detailed in Protocol 25. Co-IP was also done with this method to test AIP 
dimerisation, using the Myc-tagged and Flag-tagged AIP expression plasmids. The amount of 
DNA transfected and the number of cells varied between experiments to ensure the presence of 
clear bands in the WB images. Positive co-IP experiments for new protein partners were 
repeated at least once for confirmation. 
 
Co-IP experiments in GH3 cells with a TOMM20 10mer peptide (AQSLAEDDVE) or 0.8% 
formaldehyde as crosslinkers were also carried out to test AIP dimerisation, using the Myc-
tagged and Flag-tagged AIP plasmids, as detailed in Protocol 26 and Protocol 27.  
 
AIP indirect protein-protein interactions 
To investigate possible HSP90-mediated indirect interactions of AIP, a triple co-IP experiment 
was performed, involving AIP, HSP90 and a known HSP90 partner, the cAMP-dependent PKA 
catalytic subunit alpha (PRKACA). For this purpose, two-step site directed mutagenesis 
(following Protocol 6) of the pSF-CMV-NH2-HA-EKT-NcoI-PRKACA (plasmid pre-existent in the 
laboratory stocks) was carried out to obtain a Flag-tagged plasmid (pSF-CMV-NH2-Flag-EKT-
NcoI-PRKACA), as shown in Figure 25. The primers used for the first step of site-directed 
mutagenesis were: 
 
del882-899_F: 5’-GGAGGTACTCACGATGGATTATGCGGATGACG-3’ 
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del882-899_R: 5’-CGTCATCCGCATAATCCATCGTGAGTACCTCC-3’ 
 
The mutagenised plasmid underwent a second site-directed mutagenesis using the primers: 
 
HA_to_Flag_F 5’-GGAGGTACTCACGATGGATTATAAGGATGACG-3’ 
HA_to_Flag_R  5’-CGTCATCCTTATAATCCATCGTGAGTACCTCC-3’ 
 
The expected sequences were confirmed and the plasmid was produced as described before. 
 
Figure 25. HA to Flag site-directed mutagenesis. In the plasmid of origin (top panel), the sequence between the end of 
the HA tag and the NcoI restriction site (PDYADDDD) is very similar to the sequence of the Flag tag (MDYKDDDD). 
Therefore, the HA tag was deleted from Y to P, and in a second step, A (GCG) was mutagenised to K (AAG) to obtain a 
Flag tag. Black background: HA and Flag tags; grey background: start of the AIP CDS. 
 
Co-localisation 
Co-localisation experiments using immunocytofluorescence were carried out to verify 
interactions with the proteins NEFL and TUBB2A, which are known to have a specific cellular 
distribution (cytoskeletal filaments), different to the distribution described for AIP. For these 
experiments, 5X10
4 
HEK293 cells were plated on each of the wells of a chamber slide and 
grown for 48 h. The cells were fixed with 4% formaldehyde, permeabilised, blocked with goat 
serum and incubated overnight with primary antibodies against AIP and one of the candidate 
partners. The cells were washed, incubated with fluorescent secondary antibodies, washed 
again, counterstained with 4',6-diamidino-2-phenylindole (DAPI) and mounted for confocal 
microscopy analysis, as detailed in Protocol 28. Z-stack images were obtained and 
reconstructed using the ImageJ v.1.47 software.
672
 Co-localisation was analysed on 
representative slices of the z-stacks, employing the JACoP (Just Another Colocalization Plugin) 
plugin,
673
 using the Pearson’s correlation coefficient and the overlap coefficient.
673;674
 
 
Results 
Identification of candidate partners for AIP 
The manually validated qualitative MS results (peptides grouped by proteins) are presented in 
Table 25 (Appendix 1), accounting for a total of 155 proteins identified. For some of the proteins 
with low coverage, one peptide was assigned to more than one protein. The qualitative analysis 
was used with two purposes: first, to filter the results, eliminating those peptides present with 
higher intensity values in the negative control (GST) compared to the samples, and second, to 
compare the normalised values (once the values for the negative control had been subtracted) 
143 
 
between the different pull-down baits. Table 15 lists the 35 proteins identified as candidate AIP 
partners (considering the results for the WT protein only) after the filters were applied, according 
to the Mascot search with taxonomy R. norvegicus. The proteins in grey cells are considered 
highly probable candidates (including two known AIP partners), because of having three or 
more assigned peptides. Different isoforms of GST were identified, but they were considered 
artefacts due to the use of a GST tag for the pull-down experiments. The peptides identified for 
each protein are listed in the last column. The human homologues for each of the candidate AIP 
partners identified were searched in UniProt
510
. The human homologues and the percentage of 
identity with the rat proteins are presented in Table 16.  
 
Table 15. Candidate AIP partners and peptides identified by qMS 
# 
 
UniProt 
entry
510
 
Protein description (gene name) 
Mass 
(kDa)
510
 
Peptides identified 
1 P60711 ACTB_RAT Actin, cytoplasmic 1(Actb) 41.7 
VAPEEHPVLLTEAPLNPKANR 
KDLYANTVLSGGTTMYPGIADR 
2 Q5FWY5 AIP_RAT AH receptor-interacting protein (Aip)  37.6 
EDGIQK 
AKAVPLIHQEGNR 
GELPEFQDGTK 
GKAHAAVWNAQEAQADFAK 
GKAHAAVWNAQEAQADFAKVLELDPALAPVVSR 
3 P29419 
ATP5I_RAT ATP synthase subunit e, 
mitochondrial (Atp5i) 
8.3 ELAEAEDVSIFK 
4 P15999 
ATPA_RAT ATP synthase subunit alpha, 
mitochondrial (Atp5a1) 
59.8 VGLKAPGIIPR 
5 P35434 
ATPD_RAT ATP synthase subunit delta, 
mitochondrial (Atp5d) 
17.6 ANLEKAQSELSGAADEAAR 
6 P47727 
CBR1_RAT Carbonyl reductase [NADPH] 1 
(Cbr1) 
30.6 
EDKILLNACCPGWVR 
ELLPIIKPQGR 
GHEAVKQLQTEGLSPR 
GVHAKEGWPNSAYGVTKIGVTVLSR 
KFLGDVVLTAR 
REDKILLNACCPGWVR 
SCSPELQQKFR 
7 P08649 
CO4_RAT Complement C4  
(C4) 
192.2 ADLEKLTSLSDR 
8 Q497C3 
CP013_RAT UPF0585 protein C16orf13 
homolog 
22.6 
MVDMPANNKCLIFR 
NKEPILCVLR 
9 P63255 CRIP1_RAT Cysteine-rich protein 1(Crip1) 8.6 GGAESHTFK 
10 Q68FR6 EF1G_RAT Elongation factor 1-gamma (Eef1g) 50.1 
KLDPGSEETQTLVR 
AFKALIAAQYSGAQIR 
ILGLLDTHLKTR 
KFPAGKVPAFEGDDGFCVFESNAIAYYVSNEELR 
11 D4ABP9 FBX3_RAT F-box only protein 3 (Fbxo3) 55.4 
EEDLDAVEAQIGCKLPDDYR 
ITNAKGDVEEVQGPGVVGEFPIISPGR 
12 Q99PF5 FUBP2_RAT Far upstream element-binding 74.2 KDAFADAVQR 
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# 
 
UniProt 
entry
510
 
Protein description (gene name) 
Mass 
(kDa)
510
 
Peptides identified 
protein 2 (Khsrp) 
13 P48721 
GRP75_RAT Stress-70 protein, mitochondrial 
(Hspa9) 
73.9 
EMAGDNKLLGQFTLIGIPPAPR 
QATKDAGQISGLNVLR 
MPKVQQTVQDLFGR 
KDSETGENIR 
QAVTNPNNTFYATKR 
14 P06761 
GRP78_RAT 78 kDa glucose-regulated protein 
(Hspa5) 
72.3 
KSDIDEIVLVGGSTR 
IINEPTAAAIAYGLDKR 
NQLTSNPENTVFDAKR 
AKFEELNMDLFR 
15 P14942 
GSTA4_RAT Glutathione S-transferase alpha-4  
(Gsta4) 
25.5 
APQEKEESLALAVKR 
EESLALAVKR 
16 P04905 
GSTM1_RAT Glutathione S-transferase Mu 1 
(Gstm1) 
25.9 
FKLGLDFPNLPYLIDGSR 
LAQWSNK 
KHHLCGETEEER 
KITQSNAIMR 
ISAYMKSSR 
YLSTPIFSKLAQWSNK 
17 P08009 
GSTM4_RAT Glutathione S-transferase Yb-3  
(Gstm3) 
25.7 
MAIWGSK 
LKPGYLEQLPGMMR 
FLPRPLFTKMAIWGSK 
NQVFEATCLDAFPNLKDFIAR 
18 P04906 
GSTP1_RAT Glutathione S-transferase P 
(Gstp1) 
23.4 
SLGLYGKDQKEAALVDMVNDGVEDLR 
AFLSSPDHLNRPINGNGKQ 
DQKEAALVDMVNDGVEDLR 
STCLYGQLPKFEDGDLTLYQSNAILR 
19 P34058 
HS90B_RAT Heat shock protein HSP 90-beta  
(Hsp90ab1) 
83.3 ELISNASDALDKIR 
20 P63018 
HSP7C_RAT Heat shock cognate 71 kDa 
protein (Hspa8) 
70.9 
MVNHFIAEFKR 
QATKDAGTIAGLNVLR 
NQVAMNPTNTVFDAKR 
GTLDPVEKALR 
LIGDAAKNQVAMNPTNTVFDAKR 
21 Q5FVL7 KTU_RAT Protein kintoun (Dnaaf2) 89.3 EWYWGLNKDSLEER 
22 Q9QX69 LANC1_RAT LanC-like protein 1 (Lancl1) 45.2 AFPNPYADYNKSLAENYFDSTGR 
23 Q05982 
NDKA_RAT Nucleoside diphosphate kinase A 
(Nme1) 
17.2 TFIAIKPDGVQR 
24 P19527 NFL_RAT Neurofilament light polypeptide (Nefl) 61.3 
KGADEAALAR 
LAAEDATNEKQALQGER 
FTVLTESAAKNTDAVR 
AAKDEVSESR 
QKHSEPSR 
25 P63324 RS12_RAT 40S ribosomal protein S12 (Rps12) 14.5 LGEWVGLCKIDR 
26 P13471 RS14_RAT 40S ribosomal protein S14 (Rps14) 16.3 TKTPGPGAQSALR 
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# 
 
UniProt 
entry
510
 
Protein description (gene name) 
Mass 
(kDa)
510
 
Peptides identified 
27 P60868 RS20_RAT 40S ribosomal protein S20 (Rps20) 13.4 SLEKVCADLIR 
28 P05765 RS21_RAT 40S ribosomal protein S21 (Rps21) 9.1 LAKADGIVSKNF 
29 P62859 RS28_RAT 40S ribosomal protein S28 (Rps28) 7.8 NVKGPVREGDVLTLLESER 
30 Q6PEC4 
SKP1_RAT S-phase kinase-associated protein 
1 (Skp1) 
18.7 KTFNIKNDFTEEEEAQVR 
31 P07632 
SODC_RAT Superoxide dismutase [Cu-Zn] 
(Sod1) 
15.9 GGNEESTKTGNAGSR 
32 P85108 TBB2A_RAT Tubulin beta-2A chain (Tubb2a) 49.9 INVYYNEAAGNKYVPR 
33 Q6P9T8 TBB4B_RAT Tubulin beta-4B chain (Tubb4b)  49.8 INVYYNEATGGKYVPR 
34 P69897 TBB5_RAT Tubulin beta-5 chain (Tubb5)  49.7 ISVYYNEATGGKYVPR 
35 Q9Z270 
VAPA_RAT Vesicle-associated membrane 
protein-associated protein A (Vapa)  
27.8 
FKGPFTDVVTTNLKLQNPSDR 
QDGPLPKPHSVSLNDTETR 
 
Table 16. Candidate AIP partners in R. norvegicus and their human homologues 
# 
R. norvegicus proteins Human homologues 
UniProt 
entry
510
 
Protein description  
(gene name) 
% of 
identity 
UniProt 
entry
510
 
Protein description  
(gene name) 
Mass 
(kDa) 
1 P60711 
ACTB_RAT Actin, cytoplasmic 1 
(Actb) 
100 P60709 
ACTB_HUMAN Actin, 
cytoplasmic 1 (ACTB) 
41.7 
2 Q5FWY5 
AIP_RAT AH receptor-interacting 
protein (Aip)  
94 O00170 
AIP_HUMAN AH receptor-
interacting protein (AIP) 
37.6 
3 P29419 
ATP5I_RAT ATP synthase 
subunit e, mitochondrial (Atp5i) 
83 P56385 
ATP5I_HUMAN ATP synthase 
subunit e, mitochondrial (ATP5I) 
7.9 
4 P15999 
ATPA_RAT ATP synthase 
subunit alpha, mitochondrial 
(Atp5a1) 
97 P25705 
ATPA_HUMAN ATP synthase 
subunit alpha, mitochondrial 
(ATP5A1) 
59.8 
5 P35434 
ATPD_RAT ATP synthase 
subunit delta, mitochondrial 
(Atp5d) 
87 P30049 
ATPD_HUMAN ATP synthase 
subunit delta, mitochondrial 
(ATP5D) 
17.5 
6 P47727 
CBR1_RAT Carbonyl reductase 
[NADPH] 1 (Cbr1) 
86 P16152  
CBR1_HUMAN Carbonyl 
reductase [NADPH] 1 (CBR1) 
30.4 
7 P08649 CO4_RAT Complement C4 (C4) 80 P0C0L4  
CO4A_HUMAN Complement C4-
A (C4A) 
192.8 
8 Q497C3 
CP013_RAT UPF0585 protein 
C16orf13 homolog 
90 Q96S19  
CP013_HUMAN UPF0585 
protein C16orf13 (C16orf13) 
22.6 
9 P63255 
CRIP1_RAT Cysteine-rich 
protein 1 (Crip1) 
97 P50238  
CRIP1_HUMAN Cysteine-rich 
protein 1 (CRIP1) 
8.5 
10 Q68FR6 
EF1G_RAT Elongation factor 1-
gamma (Eef1g) 
98 P26641 
EF1G_HUMAN Elongation factor 
1-gamma (EEF1G) 
50.1 
11 D4ABP9 
FBX3_RAT F-box only protein 3 
(Fbxo3) 
91 Q9UK99 
FBX3_HUMAN F-box only 
protein 3 (FBXO3) 
54.6 
12 Q99PF5 
FUBP2_RAT Far upstream 
element-binding protein 2 (Khsrp) 
98 Q92945 
FUBP2_HUMAN Far upstream 
element-binding protein 2 
(KHSRP) 
73.1 
13 P48721 
GRP75_RAT Stress-70 protein, 
mitochondrial (Hspa9) 
98 P38646 
GRP75_HUMAN Stress-70 
protein, mitochondrial (HSPA9) 
73.7 
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# 
R. norvegicus proteins Human homologues 
UniProt 
entry
510
 
Protein description  
(gene name) 
% of 
identity 
UniProt 
entry
510
 
Protein description  
(gene name) 
Mass 
(kDa) 
14 P06761 
GRP78_RAT 78 kDa glucose-
regulated protein (Hspa5) 
98 P11021 
 GRP78_HUMAN 78 kDa 
glucose-regulated protein 
(HSPA5) 
72.3 
15 P14942 
GSTA4_RAT Glutathione S-
transferase alpha-4 (Gsta4) 
60 P08263  
GSTA1_HUMAN Glutathione S-
transferase A1 (GSTA1) 
25.6 
16 P04905 
GSTM1_RAT Glutathione S-
transferase Mu 1 (Gstm1) 
79 P09488 
GSTM1_HUMAN Glutathione S-
transferase Mu 1 (GSTM1) 
25.7 
17 P08009 
GSTM4_RAT Glutathione S-
transferase Yb-3 (Gstm3) 
85 P28161 
GSTM2_HUMAN Glutathione S-
transferase Mu 2 (GSTM2) 
25.7 
18 P04906 
GSTP1_RAT Glutathione S-
transferase P (Gstp1) 
86 P09211 
GSTP1_HUMAN Glutathione S-
transferase P (GSTP1) 
23.4 
19 P34058 
HS90B_RAT Heat shock protein 
HSP 90-beta (Hsp90ab1) 
99 P08238 
HS90B_HUMAN Heat shock 
protein HSP 90-beta 
(HSP90AB1) 
83.3 
20 P63018 
HSP7C_RAT Heat shock 
cognate 71 kDa protein (Hspa8) 
99 P11142 
HSP7C_HUMAN Heat shock 
cognate 71 kDa protein (HSPA8) 
70.9 
21 Q5FVL7 
KTU_RAT Protein kintoun 
(Dnaaf2) 
65 Q9NVR5 
KTU_HUMAN Protein kintoun 
(DNAAF2) 
91.1 
22 Q9QX69 
LANC1_RAT LanC-like protein 1 
(Lancl1) 
91 O43813 
LANC1_HUMAN LanC-like 
protein 1 (LANCL1) 
45.3 
23 Q05982 
NDKA_RAT Nucleoside 
diphosphate kinase A (Nme1) 
95 P15531 
NDKA_HUMAN Nucleoside 
diphosphate kinase A (NME1) 
17.1 
24 P19527 
NFL_RAT Neurofilament light 
polypeptide (Nefl) 
97 P07196 
NFL_HUMAN Neurofilament light 
polypeptide (NEFL) 
61.5 
25 P63324 
RS12_RAT 40S ribosomal 
protein S12 (Rps12) 
99 P25398 
RS12_HUMAN 40S ribosomal 
protein S12 (RPS12) 
14.5 
26 P13471 
RS14_RAT 40S ribosomal 
protein S14 (Rps14) 
99 P62263 
RS14_HUMAN 40S ribosomal 
protein S14 (RPS14) 
16.3 
27 P60868 
RS20_RAT 40S ribosomal 
protein S20 (Rps20) 
100 P60866 
RS20_HUMAN 40S ribosomal 
protein S20 (RPS20) 
13.4 
28 P05765 
RS21_RAT 40S ribosomal 
protein S21 (Rps21) 
95 P63220 
RS21_HUMAN 40S ribosomal 
protein S21 (RPS21) 
9.1 
29 P62859 
RS28_RAT 40S ribosomal 
protein S28 (Rps28) 
100 P62857 
RS28_HUMAN 40S ribosomal 
protein S28 (RPS28) 
7.8 
30 Q6PEC4 
SKP1_RAT S-phase kinase-
associated protein 1 (Skp1) 
99 P63208 
SKP1_HUMAN S-phase kinase-
associated protein 1 (SKP1) 
18.7 
31 P07632 
SODC_RAT Superoxide 
dismutase [Cu-Zn] (Sod1) 
83 P00441 
SODC_HUMAN Superoxide 
dismutase [Cu-Zn] (SOD1) 
15.9 
32 P85108 
TBB2A_RAT Tubulin beta-2A 
chain (Tubb2a) 
100 Q13885 
TBB2A_HUMAN Tubulin beta-2A 
chain (TUBB2A) 
49.9 
33 Q6P9T8 
TBB4B_RAT Tubulin beta-4B 
chain (Tubb4b)  
99 P68371 
TBB4B_HUMAN Tubulin beta-4B 
chain (TUBB4B) 
49.8 
34 P69897 
TBB5_RAT Tubulin beta-5 chain 
(Tubb5)  
100 P07437 
TBB5_HUMAN Tubulin beta 
chain (TUBB) 
49.7 
35 Q9Z270 
VAPA_RAT Vesicle-associated 
membrane protein-associated 
protein A (Vapa ) 
97 Q9P0L0 
VAPA_HUMAN Vesicle-
associated membrane protein-
associated protein A (VAPA) 
27.9 
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Pathways analysis 
The final list of human homologues of the AIP candidate partners identified was submitted for 
pathway analysis, using the Ingenuity Pathways Analysis software.
670
 The results of this 
analysis are summarised in Table 17. 
 
Table 17. Summary of pathway analysis results 
Top networks 
Associated network functions ID Score 
Cellular assembly and organisation, nervous system development and function, free radical 
scavenging 
1 30 
Cancer, gastrointestinal disease, organismal injury and abnormalities 2 22 
Cancer, reproductive system disease, cell morphology 3 2 
Cell morphology, developmental disorder, drug metabolism 4 2 
Hereditary disorder, neurological disease, cell death and survival 5 2 
Top diseases and disorders 
Name P No. of molecules 
Cancer 1.11E-07 - 4.48E-02 18 
Gastrointestinal disease 1.11E-07 - 4.88E-02 9 
Respiratory disease 2.34E-07 - 4.16E-03 7 
Organismal injury and abnormalities 5.39E-07 - 4.88E-02 16 
Reproductive system disease 5.39E-07 - 3.48E-02 13 
Top molecular and cellular functions 
Name P No. of molecules 
Drug metabolism 1.95E-09 - 1.24E-02 6 
Protein synthesis 9.16E-06 - 4.26E-02 7 
Small molecule biochemistry 1.26E-05 - 2.57E-02 9 
Cell death and survival 4.15E-04 - 4.88E-02 13 
Cell cycle 2.08E-03 - 3.48E-02 4 
Top physiological system development and function 
Name P No. of molecules 
Organ development 3.92E-05 - 5.01E-03 6 
Behaviour 2.08E-03 - 2.88E-02 1 
Tissue development 2.08E-03 - 4.88E-02 3 
Tumour morphology 2.08E-03 - 2.27E-02 2 
Organism survival 2.20E-03 - 2.20E-03 4 
Top canonical pathways 
Name P Ratio 
NRF2-mediated oxidative stress response 6.53E-08 7/187 (0.037) 
Glutathione-mediated detoxification 1.35E-07 4/23 (0.174) 
Remodelling of epithelial adherens junctions 2.34E-07 5/66 (0.076) 
Aryl hydrocarbon receptor signalling 2.90E-07 6/141 (0.043) 
Regulation or eIF4 and p70S6K signalling 1.05E-05 5/158 (0.032) 
 
The top two networks reported in the analysis, including most of the protein in the list, are 
presented in Figure 26. 
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Figure 26. Pathway analysis top networks. Networks 1 (a) and 2 (b) included the majority of AIP interacting partners. 
Note that networks in this type of analysis denote functional relationships, and not necessarily protein-protein 
interactions. Proteins in grey are included in the list of AIP candidate interacting partners.  
 
Differential interaction repertoire among AIP variants 
For each pull-down experiment, a list including the normalised intensity values for all the 
peptides identified, grouped in proteins, was created. Intensity values for the peptides were 
a
b
Relationships
Shapes
Legends
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compared between the different experiments and expressed as fold change, considering the 
intensity value for each peptide in the experiment done with the WT protein as 1, as presented 
in Table 18; only proteins present in the WT experiment were included (all the peptides detected 
for those proteins, even if not present in the WT experiment, are shown). Negative normalised 
intensity values (higher intensity in the negative control than in the experiment) were not 
compared, and are shown as grey squares. Comparisons were not possible in cases where the 
normalised intensity value in the WT experiment was negative, and they are shown as hyphens 
in the table. Finally, peptides not detected at all in one experiment are presented as black 
squares.  
 
The comparative table of results (Table 18) includes peptides found in all the experiments and 
peptides present in only one, two, three or four of the pull-down assays for AIP variants. It is 
difficult to analyse the relevance of these differences, as some peptides for some of the proteins 
were not detected in the experiment for the WT protein. Therefore, comparative results 
including only those proteins for which at least one peptide was detected in the WT AIP pull-
down are presented as a graph in Figure 27. The differences in the intensity values of the 
peptides among the pull-down experiments were interpreted as differential binding of the 
corresponding proteins for each bait AIP protein. Proteins in bold characters in Table 18 were 
considered of interest, either because one or more of their assigned peptides showed a ≥1.5 
fold difference in binding (positive or negative) when comparing the pathogenic AIP mutant 
p.R304* to the WT protein, and the other peptides in the same protein did not show an opposite 
pattern, or because they bound the WT but not the mutant protein. 
 
Validation experiments 
As it would be technically complex to confirm by other experimental methods all the protein-
protein interactions identified, certain proteins showing differential binding were selected for 
validation. On this regard, the loss of interactions by the p.R304* AIP mutant was of special 
interest, as this is a clearly pathogenic variant. Plasmids containing the CDS for the proteins of 
interest were constructed as detailed in Methods. The characteristics of the tagged proteins 
expressed after the transfection of these plasmids are summarised in Table 19. 
 
Validation of protein-protein interactions 
AIP self-association occurs only in the presence of a chemical crosslinker 
The ability of AIP to self-associate to form dimers or oligomers, in the absence of HSP90 or 
AHR, had been suggested before.
587
 Additionally, the crystal structure of AIP TPR domain in 
complex with a 10mer of TOMM20 suggested the possibility that the TPR could form a 
biological dimer.
523
 Co-IP experiments were carried out to test AIP self-association in GH3 cells 
(Figure 28).  
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Table 18. Comparative intensity values of peptides identified per bait protein 
# Protein description (gene name) Peptide sequence 
GST-normalised intensity value/WT 
WT K266A A299V R304* R304Q 
1 1433T_RAT 14-3-3 protein theta (Ywhaq) EKVESELR     -     
2 1433Z_RAT 14-3-3 protein zeta/delta (Ywhaz)  NLLSVAYKNVVGAR   - -     
3 ACTB_RAT Actin, cytoplasmic 1 (Actb) 
VAPEEHPVLLTEAPLNPKANR 1.0 0.8 0.8 0.3 0.6 
KDLYANTVLSGGTTMYPGIADR     -     
4 AIP_RAT AH receptor-interacting protein (Aip) 
EDGIQK 1.0 1.1 1.9 2.4 0.5 
AKAVPLIHQEGNR 1.0 26.1 36.2 11.7 8.3 
GELPEFQDGTK   - - -   
GKAHAAVWNAQEAQADFAK       -   
GKAHAAVWNAQEAQADFAKVLELDPALAPVVSR 1.0 1.9       
5 ALBU_RAT Serum albumin (Alb) AFKAWAVAR   - - - - 
6 ATP5I_RAT ATP synthase subunit e, mitochondrial (Atp5i)  ELAEAEDVSIFK 1.0 1.3 1.9 3.0   
7 ATPA_RAT ATP synthase subunit alpha, mitochondrial (Atp5a1) VGLKAPGIIPR 1.0 0.9 1.8 0.3 0.1 
8 ATPD_RAT ATP synthase subunit delta, mitochondrial (Atp5d) ANLEKAQSELSGAADEAAR 1.0 2.7 4.7 4.2 6.9 
9 CBR1_RAT Carbonyl reductase [NADPH] 1 (Cbr1) 
EDKILLNACCPGWVR     -     
ELLPIIKPQGR 1.0   0.8   0.2 
GHEAVKQLQTEGLSPR     -   - 
GVHAKEGWPNSAYGVTKIGVTVLSR     -     
KFLGDVVLTAR       -   
REDKILLNACCPGWVR 1.0   4.1 6.4   
SCSPELQQKFR   - -   - 
10 CO4_RAT Complement C4 (C4) ADLEKLTSLSDR 1.0 0.3 5.7 4.2 3.2 
11 CP013_RAT UPF0585 protein C16orf13 homolog  
MVDMPANNKCLIFR 1.0   2.1 1.1   
NKEPILCVLR       -   
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# Protein description (gene name) Peptide sequence 
GST-normalised intensity value/WT 
WT K266A A299V R304* R304Q 
12 CRIP1_RAT Cysteine-rich protein 1 (Crip1) GGAESHTFK 1.0   80.5     
13 DEFI8_RAT Differentially expressed in FDCP 8 homolog (Def8) QTCDK   - -     
14 DEST_RAT Destrin (Dstn) YALYDASFETKESR     - -   
15 ECHA_RAT Trifunctional enzyme subunit alpha, mitochondrial (Hadha) 
DLANNSSKKFYQ       -   
LPAKPEVSSDEDIQYR     - -   
16 EF1A2_RAT Elongation factor 1-alpha 2 (Eef1a2)  EGNASGVSLLEALDTILPPTRPTDKPLR     -     
17 EF1G_RAT Elongation factor 1-gamma (Eef1g) 
KLDPGSEETQTLVR 1.0   1.7 1.1   
AFKALIAAQYSGAQIR   - - -   
ILGLLDTHLKTR     - -   
KFPAGKVPAFEGDDGFCVFESNAIAYYVSNEELR 1.0     0.1   
18 EF2_RAT Elongation factor 2 (Eef2)  YLAEKYEWDVAEAR   - - -   
19 FBX3_RAT F-box only protein 3 (Fbxo3)  
EEDLDAVEAQIGCKLPDDYR 1.0 0.8 1.8 1.5 0.6 
ITNAKGDVEEVQGPGVVGEFPIISPGR     - -   
20 FUBP2_RAT Far upstream element-binding protein 2 (Khsrp) KDAFADAVQR 1.0 2.6 10.0 0.8 1.5 
21 GRP75_RAT Stress-70 protein, mitochondrial (Hspa9) 
EMAGDNKLLGQFTLIGIPPAPR 1.0 2.1 5.2 0.9 2.7 
QATKDAGQISGLNVLR     -     
MPKVQQTVQDLFGR     -     
KDSETGENIR     -     
QAVTNPNNTFYATKR     -     
22 GRP78_RAT 78 kDa glucose-regulated protein (Hspa5) 
KSDIDEIVLVGGSTR 1.0 1.0 4.7 1.3 1.4 
IINEPTAAAIAYGLDKR     -     
NQLTSNPENTVFDAKR 1.0 2.9 8.1     
AKFEELNMDLFR 1.0 7.7 35.0 1.9   
23 GSTA4_RAT Glutathione S-transferase alpha-4 (Gsta4) APQEKEESLALAVKR     - -   
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# Protein description (gene name) Peptide sequence 
GST-normalised intensity value/WT 
WT K266A A299V R304* R304Q 
EESLALAVKR 1.0 1.6 3.5 0.7 1.5 
24 GSTA6_RAT Glutathione S-transferase A6 (Gsta6) FIHTNEDLEKLR     - -   
25 GSTM1_RAT Glutathione S-transferase Mu 1 (Gstm1)  
FKLGLDFPNLPYLIDGSR     -     
LAQWSNK 1.0 2.6 2.9 0.2 4.0 
KHHLCGETEEER   - - - - 
KITQSNAIMR     - -   
ISAYMKSSR 1.0 6.0 12.5   12.1 
YLSTPIFSKLAQWSNK       -   
26 GSTM4_RAT Glutathione S-transferase Yb-3 (Gstm3) 
MAIWGSK 1.0 1.5 1.1   2.3 
LKPGYLEQLPGMMR 1.0   4.0     
FLPRPLFTKMAIWGSK 1.0 1.1 3.9 3.9 0.1 
NQVFEATCLDAFPNLKDFIAR       -   
27 GSTM5_RAT Glutathione S-transferase Mu 5 (Gstm5) 
NKITQSNAILR     -     
FEALEKIAAFLQSDR     - -   
MLLEFTDTSYEEKQYTCGEAPDYDR     - -   
28 GSTP1_RAT Glutathione S-transferase P (Gstp1) 
SLGLYGKDQKEAALVDMVNDGVEDLR 1.0     2.4   
AFLSSPDHLNRPINGNGKQ 1.0   14.7 8.1 6.1 
DQKEAALVDMVNDGVEDLR     -     
STCLYGQLPKFEDGDLTLYQSNAILR 1.0     2.8 7.9 
29 HS90B_RAT Heat shock protein HSP 90-beta (Hsp90ab1)  ELISNASDALDKIR 1.0 1.0 2.8 0.3 0.3 
30 HSP7C_RAT Heat shock cognate 71 kDa protein (Hspa8) 
MVNHFIAEFKR 1.0 0.1 0.9   0.3 
QATKDAGTIAGLNVLR 1.0 0.3 1.6 0.0 0.5 
NQVAMNPTNTVFDAKR 1.0 0.3 1.8   0.5 
GTLDPVEKALR 1.0 0.5 1.6   5.8 
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# Protein description (gene name) Peptide sequence 
GST-normalised intensity value/WT 
WT K266A A299V R304* R304Q 
LIGDAAKNQVAMNPTNTVFDAKR 1.0   1.5     
31 KTU_RAT Protein kintoun (Dnaaf2) EWYWGLNKDSLEER 1.0 1.0 3.5 2.1 0.5 
32 LANC1_RAT LanC-like protein 1 (Lancl1) AFPNPYADYNKSLAENYFDSTGR 1.0 1.9 2.8 0.9   
33 NDKA_RAT Nucleoside diphosphate kinase A (Nme1) TFIAIKPDGVQR 1.0 0.9 0.2     
34 NFL_RAT Neurofilament light polypeptide (Nefl) 
KGADEAALAR 1.0 1.3 0.5 2.1 1.9 
LAAEDATNEKQALQGER 1.0 0.5   1.5 1.1 
FTVLTESAAKNTDAVR 1.0 0.9 438.9 2.1 1.2 
AAKDEVSESR 1.0 1.5 1287.4 4.6 2.4 
QKHSEPSR 1.0 143.9 354.0 303.7 242.6 
35 RS12_RAT 40S ribosomal protein S12 (Rps12) LGEWVGLCKIDR 1.0 1.2 2.4 0.7 0.7 
36 RS14_RAT 40S ribosomal protein S14 (Rps14) TKTPGPGAQSALR 1.0 0.1 75.8 0.3   
37 RS20_RAT 40S ribosomal protein S20 (Rps20) SLEKVCADLIR 1.0 2.2 1.2 1.0 0.9 
38 RS21_RAT 40S ribosomal protein S21 (Rps21) LAKADGIVSKNF 1.0 2.0 2.0 2.8   
39 RS25_RAT 40S ribosomal protein S25 (Rps25) NTKGGDAPAAGEDA   - -     
40 RS27A_RAT Ubiquitin-40S ribosomal protein S27a (Rps27a) LIFAGKQLEDGR     - -   
41 RS28_RAT 40S ribosomal protein S28 (Rps28) NVKGPVREGDVLTLLESER 1.0       0.7 
42 RSSA_RAT 40S ribosomal protein SA (Rpsa) AVLKFAAATGATPIAGR   - - - - 
46 SKP1_RAT S-phase kinase-associated protein 1 (Skp1) KTFNIKNDFTEEEEAQVR 1.0 0.5 6.8 3.3   
44 SODC_RAT Superoxide dismutase [Cu-Zn] (Sod1) GGNEESTKTGNAGSR 1.0 1.1 1.4     
45 SSRG_RAT Translocon-associated protein subunit gamma (Ssr3)  APKGGSKQQSEEDLLLQDFSR     - -   
46 TBB2A_RAT Tubulin beta-2A chain (Tubb2a) INVYYNEAAGNKYVPR 1.0 1.8   0.2 1.1 
47 TBB4B_RAT Tubulin beta-4B chain (Tubb4b) INVYYNEATGGKYVPR 1.0 2.2 1.6 0.9 1.1 
48 TBB5_RAT Tubulin beta-5 chain (Tubb5) ISVYYNEATGGKYVPR 1.0 2.4   0.3 1.3 
49 THIO_RAT Thioredoxin (Txn) EKLEATITEFA     -     
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# Protein description (gene name) Peptide sequence 
GST-normalised intensity value/WT 
WT K266A A299V R304* R304Q 
VGEFSGANKEKLEATITEFA     -     
50 TPIS_RAT Triosephosphate isomerase (Tpi1)  
VNHALSEGLGVIACIGEKLDER     -     
TATPQQAQEVHEKLR     -     
GWLKCNVSEGVAQCTR     - -   
51 UCHL1_RAT Ubiquitin carboxyl-terminal hydrolase isozyme L1 (Uchl1) MPFPVNHGASSEDSLLQDAAKVCR     -     
52 VAPA_RAT Vesicle-associated membrane protein-associated protein A (Vapa)  
FKGPFTDVVTTNLKLQNPSDR 1.0   0.8 0.6   
QDGPLPKPHSVSLNDTETR     -     
53 VAPB_RAT Vesicle-associated membrane protein-associated protein B (Vapb) QLKEEDGLR     - -   
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Figure 27. Graphic representation of the comparative intensity values of peptides identified per bait protein: candidate partners of WT AIP only. In a broad sense, proteins whose peptides were 
underrepresented in the experiments for the mutant proteins, compared to the WT, can be interpreted as lost interactions.  
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Table 19: Tagged proteins selected for co-immunoprecipitation 
Protein CDS (bp) Amino acids pI Mass (kDa) 
Myc-AIP 1026 341 5.8 39.0 
AIP-Flag 1017 338 5.7 38.7 
HA-CBR1 918 305 6.3 33.8 
HA-DSTN 546 181 5.6 20.4 
HA-EEF1G 1362 453 5.6 52.0 
HA-FBXO3 1476 491 4.8 56.9 
HA-HSPA5 2025 674 5.0 74.7 
HA-HSPA8  2043 680  5.2  74.6 
HA-HSPA9 2094 697 5.5 75.8 
HA-HSP90A 2253 750  4.9 86.8 
HA-HSP90B 2259 752 4.9 86.7 
HA-NEFL 1686 561 4.6 63.6 
HA-NME1 519 172 5.0 19.5 
HA-SOD1 513 170 5.0 17.8 
HA-SKP1 546 181 4.3 20.8 
HA-TUBB 1395 464 4.7 52.5 
HA-TUBB2A 1398 465 4.7 52.3 
HA-VAPA 810 269 6.5 30.2 
 
Under standard experimental conditions (i.e., without adding a crosslinker), it was not possible 
to co-immunoprecipitate Myc and Flag tagged AIP (Figure 28a), and the addition of a 10mer 
peptide of TOMM20 did not change the results (Figure 28b). However, in the presence of 0.8% 
formaldehyde as a crosslinker, only very weak co-immunoprecipitated bands were observed 
(Figure 28c). These results are supported by isothermal calorimetry assays, demonstrating that 
the stoichiometry of the interaction between the TPR domain of AIP and HSP90 is 0.3:1, thus 
implying that one molecule of AIP interacts with an HSP90 dimer.
523
 In conclusion, AIP self-
association, if existent, might not be biologically relevant.  
 
AIP interacts with multiple molecular chaperones of the HSP70 and HSP90 families 
Originally described as stress-responsive proteins, involved in the response to thermal and 
other proteotoxic stresses, human heat shock proteins (HSPs) are also constitutively 
expressed
675
 and are abundantly represented in the proteome. Two of the best known 
molecular partners of AIP are the heat shock proteins HSP90 and HSPA8 (HSC70). Both 
HSPA8, a constitutively expressed protein of the HSPA (HSP70) family, and the constitutive 
isoform of HSP90, HSP90B, were detected in the MS analysis. Co-IP of these proteins was 
carried out to validate the experimental protocol (i.e. they were used as positive controls). 
Additionally, the inducible form of HSP90, HSP90A,
676
 was also tested. A successful co-IP of 
AIP and HSPA8, with a clean negative control, was obtained, as shown in Figure 29. Also, the 
co-IP experiments confirmed an interaction of AIP with both the inducible and the constitutive 
isoforms of HSP90 (Figure 30).  
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Figure 28. Myc-AIP and AIP-Flag co-immunoprecipitation. a) Standard protocol, b) with 1 µg of a TOMM20 10mer, and 
c) with 0.8% formaldehyde. Cells were co-transfected with pcDNA3.0-Myc-WT_AIP and pCI-Neo-WT_AIP-Flag and IP 
was performed using anti-Myc, anti-Flag or no antibody (or mouse IgG). Left panels: anti-Myc WB, right panels: anti-
Flag WB. Arrow on the left panel: Myc-AIP, arrow on the right panel: AIP-Flag. Arrowheads on both panels: heavy (top) 
and light (bottom) chains of mouse immunoglobulins. IP: immunoprecipitation, MWM: molecular weight marker. 
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The qMS results predicted total loss of HSPA8 binding and partial loss of HSP90B binding to 
the AIP mutant p.R304*, when compared to the WT protein. To determine the reliability of the 
comparative analysis for assuming loss of interaction, a co-IP experiment was carried out to 
verify the loss of interaction between HSPA8 and AIP p.R304* (Figure 31). An apparent loss of 
co-immunoprecipitated HA-HSPA8 was observed when immunoprecipitating with anti-Myc 
antibody. Likewise, the co-immunoprecipitated Myc-AIP band when immunoprecipitating with 
anti-HA antibody was weaker than in the experiment done with the WT protein. Although these 
results are only qualitative, they seem to confirm a reduced HSPA8 binding by the mutant 
p.R304*, as shown by qMS. 
 
Interactions of AIP with two other members of the HSP70 family, HSPA5 and HSPA9, were also 
detected. HSPA5 (also know as GRP78 and BiP) is a molecular chaperone resident in the ER, 
involved in protein quality control by regulating the folding and assembly of nascent proteins 
and the retention of misfolded proteins.
677
 By co-IP an interaction between AIP and HSPA5 was 
confirmed (Figure 32). The interaction of HSPA5 and AIP has not been reported before. 
HSPA9, also known as GRP75 or mortalin, is also a member of the HSP70 family of 
chaperones. HSPA9 in localised mainly in the mitochondria, but it can also be found in the ER, 
cytoplasmic vesicles, and cytosol in human transformed cell lines.
678
 HSPA9 interacts with the 
tumour suppressor TP53, inactivating its functions as a transcriptional activator and pro-
apoptotic molecule.
679
 An interaction between AIP and HSPA9 was confirmed by the co-IP 
experiment (Figure 33).  
 
 
Figure 29. Myc-AIP and HA-HSPA8 co-immunoprecipitation. Cells were co-transfected with pcDNA3.0-Myc-WT_AIP 
and pSF-CMV-NH2-HA-EKT-NcoI-HSPA8 and the IP was performed using anti-Myc, anti-HA or mouse IgG. Left panel: 
anti-Myc WB, right panel: anti-HA WB. Arrow on the left panel: Myc-AIP, arrow on the right panel: HA-HSPA8. 
Arrowheads on both panels: heavy (top) and light (bottoms) chains of mouse immunoglobulins. IP: immunoprecipitation, 
MWM: molecular weight marker. 
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Figure 30. Myc-AIP and HA-HSP90A/B co-immunoprecipitation. Top panels: co-IP experiment for HSP90A, bottom 
panels: co-IP for HSP90B. In both cases, the cells were co-transfected with pcDNA3.0-Myc-WT_AIP and pSF-CMV-
NH2-HA-EKT-NcoI-HSP90A (top) or pSF-CMV-NH2-HA-EKT-NcoI-HSP90B (bottom) and IP was carried out using anti-
Myc, anti-HA or mouse IgG. Left panels: anti-Myc WB, right panels: anti-HA WB. Arrow on the left panels: Myc-AIP, 
arrow on the right panels: HA-HSP90A (top) or HA-HSP90B (bottom). Arrowheads on both panels: heavy (top) and light 
(bottom) chains of mouse immunoglobulins. IP: immunoprecipitation, MWM: molecular weight marker. 
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Figure 31. Myc-AIP p.R304* and HA-HSPA8 co-immunoprecipitation. Cells were co-transfected with pcDNA3.0-Myc-
AIP_p.R304* and pSF-CMV-NH2-HA-EKT-NcoI-HSPA8 and the IP was performed using anti-Myc, anti-HA or mouse 
IgG. Left panel: anti-Myc WB, right panel: anti-HA WB. Arrow on the left panel: Myc-AIP, arrow on the right panel: HA-
HSPA8. Arrowheads on both panels: heavy (top) and light (bottom) chains of mouse immunoglobulins. The molecular 
weight marker is not visible in these images, as it was loaded in a different part of the gel, but the marks indicating the 
size of the bands were placed accordingly. IP: immunoprecipitation, MWM: molecular weight marker. 
 
 
Figure 32. Myc-AIP and HA-HSPA5 co-immunoprecipitation. Cells were co-transfected with pcDNA3.0-Myc-WT_AIP 
and pSF-CMV-NH2-HA-EKT-NcoI-HSPA5 and the IP was performed using anti-Myc, anti-HA or mouse IgG. Left panel: 
anti-Myc WB, right panel: anti-HA WB. Arrow on the left panel: Myc-AIP, arrow on the right panel: HA-HSPA5. 
Arrowheads on both panels: heavy (top) and light (bottom) chains of mouse immunoglobulins. IP: immunoprecipitation, 
MWM: molecular weight marker. 
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Figure 33. Myc-AIP and HA-HSPA9 co-immunoprecipitation. Cells were co-transfected with pcDNA3.0-Myc-WT_AIP 
and pSF-CMV-NH2-HA-EKT-NcoI-HSPA9 and the IP was performed using anti-Myc, anti-HA or mouse IgG. Left panel: 
anti-Myc WB, right panel: anti-HA WB. Arrow on the left panel: Myc-AIP, arrow on the right panel: HA-HSPA9. 
Arrowheads on both panels: heavy (top) and light (bottom) chains of mouse immunoglobulins. IP: immunoprecipitation, 
MWM: molecular weight marker. 
 
Cytoskeletal proteins are novel AIP partners, and also experimental artefacts 
Multiple cytoskeletal proteins were reported in the MS results. These proteins are abundantly 
expressed in all the cells, and therefore they are frequently found artefacts in pull-down assays. 
However, some of these proteins displayed differential binding between WT AIP and the mutant 
proteins, pointing out the need for validation of these interactions. 
 
Microtubules are essential cytoskeletal structures composed of heterodimers of beta tubulins 
and alpha tubulins; these structures are involved in mitosis, intracellular transport and cellular 
motility.
680
 Microtubules are also targets of anti-cancer drugs and the impaired expression of 
tubulins in cancer cells is a frequent cause of tumour progression and drug resistance.
681
 Two 
isotypes of beta tubulins were found underrepresented in the pull-down experiment for the 
mutant p.R304*, compared to WT AIP: TUBB and TUBB2A. TUBB is constitutively expressed in 
multiple cell lines, while TUBB2A is the major isotype in neurons and in prostate 
adenocarcinoma.
681
  
 
In the AIP-TUBB co-IP experiment (Figure 34), Myc-AIP was co-immunoprecipitated when using 
anti-HA antibody, while the immunoprecipitation with anti-Myc failed to co-immunoprecipitate 
HA-TUBB (the experiment was repeated, with identical results), which could indicate a positive 
but weak protein-protein interaction. On the other hand, the co-IP experiment clearly confirmed 
the interaction of AIP with TUBB2A (Figure 35, top). In the confocal immunocytofluorescence 
images (Figure 35, bottom), TUBB2A appears distributed in cytoplasmic filaments, while AIP 
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has a predominantly cytoplasmic diffuse distribution. There is clear overlap of both proteins 
(yellow areas) in the cytoplasmic network constituted by TUBB2A. Calculation of the co-
localisation in the whole z-stack rendered a Pearson’s coefficient of 0.642 and an overlap 
coefficient of 0.763, for an apparently positive co-localisation. 
 
Actins are proteins highly expressed in most of the cell types, involved in cell motility.
510
 In the 
cell, monomeric ATP-bound actin assembles in polymers (nucleation), which elongate into 
filaments, and these processes are regulated by actin-binding proteins.
682
 ACTB was reported 
as an AIP partner in the MS experiments, underrepresented in the experiments for the mutants 
AIP p.R304Q and AIP p.R304*.  
 
Validation of this interaction was attempted by co-IP of Myc-AIP and endogenous ACTB, using 
the anti-Myc antibody, as before, and a mouse monoclonal anti-ACTB antibody (SIGMA 
A1978). Although the co-IP reactions were positive in both directions, bands for the co-
immunoprecipitated proteins were also observed in the negative control (mouse IgG), indicating 
a non-specific binding of ACTB to mouse IgG (Figure 36). Therefore, it was not possible to 
confirm or disprove an interaction between AIP and ACTB by this method. In order to overcome 
this limitation, the experiment should be repeated using antibodies from a different origin, or a 
different experimental approach could be employed. 
 
 
Figure 34. Myc-AIP and HA-TUBB co-immunoprecipitation. Cells were co-transfected with pcDNA3.0-Myc-WT_AIP and 
pSF-CMV-NH2-HA-EKT-NcoI-TUBB and the IP was performed using anti-Myc, anti-HA or mouse IgG. Left panel: anti-
Myc WB, right panel: anti-HA WB. Arrow on the left panel: Myc-AIP, arrow on the right panel: HA-TUBB. Arrowheads on 
both panels: heavy (top) and light (bottom) chains of mouse immunoglobulins. IP: immunoprecipitation, MWM: 
molecular weight marker. 
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Figure 35. Myc-AIP and HA-TUBB2A validation experiments. Top panel: co-IP. Cells were co-transfected with 
pcDNA3.0-Myc-WT_AIP and pSF-CMV-NH2-HA-EKT-NcoI-TUBB2A; IP was performed with anti-Myc, anti-HA or 
mouse IgG. Left panel: anti-Myc WB, right panel: anti-HA WB. Arrow on the left panel: Myc-AIP, arrow on the right 
panel: HA-TUBB2A. Arrowheads on both panels: heavy (top) and light (bottom) chains of mouse immunoglobulins. IP: 
immunoprecipitation, MWM: molecular weight marker. Bottom panel: co-localisation of endogenous AIP and TUBB2A, 
63X z-stack reconstruction. a) Merged image, b) nuclei (DAPI), c) TUBB2A, d) AIP. Antibodies: 1:100 (v/v) rabbit 
polyclonal anti-AIP (Novus NBP1-31347) and 1:100 (v/v) mouse monoclonal anti-TUBB2A (Abnova H00007280-M03). 
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Figure 36: Co-immunoprecipitation Myc-AIP and ACTB. Cells were transfected with pcDNA3.0-Myc-WT_AIP and the IP 
was performed using anti-Myc, anti-ACTB or mouse IgG. Left panels: anti-Myc WB, right panels: anti-ACTB WB. Arrow 
on the left panel: Myc-AIP, arrow on the right panel: ACTB. Arrowheads on both panels: heavy (top) and light (bottom) 
chains of mouse immunoglobulins. IP: immunoprecipitation, MWM: molecular weight marker. 
 
NEFL forms intermediate filaments in the neural cells and it may have a tumour suppressor 
activity in cancer cells, inducing apoptosis and inhibiting invasion.
683
 The co-IP experiment 
between NEFL protein and AIP failed to prove an interaction (Figure 37, top). In the confocal 
immunocytofluorescence experiment, the reconstructed z-stack image presents very few areas 
of overlap between the two proteins by direct visualisation (yellow areas). Likewise, the co-
localisation analysis reported a Pearson's coefficient of 0.347 and an overlap coefficient of 
0.538. These data can be interpreted as apparently absent or minimal intracellular co-
localisation of both endogenous proteins. 
 
The protein DSTN was included among the validation experiments, because it was found as a 
candidate interacting partner for one of the mutants (p.R304*) but not for the WT AIP. DSTN, 
also known as ADF or cofilin, is involved in the organisation of the cytoskeleton, and it can 
either promote actin assembly or disassembly depending of the concentration of DSTN relative 
to actin and also depending on other actin-binding proteins.
684
 Co-IP experiments for this protein 
were carried out using the WT or p.R304* AIP, but none of them confirmed an interaction 
(Figure 38). Therefore, it can be concluded that the presence of DSTN in the pull-down fraction 
of p.R304* represents an artefact and not a real protein-protein interaction.  
 
The E3 ubiquitin-ligase FBXO3 interacts with AIP  
Two members of the SCF E3 ubiquitin-ligase complex were detected in the pull-down results: 
the F-box containing protein FBXO3 and SKP1, with differential representation among different 
pull-down experiments. Validation by co-IP with AIP was positive for FBXO3 (Figure 39), but not 
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Figure 37. Myc-AIP and HA-NEFL validation experiments. Top panel: co-IP. Cells were co-transfected with pcDNA3.0-
Myc-WT_AIP and pSF-CMV-NH2-HA-EKT-NcoI-NEFL, and the IP was performed using anti-Myc, anti-HA or mouse 
IgG. Left panels: anti-Myc WB, right panels: anti-HA WB. Arrow on the left panel: Myc-AIP, arrow on the right panel: 
NEFL. Arrowheads on both panels: heavy (top) and light (bottom) chains of mouse immunoglobulins. IP: 
immunoprecipitation, MWM: molecular weight marker. Bottom panel: co-localisation of endogenous AIP and NEFL, 63X 
z-stack reconstruction. a) Merged image, b) nuclei (DAPI), c) AIP, d) NEFL. Antibodies: 1:100 (v/v) mouse monoclonal 
anti-AIP (Novus NB100-127) and 1:50 rabbit monoclonal anti-NEFL (Cell Signalling CST2837). 
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Figure 38. Co-immunoprecipitation HA-DSTN and Myc-AIP p.R304* (a) and HA-DSTN and Myc-WT AIP (b). Cells were 
co-transfected with pcDNA3.0-Myc-AIP_p.R304* or pcDNA3.0-Myc-WT_AIP and pSF-CMV-NH2-HA-EKT-NcoI-DSTN, 
and the IP was performed using anti-Myc, anti-HA or mouse IgG. Left panels: anti-Myc WB, right panels: anti-HA WB. 
Arrow on the left panel: Myc-AIP, arrow on the right panel: NEFL. Arrowheads on both panels: heavy (top) and light 
(bottom) chains of mouse immunoglobulins. IP: immunoprecipitation, MWM: molecular weight marker. 
 
for SKP1 (Figure 40). However, if AIP is directed to ubiquitination by the SCF complex, it would 
be expected to be bound by FBXO3 and not by SKP1. These data suggests that AIP undergoes 
ubiquitination and posterior proteasomal degradation, initiated by an FBXO3 containing SCF E3 
ubiquitin-ligase complex. Although these results are a good proof of this mechanism, further  
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Figure 39. Myc-AIP and HA-FBXO3 co-immunoprecipitation. Cells were co-transfected with pcDNA3.0-Myc-WT_AIP 
and pSF-CMV-NH2-HA-EKT-NcoI-FBXO3, and IP was performed using anti-Myc, anti-HA or mouse IgG. Left panels: 
anti-Myc WB, right panels: anti-HA WB. Arrow on the left panel: Myc-AIP, arrow on the right panel: FBXO3. Arrowheads 
on both panels: heavy (top) and light (bottom) chains of mouse immunoglobulins. IP: immunoprecipitation, MWM: 
molecular weight marker. 
 
 
Figure 40. Myc-AIP and HA-SKP1 co-immunoprecipitation. Cells were co-transfected with pcDNA3.0-Myc-WT_AIP and 
pSF-CMV-NH2-HA-EKT-NcoI-SKP1, and IP was performed using anti-Myc, anti-HA or mouse IgG. Left panels: anti-Myc 
WB, right panels: anti-HA WB. Arrow on the left panel: Myc-AIP, arrow on the right panel: SKP1. Arrowheads on both 
panels: heavy (top) and light (bottom) chains of mouse immunoglobulins. IP: immunoprecipitation, MWM: molecular 
weight marker. 
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experiments should be done to ensure that FBXO3 is indeed the specific protein directing AIP to 
ubiquitination, considering the very large number of E3 ubiquitin-ligases encoded in the human 
genome (reviewed in Chapter 4). 
 
Miscellaneous interacting partners, not confirmed 
Also known as VAP-33, VAPA is a protein implicated in vesicle docking and fusion, localised in 
intracellular vesicles and at the tight junctions.
685
 VAPA binds SNARE proteins, thereby 
contributing to the secretory process.
686
 This protein was detected as an AIP interacting partner, 
underrepresented in the pull-down experiments for some of the AIP mutants. Considering the 
function of this protein, an interaction between AIP and VAPA could be important for GH 
secretion in the somatotroph cells, where AIP has been localised surrounding GH secretory 
vesicles. However, the co-IP experiment has discarded a direct interaction between AIP and 
VAPA (Figure 41). 
 
 
Figure 41. Myc-AIP and HA-VAPA co-immunoprecipitation. Cells were co-transfected with pcDNA3.0-Myc-WT_AIP and 
pSF-CMV-NH2-HA-EKT-NcoI-VAPA, and IP was performed using anti-Myc, anti-HA or mouse IgG. Left panels: anti-
Myc WB, right panels: anti-HA WB. Arrow on the left panel: Myc-AIP, arrow on the right panel: VAPA. Arrowheads on 
both panels: heavy (top) and light (bottom) chains of mouse immunoglobulins. IP: immunoprecipitation, MWM: 
molecular weight marker. 
 
CBR1 is an NADPH-dependent reductase, catalysing the reduction of several carbonyl 
compounds.
510
 Human CBR1 is highly expressed in the liver, placenta and central nervous 
system and it apparently has a protective role, involving the metabolic reduction of xenobiotic 
carbonyls and quinones.
687
 Co-IP experiments for this protein showed no interaction with WT 
AIP. CBR1 can bind glutathione,
510
 so this protein could constitute an artefact due to the GST 
tag and glutathione elution used in the pull-down experiments. 
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Figure 42. Myc-AIP and HA-CBR1 co-immunoprecipitation. Cells were co-transfected with pcDNA3.0-Myc-WT_AIP and 
pSF-CMV-NH2-HA-EKT-NcoI-CBR1, and IP was performed using anti-Myc, anti-HA or mouse IgG. Left panels: anti-
Myc WB, right panels: anti-HA WB. Arrow on the left panel: Myc-AIP, arrow on the right panel: CBR1. Arrowheads on 
both panels: heavy (top) and light (bottom) chains of mouse immunoglobulins. IP: immunoprecipitation, MWM: 
molecular weight marker. 
 
EEF1G is a component of the translational apparatus, together with eIF4A, eIF4E, eEF1A and 
eEF1; this complex is frequently overexpressed in tumoral cells.
688
 WB bands for both EEF1G 
and AIP were detected when immunoprecipitating with anti-Myc and anti-HA antibodies, but the 
immunoprecipitation with mouse IgG (negative control) was also positive for both proteins 
(Figure 43). With these results it is not possible to discard or to prove the interaction reported in 
the MS data. It is important to mention that EEF1G contains a GST domain,
689
 and therefore it 
could have been pulled-down and eluted due to its affinity for glutathione.   
 
NME1 (NM23, NDKA) is a regulator of the cell cycle progression (from G2 to M), through 
downregulation of cyclin B, and this activity is inhibited by cAMP.
77
 In pituitary adenomas, the 
expression of NME1 (measured by IHC) is inversely correlated with invasiveness.
690
 Co-IP of 
NME1 was negative when immunoprecipitating with anti-Myc, but co-IP of AIP was positive 
when immunoprecipitating with anti-HA, though AIP was also detected in the negative control 
(Figure 44). These results were interpreted as no direct interaction between AIP and NME1. 
Finally, validation of an interaction between AIP and the mitochondrial protein SOD1 was also 
attempted (Figure 45). Co-IP of AIP when immunoprecipitating with anti-HA was detected, but 
there was no co-immunoprecipitation of SOD1 when immunoprecipitating with anti-Myc. These 
results could possibly be interpreted as a weak interaction between these two proteins. 
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Figure 43. Myc-AIP and HA-EEF1G co-immunoprecipitation. Cells were co-transfected with pcDNA3.0-Myc-WT AIP and 
pSF-CMV-NH2-HA-EKT-NcoI-EEF1G, and IP was performed using anti-Myc, anti-HA or mouse IgG. Left panels: anti-
Myc WB, right panels: anti-HA WB. Arrow on the left panel: Myc-AIP, arrow on the right panel: EEF1G. Arrowheads on 
both panels: heavy (top) and light (bottom) chains of mouse immunoglobulins. IP: immunoprecipitation, MWM: 
molecular weight marker. 
 
 
Figure 44. Myc-AIP and HA-NME1 co-immunoprecipitation. Cells were co-transfected with pcDNA3.0-Myc-WT AIP and 
pSF-CMV-NH2-HA-EKT-NcoI-NME1, and IP was performed using anti-Myc, anti-HA or mouse IgG. Left panels: anti-
Myc WB, right panels: anti-HA WB. Arrow on the left panel: Myc-AIP, arrow on the right panel: NME1. Arrowheads on 
both panels: heavy (top) and light (bottom) chains of mouse immunoglobulins. IP: immunoprecipitation, MWM: 
molecular weight marker. 
Anti-Myc (Myc-AIP=39 kDa) Anti-HA (HA-EEF1G= 52 kDa)
M
W
M
In
p
u
t
IP
 M
yc
 
IP
 H
A
IP
 I
g
G
M
W
M
In
p
u
t
IP
 M
yc
 
IP
 H
A
IP
 I
g
G
50kDa
20kDa
80kDa
15kDa
10kDa
60kDa
110kDa
160kDa
Anti-Myc (Myc-AIP=39 kDa) Anti-HA (HA-NME1= 19.5 kDa)
M
W
M
In
p
u
t
IP
 M
yc
 
IP
 H
A
IP
 I
g
G
M
W
M
In
p
u
t
IP
 M
yc
 
IP
 H
A
IP
 I
g
G
50kDa
20kDa
80kDa
15kDa
10kDa
60kDa
110kDa
160kDa
171 
 
 
Figure 45. Myc-AIP and HA-SOD1 co-immunoprecipitation. Cells were co-transfected with pcDNA3.0-Myc-WT AIP and 
pSF-CMV-NH2-HA-EKT-NcoI-SOD1, and IP was performed using anti-Myc, anti-HA or mouse IgG. Left panels: anti-
Myc WB, right panels: anti-HA WB. Arrow on the left panel: Myc-AIP, arrow on the right panel: SOD1. Arrowheads on 
both panels: heavy (top) and light (bottom) chains of mouse immunoglobulins. IP: immunoprecipitation, MWM: 
molecular weight marker. 
 
The pituitary-specific function of AIP could occur via chaperone client proteins 
AIP could exert functions relevant for pituitary physiology via indirect interactions with client 
proteins of molecular chaperones of the HSP90 or HSP70 families. For this reason, a possible 
indirect interaction of AIP with PRKACA, an HSP90 client protein with an important role in the 
somatotroph cell function, was explored. This protein was not part of the list of candidate 
partners for AIP, but it was selected after finding some similarities between its protein partners 
and those of AIP in the BIOGRID protein-protein interaction database.
541
 
 
PRKACA is part of the complex of proteins that constitute PKA, a key member of the cAMP 
pathway. An important role for this pathway in the tumorigenesis of different endocrine organs is 
well established.
81
 Recently, the activating PRKACA mutation p.L206R has been shown to be 
causative of cortisol-producing adrenal tumours, leading to Cushing’s syndrome.
691
   
 
AIP and PRKACA do not interact directly (Figure 46), but when a triple co-IP experiment 
including AIP, PRKACA and HSP90A was attempted, the three proteins were successfully co-
immunoprecipitated (Figure 47). Although these findings support a possible interaction between 
the three proteins, they do not prove the existence of a complex containing the three proteins in 
the cell. 
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Figure 46. Myc-AIP and HA-PRKACA co-immunoprecipitation. Cells were co-transfected with pcDNA3.0-Myc-WT_AIP 
and pSF-CMV-NH2-HA-EKT-NcoI-PRKACA, and IP was performed using anti-Myc, anti-HA or mouse IgG. Left panel: 
anti-Myc WB, right panel: anti-HA WB. Arrow on the left panel: Myc-AIP, arrow on the right panel: HA-PRKACA. 
Arrowheads on both panels: heavy (top arrowheads) and light (bottom arrowheads) chains of mouse immunoglobulins. 
IP: immunoprecipitation, MWM: molecular weight marker. 
 
 
Figure 47. Myc-AIP, HA-HSP90B and Flag-PRKACA co-immunoprecipitation. Cells were co-transfected with pcDNA3.0-
Myc-WT_AIP, pSF-CMV-NH2-HA-EKT-NcoI-HSP90B and pSF-CMV-NH2-Flag-EKT-NcoI-PRKACA and IP was 
performed using anti-Myc, anti-HA, anti-Flag or mouse IgG. Left panel: anti-Myc WB, central panel: anti-HA WB, right 
panel: anti-Flag WB. Arrow on the left panel: Myc-AIP, arrow on the central panel: HA-HSP90B, arrow on the right 
panel: Flag-PRKACA. Arrowheads on all the panels: heavy (top arrowheads) and light (bottom arrowheads) chains of 
mouse immunoglobulins. IP: immunoprecipitation, MWM: molecular weight marker. 
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Discussion 
Biological functions are orchestrated and regulated by dynamic networks of interacting proteins, 
and a wide variety of proteomic methods are currently available for the study of protein-protein 
interactions.
692
 The two-hybrid (2H) system, originally employing yeast and therefore termed 
yeast-2H assay, is one of the most common methods for testing protein-protein interactions.
693
 
In this system, plasmids are constructed to express two proteins whose interaction is being 
tested. In one of them, a functional domain that binds a promoter DNA sequence is fused to the 
CDS for one of the proteins of interest. In the other plasmid, the CDS for the other protein is 
fused to a transcriptional activator. Both proteins are co-expressed in a cell and, if interaction 
exists, the transcription of a reporter gene will be activated.
694
 Although this method can only 
screen interactions of two proteins at a time, it can be scaled-up to create libraries of interacting 
partners.
693
 A limitation of this system is that, if yeasts are used (heterologous system), the 
mammalian proteins expressed may not carry all the posttranslational modifications relevant for 
their function.
695
  
 
The gold-standard assay for protein-protein interactions is the co-IP of untagged proteins at 
their endogenous level. However, this is frequently difficult to do, due to the variable expression 
of the proteins of interest in the cells, and it is limited by the availability of suitable antibodies. 
Even more, only two proteins can be studied at a time by co-IP.
695
 
 
For “fishing” experiments, trying to investigate protein interactions in a proteome scale, high-
throughput methods are required. For these purposes, proteins complexes are first isolated 
from an appropriate biological sample and purified, using a variety of techniques, and protein 
identification is carried out in a second step, generally involving peptide identification by MS.
692
 
Affinity fusion-based techniques for protein purification take advantage of the use of genetically 
fused affinity tags, and in these methods proteins of interest are expressed in frame with an 
epitope tag.
692
 Plasmids encoding the tagged proteins are transfected into cells and left to be 
expressed for a certain period of time. The cells are then lysed, and the tagged bait along with 
its interacting partners (“prey”) is isolated using a chemical or biological ligand linked to a solid 
support, and then eluted.
694
 Proteins in the eluted fraction can be resolved by PAGE and then 
identified by MS.  
 
A variant of this method is tandem affinity purification (TAP). In this method, a so called TAP-
tag, composed of two sequential affinity tags spaced by a cleavage site of tobacco etch virus 
(TEV) protease, is fused to the CDS for the protein of interest.
694
 After expression of the bait 
protein and cell lysis, a first affinity purification step is done, using the protein A moiety in the 
TAP tag, which binds IgG-sepharose.
692
 Then, TEV protease is added, cleaving the TEV tag 
and therefore eluting the proteins. These samples undergo a second affinity purification step via 
the calmodulin binding peptide present in the TAP tag (using calmodulin-sepharose), and they 
are finally eluted. This method reduces the background due by nonspecific interactions; 
however, given the need of two purification steps, transient interactions are frequently lost.
694
 
174 
 
Other types of TAP tags have been described, with variable structure, but following the same 
principle.
696
 
 
An advantage of affinity purification is that the proteins are expressed in vivo, and therefore they 
can undergo posttranslational modifications that could possibly affect the binding to certain 
partners. However, after cell lysis, the bait protein is put in contact with proteins that are not 
normally expressed in the same subcellular compartment. Also, due to the purification step and 
the stringent washes required to eliminate contaminants during the purification step, this method 
is biased towards proteins that interact with high affinity, and is therefore not useful to detect 
transient protein interactions. Because the tagged bait protein is overexpressed, its assembly 
could be compromised, and this could result in high levels of chaperones interacting with the 
misfolded protein, obscuring interactions with other less abundant proteins.
694
 Also, affinity 
purification approaches can only generate a list of proteins detected at a given time, not 
revealing the composition of individual protein complexes. This is due to the fact that only 
protein interactions that are resistant to the lysis and purification conditions can survive to be 
detected by MS. This problem can be solved by the use of chemical crosslinkers, which stabilise 
the proteins in complexes. However, crosslinking can also frequently introduce false positive 
results.
692
   
 
The pull-down assay, which was the method used in the present study, also includes affinity 
purification, but in this method a synthetic protein, usually fused to an affinity tag, is exposed to 
a cell lysate, and proteins interacting with the bait are then recovered by affinity purification.
667
 
The GST tag is frequently used in this method, both for protein production and for pull-down. 
The pull-down asssay does not require transfection, allowing the use of a wider diversity of 
starting material (cells, tissues) for the lysates and facilitating the use of different amounts of 
bait protein, according to the experimental needs. However, tags used for protein production, as 
GST, are usually long and therefore they can modify the interactions of the normal protein. Also, 
false positive results can be introduced due to proteins interacting not with the protein of 
interest, but with the tag instead.  
 
MS is the method of choice for peptide sequencing because of its high sensitivity and 
compatibility with high-throughput experimental strategies. Mass spectrometric analyses take 
place in the gas phase of ionised analytes.
697
 Two main strategies to ionise and volatilise 
peptides, previously separated by reverse phase liquid chromatography, are currently used: ESI 
and matrix-assisted laser desorption/ionisation (MALDI).
692
 The mass spectrometer is 
composed of an ion source, a mass analyser that separates ionised analytes based on their 
mass-to-charge ratio (m/z), and a detector that registers the number of ions at each m/z 
value.
698
 For proteomic analyses, it is necessary to have sensitive instruments, providing high 
resolution/mass accuracy and with the ability to generate information-rich ion mass spectra from 
peptide fragments, which is referred to as the tandem mass or MS/MS spectra.
697
 Four basic 
types of mass spectrometers are currently used, and they can be used separately or in tandem: 
175 
 
quadrupole, ion trap (quadrupole ion trap or linear ion trap), time-of-flight, quadrupole and 
Fourier-transform ion cyclotron resonance, together with a variant of ion trap, Orbitrap.
698
 The 
instrument used in the present study was a hybrid linear ion trap-Orbitrap mass analyser. The 
ion-trap technology consists on “trapping” the ions for a certain period of time, before subjecting 
them to MS or MS/MS analysis.
697
 In the Orbitrap, the ions are trapped and orbit around a 
spindle-like electrode, oscillating harmonically along its axis with a frequency characteristic of 
their m/z values. This induces an image current in the outer electrodes that is transformed into 
the time domain, producing mass spectra. This technology improves the mass accuracy and 
high resolution or MS.
698
 The most frequently used fragmentation method in MS/MS is collision-
induced dissociation. In this technique, gas-phase peptide/protein cations are internally heated 
by multiple collisions with rare gas atoms, causing peptide backbone fragmentation and 
resulting in a series of b-fragment and y-fragment ions. Other fragmentation methods are 
electron-capture dissociation and electron-transfer dissociation.
698
 
 
Two main approaches exist regarding the type of samples that are submitted for MS. In the 
bottom-up approach the proteins of interest are subjected to enzymatic digestion (e.g. trypsin) 
and the resulting peptides are submitted for ionisation. The analysis of the ionised peptides 
takes place in two steps: first the masses of the peptides are determined and then the peptide 
ions are fragmented to produce information on their sequence and modifications. As only a very 
small fraction of the peptides produces useful fragmentation ladders, this method is not optimal 
for the study of posttranslational modifications and alternative splice variants.
699
 In the present 
study, a bottom-up approach was used, based on in-gel trypsin digestion. The top-down 
approach consists on submitting intact proteins for ionisation, to be subsequently fragmented in 
the mass spectrometer, reporting the masses of both the protein and the fragmented ions, 
which under optimal conditions provides a complete description of the protein sequence and its 
posttranslational modifications.
699
 
 
High throughput interaction data derived from affinity purification experiments are enriched in 
proteins of high abundance. The best way of distinguishing true interaction partners from non-
specific contaminants is the use of quantitative proteomics. The rationale for this technology is 
to compare the abundance of proteins identified in a sample with a suitable control.
695
 The 
present study has used qMS based on isotopomer labels, named TMT or isobaric mass tags.
668
 
TMT are a set of structurally identical tags which label the free N-terminus and ε-amino 
functions of K residues.
700
 Different samples can be labelled with different TMT and then 
combined and processed as one sample, whose results can be quantitatively analysed. The 
tags are composed of a reactive group, which binds amino groups in the peptide, a mass 
normalisation group (balancer group), balancing the mass differences from individual ion 
reporters to ensure the same overall mass of the label reagents, a cleavable linker, enabling the 
release of the reporter ion from the tag during MS/MS fragmentation, and a reporter ion. 
“Heavy” isotopes (
13
C or 
15
N) are contained in the reporter group and in the balancer ion. The 6-
176 
 
plex TMT tags used in the present study have specific reporters that appear at m/z=126.1, 
127.1, 128.1, 129.1, 130.1 and 131.1.
700
 
 
Once a protein-protein interaction has been identified, it is necessary to verify the binding by 
additional methods. One frequently used method is immunofluorescent staining to detect co-
localisation in confocal microscopy images. The purpose of this method is to determine if two 
proteins display overlapping distribution within the cell, which would make their interaction more 
plausible. Imaging can be done in the intact cells, expressing endogenous proteins, or in 
previously transfected cells overexpressing the proteins of interest, though the first approach is 
usually preferred. Another confirmatory method is co-IP, where one of the proteins of interest 
(endogenous or overexpressed) is immunoprecipitated with a specific antibody, and the 
interacting protein is searched in the immunoprecipitated material by WB or MS.
694
 The finding 
of multiple qMS artefacts in this study, with negative co-IP assays, points out one of the 
weaknesses of proteomics studies, and emphasises the need for validation. 
 
The novel interacting partners of AIP identified and confirmed in this study correspond to three 
different categories. The first category is heat shock proteins. In addition to the previously 
known AIP partners HSPA8 and HSP90, interactions with two more heat shock proteins of the 
HSP70 family, HSPA5 and HSPA9, have been demonstrated. In contrast with HSPA8 and 
HSP90, which are widely distributed in the cytoplasm, these two HSP70 proteins have specific 
subcellular distributions: HSPA5 preferentially resides in the ER, while HSPA9 is mainly 
expressed in the mitochondria, though small amounts of both proteins can also be observed in 
other subcellular localisations (see below). Interestingly, the proteins HSPA5 and HSPA9 do not 
contain a MEEVD (like HSP90) or IEEVD (like HSPA8) domain, and according to the qMS data, 
none of the variants studied disturbed these interactions. A member of the HSP70 family, 
HSPA2 (HSP72), is expressed in around 90% of all the pituitary adenomas (including all 
subtypes), showing areas of focal induction when detected by IHC,
701
 but this protein was not 
identified as an AIP interacting partner. Further experiments should be done, involving HSPA5 
and HSPA9 mutagenesis, to better characterise these novel AIP interactions (i.e. defining 
residues involved in the interaction, studying co-localisation in pituitary adenoma tissue). 
 
Under physiological conditions, HSPA5 and other ER resident chaperones serve to ensure an 
adequate folding of the nascent proteins, preventing their aggregation. Stressful factors such as 
hypoxia, pH changes, and reduced nutrient supply impair the ER function and activate a cellular 
mechanism known as unfolded protein response (UPR).
702
 The function of the UPR is to limit 
damage to other organelles and to the whole organism, and this is accomplished by limiting the 
accumulation of unfolded proteins, targeting them to degradation, and eliminating cells 
subjected to prolonged stress, therefore including both cytoprotective and apoptotic 
responses.
703
 In the absence of ER stress, HSPA5 binds the luminal domain of the UPR 
transducers inositol-requiring gene 1 (IRE1), PKR-like ER kinase (PERK) and activating 
transcription factor 6 (ATF6), keeping them inactive.
704
 When unfolded proteins accumulate in 
177 
 
the ER, HSPA5 is released and the transducers are activated, causing activation of NF-κB, 
caspase-12 and MAPK1, as well as G1 arrest and increased angiogenesis. In the presence of 
sustained ER stress, these responses may elicit the selective proliferation of transformed cells, 
with anti-apoptotic mutations and angiogenic abilities.
703
  
 
UPR activation is a key event in solid tumours, and HSPA5, overexpressed in various human 
cancer types (acute lymphoblastic leukaemia, lung, breast, prostate, colon, stomach and liver), 
exhibits oncogenic abilities and is associated with poor prognosis and drug resistance.
702;703;705
 
In a rat gliosarcoma cell line, HSPA5 expression is induced by PKA and MAPK1.
706
 In addition 
to its ER localisation, HSPA5 is also localised on the cell surface in different cancer types, were 
it is activated by the binding to α2-macroglobulin and acts as an oncogene, promoting cell 
proliferation (via RAS/RAF/MEK/ERK and phosphatidylinositol 3-kinase [PI3K] signalling) and 
survival (mediated by Akt and NF-κB).
707
 HSPA5 has recently been identified as a therapeutic 
target in cancer: adenoviral E1A-induced HSPA5 ubiquitination and proteasomal degradation 
suppresses the metastatic potential of human breast cancer cells
708
 and treatment with the 
synthetic HSPA5 inhibitor (OSU-03012), in combination with sildenafil, induces lethality on a 
human glioblastoma cell line.
709
  
 
Cell surface HSPA5 also responds to other stimuli, such as plasminogen kringle 5, 
microplasminogen and angiogenic peptides, and is involved in viral entry of coxsackie B and 
dengue fever viruses.
710
 The co-chaperone MTJ-1 is one of the regulators of HSPA5 function in 
the ER, and it is also essential for the HSPA5 localisation on the cell surface.
711
 No data exists 
about the role of the UPR or specifically HSPA5 on pituitary function or tumorigenesis; 
therefore, it is not possible to make assumptions about the possible functional role of the 
interaction between this chaperone and AIP.  
 
HSPA9 was originally identified as a mitochondrial chaperone, but it is also expressed in other 
subcellular localisations (nucleus, cell membrane, ER, and cytosol), mainly in cancer cells, 
which may be relevant for its function as a regulator of cell growth and survival.
712-714
 HSPA9 
overexpression is induced by cellular stress and is a frequent finding in different types of human 
neoplasms, including colon, prostate, cervix, lung, liver, brain, breast, skin and medullary thyroid 
cancer.
679;715
 In the late G1 phase of the cell cycle, HSPA9 is localised at the centrosomes, 
remains there during S and G2 and dissociates from the centrosomes during M.
716
 In cancer 
cells subjected to stress (either due to TP53 mutations or to stress-inducing chemicals), the 
tumour suppressor protein TP53 interacts with HSPA9 and this chaperone regulates the 
intracellular location of TP53 during the cell cycle.
679;716
 Overexpressed HSPA9 sequesters 
TP53 in the cytoplasm, preventing its nuclear translocation and thus abrogating the regulation of 
cell cycle progression by TP53.
717
 Overexpressed HSPA9 is also a negative regulator of the 
CDKN1A-mediated tumour suppressive MAPK1 signalling pathway in a TP53-dependent or 
independent manner, an important mechanism for CDKN1A silencing in BRAF p.V600E-
transformed cancers, such as melanoma and medullary thyroid carcinoma.
713;718
 When located 
178 
 
in the nucleus, HSPA9 exerts an additional pro-oncogenic activity, by interacting with the 
telomerase transcriptase (hTERT) and the heterogeneous ribonucleoprotein K (hnRNP-K) 
proteins, activating them.
719
  
 
Due to these pro-tumorigenic activities, HSPA9 represents a potential therapeutic target for 
cancer. In contrast, missense mutations in the HSPA9 gene are associated to Parkinson’s 
disease: mutant HSPA9 increases the endogenous oxidative stress and the sensitivity to 
exogenous oxidative stress, resulting in neuronal senescence.
714
 Normal levels of HSPA9 are 
necessary for normal B lymphopoiesis, and the HSPA9 locus (5q31.1) is included in a region 
frequently deleted in in patients with myeloid malignancies, such as myelodysplastic 
syndrome.
720
 Besides the multiple studies addressing the HSPA9 functions in normal and 
neoplastic cells, there is no information available about the co-chaperones that regulate HSPA9 
cellular localisation and functions in different settings. By acting as a co-chaperone of HSPA9, 
AIP could possibly regulate HSPA9-mediated TP53 trafficking or its interaction with members of 
the RAS/RAF/MEK/ERK signalling pathway. However, it would be necessary to first study the 
expression and the function of this chaperone in the normal pituitary gland and in pituitary 
adenomas, an issue that has not been addressed before. 
 
HSP90 has been found overexpressed in adrenocorticotropinomas, impairing the sensitivity of 
the glucocorticoid receptor and therefore adrenal-pituitary negative feedback, and the C-
terminal HSP90 inhibitor silibinin showed anti-tumorigenic effects in an allograft mouse model of 
Cushing’s disease, by releasing GR from HSP90,
721
 but the role of HSP90 in AIPmut-associated 
pituitary adenomas has not been explored. Previously reported co-IP experiments, and now our 
data, showed that the TPR domain of AIP is required for the interaction with HSP90.
546
 The 
highly conserved residue of HSP90 G272 seems to be necessary for this interaction.
521
 Under 
our experimental conditions, the AIP p.K266A, also predicted to be necessary for this interaction 
to occur, did not impair the binding of HSP90 to AIP, while mutations affecting the C-terminal α-
helix of the protein (p.R304* and p.R304Q) resulted in a reduced binding. Although these 
mutations do not affect the HSP90 binding site directly, an abnormal C-terminal α-helix could 
possibly disrupt the folding of the TPR3, affecting the interaction with the HSP90 MEEVD motif. 
An interaction of HSP90 with the PPIase-like domain of AIP has recently been described,
518
 but 
our data seem to indicate that the binding through the TPR domain might be more important for 
this protein-protein interaction to occur. Also interestingly, the binding to HSPA8 was one of the 
interactions more strikingly affected by the pathogenic AIP mutation p.R304* in the pull-down 
experiments.  
 
Both chaperones, HSP90 and HSPA8, have a large list of interacting partners, and it would be 
necessary to perform another “fishing” experiment to identify the specific client proteins that can 
bind HSP90 or HSPA8 and AIP concomitantly in pituitary cells. In this sense, our triple co-IP 
experiment has identified an interaction between AIP, HSP90 and PRKACA, a known HSP90 
client protein with a central role in somatotroph cell function. PRKACA forms part of the 
179 
 
heterotetrameric enzyme PKA. Upon activation by cAMP, the catalytic subunits of the enzyme 
(PRKACA and other isoforms) are translocated to the cell nucleus, where they phosphorylate 
CREB at the residue S133; activated CREB can then induce the transcription of genes 
containing a cAMP response element (CRE).
722
 Subcellular localisation of the catalytic subunits 
of PKA is regulated by A-kinase anchor proteins (AKAPs), but its nuclear translocation is 
considered to be a passive process.
723
 The interaction between HSP90 and PRKACA was 
found in a high throughput proteomic study
549
 and has not been further functionally or 
structurally characterised. Considering the effect of the HSP90/AIP complex over the AHR 
function, it is feasible that this complex could regulate PKA localisation, by maintaining it in the 
cytoplasm, in which case they would possibly also interact with the PRKAR1A, as it has recently 
been suggested.
724
  
 
The second category of interacting partners includes cytoskeletal proteins. Interaction of AIP 
with the microtubule structural proteins TUBB and TUBB2A has been validated, while 
interaction with other cytoskeletal proteins has been found by pull-down and MS, but not 
confirmed. This is not the first time that a role of AIP or other immunophilins as regulators of the 
cytoskeleton is proposed. The HSP90-binding immunophilin FKBP2 mediates the nuclear 
translocation of nuclear receptors by interacting with dynein, a regulator or the organisation of 
tubulin networks, through its PPIase domain.
725
 However, previous studies addressing the 
interaction of AIP with cytoskeletal proteins rendered contradictory results. While no binding or 
very weak binding of the PPIase-like domain of AIP to dynein was found by one group,
726
 a 
different study demonstrated that the AIP-mediated cytoplasmic localisation of the AHR requires 
the anchoring of the complex to actin filaments.
542
 Even more, while the latter study proved a 
direct interaction between AIP and actin when AHR is inactive, a different group disproved this 
interaction.
570
  
 
The microtubules are structures formed by heterodimers of α and β-tubulins of various isotypes 
(six of α and seven of β-tubulin), involved in cell movement, intracellular transport and cell 
division.
681;727
 The microtubule-associated proteins regulate microtubule dynamics and also the 
interactions between microtubules and other cellular components.
728
 Posttranslational 
modifications define distinctive groups of microtubules within the cell, and shape them to form 
structures with specific functions, e.g. mitotic spindle, cilia, flagella, basal bodies.
727
 
Microtubules forming the mitotic spindle are the target of anti-mitotic drugs used in the treatment 
of cancer, including microtubule-stabilising (taxanes and epothilones) and microtubule-
destabilising (vincristine, vinblastine and vinorelbine) drugs; changes in the expression of β-
tubulin isotypes and microtubule-associated proteins can modify the response to those drugs.
681
  
 
Cytoskeletal disorganisation is a key feature of epithelial-mesenchymal transition (EMT), a 
process by which polarised epithelial cells develop increased migratory capacity, invasiveness, 
resistance to apoptosis and increased production of extracellular matrix, ultimately acquiring a 
mesenchymal cell phenotype.
729
 One of the hallmarks of EMT is the loss of expression of e-
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cadherin, a protein implicated in the formation of the adherens junction, and in 
somatotropinomas, e-cadherin expression correlates positively with GH and IGF-1 levels and 
response to SSA treatment, and negatively with tumour size and invasiveness.
730
 The 
characteristics of somatotropinomas with low e-cadherin expression recapitulate the phenotype 
described in the AIPmut positive setting.
730
 The EMT phenotype in somatotropinomas depends 
on the expression of ESRP1, an epithelial‐specific splicing regulator.730;731 A function of AIP as a 
microtubule-associated protein in the somatotroph cells, suggested by our results, would 
explain why the cells acquire an EMT phenotype in the setting of AIPmut positive pituitary 
adenomas (unpublished data by our group). 
 
The third group is composed of proteins belonging to the ubiquitination pathway: FBXO3, SKP1 
and RS27A. FBXO3 and SKP1 are part of the SCF E3 ubiquitin-ligase complex, while RS27A 
forms part of the ubiquitin chains. These findings suggest that AIP is degraded by the ubiquitin-
proteasome system (UPS) via the SCF complex, and that this interaction is mediated by specific 
recognition of AIP via the F-box containing protein FBXO3. The cullin-really interesting new 
gene (RING) E3 ubiquitin-ligases (CRLs) are protein complexes composed of one of seven 
cullin family scaffold proteins, a RING domain enzyme (RBX1 or RBX2) bound to the C-terminal 
domain of the cullin protein, an adaptor protein, bound to the N-terminal cullin-repeat motifs of 
the cullin protein, and an F-box containing protein, bound to the adaptor protein.
732;733
 The RING 
domain is responsible for binding to the E2 enzyme and stimulating ubiquitin transfer.
732
 The 
SCF is the prototypical CRL, composed of the RING-containing enzyme RBX1, the cullin 
scaffold CUL1, the adaptor protein SKP1 and a variable F-box containing protein; this last 
protein regulates the specificity of the protein degradation via the UPS (reviewed in Chapter 
4).
733;734
  
 
F-box containing proteins are divided in three classes according to the domain used for 
interacting with the substrate: Fbxl (containing a C-terminal leucine-rich repeat domain), Fbxw 
(C-terminal WD40 repeat domain) and Fbxo (other domains or no recognisable domains).
735
 
Besides AIP, other proteins recognised by FBXO3 are the tumour necrosis factor receptor-
associated factor inhibitor Fbxl2,
736
 the Smurf1 ubiquitin ligase,
737
 the serine/threonine-protein 
kinase homeodomain-interacting protein kinase 2 (HIPK2) and the histone acetyltransferase 
p300 HAT.
738
 Given the great diversity of E3 ubiquitin-ligases encoded in the genome, further 
studies should be carried out to completely characterise this interaction. Interestingly, the qMS 
data showed an increased binding of FBXO3 and SKP1 to AIP p.R304* when compared to the 
WT protein. This differential affinity could possibly mean that the AIP p.R304* mutant protein is 
more prone to be ubiquitinated than the WT protein, a theory that will be further explored in 
Chapter 4. 
 
Among the candidate AIP interacting partners not fully validated, two proteins, NME1 and 
SOD1, displayed positive co-IP only when using one of the anti-tag antibodies, but not when 
using the other one, and therefore, these molecular interactions cannot be discarded at the 
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moment. Of particular interest is NME1, the first metastasis suppressor gene identified, which is 
now also considered a tumour suppressor.
739-741
 NME1 negatively regulates cell migration and 
motility, and displays both nucleoside diphosphate kinase and histidine protein kinase activity.
740
 
NME1 expression is upregulated by the G protein signalling regulator RGS19, and it 
phosphorylates the kinase suppressor of HRAS (KSR1), inhibiting the activity of HRAS and 
therefore the RAS/RAF/MEK/ERK signalling pathway;
742
 for this reason, NME1 is also 
considered a tumour suppressor.
741
  
 
NME1 mRNA levels are high in cell lines with low metastatic potential (murine K-1735 
melanoma and N-nitroso-Nmethylurea-induced rat mammary carcinomas).
739
 In contrast, LOH 
involving the NME1 locus (17q21.3), resulting in reduced protein expression, increases the risk 
of metastasis in colorectal cancer.
743
 Low NME1 expression correlates with metastasis and poor 
clinical prognosis in different human epithelial cancer types, but in other tumour types 
(neuroblastoma and haematological malignancies) NME1 overexpression correlates with bad 
prognosis.
744
 Moreover, NME1 KD in various human cancer cell lines disrupts e-cadherin-
mediated cell adhesion, resulting in CTNNB1 nuclear translocation and transactivation of the T-
cell factor/lymphoid-enhancing factor-1, a component of the WNT signalling pathway.
745
 In 
contrast, overexpression of NME1 inhibits the metastatic potential of TP53-deficient HeLa 
cells.
741
 NME1 co-localises with e-cadherin in epithelial cancer cell lines, suggesting a possible 
regulatory role of NME1 in the stabilisation of the adherens junction.
745
 In pituitary adenomas, 
NME1 expression inversely correlates with tumour extension into the cavernous sinus.
690
 A 
possible interaction between AIP and NME1 with a positive effect on NME1 function is feasible, 
as AIPmut positive pituitary adenomas are characterised by increased invasiveness. Low e-
cadherin expression in pituitary adenomas, together with other markers of EMT, is an indicator 
of tumour progression and bone destruction, and NME1 could have a role in regulating e-
cadherin function and therefore the organisation of the adherens junction in these tumours.  
 
The enzyme SOD1, required for the conversion of superoxide to hydrogen peroxide, is located 
mainly in the cytoplasm, but also in the nucleus and in the intermembrane space of the 
mithochondria.
746
 Mutations in the SOD1 gene cause one fifth of the cases of familial 
amyotrophic lateral sclerosis.
747
 SOD1 is overexpressed in breast and lung cancer cells. 
Treatment of non-small-cell lung cancer with a SOD1 inhibitor (ATN-224) induces MAPK1-
mediated cell death in vitro and in vivo.
748
 SOD1 is secreted by many cell lines, including the rat 
somatotropinoma-derived GH3 cells, both constitutively and in response to depolarisation 
through calcium-dependent mechanisms.
749
 In GH3 cells, extracellular SOD1, through activation 
of a muscarinic M1 receptor, reduces the activity of the MAPK1 signalling pathway, via inhibition 
of MAPK3 phosphorylation, which resembles the effect of SSA on pituitary adenoma cells.
749;750
 
Therefore, SOD1 seems to be an interesting target for the effect of AIP on the SS pathway.  
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Conclusions 
New molecular partners of AIP have been described. In line with the previously known function 
of AIP as a co-chaperone of HSP90 and HSPA8, interactions with two new members of the 
HSP70 families, HSPA5 and HSPA9 have been validated. These new interactions expand the 
repertoire of interactions between heat shock proteins and client proteins that could be 
modulated by AIP, but also opens a new window for possible anti-tumorigenic functions of AIP, 
as a regulator of stress-induced heat-shock protein functions. In addition, novel molecular 
interactions with the cytoskeletal proteins TUBB and TUBB2A indicate a possible role for AIP as 
a regulator of microtubule organisation, cell motility and adhesion, cellular functions which 
become of primordial importance in tumour development. Interactions with the proteins NME1 
and SOD1 were only partially validated, and will require further study. Finally, an interaction of 
AIP with the SCF E3 ubiquitin-ligase complex indicates that AIP is processed via ubiquitination 
and proteasomal degradation, a pathway that will be further explored in the next chapter.  
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Chapter 4: Missense AIP variants and protein stability: 
implications for pituitary tumorigenesis 
 
Introduction 
The great majority of the AIPmuts identified in patients are truncating mutations, and multiple 
mechanisms have been postulated to explain why they lead to LOF of the protein (see “AIP as a 
pituitary-specific tumour suppressor: questions to be solved”). While the functional effects of 
truncating mutations are usually evident, predicting the possible pathogenic effect of missense 
variants can be challenging. The amino acid substitutions caused by missense mutations can 
alter the structure, folding or stability of the protein, but they may also have no functional effect 
on the protein. In addition to in silico prediction platforms (reviewed in
751
), different methods can 
be used to determine whether missense variants are indeed pathogenic or not.  
 
One option is evaluating the variant segregation in association with the phenotype,
752
 but this 
should ideally be studied in large pedigrees with full familial medical history, which are not 
available for most of the patients. In the setting of a germline variant in a tumour suppressor 
gene, the finding of LOH involving that locus in a tumoral tissue is usually considered as a 
confirmation of involvement of the genetic variant on tumorigenesis.
753
 Nevertheless, LOH is not 
an invariable finding in AIPmut-associated pituitary adenomas, even in those associated to 
clearly pathogenic variants; therefore, this parameter does not accurately determine 
pathogenicity. Functional studies could also be useful;
752
 however, it is not clear which would be 
the most appropriate functional assay to evaluate AIPmuts. Variants located in a mutational 
hotspot are more likely to be pathogenic,
754
 but this parameter would be helpful to predict 
pathogenicity only for a minority of variants. The evaluation of protein stability could help to 
determine if the mutant protein is produced and if it has a normal turnover, regardless of its 
function.
755
 The protein half-life depends on the rate of protein degradation and it is expected to 
be reduced in truncated or misfolded proteins, which is the role of the protein quality control 
system.  
 
Missense AIPmuts probably lead to unstable, rapidly degraded proteins, which is a possible 
mechanism for losing AIP tumour suppressor activity. This effect could be assessed by 
measuring the half-lives of mutant proteins. A similar study has been carried out before to 
characterise missense MEN1 variants, showing that menin also degraded by the UPS, and that 
proteasome inhibitors rescue the short-lived mutants. Mutant menin is bound by HSC70 and 
then recognised by the E3 ubiquitin ligase CHIP, which drives the defective protein to 
ubiquitination and proteasomal degradation.
756
 AIP might be degraded by ubiquitination and 
proteasomal degradation, based on its affinity for ubiquitin and the E3-ligase FBXO3 (see 
Chapter 2), but this degradation mechanism has not been proven before. 
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Aims 
General 
− To analyse the mechanism and speed of protein turnover of WT AIP and AIP missense 
variants, and to correlate the protein half-life with the phenotype, using protein stability 
as an indicator of LOF. 
Specific 
1. To determine the half-life under cycloheximide (CHX) treatment of the endogenous WT 
AIP protein in different cell lines. 
2. To determine the half-life under CHX treatment of the endogenous AIP protein in a cell 
line derived from a p.R304* AIP mutation carrier. 
3. To determine the half-life under CHX treatment of WT AIP, missense AIP variants and 
the nonsense AIP variant p.R304* overexpressed in a cell line. 
4. To analyse the correlation between the half-life and the clinical phenotype in AIPmut 
positive patients. 
5. To study the effect of the proteasome inhibitor MG-132 over the half-life of unstable AIP 
variants. 
Hypotheses 
− Missense AIP variants catalogued as pathogenic or likely pathogenic by in silico 
prediction are unstable proteins, and this is translated into reduced half-life. 
− Missense mutant affecting conserved residues on the TPR domain are more likely to be 
unstable. 
− AIP is degraded via ubiquitination and proteasomal degradation. 
− Missense mutants with reduced half-life can be rescued by the treatment with a 
proteasome inhibitor. 
 
Methods 
Determining the half-life of endogenous AIP 
The half-life of the endogenous AIP protein was measured in three different cell lines: HEK293 
(human embryo kidney, ECACC 85120602) and two EBV-immortalised human B-
lymphoblastoid cell (LC) lines: a commercially available cell line, derived from a healthy control 
(ECACC C0137, referred as EBV-LC-WT AIP), and a similar cell line, EBV-immortalised by 
ECACC, derived from an AIP c.910C>T (p.R304*) mutation carrier, member of a FIPA family 
(F70M38), with no pituitary adenoma (referred as EBV-LC-AIP p.R304*).  
 
For experiments with HEK293, 12-well plates were plated with 5X10
5
 cells per well in complete 
medium (minimum essential medium [MEM] supplemented with 10% foetal bovine serum 
[FBS]/1X non-essential amino acids [NEAA]/2mM L-glutamine) and grown at 37°C/5% CO2. 
Forty-eight hours later, the cells were treated with 100 µg/ml CHX diluted in complete medium, 
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or a similar volume of vehicle (dimethyl sulfoxide [DMSO]). Considering time 0 as the moment 
when the treatment started, three wells of cells were harvested at 0, 6, and 24 h for each 
experimental condition (cells harvested at time 0 received no treatment). For this purpose, the 
medium was removed, the cells were washed with 1X phosphate buffered saline (PBS), 75 µl of 
ice-cold lysis buffer were added, the cells were scraped from the wells and the content of each 
well was transferred to a microcentrifuge tube. After incubation at 4°C and centrifugation to 
pellet cell debris, 20 µg of total protein from these cell lysates were used for WB for AIP and 
beta actin (ACTB) as a loading control.  
 
The amount of protein for each repeat at each time point was calculated by band densitometry, 
using the Odyssey application software v.2.1.12 (LI-COR Biosciences). The integrated density 
values for AIP were copied in an individual Excel spreadsheet for each experiment, and 
normalised by dividing each value by the value for the loading control in the same well. The 
values for the different time points were compared with the one-way ANOVA test for matched 
measures, followed by the post-hoc Tukey’s test for multiple comparisons, using the GraphPad 
software.  
 
The procedure for the EBV-LC-WT-AIP and AIP p.R304* cells was similar, but 3x10
6
 cells per 
well, plated in 6-well plates in suspension, were used, and the time points for cell harvesting 
were 0, 6, and 24 h for the WT AIP cell line and 0, 2, 4, 10, 12 and 24 h AIP p.R304*. In the AIP 
p.R304* experiment, 40 µg of total protein were used for WB. The experimental procedures are 
detailed in Protocol 30 (HEK293) and Protocol 31 (EBV-LC-WT AIP and AIP p.R304*).  
 
Selection of AIP variants 
A group of 14 missense AIP variants detected in pituitary adenoma patients from our cohort or 
reported in the literature was selected for the study. The variants were classified according to 
their pathogenicity likelihood, based on in silico prediction (see “Genetic screening”). Comments 
on the specific effect on the protein structure were kindly provided by C. Prodromou (some of 
them included in
523
), as shown in Table 20. Additionally, we included the WT AIP protein, as a 
“normal half-life control” (negative control) and the pathogenic nonsense AIPmut as a “short 
half-life” control (positive control), as this variant has been reported to be rapidly degraded in 
previous half-life experiments (unpublished data by F. Martucci and M. Korbonits).  
 
Preparation of expression plasmids 
A plasmid for the expression of the variant c.769A>G (p.I257V) was created by site directed 
mutagenesis from the pcDNA3.0-Myc-AIP plasmid. The following primers for site-directed 
mutagenesis were designed using the QuikChange Primer Design tool:
666
  
 
c.769A>G_F: 5’-TGGACCACTGTTCTTCCGTCCTCAACAAGTACGAC-3’ 
c.769A>G_R: 5’-GTCGTACTTGTTGAGGACGGAAGAACAGTGGTCCA-3’ 
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Table 20. Missense variants included in the study 
Variant Location in protein Pathogenic Effect on protein structure 
c.47G>A (p.R16H) N-terminus No No effect, protein out in solvent 
c.145G>A (p.V49M) PPIase domain Unlikely 
Out in solvent, strange for a hydrophobic change. 
Probably involved in interactions 
c.509T>C (p.M170T) 
Between PPIase and 
TPR1 domains 
Likely No structure available* 
c.562C>T (p.R188W) TPR1 domain Likely No prediction available 
c.713G>A (p.C238Y) TPR2 domain Yes 
Mutation causes severe steric clashes, disrupts 
packing of hydrophobic core
523
 
c.760 C>T (p.C254R) TPR2 domain Likely No prediction available 
c.762C>G (p.C254W) TPR2 domain Likely No prediction available 
c.769A>G (p.I257V) TPR2 domain Likely Disrupts packing of hydrophobic core
523
 
c.811C>T (p.R271W) TPR3 domain Yes 
Involved in packing by numerous polar 
interactions. W at this position is likely to be 
disruptive
523
 
c.827C>T (p.A276V) TPR3 domain Unlikely 
Involved in packing, some steric clash with V, but 
difficult to draw a definitive conclusion on the 
effect 
c.871G>A (p.V291M) TPR3 domain Likely 
Disrupts packing of hydrophobic core (forms base 
of hydrophobic pocket interacting with bound 
peptide)
523
 
c.896C>T (p.A299V) TPR3 domain Unlikely 
At start of C-terminal α-7 helix and may disrupt 
some small degree of packing with L292
523
 
c.911G>A (p.R304Q) TPR3 domain Yes 
Not involved in packing, but probably required for 
client protein interaction
523
 
c.974G>A (p.R325Q) C-terminal α-helix Likely 
Part of the C-terminal α-7 helix, may affect client 
protein binding
523
 
*This residue is neither included in the NMR structure of the PPIase domain, nor in the crystal structure of the TPR 
domain. 
 
Site-directed mutagenesis was carried out using the QuikChange II XL Site-Directed 
Mutagenesis Kit (Agilent Technologies 200521), according to the protocol suggested by the 
manufacturer (details in Protocol 6). Colonies were selected and grown overnight at 250 
rpm/37°C in 10 ml LB broth supplied with 100 µg/ml ampicillin; 1 ml of this bacterial culture was 
used to seed 250 ml of LB broth supplied with 100 µg/ml ampicillin (grown overnight at 250 
rpm/37°C). The remaining 9 ml were centrifuged at for 10 min at 4000 g/4°C, and the bacterial 
pellets were used for plasmid DNA extraction, using the QIAprep Spin Miniprep Kit, as detailed 
in Protocol 5. The 250 ml cultures were pelleted likewise, the supernatants were discarded and 
the pellets were stored at 80°C until sequence confirmation.  
 
Samples of 100 ng/µl plasmid DNA were submitted for Sanger sequencing at the Genome 
Centre, Barts and The London School of Medicine (BigDye Terminator v.3.1 kit in an ABI 3730 
capillary sequencer, Applied Biosystems, Foster City, CA, USA) using the following primers: 
 
pcDNA3.0_F: 5’-TCACTATAGGGAGACCCAAGC-3’ 
pcDNA3.0_R: 5’-CAACAGATGGCTGGCAACTA-3’ 
 
A contig was built using the ContigExpress software (Life Technologies), including the obtained 
sequences and the sequence of the WT plasmid, and the presence of the expected single 
nucleotide change was verified (Figure 48). 
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Figure 48. Chromatograms of WT AIP and AIP c.769A>G (p.I257V). These are the sequencing results for the CDS of 
the WT and the variant, cloned in pcDNA3.0. The mutant plasmid presents an unexpected nucleotide change probably 
induced during the SDM reaction (c.762C>T, highlighted C) resulting in a synonymous variant (at C254) that does not 
affect the protein sequence; therefore, the plasmid was used carrying this variant. The expected single nucleotide 
change is also observed (highlighted A). 
 
After confirmation of the expected sequences, plasmid DNA was extracted from the frozen 
bacterial pellets using the GenElute™ HP Plasmid Maxiprep Kit according to the manufacturer’s 
instructions (details in Protocol 7). For the rest of the mutants, a pre-existent collection of 
plasmids expressing Myc-tagged AIP missense mutants (obtained by site-directed mutagenesis 
from the pcDNA3.0-Myc-AIP plasmid), was used. When necessary, DH5α E.coli were 
transformed with plasmids from the pre-existent collection (Protocol 4) and plasmid DNA 
maxipreps were obtained after sequence confirmation, as described before. 
 
Determining the half-life of overexpressed AIP 
To determine the concentration of CHX to be used in these experiments, 12-well plates were 
plated with 2.5X10
5
 HEK293 cells per well in complete medium. Twenty-four hours later, the 
cells were transfected with 1 µg per well of the pcDNA3.0-Myc-WT_AIP plasmid, using 
Lipofectamine 2000, according to the manufacturer’s instructions. Twenty-four hours later, the 
cells were treated with 5, 10, 20 or 50 µg/ml CHX, or a similar volume of DMSO. Considering 
time 0 as the moment when the treatment started, three wells of cells were harvested at 0, 6, 12 
and 24 h for each experimental condition, and protein extraction, WB and protein quantification 
were performed as described before. Experiments using the WT AIP plasmid had an extra time 
point at 48 h. The experiment with DMSO was done with the WT AIP plasmid only. Using the 
same parameters than for the experiments with endogenous protein, the concentration of 20 
µg/ml of CHX was chosen. Experiments using the WT and each of the mutant plasmids were 
performed at least twice with the chosen CHX, for a total of at least six repeats of each 
condition. The final experimental procedure used is detailed in Protocol 32.  
 
Calculation and comparison of the protein half-lives  
For all the experiments, the normalised protein levels were converted to percentages, 
considering time 0 as 100%, in a single Excel spreadsheet per experiment, as shown in Table 
21. The results of all the experiments (expressed as percentages) were copied into a GraphPad 
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XY table, resulting in at least six repeats of each time point, for a total of three to four time 
points. These results were fit to a non-linear curve using the One Phase Decay equation, with 
the following parameters:  
 
X: time 
Y: starts at Y0 and decays (with one phase) down to plateau 
Y0 and plateau: same units as Y 
K: rate constant equal to the reciprocal of the X axis units 
Initial value of Y0: 1 (*YMAX) 
Initial value of plateau: 1 (*YMIN) 
Initial value of K: 1 (/(value of X at YMID) 
Constrains: Y0=100, plateau=0 
 
These results were plotted as curves (with SEM for each time point) for each WT or mutant 
protein (including two experiments per mutation, in triplicates). The half-life of each protein was 
calculated based on these curves, using the formula: half-life=ln(2)/k. The degradation speed, 
represented by the K value, was compared between each mutant protein and the WT protein 
using the extra sum-of-squares F test. P <0.05 was considered significant and the variants 
tested were classified according to this values as “normal half-life” (P>0.05), “intermediate half-
life” (P<0.05 but >0.0001) and “very short half-life” (P<0.0001). 
 
Correlating half-life with phenotype  
To analyse the possible impact of the half-life on the clinical phenotype in pituitary adenoma 
patients, clinical data from pituitary adenoma patients carrying the mutations in study was 
collected, including individuals from our cohorts of FIPA and young-onset sporadic pituitary 
adenomas and also cases reported in the literature by other research groups. Using the 
GraphPad software, the Spearman R test was employed to establish correlations between half-
life and age at disease onset, age at diagnosis and maximum tumour diameter. The frequency 
of macroadenomas was compared between variants with very short half-life and normal or 
reduced half-life, using the Fisher’s exact test. Results were considered statistically significant 
when P was <0.05. 
 
Rescuing very short-lived mutants 
Experiments to counteract the degradation via the UPS of AIP variants with very short half-life 
were done using the proteasome inhibitor MG-132. To optimise the conditions for these 
experiments, HEK293 cells were plated, transfected with plasmids to express the short-lived 
variants (as described before) and treated with 20 µg/ml of CHX. After 6 h of treatment, MG-132 
was added to a final concentration of 0, 20, 40 or 80 µM, the cells were harvested at 0 and 6 h 
and the results were plotted as a dose curve. The concentration of 20 µM, corresponding to the 
exponential phase of the curve, was chosen for the next experiments. 
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Table 21: Normalisation of integrated density values and conversion to percentages of the value at time 0 
Integrated density of WB bands 
Sample: 
AIPWT1  
0-A 
AIPWT1  
6-A 
AIPWT1  
12-A 
AIPWT1  
24-A 
AIPWT1  
0-B 
AIPWT1  
6-B 
AIPWT1  
12-B 
AIPWT1  
24-B 
AIPWT1 
 0-C 
AIPWT1  
6-C 
AIPWT1  
12-C 
AIPWT1  
24-C 
Integrated 
density AIP: 
B3 C3 D3 E3 F3 G3 H3 I3 J3 K3 L3 M3 
Integrated 
density 
ACTB: 
B4 C4 D4 E4 F4 G4 H4 I4 J4 K4 L4 M4 
Ratio 
(AIP/ACTB): 
=B3/B4 =C3/C4 =D3/D4 =E3/E4 =F3/F4 =G3/G4 =H3/H4 =I3/I4 =J3/J4 =K3/K4 =L3/L4 =M3/M4 
Time point: 0 h 6 h 12 h 24 h                 
Average ratio 
(AIP/ACTB):  
=AVERAGE              
(B5,F5,J5) 
=AVERAGE            
(C5,G5,K5) 
=AVERAGE               
(D5,H5,L5) 
=AVERAGE             
(E5,I5,M5)   
      
  
Standard 
error of the 
mean (SEM): 
=STDEV          
(B5,F5,J5)/             
SQRT(3) 
=STDEV      
(C5,G5,K5)/             
SQRT(3) 
=STDEV         
(D5,H5,L5)/      
SQRT(3) 
=STDEV           
(E5,I5,M5)/         
SQRT(3)                 
Results expressed as percentages (time 0=100%) 
Sample: =B2 =C2 =D2 =E2 =F2 =G2 =H2 =I2 =J2 =K2 =L2 =M2 
Percentage 
of time 0: 
=((B5*100)/             
(AVERAGE                  
($B$5,$F$5,
$J$5))) 
=((C5*100)/             
(AVERAGE                  
($B$5,$F$5,
$J$5))) 
=((D5*100)/             
(AVERAGE                  
($B$5,$F$5,
$J$5))) 
=((E5*100)/             
(AVERAGE                  
($B$5,$F$5,
$J$5))) 
=((F5*100)/             
(AVERAGE                  
($B$5,$F$5,
$J$5))) 
=((G5*100)/             
(AVERAGE                  
($B$5,$F$5,
$J$5))) 
=((H5*100)/             
(AVERAGE                  
($B$5,$F$5,
$J$5))) 
=((H5*100)/             
(AVERAGE                  
($B$5,$F$5,
$J$5))) 
=((J5*100)/             
(AVERAGE                  
($B$5,$F$5,
$J$5))) 
=((K5*100)/             
(AVERAGE                  
($B$5,$F$5,
$J$5))) 
=((L5*100)/             
(AVERAGE                  
($B$5,$F$5,
$J$5))) 
=((M5*100)/             
(AVERAGE                  
($B$5,$F$5,
$J$5))) 
Time point: 0 h 6 h 12 h 24 h                 
Average 
percentage:  
=AVERAGE             
(B14,F14, 
J14) 
=AVERAGE               
(C13,G13, 
K13) 
=AVERAGE           
(D13,H13, 
L13) 
=AVERAGE                 
(E13,I13, 
M13)   
      
  
Standard 
error of the 
mean (SEM): 
=STDEV                
(B14,F14, 
J14)/         
SQRT(3) 
=STDEV                
(C13,G13, 
K13)/           
SQRT(3) 
=STDEV               
(D13,H13, 
L13)/              
SQRT(3) 
=STDEV                
(E13,I13, 
M13)/                     
SQRT(3)                 
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The experiment was also done for 20 µM MG-132, using a CHX pre-treatment time of 3 h, but 
the difference between the protein level at 0 and 6 h (using a Student’s t test) was not 
significant for any of the doses. The final protocol consisted of CHX pre-treatment for 6 h, 
followed by addition of 20 µM MG-132, harvesting cells at 0, 6, 12 and 24 h after the addition of 
the proteasome inhibitor (Protocol 33).  
 
The results were normalised and analysed as for the half-life experiments, except that they 
were expressed as percentages of the last time point (value at 24 h=100%) and also as fold-
change from time 0 (value at time 0=1). The results of the independent experiments for each 
protein were pooled and the protein levels at different time points were compared using the one-
way ANOVA test for repeated measures (Geisser-Greenhouse correction) and the post-hoc 
Dunnett’s test to compare results at each time point with results at time 0. The Spearman R test 
was used to correlate the half-life of each variant with the results of the MG-132 “rescue” 
(expressed as fold-change) at 6, 12 and 24 h. Results were considered statistically significant 
when P was <0.05. 
 
Results 
Half-life of endogenous AIP in different cell lines 
Half-life of AIP in HEK293 cells (68.2 h) was not significantly different to the value obtained in 
EBV-LC-WT AIP cells (33.1 h, P=0.1644). The average of the values at each time point in these 
two cell lines resulted in an average half-life of 34.1 h. In both cell lines the measured AIP half-
life was significantly lower under CHX treatment compared to the DMSO control (P=0.0006 for 
CHX vs. DMSO in HEK293 cells and P<0.0001 in EBV-LC-WT AIP, confirming that the findings 
under this experimental conditions are due to the effect of CHX. 
 
AIP half-life was practically identical in EBV-LC-WT AIP and in AIP heterozygous p.R304* cells 
(33.1 and 33.2 h, respectively). However, the measured WB bands corresponded to the WT 
protein in both cell lines, while the expected band for the mutant protein was not visible. 
Assuming biallelic expression, bands of 37.6 kDa for WT AIP and 34.5 kDa for the truncated 
protein AIP p.R304* (as calculated by the Expasy Compute pI/Mw tool)
757
 would be expected in 
the WB images (Figure 49). 
 
Findings were similar when repeating the experiment using 80 µg of total protein (data not 
shown), indicating that the mutant protein is either not expressed or very rapidly degraded. The 
later possibility was further explored in proteasome inhibition experiments (see “Rescuing very 
short-lived mutants”). However, the finding that the half-life of the WT protein is normal in these 
cells excludes the possibility of a dominant negative effect of the heterozygous nonsense 
mutation on the normal protein, at least regarding protein stability, under these experimental 
conditions.  
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Figure 49. Half-life of endogenous AIP in different cell lines. a) AIP half-life was significantly lower under CHX treatment 
compared to the DMSO control in HEK293 and EBV-LC-WT AIP cells. b) AIP half-life in HEK293 cells was not 
significantly different to the half-life in EBV-LC-WT AIP. c) AIP half-life was almost the same in EBV-LC-WT AIP and AIP 
p.304* cells, when considering band densitometry for the normal protein. d) Representative WB images. The top panels 
are for the experiments with CHX and DMSO in HEK293 and EBV-LC-WT AIP cells, and the bottom panels are for EBV-
LC-AIP p.R304* cells. WB bands for AIP (37.6kDa) and the loading control ACTB (41.7kDa) are shown in each case. 
Note the absence of the band for the mutant AIP p.R304* (expected mass: 34.5 kDa). 
 
0
 h
o
u
rs
6
 h
o
u
rs
2
4
 h
o
u
rs
0
 h
o
u
rs
6
 h
o
u
rs
2
4
 h
o
u
rs
0
 h
o
u
rs
2
 h
o
u
rs
4
 h
o
u
rs
1
0
 h
o
u
rs
0
 h
o
u
rs
1
2
 h
o
u
rs
2
4
 h
o
u
rs
AIP
ACTB
EBV-LC-AIP p.R304* (CHX 100µg/ml)
AIP                 
(HEK293)
ACTB               
(HEK293)
AIP                
(EBV-LC-
WT AIP)
ACTB                  
(EBV-LC-
WT AIP)
CHX 100µg/ml DMSO
192 
 
Half-life of overexpressed WT AIP and missense variants 
The results of the half-life of the overexpressed proteins in HEK293 cells are summarised in 
Table 22 and Figure 50. Comparisons with the WT protein were established by means of the 
degradation speed (K) calculated from each half-life curve (Figure 50a and b). The AIP 
missense variants p.R16H, p.M170T, p.R304Q and p.R325Q behaved as stable proteins, with a 
similar half-life compared to the WT protein (normal half-lived variants, Figure 50c). The rest of 
the missense variants tested displayed a reduced half-life when compared to the WT protein. A 
group of variants (p.V49M, p.I257V, p.A299V) was considered to have an “intermediate” or 
“short” half-life, as the difference between their K and that of the WT protein resulted in P<0.05 
but >0.0001 (Figure 50d). Variants whose K displayed maximum statistical significance 
(P<0.0001) when compared to the WT protein where considered to have “very short” half-life: 
p.R188W, p.C238Y, p.C254R, p.C254W, p.R271W, p.A276V, p.V291M, Figure 51). The 
variants with the shortest half-lives (p.C238Y and p.C254R) were located in the second TPR 
motif of the protein.  
 
The pathogenic nonsense AIP variant p.R304* had a “very short” half-life (5.9 h), compatible 
with the proposed unstable behaviour of this variant (F. Martucci and M. Korbonits, 
unpublished). Interestingly, all the missense variants with “very short” half-life, except p.R188W 
and p.V291M, had degradation speeds comparable to that of the p.R304* variant (Figure 51 
and Table 23). Also similar to p.R304*, their degradation curves were characterised for a fast 
decay of the protein in the first 6 h, followed by a plateau. In contrast, the curves for p.R188W 
and p.V291M displayed gradual decay throughout the duration of the experiment, similar in 
shape to that of the variants with “intermediate” half-life.  
 
Table 22. Half-life of overexpressed AIP (WT and variants) in HEK293 cells 
Variant Location in protein 
Half-life transfected 
protein (h) 
Degradation 
speed (K) 
P value          
(K vs. WT K) 
c.47G>A (p.R16H) N-terminus 94.2 0.0074 0.0512 
c.145G>A (p.V49M) PPIase domain 27.0 0.0257 0.0359 
c.509T>C (p.M170T) 
Between PPIase and TPR1 
domains 
66.6 0.0104 0.2931 
c.562C>T (p.R188W) TPR1 domain 21.0 0.0331 < 0.0001 
c.713G>A (p.C238Y) TPR2 domain 5.5 0.1270 < 0.0001 
c.760 C>T (p.C254R) TPR2 domain 4.7 0.1467 < 0.0001 
c.762C>G (p.C254W) TPR2 domain 8.4 0.0830 < 0.0001 
c.769A>G (p.I257V) TPR2 domain 28.7 0.0241 0.0222 
c.811C>T (p.R271W) TPR3 domain 8.2 0.0849 < 0.0001 
c.827C>T (p.A276V) TPR3 domain 7.2 0.0957 < 0.0001 
c.871G>A (p.V291M) TPR3 domain 11.2 0.0621 < 0.0001 
c.896C>T (p.A299V) TPR3 domain 21.6 0.0321 0.0002 
c.911G>A (p.R304Q) TPR3 domain 58.7 0.0118 0.5644 
c.910C>T (p.R304*) C-terminal α-helix 5.9 0.1183 < 0.0001 
c.974G>A (p.R325Q) C-terminal α-helix 88.8 0.0078 0.0948 
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Figure 50. Half-life of WT AIP and variants, overexpressed in HEK293 cells (part 1). a) The WT AIP protein had a half-
life of 48 h under the experimental conditions used. b) Half-life curves for all the variants studied, compared to the WT 
protein. c) Half-life curves for missense AIP variants with normal half-life (p.R16H, p.M170T, p.R304Q and p.R325Q) 
and representative WB images, compared to the WT protein. d) Half-life curves for variants with short or “intermediate” 
half-life (p.V49M, p.I257V, p.A299V) and representative WB images, compared to the WT protein. Myc-AIP=39 kDa, 
ACTB=41.7 kDa (the representative ACTB loading control shown corresponds to the WT experiment in each case). 
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Figure 51. Half-life of WT AIP and variants, overexpressed in HEK 293 cells (part 2). a) Half-life curves for missense AIP 
variants with “very short” half-life (p.R188W, p.C238Y, p.C254R, p.C254W, p.R271W, p.A276V, p.V291M) and 
representative WB images, compared to the WT protein. d) Half-life curves for variants with half-life similar to the 
nonsense variant p.R304* (p.C238Y, p.C254R, p.C254W, p.R271W, p.A276V) and representative WB images, 
compared to p.R304*. Myc-AIP=39 kDa, Myc-AIP p.R304*=35.8 kDa, ACTB=41.7 kDa (ACTB loading control shown 
corresponds to the WT experiment in each case). 
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Table 23. Half-life of missense AIP variants with very short half-life 
Variant Location in protein 
Half-life transfected 
protein (h) 
Degradation 
speed (K) 
P           
(K* vs. p.R304*) 
c.562C>T (p.R188W) TPR1 domain 21.0 0.0331 < 0.0001 
c.713G>A (p.C238Y) TPR2 domain 5.5 0.1270 0.7065 
c.760 C>T (p.C254R) TPR2 domain 4.7 0.1467 0.3735 
c.762C>G (p.C254W) TPR2 domain 8.4 0.0830 0.0652 
c.811C>T (p.R271W) TPR3 domain 8.2 0.0849 0.1141 
c.827C>T (p.A276V) TPR3 domain 7.2 0.0957 0.2749 
c.871G>A (p.V291M) TPR3 domain 11.2 0.0621 0.0003 
* K= degradation speed 
 
Correlating protein half-life and phenotype 
Clinical data of 100 pituitary adenoma patients (60 from our cohort and 40 cases reported in the 
literature) carrying the missense AIP variants and the nonsense variant included in the half-life 
experiments (Table 24). The variants c.47G>A (p.R16H), c.145G>A (p.V49M) and c.896C>T 
(p.A299V) were not included, as they are not considered pathogenic. The variant c.827C>T 
(p.A276V) was also excluded, as it has never been found in pituitary adenoma patients 
(detected only in a screening for AIP SNPs in DNA samples from different populations).
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Table 24: Missense AIP variants in pituitary adenoma patients: clinical features 
Variant 
No. of cases 
Clinical 
presentation 
Gender 
(M/F) 
Age at 
onset, 
median 
(IQR) 
Age at 
diagnosis
, median 
(IQR) 
Macro/ 
micro, 
no. 
References Our 
cases 
Other 
cases 
Total 
c.509T>C 
(p.M170T) 
0 1 1 Simplex 1/0 NA 32 NA 
13
 
c.562C>T 
(p.R188W) 
1 0 1 Simplex 1/0 10 12 NA Unpublished 
c.713G>A 
(p.C238Y) 
3 0 3 Familial 3/0 
20  
(18-22) 
21  
(19-23) 
2/0 
9;495
 
c.760 C>T 
(p.C254R) 
1 0 1 Familial 0/1 14 17 1/0 Unpublished 
c.762C>G 
(p.C254W) 
2 0 2 Familial 1/1 
26  
(21-31) 
28  
(23-33) 
1/0 Unpublished 
c.769A>G 
(p.I257V) 
0 1 1 Simplex 1/0 NA NA NA 
11
 
c.811C>T 
(p.R271W) 
1 8 9 Both 7/2 
15.5  
(12.8-
18.3) 
22  
(14-28) 
9/0 
7;10;484;629
 
c.871G>A 
(p.V291M) 
0 1 1 Simplex 0/1 NA 30 NA 
632
 
c.911G>A 
(p.R304Q) 
13 8 21 Both 6/13 
27  
(22-37) 
36  
(24.3-
39.5) 
14/3 
7;9;10;12;13;498;53
9;615;632
 
c.910C>T 
(p.R304*) 
39 18 57 Both 31/26 
17  
(15-25.8) 
19.5  
(17-28.5) 
43/5 
7;9;10;12;13;498;50
7;631
 
c.974G>A 
(p.R325Q) 
0 3 3 Both 1/2 
16  
(7-33) 
18  
(16-35) 
3/0 
13;758
 
Total: 60 40 100   52/46 
18  
(15-27) 
23  
(17-32) 
73/8   
Age at onset and at diagnosis is expressed in years. Macro/micro: macroadenomas/microadenomas. 
 
Spearman correlation tests were ran to determine whether the half-life of the mutant proteins 
could correlate with the clinical features in these patients (age at onset, age at diagnosis, 
tumour size), expecting that less stable proteins would lead to a more aggressive phenotype 
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(Figure 52). A direct correlation between age at diagnosis and protein half-life was found 
(r=0.3810, P=0.0015), which remained significant after excluding patients carrying the p.R304* 
nonsense variant (r=0.3478, P=0.0259). The significance of this correlation increased when only 
patients with GH excess (acromegaly or gigantism) were considered (r=0.411, P=0.002). 
Correlation between half-life and maximum tumoral diameter or age at disease onset did not 
reach statistical significance (r=0.1399 [P=0.3788] and r=0.2205 [P=0.0540]); however, clinical 
data for these parameters was missing in a large number of patients. The proportion of patients 
with macroadenomas (vs. microadenomas) was similar for very short half-lived variants and 
other variants (P=0.4007).  
 
Short-lived AIP variants are partially rescued by proteasome inhibition 
Stable WT AIP protein levels were found under proteasome inhibition with MG-132, with 
minimal, but not significant increase at 0, 6, 12 and 24 h of treatment (fold change at 24 h: 1.1, 
global P=0.3592). Likewise, levels of the AIP variants p.R188W (fold change at 24 h: 1.1, global 
P=0.5080) and p.V291M (fold change at 24 h: 1.4, global P=0.1263) remained stable. In 
contrast, levels of the rest of the variants studied, including the p.R304* nonsense variant, 
significantly raised in response to MG-132: p.C238Y (fold change at 24 h: 2.1, P=0.0403, 
0.0170 and 0.0015 at 6, 12 and 24 h, respectively), p.C254R (fold change at 24 h: 2.6, P= 
0.0087, 0.0008 and 0.0094), p.C254W (fold change at 24 h: 1.7, P=0.0910, 0.0006 and 0.0087), 
p.R271W (fold change at 24 h: 1.7, P=0.1796, 0.0229 and 0.0676), p.A276V (fold change at 24 
h: 3.9, P=0.0072, 0.0120 and 0.0225) and p.R304* (fold change at 24 h: 2.4, P=0.0055, 0.0041 
and <0.0001, Figure 53a, b and c).  
 
Pooling all these results together, a significant indirect correlation was found between protein 
half-life and protein levels at 6 (r=-0.6279), 12 (r=-0.8292) and 24 h (r=-0.8022) of MG-132 
treatment (P<0.0001 for all the time points), meaning that proteins with shorter half-lives 
displayed a more dramatic response to proteasome inhibition (Figure 53d). These findings 
confirm that WT AIP is a very stable protein, whose degradation is driven by the proteasome 
system, and that an enhanced proteasomal degradation is responsible for the reduced half-life 
shown by some missense variants.  
 
After the treatment of EBV-LC-AIP p.R304* cells with the proteasome inhibitor MG-132 for 3 or 
6 h, the WB images displayed an additional band with a slightly faster migration, compared to 
the WT protein (Figure 54). A third extra band, below the second one was present at 0 h and 
disappeared after treatment with the proteasome inhibitor. Though both of these bands could 
represent degradation products (a frequent finding in WB images), it is possible that one of 
them, (more likely the highest one) could correspond to the mutant protein p.R304*, meaning 
that the mutant protein is expressed, but rapidly degraded via the proteasome system, and 
therefore it is not visible in basal conditions. A similar behaviour could be assumed for the 
unstable missense AIP variants.  
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Figure 52. Implications of AIP half-life for the phenotype in pituitary adenoma patients. a) The half-life of very AIP variants directly correlated with the age at diagnosis, b) even when excluding patients with 
the p.R304* mutant; c) the significance increased when considering only patients with acromegaly or gigantism. d) There was no significant correlation between half-life and maximum tumoral diameter or e) 
age at onset. f) The frequency of macroadenomas did not differ between patients with very short half-lived variants and other variants. 
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Figure 53. Blocking of proteasomal degradation with MG-132 (“rescue experiments”). a) Curves of protein contents 
for the experiments with the variants and WT protein, expressed as percentages (level at time 24 h was considered 
as 100% for each protein) and b) representative WB images. c) Same results, expressed at fold change from time 0 
for each protein (time 0=1). d) Correlation between half-life and fold change after MG-132 treatment at 6, 12 and 24 
h. A significant indirect correlation was found at the three time points, indicating proteins with shorter half-lives 
responded better to proteasome inhibition.  
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Figure 54. MG-132 treatment of EBV-LC-AIP p.R304* cells. In the AIP WB (using 40 µg of total protein) the 
strongest band (arrow) corresponds to the WT protein (37.6 kDa). Two faint extra bands can be observed: a first 
band which is absent at time 0 and appears after the treatment with MG-132 (top arrowhead) and a second, lower 
band (bottom arrowhead), which is more evident at time 0. Though both bands could correspond to degradation 
products, the largest band could possibly be given by a small amount of truncated protein, appearing after 
proteasomal degradation is stopped (expected size: 34.5 kDa). Loading control: ACTB (41.7 kDa). 
 
Discussion 
Although the four fundamental cellular processes involved in gene expression, i.e. 
transcription, mRNA degradation, translation and protein degradation, are targets for 
regulatory events, cellular abundance of proteins is predominantly controlled at the level of 
translation. Protein stability seems to have a smaller role in cellular protein abundance under 
basal conditions, but could be important under stimulation.
759
 The maintenance of 
intracellular proteostasis requires the correct functioning of complex regulatory mechanisms, 
which are frequently disrupted in human diseases. 
 
Different in vitro experimental approaches can be used to determine protein turnover, usually 
expressed as half-life, i.e. the time it takes for the protein of interest to be reduced by 50% 
relative to its level at time 0. Pulse-labelling (pulse-chase analysis) is considered the “gold 
standard” method for this purpose),
759
 with the advantage of causing minimal disruption on 
cell growth and metabolism. In this method the protein of interest is labelled in previously 
amino acid starved cells (to deplete the pool of the amino acid to be used for labelling) using 
a radioactive precursor (e.g. 
35
S-methinine or cysteine) or heavy stable-isotope versions of 
essential amino acids (stable isotope labelling by amino acids in cell culture [SILAC]), and 
after a time period, an excess of a non-labelled precursor is added to prevent further 
incorporation of the labelled amino acid.
759;760
 Cells are harvested at different time points and 
then they are either immunoprecipitated, resolved by PAGE and quantified by phosphor 
imaging or autoradiography, or quantified by qMS.
760;761
 A disadvantage of this method is the 
requirement of either radioactive reagents or costly MS reagents and equipment. Another 
problem is a possibly enhanced ubiquitin-proteasomal activity after amino acid starvation, 
which can influence the results.
760
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Another frequently used technique is blocking protein synthesis with CHX (CHX chase), a 
chemical translation inhibitor, which exerts its effect by blocking eEF2-mediated tRNA 
translocation.
762;763
 In this approach, protein synthesis is stopped at some point by the 
addition of CHX, and the decay of the target protein over time is measured by harvesting 
cells at different time points and determining the amount of target protein in WB membranes 
by protein band densitometry. When antibodies against the protein of interest are not 
available or when studying the effect of mutations on protein stability (and there are no cell 
lines available endogenously expressing these mutants) tagged proteins can be expressed 
in cell lines and detected with antibodies raised against the tag. Small tags (e.g. Myc, Flag, 
HA, V5) are usually employed, but the location of the tag in the protein (N- or C-terminal) 
could interfere with the normal protein structure.
760
  
 
A disadvantage of this method is that, given that the protein half-life is measured when 
protein synthesis has been stopped, the results might not reflect the real turnover rate under 
physiological conditions, as the abundance of the proteolytic enzymes can also be 
affected.
761
 Inhibition of protein synthesis also activates (via the PI3K signalling pathway) the 
serine/threonine kinase AKT (transforming murine retrovirus AKT8-related oncogene), 
resulting in phosphorylation of AKT target substrates such as FoxO1,GSK-3α/β, p70S6 
kinase, AS160 and the E3 ubiquitin ligase MDM2, and this leads to altered degradation of 
some proteins.
764
 Although this means that half-life measurements obtained under CHX 
treatment might not accurately reflect the values under physiological conditions, these 
problems can be partially solved by comparing the results against a control protein. 
Moreover, good correlation of half-lives obtained by SILAC and CHX chase experiments was 
recently reported for high turnover proteins in a proteome-scale protein/mRNA half-life 
quantification study.
759
  
 
Protein and mRNA half-lives are not randomly regulated. Genes with stable mRNAs and 
stable proteins, such as housekeeping genes, are enriched in constitutive cell functions 
(translation, respiration and metabolism), while genes with unstable mRNAs and unstable 
proteins are enriched among transcription factors, signalling, chromatin modifying enzymes 
and genes with cell-cycle specific functions. Abundant proteins are more stable than the less 
abundant ones, and highly structured proteins are more stable than the less structured 
ones.
759
 Determining which proteins are to be repaired or degraded, often referred as 
“protein quality control”, depends on different co-translational and posttranslational 
mechanisms to repair or remove misfolded proteins.
765
 Protein folding, unfolding, 
disaggregation and remodelling are functions carried out by the chaperone network of 
proteins.
766
 Cells use two main mechanisms for protein degradation: autophagy and the 
UPS. 
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Cytoplasmic contents are degraded by lysosomes through a mechanism known as 
autophagy or “self-eating”, which is divided in three types according to their substrates and 
mechanisms of sequestration: microautophagy, chaperone-mediated autophagy (CMA) and 
macroautophagy.
765;767
 In microautophagy, cytoplasmic materials are transported into the 
lysosomes by invagination of the lysosomal membrane and posterior formation of 
intralysosomal vesicles, which are then degraded.
765
 CMA starts by the binding of an 
individual cytoplasmic protein to HSC70 through a pentapeptide motif located on the target 
protein (KFERQ-like); then the chaperone-substrate complex is recognised by the lysosomal 
membrane associated protein 2A (LAMP2A), the substrate is unfolded and translocated into 
the lysosome via polymerised LAMP2A, and finally degraded into the lysosomal lumen. 
Macroautophagy can be selective or nonselective and it is regulated by several intracellular 
and extracellular stimuli.
767
 In this process large portions of cytoplasm, sometimes including 
organelles, are engulfed within a compartment termed as phagophore, which matures into a 
double-membrane enclosed structure known as an autophagosome that fuses with the 
lysosomal membrane, allowing degradation of the cargo.
765;767
 Independently of the delivery 
process, proteins processed by autophagy are degraded by hydrolases in the lysosome and 
the breakdown products are released back into the cytosol through permeases, therefore 
allowing their recycling for protein synthesis or energy production.
767
  
 
The ubiquitin-proteasome pathway follows two steps: a specific recognition process, 
involving the ubiquitin conjugation cascade, and a proteolytic step, carried out by the 
proteasome core. Ubiquitin, a highly conserved 8.5 kDa protein, is activated by the ubiquitin-
activating E1 enzyme, which, in an ATP-dependent reaction, forms a thioester bound with 
the ubiquitin G76 (C-terminus).
732
 Ubiquitin is then transferred by transacylation to a thiol 
group of an active C residue of an E2 enzyme (ubiquitin carrier protein or ubiquitin-
conjugating enzyme), to yield an E2-Ub thioester intermediate.
732;768
 Finally, an E3 ubiquitin-
ligase (or ubiquitin-protein ligase) enzyme, consisting of either a single protein or a protein 
complex, catalyses the transfer of the ubiquitin from the E2 to the substrate, where it binds 
either an ε-amino group of a K or the N-terminus.
732;768
 E3 ubiquitin-ligases can catalyse 
direct transfer of ubiquitin from E2 to the substrate (binding both the E2-Ub complex and the 
substrate) or function in a two-step reaction, in which ubiquitin is transferred from the E2 to 
an active site C on E3 and then from the E3 to the substrate.
732
 Once the substrate is mono-
ubiquitinated, a polyubiquitin chain of four or more ubiquitin subunits bound through their 
K48 residues is formed to serve as a recognition signal for proteasomal degradation, a 
process counteracted by the removal of ubiquitin subunits from ubiquitinated proteins by 
more than 100 different deubiquitinating enzymes (DUBs).
765
  
 
The specificity of ubiquitination is determined by a variety of E1, E2 and, more importantly, 
E3 enzymes. The E1 function can be performed by two E1 enzymes in humans, binding 
different E2s: ubiquitin-like modifier-activating enzyme 1 (UBA1) and ubiquitin-like modifier-
activating enzyme 6 (UBA6), while thirty-five different E2 enzymes exist in humans, with 
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specificity for different E3 enzymes.
769
 In contrast, more than 1000 human E3 enzymes have 
been described, divided in five classes: the cullin-RING and U-box containing E3 ubiquitin-
ligases families, the homology to E6AP C-terminus (HECT), the RING-between-RING (RBR) 
family and the PHD-containing E3 ubiquitin-ligases.
732;769-771
  
 
The proteasome is a large multi-subunit protease formed by ~33 different proteins, which is 
found free in the cytosol and also attached to the ER, as well as in the nucleus of eukaryotic 
cells.
765
 The eukaryotic proteasome is formed by two subunits: a catalytic core particle (20S 
proteasome) and a regulatory subunit (19S proteasome, 11S proteasome or both). 
The ~700 kDa core particle of the proteasome is composed of 28 subunits, arranged into 
four stacked heptameric rings (two rings consisting of related α-subunits and two consisting 
of related β-subunits) forming a compact hollow cylinder.
772
 There are a total of six 
proteolytic sites on the proteasome, located on three of the β-subunits in the central cavity, 
with relatively weak preferences for specific target amino acids, being able to cleave almost 
any sequence; however, their location makes them inaccessible for folded proteins due to 
the narrow pores at the entrance to the core particle.
768;772
 The proteasome β-subunits with 
proteolytic activity are sometimes referred as caspase-like (β1), trypsin-like (β2), and 
chymotrypsin-like (β5) subunits, due to their mechanisms of action.
773
 The pores at the 
entrance of the core particle are usually closed in the inactive state, and open after activators 
or caps bind the core particle. Two types of activators, the 11S cap (proteasome activator 28 
[PA28, also known as REG] in mammals) and bleomycin-sensitive 10 cap (Blm10, also 
known as PA200 in humans) trigger ATP-independent protein degradation of non-
ubiquitinated substrates. The 19S regulatory particle recognises ubiquitinated proteins, 
unfolds them (requiring ATP hydrolysis) and translocates them into the core particle. Most of 
the eukaryotic proteasomes are formed by one 20S and one or two 19S proteasome 
subunits, forming together the 26S proteasome.
772
 
 
The 19S regulatory particle (~900 kDa) is formed by at least 19 subunits organised in a 
“base and lid” conformation. The base consists of six ATPases, two large organising and two 
established ubiquitin receptors (Rpn10 and Rpn13), binding polyubiquitin via their ubiquitin 
interacting motif (UIM).
765;772
 The lid consists of the deubiquitinating enzyme Rpn11 and, in 
addition to proteasome subunits, a large number of proteins associate with the 
19S regulatory particle to modulate degradation.
772
  
 
In addition to ubiquitin, proteasomal degradation can also be triggered by ubiquitin-like 
proteins, such as neural precursor cell expressed developmentally down-regulated protein 8 
(NEDD8), small ubiquitin-like modifier (SUMO) and interferon-induced 15 kDa protein 
(ISG15), following a similar activation cascade.
769
 Misfolded or unassembled proteins located 
in the ER can also be directed to ubiquitination and proteasomal degradation by the process 
termed as ER-associated protein degradation (ERAD).
774
 A crosstalk between the UPS and 
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autophagy exists, as ubiquitination can serve as a posttranscriptional modification regulating 
autophagy.
767
 
 
Considering all these factors, the CHX-mediated synthesis inhibition approach was used for 
studying AIP half-life. Under the experimental conditions used, WT AIP behaved as a stable 
protein, either studied as an endogenous or an overexpressed protein, with a half-life of 
33.1-68.2 h (median: 48 h), which is near the median half-life of 46 h calculated for the whole 
mammalian proteome (range of <30 min to >200 h).
759
 The half-life of human AIP in EBV-LC-
WT AIP cells (33.1 h) was very similar to the half-life of mouse Aip, measured by SILAC in 
NIH 3T3 cells (mouse fibroblast), which is 30.4 h.
759
 
 
Co-chaperones play important roles as regulators of protein quality control. Different co-
chaperones, by their interaction with HSP90 or HSP70, can enhance the ubiquitination and 
proteasomal degradation of client proteins. Examples of proteins with this function include 
FKBP25,
775
 cyclophilin B
776
 and the TPR-containing protein AIPL1, which shares around 
50% amino acid homology with AIP.
777
 Interestingly, the co-chaperone CHIP is itself, an E3-
ubiquitin ligase.
778
 However, AIP has no structural characteristics compatible with any of the 
E3-ubiquitin ligase classes, and its function as a co-chaperone seems to be more directed to 
stabilise its client proteins, and not to promote their degradation, though the later possibility 
has not been explored. On the other hand, immunophilins, such as FKBP12 can also be 
degraded via ubiquitination,
779
 and this has now been proven also for AIP. 
 
The amino acid sequence of the TPR motifs of AIP is important to ensure a correct 
interaction of residues in contiguous chains, and therefore, a correct protein folding.
528
 The 
amino acids located in the pocket between TPRs 2 and 3 are essential for the interaction of 
AIP with HSP90, and amino acids at this location are among the most conserved ones.
523
 
Missense mutations affecting residues involved in folding of the TPR domain could lose their 
ability to interact with other proteins. Moreover, misfolded proteins could be unstable, and 
display a rapid turnover, when compared to the WT protein, which was the case of most of 
the missense variants studied.  
 
Half-life experiments are only one of many possible approaches for evaluating protein 
functionality, and therefore, the possible pathogenicity of gene variants. While for most of the 
variants the pathogenicity predictions (based on in silico prediction and other 
functional/clinical data, as explained in Chapter 2) matched the half-life results (i.e. 
pathogenic variants had very short half-life). Considering that defining the pathogenicity of 
missense mutants is not an easy process and there are no experimental methods that could 
possibly render “black and white” results, we observed some discrepancies. First, only one 
of the four variants included in the group with normal half-life is currently considered a non-
pathogenic variant (p.R16H), while the other three (p.M170T, p.R304Q, p.R325Q) are 
considered truly pathogenic. While the variant p.M170T has only been reported in one 
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patient,
13
 and p.R325Q has been detected in three cases,
13;758
 p.R304Q seems to be much 
more common (21 patients reported so far).7;9;10;12;13;498;539;615;632 Apart of the in silico prediction 
and clinical data, no functional data are available for p.R325Q (MAF 0.0001)
217
 and p.M170T 
(MAF not available at the NHLBI EVS, ExAC or 1000 Genomes databases). For p.R304Q 
(MAF 0.0007
216
 and 0.0015
217
 according to two different databases), though clinical data 
supports a pathogenic role, experimental results are against a negative effect on protein 
function.
10;539
 If these variants are really pathogenic, the mechanism should be related to 
loss of protein function, independent of protein stability.  
 
Second, the definition of “intermediate half-life” was arbitrary (based on statistical 
significance) but it is important to remark that the three variants included in this group had 
reduced half-life, two of them considered unlikely pathogenic (p.A299V and p.V49M) and 
one considered truly pathogenic (p.I257V). The study of the AIP 3D molecule predicted a 
possible structural effect for p.A299V and p.I257V (Table 20), and, though no prediction was 
available for p.V49M, the change of a hydrophobic (V) for a polar (M) amino acid could 
possibly disrupt the folding of the PPIase domain. While for p.I257V the half-life results 
match the pathogenicity prediction, this is not the case for p.A299V and p.V49M. The AIP 
variant c.896C>T (p.A299V) is an apparently non-pathogenic SNP (MAF of 0.001
216;218
 and 
0.0004
217
 according to three databases) and the analysis of the clinical data of variant 
carriers, together with the results of different functional studies support an apparently benign 
behaviour of this variant.
9;10;539
 On the other hand, p.V49M is an uncommon SNP (MAF 
0.0002
216;217
) which has only been reported in one patient, a male with gigantism presenting 
as a simplex case, with no LOH in the tumour.
640
 The clinical data available, the rarity of the 
SNP and now the half-life data support a pathogenic role for this variant, and its classification 
as unlikely pathogenic should be reconsidered.  
 
In the half-life experiments with the cell line EBV-LC-AIP p.R304* the mutant protein was not 
detected by WB, except (probably) when the cells were treated with a proteasome inhibitor, 
supporting the finding of a very unstable behaviour of this protein. The p.R304* mutant is a 
truncated protein with loss of the C-terminal α-helix. While no direct effect of the mutation is 
expected on the TPR motifs of the protein, protein interaction studies (see Chapter 3) have 
shown a partial loss of interaction with HSP90 and HSC70 for this mutant. Considering that 
the main interaction site for those chaperones is located on the TPR motif, it is probable that 
the loss of the C-terminal α-helix could somehow disrupt also the folding of the TPR motifs. 
This is also supported by the fact that the effect of this nonsense mutation on protein half-life 
has similar to that of the missense mutations affecting the TPR 2 and 3. Also, the loss of 
certain protein interactions can make proteins more prone to ubiquitination and proteasomal 
degradation. It has been shown that AIP TPR mutants unable to bind HSP90 or to assemble 
AHR/HSP90 complexes apparently have a normal half-life, meaning that AIP stability is 
probably independent of HSP90 binding,
521
 though other ligands could possibly stabilise the 
protein. Conversely, if a short half-life is translated into an almost absent protein under 
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physiological conditions, it could be assumed that the endogenously expressed short half-
lived missense variants would be present also at very low levels in the cells. As it was 
pointed out in the results, some of the studied variants behaved as unstable as p.R304*, 
while others had a still reduced, but longer half-life. Whether these “intermediate” half-lived 
variants could be endogenously expressed at higher levels compared to “very short” half-
lived variants would be an interesting avenue for further research.  
 
As mentioned before, LOH is not a universal finding in AIPmut positive pituitary adenomas. 
As AIPmuts are always found in the heterozygous state, other mechanisms inhibiting the 
function of the normal allele should be explored. On this regard, the half-life experiments 
have two different implications. First, the fact the half-life of the WT AIP is normal in the 
presence of a heterozygous unstable variant, rules out the possibility of a dominant negative 
effect of the mutant protein, an effect which accounts, for example, for the loss of tumour 
suppressor function of TP53.
780
 Second, as the expression of AIP is apparently biallelic, the 
expression of both alleles might be necessary for AIP to perform its tumour suppressor 
function, under basal or stimulated conditions, and the reduction on total AIP expression 
could be translated on an insufficient anti-tumorigenic response (haploinsufficiency) in the 
pituitary gland.
781
 It would also be interesting to determine whether the apparently 
pathogenic variants with normal half-life behave in a similar way, or if in those cases the 
proteins are expressed at normal levels, but interfere with the stability or function of the 
normal protein (i.e. if they have dominant negative effect).  
 
Interestingly, the half-life of the AIP variants studied directly correlated with the age at 
diagnosis in pituitary adenoma patients carrying those mutations. Correlation with age at 
disease onset and tumour size was not statistically significant, perhaps due to the small 
number of patients for whom those parameters were available. This finding contributes to 
validate the half-life assay as a method for determining the pathogenicity of AIP variants, and 
it suggests that disease penetrance in the setting of AIPmuts can be determined by the 
amount of functional protein available. Nevertheless, protein stability is a parameter that 
cannot be evaluated with routine diagnostic histopathological procedures. As IHC represents 
a static image of a tissue, pituitary adenomas with very unstable missense AIPmuts and 
LOH could display normal immunostaining for AIP, and still be almost devoid of functional 
AIP. The use of a protein stability assay as a means to evaluate the pathogenic effect of 
missense variants has also been applied for MEN1.
756;782
 
 
Dysfunction of the ubiquitination pathway is related to a variety of human disorders, such as 
different cancer types (tumour-suppressing and tumour-promoting pathways are regulated 
by ubiquitination and DUBs, such as A20, CYLD and BAP1 are tumour suppressors 
frequently mutated in cancer), autoimmune, neurodegenerative and metabolic diseases.
783
 
Of special interest for endocrine tumorigenesis, mutations in the VHL gene, an E3 ubiquitin-
ligase lead to accumulation of HIF-1α, which stimulates rapid vascularization of tumours, 
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promoting the development of the neoplasms characteristic of the Von Hippel-Lindau 
syndrome.
475;783
 Different steps of the ubiquitin-proteasome pathway are targets for recently 
developed drugs for the treatment of human neoplasms and other conditions.
773
  
 
Considering the interaction of AIP with FBXO3, a member of the SCF E3 ubiquitin-ligase 
complex described in Chapter 3 and the response of unstable AIP variants to proteasome 
inhibition, is now clear that AIP is processed via ubiquitination and proteasomal degradation. 
The proteasome inhibitor MG-132 acts at the chymotrypsin-like site of the proteasome (and 
also at the caspase-like site at high concentrations), in a similar way to the clinically available 
proteasome inhibitor Bortezomib (PS-341).
784
 Bortezomib is the first proteasome inhibitor 
approved for clinical use, currently indicated in the treatment of relapsed multiple myeloma 
and mantle cell lymphoma and under study for as an anticancer drug in other haematological 
malignancies, prostate, breast and non-small-cell lung cancers, as well as for the treatment 
of amyloidosis.
785;786
 The second-generation proteasome inhibitor Carfizomib is now 
approved for the treatment of Bortezomib-resistant multiple myeloma cases and other 
second-generation proteasome inhibitors (Ixazomib, Delanzomib, Oprozomib and 
Marizomib) are under investigation.
786
 Proteasome inhibitors could theoretically restore the 
levels of mutant AIP, as it has recently been proposed also for menin,
756
 and therefore they 
could have a role in the treatment of aggressive pituitary adenomas. However, the effects of 
these drugs include regulation of multiple pathways implicated in tumorigenesis, and 
therefore this possible pre-clinical application should be explored in depth. 
 
Conclusions 
Human AIP is a stable protein with an endogenous half-life between 33.1 and 68.2 h whose 
degradation is driven by ubiquitination and proteasomal degradation, probably mediated by 
the FBXO3-containing SCF1 E3 ubiquitin-ligase complex. Multiple clinically relevant 
missense AIP variants, especially those affecting the TPR domain of the protein, and the 
nonsense mutant p.R304* display reduced half-lives due to enhanced proteasomal 
degradation. These unstable proteins can be partially rescued by proteasome inhibition. 
Interestingly, a direct correlation between protein half-life and age at diagnosis in AIPmut 
positive pituitary patients was found. Unstable AIP variants seem to be present only at very 
low levels in cells with heterozygous AIPmuts, indicating that, under physiological conditions, 
the function of these variants is very probably completely lost. However, the presence of an 
unstable AIP mutant does not seem to affect the function of the WT AIP protein. The 
reduced half-life of missense AIP mutants is an additional pathogenic mechanism for 
AIPmuts, not described before. 
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General conclusions and avenues for future research 
 
Although the studies presented in this thesis have hopefully helped to better understand the 
function of AIP in the pituitary gland, as well as to further address the pathogenic 
mechanisms of AIPmuts and the clinical presentation of AIPmut-associated pituitary 
adenomas, some questions remain still open and represent excellent avenues for future 
research. The next paragraphs summarise the main results of the three research projects 
presented in this thesis, emphasising the novel findings and establishing questions to be 
addressed by future studies. 
 
Phenotype of AIPmut positive pituitary adenomas 
Besides the familial presentation, the distinctive characteristics of pituitary adenomas 
associated to AIPmuts are the disease onset between the second and third decades of life, 
an overrepresentation of cases of gigantism (a rather uncommon clinical presentation), 
along with acromegaly, and the great predominance of macroadenomas. Based on this and 
on the results of previous studies, genetic testing for AIPmuts should be directed to FIPA 
families, cases of gigantism and pituitary adenoma patients with disease onset in 
adolescence and early adulthood. There is currently no apparent indication for testing other 
subgroups of patients out of the setting of research studies.  
 
In this sense, it is important to remark that AIPmut testing is not widely available in clinical 
centres worldwide, and this is probably hampering the recognition of more AIPmut positive 
cases, and therefore a better characterisation of the disease features. This could also limit 
the application of strategies for the follow-up of patients and carriers, or specific therapies 
based on the molecular basis of these tumours in the future. The development of affordable 
genetic tests, not only for AIP but for other inherited conditions that could benefit from 
preclinical diagnosis, is therefore required.  
 
Usefulness of clinical screening of AIPmut positive apparently unaffected carriers 
Up to one quarter of the apparently unaffected individuals carrying AIPmuts develop a 
pituitary adenoma at some point in their lives. The detection of such cases is primordial, to 
ensure early treatment and therefore better prognosis. However, clinical testing means an 
investment from the public health systems on individuals that are otherwise healthy. 
Although it is true than treating small, non-invasive pituitary adenomas is safer and less 
costly than treating large, complicated tumours, this study was not focused on calculating 
the economic impact of clinical testing on public health systems. This issue should be 
addressed in future studies, considering the clinical experience with the long-term follow-up 
of unaffected AIPmut carriers.  
 
No role for the gsp oncogene in AIPmut positive pituitary adenomas 
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Interestingly, the most common disease modifier in pituitary adenomas, the gsp oncogene 
(GNAS1 mutations) was not detected in AIPmut positive pituitary adenomas. This finding 
enforces the idea that AIPmut positive pituitary adenomas are originated by a unique 
molecular mechanism, different from other sporadic somatotropinomas. It is now apparent 
that AIP somehow regulates the cAMP pathway in the pituitary gland and it has generally 
been accepted that an overactive cAMP pathway is a hallmark of somatotroph 
tumorigenesis. At the moment, there is no good theoretical explanation to address the 
question of why mutations in two genes affecting the same pathway are mutually exclusive 
in these tumours. This is an interesting point to investigate, as the discovery of more 
regulatory events in the cAMP pathway, including crosstalk with other signalling pathways, 
could be useful for the development of new therapeutic targets. 
 
AIPmut positive pituitary adenomas are prone to apoplexy 
This is not a new observation, but it has been reinforced by the recruitment and analysis of a 
large number of AIPmut positive cases. It could be assumed that the increased frequency of 
this complication among AIPmut positive individuals is due to the high prevalence of 
macroadenomas among this population. However, there are some unusual features 
suggesting that this is not the case, including the type of tumours, the age at presentation 
and the presence of multiple cases in the same family. Whether LOF of AIP could have an 
effect on the pattern and organisation of the tumoral vessels in pituitary adenomas, is a 
matter to be investigated.  
 
AIP is a co-chaperone of multiple heat shock proteins of the HSP90 and HSP70 
families 
While the finding of new chaperones interacting with AIP has shed light on the repertoire of 
interacting partners of AIP, it has also increased the number of chaperone-client proteins 
that could be regulated by the co-chaperone activity of AIP. Although mapping all these 
possible indirect interactions would be complicated, future studies could concentrate on 
determining which interactions of these chaperones in the somatotroph cells are mediated 
by AIP, as has been shown for PRKACA. On the other hand, the expression of these heat 
shock proteins in the normal pituitary gland and in pituitary adenomas should be further 
investigated, as they represent potential therapeutic targets. 
 
The regulation of the cytoskeletal organisation might be a mechanism for the tumour 
suppressor function of AIP 
Disorganisation of the cytoskeletal network and of the cell-cell junctions is a characteristic of 
invasive tumours. The possible function of AIP as a microtubule-associated protein could 
explain why loss of AIP function produces pituitary adenomas with an EMT phenotype. 
However, it is necessary to determine whether this function occurs specifically in the pituitary 
gland, and the reason for that, as it could represent a potential therapeutic target for invasive 
pituitary adenomas.  
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The E3 ubiquitin-ligase complex SCF targets AIP 
It has been demonstrated that AIP degradation occurs via ubiquitination and proteasomal 
degradation, and the specific E3 ubiquitin-ligase complex mediating this mechanism has 
been identified. Rapid degradation of unstable AIP mutants can be partially reverted by the 
treatment with a proteasome inhibitor. However, it is not clear whether restoring the protein 
stability means restoring the normal function, as those proteins could still be abnormal, due 
to loss of protein-protein interactions.  
 
Human AIP is a stable protein 
In general, proteins with stable half-life are stably expressed, and proteins whose expression 
fluctuates during the cell cycle have been found to be less stable.
759
 This finding is probably 
an indicator that the tumour suppressor function of AIP does not implicate direct regulation 
of the proteins involved in cell-cycle progression. The specific proteins mediating the AIP 
tumour suppressor function remain elusive.  
 
 Short half-life is a mechanism for LOF in missense AIP variants and the expression 
of unstable AIP variants under physiological conditions is probably negligible 
It has been hypothesised that LOF of AIP missense mutants could lead to loss of protein-
protein interactions. However, considering the very low or null endogenous level of the short 
half-lived AIP nonsense mutant p.R304*, it is very probable that very short half-lived mutants 
are also present in the cells at negligible levels under physiological conditions. This means 
that the final effect of these mutations on the protein would be loss of the protein. However, 
it is not clear why pituitary adenomas can develop in some cases in absence of LOH, in the 
presence of one normal, half-lived allele. Further studies to address this issue are required.  
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Appendix 1: Supplementary mass spectrometry results 
Table 25. Qualitative mass spectrometry results after manual validation 
# Protein description (gene name) 
UniProt 
entry 
Mass 
(kDa)
483
 
Protein ID 
probability 
% of 
total 
spectra 
Assigned 
spectra 
Unique 
peptides 
Unique 
spectra 
Coverage 
Best 
Mascot 
ion score 
Calculated 
+1H peptide 
mass (AMU) 
1 AIP_RAT AH receptor-interacting protein (Aip) Q5FWY5 37.6 100% 0.2% 223 29 42 41.0%     
  AHAAVWNAQEAQADFAK                 89.6 1827.9 
  AHAAVWNAQEAQADFAKVLELDPALAPVVSR                 47 3516.9 
  AKAVPLIHQEGNR                 27.3 1662.0 
  AVPLIHQEGNR                 41.2 1233.7 
  DPLEGQR                 31.4 814.4 
  EAAAKYYDAIACLK                 34.5 1816.0 
  EAAAKYYDAIACLKNLQMK                 51.1 2675.4 
  EDGIQK                 24.1 918.5 
  FRGIFSH                 26.4 863.5 
  GELPEFQDGTK                 23.4 1449.7 
  GKAHAAVWNAQEAQADFAK                 81.2 2242.2 
  GKAHAAVWNAQEAQADFAKVLELDPALAPVVSR                 83.6 3702.0 
  GKPMELIIGK                 48.6 1101.6 
  GKPMELIIGKK                 35.1 1442.9 
  IRQKDEEDKAR                 27.6 1616.9 
  LREDGIQK                 24.5 958.5 
  LREDGIQKR                 41 1114.6 
  MADLIAR                 47.5 789.4 
  QKDEEDK                 26 1103.5 
  QKDEEDKAR                 45.9 1330.7 
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# Protein description (gene name) 
UniProt 
entry 
Mass 
(kDa)
483
 
Protein ID 
probability 
% of 
total 
spectra 
Assigned 
spectra 
Unique 
peptides 
Unique 
spectra 
Coverage 
Best 
Mascot 
ion score 
Calculated 
+1H peptide 
mass (AMU) 
  RGKAHAAVWNAQEAQADFAK                 42.4 2398.3 
  VESPGTYQQDPWAMTDEEK                 50.7 2226.9 
  VESPGTYQQDPWAMTDEEKAK                 77.4 2655.2 
  VIQEGR                 41.7 701.4 
  VLELDPALAPVVSR                 67.7 1478.9 
  VLELDPALAPVVSRELR                 43.8 1877.1 
  YDDNVKAYFK                 21 1491.8 
  YYDAIACLK                 42.9 1116.5 
  YYDAIACLKNLQMK                 48.2 1960.0 
2 GSTP1_RAT Glutathione S-transferase P (Gstp1) P04906 23.4 100% 0.2% 135 22 33 70.0%     
  AFLSSPDHLNRPINGNGK                 30.3 1937.0 
  AFLSSPDHLNRPINGNGKQ                 21.5 2294.2 
  ALPGHLKPFETLLSQNQGGK                 46.6 2364.3 
  CKYGTLIYTNYENGK                 55.7 2053.0 
  CKYGTLIYTNYENGKDDYVK                 60.9 2673.3 
  DQKEAALVDMVNDGVEDLR                 93 2346.2 
  EAALVDMVNDGVEDLR                 123 1761.8 
  FEDGDLTLYQSNAILR                 112 1854.9 
  FEDGDLTLYQSNAILRHLGR                 46.4 2318.2 
  IKAFLSSPDHLNRPINGNGK                 22.8 2407.3 
  LSARPKIK                 24.1 1141.8 
  MLLADQGQSWK                 35.8 1276.6 
  MPPYTIVYFPVR                 79.8 1498.8 
  PPYTIVYFPVR                 42.4 1351.7 
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# Protein description (gene name) 
UniProt 
entry 
Mass 
(kDa)
483
 
Protein ID 
probability 
% of 
total 
spectra 
Assigned 
spectra 
Unique 
peptides 
Unique 
spectra 
Coverage 
Best 
Mascot 
ion score 
Calculated 
+1H peptide 
mass (AMU) 
  PPYTIVYFPVRGR                 41.9 1564.9 
  SLGLYGK                 47.1 737.4 
  SLGLYGKDQK                 37.3 1108.6 
  SLGLYGKDQKEAALVDMVNDGVEDLR                 80.5 3064.6 
  STCLYGQLPK                 37.4 1166.6 
  STCLYGQLPKFEDGDLTLYQSNAILR                 63.2 3231.7 
  YGTLIYTNYENGK                 44.8 1535.7 
  YGTLIYTNYENGKDDYVK                 71.4 2156.0 
3 GSTM4_RAT Glutathione S-transferase Yb-3 (Gstm3) P08009 25.7 100% 0.0% 37 14 18 48.0%     
  FLPRPLFTK                 25.7 1118.7 
  FLPRPLFTKMAIWGSK                 24.2 2366.4 
  IRVDILENQLMDNR                 50 1728.9 
  ISDYMKSSR                 19.8 1331.7 
  KISDYMKSSR                 28.2 1443.8 
  LCYNPDFEK                 39.8 1185.5 
  LCYNPDFEKLKPGYLEQLPGMMR                 22 3028.5 
  LKPGYLEQLPGMMR                 53.1 1878.0 
  MAIWGSK                 38.9 1021.6 
  NQVFEATCLDAFPNLK                 48.6 1866.9 
  NQVFEATCLDAFPNLKDFIAR                 49.9 2698.4 
  VDILENQLMDNR                 107 1459.7 
  YTMGDAPDFDR                 66.9 1303.5 
  YTMGDAPDFDRSQWLNEKFK                 33.8 2693.3 
4 GSTA4_RAT Glutathione S-transferase alpha-4 (Gsta4)  P14942 25.5 100% 0.1% 75 19 23 38.0%     
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# Protein description (gene name) 
UniProt 
entry 
Mass 
(kDa)
483
 
Protein ID 
probability 
% of 
total 
spectra 
Assigned 
spectra 
Unique 
peptides 
Unique 
spectra 
Coverage 
Best 
Mascot 
ion score 
Calculated 
+1H peptide 
mass (AMU) 
  AILSYLAAK                 38.4 949.6 
  AILSYLAAKYNLYGK                 29.7 1917.1 
  AILSYLAAKYNLYGKDLK                 32 2502.5 
  AKNRYFPVFEK                 18.9 1627.9 
  APQEKEESLALAVK                 65.3 1512.8 
  APQEKEESLALAVKR                 25.1 2127.3 
  EESLALAVK                 43 959.5 
  EESLALAVKR                 32.5 1344.8 
  GRMESIR                 21.8 848.4 
  ISNIPTIK                 52.3 885.5 
  ISNIPTIKK                 36.1 1242.8 
  KPPPDGHYVDVVR                 59.5 1707.9 
  KPPPDGHYVDVVRTVLKF                 17.3 2296.3 
  LYYFQGR                 25.5 946.5 
  NRYFPVFEK                 23.8 1199.6 
  WLLATAGVEFEEEFLETR                 81.5 2140.1 
  YFPVFEK                 21.6 929.5 
  YNLYGKDLK                 20 1342.8 
  YNLYGKDLKER                 20.3 1627.9 
5 FIBA_RAT Fibrinogen alpha chain (Fga)  P06399 86.7 85% 0.0% 6 1 1 1.3%     
  LEVDIDIKIR                 37.1 1442.9 
6 CBR1_RAT Carbonyl reductase [NADPH] 1 (Cbr1) P47727 30.6 100% 0.1% 75 28 31 78.0%     
  ALKSCSPELQQK                 28.9 1617.9 
  EDKILLNACCPGWVR                 52.2 2060.1 
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# Protein description (gene name) 
UniProt 
entry 
Mass 
(kDa)
483
 
Protein ID 
probability 
% of 
total 
spectra 
Assigned 
spectra 
Unique 
peptides 
Unique 
spectra 
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Mascot 
ion score 
Calculated 
+1H peptide 
mass (AMU) 
  EGWPNSAYGVTK                 41.2 1308.6 
  ELLPIIKPQGR                 21.5 1492.9 
  FHQLDIDNPQSIR                 57.5 1582.8 
  FIEDAK                 30.5 722.4 
  FIEDAKK                 24.3 1079.6 
  FLGDVVLTAR                 50.4 1090.6 
  FRSETITEEELVGLMNK                 54.1 1996.0 
  GHEAVKQLQTEGLSPR                 45 1979.1 
  GIGFAIVR                 33.7 832.5 
  GVHAKEGWPNSAYGVTK                 37.3 2030.1 
  GVHAKEGWPNSAYGVTKIGVTVLSR                 25.9 3084.7 
  IGVTVLSR                 60.1 844.5 
  ILLNACCPGWVR                 56.4 1458.7 
  KFLGDVVLTAR                 21 1447.9 
  KFLGDVVLTAR                 51.5 1447.9 
  QLQTEGLSPR                 67.3 1128.6 
  REDKILLNACCPGWVR                 40.7 2216.2 
  SCSPELQQK                 20.8 1076.5 
  SCSPELQQKFR                 30.9 1608.8 
  SETITEEELVGLMNK                 62.4 1708.8 
  SETITEEELVGLMNKFIEDAKK                 19.1 2982.6 
  SPEEGAETPVYLALLPPGAEGPHGQFVQDKK                 50.9 3490.8 
  TDMAGPKATK                 38.6 1264.7 
  TNFFGTQDVCK                 61.9 1316.6 
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# Protein description (gene name) 
UniProt 
entry 
Mass 
(kDa)
483
 
Protein ID 
probability 
% of 
total 
spectra 
Assigned 
spectra 
Unique 
peptides 
Unique 
spectra 
Coverage 
Best 
Mascot 
ion score 
Calculated 
+1H peptide 
mass (AMU) 
  VVDPTPFHIQAEVTMK                 47 1811.9 
  VVNVSSSVSLR                 63.4 1146.6 
7 EF1G_RAT Elongation factor 1-gamma (Eef1g)  Q68FR6 50.1 100% 0.1% 79 22 26 38.0%     
  AFKALIAAQYSGAQIR                 64.7 1937.1 
  AILGEVK                 32.8 729.5 
  AILGEVKLCEK                 24.4 1488.9 
  AKDPFAHLPK                 31.9 1352.8 
  ALIAAQYSGAQIR                 74.4 1361.8 
  DPFAHLPKSTFVLDEFK                 36.4 2220.2 
  DPFAHLPKSTFVLDEFKR                 24.5 2376.3 
  EEKQKPQTER                 18.1 1501.8 
  EYFSWEGAFQHVGK                 52.8 1684.8 
  ILGLLDTHLK                 41.2 1122.7 
  ILGLLDTHLKTR                 26.5 1609.0 
  KFAESQPK                 23.3 1163.7 
  KFPAGKVPAFEGDDGFCVFESNAIAYYVSNEELR                 65.7 4285.1 
  KLDPGSEETQTLVR                 67.3 1802.0 
  LDPGSEETQTLVR                 98.6 1444.7 
  QAFPNTNR                 36.8 947.5 
  QATENAKEEVK                 25.5 1458.8 
  STFVLDEFK                 30.5 1085.6 
  STFVLDEFKR                 40.7 1241.7 
  TFLVGER                 47.8 821.5 
  TPEFLR                 35.8 762.4 
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# Protein description (gene name) 
UniProt 
entry 
Mass 
(kDa)
483
 
Protein ID 
probability 
% of 
total 
spectra 
Assigned 
spectra 
Unique 
peptides 
Unique 
spectra 
Coverage 
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Mascot 
ion score 
Calculated 
+1H peptide 
mass (AMU) 
  VLSAPPHFHFGQTNR                 37 1707.9 
8 GSTM5_RAT Glutathione S-transferase Mu 5 (Gstm5) Q9Z1B2 26.6 100% 0.1% 71 22 25 72.0%     
  CLDEFPNLKAFMCR                 19.9 2030.0 
  FEALEK                 39.7 736.4 
  FEALEKIAAFLQSDR                 49.8 1967.1 
  FKLDLDFPNLPYLMDGK                 21.3 2271.2 
  FTWFAGEK                 33.7 985.5 
  IAAFLQSDR                 70.6 1020.5 
  KHNMCGDTEEEK                 52.6 1706.8 
  LCYNSNHESLKPQYLEQLPAQLK                 38.2 2773.4 
  LDLDFPNLPYLMDGK                 31.4 1766.9 
  LDLDFPNLPYLMDGKNK                 46.8 2222.2 
  MFEPKCLDEFPNLK                 19 2013.0 
  MLLEFTDTSYEEK                 69.3 1621.7 
  MLLEFTDTSYEEKQYTCGEAPDYDR                 55.9 3306.5 
  MPINNKMAK                 22.5 1307.7 
  NKITQSNAILR                 50.2 1486.9 
  QFSLFLGK                 20.1 939.5 
  QYTCGEAPDYDR                 97.4 1474.6 
  QYTCGEAPDYDRSQWLDVK                 24.3 2331.0 
  SMVLGYWDIR                 46.7 1239.6 
  SQWLDVK                 30.4 875.5 
  SQWLDVKFK                 22.9 1379.8 
  VDIMENQIMDFR                 119 1510.7 
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# Protein description (gene name) 
UniProt 
entry 
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(kDa)
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Protein ID 
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% of 
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spectra 
Assigned 
spectra 
Unique 
peptides 
Unique 
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9 GSTM1_RAT Glutathione S-transferase Mu 1 (Gstm1) P04905 25.9 100% 0.0% 39 19 23 65.0%     
  ADIVENQVMDNR                 89.4 1419.7 
  CLDAFPNLKDFLAR                 49.8 1679.9 
  FKLGLDFPNLPYLIDGSR                 48.8 2294.3 
  GLTHPIR                 25.2 793.5 
  HHLCGETEEER                 54.9 1396.6 
  IRADIVENQVMDNR                 49.2 1688.8 
  ISAYMKSSR                 21.2 1271.7 
  ITQSNAIMR                 51.5 1033.5 
  KHHLCGETEEER                 44.6 1753.8 
  KISAYMKSSR                 19.8 1629.0 
  KITQSNAIMR                 41.9 1406.8 
  LAQWSNK                 35.5 1075.6 
  LGLDFPNLPYLIDGSR                 96 1789.9 
  MQLIMLCYNPDFEK                 40.6 1833.8 
  PMILGYWNVR                 37.7 1264.7 
  YAMGDAPDYDR                 70.3 1289.5 
  YAMGDAPDYDRSQWLNEKFK                 24.2 2679.3 
  YLSTPIFSK                 43 1055.6 
  YLSTPIFSKLAQWSNK                 28.4 2112.2 
10 HSP7C_RAT Heat shock cognate 71 kDa protein (Hspa8) P63018 70.9 100% 0.0% 39 20 20 30.0%     
  ARFEELNADLFR                 46.9 1480.8 
  DAGTIAGLNVLR                 51.6 1199.7 
  DAKLDKSQIHDIVLVGGSTR                 31.2 2381.3 
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483
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  FEELNADLFR                 70.8 1253.6 
  GTLDPVEKALR                 20.2 1427.8 
  IINEPTAAAIAYGLDKK                 64 2017.2 
  LDKSQIHDIVLVGGSTR                 61.7 1838.0 
  LIGDAAKNQVAMNPTNTVFDAKR                 27.7 2932.6 
  LLQDFFNGKELNK                 33.9 1795.0 
  LSKEDIER                 36.8 989.5 
  MVNHFIAEFKR                 21 1620.9 
  NQVAMNPTNTVFDAK                 88.8 1649.8 
  NQVAMNPTNTVFDAKR                 42.1 2051.1 
  NSLESYAFNMK                 32.7 1303.6 
  QATKDAGTIAGLNVLR                 64.9 1857.1 
  STAGDTHLGGEDFDNR                 42 1691.7 
  TTPSYVAFTDTER                 75.9 1487.7 
  TVTNAVVTVPAYFNDSQR                 80.4 1982.0 
  VQVEYKGETK                 22.2 1409.8 
  YKAEDEKQR                 22.8 1395.7 
11 HLF_RAT Hepatic leukaemia factor (Hlf) Q64709 33.1 91% 0.0% 15 1 1 2.7%     
  QEVADLRK                 28.3 958.5 
12 TBA8_RAT Tubulin alpha-8 chain (Tuba8) Q6AY56 50.0 91% 0.0% 7 1 1 3.6%     
  GHYTVGKESIDLVLDR                 21.3 1801.9 
13 EF1A2_RAT Elongation factor 1-alpha 2 (Eef1a2)  P62632 50.5 100% 0.0% 9 7 7 19.0%     
  EGNASGVSLLEALDTILPPTRPTDKPLR                 51.5 3189.8 
  KLEDNPKSLK                 21.8 1630.0 
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  LEDNPKSLK                 22.6 1272.7 
  QTVAVGVIKNVEK                 43.1 1614.0 
  VETGILRPGMVVTFAPVNITTEVK                 62.2 2571.4 
  YDEIVK                 27.9 766.4 
  YDEIVKEVSAYIK                 22.9 1786.0 
14 TPIS_RAT Triosephosphate isomerase (Tpi1)  P48500 26.8 100% 0.0% 23 15 17 70.0%     
  DLGATWVVLGHSER                 45.7 1539.8 
  ELASQPDVDGFLVGGASLKPEFVDIINAK                 31.4 3258.7 
  GWLKCNVSEGVAQCTR                 47.6 2094.0 
  HIFGESDELIGQK                 43.9 1472.7 
  IIYGGSVTGATCK                 81.8 1326.7 
  KFFVGGNWK                 19 1311.7 
  KFFVGGNWKMNGR                 28.1 1999.1 
  LPADTEVVCAPPTAYIDFAR                 80.3 2206.1 
  TATPQQAQEVHEK                 53.1 1466.7 
  TATPQQAQEVHEKLR                 43.6 1965.1 
  VNHALSEGLGVIACIGEKLDER                 41.2 2609.4 
  VTNGAFTGEISPGMIK                 31.8 1637.8 
  VVFEQTK                 34.2 850.5 
  VVLAYEPVWAIGTGK                 49.1 1602.9 
  VVLAYEPVWAIGTGKTATPQQAQEVHEK                 41 3279.8 
15 CP013_RAT UPF0585 protein C16orf13 homolog   Q497C3 22.6 100% 0.0% 15 8 9 45.0%     
  AFPNAEWQPSDVDQR                 89.3 1759.8 
  CRNPEWGLR                 23.4 1187.6 
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  DTALLEELGQASGLTLER                 105 1916.0 
  MVDMPANNKCLIFR                 20.4 1970.0 
  NKEPILCVLR                 44.4 1241.7 
  NPEWGLR                 46.2 871.4 
  QYVDPAQR                 53.5 976.5 
  VLEVASGSGQHAAHFAR                 58.1 1736.9 
16 GRP75_RAT Stress-70 protein, mitochondrial (Hspa9) P48721 73.9 100% 0.0% 13 10 11 20.0%     
  AQFEGIVTDLIKR                 26.9 1719.0 
  DAGQISGLNVLR                 57.5 1242.7 
  EMAGDNKLLGQFTLIGIPPAPR                 27.6 2567.4 
  KDSETGENIR                 50.5 1377.7 
  MPKVQQTVQDLFGR                 50.5 1892.0 
  NAVITVPAYFNDSQR                 64 1694.8 
  QATKDAGQISGLNVLR                 53.6 1900.1 
  QAVTNPNNTFYATKR                 39.5 1954.0 
  TTPSVVAFTPDGER                 59 1476.7 
  VEAVNMAEGIIHDTETK                 60.8 1856.9 
17 LANC1_RAT LanC-like protein 1 (Lancl1) Q9QX69 45.2 100% 0.0% 14 5 6 9.8%     
  AFPNPYADYNK                 34.5 1299.6 
  AFPNPYADYNKSLAENYFDSTGR                 46.8 2869.4 
  ELLQQMER                 63.9 1046.5 
  QAEDCITR                 60.5 992.4 
  SLAENYFDSTGR                 70.5 1359.6 
18 HEXB_RAT Beta-hexosaminidase subunit beta (Hexb)  Q6AXR4 61.5 90% 0.0% 8 1 1 2.0%     
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  AEPLNFEGSEK                 26.5 1220.6 
19 ATPA_RAT ATP synthase subunit alpha, mitochondrial (Atp5a1)  P15999 59.8 100% 0.0% 15 8 8 14.0%     
  AVDSLVPIGR                 39.1 1026.6 
  ELIIGDR                 47 815.5 
  ILGADTSVDLEETGR                 105 1575.8 
  SDGKISEQSDAK                 36.4 1493.8 
  TGAIVDVPVGDELLGR                 77.3 1610.9 
  VGLKAPGIIPR                 28 1349.9 
  VLSIGDGIAR                 46.7 1000.6 
  VVDALGNAIDGK                 58.4 1171.6 
20 
ACTB_RAT Actin, cytoplasmic 1 (Actb)             
ACTG_RAT Actin, cytoplasmic 2 (Actg1)  
P60711 
P63259 
41.7, 
41.8 
100% 0.0% 15 9 9 32.0%     
  AGFAGDDAPR                 79.2 976.4 
  AVFPSIVGRPR                 33.1 1198.7 
  GYSFTTTAER                 40.8 1132.5 
  IIAPPER                 34 795.5 
  KDLYANTVLSGGTTMYPGIADR                 50.2 2588.3 
  SYELPDGQVITIGNER                 81.6 1790.9 
  TTGIVMDSGDGVTHTVPIYEGYALPHAILR                 52 3199.6 
  VAPEEHPVLLTEAPLNPK                 33.9 1954.1 
  VAPEEHPVLLTEAPLNPKANR                 23.9 2524.4 
21 ALBU_RAT Serum albumin (Alb) P02770 68.7 98% 0.0% 3 2 2 2.3%     
  AFKAWAVAR                 25.2 1248.7 
  ECCHGDLLECADDR                 35.7 1749.7 
22 HS90B_RAT Heat shock protein HSP 90-beta, (Hsp90ab1) P34058 83.3 100% 0.0% 5 3 3 4.3%     
289 
 
# Protein description (gene name) 
UniProt 
entry 
Mass 
(kDa)
483
 
Protein ID 
probability 
% of 
total 
spectra 
Assigned 
spectra 
Unique 
peptides 
Unique 
spectra 
Coverage 
Best 
Mascot 
ion score 
Calculated 
+1H peptide 
mass (AMU) 
  ALLFIPR                 33.4 829.5 
  ELISNASDALDKIR                 31.9 1774.0 
  IDIIPNPQER                 47.9 1194.6 
23 RS28_RAT 40S ribosomal protein S28, (Rps28)  P62859 7.8 100% 0.0% 8 4 5 45.0%     
  EGDVLTLLESER                 87 1360.7 
  EGDVLTLLESEREAR                 21.8 1716.9 
  NVKGPVREGDVLTLLESER                 30.8 2340.3 
  VEFMDDTSR                 48.4 1099.5 
24 GRP78_RAT 78 kDa glucose-regulated protein, (Hspa5) P06761 72.3 100% 0.0% 8 8 8 19.0%     
  AKFEELNMDLFR                 70.3 1741.9 
  IINEPTAAAIAYGLDKR                 37.8 2045.2 
  ITPSYVAFTPEGER                 51 1566.8 
  KSDIDEIVLVGGSTR                 26.5 1818.0 
  KSQIFSTASDNQPTVTIK                 30.7 2194.2 
  NQLTSNPENTVFDAKR                 37.6 2063.1 
  TWNDPSVQQDIK                 48.1 1430.7 
  VTHAVVTVPAYFNDAQR                 38.2 1888.0 
25 SYFA_RAT Phenylalanyl-tRNA synthetase alpha chain (Farsa) Q505J8 57.7 90% 0.0% 3 2 2 2.2%     
  ADNPVLEQLLR                 22.9 1267.7 
  VVDSIEDEVQR                 25.2 1288.6 
26 
VAPA_RAT Vesicle-associated membrane protein-associated 
protein A (Vapa) 
Q9Z270 27.8 100% 0.0% 6 5 5 26.0%     
  FKGPFTDVVTTNLKLQNPSDR                 38.7 2835.6 
  HLRDEGLR                 21.4 995.5 
  KVAHSDKPGSTSAVSFR                 49.1 2003.1 
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  QDGPLPKPHSVSLNDTETR                 56 2320.2 
  VAHSDKPGSTSAVSFR                 24.6 1645.8 
27 CO4_RAT Complement C4 (C4)  P08649 192.2 100% 0.0% 9 2 2 1.3%     
  ADLEKLTSLSDR                 40.4 1576.9 
  VEYGFQVKVLR                 34.5 1566.9 
28 PRDX1_RAT Peroxiredoxin-1 (Prdx1)  Q63716 22.1 100% 0.0% 9 6 6 19.0%     
  ADEGISFR                 51.9 894.4 
  GLFIIDDK                 35.7 920.5 
  GLFIIDDKGILR                 19.3 1589.0 
  QITINDLPVGR                 54 1225.7 
  SVDEILR                 29 831.5 
  TIAQDYGVLK                 28.7 1107.6 
29 SKA2_RAT Spindle and kinetochore-associated protein 2 (Ska2)  Q5I0J4 16.5 83% 0.0% 1 1 1 4.9%     
  NAVAILK                 23.3 728.5 
30 THIO_RAT Thioredoxin (Txn)  P11232 11.7 100% 0.0% 8 5 5 31.0%     
  EAFQEALAAAGDK                 49.5 1320.6 
  EKLEATITEFA                 62.5 1480.8 
  VGEFSGANK                 51.5 908.4 
  VGEFSGANKEK                 30.3 1394.7 
  VGEFSGANKEKLEATITEFA                 21.2 2599.4 
31 PYGM_RAT Glycogen phosphorylase, muscle form (Pygm) P09812 97.3 100% 0.0% 6 3 3 4.3%     
  ARPEFTLPVHFYGR                 27 1689.9 
  DYYFALAHTVR                 29.9 1355.7 
  HLQIIYEINQR                 41.1 1426.8 
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32 
SEBP2_RAT Selenocysteine insertion sequence-binding protein 
2 (Secisbp2)  
Q9QX72 93.3 89% 0.0% 4 1 1 0.8%     
  TMLETMR                 24 913.4 
33 CALD1_RAT Non-muscle caldesmon (Cald1) Q62736 60.6 82% 0.0% 2 1 1 1.9%     
  LSRSGSQGRR                 27 1103.6 
34 
ECHA_RAT Trifunctional enzyme subunit alpha, mitochondrial 
(Hadha) 
Q64428 82.7 100% 0.0% 6 6 6 10.0%     
  DLANNSSKKFYQ                 28.2 1873.0 
  ILQEGVDPK                 32.3 998.6 
  LPAKPEVSSDEDIQYR                 36.8 2076.1 
  NLNSEIDNILVNLR                 34 1626.9 
  TIEYLEEVAVNFAK                 29.7 1625.8 
  TLLKDTTVTGLGR                 19.6 1604.0 
35 GSTA6_RAT Glutathione S-transferase A6 (Gsta6)  Q6AXY0 25.8 100% 0.0% 5 5 5 16.0%     
  AIMNYFSSKYNLYGK                 26.1 2028.0 
  FIHTNEDLEK                 40 1245.6 
  FIHTNEDLEKLR                 37.8 1744.0 
  QPPVDEKSIQK                 20.8 1480.8 
  VFESHGQDYLVGNK                 46.4 1592.8 
36 MYH10_RAT Myosin-10 (Myh10)  Q9JLT0 229.0 90% 0.0% 4 1 1 0.5%     
  ARDEVIKQLR                 22.2 1227.7 
37 GSTM2_RAT Glutathione S-transferase Mu 2 (Gstm2)  P08010 25.7 100% 0.0% 4 2 2 4.1%     
  SQWLSEK                 23.8 877.4 
  SQWLSEKFK                 21.1 1381.8 
38 GRPE1_RAT GrpE protein homolog 1, mitochondrial (Grpel1)  P97576 24.3 100% 0.0% 4 2 2 8.3%     
  ALADTENLR                 69.8 1002.5 
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  SQKLVEEAK                 20.8 1260.7 
39 
G3P_RAT Glyceraldehyde-3-phosphate dehydrogenase 
(Gapdh)  
P04797 35.8 100% 0.0% 6 2 2 8.7%     
  GAAQNIIPASTGAAK                 51.8 1369.7 
  VPTPNVSVVDLTCR                 87.3 1556.8 
40 ATPB_RAT ATP synthase subunit beta, mitochondrial (Atp5b)  P10719 56.4 100% 0.0% 5 5 5 12.0%     
  AIAELGIYPAVDPLDSTSR                 53.1 1988.0 
  FTQAGSEVSALLGR                 79.4 1435.8 
  IMDPNIVGSEHYDVAR                 38.4 1815.9 
  IMNVIGEPIDER                 46.9 1385.7 
  TIAMDGTEGLVR                 72.4 1262.6 
41 PRDX2_RAT Peroxiredoxin-2 (Prdx2)  P35704 21.8 100% 0.0% 7 4 4 22.0%     
  KEGGLGPLNIPLLADVTK                 43.5 2064.2 
  NDEGIAYR                 31.2 937.4 
  QITVNDLPVGR                 58.7 1211.7 
  SVDEALR                 41.8 789.4 
42 1433T_RAT 14-3-3 protein theta (Ywhaq)  P68255 27.8 100% 0.0% 5 4 4 21.0%     
  AVTEQGAELSNEER                 88.1 1532.7 
  EKVESELR                 22 1218.7 
  KQTIENSQGAYQEAFDISK                 86.4 2386.2 
  YLAEVACGDDR                 61.3 1268.6 
43 EF1A1_RAT Elongation factor 1-alpha 1 (Eef1a1)  P62630 50.1 100% 0.0% 4 3 4 8.4%     
  AAGAGKVTK                 22.2 1031.6 
  VETGVLKPGMVVTFAPVNVTTEVK                 51.3 2760.5 
  YEEIVK                 22.8 780.4 
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44 
UBB_RAT Polyubiquitin-B (Ubb) 
RS27A_RAT Ubiquitin-40S ribosomal protein S27a (Rps27a)                                                         
RL40_RAT Ubiquitin-60S ribosomal protein L40 (Uba52)                                                               
UBC_RAT Polyubiquitin-C (Ubc) 
P0CG51     
P62982
P62986
Q63429 
34.4            
18
14.7 
91.1 
100% 0.0% 5 2 2 9.2%     
  LIFAGKQLEDGR                 25.2 1575.9 
  TITLEVEPSDTIENVK                 55.7 1787.9 
45 UBXN4_RAT UBX domain-containing protein 4 (Ubxn4) Q5HZY0 56.4 99% 0.0% 2 1 1 1.0%     
  IYRLR                 26.8 720.5 
46 
VDAC1_RAT Voltage-dependent anion-selective channel protein 
1 (Vdac1) 
Q9Z2L0 30.8 100% 0.0% 6 5 5 16.0%     
  FGIAAKYQVDPDACFSAK                 25.5 2217.1 
  LTFDSSFSPNTGK                 45.2 1400.7 
  LTLSALLDGK                 91.4 1030.6 
  VNNSSLIGLGYTQTLKPGIK                 60.5 2103.2 
  YQVDPDACFSAK                 32.3 1400.6 
47 FBX3_RAT F-box only protein 3 (Fbxo3) D4ABP9 55.4 100% 0.0% 6 6 6 17.0%     
  EEDLDAVEAQIGCK                 75 1576.7 
  EEDLDAVEAQIGCKLPDDYR                 33.9 2565.2 
  EGAREEDLDAVEAQIGCK                 43.8 1989.9 
  ITNAKGDVEEVQGPGVVGEFPIISPGR                 25.1 2994.6 
  LSQLSTHDPLWR                 45.2 1452.8 
  SEDLLDVDTAAGGFQQR                 96 1821.9 
48 NFL_RAT Neurofilament light polypeptide (Nefl) P19527 61.3 100% 0.0% 5 5 5 11.0%     
  AAKDEVSESR                 34.7 1320.7 
  FTVLTESAAKNTDAVR                 33.9 1952.1 
  KGADEAALAR                 25.3 1230.7 
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  LAAEDATNEKQALQGER                 38.5 2073.1 
  QKHSEPSR                 20.9 1180.6 
49 RS18_RAT 40S ribosomal protein S18 (Rps18)  P62271 17.7 100% 0.0% 5 5 5 25.0%     
  AGELTEDEVER                 71.3 1247.6 
  IPDWFLNR                 45.4 1060.6 
  LREDLER                 22.2 930.5 
  QYKIPDWFLNR                 28.3 1708.9 
  VLNTNIDGR                 67.8 1001.5 
50 ACON_RAT Aconitate hydratase, mitochondrial (Aco2) Q9ER34 85.4 85% 0.0% 5 1 1 1.2%     
  VDVSPTSQR                 56.7 988.5 
51 AKT3_RAT RAC-gamma serine/threonine-protein kinase (Akt3) Q63484 55.8 86% 0.0% 1 1 1 2.7%     
  SDVTIVKEDWVQK                 19.8 1546.8 
52 MCPT4_RAT Mast cell protease 4 (Mcpt4) P97592 27.0 89% 0.0% 3 1 2 2.4%     
  DIMLLK                 25.5 748.4 
53 EF2_RAT Elongation factor 2 (Eef2) P05197 95.3 100% 0.0% 3 3 3 5.4%     
  ALLELQLEPEELYQTFQR                 49 2220.2 
  ETVSEESNVLCLSK                 75.6 1594.8 
  YLAEKYEWDVAEAR                 27.6 1972.0 
54 RSSA_RAT 40S ribosomal protein SA (Rpsa) P38983 32.8 100% 0.0% 2 2 2 8.5%     
  AVLKFAAATGATPIAGR                 30.9 1844.1 
  LLVVTDPR                 30.8 912.6 
55 RS20_RAT 40S ribosomal protein S20 (Rps20) P60868 13.4 100% 0.0% 5 5 5 34.0%     
  DTGKTPVEPEVAIHR                 45.2 1878.0 
  LIDLHSPSEIVK                 34.1 1350.8 
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  NVKSLEK                 23.3 1046.6 
  SLEKVCADLIR                 23.4 1532.9 
  VCADLIR                 31.9 846.5 
56 RS12_RAT 40S ribosomal protein S12 (Rps12) P63324 14.5 100% 0.0% 5 5 5 27.0%     
  DVIEEYFK                 29.6 1042.5 
  ESQAKDVIEEYFK                 26.3 1814.9 
  LGEWVGLCK                 35.3 1061.5 
  LGEWVGLCKIDR                 28.4 1674.9 
  TALIHDGLAR                 33.5 1066.6 
57 RS29_RAT 40S ribosomal protein S29 (Rps29) P62275 6.7 100% 0.0% 2 2 2 41.0%     
  GHQQLYWSHPR                 31.6 1637.8 
  QYAKDIGFIKLD                 21.6 1622.9 
58 
H2B1_RAT Histone H2B type 1 
H2B1A_RAT Histone H2B type 1-A (Hist1h2ba) 
Q00715 
Q00729 
14               
14.2 
89% 0.0% 4 1 1 7.2%     
  LLLPGELAK                 37.9 953.6 
59 
PI51C_RAT Phosphatidylinositol-4-phosphate 5-kinase type-1 
gamma (Pip5k1c) 
Q5I6B8 75.6 79% 0.0% 3 1 1 1.2%     
  KTTSSTLK                 25.8 865.5 
60 
VAPB_RAT Vesicle-associated membrane protein-associated 
protein B (Vapb) 
Q9Z269 26.9 100% 0.0% 4 3 3 12.0%     
  QLKEEDGLR                 23.4 1299.7 
  RLQGEVQR                 32.2 985.6 
  TEAPVAAKPLTSPLDDAEVK                 34.8 2281.2 
61 ALDOA_RAT Fructose-bisphosphate aldolase A (Aldoa) P05065 39.4 100% 0.0% 2 2 2 9.1%     
  IVAPGKGILAADESTGSIAK                 27.4 2127.2 
  LQSIGTENTEENR                 41.6 1490.7 
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62 TBB4B_RAT Tubulin beta-4B chain (Tubb4b) Q6P9T8 49.8 100% 0.0% 3 2 2 7.0%     
  AVLVDLEPGTMDSVR                 78.8 1601.8 
  INVYYNEATGGKYVPR                 41.5 2073.1 
63 KPYM_RAT Pyruvate kinase isozymes M1/M2 (Pkm2) P11980 57.8 100% 0.0% 4 4 4 6.0%     
  APIIAVTR                 46.4 840.5 
  LDIDSAPITAR                 62.4 1171.6 
  NTGIICTIGPASR                 62.6 1359.7 
  RFDEILEASDGIMVAR                 20.9 1821.9 
64 SKP1_RAT S-phase kinase-associated protein 1 (Skp1) Q6PEC4 18.7 100% 0.0% 3 2 2 11.0%     
  KTFNIKNDFTEEEEAQVR                 59.5 2656.4 
  NDFTEEEEAQVR                 55.7 1466.6 
65 
UCHL1_RAT Ubiquitin carboxyl-terminal hydrolase isozyme L1  
(Uchl1) 
Q00981 24.8 100% 0.0% 4 3 3 15.0%     
  FSAVALCKAA                 52.3 1266.7 
  MPFPVNHGASSEDSLLQDAAK                 86.9 2230.0 
  MPFPVNHGASSEDSLLQDAAKVCR                 49.3 2874.4 
66 MGST1_RAT Microsomal glutathione S-transferase 1 (Mgst1) P08011 17.5 100% 0.0% 2 2 2 12.0%     
  VFANPEDCAGFGK                 46.6 1411.6 
  VFANPEDCAGFGKGENAK                 44.6 2140.0 
67 PPIA_RAT Peptidyl-prolyl cis-trans isomerase A (Ppia) P10111 17.9 100% 0.0% 3 2 3 20.0%     
  IIPGFMCQGGDFTR                 73.4 1614.7 
  VNPTVFFDITADGEPLGR                 57.4 1948.0 
68 TBA4A_RAT Tubulin alpha-4A chain (Tuba4a) Q5XIF6 49.9 100% 0.0% 1 1 1 3.3%     
  AVFVDLEPTVIDEIR                 121 1715.9 
69 
PYGB_RAT Glycogen phosphorylase, brain form (Fragment) 
(Pygb) 
P53534 96.2 85% 0.0% 3 2 2 2.3%     
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  IYYLSLEFYMGR                 31 1554.8 
  VAIQLNDTHPALSIPELMR                 23.2 2134.1 
70 GRM1_RAT Metabotropic glutamate receptor 1 (Grm1) P23385 133.2 85% 0.0% 3 1 1 0.7%     
  KICTRKPR                 31.6 1001.6 
71 MPCP_RAT Phosphate carrier protein, mitochondrial (Slc25a3) P16036 39.4 100% 0.0% 3 2 2 6.2%     
  GSTASQVLQR                 50.3 1046.6 
  IQTQPGYANTLR                 63.3 1361.7 
72 
ECHB_RAT Trifunctional enzyme subunit beta, mitochondrial 
(Hadhb) 
Q60587 51.4 100% 0.0% 3 2 2 4.6%     
  AALSGLLYR                 58.6 963.6 
  DQLLLGPTYATPK                 38.3 1416.8 
73 RS14_RAT 40S ribosomal protein S14 (Rps14) P13471 16.3 100% 0.0% 3 2 2 17.0%     
  IEDVTPIPSDSTR                 95.5 1429.7 
  TKTPGPGAQSALR                 55.9 1512.9 
74 
KCAB1_RAT Voltage-gated potassium channel subunit beta-1 
(Kcnab1) 
P63144 44.7 89% 0.0% 2 1 1 1.5%     
  QQNKLK                 28.9 758.5 
75 SCN4B_RAT Sodium channel subunit beta-4 (Scn4b) Q7M730 25.2 89% 0.0% 2 1 1 2.6%     
  SDPKVR                 33.9 701.4 
76 PRAF3_RAT PRA1 family protein 3 (Arl6ip5) Q9ES40 21.5 98% 0.0% 2 2 2 5.9%     
  AWDDFFPGSDR                 36.4 1312.6 
  FADYISK                 21.1 843.4 
77 FAS_RAT Fatty acid synthase (Fasn) P12785 272.7 76% 0.0% 1 1 1 0.4%     
  QEGVFAKEVR                 19 1162.6 
78 PGAP1_RAT GPI inositol-deacylase (Pgap1) Q765A7 104.4 79% 0.0% 1 1 1 1.2%     
  VNVVSKCTGGK                 21.5 1148.6 
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79 NUCB2_RAT Nucleobindin-2 (Nucb2) Q9JI85 50.1 89% 0.0% 1 1 1 1.7%     
  DLDMLIK                 23.4 847.5 
80 HEPS_RAT Serine protease hepsin (Hpn) Q05511 44.9 89% 0.0% 1 1 1 1.7%     
  KPGVYTK                 31.2 792.5 
81 KTU_RAT Protein kintoun (Ktu) Q5FVL7 89.3 100% 0.0% 3 3 3 4.9%     
  ESSTAYSAEEK                 28.5 1201.5 
  EWYWGLNKDSLEER                 24.7 2054.0 
  LQECSDPDGLQGKEK                 31.3 1933.0 
82 MAP4_RAT Microtubule-associated protein 4 (Map4) Q5M7W5 110.3 100% 0.0% 1 1 1 1.1%     
  TEFIPLLDGDEK                 30.9 1376.7 
83 
RPN1_RAT Dolichyl-diphosphooligosaccharide-protein 
glycosyltransferase subunit 1 (Rpn1) 
P07153 68.3 100% 0.0% 2 2 2 4.0%     
  AVTSEIAVLQSR                 60.4 1273.7 
  NIQVDSPYDISR                 70.8 1406.7 
84 ANXA1_RAT Annexin A1 (Anxa1) P07150 38.8 100% 0.0% 2 2 2 5.5%     
  ALYEAGER                 33.5 908.4 
  DITSDTSGDFR                 53.8 1213.5 
85 RS21_RAT 40S ribosomal protein S21 (Rps21) P05765 9.1 100% 0.0% 2 2 2 14.0%     
  LAKADGIVSK                 25.7 1230.8 
  LAKADGIVSKNF                 20.6 1721.0 
86 
NDKB_RAT Nucleoside diphosphate kinase B (Nme2) 
NDKA_RAT Nucleoside diphosphate kinase A (Nme1) 
P19804 
Q05982 
17.3            
17.2 
100% 0.0% 2 2 2 14.0%     
  GDFCIQVGR                 43.9 1051.5 
  TFIAIKPDGVQR                 30 1573.9 
87 CH60_RAT 60 kDa heat shock protein, mitochondrial (Hspd1) P63039 61.0 90% 0.0% 2 2 2 2.1%     
  VGGTSDVEVNEK                 22 1233.6 
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  VTDALNATR                 44.9 960.5 
88 CP4F6_RAT Cytochrome P450 4F6 (Cyp4f6) P51871 61.5 86% 0.0% 2 1 1 1.5%     
  MLQLSLSR                 44.7 963.5 
89 
H2AJ_RAT Histone H2A.J (H2afj ) 
H2A1_RAT Histone H2A type 1                                                   
H2AZ_RAT Histone H2A.Z (H2afz) 
H2A1C_RAT Histone H2A type 1-C                           
H2A1E_RAT Histone H2A type 1-E                           
H2A2A_RAT Histone H2A type 2-A (Hist2h2aa3) 
H2A4_RAT Histone H2A type 4                            
H2A3_RAT Histone H2A type 3                            
H2A1F_RAT Histone H2A type 1-F 
A9UMV8 
P02262 
P0C0S7 
P0C169 
P0C170 
P0CC09 
Q00728 
Q4FZT6 
Q64598 
14.0 
14.1    
13.6    
14.1    
14.4    
14.4   
14.3   
14.1    
14.2 
85% 0.0% 2 1 1 7.0%     
  AGLQFPVGR                 63.2 944.5 
90 DCXR_RAT L-xylulose reductase (Dcxr) Q920P0 25.7 86% 0.0% 1 1 1 2.9%     
  DLGLAGR                 33.4 701.4 
91 
LDHA_RAT L-lactate dehydrogenase A chain (Ldha)                                                                        
LDHB_RAT L-lactate dehydrogenase B chain (Ldhb) 
P04642
P42123 
36.5
36.6 
84% 0.0% 2 1 1 3.6%     
  VIGSGCNLDSAR                 60.4 1248.6 
92 RS25_RAT 40S ribosomal protein S25 (Rps25) P62853 13.7 83% 0.0% 2 1 1 11.0%     
  NTKGGDAPAAGEDA                 49.2 1502.7 
93 UBA1_RAT Ubiquitin-like modifier-activating enzyme 1 (Uba1) Q5U300 117.8 83% 0.0% 2 1 1 1.5%     
  SPPAVQQDNVDEDLIR                 111 1795.9 
94 GDF8_RAT Growth/differentiation factor 8 (Mstn) O35312 42.8 77% 0.0% 2 1 1 1.6%     
  LIKPMK                 31.2 745.5 
95 
PGRC2_RAT Membrane-associated progesterone receptor 
component 2 (Pgrmc2) 
Q5XIU9 23.4 77% 0.0% 2 1 1 6.9%     
  GGDGSPGGAGATAAR                 58.2 1201.6 
96 STRN3_RAT Striatin-3 (Strn3) P58405 87.1 89% 0.0% 1 1 1 0.9%     
  QKGQEIK                 21.5 830.5 
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97 ENOA_RAT Alpha-enolase (Eno1) P04764 47.1 84% 0.0% 1 1 1 4.1%     
  AAVPSGASTGIYEALELR                 77.2 1804.9 
98 STS_RAT Steryl-sulfatase (Sts) P15589 62.7 85% 0.0% 1 1 1 1.2%     
  LALEGVK                 20.4 729.5 
99 RN114_RAT RING finger protein 114 (Rnf114) Q6J2U6 25.7 83% 0.0% 1 1 1 3.1%     
  KDFVLSK                 25.1 836.5 
100 REEP5_RAT Receptor expression-enhancing protein 5 (Reep5) B2RZ37 21.4 100% 0.0% 2 2 2 11.0%     
  ATVNLLGDEKK                 32.5 1416.8 
  HESQVDSVVK                 22.5 1127.6 
101 GLNA_RAT Glutamine synthetase (Glul) P09606 42.3 100% 0.0% 2 2 2 9.9%     
  LTGFHETSNINDFSAGVANR                 68.9 2150.0 
  RPSANCDPYAVTEAIVR                 43.8 1918.9 
102 
DHSB_RAT Succinate dehydrogenase [ubiquinone] iron-sulfur 
subunit, mitochondrial (Sdhb) 
P21913 31.8 100% 0.0% 2 2 2 7.1%     
  IKTFAIYR                 30 1240.8 
  LAKLQDPFSLYR                 22.8 1680.0 
103 CNBP_RAT Cellular nucleic acid-binding protein (Cnbp) P62634 19.5 100% 0.0% 2 2 2 17.0%     
  EQCCYNCGKPGHLAR                 17.1 2079.0 
  GFQFVSSSLPDICYR                 72.6 1775.8 
104 1433Z_RAT 14-3-3 protein zeta/delta (Ywhaz) P63102 27.8 100% 0.0% 2 2 2 11.0%     
  NLLSVAYKNVVGAR                 28.5 1733.0 
  SVTEQGAELSNEER                 92.2 1548.7 
105 TBB2A_RAT Tubulin beta-2A chain (Tubb2a) P85108 49.9 100% 0.0% 1 1 1 3.6%     
  INVYYNEAAGNKYVPR                 38.7 2100.1 
106 ADT1_RAT ADP/ATP translocase 1 (Slc25a4)  Q05962 33.0 100% 0.0% 2 2 2 6.4%     
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  EFNGLGDCLTK                 45.1 1253.6 
  TAVAPIER                 44 856.5 
107 TPM3_RAT Tropomyosin alpha-3 chain (Tpm3 ) Q63610 29.0 100% 0.0% 2 2 2 10.0%     
  IQLVEEELDR                 54.2 1243.7 
  KIQVLQQQADDAEER                 20.1 2000.1 
108 
OST48_RAT Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase 48 kDa subunit (Ddost) 
Q641Y0 48.9 100% 0.0% 2 2 2 4.5%     
  SSLNPILFR                 65 1046.6 
  TLVLLDNLNVR                 47.5 1269.8 
109 TM109_RAT Transmembrane protein 109 (Tmem109) Q6AYQ4 26.2 100% 0.0% 2 2 2 7.4%     
  ESSADILTEIGR                 76.2 1290.7 
  QIEELR                 32.7 787.4 
110 DDB1_RAT DNA damage-binding protein 1 (Ddb1) Q9ESW0 126.9 100% 0.0% 2 2 2 2.2%     
  IGRPSETGIIGIIDPECR                 48.8 1983.0 
  VVEELTR                 42.2 845.5 
111 INSRR_RAT Insulin receptor-related protein (Fragments) (Insrr)  Q64716 144.8 99% 0.0% 1 1 1 1.2%     
  SEVTELR                 30.8 833.4 
112 ATP5I_RAT ATP synthase subunit e, mitochondrial (Atp5i)  P29419 8.3 89% 0.0% 1 1 1 17.0%     
  ELAEAEDVSIFK                 68.4 1579.8 
113 
ODBB_RAT 2-oxoisovalerate dehydrogenase subunit beta, 
mitochondrial (Bckdhb) 
P35738 42.8 85% 0.0% 1 1 1 2.8%     
  LGVSCEVIDLR                 21.2 1203.6 
114 
CNCG_RAT Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic 
phosphodiesterase subunit gamma (Pde6h) 
P61250 9.0 90% 0.0% 1 1 1 7.2%     
  QTRQFK                 23.6 807.4 
115 CLAP2_RAT CLIP-associating protein 2 (Clasp2)  Q99JD4 140.6 90% 0.0% 1 1 1 0.6%     
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  MQTKVIER                 24.8 1004.6 
116 RL38_RAT 60S ribosomal protein L38 (Rpl38) P63174 8.2 89% 0.0% 1 1 1 19.0%     
  KIEEIKDFLLTAR                 33.8 1575.9 
117 CRIP1_RAT Cysteine-rich protein 1 (Crip1) P63255 8.6 89% 0.0% 1 1 1 12.0%     
  GGAESHTFK                 37.4 1162.6 
118 
HBB1_RAT Haemoglobin subunit beta-1 (Hbb) 
HBB2_RAT Haemoglobin subunit beta-2   
P02091 
P11517 
16.0        
16.0 
84% 0.0% 1 1 1 6.8%     
  LLVVYPWTQR                 42.5 1274.7 
119 HS90A_RAT Heat shock protein HSP 90-alpha (Hsp90aa1) P82995 84.8 83% 0.0% 1 1 1 1.0%     
  ALLFVPR                 44.4 815.5 
120 MACOI_RAT Macoilin (Tmem57)  Q4V7D3 76.1 83% 0.0% 1 1 1 1.4%     
  QNISQLEKR                 19.5 1115.6 
121 FUBP2_RAT Far upstream element-binding protein 2 (Khsrp) Q99PF5 74.2 83% 0.0% 1 1 1 1.4%     
  KDAFADAVQR                 32.9 1349.7 
122 CXCR4_RAT C-X-C chemokine receptor type 4 (Cxcr4) O08565 39.3 83% 0.0% 1 1 1 1.7%     
  KLLAEK                 23.4 930.6 
123 CYB5B_RAT Cytochrome b5 type B (Cyb5b)  P04166 16.3 83% 0.0% 1 1 1 23.0%     
  FLSEHPGGEEVLLEQAGADATESFEDVGHSPDAR                 54.6 3596.6 
124 SODC_RAT Superoxide dismutase [Cu-Zn] (Sod1) P07632 15.9 83% 0.0% 1 1 1 9.7%     
  GGNEESTKTGNAGSR                 33.2 1693.8 
125 ATPD_RAT ATP synthase subunit delta, mitochondrial (Atp5d) P35434 17.6 83% 0.0% 1 1 1 11.0%     
  ANLEKAQSELSGAADEAAR                 80.8 2160.1 
126 
AN32A_RAT Acidic leucine-rich nuclear phosphoprotein 32 
family member A (Anp32a)  
P49911 28.6 79% 0.0% 1 1 1 2.4%     
  IYLELR                 33.8 806.5 
127 PHB_RAT Prohibitin (Phb) P67779 29.8 79% 0.0% 1 1 1 4.4%     
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  ILFRPVASQLPR                 32.8 1396.8 
128 DEFI8_RAT Differentially expressed in FDCP 8 homolog (Def8) Q4V8I4 52.7 79% 0.0% 1 1 1 1.1%     
  QTCDK                 25.9 823.4 
129 SNX20_RAT Sorting nexin-20 (Snx20) Q5BK61 35.7 79% 0.0% 1 1 1 3.2%     
  GATLKELTVR                 20.4 1087.6 
130 EMD_RAT Emerin (Emd) Q63190 29.7 79% 0.0% 1 1 1 6.9%     
  RPGTSLVDADDTFHHQVR                 32.9 2051.0 
131 PSME1_RAT Proteasome activator complex subunit 1 (Psme1) Q63797 28.6 79% 0.0% 1 1 1 2.8%     
  IVVLLQR                 45.3 840.6 
132 
CC127_RAT Coiled-coil domain-containing protein 127 
(Ccdc127) 
Q6PEB9 30.5 79% 0.0% 1 1 1 4.2%     
  QNIYCSLILPR                 35.3 1376.7 
133 SRA1_RAT Steroid receptor RNA activator 1 (Sra1) Q6QGW5 25.3 79% 0.0% 1 1 1 4.3%     
  VAAPQDGSPR                 48.8 997.5 
134 
PBIP1_RAT Pre-B-cell leukaemia transcription factor-interacting 
protein 1 (Pbxip1) 
A2VD12 80.3 78% 0.0% 1 1 1 1.1%     
  EKWRGGQR                 23.7 1016.5 
135 
HA11_RAT Class I histocompatibility antigen, Non-RT1.A alpha-
1 chain (RT1-Aw2) 
P15978 36.6 78% 0.0% 1 1 1 2.8%     
  YDSDAENPR                 30.9 1066.4 
136 
GNAS2_RAT Guanine nucleotide-binding protein G(s) subunit 
alpha isoforms short (Gnas)  
GNAS1_RAT Guanine nucleotide-binding protein G(s) subunit 
alpha isoforms XLas (Gnas) 
P63095 
Q63803 
45.7        
122.9 
78% 0.0% 1 1 1 2.5%     
  IEDYFPEFAR                 23.4 1286.6 
137 ARFP2_RAT Arfaptin-2 (Arfip2) Q6AY65 37.8 78% 0.0% 1 1 1 5.0%     
  HPSHSTSPSGPGDEVAR                 55.1 1717.8 
138 RS5_RAT 40S ribosomal protein S5 (Rps5) P24050 22.9 77% 0.0% 1 1 1 6.4%     
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  VNQAIWLLCTGAR                 37.5 1501.8 
139 H4_RAT Histone H4 (Hist1h4b) P62804 11.4 77% 0.0% 1 1 1 7.8%     
  VFLENVIR                 30.1 989.6 
140 CH082_RAT UPF0598 protein C8orf82 homolog Q642A4 24.4 77% 0.0% 1 1 1 5.5%     
  VSYTQGQSPEPR                 64.9 1348.6 
141 DEST_RAT Destrin (Dstn) Q7M0E3 18.5 77% 0.0% 1 1 1 8.5%     
  YALYDASFETKESR                 20.4 1909.0 
142 
OSTC_RAT Oligosaccharyltransferase complex subunit OSTC 
(Ostc) 
B0K025 16.8 76% 0.0% 1 1 1 8.1%     
  VPFLVLECPNLK                 49.6 1428.8 
143 MDHM_RAT Malate dehydrogenase, mitochondrial (Mdh2) P04636 35.7 76% 0.0% 1 1 1 6.5%     
  LTLYDIAHTPGVAADLSHIETR                 56.2 2393.2 
144 AINX_RAT Alpha-internexin (Ina) P23565 56.1 76% 0.0% 1 1 1 1.6%     
  TIEIEGLR                 40.1 930.5 
145 
RPN2_RAT Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 2 (Rpn2) 
P25235 69.1 76% 0.0% 1 1 1 3.6%     
  YHVPVVVVPEGSASDTQEQAILR                 69.9 2494.3 
146 C1TC_RAT C-1-tetrahydrofolate synthase, cytoplasmic (Mthfd1)  P27653 101.0 76% 0.0% 1 1 1 1.4%     
  TDPAALTDDEINR                 63.9 1430.7 
147 DPYL2_RAT Dihydropyrimidinase-related protein 2 (Dpysl2) P47942 62.3 76% 0.0% 1 1 1 4.7%     
  ILDLGITGPEGHVLSRPEEVEAEAVNR                 28.7 2900.5 
148 PUR6_RAT Multifunctional protein ADE2 (Paics)  P51583 47.1 76% 0.0% 1 1 1 4.7%     
  IKAEYEGDGIPTVFVAVAGR                 24.5 2092.1 
149 TBB5_RAT Tubulin beta-5 chain (Tubb5)  P69897 49.7 76% 0.0% 1 1 1 3.6%     
  ISVYYNEATGGKYVPR                 30.3 2046.1 
150 VDAC2_RAT Voltage-dependent anion-selective channel protein P81155 31.7,      76% 0.0% 1 1 1 3.4%     
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2 (Vdac2)                            
VDAC3_RAT Voltage-dependent anion-selective channel protein 
3 (Vdac3) 
Q9R1Z0 30.8 
  LTLSALVDGK                 69.8 1016.6 
151 LIPL_RAT Lipoprotein lipase (Lpl)  Q06000 53.1 76% 0.0% 1 1 1 3.6%     
  LSPDDADFVDVLHTFTR                 57.2 1947.9 
152 
SSRG_RAT Translocon-associated protein subunit gamma 
(Ssr3)  
Q08013 21.1 76% 0.0% 1 1 1 11.0%     
  APKGGSKQQSEEDLLLQDFSR                 29.2 2791.5 
153 
LSAMP_RAT Limbic system-associated membrane protein 
(Lsamp) 
Q62813 37.3 76% 0.0% 1 1 1 4.7%     
  EFEGEEEYLEILGITR                 52.2 1926.9 
154 LYAG_RAT Lysosomal alpha-glucosidase (Gaa) Q6P7A9 106.2 76% 0.0% 1 1 1 1.9%     
  THFPLDVQWNDLDYMDAR                 57.2 2236.0 
155 
VKOR1_RAT Vitamin K epoxide reductase complex subunit 1 
(Vkorc1)  
Q6TEK4 17.8 76% 0.0% 1 1 1 8.1%     
  ALCDVGTAISCSR                 55.8 1409.7 
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Protocol 1: Routine PCR and agarose DNA electrophoresis 
 
Buffers 
6X Orange G gel loading buffer 
100mg Orange G 
30% (v/v) Glycerol  
Adjust with double distilled water (ddH2O) to a final volume of 50 ml. Dispense in 5 ml 
aliquots and store at RT. 
 
Sterile ddH2O  
Sterilise 100 ml by autoclaving, dispense in 5 ml aliquots and store at RT. 
 
50X Tris-Acetate EDTA (TAE) buffer (Severn Biotech Ltd 20-6001-10) 
Dilute 1:50 with ddH2O to obtain a 1X working solution. 
 
Agarose (SIGMA A9539) 
 
Reagents 
5000 U/ml Taq DNA Polymerase with 10X Standard Taq Buffer 1.5 mM MgCl2 (New 
England Biolabs M0273) 
Dispense Taq in 20 µl aliquots and buffer in 100 µl aliquots, store at -20°C.  
 
100 mM Deoxynucleotide (dNTP) Solution Set (New England Biolabs N0446) 
To obtain a 10 mM dNTPs working solution, dilute 1:10 each deoxynucleotide in sterile 
ddH2O to a final volume of 100 µl. Dispense in 20 µl aliquots and store at -20°C. 
 
10 µM PCR primers (forward and reverse) 
Dilute 1:10 from 100 µM in sterile ddH2O or TE buffer, store at -20°C. 
 
GelRed Nucleic Acid Gel Stain, 10000X in water (Biotium 41003) 
GeneRuler 100 bp DNA Ladder (Life Technologies SM0241) 
Dilute ladder and included loading dye 1:6 in ddH2O to obtain a 1X working solution, store 
working solution at RT. 
 
1 kb DNA ladder (New England Biolabs N3232S) 
 
Samples 
DNA samples to be amplified 
 
Materials 
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0.2 ml (individual tubes or strips) or 0.5 ml and 1.5 ml polypropylene tubes 
Pipettes and tips 
Conical flask 
Tray, comb and dams for agarose gels 
Parafilm and Saran wrap 
 
Equipment 
PCR hood 
GS1 Thermal Cycler (G-Storm) 
Eppendorf 5424 microcentrifuge (Eppendorf) 
Microwave oven 
MultiSUB Mini horizontal electrophoresis tank (Cleaver Scientific Ltd) 
Consort E835 electrophoresis power supply (Cleaver Scientific Ltd) 
UVP Ultraviolet Transilluminator 
UVIDOC Gel documentation system 
 
Method 
Defrost all the reagents and samples on ice before starting. Work in the PCR hood, keeping 
all the reagents on ice. 
1. Place the racks, pipettes, tips, tubes, ddH2O and PCR buffer to be used in the PCR 
hood and expose them to UV light for 5-10 min. 
2. Working in the PCR hood, set up the following master mix in a 1.5 µl tube (adjust 
according to the number of samples to be processed, considering a 10% excess): 
Final concentration: Reagent:     
1X    10X Standard Taq Buffer 
0.2 mM   10 mM dNTPs 
0.5 µM   10 µM Forward PCR primer 
0.5 µM   10 µM Reverse PCR primer 
1.25 U per 50 µl  5 U/µl Taq DNA Polymerase 
Adjust with sterile ddH2O to the desired final volume (usually 25-50 µl)  
Mix well by pipetting or vortexing and spin down to remove any drops from the 
tube’s lid. 
3. Dispense the master mix in the PCR tubes (0.2 or 0.5 ml), placing it in the bottom of 
each tube. 
4. Add the appropriate sample to each tube and ddH2O to the negative control. 
5. Close the tubes tightly, mix by vortexing, spin down and place them on the thermal 
cycler. 
6. Run the appropriate PCR program, based on the following example: 
One cycle: 
95°C 2 min 
35 cycles: 
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95°C 15 sec 
(Variable) 15 sec 
68°C 1 min per each 1000 bp of PCR product size 
One cycle: 
68°C 5 min 
10°C Hold  
7. In the meantime, prepare an agarose gel as follows: 
- Mix an appropriate amount of agarose with 40 ml of 1X TAE buffer in a 
conical flask, cover with Saran wrap (make a hole at the centre to allow 
partial evaporation). 
- Heat up in the microwave oven until the agarose is completely dissolved 
(approximately 1:30 min). 
- Add Gel Red to a final concentration of 1X and pour on the gel tray with the 
rubber dams on both sides. Ensure no bubbles are left and place a comb on 
the gel. Let it sit at RT.  
8. Fill the electrophoresis tank with 1X TAE and place the tray with the gel inside, 
making sure that the buffer covers the gel. 
9. Place an appropriate volume of loading dye for each sample in separate drops (1X 
final concentration) on the Parafilm and mix with the desired volume of each PCR 
product.  
10. Load 5 µl of DNA ladder in the first well of the gel and the samples in the rest of the 
wells. 
11. Run the gel at 110 V until the loading dye reaches the bottom of the gel. 
12. Place the gel on the transilluminator and obtain an image using the gel 
documentation system. 
 
Note: 
- To determine the optimum annealing temperature for the primers, carry out a 
gradient PCR starting from 5°C below the lowest predicted annealing temperature 
according to the primer designing software (usually 5-6 samples spanning 10°C is 
enough). Choose the temperature rendering the strongest specific bands and no 
non-specific bands in the agarose gel. 
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Protocol 2. DNA extraction from paraffin-embedded tissues mounted 
on slides 
 
Solutions and reagents 
100%  Histo-Clear (National Diagnostics HS-200), or xylene 
 
100%  Ethanol 
 
Proteinase K (QIAGEN 19131)  
 
DNeasy Blood & Tissue Kit (QIAGEN 69504) 
 
Samples 
Unstained histological slides containing the samples to be extracted, and one H&E-stained 
slide obtained from the same block.  
 
Materials 
Plastic or glass containers 
Slide rack (optional) 
1.5ml polypropylene tubes 
Pipettes and tips 
 
Equipment 
Fume hood (if working with xylene) 
Hybridisation oven 
Hot block 
Eppendorf 5424 microcentrifuge (Eppendorf) 
Vortex 
NanoDrop 1000 spectrophotometer (Thermo Scientific) 
 
Method 
1. Place slides for extraction into a metal/plastic slide rack and place them in the oven 
at 60°C for 5 min.  
2. Verify that the wax is melted and transfer the rack to a container with enough xylene 
to cover the slides. Gently agitate the rack for a few moments, let it to sit for 5 min. 
3. Transfer the rack to a container with enough ethanol to cover the slides. Gently 
agitate the rack for a few moments, then transfer it to another container with ethanol 
and let it to sit for 5 min. 
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4. Transfer the rack to a container with enough ddH2O to cover the slides and 
thoroughly rinse the slides to remove excess ethanol. Transfer the rack to another 
container with ddH2O and let it to sit for 5 min. 
5. Label 1.5 ml according to the identity of the slides and add to each tube 150 µl of 
buffer ATL (from QIAGEN kit) and 30 µl of Proteinase K.  
6. Identify the area of interest on each slide to be extracted (use a marked H&E-
stained slide as a guide) and, using a pipette tip or a scalpel, scrape from the slide 
the relevant tissue and transfer it to the corresponding tube with ATL 
buffer/proteinase K. If necessary, pipette a little amount of the ATL buffer/proteinase 
K on the surface of the slide to facilitate the removal of the tissue.  
7. Incubate the tubes at 56°C overnight. 
8. Incubate at 90°C for 1 h. If using only one heating block, keep the sample at RT until 
the heating block has reached 90°C. 
9. Briefly centrifuge the tube to remove drops from the inside of the lid. 
10. Add 200 µl buffer AL and mix thoroughly by vortexing. Then add 200 µl ethanol (96-
100%) and mix thoroughly again by vortexing or pipetting. 
It is essential that the sample, buffer AL and ethanol are mixed immediately and 
thoroughly by vortexing or pipetting to yield a homogeneous solution. Buffer AL and 
ethanol can be premixed and added together in one step to save time when 
processing multiple samples. A white precipitate may form on addition of buffer AL 
and ethanol. This precipitate does not interfere with the procedure. 
11. Transfer the entire sample to a QIAamp MinElute spin column placed in a 2 ml 
collection tube. Close the lid gently and centrifuge for 1 min at 16000 g to wash the 
spin column membrane. Discard the flow-through. If the sample has not completely 
passed through the membrane after centrifugation, centrifuge again until the spin 
column is empty. 
12. Place the spin column in a new 2 ml collection tube. Add 500 µl of buffer AW1 to the 
spin column. Close the lid gently and centrifuge for 1 min at 16000 g to wash the 
spin column membrane. Discard the flow-through. Reuse the collection tube in the 
next step. 
13. Add 500 µl of buffer AW2 to the spin column. Close the lid gently and centrifuge for 
1 min at 16000 g to wash the spin column membrane. Discard the flow-through. 
Reuse the collection tube in the next step. 
14. Place the spin column in a new 2 ml collection tube. Centrifuge at 16000 g for 3 min. 
Discard the collection tube with the flow-through. 
15. Place the spin column in a new 1.5 ml tube and add 55 µl of buffer ATE. Close the 
lid and incubate for 1 min at 16000 g. Add 50 µl of buffer ATE and centrifuge again. 
16. Verify DNA concentration using a NanoDrop spectrophotometer and store at -20°C. 
 
Notes: 
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- If a precipitate is noted in buffer ATL, mix well and incubate at 56°C for a few min 
before use. 
- If using xylene, incubations and washes should be done in the fume hood.  
- Buffers AW1 and AW2 are supplied as concentrates. Ensure that ethanol is added 
before use, as indicated by the manufacturer. 
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Protocol 3: Preparation of calcium competent E. coli 
 
Solutions and media 
1X LB broth 
20 g LB broth powder (SIGMA L3022)  
Adjust with ddH2O to a final volume of 1 l 
Dilute the powder in the water and dispense in 250 ml aliquots. Sterilise by autoclaving, 
store at RT.  
 
1X LB agar 
20 g  LB broth powder (SIGMA L3022)  
12 g Bacteriological agar powder (SIGMA A5306) 
Adjust with ddH2O to a final volume of 1 l 
Dilute the powder in the water and dispense in 250 ml aliquots. Sterilise by autoclaving and 
store at RT. To prepare agar plates, heat up the agar in the microwave until melted 
(approximately 4min at high power), cool down in water to approximately 40°C, add the 
appropriate antibiotic and pour in Petri dishes (25-30 ml per dish) under sterile conditions 
(use Bunsen’s burner). Leave open until the agar has solidified, close and seal with Parafilm, 
label appropriately and store upside down at 4°C. 
 
0.1M CaCl2 
Adjust with ddH2O to a final volume of 1 l 
Autoclave and store in the fridge or keep at RT and chill on ice before use. 
 
0.1M CaCl2 + 15% (v/v) glycerol 
Prepare 500 ml, using sterile 0.1M CaCl2 and glycerol. Store in the fridge or keep at RT and 
chill on ice before use.   
 
Bacterial strain 
Glycerol stock (LB broth + 15% [v/v] glycerol) of E. coli strain of preference, stored at -80°C. 
 
Materials 
Sterile cryotubes or 1.5ml polypropylene tubes 
15 ml polypropylene 
Petri dishes 
500 ml conical flask, sterile 
Pipettes and tips 
Pipette controller and disposable serological pipettes 
Glass loops 
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Equipment 
Bunsen’s burner 
Incubator for bacterial plates 
Shaking incubator 
NanoDrop 1000 spectrophotometer (Thermo Scientific) or cuvette spectrophotometer 
Heraeus Multifuge 3SR Plus (Thermo Scientific) 
 
Method 
1. Plate a small amount of bacteria from the glycerol stock (~5 µl or a drop taken with 
the loop) on an LB agar plate and incubate overnight at 37°C. 
2. Inoculate one colony from the LB agar plate into 2-3 ml of LB broth in a 15 ml tube. 
Incubate overnight at 37°C/250 rpm.  
3. Inoculate 1 ml of the overnight cell culture into a conical flask with 100 ml of LB 
broth. Read the OD600 in a spectrophotometer. Incubate for 1 h at 37°C/250 rpm. 
4.  Read the OD600 every 15-30 min until it reaches ~0.25-0.3 (it usually takes1.5-2 h). 
5. Chill the culture on ice for 15 min.  
6. Centrifuge the cells for 10 min at 3300 g/4°C. 
7. Discard the medium and resuspend the cell pellet in 30-40 ml of cold 0.1M CaCl2 
(20 ml per 50 ml culture if using conical tubes). Resuspend using a serological 
pipette, do not vortex. 
8. Incubate the cells on ice for 30 min. Centrifuge the cells as above. 
9. Remove the supernatant, and resuspend the cell pellet in 6 ml 0.1M CaCl2 + 15% 
glycerol. 
- 3 ml per 50 ml culture if using conical tubes. 
- If preparing using multiple Falcon tubes, once the 3 ml is added, pool all the 
samples together and mix well using the serological pipette, so that all the 
aliquots will have the same transformation efficiency when tested. 
10. Label and chill cryotubes or 1.5 ml tubes at -80°C. 
11. Pipette 400-500 µl of the cell suspension into the chilled tubes. Freeze these tubes 
on dry ice and then transfer them to -80°C freezer.  
- If using many tubes, take six out from the freezer at a time, keep them on ice 
and aliquot out. Once filled, immediately place them at -80°C, preferably on the 
ice to speed up the freezing, or alternatively use dry ice. 
Notes: 
- Open tubes or plates with bacteria only under sterile conditions (Bunsen’s burner). 
- The agar plate with bacteria can be taken out from the incubator in the morning and 
kept in the fridge (sealed with Parafilm), so the colonies can be isolated in the 
afternoon and incubated overnight. 
- Preferably, isolate two or more colonies, in case some of them do not grow. 
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- If using a NanoDrop for reading the OD600, it is important to note that Beer 
Lamberts law uses a light path length of 1cm, but the NanoDrop is 1mm.To account 
for this, an OD600 of ~0.025-0.03 should be used instead. 
- All the steps after harvesting the cells should be done on ice (or at 4°C). 
- The transformation efficiency is about 1-5x10
6
/µl DNA when using the competent 
cells prepared with this method. 
- The frozen competent cells are stable for 6 months, but once a tube is taken from 
the freezer and thawed, any unused portion should be discarded (it can be reused, 
but the transfection efficiency will be lower). 
- After the competent cells are made, the transformation efficiency should be checked 
by transformation using plasmid DNA of known concentration, using the formula: 
 
Transformation efficiency =  total no. of colonies on plate 
Amount of DNA plated (µg/ml) 
 
Reference: 
Ausubel FM. Current protocols in Molecular Biology. John Wiley & Sons, 1998. Protocol 1.8.2. 
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Protocol 4: Transformation of calcium competent E. coli 
 
Reagents, solutions and media 
1X LB broth 
20 g LB broth powder (SIGMA L3022)  
Adjust with ddH2O to a final volume of 1 l 
Dilute the powder in the water and dispense in 250 ml aliquots. Sterilise by autoclaving and 
store at RT. Once antibiotic has been added, store at 4°C. 
 
1X LB agar 
20 g  LB broth powder (SIGMA L3022)  
12 g Bacteriological agar powder (SIGMA A5306) 
Adjust with ddH2O to a final volume of 1 l 
Dilute the powder in the water and dispense in 250 ml aliquots. Sterilise by autoclaving and 
store at RT. To prepare agar plates, heat up the agar in the microwave until melted 
(approximately 4min at high power), cool down in water to approximately 40°C, add the 
appropriate antibiotic and pour in Petri dishes (25-30 ml per dish) under sterile conditions 
(use Bunsen’s burner). Leave open until the agar has solidified, close and seal with Parafilm, 
label appropriately and store upside down at 4°C. 
 
SOC medium 
2%(w/v)  Tryptone 
0.5%(w/v)  Yeast extract 
10 mM  NaCl (dilute from 1 M stock) 
2.5 mM  KCl (dilute from 250 mM stock) 
10 mM  MgCl2 (dilute from 2 M stock)  
20 mM  Glucose (dilute from 1 M stock)  
Adjust with ddH2O to a final volume of 50 ml 
Dissolve the first four reagents in water and sterilise by autoclaving, then add sterile MgCl2 
and glucose. Dispense in 1 ml aliquots and store at -20°C. 
 
Antibiotics (stock solutions): 
100 mg/ml ampicillin 
1 g Ampicillin sodium salt (SIGMA A0166) 
Adjust with ddH2O to a final volume of 10 ml  
50 mg/ml kanamycin 
0.5 g Kanamycin B sulfate salt (SIGMA B5264) 
Adjust with ddH2O to a final volume of 10 ml 
Dispense in 1 ml aliquots and store at 20°C or at 4°C for a short term. These solutions are to 
be used at a 1:1000 dilution in the media. 
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Bacterial strain 
Calcium competent E. coli strain of preference, according to the experimental purpose. 
 
Plasmids 
10-500 ng of DNA of the plasmid of interest 
 
Materials 
1.5 ml polypropylene tubes 
Pipettes and tips 
Glass loops 
 
Equipment 
Bunsen’s burner 
Water bath 
Shaking incubator 
Incubator for bacterial plates 
 
Method 
Pre-heat one LB agar plate and one aliquot of SOC medium at 37°C before starting. 
1. Defrost on ice an aliquot (400-500 µl) of calcium competent cells (stored at -80°C) 
and add 10-500 ng of DNA of the plasmid of interest (DNA should not surpass 10% 
of the volume of bacteria) and mix by swirling the tube gently for a few sec. Incubate 
for 30 min on ice.  
2. Heat-shock the bacteria at 42°C for 45 sec in a water bath.  
3. Incubate the bacteria for 2 min on ice. 
4. Add 1 ml of SOC medium and incubate for 1 h at 37°C in agitation. 
5. Centrifuge the bacteria for 2 min at 16000 g. Discard the supernatant, leaving 
approximately 50 µl plus the bacterial pellet. 
6. Re-suspend the pellet in the remaining supernatant and plate on the LB agar plate, 
using the glass loop, under sterile conditions (Bunsen’s burner).  
7. Incubate overnight at 37°and select colonies by PCR or miniprep analysis.  
Note: 
- Open tubes or plates with bacteria always under sterile conditions (Bunsen’s 
burner). 
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Protocol 5: Extraction of plasmid DNA from small-scale bacterial 
cultures (miniprep) 
 
Reagents 
QIAprep Spin Miniprep Kit (QIAGEN 27106)  
Buffer P1 should be kept at 4°C, rest of the kit should be kept at RT. 
 
Bacteria 
5-10 ml bacterial cell culture 
 
Materials 
1.5 ml polypropylene tubes 
Pipettes and tips 
 
Equipment 
Heraeus Multifuge 3SR Plus (Thermo Scientific) 
Eppendorf 5424 microcentrifuge (Eppendorf) 
NanoDrop 1000 spectrophotometer (Thermo Scientific) 
 
Method 
1. Centrifuge the bacterial cell culture for 10 min at 4000 g/RT, discard the 
supernatant. 
2. Re-suspend the bacterial pellet in 250 μl of buffer P1 (resuspension buffer) for each 
5 ml of bacterial culture and transfer to an Eppendorf tube for each 5 ml of bacterial 
culture. 
3. Add 250 μl of buffer P2 (lysis buffer) to each tube and mix thoroughly by inverting 
the tube 4-6 times until the solution becomes clear. Do not allow the lysis reaction to 
proceed for more than 5 min. If LyseBlue reagent has been added to buffer P1, the 
solution will turn blue. 
4. Add 350 μl of buffer N3 (neutralisation buffer) to each tube and mix immediately and 
thoroughly by inverting the tube 4-6 times. If LyseBlue reagent has been added to 
buffer P1, the solution will turn colourless. 
5. Centrifuge for 10 min at 13000 g. 
6. Apply the supernatant from one of the tubes from step 5 to the QIAprep spin column 
assembled into a collection tube by decanting or pipetting. Centrifuge for 1 min at 
13000 rpm and discard the flow-through. If more than 5 ml of bacterial culture are 
being processed, apply the supernatant from the second Eppendorf tube to the 
column and repeat this step. Replace the collection tube.  
7. Wash the QIAprep spin column by adding 750 μl of buffer PE, centrifuge for 1 min at 
13000 rpm and discard the flow-through. Replace the collection tube. 
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8. Centrifuge for 3 min at 13000rpm to remove residual washing buffer. Discard the 
collection tube 
9. Place the QIAprep column into a clean Eppendorf tube. To elute DNA, add 100 μl of 
buffer EB (elution buffer) to the centre of the QIAprep spin column, let stand for 1 
min, and centrifuge for 1 min at 13000 rpm. 
10. Optional: repeat the previous step (plasmid concentration can be verified before). 
11. Verify plasmid DNA concentration using a NanoDrop spectrophotometer and store 
at -20°C.  
 
References: 
This is a modification of the protocol provided by the kit’s manufacturer.  
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Protocol 6: Site-directed mutagenesis 
 
Reagents and media 
QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies 200521) 
XL10-Gold Ultracompetent Cells should be kept at -80°C, rest of the kit should be kept at -
20°C. Defrost on ice before use. 
 
Sterile ddH2O 
 
1X LB broth 
20 g LB broth powder (SIGMA L3022)  
Adjust with ddH2O to a final volume of 1 l 
Dilute the powder in the water and dispense in 250 ml aliquots. Sterilise by autoclaving and 
store at RT. Once antibiotic has been added, store at 4°C. 
 
1X LB agar 
20 g  LB broth powder (SIGMA L3022)  
12 g Bacteriological agar powder (SIGMA A5306) 
Adjust with ddH2O to a final volume of 1 l 
Dilute the powder in the water in dispense in 250 ml aliquots. Sterilise by autoclaving and 
store at RT. To prepare agar plates, heat up the agar in the microwave until melted 
(approximately 4 min at high power), cool down in water to approximately 40°C, add the 
appropriate antibiotic and pour in Petri dishes (25-30 ml per dish) under sterile conditions 
(use Bunsen’s burner). Leave open until the agar has solidified, close and seal with Parafilm, 
label appropriately and store upside down at 4°C. 
 
NZY
+
 broth 
1%(w/v) NZ amine 
0.5% (w/v) Yeast extract 
0.5% (w/v) NaCl 
12.5 mM MgCl2 (dilute from 2 M stock)  
12.5 mM MgSO4 (dilute from 2 M stock)  
20 mM  Glucose (dilute from 1 M stock)  
Adjust with ddH2O to a final volume of 50 ml 
Dissolve the first four reagents in water, adjust the pH to 7.5 with NaOH and sterilise by 
autoclaving, then add sterile MgCl2, MgSO4 and glucose. Dispense in 1 ml aliquots and store 
at -20°C. 
 
100 mg/ml ampicillin 
1 g Ampicillin sodium salt (SIGMA A0166) 
Adjust with ddH2O to a final volume of 10 ml  
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Dispense in 1 ml aliquots and store at 20°C or at 4°C for a short term. Use at a 1:1000 
dilution in the media. 
 
Plasmids 
10 ng of plasmid to be mutagenised 
 
Materials 
0.2 ml and 1.5 ml polypropylene tubes 
Pipettes and tips 
Glass loops 
 
Equipment 
PCR hood 
GS1 Thermal Cycler (G-Storm) 
Eppendorf 5424 microcentrifuge (Eppendorf) 
Bunsen’s burner 
Water bath 
Shaking incubator 
Incubator for bacterial plates 
 
Method: 
Defrost all the reagents and samples on ice before starting.  
1. Place the racks, pipettes, tips, tubes ddH2O and PCR buffer to be used in the PCR 
hood and expose them to UV light for 5-10 min. 
2. Working in the PCR hood, set up the following reaction: 
5 µl    10X reaction buffer 
10 ng  Plasmid to be mutagenised 
125 ng Forward primer 
125 ng Reverse primer 
1 µl  dNTP mix 
3 µl  QuikSolution reagent 
Adjust with sterile ddH2O to a final volume of 50 µl  
Then add 1 µl of 2.5U/µl PfuUltra HF DNA polymerase 
3. Place the tube into the thermal cycler and cycle using the following program: 
One cycle: 
95°C 1 min 
18 cycles: 
95°C 30 sec 
60°C 50 sec 
68°C 1 min/kb of plasmid length 
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One cycle: 
68°C 7 min 
4. Add 1 µl of DpnI restriction enzyme (10 U/µl). Gently and thoroughly mix the 
reaction, spin down in a microcentrifuge for 1 min, immediately place the tube back 
in the thermal cycler and incubate at 37°C for 1 h. 
5. Thaw the XL10-Gold Ultracompetent Cells on ice and transfer a 45 µl aliquot to a 
pre-chilled 1.5 ml Eppendorf tube. 
6. Add 2 µl of the β-mercaptoethanol mix included in the kit, swirl the tube gently and 
incubate on ice for 10 min, swirling every 2 min. 
7.  Add 2 µl of the DpnI-treated DNA to the cells, swirl the tube gently and incubate on 
ice for 30 min. 
8. Pre-heat NZY
+
 broth at 42°C in a water bath. 
9. Heat-pulse the reaction tube in a 42°C water bath for 30 sec. 
10. Incubate on ice for 2 min. 
11. Add 500 µl of pre-heated NZY
+
 broth and incubate for 1 h at 37°C/250 rpm. 
12. Centrifuge for 2 min at 13000 g, discard the supernatant, leaving approximately 50-
100 µl. 
13. Resuspend the pellet in the remaining supernatant and plate on a LB agar plate with 
100 µg/ml ampicillin. 
14. Incubate overnight at 37°C, select 1-3 colonies and grow them overnight at 
37°C/250 rpm in LB broth with 100 µg/ml ampicillin.  
15. Extract plasmid DNA (Protocol 5), and send for sequencing. 
References: 
This is a summarised version of the protocol provided by the kit’s manufacturer. 
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Protocol 7: Extraction of plasmid DNA from large-scale bacterial 
cultures (maxiprep) 
 
Reagents 
GenElute™ HP Plasmid Maxiprep Kit (SIGMA NA0310-1KT) 
Resuspension/RNase A and neutralization solutions should be kept at 4°C, rest of the kit 
should be kept at RT 
 
Bacteria 
200-250 ml bacterial cell culture 
 
Materials 
1.5 ml and 50 ml polypropylene tubes 
Pipettes and tips 
Pipette controller and disposable serological pipettes 
 
Equipment 
Heraeus Multifuge 3SR Plus (Thermo Scientific) 
Eppendorf 5424 microcentrifuge (Eppendorf) 
NanoDrop 1000 spectrophotometer (Thermo Scientific) 
 
Method 
1. Transfer the bacterial cell culture to 50 ml tubes and centrifuge for 10 min at 4000 
g/RT, discard the supernatant. Frozen bacterial pellets (kept at -80°C) can be used 
instead. 
2. Resuspend the bacterial pellet(s) in a total of 12 ml of resuspension/RNase A 
solution by vortexing or pipetting, pool all the resuspended pellets together in one 50 
ml tube. 
3. Add 12 ml of lysis solution and gently invert the tube 6-8 times. Let the mixture to sit 
3-5 min. 
4. In the meantime, prepare a filter syringe by removing the plunger and placing the 
barrel in a rack so that the syringe barrel is upright (a 1 l conical tube can be used if 
there is an appropriate rack is not available). 
5. Add 12 ml of chilled neutralisation solution and gently invert the tube 4-6 times. 
6. Add 9 ml of binding solution and invert 1-2 times. Immediately pour into the barrel of 
the filter syringe. Allow the lysate to sit for 5 min. 
7. In the meantime, place a GenElute HP Maxiprep binding column into a 50 ml 
collection tube (included in the kit). Add 12 ml of the of the column preparation 
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solution to the column and centrifuge for 2 min at 3000 g/RT. Discard the flow-
through. 
8. Hold the filter syringe barrel over the binding column and gently apply pressure to 
the plunger to expel half of the cleared lysate into the column. Pull back slightly on 
the plunger to stop the flow of the remaining lysate. Centrifuge for 2 min at 3000 
g/RT. Discard the flow-through. Add the rest of the cleared lysate to the column and 
centrifuge again. 
9. Add 12 ml of wash solution 1 and centrifuge for 2 min at 3000 g/RT. Discard the 
flow-through. 
10. Add 12 ml of wash solution 2 and centrifuge for 5 min at 3000 g/RT. Discard the 
flow-through. 
11. Transfer the binding column to a clean 50 ml tube (included in the kit). Add 3 ml of 
elution solution and centrifuge for 3 min at 3000 g/RT.  
12. Optional: apply the eluate from the previous step back into the column and 
centrifuge again (plasmid concentration can be verified before). 
13. Verify plasmid DNA concentration using a NanoDrop spectrophotometer, dispense 
in 1 ml aliquots and store at -20°C. 
References: 
This is a summarised version of the protocol provided by the kit’s manufacturer. 
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Protocol 8: Polyacrylamide gel electrophoresis 
 
Buffers and solutions 
20X 2-(N-Morpholino)ethanesulfonic acid (MES) electrophoresis buffer (stock 
solution) 
1M   MES hydrate (SIGMA M8250)  
1M   Tris base 
69.3mM  Sodium dodecyl sulfate (SDS, 2% w/v)  
20.5mM  EDTA free acid 
Adjust with ddH2O to a final volume of 1 l 
SDS is easier to dissolve if using a hot plate. Sterilisation not needed, store at RT. Do not 
adjust pH: the final pH of this 20X stock will be 7.1, and 7.3 when diluted to 1X. Dilute 
accordingly with ddH2O to obtain a 1X working solution.   
 
6X SDS gel loading buffer   
300 mM  Tris-Cl pH 6.8 (dilute from 1M stock) 
600 mM  Dihidrothreitol (DTT) 
12% w/v  SDS 
0.6% w/v  Bromophenol blue 
60% v/v  Glycerol 
Adjust with ddH2O to a final volume of 50 ml 
SDS is easier to dissolve if using a hot plate. Sterilise by filtration. Dispense in 1 ml aliquots 
and store at -20°C.  
 
Reagents 
Novex® Sharp Pre-stained Protein Standard (Life Technologies LC5800) or Kaleidoscope™ 
Prestained Standards (BIO-RAD 161-0324) 
 
Materials 
0.2 (strips) or 1.5 polypropylene tubes 
Pipettes and tips, including long gel loading tips 
NuPAGE® Novex® 4-12% Bis-Tris Protein Gels, 1.0 mm, 10-well (Life Technologies 
NP0321BOX) or 15-well (Life Technologies NP0323BOX) 
 
Equipment 
Vortex 
Hot block (set at 95°C) or GS1 Thermal Cycler (G-Storm) 
BR4i refrigerated centrifuge (Jouan) or Eppendorf 5424 microcentrifuge (Eppendorf) 
XCell SureLock™ Mini-Cell Electrophoresis System (Life Technologies) 
Consort E835 electrophoresis power supply (Cleaver Scientific Ltd) 
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Method 
1. Combine the desired amount of protein with an appropriate volume of 6X gel loading 
buffer (to a final concentration of 1X) in 0.2 or 1.5 ml polypropylene tubes. Mix well 
by pipetting or vortexing. 
2. Denature the samples at 95°C for 5 min on a hot block or thermal cycler and spin 
them down.  
3. Assemble the electrophoresis tank. Remove the sealing tape from the bottom of one 
or two gels and place them into the buffer core of the tank with the printed side 
facing out and lock the gel tension wedge. 
4. Fill both chambers of the tank with 1X MES and carefully remove the combs from 
the gels. 
5. Using gel loading tips, load 6-10 µl of molecular weight marker in the first well and 
the samples in the next wells.  
6. Connect the tanks to the power supply and run the gels at 120 V (for 15-well gels) or 
150 V (for 10-well gels) until the blue loading buffer reaches the bottom of the gel 
(~1:15-1:35 h). 
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Protocol 9: Coomassie staining of polyacrylamide gels 
 
Solutions 
Staining solution 
50% (v/v)  Methanol  
10% (v/v)  Glacial acetic acid 
0.25% (w/v)  Coomassie brilliant blue R-250 
Adjust with ddH2O to a final volume of 1 l 
Filter using a Whatman No.1 filter. Store at RT. 
 
Destaining solution 
40% (v/v)  Methanol  
10% (v/v)  Glacial acetic acid 
Adjust with ddH2O to a final volume of 1 l 
Store at RT 
 
20% (v/v) glycerol in ddH2O (optional) 
 
Material 
Spatula 
Plastic or glass containers 
 
Equipment 
Shaking platform 
Odyssey
®
 Infrared Imaging System (LI-COR) 
 
Method 
1. After electrophoresis, take out the polyacrylamide gel from the tank and carefully 
remove it from the glass or plastic cassette. 
2. Immerse the gel in a container with at least 5 volumes of destaining solution (or 
enough volume to completely cover the gel) and incubate for 10 min on a shaking 
platform at low speed at RT. 
3. Remove the destaining solution and save it for future use. Add at least 5 volumes of 
staining solution (or enough volume to completely cover the gel) and place it back 
on the shaking platform. Incubate for at least 4 h at RT. 
4. Remove the stain and save it for future use. Destain the gel by soaking it in 
destaining solution for 4-8 h, changing the destaining solution 3-4 times, until the 
protein bands are seen without background staining. 
5. Scan the gel in an Odyssey infrared imager, using the “protein gel” option at 700 nm 
(place the stained gel directly on the surface of the scanner). 
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6. If desired, keep the gel in 20% (v/v) glycerol in ddH2O at 4°C in a sealed bag.  
 
Reference: 
Sambrook J, Russell DV. Molecular Cloning: A Laboratory Manual. CSHL Press, 2001. Vol.3, A8.46-47. 
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Protocol 10: Production and purification of GST-tagged proteins 
 
Buffers, solutions and media: 
1X LB broth with 100 µg/ml ampicillin 
20 g LB broth powder (SIGMA L3022)  
Adjust with ddH2O to a final volume of 1 l 
Dilute the powder in the water and dispense in 250 ml aliquots. Sterilise by autoclaving and 
store at RT. Add 1 ml of 100 mg/ml ampicillin before use. Once antibiotic has been added, 
store at 4°C. 
 
1X LB agar with 100 µg/ml ampicillin 
20 g LB broth powder (SIGMA L3022) 
12 g Bacteriological agar powder (SIGMA A5306)  
Adjust with ddH2O to a final volume of 1 l 
Dilute the powder in the water in dispense in 250 ml aliquots. Sterilise by autoclaving and 
store at RT. To prepare agar plates, heat up the agar in the microwave until it is melted 
(approximately 4 min at high power), cool down in water to approximately 40°C, add 1 ml of 
100 mg/ml ampicillin and pour in Petri dishes (25-30 ml per dish) in sterile conditions (use 
Bunsen’s burner). Leave open until the agar has solidified, close and seal with Parafilm, 
label appropriately and store at 4°C. 
 
1X SOC medium 
2%(w/v)  Tryptone 
0.5%(w/v)  Yeast extract 
10 mM  NaCl (dilute from 1 M stock) 
2.5 mM  KCl (dilute from 250 mM stock) 
10 mM  MgCl2 (dilute from 2 M stock)  
20 mM  Glucose (dilute from 1 M stock)  
Adjust with ddH2O to a final volume of 50 ml 
Dissolve the first four reagents in water and sterilise by autoclaving, then add sterile MgCl2 
and glucose. Dispense in 1 ml aliquots and store at -20°C. 
 
Buffer A 
100 mM  NaCl 
20 mM  Tris-HCl pH 7.5 
Adjust with ddH2O to a final volume of 2 l 
Sterilise by filtration, store at RT. 
 
Buffer B 
20 mM  Reduced glutathione in buffer A 
Adjust with ddH2O to a final volume of 50 ml 
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Adjust pH to 7.5 with NaOH. Prepare fresh before use.  
 
6M Urea in ddH2O 
Adjust with ddH2O to a final volume of 1 l 
Sterilise by filtration, store at RT. 
 
1M IPTG (Promega V3951) in ddH2O  
Adjust with ddH2O to a final volume of 50 ml 
Sterilise by filtration, dispense in 1 ml aliquots and store at -20°C. 
 
100% glycerol 
 
Reagents: 
100 mg/ml Ampicillin 
1 g  Ampicillin sodium salt (SIGMA A0166) 
Adjust with ddH2O to a final volume of 10 ml 
 
Complete® Protease Inhibitor Cocktail tablets (Roche 11836145001) 
Glutathione Sepharose 4 Fast Flow (GE Healthcare 17-5132-02) 
 
Bacterial strain 
Calcium competent BL21-PLyss E. coli 
 
Plasmids 
pTHREE-E (A. Oliver, University of Sussex) containing CDS for WT AIP and variants (10-
500 ng) 
 
Materials 
1.5, 15 and 50 ml polypropylene tubes 
Cryotubes 
Pipettes and tips 
Pipette controller and disposable serological pipettes 
Glass or plastic loops 
Petri dishes 
3 l glass conical flasks 
1 l round bottom plastic centrifuge tubes 
Econo-Column® Chromatography Column, 2.5 × 10 cm (BIO-RAD 737-2512)  
Vivaspin 20 (50000 MWCO) (Sartorius VS2032) centrifugal concentrators 
10 ml syringes and needles 
96-well, 2.2 ml plastic fraction collection block  
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Equipment 
Bunsen’s burner 
Water bath 
Shaking incubator 
Incubator for bacterial plates 
Spectrophotometer 
Centrifuge for 1 l tubes 
Vortex 
Sonicator 
Refrigerated centrifuge for 15 and 50 ml tubes 
Roller Mixer 
HiPrep 26/60 Sephacryl S-200 HR gel filtration chromatography column (GE Healthcare 17-
1195-01) 
ÄKTA Prime chromatography equipment (GE Healthcare) 
NanoDrop 1000 spectrophotometer (Thermo Scientific) 
 
Method: 
1. Prime the gel filtration chromatography equipment with buffer A, avoiding air to enter 
into the equipment.  
2. Place the gravity flow column upright on a support in the cold room. Pour ~20 ml of 
GST agarose into the column and wash it several times with buffer A, until agarose 
becomes a compact material at the bottom (let the buffer flow through by gravity). 
Lock the bottom of the column and store at 4°C until use, properly hydrated with 
buffer A. 
Glutathione agarose is a 50% solution in ethanol. The final volume of agarose will 
be ~10 ml. 
3. Transform one aliquot of BL21-PLyss cells with each of the plasmids carrying AIP 
mutations (see Protocol 4). Plate the total volume of the transformation reaction, 
divided in three LB agar plates with ampicillin. Incubate overnight at 37°C. 
4. Prepare three conical flasks with 1 l LB broth with 100 µg/ml ampicillin per plasmid 
to be grown and incubate overnight at 37°C without agitation. 
5. Harvest all the colonies by scraping the three plates and dissolving the bacteria in 
15 ml of LB broth with 100 µg/ml ampicillin. 
6. Verify that the flasks with medium remain clear and add fresh ampicillin (same 
amount than before). 
7. Inoculate each flask with 5 ml of bacteria, incubate them at 37°C/250 rpm and 
measure OD600 until it reaches 0.6-0.8 (OD600 is expected to double approximately 
every 20 min). Add 1M IPTG to a final concentration of 1mM and incubate at 
20°C/250 rpm overnight. 
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8. Transfer the cultures to 500 ml tubes and centrifuge at 4500 g for 12 min. Transfer 
bacterial pellets to 50 ml tubes containing one tablet of protease inhibitor cocktail, 
dissolved in 35 ml of buffer A and resuspend by vortexing. 
Pellets can be stored at -80°C if planned to be used later. 
9. To sonicate the bacteria, place the tube in a glass with ice (to avoid overheating) 
and perform 5 sec pulses with 10 sec pauses, for 3 min total time (40% power, 
frequency 50 Hz) twice. Save a sample for PAGE. 
10. Centrifuge the bacteria for 1 h at 20000 rpm/4°C. Transfer cleared lysates to new 
tubes and save a sample for PAGE. 
11. Pour cleared lysate into the column with glutathione agarose and mix it on a roller 
for 30 min at 4°C. 
12. Place the column upright on a support in the cold room and let the lysate flow 
through the column by gravity. Save a sample of the flow-through for PAGE. 
If the volume of cleared lysate surpasses the capacity of the column, once the flow-
through has passed, close the end of the column, add the rest of the lysate and 
repeat steps 11 and 12.   
13. Wash the glutathione sepharose with three volumes of buffer A by gravity, ensuring 
not to leave it dry in the cold room. 
14. Elute the protein with 20 ml of buffer B by gravity, in the cold room. 
Glutathione sepharose can be regenerated by incubation with 6M urea. 
15. Transfer the eluate into a concentrator and centrifuge at 4000 rpm/4°C until 
concentrated to a final volume of ~10 ml.  
Centrifuge the concentrator with ddH2O to hydrate the membrane before use. 
16. Recover the concentrated sample with a 10 ml syringe, avoiding bubble formation. 
17. Load the sample in the gel filtration chromatography equipment using the following 
parameters: flow 3 ml/min, pressure <0.7 mPa.  
18. Let the first 100 ml flow through (dead volume). Collect 1.8 ml samples following the 
chromatography curves, until no peaks are observed. 
19. Analyse 10 µl of each fraction and 10 µl of each of the samples collected in previous 
steps by PAGE-Coomassie staining (see Protocol 8 and Protocol 9). Store the 
purified fractions in the fridge until the Coomassie-stained gel has been analysed. 
20. Pool the fractions containing the expected protein into a concentrator and centrifuge 
as before, until a 1 mg/ml concentration is reached (measure the sample every 15-
20 min using the protein A280 function in the NanoDrop).  
Centrifuge the concentrator with ddH2O to hydrate the membrane before use. 
21. Add glycerol to a final concentration of 5% and dispense the purified protein in 1 ml 
aliquots in 1.5 ml tubes or cryotubes, previously labelled, transfer immediately to dry 
ice for fast freezing and store at -80°C. 
Reference: 
Protocol provided by M. Morgan, Molecular Chaperones/Structural Biology Group, Genome Damage and Stability 
Centre, University of Sussex. 
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Protocol 11: Western blotting 
  
Buffers 
Transfer buffer 
25mM Tris base 
190 mM Glycine 
20% (v/v) Methanol 
Adjust with ddH2O to a final volume of 1 l 
Dissolve tris and glycine in ddH2O, then add methanol. Store at RT. 
 
Washing buffer  
0.1%  (v/v)  Tween 20  
Adjust with 1X sterile PBS to a final volume of 1 l 
Store at RT. 
 
Blocking buffer 
5% (w/v)  Semi-skimmed milk in washing buffer 
Adjust with ddH2O to a final volume of 50 ml 
Preferably prepare fresh, but it can be stored at 4°C for a few days. 
 
1X PBS 
Adjust with ddH2O to a final volume of 1 l 
Sterilise by autoclaving and store at RT. 
 
Reagents 
Primary and secondary antibodies, according to the experimental conditions. 
 
Materials 
50 ml polypropylene tubes 
Protran BA85 nitrocellulose membrane 0.45 μm (GE Healthcare 10402594) 
BIO-RAD extra thick blot paper, 7.5X10 cm (BIO-RAD 170-3965) 
Cut one 7.5X9 cm rectangle for each mini-gel to be transferred.  
Plastic or glass containers 
Roller 
Spatula 
 
Equipment 
Semi-dry blotter SD10 (Cleaver Scientific Ltd) 
Consort E835 electrophoresis power supply (Cleaver Scientific Ltd) 
Roller Mixer SRT6 (Stuart) 
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Odyssey
®
 Infrared Imaging System (LI-COR) 
 
Method 
1. Cut the upper right corner of the membrane in diagonal and soak it in transfer buffer 
for at least 15 min (alternatively, leave it in a container with enough transfer buffer to 
cover it for the whole duration of the electrophoresis). Soak one pair of blotting 
papers just before use. 
2. Place one blotting paper on the blotter and place the membrane on top of it. 
Manipulate the membrane touching only the edges with gloved hands or tweezers. 
Pour a small amount of transfer buffer on the membrane to keep it wet. 
3. After electrophoresis, take out the polyacrylamide gel from the tank and carefully 
remove it from the glass or plastic cassette using a spatula. 
4. Place the gel on top of the membrane. Pour a small amount of transfer buffer on top 
of the gel and gently press it against the membrane to eliminate any bubbles. 
5. Place a second blotting paper on top of the membrane and pass the roller on its 
surface, to eliminate any bubbles in the WB sandwich. 
6. Place the lid of the blotter on top of the sandwich and gently fix it with the screws. 
Be careful in this step, as too much pressure can break the gel. 
7. Connect the blotter to the power pack (the positive electrode is on the bottom piece 
of the blotter and the negative one is on the lid). 
8. Turn on the power pack and set up the transfer conditions (usually 15 V/500 mA for 
30 min is enough for medium-sized proteins) and press start. Make sure that the 
power pack raises the desired voltage. 
9. Once the transference is finished, open the blotter, remove the upper blotting paper 
and then carefully separate the gel from the membrane, making sure that no 
residues of gel are left. 
10.  If necessary, mark the location of the molecular weight markers with a pencil. 
Transfer the membrane to a 50 ml tube (appropriately labelled) with ~10 ml of 
washing buffer and place it on the roller at RT, making sure that the side of the 
membrane that was in contact with the gel (protein side) is facing the inside of the 
tube. 
11. Wash the membrane for a total of three times for 2-5 min on the roller. 
12. Add 15-20 ml of blocking buffer and incubate on the roller for 1 h or as specified in 
the protocol for the primary antibody(ies) to be used. 
13. Remove the blocking buffer and add the primary antibody(ies) diluted in 5 ml of 
blocking buffer. Incubate overnight at 4°C on a roller. 
14. Remove the primary antibody and store it at -20°C (keep track of the number of 
times the antibody has been used, five times is usually fine). Wash the membrane 
three times with ~10 ml of washing buffer on the roller at RT. 
15. Add the secondary antibodies diluted in 5 ml of blocking buffer. Incubate for 40-60 
min on the roller at RT. 
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16. Remove the secondary antibodies and wash the membrane three times with ~10 ml 
of washing buffer and then once with 1X PBS on the roller at RT. 
17. Place the membrane on the Odyssey imager face down, making sure no bubbles 
are left. Open the Odyssey application and scan the membrane using “membrane” 
function (intensity and quality parameters can be adjusted if necessary). 
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Protocol 12: Pull-down assay for GST-AIP proteins 
 
Buffers and solutions 
Lysis buffer 
20 mM  Tris-Cl pH8 (dilute from 1 M stock) 
200 mM NaCl (dilute from 1 M stock) 
1 mM  EDTA pH8 (dilute from 0.5 M stock) 
0.5% (v/v)  IGEPAL® CA-630 (SIGMA I3021)  
Adjust with sterile ddH2O to a final volume of 50 ml 
Sterilisation not needed. Store at 4°C. Just before use, add 1 tablet of Complete
®
 Protease 
Inhibitor Cocktail (Roche 11836145001). The fully prepared buffer can be aliquoted and 
stored at -80°C for several weeks. 
 
Elution buffer  
50 mM Tris-Cl pH8 500μl from 1M stock 
20 mM Reduced glutathione 
Adjust with sterile ddH2O to a final volume of 10 ml 
Mix Tris-HCl with 9 ml ddH2O, add glutathione and mix well. Adjust pH to 8 with NaOH (~35 
μl of 3 M solution) and adjust volume to 10 ml with ddH2O. Prepare fresh before use.  
 
1X PBS, pH 7.4 
To obtain a 5X stock, dissolve 25 tablets of PBS (SIGMA P4417) in ddH2O and sterilise by 
autoclaving. Store at RT. Dilute accordingly with ddH2O to obtain a 1X working solution.  
 
PAGE buffers 
See Protocol 8 
 
WB buffers  
See Protocol 11. 
 
Reagents: 
Purified GST-AIP proteins  
Glutathione HiCap Matrix (QIAGEN 30900) 
Protein™ Kaleidoscope™ Standard (BIO-RAD 161-0375) 
Reagents for protein quantification (see Protocol 14) 
 
Cell culture media:  
See Protocol 13 
 
Cell line 
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See Protocol 13 
 
Materials: 
T75 or T175 cell culture flasks 
1.5 and 15 ml polypropylene tubes 
Pipettes and tips 
Pipette controller and disposable serological pipettes 
5 ml syringes, 23G needles and insulin syringes and needles 
1 l glass 
Floating rack for 1.5 ml tubes 
Slide-A-Lyzer MINI Dialysis Devices (2K MWCO) (Thermo Scientific 69580) 
Magnetic stirrer 
Materials for cell culture, protein quantification, PAGE and WB (see appropriate protocols). 
 
Equipment 
Water bath  
Set at 37°C 
Inverted microscope 
Labofuge 400 centrifuge (Heraeus) 
BR4i refrigerated centrifuge (Jouan) 
GS1 Thermal Cycler (G-Storm) 
Stuart tube rotator SB2 (Stuart) 
Equipment for cell culture, protein quantification PAGE and WB (see appropriate protocols). 
 
Protocol 
For details on growth and maintenance of GH3 and HEK293 cells see Protocol 13 and 
Protocol 17. 
Cell culture must be performed in aseptic conditions. From step 2 onwards, all the 
procedures must be done at 4ºC or on ice. 
1. Grow GH3 cells in T175 flasks until ~80-90% confluent, trypsinise, count the cells 
and pellet (see Protocol 13), and wash the pellet with 10 ml PBS.  
2. Resuspend the cell pellet in the appropriate amount of cold lysis buffer to obtain a 
solution with 12X10
6
 cells/ml. 
3. Incubate for 20 min at 4°C on a rotator (alternatively, incubate on ice, vortexing 
occasionally). Collect the lysate in a syringe and pass it through a 23G needle six 
times. 
4. Transfer to 1.5 ml tubes and centrifuge the lysates for 10 min at 17000 g/4°C and 
transfer the supernatants (cleared lysates) to new tubes.  
5. Quantify the protein concentration in the lysates using the Bradford method (see 
Protocol 14). Separate ~60 μl of cleared lysate for PAGE analysis. 
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6. Homogenise glutathione beads, transfer 50 μl to 16X1.5 ml tubes, add 500 μl of 
lysis buffer and mix well by inverting the tube. Centrifuge for 2 min at 1000 g/4ºC. 
Discard supernatant and add 25 μl of lysis buffer. 
7. Add to each of eight tubes with glutathione beads either 10 μg of one of the GST-
AIP proteins, GST or 10μl ddH2O and add 1 ml of cleared lysate to the rest of the 
tubes. Label appropriately. 
8. Incubate all the tubes for 1 h at 4ºC on a rotator. Centrifuge for 2 min at 1000 g/4ºC.  
Binding of purified GST-AIP proteins to the beads before the addition of lysate may 
improve pull-down efficiency. Exposing the lysate to the beads before the pull-down 
(“pre-cleaning” the lysate) reduces non-specific binding. 
9. Transfer the lysate to each tube with glutathione beads and GST-AIP protein (1 ml 
of lysate per reaction) and incubate for 4 h at 4ºC on a rotator. Centrifuge for 2 min 
at 1000 g/4ºC. Save supernatants in different tubes for PAGE analysis. 
10. Add 1 ml of lysis buffer to each tube, mix well by inverting the tube and centrifuge for 
2 min at 1000 g/4ºC. Discard the supernatant and repeat this step three more times. 
After the last wash, carefully eliminate any residue of lysis buffer with an insulin 
needle. 
11. Add 30 μl of elution buffer to each tube, incubate 1 h at 4ºC on a rotator and 
centrifuge for 2 min at 1000 g/4ºC. Transfer the supernatant into a new tube and 
label appropriately. Repeat this step with 20 μl of elution buffer and pool this second 
eluate together with the first one. Store at -80°C. 
12. Repeat the pull-down assay four times for each bait protein and pool together the 
eluates of the four experiments. 
13. Transfer each pooled eluate to a dialysis tube, place them all on a floater and 
dialyse against 1 l PBS overnight at 4°C, in agitation on a magnetic stirrer.  
14. Analyse the eluates and unbound fractions by PAGE (see Protocol 8) and 
Coomassie staining (see Protocol 9) or WB (see Protocol 11). 
 
Reference: 
Detection of protein-protein interactions using the GST fusion protein pull-down technique. Nat Methods. 
2004;1(3):275-276. 
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Protocol 13: Initiation and maintenance of a stock culture of GH3 cells 
 
Cell culture regents 
Dulbecco´s Eagle Modified Medium (DMEM, SIGMA D5030) 
FBS (Life Technologies 10270-106), filtered 
1X Dulbecco’s PBS (SIGMA D8537) 
1X Trypsin-EDTA (TE) (SIGMA T3924) 
Pre-heat all these reagents at 37°C before using. 
Trypan blue solution (SIGMA T8154) 
 
Cell line 
GH3 (rat somatotropinoma) (ECACC 87012603) 
 
Materials 
1.5 and 15 ml polypropylene tubes 
T75 or T175 cell culture flasks 
Pipettes and tips 
Pipette controller and disposable serological pipettes 
 
Equipment 
Water bath  
Set at 37°C 
Cell culture incubator and hood 
Inverted microscope 
Heraeus Labofuge 400 centrifuge 
Haemocytometer  
Manual cell counter 
Calculator 
 
Method 
Work in cell culture hood under aseptic conditions. For initiating a stock culture: 
1. Transfer 12 ml of complete medium (DMEM supplemented with 10% FBS) into a T75 
flask or 18 ml into a T175 flask. 
2. Take out a vial of frozen GH3 cells (stored in liquid nitrogen) and immerse it in the 
water bath for approximately 1 min or until the contents are completely thawed.    
3. Transfer the contents of the vial to the flask with medium, label appropriately and 
incubate at 37°C/5% CO2 for 24 h.  
4. Change the medium and continue incubation until cells reach ~80-90% confluence. 
For maintaining a stock culture: 
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1. When the cell culture reaches ~80-90% confluence, remove the medium the cells 
grew in and carefully wash the cells thrice with 10 ml of PBS. 
2. Add 3 ml of 1X TE for a T75 or 4 ml for a T175, ensuring it covers the totality of the 
cells and incubate at 37°C for 3 (for a T75) to 4 min (for a T175). Verify cell 
detachment under the microscope. 
3. Add complete medium, using double of the volume than for TE. Wash the surface 
where the cells grew thrice, mix well with the pipette to separate cell clumps and 
transfer to a 15 ml tube. 
4. Take 20 µl of the cell suspension and mix with 20 µl of trypan blue in a 1.5 ml tube. 
Transfer 10 µl of this mixture to each of the chambers of a haemocytometer and 
count the cells under the microscope as follows: 
a. Count the cells on each of the four external squares of the haemocytometer 
(those with large squares), avoiding blue cells (not viable) and obtain the 
average of the four squares. 
b. Multiply X2 (dilution factor with trypan blue), then X10000 to obtain number 
of cells per ml. Finally, multiply for the volume of the cell suspension, to 
obtain the total cell number. 
5. Centrifuge at 800 g for 3 min at RT. 
6. Remove the supernatant and resuspend the pellet in an appropriate volume of 
complete medium with antibiotic to obtain a suspension with 1X10
6
 cells per ml. 
7. Transfer 1 ml of this cell suspension (1x10
6 
cells) into a T75 or 2 ml (2X10
6
 cells) 
into a T175 and adjust to a final volume of 12 ml for a T75 or 18 ml for a T175 with 
complete medium. 
8. Incubate at 37°C/5% CO2 until ~80-90% confluence (approximately 6-7 days). 
Change the medium every 3-4 days. 
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Protocol 14. Protein quantification using the Bradford method 
 
Reagents 
Bio-Rad Protein Assay Dye Reagent Concentrate (BIO-RAD 500-0006) 
Dilute 1:5 with ddH2O before use (approximately 20 ml are enough for one 96-well plate) 
 
10 mg/ml Bovine Serum Albumin (BSA, Promega R3961) 
 
Material and equipment 
Plates 
0.2 µl PCR tubes 
Multichannel pipette 
Plate shaker  
Wallac Victor plate reader 
 
Method 
1. Prepare concentration standards: 
- In a PCR tube, mix 12 µl of 10 mg/ml BSA + 18 µl of ddH2O to obtain a 4000 
µg/ml standard. 
- Take 15 µl of this solution and mix with 15 µl of ddH2O to obtain a 2000 µg/ml 
standard, and continue diluting sequentially until obtaining a 125 µg/ml 
standard. For the standard 0 use ddH2O only. 
2. Add 196 µl of 1X Bradford reagent to each well of a 96-well plate using a 
multichannel pipette. 
3. Add 4 µl of each standard or sample (diluted or undiluted, as appropriate) to three 
contiguous wells with Bradford reagent (for triplicate readings). 
4. Mix for 1 min on a plate shaker. 
5. Read absorbance at 595nm on a plate reader. 
6. Export the results to an Excel file and copy the absorbance readings for the whole 
plate in “Absorbance” area of the “Bradford assay with microplate reader” Excel 
template (see printout below). 
7. Enter a label for each sample in the “Template” area. 
8. The program will plot the results for the standards and calculate and R value using a 
linear equation. The R value should be as close to 1 as possible. If necessary, 
delete one or more standards (usually the standard 4000 µg/ml) to improve the R 
value.  
9. In the “Protein concentration” area, the program will calculate the protein 
concentration for each sample using the slope curve, based on the results obtained 
for the standards. 
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10.  In the “Average concentration of samples” area, enter the dilution factor for each 
sample (if the samples were not diluted, enter 1). The concentration for each sample 
will be automatically calculated, considering an average of the triplicates. 
 
Note: 
- If the concentration of a sample displayed in the “Protein concentration” area 
lies beyond the limit of the standard curve, the sample should be diluted and 
read again.  
 
 
 
1 A B C D E F G H I J K L M
2 STD µg/ml
3 4000
4 2000 slope
5 1000 intercept
6 500
7 250
8 125
9 0
10
11
12
13
14
15 1 2 3 4 5 6 7 8 9 10 11 12
16 A STD 4000 STD 4000 STD 4000 SAMPLE 1 SAMPLE 1 SAMPLE 1 SAMPLE 9 SAMPLE 9 SAMPLE 9 SAMPLE 17 SAMPLE 17 SAMPLE 17
17 B STD 2000 STD 2000 STD 2000 SAMPLE 2 SAMPLE 2 SAMPLE 2 SAMPLE 10 SAMPLE 10 SAMPLE 10 SAMPLE 18 SAMPLE 18 SAMPLE 18
18 C STD 1000 STD 1000 STD 1000 SAMPLE 3 SAMPLE 3 SAMPLE 3 SAMPLE 11 SAMPLE 11 SAMPLE 11 SAMPLE 19 SAMPLE 19 SAMPLE 19
19 D STD 500 STD 500 STD 500 SAMPLE 4 SAMPLE 4 SAMPLE 4 SAMPLE 12 SAMPLE 12 SAMPLE 12 SAMPLE 20 SAMPLE 20 SAMPLE 20
20 E STD 250 STD 250 STD 250 SAMPLE 5 SAMPLE 5 SAMPLE 5 SAMPLE 13 SAMPLE 13 SAMPLE 13 SAMPLE 21 SAMPLE 21 SAMPLE 21
21 F STD 125 STD 125 STD 125 SAMPLE 6 SAMPLE 6 SAMPLE 6 SAMPLE 14 SAMPLE 14 SAMPLE 14 SAMPLE 22 SAMPLE 22 SAMPLE 22
22 G STD 0 STD 0 STD 0 SAMPLE 7 SAMPLE 7 SAMPLE 7 SAMPLE 15 SAMPLE 15 SAMPLE 15 SAMPLE 23 SAMPLE 23 SAMPLE 23
23 H EMPTY EMPTY EMPTY SAMPLE 8 SAMPLE 8 SAMPLE 8 SAMPLE 16 SAMPLE 16 SAMPLE 16 SAMPLE 24 SAMPLE 24 SAMPLE 24
25
26
27 1 2 3 4 5 6 7 8 9 10 11 12
28 A
29 B
30 C
31 D
32 E
33 F
34 G
35 H
36
37
38 1 2 3 4 5 6 7 8 9 10 11 12
39 A =(C27-$H$5)/$H$4 =(D27-$H$5)/$H$4 =(E27-$H$5)/$H$4 =(F27-$H$5)/$H$4 =(G27-$H$5)/$H$4 =(H27-$H$5)/$H$4 =(I27-$H$5)/$H$4 =(J27-$H$5)/$H$4 =(K27-$H$5)/$H$4 =(L27-$H$5)/$H$4 =(M27-$H$5)/$H$4 =(N27-$H$5)/$H$4
40 B =(C28-$H$5)/$H$4 =(D28-$H$5)/$H$4 =(E28-$H$5)/$H$4 =(F28-$H$5)/$H$4 =(G28-$H$5)/$H$4 =(H28-$H$5)/$H$4 =(I28-$H$5)/$H$4 =(J28-$H$5)/$H$4 =(K28-$H$5)/$H$4 =(L28-$H$5)/$H$4 =(M28-$H$5)/$H$4 =(N28-$H$5)/$H$4
41 C =(C29-$H$5)/$H$4 =(D29-$H$5)/$H$4 =(E29-$H$5)/$H$4 =(F29-$H$5)/$H$4 =(G29-$H$5)/$H$4 =(H29-$H$5)/$H$4 =(I29-$H$5)/$H$4 =(J29-$H$5)/$H$4 =(K29-$H$5)/$H$4 =(L29-$H$5)/$H$4 =(M29-$H$5)/$H$4 =(N29-$H$5)/$H$4
42 D =(C30-$H$5)/$H$4 =(D30-$H$5)/$H$4 =(E30-$H$5)/$H$4 =(F30-$H$5)/$H$4 =(G30-$H$5)/$H$4 =(H30-$H$5)/$H$4 =(I30-$H$5)/$H$4 =(J30-$H$5)/$H$4 =(K30-$H$5)/$H$4 =(L30-$H$5)/$H$4 =(M30-$H$5)/$H$4 =(N30-$H$5)/$H$4
43 E =(C31-$H$5)/$H$4 =(D31-$H$5)/$H$4 =(E31-$H$5)/$H$4 =(F31-$H$5)/$H$4 =(G31-$H$5)/$H$4 =(H31-$H$5)/$H$4 =(I31-$H$5)/$H$4 =(J31-$H$5)/$H$4 =(K31-$H$5)/$H$4 =(L31-$H$5)/$H$4 =(M31-$H$5)/$H$4 =(N31-$H$5)/$H$4
44 F =(C32-$H$5)/$H$4 =(D32-$H$5)/$H$4 =(E32-$H$5)/$H$4 =(F32-$H$5)/$H$4 =(G32-$H$5)/$H$4 =(H32-$H$5)/$H$4 =(I32-$H$5)/$H$4 =(J32-$H$5)/$H$4 =(K32-$H$5)/$H$4 =(L32-$H$5)/$H$4 =(M32-$H$5)/$H$4 =(N32-$H$5)/$H$4
45 G =(C33-$H$5)/$H$4 =(D33-$H$5)/$H$4 =(E33-$H$5)/$H$4 =(F33-$H$5)/$H$4 =(G33-$H$5)/$H$4 =(H33-$H$5)/$H$4 =(I33-$H$5)/$H$4 =(J33-$H$5)/$H$4 =(K33-$H$5)/$H$4 =(L33-$H$5)/$H$4 =(M33-$H$5)/$H$4 =(N33-$H$5)/$H$4
46 H =(C34-$H$5)/$H$4 =(D34-$H$5)/$H$4 =(E34-$H$5)/$H$4 =(F34-$H$5)/$H$4 =(G34-$H$5)/$H$4 =(H34-$H$5)/$H$4 =(I34-$H$5)/$H$4 =(J34-$H$5)/$H$4 =(K34-$H$5)/$H$4 =(L34-$H$5)/$H$4 =(M34-$H$5)/$H$4 =(N34-$H$5)/$H$4
47
48
49 SAMPLE DIL FACTOR
50 =F16
51 =F17
52 =F18
53 =F19
54 =F20
55 =F21
56 =F22
57 =F23
58 =J16
59 =J17
60 =J18
61 =J19
62 =J20
63 =J21
64 =J22
65 =J23
66 =L16
67 =L17
68 =L18
69 =L19
70 =L20
71 =L21
72 =L22
73 =L23 =AVERAGE(L45:N45)*C72
AVERAGE CONCENTRATION OF SAMPLES IN µg/ml:
=AVERAGE(L40:N40)*C67
=AVERAGE(L41:N41)*C68
=AVERAGE(L42:N42)*C69
=AVERAGE(L43:N43)*C70
=AVERAGE(L44:N44)*C71
=AVERAGE(I43:K43)*C62
=AVERAGE(I44:K44)*C63
=AVERAGE(I45:K45)*C64
=AVERAGE(L38:N38)*C65
=AVERAGE(L39:N39)*C66
=AVERAGE(I38:K38)*C57
=AVERAGE(I39:K39)*C58
=AVERAGE(I40:K40)*C59
=AVERAGE(I41:K41)*C60
=AVERAGE(I42:K42)*C61
=AVERAGE(F41:H41)*C52
=AVERAGE(F42:H42)*C53
=AVERAGE(F43:H43)*C54
=AVERAGE(F44:H44)*C55
=AVERAGE(F45:H45)*C56
=SLOPE(E3:E9,D3:D9)
µg/ml
=AVERAGE(F38:H38)*C49
=AVERAGE(F39:H39)*C50
=AVERAGE(F40:H40)*C51
=AVERAGE(C32:E32)
=AVERAGE(C33:E33)
=INTERCEPT(E3:E9,D3:D9)
X=Y-Intercept/Slope
PROTEIN CONCENTRATION IN µg/ml:
ABSORBANCE
TEMPLATE
ABS 595
=AVERAGE(C27:E27)
=AVERAGE(C28:E28)
=AVERAGE(C29:E29)
=AVERAGE(C30:E30)
=AVERAGE(C31:E31)
y = 0
R² = #N/A
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Protocol 15. Tandem mass tagging and in-gel digestion of proteins 
separated by polyacrylamide gel electrophoresis for analysis by mass 
spectrometry 
 
Buffers and solutions 
1 M Triethylammonium bicarbonate (TEAB) buffer, pH 8.5 (SIGMA T7408)  
Store at RT. 
 
2% (w/v)  SDS 
Dilute in ddH2O to a final volume of 10 ml. 
Store at RT. 
 
20 mM Tris(2-carboxyethyl)phosphine hydrochloride (TCEP) 
Dilute in ddH2O to a final volume of 1 ml. 
Prepare fresh. 
 
100 mM  Ammonium bicarbonate (SIGMA A6141) 
Dilute in ddH2O to a final volume of 100 ml. 
Store at RT. 
 
50 mM  Ammonium bicarbonate (SIGMA A6141) 
Dilute in ddH2O to a final volume of 80 ml. 
Store at RT. 
 
10 mM DTT, SIGMA D5545) 
Dilute in 100 mM ammonium bicarbonate to a final volume of 1 ml. 
Prepare fresh. 
 
55mM  Iodoacetamide (IAA, SIGMA I1149) 
Dilute in 100 mM ammonium bicarbonate to a final volume of 1 ml. 
Prepare fresh. 
 
PAGE buffers 
See Protocol 8 
 
Coomassie staining solutions 
Brilliant Blue G-colloidal concentrate (SIGMA B2025) 
See Protocol 9 for the rest of the solutions. 
 
Reagents 
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Trypsin, bovine sequencing grade (Roche 11418475001) 
Dilute in trifluoroacetic acid (Merck 108178) to a final concentration of 0.1% (w/v) and final 
volume of 250 µl. Dispense in 30 µl aliquots and store at -20°C. 
 
Acetonitrile (ACN, Fisher Scientific A998-212) 
TMTsixplex™ Label Reagent Set, 1 x 0.8 mg (Thermo Scientific 90061) 
Pull-down eluates 
Reagents for protein quantification (Protocol 14) and PAGE. 
 
Materials 
1.5, 15 and 50 ml polypropylene tubes 
Pipette controller and disposable serological pipettes 
Materials for cell culture, protein quantification, PAGE and WB (see appropriate protocols). 
 
Equipment 
Savant™ SpeedVac concentrator (Thermo Scientific) 
Eppendorf Thermomixer Compact (Eppendorf) 
Equipment for cell culture, protein quantification PAGE and WB (see appropriate protocols). 
 
Method  
1. Mix 10 µg of the samples to be analysed with 2% SDS to a final concentration of 
0.1% (w/v) and 1M TEAB buffer to a final concentration of 100 mM. Adjust with 
ddH2O to a final volume of 50 µl. 
2. Add 2.6 µl of the TCEP solution to each sample (to a final concentration of 1 mM 
TCEP) and incubate for 1 h at 55°C. 
3. Add 18.5 µl of TMT label reagent stock to the respective sample (each eluate will be 
tagged with a different TMT, to a final concentration of 25 mM of TMT reagent) and 
incubate for 1 h at RT. 
4. Add 3.9 µl of 5% hydroxylamide to each sample (to adjust to a final concentration of 
15 mM TMT reagent) and incubate for 15 min at RT. 
5. Combine all the samples in one tube and incubate the pooled sample for 15 min at 
RT. 
6. Separate the samples by PAGE and stain the gel with Coomassie staining (see 
Protocol 8 and Protocol 9, but use Brilliant Blue G-colloidal concentrate from SIGMA 
instead of preparing the dye). 
7. Excise bands cutting as close to the edge as possible. Chop into ~2 mm
2
 pieces and 
transfer into a 1.5 ml tube.  
Gel pieces can be stored at 4°C until required. 
8. Wash the gel cubes with 200 µl of 100 mM ammonium bicarbonate for 5 min (decant 
water first if gel pieces have been stored) and decant. Repeat two more times. 
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9. Add 200 µl of ACN, decant and add the same volume again to fully and quickly 
dehydrate the gel pieces, decant and dry in SpeedVac for 5 min.  
10.  Rehydrate the gel with 100 µl of 10 mM DTT and heat up at 56°C for 30 min. 
11. Decant DTT, wash with ACN twice (as on step 9), decant and dry in SpeedVac for 5 
min. 
12. Add 100 µl of 55 mM IAA, incubate for 20 min at RT in the dark. 
13. Discard the supernatant, wash briefly with 100 µl of 100 mM ammonium 
bicarbonate, then replace and wash for a further 5 min and discard the buffer.  
14. To destain the gel, wash with 200 µl of a 1:1 solution of 100 mM ammonium acetate 
and ACN. Incubate for 30 min at 37°C, shaking. Repeat this step until the gel is 
destained). 
15. Decant the liquid, dehydrate once again with ACN (as in step 9) and dry off in a 
SpeedVac for 5 min.  
16. Mix 30 µl of the trypsin solution and 200 µl of 50 mM ammonium bicarbonate to a 
final concentration of 13 ng/µl trypsin.  
17. Rehydrate the gel pieces in a minimal volume of trypsin solution (i.e. just enough to 
cover and rehydrate the gel pieces) for 20 min at 4°C.  
18. Remove unabsorbed trypsin and add a minimal volume of 50 mM ammonium 
bicarbonate (10-20 µl) to cover the gel pieces and keep them wet during enzyme 
cleavage.  
19. Incubate at 37°C for 2 h and then overnight at RT. 
20. Decant supernatant from gel pieces and collect it into a new tube. 
21. Wash gel pieces with 50-100 µl of 50 mM ammonium bicarbonate for 5 min at 37°C, 
decant and pool into the tube from step 20. 
22. Dehydrate gel pieces with 50-100 µl of ACN for 10 min at 37°C, decant and pool into 
the tube from step 20. 
23. Repeat steps 21 and 22. 
24. Freeze the peptide extract and dry down the pooled supernatants to completion, 
avoid over drying. Store at -80°C until required. 
 
Reference: 
Protocol provided by Steven Lynham, Centre of Excellence for Mass Spectrometry, King's College London. 
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Protocol 16. RNA extraction from HEK293 cells 
 
Solutions and reagents 
70%  Ethanol 
Dilute in ddH2O to a final volume of 50 ml. 
 
RNeasy Mini Kit (QIAGEN 74104) 
RNase-Free DNase Set (QIAGEN 79254) 
RNase AWAY (Thermo Scientific 7002) 
 
Materials 
1.5 and 15 ml polypropylene tubes 
Pipettes and tips 
Materials for cell culture (see Protocol 17). 
 
Equipment 
Hot block 
Vortex 
Eppendorf 5424 microcentrifuge (Eppendorf) 
NanoDrop 1000 spectrophotometer (Thermo Scientific) 
Equipment for cell culture (see Protocol 17). 
 
Method 
1. Clean the working surface and the pipettes to be used with RNase away. 
2. Trypsinise and pellet one T75 flask of HEK293 cells (~80-90% confluent) as 
specified in Protocol 17. Wash the pellet once with PBS. 
3. Resuspend the cells in 600 µl of Buffer RLT by vortexing or pipetting. 
4. Pipet the lysate directly into a QIAshredder spin column placed in a 2 ml collection 
tube, and centrifuge for 2 min at 16000 g. 
5. Add 1 volume of 70% ethanol to the homogenised lysate, and mix well by pipetting. 
Do not centrifuge. 
6. Transfer up to 700 μl of the sample, including any precipitate that may have formed, 
to an RNeasy spin column placed in a 2 ml collection tube (supplied). Close the lid 
gently, and centrifuge for 15 sec at 16000 g. Discard the flow-through. Transfer the 
rest of the sample to the column and centrifuge again, reusing the same collection 
tube. Discard the flow-through and reuse the collection tube in the next step. 
7. Add 350 μl of buffer RW1 to the RNeasy spin column. Close the lid gently, and 
centrifuge for 15 sec at 16000 g. Discard the flow-through and reuse the collection 
tube in the next steps. 
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8. Add 10 μl of DNase I stock solution to 70 μl of buffer RDD. Mix by gently inverting 
the tube and centrifuge briefly to collect residual liquid from the sides of the tube. 
9. Add the DNase I incubation mix (80 μl) directly to the RNeasy spin column 
membrane, and incubate for 15 min at RT. 
10.  Add 350 μl of buffer RW1 to the RNeasy spin column. Close the lid gently, and 
centrifuge for 15 sec at 16000 g; discard the flow-through. 
11. Add 500 μl of buffer RPE to the RNeasy spin column. Close the lid gently, and 
centrifuge for 15 sec at 16000 g to wash the spin column membrane. Discard the 
flow-through and reuse the collection tube in the next step. 
12. Add 500 μl of buffer RPE to the RNeasy spin column. Close the lid gently, and 
centrifuge for 3 min at 16000 g. 
13. Place the RNeasy spin column in a new 1.5 ml collection tube (included in the kit). 
Add 30–50 μl of RNase-free water directly to the spin column membrane. Close the 
lid gently and centrifuge for 1 min at 16000 g to elute the RNA. Add the same 
volume of RNase-free water and centrifuge again, collecting the eluate in the same 
tube. 
14. Verify RNA concentration using a NanoDrop spectrophotometer, dispense in 
aliquots and store at -20°C. 
 
Note: 
- Before using RPE for the first time, add 4 volumes of ethanol (96–100%) to 
obtain a working solution. 
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Protocol 17: Initiation and maintenance of a stock of HEK293 cells 
 
Cell culture regents 
MEM, no glutamine (Life Technologies 21090-022)  
1X Opti-MEM® Reduced Serum Medium, GlutaMAX™ Supplement (Life Technologies 
51985-034) 
100X MEM NEAA (Life Technologies 11140-050) 
20 mM L-Glutamine (Life Technologies 25030-024) 
FBS (Life Technologies 10270-106), filtered 
1X Dulbecco’s PBS (SIGMA D8537) 
1X Trypsin-EDTA (TE) (SIGMA T3924) 
Pre-heat all these reagents at 37°C before using. 
 
Trypan blue solution (SIGMA T8154) 
 
Cell line 
HEK 293 (human embryo kidney) (ECACC 85120602) 
 
Materials 
1.5 and 15 ml polypropylene tubes 
T75 or T175 cell culture flasks 
Pipettes and tips 
Pipette controller and disposable serological pipettes 
 
Equipment 
Water bath  
Set at 37°C 
Cell culture incubator and hood 
Inverted microscope 
Heraeus Labofuge 400 centrifuge 
Haemocytometer  
Manual cell counter 
Calculator 
 
Method 
Work in cell culture hood under aseptic conditions. For initiating a stock culture: 
1. Transfer 12 ml of complete medium (MEM supplemented with 10% FBS, 2 mM L-
glutamine and 1% NEAA) into a T75 flask or 18 ml into a T175 flask. 
2. Take out a vial of frozen HEK293 cells (stored in liquid nitrogen) and immerse it in 
the water bath for approximately 1 min or until the contents are completely thawed.    
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3. Transfer the contents of the vial to the flask with medium, label appropriately and 
incubate at 37°C/5% CO2 for 24 h.  
4. Change the medium and continue incubation until cells reach ~80-90% confluence. 
 
For maintaining a stock culture: 
1. When the cell culture reaches ~80-90% confluence, remove the medium the cells 
grew in and carefully wash the cells twice with 10 ml of PBS. 
2. Add 3 ml of 1X TE for a T75 or 4ml for a T175, ensuring it covers the totality of the 
cells and incubate at 37°C for three (for a T75) to four min (for a T175). Verify cell 
detachment under the microscope. 
3. Add complete medium, using double of the volume than for TE. Wash the surface 
where the cells grew thrice, mix well with the pipette to separate cell clumps and 
transfer to a 15 ml tube. 
4. Take 20 µl of the cell suspension and mix with 20 µl of trypan blue in a 1.5 ml tube. 
Transfer 10 µl of this mixture to each of the chambers of a haemocytometer and 
count the cells under the microscope as follows: 
a. Count the cells on each of the four external squares of the haemocytometer 
(those with large squares), avoiding blue cells (not viable) and obtain the 
average of the four squares. 
b. Multiply X2 (dilution factor with trypan blue), then X10000 to obtain number 
of cells per ml. Finally, multiply for the volume of the cell suspension, to 
obtain the total cell number. 
5. Centrifuge at 800 g for 3 min at RT. 
6. Remove the supernatant and resuspend the pellet in an appropriate volume of 
complete medium with antibiotic to obtain a suspension with 1X10
6
 cells per ml. 
7. Transfer 1 ml of this cell suspension (1x10
6 
cells) into a T75 or 2 ml (2X10
6
 cells) 
into a T175 and adjust to a final volume of 12 ml for a T75 or 18 ml for a T175 with 
complete medium. 
8. Incubate at 37°C/5% CO2 until ~80-90% confluence (approximately 6-7 days). 
Change the medium every 3-4 days. 
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Protocol 18. RNA reverse transcription 
 
Reagents 
50-100 U/µl M-MLV Reverse Transcriptase, RNase H Minus, Point Mutant and 5X Reaction 
Buffer (Promega M3681) 
500 ng/µl Random Primers (Promega C1181) 
100 mM Deoxynucleotide (dNTP) Solution Set (New England Biolabs N0446) 
To obtain a 10 mM dNTPs working solution, dilute 1:10 each dNTP in sterile ddH2O to a final 
volume of 100 µl. Dispense in 20 µl aliquots and store at -20°C. 
 
10 µM PCR primers (forward and reverse) 
Sterile ddH2O  
Sterilise 100 ml by autoclaving, dispense in 5 ml aliquots and store at RT. 
 
Samples 
RNA samples to be reverse transcribed 
 
Materials 
0.2 ml (individual tubes or strips) or 0.5 ml and 1.5 ml polypropylene tubes 
Pipettes and tips 
 
Equipment 
PCR hood 
GS1 Thermal Cycler (G-Storm) 
Eppendorf 5424 microcentrifuge (Eppendorf) 
 
Method 
Defrost all the reagents and samples on ice before starting. Work in the PCR hood, keeping 
all the reagents on ice. 
1. Place the racks, pipettes, tips, tubes, ddH2O and PCR buffer to be used in the PCR 
hood and expose them to UV light for 5-10 min. 
2. In a 0.2 µl tube, mix 1 µg of RNA and 250 ng of random primers. Adjust with ddH2O 
to a final volume of 17.75 µl. 
3. Place the tube in the thermal cycler and incubate for 5 min at 70°C and then for 5 
min on ice  
4. Add the following reagents (a master mix can be prepared if working with many 
samples): 
Final concentration: Reagent:     
1X    5X M-MLV RT 5X Reaction Buffer 
0.2 mM   10 mM dNTPs 
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50-100 U (1 µl)   M-MLV RT (H-) Point Mutant 
The final reaction volume is 25 µl. 
Mix well by pipetting or vortexing and spin down. 
5. Transfer the samples to the thermal cycler and run the following program: 
One cycle: 
25°C 10 min 
55°C 50 min 
70°C 15 min 
10°C Hold 
6. Store the samples at -20°C. 
 
References: 
This is a modification of the protocol provided by the kit’s manufacturer.  
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Protocol 19. High-fidelity PCR for cloning, addition of 3’A overhangs 
and agarose gel electrophoresis 
 
Buffers 
6X Orange G gel loading buffer 
100mg Orange G 
30% (v/v) Glycerol  
Adjust with ddH2O to a final volume of 50 ml. Dispense in 5 ml aliquots and store at RT. 
 
Sterile ddH2O  
Sterilise 100 ml by autoclaving, dispense in 5 ml aliquots and store at RT. 
 
50X TAE buffer (Severn Biotech Ltd 20-6001-10) 
Dilute 1:50 with ddH2O to obtain a 1X working solution. 
 
Agarose (SIGMA A9539) 
 
Reagents 
2 U/µl Q5 High-Fidelity DNA Polymerase and 5X Q5 Reaction Buffer (2 mM MgCl2) (New 
England Biolabs M0491S) 
Dispense Q5 in 20 µl aliquots and buffer in 100 µl aliquots, store at -20°C.  
 
100 mM Deoxynucleotide (dNTP) Solution Set (New England Biolabs N0446) 
To obtain a 10 mM dNTPs working solution, dilute 1:10 each dNTP in sterile ddH2O to a final 
volume of 100 µl. Dispense in 20 µl aliquots and store at -20°C. To obtain a 10 mM dATP 
solution, dilute the dATP stock 1:10 in sterile ddH2O to a final volume of 50 µl. 
 
10 µM PCR primers (forward and reverse) 
Dilute 1:10 from 100 µM in sterile ddH2O or TE buffer, store at -20°C. 
 
5000 U/ml Taq DNA Polymerase with 10X Standard Taq Buffer 1.5 mM MgCl2 (New 
England Biolabs M0273) 
Dispense Taq in 20 µl aliquots and buffer in 100 µl aliquots, store at -20°C.  
 
GelRed Nucleic Acid Gel Stain, 10,000X in water (Biotium 41003) 
GeneRuler 100 bp DNA Ladder (Life Technologies SM0241)  
Dilute ladder and included loading dye 1:6 in ddH2O to obtain a 1X working solution, store 
working solution at RT. 
 
1 kb DNA ladder (New England Biolabs N3232S) 
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Samples 
DNA samples to be amplified 
 
Materials 
0.2 ml (individual tubes or strips) or 0.5 ml and 1.5 ml polypropylene tubes 
Pipettes and tips 
Conical flask 
Tray, comb and dams to prepare agarose gels 
Parafilm and Saran wrap 
 
Equipment 
PCR hood 
GS1 Thermal Cycler (G-Storm) 
Eppendorf 5424 microcentrifuge (Eppendorf) 
Microwave oven 
MultiSUB Mini horizontal electrophoresis tank (Cleaver Scientific Ltd) 
Consort E835 electrophoresis power supply (Cleaver Scientific Ltd) 
UVP Ultraviolet Transilluminator 
UVIDOC Gel documentation system 
 
Method 
Defrost all the reagents and samples on ice before starting. Work in the PCR hood, keeping 
all the reagents on ice. 
1. Place the racks, pipettes, tips, tubes ddH2O and PCR buffer to be used in the PCR 
hood and expose them to UV light for 5-10 min. 
2. Working in the PCR hood, set up the following master mix in a 1.5 µl tube (adjust 
according to the number of samples to be processed, considering a 10% excess): 
Final concentration: Reagent:     
1X    5X Q5 Reaction Buffer  
0.2 mM   10 mM dNTPs 
0.5 µM   10 µM Forward PCR primer 
0.5 µM   10 µM Reverse PCR primer 
1 U per 50 µl  2U/µl Q5 High-Fidelity DNA Polymerase 
Adjust with sterile ddH2O to the desired final volume (usually 50 µl)  
Mix well by pipetting or vortexing and spin down to remove any drops from the 
tube’s lid. 
3. Dispense the master mix in the PCR tubes (0.2 or 0.5 ml), trying to place it in the 
bottom of each tube. 
4. Add the appropriate sample to each tube and ddH2O to the negative control. 
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5. Close the tubes tightly, mix by vortexing, spin down and place them on the thermal 
cycler. 
6. Run the appropriate PCR program, based on the following example: 
One cycle: 
95°C 2 min 
35 cycles: 
95°C 15 sec 
(Variable) 15 sec 
72°C 30 sec per each 1000 bp of PCR product size 
One cycle: 
72°C 5 min 
10°C Hold 
7. Optional: add 3’ A-overhangs if the PCR product is intended to be cloned into a PCR 
cloning vector, as follows: 
- Place the PCR products on ice and add 10 mM dATP to a final concentration of 
0.2 mM and 5U/µl Taq DNA Polymerase to a final concentration of 1.25 U per 
50 µl. 
- Transfer the tubes back to the thermal cycler and incubate for 15 min at 68°C. 
8. Prepare an agarose gel as follows: 
- Mix an appropriate amount of agarose with 40 ml of 1X TAE buffer in a 
conical flask, cover with Saran wrap (make a hole at the centre to allow 
partial evaporation). 
- Heat up in the microwave oven until the agarose is completely dissolved 
(approximately 1:30 min). 
- Add Gel Red to a final concentration of 1X and pour on the gel tray with the 
rubber dams on both sides. Ensure no bubbles are left and place a comb on 
the gel. Let it sit at RT.  
9. Fill the electrophoresis tank with 1X TAE and place the tray with the gel inside, 
making sure that the buffer covers the gel. 
10. Place an appropriate volume of loading dye for each sample in a separate drop (1X 
final concentration) on the Parafilm and mix with the desired volume of each PCR 
product.  
11. Load 5 µl of DNA ladder in the first well of the gel and the samples in the rest of the 
wells. 
12. Run the gel at 110 V until the loading dye reaches the bottom of the gel. 
13. Place the gel on the transilluminator and obtain an image using the gel 
documentation system. 
Note: 
- To determine the optimum annealing temperature for the primers, carry out a 
gradient PCR starting from 5°C below the lowest predicted annealing temperature 
for the primers according to the primer designing software (usually 5-6 samples 
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spanning 10°C is enough). Choose the temperature rendering the strongest specific 
bands and no non-specific bands in the agarose gel. 
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Protocol 20. DNA extraction from agarose gels 
 
Reagents 
QIAquick Gel Extraction Kit (QIAGEN 28704) 
 
Samples 
Agarose gel containing bands of interest 
 
Materials 
1.5 ml polypropylene tubes 
Pipettes and tips 
Scalpel blade 
 
Equipment 
Precision scale 
UVP Ultraviolet Transilluminator 
Anti-UV protective mask and goggles 
Hot block 
Eppendorf 5424 microcentrifuge (Eppendorf) 
 
Method 
1. Wearing appropriate anti-UV protection, place the gel on the transilluminator and 
excise the DNA band of interest from the agarose gel with a clean scalpel blade. 
Minimise the size of the gel slice by removing extra agarose and work as fast as 
possible, to reduce UV exposure. Transfer the band to a 1.5 ml tube. 
2. Weigh the band and add three volumes of buffer QG to one volume of gel (100 mg 
~100 μl). 
3. Incubate for 10 min at 50°C, or until the gel slice has completely dissolved. To help 
dissolve the gel, mix by vortexing the tube every 2–3 min during the incubation. 
4. Place a QIAquick spin column in a provided 2 ml collection tube and apply the 
sample to the column. Centrifuge for 1 min at 16000 g. Discard the flow-through and 
place the column back in the same collection tube. 
The maximum volume of the column reservoir is 800 μl. For sample volumes of 
more than 800 μl, load and spin again. 
5. Add 750 μl of buffer PE and centrifuge for 1 min at 16000 g. Discard the flow-
through and place the column back in the same collection tube. 
6. Centrifuge the column for 3 min at 16000 g. 
7. Place the column into a clean 1.5 ml microcentrifuge tube and apply 50 μl of Buffer 
EB on the centre of the membrane. Incubate for 1 min at RT and centrifuge for 1 min 
at 16000 g. 
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8. Place the eluate into the column and centrifuge again, using the same collection 
tube. 
9. Verify DNA concentration using a NanoDrop spectrophotometer and store at -20°C. 
 
References: 
This is a modification of the protocol provided by the kit’s manufacturer.  
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Protocol 21. TA cloning 
 
Media 
1X LB agar plates for blue-white screening 
20 g   LB broth powder (SIGMA L3022)  
12 g  Bacteriological agar powder (SIGMA A5306) 
Adjust with ddH2O to a final volume of 250 ml 
Dilute the powder in the water, sterilise by autoclaving and store at RT. To prepare agar 
plates, heat up the agar in the microwave until melted (approximately 4 min at high power), 
cool down in water to approximately 40°C, and add the following reagents: 
100 µg/ml Ampicillin (dilute from 100 mg/ml stock) (SIGMA A0166) 
0.1 mM  IPTG (dilute from 1M stock) (Promega V3951) 
20 µg/ml X-Gal (dilute from 20 mg/ml [in DMSO] stock) (SIGMA B4252) 
Mix well and pour in Petri dishes (25-30 ml per dish) under sterile conditions (use Bunsen’s 
burner). Leave open until the agar has solidified, close and seal with Parafilm, label 
appropriately and store upside down at 4°C. 
 
SOC medium 
2% (w/v)  Tryptone 
0.5% (w/v)  Yeast extract 
10 mM  NaCl (dilute from 1 M stock) 
2.5 mM  KCl (dilute from 250 mM stock) 
10 mM  MgCl2 (dilute from 2 M stock)  
20 mM  Glucose (dilute from 1 M stock)  
Adjust with ddH2O to a final volume of 50 ml 
Dissolve the first four reagents in water and sterilise by autoclaving, then add sterile MgCl2 
and glucose. Dispense in 1 ml aliquots and store at -20°C. 
 
Reagents 
TA cloning kit with pCR2.1 vector (Life Technologies K2020-20) 
 
Samples 
Purified DNA band to be ligated 
 
Materials and equipment 
0.5 ml polypropylene tubes 
Pipettes and tips 
Materials and equipment for transformation of calcium competent E. coli (see Protocol 4). 
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Method 
Defrost all the reagents and samples on ice before starting.  
1. Calculate the amount of insert to be ligated, using the following formula: 
 
ng of insert =
(50 ng of pCR2.1) (size of the insert in bp)
3900 bp
×3 
 
2. Set up the ligation reaction as follows: 
Final concentration: Reagent:     
1X    5X T4 DNA Ligase Reaction Buffer 
(As calculated) ng Insert 
50 ng   25 µg/µl pCR2.1 
5 U    5 U/µl ExpressLink T4 DNA Ligase 
Adjust with sterile ddH2O to a final volume of 10 µl 
Mix well by pipetting. 
3. Incubate for 2 h at RT. 
4. Use the whole ligation volume for transformation of DH5α cells, according to 
Protocol 4. 
5. Plate the transformed cells in agarose plates with IPTG and X-Gal. 
6. Incubate overnight at 37°C and select white colonies only for screening by colony 
PCR. 
 
Note: 
- The proportion of plasmid: insert (3:1) suggested can be adjusted if necessary.   
 
Reference: 
This is a modification of the protocol provided by the reagents’ supplier. 
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Protocol 22. Colony PCR 
 
Buffers 
6X Orange G gel loading buffer 
100 mg Orange G 
30% (v/v) Glycerol  
Adjust with ddH2O to a final volume of 50 ml. Dispense in 5 ml aliquots and store at RT. 
 
Sterile ddH2O  
Sterilise 100 ml by autoclaving, dispense in 5 ml aliquots and store at RT. 
 
50X TAE buffer (Severn Biotech Ltd 20-6001-10) 
Dilute 1:50 with ddH2O to obtain a 1X working solution. 
 
Agarose (SIGMA A9539) 
 
Reagents 
5000 U/ml Taq DNA Polymerase with 10X Standard Taq Buffer 1.5 mM MgCl2 (New 
England Biolabs M0273) 
Dispense Taq in 20 µl aliquots and buffer in 100 µl aliquots, store at -20°C.  
 
100 mM Deoxynucleotide (dNTP) Solution Set (New England Biolabs N0446) 
To obtain a 10 mM dNTPs working solution, dilute 1:10 each dNTP in sterile ddH2O to a final 
volume of 100 µl. Dispense in 20 µl aliquots and store at -20°C. 
 
10 µM PCR primers (forward and reverse) 
Dilute 1:10 from 100 µM in sterile ddH2O or TE buffer, store at -20°C. 
 
GelRed Nucleic Acid Gel Stain, 10,000X in water (Biotium 41003) 
GeneRuler 100 bp DNA Ladder (Life Technologies SM0241) 
Dilute ladder and included loading dye 1:6 in ddH2O to obtain a 1X working solution, store 
working solution at RT. 
 
1 kb DNA ladder (New England Biolabs N3232S) 
 
Samples 
Agar plate with colonies to be screened 
 
Materials 
0.2 ml (individual tubes or strips) or 0.5 ml and 1.5 ml polypropylene tubes 
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Pipettes and tips 
Conical flask 
Tray, comb and dams to prepare agarose gels 
Parafilm and Saran wrap 
 
Equipment 
PCR hood 
GS1 Thermal Cycler (G-Storm) 
Eppendorf 5424 microcentrifuge (Eppendorf) 
Microwave oven 
MultiSUB Midi horizontal electrophoresis tank (Cleaver Scientific Ltd) 
Consort E835 electrophoresis power supply (Cleaver Scientific Ltd) 
UVP Ultraviolet Transilluminator 
UVIDOC Gel documentation system 
 
Method 
Defrost all the reagents and samples on ice before starting. Prepare PCR reactions in the 
PCR hood, keeping all the reagents on ice. 
1. Under sterile conditions, transfer 20 µl of ddH2O to 0.2 ml tubes and 1 ml of LB broth 
with the appropriate antibiotic to 1.5 ml tubes; prepare one tube with water and one 
with LB broth for each colony to be screened (usually 10 colonies per plate).  
2. Using a pipette and a sterile tip, pick one colony and dissolve it in the 20 µl of 
ddH2O. Take 15 µl of this mixture and use them to inoculate the tubes with medium. 
Label each PCR tube and each 1.5 ml tube accordingly. 
3. Incubate the 1.5 ml tubes at 37°C/250rpm. 
4. Prepare the following PCR master mix (adjust volume according to the number of 
samples to be processed, considering a 10% excess): 
Final concentration: Reagent:     
1X    10x Standard Taq Buffer 
0.2 mM   10 mM dNTPs 
0.5 µM   10 µM Forward PCR primer 
0.5 µM   10 µM Reverse PCR primer 
1.25 U per 50 µl  5U/µl Taq DNA Polymerase 
Adjust with sterile ddH2O to a final volume of 12.5 µl)  
Mix well by pipetting or vortexing and spin down to remove any drops from the 
tube’s lid. 
5. Add 7.5 µl of master mix to each PCR tube with ~5 µl of dissolved bacteria, mix well. 
Prepare negative (5 µl ddH2O) and positive (1 ng of a control plasmid, adjust to 5 µl 
with ddH2O) controls in the same way. Close the tubes tightly. 
6. Place the samples in the thermal cycler and run the following program: 
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One cycle: 
95°C 10 min 
25 cycles: 
95°C 15 sec 
(Variable)* 15 sec 
68°C 1 min per each 1000 bp of PCR product size 
One cycle: 
68°C 5 min 
10°C Hold  
* 58°C for CMV_F and R3 primers, 55°C for pUC/mM13_F and R primers 
7. In the meantime, prepare an agarose gel as follows: 
- Mix an appropriate amount of agarose with 80 ml of 1X TAE buffer in a 
conical flask, cover with Saran wrap (make a hole at the centre to allow 
partial evaporation). 
- Heat up in the microwave oven until the agarose is completely dissolved 
(approximately 1:30 min). 
- Add Gel Red to a final concentration of 1X and pour on the gel tray with the 
rubber dams on both sides. Ensure no bubbles are left and place a comb 
(20 wells) on the gel. Let it sit at RT.  
8. Fill the electrophoresis tank with 1X TAE and place the tray with the gel inside, 
making sure that the buffer covers the gel. 
9. Add 2.5 µl of 6X gel-loading dye to each sample and load 10 µl of this mixture in 
each of the wells of the agarose gel. Load an appropriate DNA ladder as a 
reference.  
10. Run the gel at 110 V until the loading dye reaches the bottom of the gel. 
11. Place the gel on the transilluminator and use the gel documentation system to 
obtain a representative image. Choose positive colonies. 
12. Transfer the inoculated medium for each of the positive colonies to a tube with 10 ml 
of LB broth with an appropriate antibiotic and incubate overnight at 37°C/250 rpm. 
Use these cultures for minipreps and for inoculating a large-scale culture. 
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Protocol 23. DNA digestion with restriction enzymes and 
dephosphorylation of digested plasmids 
 
Buffers 
6X Orange G gel loading buffer 
100mg Orange G 
30% (v/v) Glycerol  
Adjust with ddH2O to a final volume of 50 ml. Dispense in 5 ml aliquots and store at RT. 
 
50X TAE buffer (Severn Biotech Ltd 20-6001-10) 
Dilute 1:50 with ddH2O to obtain a 1X working solution. 
 
Agarose (SIGMA A9539) 
 
Reagents 
Restriction enzymes and 10X reaction buffer, as indicated (New England Biolabs or 
Promega) 
Optional: 10 mg/ml Bovine serum albumin (BSA) (if using Promega’s enzymes or old New 
England Biolabs buffers) 
Shrimp Alkaline Phosphatase and 10X Cut Smart buffer (NEB M0371) 
GelRed Nucleic Acid Gel Stain, 10,000X in water (Biotium 41003) 
GeneRuler 100 bp DNA Ladder (Life Technologies SM0241) 
Dilute ladder and included loading dye 1:6 in ddH2O to obtain a 1X working solution, store 
working solution at RT. 
 
1 kb DNA ladder (New England Biolabs N3232S) 
 
Samples 
pSF-CMV-NH2-HA-EKT-NcoI plasmid 
Plasmid or PCR product containing the insert of interest 
 
Materials 
0.2 ml (individual tubes or strips) or 0.5 ml and 1.5 ml polypropylene tubes 
Pipettes and tips 
Conical flask 
Tray, comb and dams to prepare agarose gels 
Saran wrap 
 
Equipment 
Water bath 
364 
 
Eppendorf 5424 microcentrifuge (Eppendorf) 
Microwave oven 
MultiSUB Mini horizontal electrophoresis tank (Cleaver Scientific Ltd) 
Consort E835 electrophoresis power supply (Cleaver Scientific Ltd) 
UVP Ultraviolet Transilluminator 
UVIDOC Gel documentation system 
 
Method 
Defrost reagents and samples on ice before starting and keep all the reagents on ice while 
setting up the reaction. 
1. Set up the following reaction in a 1.5 ml tube: 
Final concentration: Reagent:  
1X    10X Reaction buffer 
10 U   Restriction enzyme 1 
10 U   Restriction enzyme 2 
0.1 mg/ml BSA (only if using Promega’s enzymes or old New England 
Biolabs buffers) 
Add the whole volume of the purified insert or 3 µg of plasmid 
Adjust with ddH2O to a final volume of 50 µl  
Mix well by pipetting or and spin down 
2. Incubate in a water bath at 37°C for 1 h. 
3. Transfer to ice. If phosphorylation is not required, continue with step 5. 
4. Add 1 µl of shrimp alkaline phosphatase and 5 µl of Cut Smart buffer (if the 
digestion was done in a different buffer). Incubate at 37°C for 30 min and then at 
65°C for 5 min. 
5. Prepare an agarose gel as follows: 
- Mix an appropriate amount of agarose with 60 ml of 1X TAE buffer in a 
conical flask, cover with Saran wrap (make a hole at the centre to allow 
partial evaporation). 
- Heat up in the microwave oven until the agarose is completely dissolved 
(approximately 1:30 min). 
- Add Gel Red to a final concentration of 1X and pour on the gel tray with the 
rubber dams on both sides. Ensure no bubbles are left and place a comb on 
the gel (6 deep and wide wells). Let it sit at RT.  
6. Fill the electrophoresis tank with 1X TAE and place the tray with the gel inside, 
making sure that the buffer covers the gel. 
7. Add 10 µl of loading to each digestion reaction and mix by pipetting. 
8. Load 5 µl of DNA ladder in the first well of the gel and carefully load the whole 
volume of each digestion reaction in one well. 
9. Run the gel at 110 V until the loading dye reaches the bottom of the gel. 
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10. Place the gel on the transilluminator and print an image using the gel documentation 
system. 
11. Cut the bands of interest and extract DNA as specified in Protocol 20. 
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Protocol 24. Ligation with T4 DNA ligase 
 
Reagents 
T4 DNA Ligase (400000 cohesive end units/ml and 2000000 cohesive end units/ml) and 10X 
T4 DNA Ligase Buffer (New England Biolabs M0202) 
Dispense the buffer in 20 µl aliquots and store at -20°C. 
 
Samples 
Insert and plasmid to be ligated, digested and gel-extracted 
 
Materials 
0.5 ml polypropylene tubes 
Pipettes and tips 
 
Method 
Defrost reagents and samples on ice before starting and keep all the reagents on ice while 
setting up the reaction. 
1. Calculate the amount of insert to be ligated, using the following formula: 
 
ng of insert =
(100 ng of plasmid) (size of the insert in bp)
size of plasmid in bp
×3 
 
2. Set up the following reaction: 
Final concentration: Reagent: 
2 μl    10X T4 DNA Ligase Buffer 
100 ng   Plasmid 
(As calculated) ng Insert 
1 μl     T4 DNA Ligase 
Adjust with ddH2O to a final volume of 20 μl 
3. Incubate at RT for 4 h. 
4. Transform bacteria with the whole reaction volume according to Protocol 4. 
 
Note: 
- The proportion of plasmid: insert (3:1) suggested can be adjusted if necessary.   
 
Reference: 
This is a modification of the protocol provided by the reagents’ supplier. 
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Protocol 25: Co-immunoprecipitation of AIP and AIP candidate partners 
 
Buffers and solutions 
Lysis buffer 
150 mM  NaCl (dilute from 1 M stock) 
10 mM  Tris-Cl pH 7.5 (dilute from 1 M stock) 
10% (v/v) Glycerol 
1% (v/v)  IGEPAL® CA-630 (SIGMA I8896)  
Adjust with ddH2O to a final volume of 1 l 
Sterilisation not needed, store at 4°C. Just before use, dispense in 50 ml aliquots and add 1 
tablet of Complete
®
 Protease Inhibitor Cocktail (Roche 11836145001) to each aliquot. The 
fully prepared buffer can be stored at -20°C for several weeks. 
 
1X PBS, pH 7.4 
To obtain a 5X stock, dissolve 25 tablets of PBS (SIGMA P4417) in ddH2O and sterilise by 
autoclaving. Store at RT. Dilute accordingly with ddH2O to obtain 1X working solution.  
 
PAGE buffers 
See Protocol 8 
 
WB buffers  
See Protocol 11 
 
Cell culture media  
See Protocol 17 
1X Opti-MEM® Reduced Serum Medium, GlutaMAX™ Supplement (Life Technologies 
51985-034) 
 
Reagents and antibodies 
Lipofectamine 2000 (Life Technologies 11668027) 
Protein G Sepharose 4 Fast Flow (GE Healthcare 17-0618-01) 
Monoclonal anti-Myc from mouse (SIGMA M4439) 
Monoclonal anti-HA antibody from mouse (SIGMA H3663) 
Polyclonal anti-HA antibody from rabbit (SIGMA H6908) 
Mouse IgG (SIGMA I5381) 
IRDye® 680 RD Goat anti-Mouse IgM (µ chain specific) (LI-COR 926-68180) 
IRDye® 800CW Goat anti-Rabbit IgG (H + L) (LI-COR 926-32211) 
Reagents for cell culture and protein quantification (see Protocol 14). 
 
Cell line 
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See Protocol 17 
 
Nucleic acids and oligonucleotides 
100 ng/µl pcDNA3.0-Myc-WT_AIP and 100 ng/µl pCI-neo-WT_AIP or psF-CMV-NH2-HA-
EKT-NcoI plasmid containing the candidate AIP partner to be studied. 
 
Materials 
0.2 (strips), 1.5, 2, 15 and 50 ml polypropylene tubes 
T75 or T175 cell culture flasks 
Pipette controller and disposable serological pipettes 
5 ml syringes, 23G needles and insulin syringes and needles 
Materials for cell culture, protein quantification, PAGE and WB (see appropriate protocols). 
 
Equipment 
Water bath  
Set at 37°C 
Inverted microscope 
Labofuge 400 centrifuge (Heraeus) 
Vortex 
BR4i refrigerated centrifuge (Jouan) 
Hot block 
Stuart tube rotator SB2 (Stuart) 
Equipment for cell culture, protein quantification PAGE and WB (see appropriate protocols). 
 
Method 
For details on growth and maintenance of HEK293 cells see Protocol 17. Cell culture must 
be performed in aseptic conditions. From step 11 onwards, all the procedures must be done 
at 4ºC or on ice. 
1. Plate 10X10
6
 HEK 293 cells in a T175 flask in 18 ml of complete medium and 
incubate for 24 h at 37ºC/5% CO2. 
2. In a 1.5 ml tube, mix equimolar amounts of pcDNA3.0-Myc-AIP (Myc-AIP 
CDS=1026 bp) and of pCI-neo-WT_AIP or pSF-CMV-NH2-HA-EKT-NcoI containing 
the candidate AIP partner to be studied, calculated according to the size of their 
inserts (CDS for the tagged proteins), to obtain final amount of 20 µg of total 
plasmid. Add Opti-MEM to a final volume of 500 µl (TUBE 1). 
3. In a different 1.5 ml tube, mix 480 µl (490 µl for a T75) of Opti-MEM and 20 µl of 
Lipofectamine 2000 (TUBE 2). Incubate for 5 min at RT, shaking occasionally.  
4. Mix the contents of TUBES 1 and 2 to obtain a final volume of 1 ml of cotransfection 
mixture. Incubate for 20 min at RT, shaking occasionally. 
5. Discard the medium the cells grew in. Add 1 ml of cotransfection mixture and 17 ml 
of complete medium and incubate for 8-12 h at 37ºC/5% CO2. 
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6. Replace the medium with complete medium and continue incubation for 24 h more. 
7. Discard the medium, wash the cells with 10 ml PBS and discard the PBS. 
8. Add 4 ml of 1X TE and incubate for 3 min at 37°C. Verify cell detachment under the 
microscope. 
9. Add 8 ml of complete medium, transfer to a 15 ml tube and centrifuge for 3 min at 
800 g. Discard the supernatant. 
10. Wash the pellet with 10 ml of PBS and centrifuge for 3 min at 800 g. Discard the 
supernatant. 
11. Re-suspend the pellet in 1.5 ml of lysis buffer and transfer to a 2 ml tube. Incubate 
for 20 min at 4°C on a rotator (alternatively, incubate on ice, vortexing occasionally). 
Collect the lysate in a syringe and pass it through a 23G needle six times. 
12. Centrifuge the lysate for 10 min at 17000 g/4°C 
13. In the meantime, transfer 50 µl of Protein G Sepharose (80% slurry) to 1X2 ml and 
3X1.5 ml tubes, and add 1 ml of lysis buffer to each tube. Shake well and centrifuge 
for 30 sec at 17000 g/4°C. Discard the supernatant and repeat this step two more 
times. Add 50 µl of lysis buffer to obtain a ~50% slurry. 
14. Transfer the cleared lysate to a 2 ml tube with equilibrated slurry. Incubate for 1 h at 
4ºC on a rotator. 
15. Centrifuge for 30 sec at 17000 g/4°C. Reserve ~60 µl of this pre-cleaned lysate in a 
different tube, for protein quantification and PAGE analysis. 
16. Label 3X1.5 ml tubes as “Myc”, “HA” and “IgG”, indicating the immunoprecipitation 
to be done in each tube, and transfer ~500 µl of the pre-cleaned lysate to each tube. 
17. Add 5 µg of anti-Myc, anti-HA or mouse IgG (approximately 2.5 µl of anti-Myc and 5 
µl of the other two antibodies) to each tube, according to the labelling.  
18. Incubate for 1 h at 4ºC on a rotator. In the meantime, quantify the total protein 
content of the lysates (see appropriate protocol). Reserve 20-50 µg (~20 µl) for 
loading in gel. 
19. Transfer the content of each tube to a 1.5 ml tube with equilibrated slurry, label 
appropriately. Incubate overnight at 4ºC on a rotator. 
20. Centrifuge for 30 sec at 17000 g/4°C.  
21. Wash the pellet thrice with 1 ml lysis buffer and once with PBS, centrifuging at for 30 
sec at 17000 g/4°C between washes. After the last wash, eliminate carefully any 
remnants of the supernatant using an insulin needle.   
22. Re-suspend the final pellet in 30 µl of 2XSDS gel-loading buffer. Heat to 95ºC for 3 
min, shake, rotate or vortex for 5 min (to ensure the release of most of the 
immunoprecipitated proteins), heat again and finally centrifuge for 30 sec at 16000 
g/RT to separate the beads. The final volume of the supernatant will be ~25 µl. 
23. Load the supernatants in a 4-12% 10-well NuPAGE Bis-Tris gel as follows: 
Lane Sample Volume 
1 Novex® Sharp Pre-stained Protein Standard 6 µl 
2 Input (cleared lysate) ~20 µl + 4 µl 6X SD gel-loading buffer 
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3 IP Myc ~25 µl 
4 IP HA ~25 µl 
5 IP IgG ~25 µl 
 
24. Run the gel in 1X MES at 150 V for ~1:15 h. 
25. Use this gel for WB (refer to appropriate protocol), applying the following conditions:  
- Transference for 30 min at 15V. 
- Blocking for 2 h at RT with 5% semi-skimmed milk in washing buffer. 
- Overnight incubation at 4°C with 1:3000 (v/v) mouse anti-Myc and rabbit anti-HA 
primary antibodies in blocking buffer.  
- Incubation for 1 h at RT with 1:20000 (v/v) secondary antibodies in blocking 
buffer.  
26. Obtain image at 700 and 800nm using Odyssey imager.  
 
Notes:  
- To calculate amount of plasmids to be used: [(1 µg pcDNA3.0-Myc-AIP)(size of 2
nd
 
CDS)]/(size of pcDNA3.0-Myc-AIP CDS). The result of this equation added to 1 is 
equal to 100%, calculate the corresponding % of each plasmid and transform to µg 
considering a final amount of 6 µg as 100%. 
- Centrifugation steps for 30 sec can be carried out at RT, but care should be taken 
not to leave the samples at RT for longer periods of time.  
- Each 10-well gel can be used for 2 different experiments. 
- The transferring conditions are optimal for AIP, but time can be adjusted, if required, 
according to the AIP candidate partners to be tested. 
- This experiment can be done in a T75, using 1X10
5
 cells and adjusting the rest of 
the reagents proportionally. 
 
References: 
Moreno-Mateos MA, Espina AG, Torres B et al. PTTG1/securin modulates microtubule nucleation and cell 
migration. Mol Biol Cell 2011; 22(22):4302-4311. 
Lee C. Coimmunoprecipitation assay. Methods Mol Biol 2007; 362:401-406. 
http://www.gelifesciences.co.jp/tech_support/manual/pdf/71501754.pdf 
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Protocol 26: Co-immunoprecipitation of Myc-AIP and AIP-FLAG with 
TOMM20 10mer as a crosslinker 
 
Buffers and solutions 
Lysis buffer 
150 mM  NaCl (dilute from 1 M stock) 
10 mM  Tris-Cl pH 7.5 (dilute from 1 M stock) 
10% (v/v) Glycerol 
1% (v/v)  IGEPAL® CA-630 (SIGMA I8896)  
Adjust with ddH2O to a final volume of 1 l 
Sterilisation not needed, store at 4°C. Just before use, dispense in 50 ml aliquots and add 1 
tablet of Complete
®
 Protease Inhibitor Cocktail (Roche 11836145001) to each aliquot. The 
fully prepared buffer can be stored at -20°C for several weeks. 
 
1X PBS, pH 7.4 
To obtain a 5X stock, dissolve 25 tablets of PBS (SIGMA P4417) in ddH2O and sterilise by 
autoclaving. Store at RT. Dilute accordingly with ddH2O to obtain 1X working solution.  
 
PAGE buffers 
See Protocol 8 
 
WB buffers  
See Protocol 11 
 
Cell culture media  
See Protocol 13 
1X Opti-MEM® Reduced Serum Medium, GlutaMAX™ Supplement (Life Technologies 
51985-034) 
 
Reagents and antibodies 
Lipofectamine 2000 (Life Technologies 11668027) 
Protein G Sepharose 4 Fast Flow (GE Healthcare 17-0618-01) 
Monoclonal anti-Myc from mouse (SIGMA M4439) 
Monoclonal anti-Flag antibody from mouse (SIGMA F3165) 
Mouse IgG (SIGMA I5381) 
TOMM20 10mer peptide (C. Prodromou’s laboratory) 
IRDye® 680 RD Goat anti-Mouse IgM (µ chain specific) (LI-COR 926-68180) 
Reagents for cell culture and protein quantification (see Protocol 14). 
 
Cell line 
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See Protocol 17 
 
Nucleic acids and oligonucleotides 
100 ng/µl pcDNA3.0-Myc-WT_AIP and 100 ng/µl pCI-neo-WT_AIP  
 
Materials 
0.2 (strips), 1.5, 2, 15 and 50 ml polypropylene tubes 
T75 or T175 cell culture flasks 
Pipette controller and disposable serological pipettes 
5 ml syringes, 23G needles and insulin syringes and needles 
Materials for cell culture, protein quantification, PAGE and WB (see appropriate protocols). 
 
Equipment 
Water bath  
Set at 37°C 
Inverted microscope 
Labofuge 400 centrifuge (Heraeus) 
Vortex 
BR4i refrigerated centrifuge (Jouan) 
Hot block 
Stuart tube rotator SB2 (Stuart) 
Equipment for cell culture, protein quantification PAGE and WB (see appropriate protocols). 
 
Method 
For details on growth and maintenance of HEK293 cells see Protocol 17. Cell culture must 
be performed in aseptic conditions. From step 8 onwards, all the procedures must be done 
at 4ºC or on ice. 
1. Plate 2X10
6
 GH3 cells in a T25 flask with 5 ml of complete medium and incubate for 
24 h at 37ºC/5% CO2. 
2. In a 1.5 ml tube, mix 450 µl Opti-MEM and 2.5 µg of each vector (~25 µl each one) 
to obtain a final volume of 500 µl (TUBE 1). 
3. In a different 1.5 ml tube, mix 490 µl of Opti-MEM and 10 µl of Lipofectamine 2000 
(TUBE 2). Incubate for 5 min at RT, shaking occasionally. 
4. Mix the contents of TUBES 1 and 2 to obtain a final volume of 1 ml of cotransfection 
mixture. Incubate for 20 min at RT, shaking occasionally. 
5. Discard the medium the cells grew in. Add 1 ml of cotransfection mixture and 4 ml of 
complete medium and incubate overnight at 37ºC/5% CO2.  
6. Replace the medium with complete medium and continue incubation for 24 h more. 
7. Discard the medium, wash the cells with 5 ml of ice-cold PBS and discard the PBS. 
8. Add 1 ml of lysis buffer, scrape the cells and transfer the content of the flask to a 1.5 
ml tube (label appropriately). Incubate for 20 min at 4°C on a rotator (alternatively, 
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incubate on ice, vortexing occasionally). Collect the lysate in a syringe and pass it 
through a 23G needle six times. 
9. Centrifuge the lysate for 10 min at 17000 g/4°C 
10. In the meantime, transfer 50 µl of Protein G Sepharose (80% slurry) to 1X2 ml and 
3X1.5 ml tubes, and add 1 ml of lysis buffer to each tube. Shake well and centrifuge 
for 30 sec at 17000 g/4°C. Discard the supernatant and repeat this step two more 
times. Add 50 µl of lysis buffer to obtain a ~50% slurry. 
11. Transfer the cleared lysate to a 2 ml tube with equilibrated slurry. Incubate for 1 h at 
4ºC on a rotator. 
12. Centrifuge for 30 sec at 17000 g/4°C. Reserve ~60 µl of this pre-cleaned lysate in a 
different tube, for protein quantification and PAGE analysis. 
13. Centrifuge at 12000 g for 20 sec at 4ºC. For each lysate (A to E), label 3X1.5 ml 
tubes as “Myc”, “Flag” and “IgG” (indicating the immunoprecipitation [IP] to be 
performed in each tube), respectively, and transfer 1/3 of the pre-cleaned lysate to 
each tube. 
14. Add 2 µg (approximately 1 µl of anti-Myc and anti-Flag and 2 µl of IgG) of anti-Myc, 
anti-Flag or mouse IgG to each tube, according to the labelling. Add 1 µg of 
TOMM20 10mer peptide (~50 µl) to each tube. 
15. Incubate for 1 h at 4ºC on a rotator. In the meantime, quantify the total protein 
content of the lysates (see appropriate protocol). Reserve ~50 µl for loading in gel.  
16. Transfer the content of each tube to a 1.5 ml tube with equilibrated slurry, label 
appropriately. Incubate overnight at 4ºC on a rotator. 
17. Centrifuge for 30 sec at 17000 g/4°C.  
18. Wash the pellet thrice with 1 ml lysis buffer and once with PBS, centrifuging at for 30 
sec at 17000 g/4°C between washes. After the last wash, eliminate carefully any 
remnants of the supernatant using an insulin needle.   
19. Re-suspend the final pellet in 40 µl of 2XSDS gel-loading buffer. Heat to 95ºC for 3 
min, shake, rotate or vortex for 5 min (to ensure the release of most of the 
immunoprecipitated proteins), heat again and finally centrifuge for 30 sec at 16000 
g/RT to separate the beads. The final volume of the supernatant will be ~25 µl. 
20. Load the supernatants in a 4-12% 10-well NuPAGE Bis-Tris gel as follows: 
Lane Sample Volume 
1 Kaleidoscope pre-stained protein standard 6 µl 
2 Input (cleared lysate) 20 µl + 4 µl 6X SD gel-loading buffer 
3 IP Myc 20 µl 
4 IP Flag 20 µl 
5 IP IgG 20 µl 
6 Kaleidoscope pre-stained protein standard 6 µl 
7 Input (cleared lysate) 20 µl + 4 µl 6X SD gel-loading buffer 
8 IP Myc 25 µl 
9 IP Flag 25 µl 
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10 IP IgG 25 µl 
 
21. Run the gel in 1X MES at 150 V for ~1:15 h. 
22. Use this gel for WB (refer to appropriate protocol), applying the following conditions:  
- Transference for 30 min at 15 V. 
- Blocking for 2 h at RT with 5% semi-skimmed milk in washing buffer. 
- Cut by the half and incubate overnight at 4°C in blocking buffer, one half with 
1:3000 (v/v) mouse anti-Myc and the other half with 1:3000 (v/v) mouse anti-
Flag.  
- Incubation for 1 h at RT with 1:20000 (v/v) secondary antibody in blocking 
buffer.  
23. Obtain image at 700 using Odyssey imager.  
 
Note:  
- Centrifugation steps for 30 sec can be carried out at RT, but care should be taken 
not to leave the samples at RT for longer periods of time.  
 
References: 
Moreno-Mateos MA, Espina AG, Torres B et al. PTTG1/securin modulates microtubule nucleation and cell 
migration. Mol Biol Cell 2011; 22(22):4302-4311. 
Lee C. Coimmunoprecipitation assay. Methods Mol Biol 2007; 362:401-406. 
http://www.gelifesciences.co.jp/tech_support/manual/pdf/71501754.pdf 
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Protocol 27: Co-immunoprecipitation of Myc-AIP and AIP-Flag with 
formaldehyde as a crosslinker 
 
Buffers and solutions 
Lysis buffer 
150 mM  NaCl (dilute from 1M stock) 
10 mM  Tris-Cl pH 7.5 (dilute from 1M stock) 
10% (v/v) Glycerol 
1% (v/v)  IGEPAL® CA-630 (SIGMA I8896)  
Adjust with ddH2O to a final volume of 1 l 
Sterilisation not needed, store at 4°C. Just before use, dispense in 50 ml aliquots and add 1 
tablet of Complete
®
 Protease Inhibitor Cocktail (Roche 11836145001) to each aliquot. The 
fully prepared buffer can be stored at -20°C for several weeks. 
 
1X PBS, pH 7.4 
To obtain a 5X stock, dissolve 25 tablets of PBS (SIGMA P4417) in ddH2O and sterilise by 
autoclaving. Store at RT. Dilute accordingly with ddH2O to obtain 1X working solution.  
 
0.8% (w/v)  Formaldehyde 
Adjust with 1X PBS to a final volume of 50 ml 
Sterilisation not needed. Dispense in 5 ml aliquots and store at -20ºC, protected from light. 
 
1.25 M  Glycine 
Adjust with 1X PBS to a final volume of 100 ml 
Sterilisation not needed. Store at 4°C. 
 
PAGE buffers 
See Protocol 8 
 
WB buffers  
See Protocol 11 
 
Cell culture media  
See Protocol 13 
1X Opti-MEM® Reduced Serum Medium, GlutaMAX™ Supplement (Life Technologies 
51985-034) 
 
Reagents and antibodies 
Lipofectamine 2000 (Life Technologies 11668027) 
Protein G Sepharose 4 Fast Flow (GE Healthcare 17-0618-01) 
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Monoclonal anti-Myc from mouse (SIGMA M4439) 
Monoclonal anti-Flag antibody from mouse (SIGMA F3165) 
Mouse IgG (SIGMA I5381) 
IRDye® 680 RD Goat anti-Mouse IgM (µ chain specific) (LI-COR 926-68180) 
Reagents for cell culture and protein quantification (see Protocol 14). 
 
Cell line 
See Protocol 17 
 
Nucleic acids and oligonucleotides 
100 ng/µl pcDNA3.0-Myc-WT_AIP and 100 ng/µl pCI-neo-WT_AIP  
 
Materials 
0.2 (strips), 1.5, 2, 15 and 50 ml polypropylene tubes 
T75 or T175 cell culture flasks 
Pipette controller and disposable serological pipettes 
5 ml syringes, 23G needles and insulin syringes and needles 
Materials for cell culture, protein quantification, PAGE and WB (see appropriate protocols). 
 
Equipment 
Water bath  
Set at 37°C 
Inverted microscope 
Labofuge 400 centrifuge (Heraeus) 
Vortex 
BR4i refrigerated centrifuge (Jouan) 
Hot block 
Stuart tube rotator SB2 (Stuart) 
Equipment for cell culture, protein quantification PAGE and WB (see appropriate protocols). 
 
Method 
For details on growth and maintenance of HEK293 cells see Protocol 17. Cell culture must 
be performed in aseptic conditions. From step 10 onwards, all the procedures must be done 
at 4ºC or on ice. 
1. Plate 3.6X10
6
 GH3 cells in a T75 flask with 12 ml of complete medium and incubate 
for 24 h at 37ºC/5% CO2. 
2. In a 1.5 ml tube, mix 400 µl Opti-MEM and 5 µg of each vector to obtain a final 
volume of 500 µl (TUBE 1). 
3. In a different 1.5 ml tube, mix 480 µl of Opti-MEM and 20 µl of Lipofectamine 2000 
(TUBE 2). Incubate for 5 min at RT, shaking occasionally. 
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4. Mix the contents of TUBES 1 and 2 to obtain a final volume of 1 ml of cotransfection 
mixture. Incubate for 20 min at RT, shaking occasionally. 
5. Discard the medium the cells grew in. Add 1 ml of cotransfection mixture and 11 ml 
of complete medium and incubate overnight at 37ºC/5% CO2. 
6. Replace the medium with complete medium and continue incubation for 24 h more. 
7. Discard the medium, wash the cells with 10 ml of warm PBS and discard the PBS. 
8. Add 2 ml of 0.8% formaldehyde solution and incubate for 10 min at 37ºC (this step 
can also be done at RT). 
9. Discard formaldehyde and add 2 ml of ice-cold 1.25 M glycine solution. Incubate for 
5 min at RT. 
10. Discard glycine. Add 1 ml of lysis buffer, scrape the cells and transfer the content of 
the flask to a 1.5 ml tube (label appropriately). Incubate for 20 min at 4°C on a 
rotator (alternatively, incubate on ice, vortexing occasionally). Collect the lysate in a 
syringe and pass it through a 23G needle six times. 
11. Centrifuge the lysate for 10 min at 17000 g/4°C. 
12. In the meantime, transfer 50 µl of Protein G Sepharose (80% slurry) to 1X2 ml and 
3X1.5 ml tubes, and add 1 ml of lysis buffer to each tube. Shake well and centrifuge 
for 30 sec at 17000 g/4°C. Discard the supernatant and repeat this step two more 
times. Add 50 µl of lysis buffer to obtain a ~50% slurry. 
13. Transfer the cleared lysate to a 2 ml tube with equilibrated slurry. Incubate for 1 h at 
4ºC on a rotator. 
14. Centrifuge for 30 sec at 17000 g/4°C. Reserve ~60 µl of this pre-cleaned lysate in a 
different tube, for protein quantification and PAGE analysis. 
15. Centrifuge for 30 sec at 17000 g/4ºC. For each lysate (A to E), label 3X1.5 ml tubes 
as “Myc”, “Flag” and “IgG” (indicating the immunoprecipitation [IP] to be performed 
in each tube), respectively, and transfer 1/3 of the pre-cleaned lysate to each tube. 
16. Add 2 µg (approximately 1 µl of anti-Myc and anti-Flag and 2 µl of IgG) of anti-Myc, 
anti-Flag or mouse IgG to each tube, according to the labelling. Add 1 µg of 
TOMM20 10mer peptide (~50 µl) to each tube. 
17. Incubate for 1 h at 4ºC on a rotator. In the meantime, quantify the total protein 
content of the lysates (see appropriate protocol). Reserve ~50 µl for loading in gel.  
18. Transfer the content of each tube to a 1.5 ml tube with equilibrated slurry, label 
appropriately. Incubate overnight at 4ºC on a rotator. 
19. Centrifuge for 30 sec at 17000 g/4°C.  
20. Wash the pellet thrice with 1 ml lysis buffer and once with PBS, centrifuging at for 30 
sec at 17000 g/4°C between washes. After the last wash, eliminate carefully any 
remnants of the supernatant using an insulin needle.   
21. Re-suspend the final pellet in 40 µl of 2XSDS gel-loading buffer. Heat to 95ºC for 3 
min, shake, rotate or vortex for 5 min (to ensure the release of most of the 
immunoprecipitated proteins), heat again and finally centrifuge for 30 sec at 16000 
g/RT to separate the beads. The final volume of the supernatant will be ~25 µl. 
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22. Load the supernatants in a 4-12% 10-well NuPAGE Bis-Tris gel as follows: 
Lane Sample Volume 
1 Kaleidoscope pre-stained protein standard 6 µl 
2 Input (cleared lysate) 20 µl+4 µl 6X SD gel-loading buffer 
3 IP Myc 20 µl 
4 IP Flag 20 µl 
5 IP IgG 20 µl 
6 Kaleidoscope pre-stained protein standard 6 µl 
7 Input (cleared lysate) 20 µl+4 µl 6X SD gel-loading buffer 
8 IP Myc 25 µl 
9 IP Flag 25 µl 
10 IP IgG 25 µl 
 
23. Run the gel in 1X MES at 150 V for ~1:15 h. 
24. Use this gel for WB (refer to appropriate protocol), applying the following conditions:  
- Transference for 30 min at 15 V. 
- Blocking for 2 h at RT with 5% semi-skimmed milk in washing buffer. 
- Cut by the half and incubate overnight at 4°C in blocking buffer, one half with 
1:3000 (v/v) mouse anti-Myc and the other half with 1:3000 (v/v) mouse anti-
Flag.  
- Incubation for 1 h at RT with 1:20000 (v/v) secondary antibody in blocking 
buffer.  
25. Obtain image at 700 using Odyssey imager.  
 
Note:  
- Centrifugation steps for 30 sec can be carried out at RT, but care should be taken 
not to leave the samples at RT for longer periods of time.  
 
References: 
Moreno-Mateos MA, Espina AG, Torres B et al. PTTG1/securin modulates microtubule nucleation and cell 
migration. Mol Biol Cell 2011; 22(22):4302-4311. 
Lee C. Coimmunoprecipitation assay. Methods Mol Biol 2007; 362:401-406. 
http://www.gelifesciences.co.jp/tech_support/manual/pdf/71501754.pdf 
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Protocol 28. Co-localisation of AIP and its candidate interacting 
partners in HEK293 cells by immunocytofluorescence 
 
Buffers and solutions 
Fixation buffer 
4% (w/v)  Formaldehyde 
Adjust with 1X PBS to a final volume of 40 ml 
Dispense in 5 ml aliquots and store at -20°C, protected from light, and pre-heat at 37°C 
before use. 
 
1X PBS 
Store at RT and pre-heat at 37°C before use. 
 
Permeabilisation buffer 
0.1% (v/v)  Triton X-100 
Adjust with 1X PBS to a final volume of 50 ml 
Store at RT 
 
Blocking buffer 
10% (v/v)  Normal Goat Serum Blocking Solution (VECTOR Laboratories S-1000)  
Adjust with permeabilisation buffer to a final volume of 5 ml 
Store at 4°C. 
 
Cell culture media  
See Protocol 17 
 
Reagents and antibodies 
UltraCruz Hard-set Mounting Medium (Santa Cruz Biotechnology sc-359850) 
Store at 4°C, protected from light. 
Primary antibodies according to experimental purpose 
Alexa Fluor® 488 Goat Anti-Mouse IgG (H+L) Antibody (green) (Life Technologies A-11029) 
Alexa Fluor® 568 Goat Anti-Rabbit IgG (H+L) Antibody (orange) (Life Technologies A-
11036) 
Reagents for cell culture (see appropriate protocols). 
 
Cell lines 
See Protocol 17 
 
Materials 
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0.5,1.5, and 15 ml polypropylene tubes 
Pipette controller and disposable serological pipettes 
8 wells 25X75 mm Nunc™ Lab-Tek™ II Chamber Slides (Thermo Scientific 154534) 
Disposable Pasteur pipettes 
24x50 mm #1.5 Menzel-Gläser cover slips (Thermo Scientific) 
Nail polish 
Materials for cell culture (see appropriate protocols) 
 
Equipment 
Water bath  
Set at 37°C 
Inverted microscope 
Labofuge 400 centrifuge (Heraeus) 
Cell culture incubator and hood  
Zeiss LSM 510 (Mark 4) Laser Scanning Confocal Microscope 
Humidity chamber (alternatively, use a Petri dish with a wet paper towel) 
Equipment for cell culture (see appropriate protocols) 
 
Method 
1. Plate 5X10
4
 cells/well in 400 μl of complete medium in a chamber slide and incubate 
for 48 h at 37°C/5% CO2.  
2. Take the slide to the lab bench, add 200 μl of fixation buffer and incubate for 2 min 
at RT (pre-fixation). 
3. Remove the medium with a Pasteur pipette, add 200 μl of fixation buffer and 
incubate for 10 min at RT (fixation). 
4. Remove the buffer with a Pasteur pipette or by inverting the slide and wash the cells 
thrice with 400 μl of PBS. 
5. Incubate the cells with 400 µl of permeabilisation buffer for 20 min at RT. 
6. Remove the permeabilisation buffer with a Pasteur pipette or by inverting the slide 
and incubate the cells with 200 µl of blocking buffer for 1 h at RT. 
7. Remove the blocking buffer and add the appropriate primary antibodies (adjust 
dilution in each case) diluted in 100 µl of blocking buffer. Incubate overnight at 4°C 
in a humidity chamber.  
8. Wash the chambers with 400 µl of permeabilisation buffer for 5 min three times. 
9. Add the appropriate secondary antibodies, diluted 1:500 in 100μl of blocking buffer, 
and incubate for 1 h at RT protected from light. 
10. Wash the chambers with 400 µl of permeabilisation buffer for 5 min three times. 
11. Remove the chamber walls and make sure that the surface of the slide is even 
(remove any residues of plastic or glue).  
12. Add a few drops of mounting medium, cover with a cover slip, ensuring no bubbles 
are left, seal the edges with nail polish (optional) and store at 4°C overnight, 
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protected from light (to allow mounting medium to harden completely). Keep at 4°C, 
protected from light, until analysis.  
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Protocol 29: Initiation and maintenance of a stock of EBV-immortalised 
lymphoblastoid cells 
 
Cell culture regents 
Roswell Park Memorial Institute (RPMI)-1640 medium (SIGMA R8758) 
20 mM L-Glutamine (Life Technologies 25030-024) 
FBS (Life Technologies 10270-106), filtered 
1X Dulbecco’s PBS (SIGMA D8537) 
Pre-heat all these reagents at 37°C before use. 
Trypan blue solution (SIGMA T8154) 
 
Cell lines 
EBV-transformed LC (ECACC CO137 for WT AIP or F70M38 for AIP p.R304* mutation 
carrier) 
 
Materials 
1.5, 15 and 50 ml polypropylene tubes 
T175 cell culture flasks 
Pipettes and tips 
Pipette controller and disposable serological pipettes 
 
Equipment 
Water bath  
Set at 37°C 
Cell culture incubator and hood 
Inverted microscope 
Heraeus Labofuge 400 centrifuge 
Haemocytometer  
Manual cell counter 
Calculator 
 
Method 
Work in cell culture hood under aseptic conditions. For initiating a stock culture: 
1. Transfer 5 ml of complete medium (RPMI-1640 supplemented with 10% FBS, and 
2mM L-glutamine) into a 15 ml tube. 
2. Take out a vial of frozen cells (stored in liquid nitrogen) and immerse it in the water 
bath for approximately 1 min or until the contents are completely thawed.    
3. Take 20 µl of the cell suspension and mix with 20 µl of trypan blue in a 1.5 ml tube. 
Transfer 10 µl of this mixture to each of the chambers of a haemocytometer and 
count the cells under the microscope as follows: 
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a. Count the cells on each of the four external squares of the haemocytometer 
(those with large squares), avoiding blue cells (not viable) and obtain the 
average of the four squares. 
b. Multiply X2 (dilution factor with trypan blue), then X10000 to obtain number 
of cells per ml. Finally, multiply for the volume of the cell suspension, to 
obtain the total cell number. 
4. Transfer the cells to a T175 flask and adjust the cell confluence with complete 
medium to 5X10
5 
cells/ml in 15 ml, label appropriately and incubate at 37°C/5% 
CO2. 
5. Check the cell confluence twice per week, maintaining it between 3X10
5
 and 2X10
6
 
cells/ml by adding complete medium to a maximum of 60 ml.  
For maintaining a stock culture: 
1. When the cell culture reaches maximum confluence and volume, transfer the cells to 
50 ml tubes, mix well and take 20 µl of the cell suspension to quantify, as described 
before. 
2. Centrifuge the rest of the cells at 800 g for 3 min at RT.  
3. Resuspend the cells in complete medium to a concentration of 1X10
6
 cells per ml. 
4. Transfer 4.5 ml of this cell suspension (4.5x10
6 
cells) into a T175 and adjust to a 
final volume of 15 ml with complete medium. 
5. Check the cell confluence twice per week, maintaining it between 3X10
5
 and 2X10
6
 
cells/ml by adding complete medium to a maximum of 60 ml.  
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Protocol 30: Determining the half-life of endogenous AIP in HEK293 
cells 
 
Buffers and solutions 
Lysis buffer 
150 mM  NaCl (dilute from 1M stock) 
10 mM  Tris-Cl pH 7.5 (dilute from 1M stock) 
10% (v/v) Glycerol 
1% (v/v)  IGEPAL® CA-630 (SIGMA I8896)  
Adjust with ddH2O to a final volume of 1 l 
Sterilisation not needed, store at 4°C. Just before use, dispense in 50 ml aliquots and add 1 
tablet of Complete
®
 Protease Inhibitor Cocktail (Roche 11836145001) to each aliquot. The 
fully prepared buffer can be stored at -20°C for several weeks. 
 
PAGE buffers 
See Protocol 8 
 
WB buffers  
See Protocol 11 
 
Cell culture media  
See Protocol 17 
 
Reagents and antibodies 
100 mg/ml CHX solution in DMSO (SIGMA C4859-1ML) 
DMSO (SIGMA W387509) 
Novex® Sharp Pre-stained Protein Standard (Life Technologies LC5800) 
Monoclonal anti-AIP antibody from mouse (Novus NB100-127) 
Polyclonal anti-ACTB antibody from rabbit (Abcam ab8227) 
IRDye® 680 RD Goat anti-Mouse IgM (µ chain specific) (LI-COR 926-68180) 
IRDye® 800CW Goat anti-Rabbit IgG (H + L) (LI-COR 926-32211) 
Reagents for cell culture and protein quantification (see Protocol 14). 
 
Cell line 
See Protocol 17. 
 
Materials 
0.2 (strips), 1.5, 2, 15 and 50 ml polypropylene tubes 
12-well cell culture plates 
Pipette controller and disposable serological pipettes 
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Cell scrapers 
Materials for cell culture, protein quantification, PAGE and WB (see appropriate protocols) 
 
Equipment 
Water bath  
Set at 37°C 
Inverted microscope 
Labofuge 400 centrifuge (Heraeus) 
BR4i refrigerated centrifuge (Jouan) 
GS1 Thermal Cycler (G-Storm) 
Stuart tube rotator SB2 (Stuart) 
Equipment for cell culture, protein quantification PAGE and WB (see appropriate protocols) 
 
Method 
For details on growth and maintenance of HEK293 cells see Protocol 17. Cell culture must 
be performed in aseptic conditions. From step 4c onwards, all the procedures must be done 
at 4ºC or on ice. 
1. Plate 5X10
5
 cells per well in 1 ml of complete medium in one column of three wells 
(repeats A, B, and C) of 4X12-well plates for each experimental condition (a total of 
12 wells divided in four plates for CHX treatment and the same for DMSO 
treatment). Incubate for 48 h at 37ºC/5% CO2.  
2. Prepare the following dilutions of CHX and DMSO: 
Experimental condition CHX solution DMSO Complete medium 
100 µg/ml CHX 10 µl - 10 ml 
DMSO control - 10 µl 10 ml 
 
3. Label the plates with the experimental condition and the appropriate time point. 
Remove the medium where the cells grew and add 1 ml of CHX or DMSO dilution to 
each well, except for the first plate with 3 wells. Consider the moment when CHX or 
DMSO was added as time 0. 
4. Harvest the first plate with three wells for each experimental condition at time 0, the 
second one after 6 h of treatment, the third one at 12 h and the fourth one at 24 h, 
as follows: 
a. Take the plate to the lab bench. 
b. Wash each well with 1 ml of RT PBS and remove it carefully.  
c. Add 75 µl of lysis buffer and scrape the cells. 
d. Incubate the plate on ice for 5 min. 
e. Collect the lysate in a 1.5 ml tube, label appropriately, and incubate for at 
least 20 min at 4°C on a rotator. 
f. Centrifuge the lysates for 10 min at 17000 g/4°C and transfer the 
supernatants (cleared lysates) to new tubes. 
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g. The lysates for the 0, 12 and 24 h should be stored at -80°C until the all the 
samples are ready for protein quantification and WB. 
h. Quantify the protein concentration in the lysates using the Bradford method 
(see Protocol 14). 
5. Transfer 10-20 µg of each sample to a 0.2 ml tube with an appropriate amount of 6X 
SDS gel loading buffer and denature for 5 min at 95-100°C on a thermal cycler 
(Protocol 8). 
6. Load the samples in a 15-well PAGE gel (one gel per plate). Preferably load the 
repeat “A” for 0, 12, 24 and 48 h sequentially, then samples for repeat “B” and finally 
samples for repeat “C”. 
7. Run the gel in 1X MES at 120 V for ~1:35 h. 
8. Use this gel for WB (refer to Protocol 11), applying the following conditions:  
a. Transference at 15VX30 min using a nitrocellulose membrane.  
b. Blocking for 1 h at RT in PBS with 1% Tween 20 and 5% w/v non-fat dry 
milk. 
c. Overnight incubation at 4°C with 1:1000 v/v mouse anti-AIP and rabbit anti-
ACTB primary antibodies in blocking buffer.  
d. Incubation for 1 h at RT with 1:20000 v/v secondary antibodies in blocking 
buffer.  
9. Obtain images at 700 and 800nm using the Odyssey imager. 
10. Quantify the integrated density of the bands using the Odyssey software or ImageJ 
and use these values to calculate the AIP/ACTB ratios.  
11. Calculate the protein half-life under the different treatments.  
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Protocol 31: Determining the half-life of endogenous AIP in EBV-LC 
cells 
 
Buffers and solutions 
Lysis buffer 
150 mM  NaCl (dilute from 1M stock) 
10 mM  Tris-Cl pH 7.5 (dilute from 1M stock) 
10% (v/v) Glycerol 
1% (v/v)  IGEPAL® CA-630 (SIGMA I8896)  
Adjust with ddH2O to a final volume of 1 l 
Sterilisation not needed, store at 4°C. Just before use, dispense in 50 ml aliquots and add 1 
tablet of Complete
®
 Protease Inhibitor Cocktail (Roche 11836145001) to each aliquot. The 
fully prepared buffer can be stored at -20°C for several weeks. 
 
PAGE buffers 
See Protocol 8 
 
WB buffers  
See Protocol 11 
 
Cell culture media  
See Protocol 29 
 
Reagents and antibodies 
100 mg/ml CHX solution in DMSO (SIGMA C4859-1ML) 
DMSO (SIGMA W387509) 
Novex® Sharp Pre-stained Protein Standard (Life Technologies LC5800) 
Monoclonal anti-AIP antibody from mouse (Novus NB100-127) 
Polyclonal anti-ACTB antibody from rabbit (Abcam ab8227) 
IRDye® 680 RD Goat anti-Mouse IgM (µ chain specific) (LI-COR 926-68180) 
IRDye® 800CW Goat anti-Rabbit IgG (H + L) (LI-COR 926-32211) 
Reagents for cell culture and protein quantification (see Protocol 14) 
 
Cell lines 
See Protocol 29 
 
Materials 
0.2 (strips), 1.5, 2, 15 and 50 ml polypropylene tubes 
6-well cell culture plates 
Pipette controller and disposable serological pipettes 
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5 ml syringes and 23G needles 
Materials for cell culture, protein quantification, PAGE and WB (see appropriate protocols) 
 
Equipment 
Water bath  
Set at 37°C 
Inverted microscope 
Labofuge 400 centrifuge (Heraeus) 
BR4i refrigerated centrifuge (Jouan) 
GS1 Thermal Cycler (G-Storm) 
Stuart tube rotator SB2 (Stuart) 
Equipment for cell culture, protein quantification PAGE and WB (see appropriate protocols) 
 
Method 
For details on growth and maintenance of EBV-LC cells see Protocol 29. 
Cell culture must be performed in aseptic conditions. From step 2e onwards, all the 
procedures must be done at 4ºC or on ice. 
1. Plate 3X10
6
 cells per well in 2 ml of complete medium in one column of three wells 
(repeats 1, 2, and 3) of 4X6-well plates for each experimental condition (a total of 12 
wells divided in four plates for CHX treatment and the same for DMSO treatment). 
Incubate for 48 h at 37ºC/5% CO2. The wells for time 0 hours should contain 
complete medium with nothing added. For the rest of the wells, prepare the following 
dilutions of CHX and DMSO: 
Experimental condition CHX solution DMSO Complete medium 
100 µg/ml CHX 20 µl - 20 ml 
DMSO control - 20 µl 20 ml 
 
2. Considering the moment when the cells were plated as time 0, harvest the first row 
of three wells at time 0 hours, the second column after 6 h, the third one at 12 h and 
the fourth one at 24 hours, as follows: 
a. Take the plate to the lab bench. 
b. Transfer the contents of each well to a 2 ml tube, appropriately labelled. 
c. Centrifuge at 1200 g for 5 min and discard the supernatant. 
d. Wash the pelled with 1 ml of RT PBS and remove it carefully and centrifuge 
again. 
e. Discard the supernatant and resuspend the pellet in 75 µl of lysis buffer by 
vortexing. 
f. Pass the lysates through a 23G needle six times. 
g. Incubate the lysates for at least 20 min at 4°C on a rotator. 
h. Centrifuge the lysates for 10 min at 17000 g/4°C and transfer the 
supernatants (cleared lysates) to new tubes. 
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i. The lysates for the 0, 6 and 12 h should be stored at -80°C until the all the 
samples are ready for protein quantification and WB. 
j. Quantify the protein concentration in the lysates using the Bradford method 
(see Protocol 14). 
3. Transfer 20-25 µg of each sample to a 0.2 ml tube with an appropriate amount of 6X 
SDS gel loading buffer and denature for 5 min at 95-100°C on a thermal cycler 
(Protocol 8). 
4. Load the samples in a 15-well PAGE gel (one gel per plate). Preferably load the 
repeat “1” for 0, 6, 12 and 24 h sequentially, then samples for repeat “2” and finally 
samples for repeat “3”. 
5. Run the gel in 1X MES at 120 V for ~1:35 h. 
6. Use this gel for WB (refer to Protocol 11), applying the following conditions:  
a. Transference at 15VX30 min using a nitrocellulose membrane.  
b. Blocking for 1 h at RT in PBS with 1% Tween 20 and 5% w/v non-fat dry 
milk. 
c. Overnight incubation at 4°C with 1:1000 v/v mouse anti-AIP and rabbit anti-
ACTB primary antibodies in blocking buffer.  
d. Incubation for 1 h at RT with 1:20000 v/v secondary antibodies in blocking 
buffer.  
7. Obtain images at 700 and 800nm using the Odyssey imager. 
8. Quantify the integrated density of the bands using the Odyssey software or ImageJ 
and use these values to calculate the AIP/ACTB ratios.  
9. Calculate the protein half-life under the different treatments.  
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Protocol 32: Determining the half-life of overexpressed AIP in HEK293 
cells  
 
Buffers and solutions 
Lysis buffer 
150 mM  NaCl (dilute from 1 M stock) 
10 mM  Tris-Cl pH 7.5 (dilute from 1 M stock) 
10% (v/v) Glycerol 
1% (v/v)  IGEPAL® CA-630 (SIGMA I8896)  
Adjust with ddH2O to a final volume of 1 l 
Sterilisation not needed, store at 4°C. Just before use, dispense in 50 ml aliquots and add 1 
tablet of Complete
®
 Protease Inhibitor Cocktail (Roche 11836145001) to each aliquot. The 
fully prepared buffer can be stored at -20°C for several weeks. 
 
PAGE buffers 
See Protocol 8 
 
WB buffers  
See Protocol 11 
 
Cell culture media  
See Protocol 17 
1X Opti-MEM® Reduced Serum Medium, GlutaMAX™ Supplement (Life Technologies 
51985-034) 
 
Reagents and antibodies 
Lipofectamine 2000 (Life Technologies 11668027) 
100 mg/ml CHX solution in DMSO (SIGMA C4859-1ML) 
DMSO (SIGMA W387509) 
Novex® Sharp Pre-stained Protein Standard (Life Technologies LC5800) 
Monoclonal anti-Myc from mouse (SIGMA MM4439-100UL) 
Polyclonal anti-ACTB antibody from rabbit (Abcam ab8227) 
IRDye® 680 RD Goat anti-Mouse IgM (µ chain specific) (LI-COR 926-68180) 
IRDye® 800CW Goat anti-Rabbit IgG (H + L) (LI-COR 926-32211) 
Reagents for cell culture and protein quantification (see Protocol 14) 
 
Cell line 
See Protocol 17 
 
Nucleic acids and oligonucleotides 
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100 ng/µl pcDNA3.0-Myc-AIP, WT or mutant  
 
Materials 
0.2 (strips), 1.5, 15 and 50 ml polypropylene tubes 
12-well cell culture plates 
Pipette controller and disposable serological pipettes 
Cell scrapers 
Materials for cell culture, protein quantification, PAGE and WB (see appropriate protocols) 
 
Equipment 
Water bath  
Set at 37°C 
Inverted microscope 
Labofuge 400 centrifuge (Heraeus) 
Vortex 
BR4i refrigerated centrifuge (Jouan) 
GS1 Thermal Cycler (G-Storm) 
Stuart tube rotator SB2 (Stuart) 
Equipment for cell culture, protein quantification PAGE and WB (see appropriate protocols) 
 
Method 
For details on growth and maintenance of HEK293 cells see Protocol 17. Cell culture must 
be performed in aseptic conditions. From step 9c onwards, all the procedures must be done 
at 4ºC or on ice.  
1. Plate 2.5X10
5
 HEK293 cells/well in 1 ml of complete medium in one column of three 
wells (repeats A, B, and C) of 4X12-well plates for each experimental condition. 
Incubate for 24 h at 37ºC/5% CO2. 
2. In a 15 ml tube mix 520μl (40μl/well*13) of Opti-MEM+ GlutaMAX medium and 130μl 
(13 μg=1μg/well*13) of plasmid DNA (TUBE 1).  
3. In a different 15ml tube mix 637μl (49μl/well*13) of Opti-MEM+GlutaMAX medium 
and 13μl (1 μl/well*13) of Lipofectamine 2000 (TUBE 2). Incubate for 5 min at RT, 
shaking occasionally. 
4. Mix the contents of TUBES 1 and 2 by vortexing and incubate for 30 min at RT, 
vortexing occasionally.  
5. Remove the medium where the cells grew and add 100μl of the transfection mix and 
900μl of complete medium to each well. Incubate for 24 h at 37ºC/5% CO2. 
6. Prepare the following dilution of CHX or DMSO (vehicle control): 
Experimental condition CHX solution DMSO Complete medium 
20 µg/ml CHX 2 µl - 10 ml 
DMSO control - 2 µl 10 ml 
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7. Remove the medium the cells grew in and add 1 ml of the CHX or DMSO dilution to 
each well, except for the first three wells. Consider the moment when the CHX or 
DMSO was added as time 0. 
8. Label the plates with the appropriate experimental condition and the time point. 
Remove the medium the cells grew in and add 1 ml of CHX or DMSO dilution to 
each well, except for the first three wells. Consider the moment when CHX or DMSO 
was added as time 0. 
9. Harvest the first column of three wells for each experimental condition at time 0, the 
second one after 6 h of treatment, the third one at 12 h and the fourth one at 24 h, 
as follows: 
a. Take the plate to the lab bench. 
b. Wash each well with 1 ml of RT PBS and remove it carefully.  
c. Add 50 µl of lysis buffer and scrape the cells. 
d. Incubate the plate on ice for 5 min. 
e. Collect the lysate in a 1.5 ml tube, label appropriately, and incubate for at 
least 20 min at 4°C on a rotator. 
f. Centrifuge the lysates for 10 min at 17000 g/4°C and transfer the 
supernatants (cleared lysate) to new tubes. 
g. The lysates for the 0, 6 and 12 h should be stored at -80°C until the all the 
samples are ready for protein quantification and WB. 
h. Quantify the protein concentration in the lysates using the Bradford method 
(see Protocol 14). 
10. Transfer 10-20 µg of each sample to a 0.2 ml tube with an appropriate amount of 6X 
SDS gel loading buffer and denature for 5 min at 95-100°C on a thermal cycler 
(Protocol 8). 
11. Load the samples in a 15-well PAGE gel (one gel per plate). Preferably load the 
repeat “A” for 0, 6, 12 and 24 h sequentially, then samples for repeat “B” and finally 
samples for repeat “C”. 
12. Run the gel in 1X MES at 120 V for ~1:35 h. 
13. Use this gel for WB (refer to Protocol 11), applying the following conditions:  
a. Transference at 15VX30 min using a nitrocellulose membrane.  
b. Blocking for 1 h at RT in PBS with 1% Tween 20 and 5% w/v non-fat dry 
milk. 
c. Overnight incubation at 4°C with 1:1000 v/v mouse anti-AIP and rabbit anti-
ACTB primary antibodies in blocking buffer.  
d. Incubation for 1 h at RT with 1:20000 v/v secondary antibodies in blocking 
buffer.  
14. Obtain images at 700 and 800nm using the Odyssey imager. 
15. Quantify the integrated density of the bands using the Odyssey software or ImageJ 
and use these values to calculate the AIP/ACTB ratios.  
16. Calculate the protein half-life under the different treatments.  
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Protocol 33: Rescuing overexpressed short half-life AIP variants with 
the proteasome inhibitor MG-132 in HEK293 cells 
 
Buffers and solutions 
Lysis buffer 
150 mM  NaCl (dilute from 1 M stock) 
10 mM  Tris-Cl pH 7.5 (dilute from 1 M stock) 
10% (v/v) Glycerol 
1% (v/v)  IGEPAL® CA-630 (SIGMA I8896)  
Adjust with ddH2O to a final volume of 1 l 
Sterilisation not needed, store at 4°C. Just before use, dispense in 50 ml aliquots and add 1 
tablet of Complete
®
 Protease Inhibitor Cocktail (Roche 11836145001) to each aliquot. The 
fully prepared buffer can be stored at -20°C for several weeks. 
 
PAGE buffers 
See Protocol 8 
 
WB buffers  
See Protocol 11 
 
Cell culture media  
See Protocol 17 
1X Opti-MEM® Reduced Serum Medium, GlutaMAX™ Supplement (Life Technologies 
51985-034) 
 
Reagents and antibodies 
Lipofectamine 2000 (Life Technologies 11668027) 
100 mg/ml CHX solution in DMSO (SIGMA C4859-1ML) 
100 mM MG-132 (Enzo Life Sciences BML-PI102-0005), diluted in DMSO 
DMSO (SIGMA W387509) 
Novex® Sharp Pre-stained Protein Standard (Life Technologies LC5800) 
Monoclonal anti-Myc from mouse (SIGMA MM4439-100UL) 
Polyclonal anti-ACTB antibody from rabbit (Abcam ab8227) 
IRDye® 680 RD Goat anti-Mouse IgM (µ chain specific) (LI-COR 926-68180) 
IRDye® 800CW Goat anti-Rabbit IgG (H + L) (LI-COR 926-32211) 
Reagents for cell culture and protein quantification (see Protocol 14). 
 
Cell line 
See Protocol 17 
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Nucleic acids and oligonucleotides 
100 ng/µl pcDNA3.0-Myc-AIP, WT or mutant  
 
Materials 
0.2 (strips), 1.5, 15 and 50 ml polypropylene tubes 
12-well cell culture plates 
Pipette controller and disposable serological pipettes 
Cell scrapers 
Materials for cell culture, protein quantification, PAGE and WB (see appropriate protocols) 
 
Equipment 
Water bath  
Set at 37°C 
Inverted microscope 
Labofuge 400 centrifuge (Heraeus) 
Vortex 
BR4i refrigerated centrifuge (Jouan) 
GS1 Thermal Cycler (G-Storm) 
Stuart tube rotator SB2 (Stuart) 
Equipment for cell culture, protein quantification PAGE and WB (see appropriate protocols) 
 
Method 
For details on growth and maintenance of HEK293 cells see Protocol 17. 
Cell culture must be performed in aseptic conditions. From step 8c onwards, all the 
procedures must be done at 4ºC or on ice. 
1. Plate 2.5X10
5
 HEK293 cells/well in 1 ml of complete medium in one column of three 
wells (repeats A, B, and C) of 4X12-well plates for each experimental condition. 
Incubate for 24 h at 37ºC/5% CO2. 
2. In a 15 ml tube mix 520 μl (40 μl/well*13) of Opti-MEM+ GlutaMAX medium and 130 
μl (13 μg=1μg/well*13) of plasmid DNA (TUBE 1).  
3. In a different 15ml tube mix 637μl (49μl/well*13) of Opti-MEM+GlutaMAX medium 
and 13μl (1 μl/well*13) of Lipofectamine 2000 (TUBE 2). Incubate for 5 min at RT, 
shaking occasionally. 
4. Mix the contents of TUBES 1 and 2 by vortexing and incubate for 30 min at RT, 
vortexing occasionally.  
5. Remove the medium the cells grew in and add 100μl of the transfection mix and 
900μl of complete medium to each well. Incubate for 24 h at 37ºC/5% CO2. 
6. Prepare 15 ml of 20 µg/ml CHX in complete medium. Remove the medium the cells 
grew in and replace it for 1 ml of this dilution. Incubate for 6 h at 37ºC/5% CO2 
7. Label the plates with the appropriate time point. Prepare 10 ml of 20 µg/ml CHX plus 
20µM MG-132 in complete medium. Replace the medium in the wells for 1 ml of this 
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dilution, except for the first three wells. Consider the moment when the MG-132 was 
added as time 0. 
8. Harvest the first column of three wells at time 0 (untreated), the second one after 6 h 
of treatment, the third one at 12 h and the fourth one at 24 h, as follows: 
a. Take the plate to the lab bench. 
b. Wash each well with 1 ml of RT PBS and remove it carefully.  
c. Add 50 µl of lysis buffer and scrape the cells. 
d. Incubate the plate on ice for 5 min. 
e. Collect the lysate in a 1.5 ml tube, label appropriately, and incubate for at 
least 20 min at 4°C on a rotator. 
f. Centrifuge the lysates for 10 min at 17000 g/4°C and transfer the 
supernatants (cleared lysate) to new tubes. 
g. The lysates for the 0, 6 and 12 h should be stored at -80°C until the all the 
samples are ready for protein quantification and WB. 
h. Quantify the protein concentration in the lysates using the Bradford method 
(see Protocol 14). 
9. Transfer 10-20 µg of each sample to a 0.2 ml tube with an appropriate amount of 6X 
SDS gel loading buffer and denature for 5 min at 95-100°C on a thermal cycler 
(Protocol 8). 
10. Load the samples in a 15-well PAGE gel (one gel per plate). Preferably load the 
repeat “A” for 0, 6, 12 and 24 h sequentially, then samples for repeat “B” and finally 
samples for repeat “C”. 
11. Run the gel in 1X MES at 120 V for ~1:35 h. 
12. Use this gel for WB (refer to Protocol 11), applying the following conditions:  
a. Transference at 15VX30 min using a nitrocellulose membrane.  
b. Blocking for 1 h at RT in PBS with 1% Tween 20 and 5% w/v non-fat dry 
milk. 
c. Overnight incubation at 4°C with 1:1000 v/v mouse anti-AIP and rabbit anti-
ACTB primary antibodies in blocking buffer.  
d. Incubation for 1 h at RT with 1:20000 v/v secondary antibodies in blocking 
buffer.  
13. Obtain images at 700 and 800nm using the Odyssey imager. 
14. Quantify the integrated density of the bands using the Odyssey software or ImageJ 
and use these values to calculate the AIP/ACTB ratios.  
15. Calculate the protein half-life under the different treatments.  
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Appendix 3: Abstracts presented in scientific meetings 
 
2015:  Hernández-Ramírez LC, Martucci F, Ferraù F, Morgan RM, Trivellin G, 
Begum F, Tilley D, Ramos-Guajardo N, Iacovazzo D, Prodromou C, and 
Korbonits M. The enhanced proteasomal degradation of AIP mutant 
proteins is a mechanism for AIP deficiency in AIP mutation-associated 
pituitary adenomas. OR35-2. 
 Oral presentation at the The Endocrine Society Annual Meeting ENDO 2015, 
San Diego, USA, March 5-8, 2015.  
 
Schernthaner-Reiter MH, Trivellin G, Hernández-Ramírez LC, Korbonits M, 
and Stratakis C. Interaction between AIP and the cAMP-dependent 
protein kinase (PKA) pathway in pituitary tumor formation. SAT-427. 
Poster presentation by M.H. Schernthaner-Reiter at the The Endocrine 
Society Annual Meeting ENDO 2015, San Diego, USA, March 5-8, 2015. 
 
Hernández-Ramírez LC, Morgan RML, Prodromou C, and Korbonits M. A 
proteomic approach for explaining AIP mutation-associated pituitary 
tumorigenesis.  
Oral presentation at the New Year Celebration, William Harvey Research 
Institute, Barts and The London School of Medicine, Queen Mary University 
of London, London, UK, February 13
th
, 2014. 
 
2014:  Hernández-Ramírez LC, Gabrovska P, Dénes J, Trivellin G, Radian S, Tilley 
D, Ferraù F, Akker SA, Grossman AB, Gadelha MR, Korbonits M, and The 
International FIPA Consortium. Pituitary adenomas in AIP mutation 
positive individuals: genotype-phenotype associations and role of the 
germline FGFR4 G388R variant and the somatic GNAS1 mutations.  
 Poster presented at the William Harvey Day, William Harvey Research 
Institute, Barts and The London School of Medicine, Queen Mary University 
of London, London, UK, October 21
st
, 2014.  
 
Hernández Ramírez LC, Ferraù F, Miljic D, Kastelan D, Drake W, Musat M, 
Mercado-Atri M, Musolino N, Karavitaki N, Korbonits M, and The 
International FIPA Consortium. Absence of GNAS1 mutations in 
somatotropinomas from AIPmut positive patients: possible 
implications for phenotype. 
Oral presentation by M. Korbonits at the 14
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Abstract
Mutations of the aryl hydrocarbon receptor interacting protein (AIP) have been associated with familial isolated pituitary
adenomas predisposing to young-onset acromegaly and gigantism. The precise tumorigenic mechanism is not well
understood as AIP interacts with a large number of independent proteins as well as three chaperone systems, HSP90, HSP70
and TOMM20. We have determined the structure of the TPR domain of AIP at high resolution, which has allowed a detailed
analysis of how disease-associated mutations impact on the structural integrity of the TPR domain. A subset of C-terminal a-
7 helix (Ca-7h) mutations, R304* (nonsense mutation), R304Q, Q307* and R325Q, a known site for AhR and PDE4A5 client-
protein interaction, occur beyond those that interact with the conserved MEEVD and EDDVE sequences of HSP90 and
TOMM20. These C-terminal AIP mutations appear to only disrupt client-protein binding to the Ca-7h, while chaperone
binding remains unaffected, suggesting that failure of client-protein interaction with the Ca-7h is sufficient to predispose to
pituitary adenoma. We have also identified a molecular switch in the AIP TPR-domain that allows recognition of both the
conserved HSP90 motif, MEEVD, and the equivalent sequence (EDDVE) of TOMM20.
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Introduction
Recently, mutations in aryl hydrocarbon receptor interacting
protein (AIP) [1,2] have been linked to familial isolated pituitary
adenomas (FIPA) [3–5], a condition most often characterized by
young-onset growth hormone and prolactin-secreting pituitary
tumors (reviewed by [6]), which leads to acromegaly and gigantism.
The human AIP gene encodes a 37 kDa protein of 330 amino acids
that, based on similarities to other proteins, is predicted to have an
N-terminal immunophilin-like domain [7] and a C-terminal
tetratricopeptide repeat (TPR) domain. Typically, TPR domains
consist of three sets of a highly degenerate consensus sequence of 34
amino acids, often arranged in tandem repeats, formed by two
alpha-helices forming an antiparallel amphipathic structure and a
final C-terminal a-7 helix (Ca-7h; Fig. 1A). The TPR domain of AIP
appears to be similar to the corresponding domains of HOP, CHIP,
CYP40, PP5, FKBP51 and FKBP52 and the aryl hydrocarbon
receptor-interacting protein like 1 (AIPL1) (Fig. 1A). Although the
immunophilin domain of AIP shows significant homology to
equivalent domains of FKBP12 and FKBP52, AIP does not bind
immunosuppressant drugs such as FK506 and rapamycin [2] and
displays no PPIase activity [8,9].
AIP has been reported to interact with a number of different
proteins: chaperones (HSP90, HSP70, TOMM20), and client
proteins including nuclear receptors (AhR, ERa), phosphodiester-
ase 4A5 (rat isoform of human PDE4A4) and PDE2A3, survivin,
G proteins, RET and EBNA3 amongst others (see recent review
by [10]). Interestingly, HSP90, HSP70 and TOMM20 share a
common conserved C-terminal motif, EEVD (HSP90 and HSP70)
and DDVE (TOMM20) that potentially act as the binding sites for
the AIP TPR-domain [11,12]. A similar motif, EELD, has been
identified in PDE4A5 [13]. HSP90 is a molecular chaperone that
is involved in the maturation of many signal transduction proteins
([14–16]), while HSP70 is a more generalised protein-folding
chaperone [17,18]. In contrast, TOMM20 acts as a receptor for
unfolded proteins destined for translocation across the outer
mitochondrial membrane [19]. Together, these chaperones are
responsible for the activation and maturation of a vast array of
other proteins.
AhR, a client protein of the HSP90-AIP complex, may function
as a tumor suppressor that becomes silenced. [4,5,20–25], but its
precise role in predisposition to pituitary adenoma is not well
understood. AhR binds environmental dioxins, such as the non-
metabolizable agonist 2,3,7,8 tetra-chlorodibenzo-r-dioxin
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(TCDD), which is known to promote tumorigenesis, but it is
unclear whether this has a role in AIP-related tumorigenesis.
The cAMP pathway is important for somatotroph cell function
and proliferation. As AIP interacts with phosphodiesterases
(PDE4A5 and PDE2A), enzymes which degrade cAMP, this
interaction may have an important role in AIP-related pituitary
tumorigenesis. AIP has an opposite effect on PDE4A5 and PDE2A
function [13,26,27] and very little data exist on the possible
interaction with other PDEs. As there are over 52 different PDEs
known, this aspect remains an important field of study.
Recently, AIP was shown to inhibit ERa transcriptional activity
and AIP mutations lead to enhanced ERa transcriptional activity.
Prolonged and a high-level exposure to estrogen is a known risk
factor for developing a variety of tumors [28–31] including
pituitary tumors [32,33]. Furthermore, AIP has also been shown
to upregulate PLAGL1 (also known as ZAC1), a zinc finger
protein with apoptotic and cell cycle arrest activity [34,35].
Around 75% of AIP mutations completely disrupt the C-
terminal TPR domain and/or the Ca-7h [36]. The vast majority
of the missense variants affect the two final TPR-motifs and the
Ca-7h, both of which are involved in protein interactions. The
client proteins AhR and PDE4A5 have been shown to bind to the
Ca-7h part of the AIP molecule. How the lack of AIP or its
dysfunction leads to tumorigenesis and how interactions are
disrupted that predispose cells to tumorigenesis are poorly
understood and difficult to predict as AIP interacts directly with
a number of proteins and indirectly, via the three chaperone
systems, with a bewildering number of proteins [10].
Figure 1. PyMol cartoon of the structure of human AIP. (A), PyMol cartoon of the HSP90b EDASRMEEVD-peptide (green) bound to the TPR
domain of AIP (cyan). Only SRMEEVD of the peptide was visible. The structure was obtained at 2.0 A˚ (PDB, 4AIF) while that with the TOMM20
AQSLAEDDVE-peptide was obtained at 1.9 A˚ (PDB, 4APO, not shown). The A and B helices of each TPR motif (TPR1 to 3) and the C-terminal alpha
helix (a-7) are indicated. (B), Superimposition of peptide conformations of HSP90b EDASRMEEVD (green), TOMM20 AQSLAEDDVE (cyan) bound to AIP
(only SRMEEVD and AEDDVE of the peptides is shown), and HSP90a DTSRMEEVD (yellow) peptide bound to CHIP, showing that the peptide
backbone conformation is essentially the same.
doi:10.1371/journal.pone.0053339.g001
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Here we aim to classify the effect of a variety of FIPA associated
mutations on the structural integrity of AIP. We present the
structure showing the molecular interactions of the TPR domain
of AIP in complex with the peptide-binding motifs of HSP90 and
TOMM20. Our results show that no known disease-associated
mutation causes loss of binding of chaperones alone. However, a
subset of mutations affects binding of client proteins to the Ca-7h
of AIP. Consequently, loss of client protein interaction with the
Ca-7h of AIP is sufficient for pituitary adenoma predisposition.
Materials and Methods
Protein Purification
The TPR domain (residues 166–330) of human AIP was
expressed as a PreScission cleavable His-tagged protein from
pTWO-E (pET-17b derived; personal communication, A. W.
Oliver, Sussex University). The TPR domain was purified by
talon-affinity chromatography (Clontech, Oxford, UK), then
concentrated and desalted on a HIPrep 26/10 desalting column
equilibrated in 20 mM Tris pH 7.5 containing 1 mM EDTA. The
sample was then cleaved overnight with GST-tagged PreScision
protease. The cleaved protein was subsequently passed through a
GST column equilibrated in 20 mM Tris pH 7.5, 1 mM EDTA
and 150 mM NaCl and then through a second Talon column to
remove any remaining uncleaved protein. The flow through was
then concentrated and subjected to superdex 75HR gel-filtration
chromatography equilibrated in 20 mM Tris pH 7.5, 1 mM
EDTA, 1 mM DTT and 500 mM NaCl. Pure TPR domain were
concentrated and then desalted on a HIPrep 26/10 column
equilibrated in 20 mM Tris pH 7.5 containing 1 mM EDTA. The
protein was stored frozen at 2 mg ml21.
Structure Determination and Analysis
Human AIP TPR-domain was mixed with EDASRMEEVD
(HSP90b) or AQSLAEDDVE (TOMM20) peptide at a 1:20
molar ratio and concentrated to 15 mg ml21. Crystals of AIP
TPR-domain in complex with peptide were obtained at
7.5 mg ml21 from sitting well drops equilibrated against 1 M
ammonium sulphate, 1% PEG 3350, 0.1 M Bis-Tris pH5.5.
Crystals appeared at 14uC and were harvested by successive
transfer to crystallization buffer with increasing glycerol to 30%.
Crystals were flash frozen in liquid nitrogen. Diffraction data were
collected from crystals frozen at 100 K on Station I03 at the
Diamond Light Source (Didcot, UK). Refinement was carried out
using Phenix Refine [37,38], and manual rebuilding was
Figure 2. Binding of peptide to the TPR domains of Hop and AIP. (A), PyMol Space-filling model showing the binding of the MEEVD peptide
of HSP90 to the TPR domain of Hop TPR2A and (B), the EDASRMEEVD peptide of HSP90b bound to the TPR domain of AIP (only SRMEEVD of the
peptide is shown). (C), Superimposition of the peptides bound to the TPR domains of HOP2A (yellow) and AIP (green).
doi:10.1371/journal.pone.0053339.g002
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performed in Coot [39]. All other programs used were part of the
CCP4 suite [40]. Evolutionary conservation was calculated using
the ConSurf server [41–43] and conservation, as well as other
PDB files, displayed using PyMol (The PyMOL Molecular
Graphics System, Version 1.2r3pre, Schro¨dinger, LLC, USA).
Isothermal Titration Calorimetry and HSP90 ATPase
Assays
The heat of interaction was measured on an ITC200 microcal-
orimeter (Microcal), with a cell volume of 200 mL, under the same
buffer conditions (20 mM Tris, pH 7.5, containing 5 mM NaCl)
at 30uC. Twenty 1.9 mL aliquots of AIP TPR-domain at 350 mM
were injected into 30 mM of human HSP90b. For peptide
interactions twenty 1.9 mL aliquots of peptide ranging from 350
to 600 mM were injected into 30 mM of AIP TPR-domain. Heats
of dilution were determined in a separate experiment by diluting
protein or peptide into buffer, and the corrected data were fitted
using a non-linear least-squares curve-fitting algorithm (Microcal
Origin) with three floating variables: stoichiometry, binding
constant and change in enthalpy of interaction. ATPase assays
were previously described [44–46].
Co-immunoprecipitation
The vectors used were pCI-neo-AIP-Flag and pcDNA 3.0-Myc-
AIP, containing wild-type AIP cDNA with the Flag tag located
downstream AIP and the Myc tag placed upstream, respectively.
GH3 cells (3.66106) were cultured in Dulbeccos Modified Eagles
Medium (SIGMA) containing 10% fetal bovine serum and 1%
penicillin/streptomycin (SIGMA) for 24 hours before transfection
with 2.5 mg of each vector, using Lipofectamine 2000 (Life
Technologies). The cells were then lysed (20 mM Tris-Cl pH 8.0,
200 mM NaCl, 1 mM EDTA pH 8.0, 0.5% Igepal and Complete
Protease Inhibitor Cocktail [Roche]) and ,150 mg of total protein
was used for immunoprecipitation with 1 mg of TOMM20 peptide
and 2 mg of either anti-Myc (SIGMA), anti-Flag (SIGMA) or
mouse IgG (SIGMA) antibodies, respectively. Co-immunoprecip-
itation was carried out with Protein G Sepharose 4 Fast Flow (GE
Healthcare) according to the protocol suggested by the manufac-
turer. Finally, the proteins were eluted by incubation for 5 minutes
at 95uC with 40 ml of 16 Laemmli buffer, fractionated by SDS-
PAGE and then transferred to a nitrocellulose membrane. Proteins
were detected with 1:3000 of either anti-Myc or anti-Flag
antibodies. The bands were visualized on an Odyssey infrared
scanner after incubation with of 1:20000 goat anti-mouse 680
IRDye secondary antibody (Licor). As controls, we performed the
Table 1. Crystallography statistics.
Data collection HSP90 (SRMEEVD)* TOMM20 (AEDDVE)*
Space group C2 C2
Unit cell a, b, c (A˚)
a b, c (u)
63.82, 104.49, 69.27
90, 97.41, 90
60.2, 106.82, 68.47
90, 100.85, 90
Maximal resolution (A˚) 2.01 1.9
Highest resolution bin 2.0622.01 221.9
Observations 98171 92304
Unique reflections 29974 28523
Completeness (%) 99.4(98.5) 84.8 (68.1)
Rmerge 0.061(0.588) 0.049 (0.246)
Mean I/sI 10.9(2.4) 13.6 (4.2)
Multiplicity 3.3(3.2) 3.2 (3.1)
Refinement HSP90 (SRMEEVD)* TOMM20 (AEDDVE)*
Total atoms 2732 3007
Protein atoms 2402 2486
Ligand atoms 100 94
Residues modeled D/1-7;E1-7 D/1-6; E/1-6
Non-protein residues modeled 327 waters, 1SO4 484 waters, 1 SO4, 1 PEG
Resolution range (A˚) 40.422.01 28.4621.9
Rconv 0.1879 0.1809
Rfree 0.236 0.2344
Residues in most favored regions (%) 98 100
Residues in allowed regions (%) 99.7 100
Residues in outlier regions (%) 0.3 0
RMSD bond (A˚) 0.006 0.006
RMSD angle 0.960 0.906
Mean B-factor (A˚2) Protein 36.03
Solvent 50.34
Protein 29.98
Solvent 45.1
*10-mer peptides were used in the crystallization, but only 6–7 resides were visible.
doi:10.1371/journal.pone.0053339.t001
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same experiments using the following combinations of vectors:
pCI-neo-Flag+pcDNA 3.0-Myc, pCI-neo-AIP-Flag+pcDNA 3.0-
Myc, pCI-neo-Flag+pcDNA 3.0-Myc-AIP and no co-transfection.
Results
The Structural Features of the TPR Domain of AIP in
Complex with HSP90 and TOMM20 Peptide
TPR domains that bind HSP90, HSP70 and TOMM20 are
known to bind a specific short conserved motif at the C-terminal
end of these chaperones (HSP90, MEEVD; HSP70, IEEVD; and
TOMM20, EDDVE) [11,12,47]. The structures of the AIP TPR-
domain in complex with peptide fragments from human HSP90b
and TOMM20 were solved at 2.0 (PDB 4AIF) and 1.9 A˚ (PDB
4APO) resolution, respectively (Table 1). The TPR domain of AIP
is similar to other TPR-domain proteins consisting of three pairs of
anti-parallel helices and a Ca-7h (Fig. 1A). We found that the
EDASRMEEVD (HSP90) and AQSLAEDDVE (TOMM20)
peptides bind within the TPR-domain cleft and adopt a similar
backbone conformation (Fig. 1). The mode of interaction of these
peptides resembles that of the HSP90 and HSP70 C-terminal
peptides binding to the TPR-domain of CHIP rather than that of
HOP [11,12] (Fig. 1 and 2).
The residues lining the TPR-binding site are highly conserved
(Fig. 3). The structures show that the C-terminal carboxylate
group and the C-terminal aspartate (HSP90) or glutamate
(TOMM20) side-chain are involved in a series of hydrogen bonds
that is reminiscent of the carboxylate clamp seen in the MEEVD-
HOP complex [11] (Fig. 4). In the AIP-EDASRMEEVD (HSP90)
structure the C-terminal carboxylic acid makes direct hydrogen
bonds to one of the ring nitrogens of His 183 and to the amine
nitrogen of Asn 187 and Asn 236. The aspartate group makes
water-mediated interactions to the main-chain carbonyl of Pro
232, to the carboxylic-acid oxygen of Asn 236, to the amine-group
nitrogen of Lys 266 as well as an intramolecular interaction to the
main-chain carbonyl of the serine of the EDASRMEEVD peptide.
The C-terminal aspartic acid side-chain carboxyl-group also forms
a direct interaction with the amine group of Lys 266.
For the peptide valine the main-chain carbonyl is hydrogen
bonded to the secondary amine of Arg 191 via a water molecule,
and via this same water molecule but also directly, to the
carboxylic-acid oxygens of the second glutamate residue of the
HSP90 peptide (EDASRMEEVD). The other carboxyl-group
oxygen of this glutamate (EDASRMEEVD) is hydrogen-bonded
to the secondary amine of Arg 191, while the other oxygen forms
an intramolecular interaction with the main-chain amide of serine
of the HSP90 peptide. The main-chain amide group of the peptide
valine is also hydrogen bonded to one of the oxygens of the second
glutamate of the peptide. The valine side-chain is itself packed into
a hydrophobic pocket formed by the side chains of Asn 187, Tyr
190, Arg 191 and Asn 236.
The carbonyl of the second glutamate of the HSP90 peptide
(EDASRMEEVD) forms a direct interaction with the side-chain
amine of Lys 266, and via a water molecule to the side-chain
amine group of Lys 270. The side-chain hydroxyl of Tyr 190
forms a direct interaction with the main-chain carbonyl of the
second glutamate in the HSP90 peptide.
The methionine of the HSP90 peptide is itself packed into a
hydrophobic pocket formed by the side chains of Val 265, Lys 266,
Phe 269, Lys 270 and Leu 298. Interestingly, Lys 266 was
predicted to be a ligand-binding residue [48]. However, the main-
chain amine of the peptide methionine also forms both a direct
interaction and a water-mediated hydrogen bond with the side-
chain amine of Lys 270. The main-chain carbonyl of the peptide
arginine directly interacts with the side-chain amine of Lys 266,
while the main-chain carbonyl of the peptide serine forms
Figure 3. PyMol diagram showing the conservation of residues on the surface of AIP TPR-domain. The most highly conserved residues
line the cavity of the TPR domain in which the TPR-motif containing peptides bind to.
doi:10.1371/journal.pone.0053339.g003
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hydrogen bonds via a water molecule to the side-chain amine of
Lys 266.
Interactions between the TOMM20 peptide and the TPR
domain of AIP are similar but not identical. The main differences
result due to the need to pack the first glutamate side-chain of the
TOMM20 peptide (AQSLAEDDVE) into the hydrophobic pocket
that accepts the methionine residue in the case of HSP90 peptide
(MEEVD) (Fig. 4). While the side chain of this glutamate enters
the hydrophobic pocket the carboxylate oxygens point back
towards and interacts with the side-chain amine of Lys 266.
Consequently, Lys 266 adopts an alternative conformation to that
seen with the HSP90 bound peptide. The conformational change
in Lys 266 acts like a switch that not only allows the binding of the
TOMM20 glutamate in the methionine pocket, but also allows the
longer C-terminal glutamate side-chain of TOMM20 (Asp in
HSP90), to pack between the side chain of Pro 232 and Lys 266;
and consequently form a hydrogen bond via a water molecule with
the side-chain amine of Asn 264 (Fig. 4C).
Although attempts to obtain the structure of an equivalent
HSP70 peptide bound to the TPR domain of AIP failed, we
assume that the isoleucine (IEEVD) binds to the same hydropho-
bic pocket as the methionine of HSP90.
Dimerization of the AIP TPR-domain and the Role of Arg
304
The crystal structure of the TPR domain of AIP in complex
with peptide revealed the possibility that the TPR domain might
form a biological dimer (Fig. 5A and B). Significantly, Arg 304,
whose missense mutation is linked to disease, was found to form
interactions with the aspartates of the TOMM20 peptide
(AQSLAEDDVE) bound in the neighbouring TPR domain. In
contrast, in the HSP90 peptide bound structure Arg 304 is
disordered and no significant interactions are made. The question
therefore arises as to whether Arg 304 is naturally involved in
intermolecular or intramolecular interactions with bound peptide
(or intact chaperone) and whether the TPR AIP-domain forms a
biological dimer. It has been previously reported that two
molecules of AIP can be found in some HSP90 complexes, but
whether AIP was a biological dimer in these complexes was not
established [49].
We conducted reciprocal co-immunoprecipitations experiments
(Fig. 5C) in which cells were transfected with Flag- and Myc-
tagged AIP in the presence of the TOMM20 peptide. We found
that using either anti-Flag or anti-Myc antibodies failed to co-
immunoprecipitate the tagged proteins suggesting that AIP
dimerization is not biologically relevant. Furthermore, using
isothermal titration calorimetry (ITC) the stoichiometry of the
interaction between the TPR domain of AIP and HSP90b was
found to be 0.3:1, showing that one molecule of AIP interacts with
a dimer of HSP90 (Table 2). In addition, the E192R AIP mutant,
where Glu 192 forms the core of the interaction interface of the
AIP dimer (Fig. 5D), did not alter the stoichiometry or
thermodynamics of the interaction with HSP90b (0.47:1, AIP-
TPR-E192R: HSP90b, Table 2). We next tested the effect of
mutating Arg 304, which directly interacts with TOMM20 peptide
bound in the neighbouring AIP molecule. The binding of
HSP90b, HSP70 and TOMM20 peptides to the R304A and
R304Q mutants was unaltered relative to the wild type interaction
(Table 2). Failure to form stable dimerization of AIP, caused by
these mutations, would significantly change the thermodynamic
properties of the interaction. We therefore conclude that the
dimerization interface seen in the crystals is not a true biological
interface, but a crystallographic one.
Selectivity in the Binding of Proteins to the TPR Domain
of AIP
We next wanted to understand the selectivity for the different
chaperones that bind to AIP and utilised ITC to measure the
affinity for these interactions. The TPR domain of AIP bound full-
length HSP90b with a Kd = 13.361.8 mM and showed a
favourable entropic contribution (Table 2). The peptides repre-
senting the extreme C-terminus of HSP90 (MEEVD), HSP90b
(EDASRMEEVD), HSP90a (DDTSRMEEVD) and TOMM20
(AQSLAEDDVE) also bound with similar affinities
(Kd = 12.661.6; 14.461.0; 9.560.6 and 12.360.5 mM, respec-
tively; Table 2), suggesting that the core interaction between these
Figure 4. PyMOL diagram showing binding interactions. (A)
Interactions with HSP90b EDASRMEEVD peptide and (B), with TOMM20
AQSLAEDDVE peptide bound to the TPR domain of AIP. Peptide
residues that where visible (SRMEEVD and AEDDVE) are shown in red as
single letter code. Dotted blue lines represent hydrogen bonds and
green, the amino acid residues involved; red-colored spheres, water
molecules and yellow residues, residues solely in van der Waals contact.
The structures were obtained at 2.0 (PDB, 4AIF) and 1.9 A˚ (PDB, 4APO),
respectively. (C), Molecular switching in the TPR domain of AIP. The
alternative conformations of Lys 266 allow selection of the Hsp90
MEEVD- (green) or TOMM20 EDDVE-motif (cyan). Dotted blue lines
represent hydrogen bonds while red-colored spheres represent water
molecules.
doi:10.1371/journal.pone.0053339.g004
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chaperones and the TPR domain of AIP involves the terminal five
amino acids of these proteins.
Although we were unable to test the binding of intact PDE4A5
to AIP, we instead measured the affinity for the interaction of the
peptide TLEELDW, which contains the core binding sequence
LEELD (identified in PDE2A as LYDLD). The LEELD motif of
PDE4A5 is not a C-terminal sequence and its ability to bind to the
TPR domain is questionable. The binding affinity of the PDE4A5
peptide (TLEELDW; Kd = 64.563.2 mM) was found to be
significantly weaker than the equivalent peptides form HSP90a,
HSP90b and TOMM20 (Kd = 9.5, 14.4–18.6; and 12.3 mM,
respectively; Table 2). Furthermore, a structural analysis of the
PDE2A homologue indicates that the homologous LYDLD
sequence is unlikely to be accessible for binding to the TPR
domain of AIP as it is involved in folding of the protein.
Consequently, the interaction of AIP with PDE4A5 is not
mediated by binding to the LEELD peptide sequence.
AIP does not Affect the HSP90 ATPase Activity
The first TPR-domain protein shown to influence the ATPase
activity of HSP90 was Sti1p [45]. We wanted to see if AIP could
similarly affect HSP90 ATPase activity. A 20-fold molar excess of
full-length AIP did not influence the ATPase activity of HSP90
(Link to Supporting information).
Disease Associated Mutations of AIP
Nonsense, splice variant and frameshift mutations (Table 3)
clearly disrupt the TPR-domain of AIP and lead to a dysfunctional
Figure 5. PyMol cartoon showing dimerization of AIP TPR-domain through crystal lattice contacts. (A), The AIP domains are in green
and yellow. Amino acid residues are in magenta or cyan, hydrogen bonds as blue dotted lines, water molecules as red spheres and bound TOMM20
AQSLAEDDVE-peptide used in the crystallization in gold. However, only residues AEDDVE are visible in the structure. The TPR domains are
symmetrically related and hydrogen bonding is shown in only one half of the figure. The cartoon shows that Arg 304 is hydrogen bounded directly to
the neighboring TOMM20 bound peptide (gold). (B), PyMol cartoon showing a close up of the main interactions between Arg 304 and bound peptide
used in the crystallization (AQLSLAED3D4VE) in panel A. However, only residues AED3D4VE are visible in the structure. (C), Co-immunoprecipitation of
Flag-AIP and Myc-AIP in the presence of TOMM20 peptide (AQSLAEDDVE). The results show that Flag-AIP and Myc-AIP do not co-immunoprecipitate.
M, molecular mass markers, with molecular mass indicated to the left of the panel; lane 1 and 5 AIP input (cleared lysate) protein; lane 2 and 6 are
anti-Myc co-immunoprecipitation, lanes 3 and 7 are anti-Flag co-immunoprecipitations, while lanes 4 and 8 are IgG control. Lanes 1–4 (first gel) was
blotted for Myc tag and lanes 5–8 (second gel) for Flag tag. The arrow indicates the position where the flag- and myc-tagged AIP runs (40 Kd). (D),
The core interaction of the AIP dimerization interface shows that E192 is buried and shielded from solvent by Ala 312, Arg 188 and Trp 279.
doi:10.1371/journal.pone.0053339.g005
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protein. However, the effect of missense mutations is difficult to
predict. We have used our structure to define mutations associated
with disease to understand how they might affect the function of
this domain. Many of the missense mutations are involved in the
folding and stability of the TPR AIP-domain. C238Y, K241E,
I257V, R271W, and possibly A299V all disrupt either hydropho-
bic or polar interactions that impact on the folding of the domain
(Table 3). In fact, attempts to purify C238Y and A299V resulted in
much of the protein aggregating suggesting that the proteins were
at least partly unfolded. In contrast, R304* (nonsense mutation),
R304Q, Q307* and R325Q were identified as ‘disease-associated’
mutations that, in vitro at least, do not disrupt chaperone binding.
Our ITC results show that for R304A and R304Q the HSP90,
HSP70 and TOMM20 peptides bind normally (Table 2). Struc-
tural analysis showed that the Gln 307 and Arg 325 amino acid
residues (all clearly visible in the TOMM20-AIP structure), are
further away from the TPR domain-binding site than Arg 304,
and are not involved in packing interactions or in binding of the
bound conserved peptide motifs. Thus, at least in vitro, these
residues do not disrupt chaperone binding although they have
been strongly implicated in causing FIPA [4,6,50–52]. Further-
more, the extreme C-terminus of AIP has been shown to represent
the binding site for the client proteins AhR and PDE4A5 [48,52].
These results suggest that disruption of client-protein binding
alone is sufficient for pituitary tumor predisposition.
Further analyses of the extreme C-terminus of the Ca-7h shows
that there are a number of conserved charged and hydrophobic
residues (Fig. 6). These residues are predicted to be part of a helical
structure (PSIPRED, UCL Department of Computer Science,
Bioinformatics Group), and form two conserved regions on either
side of the helix (Fig. 6C). Hydrophobic residues beyond Ile 313,
the last residue in the structure that is involved in packing with the
main fold of the domain, would not be buried if the Ca-7h
continues as such into solvent. The conservation of these residues
suggests that they represent a binding site for specific client
proteins; especially for AhR and PDE4A5, which are client
proteins known to interact with this helix (Fig. 6D).
Discussion
The structure of the TPR domain of AIP in complex with
peptide representing the TPR-domain binding motif from HSP90
and TOMM20 were determined to high resolution. The structure
with TOMM20 peptide showed that electron density for residues
Asp 172 to Arg 325 of the TPR domain was visible. We show that
HSP90, HSP70 and TOMM20, but not the PDE4A5
TLEELDW-peptide, can interact with the TPR domain of AIP
with similar affinity. Using ITC we show that the stoichiometry of
the interaction between AIP and intact HSP90 was 0.5:1
(AIP:HSP90).
AIP binding of these conserved peptide sequences is similar to
that observed for CHIP, rather than that seen with HOP. Unlike
HOP-bound peptides, for AIP and CHIP the upstream sequence
of the peptides is directed up and out of the binding cleft to avoid
interaction with these upstream sequences, which differ between
HSP70 and HSP90 [11,12]. HOP is a co-chaperone of HSP90
that not only acts as scaffold between HSP70 and HSP90, but also
silences the ATPase activity of HSP90 [45]. It thus stalls the
ATPase-coupled conformational cycle of HSP90 and allows client
protein loading from HSP70 to HSP90 [11,44,45]. HOP binds
HSP70 and HSP90 using separate TPR-domain modules [11],
and therefore can associate with both chaperone systems
simultaneously. CHIP on the other hand is a U box E3 ubiquitin
ligase that binds either HSP70 or HSP90 using a single TPR-
domain module and appears to ubiquitinate client proteins of
these chaperone systems [12,53,54]. The conformation that the
bound peptides adopt with HOP and CHIP/AIP is largely
dependent on the position of the hydrophobic pockets that accept
the methionine and valine amino acid residues of the conserved
binding motif MEEVD, in the case for HSP90. Thus, the TPR
domains can be reclassified depending on the relative position of
these hydrophobic pockets. When both pockets are on the same
side of the TPR-binding cleft we observe the HOP-type mediated
binding (cis-mode). When the methionine pocket is on the other
side we see the CHIP/AIP (trans-mode) of binding. The trans-mode
of binding appears to be used where numerous similarly related
peptides are binding to the same TPR domain.
Another interesting feature by which AIP accommodates these
different TPR-binding sequences is by way of a specific side chain
rearrangement (Fig. 4C). The methionine side-chain of the
conserved MEEVD motif being hydrophobic in nature can enter
the appropriate hydrophobic pocket, while for the TOMM20
glutamate its side chain enters the hydrophobic pocket but the
carboxylic acid group points back out and interacts with the side-
chain amine group of Lys 266. The ‘switched’ conformation of Lys
266 then allows the side-chain of the C-terminal glutamate to pack
between Lys 266 and Pro 232 and to form a water-mediated
interaction to the side-chain amine of Asn 264. In contrast, for the
HSP90 peptide, Lys 266 forms direct hydrogen bonds with the
carboxyl group of the shorter C-terminal aspartic acid side-chain
as part of the carboxylate clamp. Thus, the rearrangement that
allows the glutamate residue of TOMM20 (EDDVE) to bind the
Table 2. Isothermal titration calorimetry binding of AIP and
target.
TPR-domain Ligand Kd (mM) N
DH
(cal/mol)
DS
(Cal/mol/
deg)
WT FL-hHSP90b 13.361.8 0.30 24554 7.29
E192R FL-hHSP90b 11.161.3 0.47 24114 9.11
WT MEEVD (HSP90) 12.661.6 1.0 24140 8.75
WT EDASRMEEVD
(hHSP90b)
18.662.0
14.461.0
1.2
1.1
25041
23921
5.02
9.22
R304A EDASRMEEVD
(hHSP90b)
15.660.85 0.96 26435 0.76
R304Q EDASRMEEVD
(hHSP90b)
16.261.1 0.98 26417 0.76
WT DDTSRMEEVD
(hHSP90a)
9.560.6 1.2 23529 11.3
WT GSGPTIEEVD
(hHSP70)
18.161.9 0.63 26348 0.76
R304A GSGPTIEEVD
(hHSP70)
22.861.6 0.66 25456 3.24
R304Q GSGPTIEEVD
(hHSP70)
31.162.6 0.84 25498 2.48
WT AQSLAEDDVE
(hTomm20)
12.360.5 0.87 26765 0.16
R304A AQSLAEDDVE
(hTomm20)
16.660.5 0.69 24508 7.0
R304Q AQSLAEDDVE
(hTomm20)
22.562.2 0.66 26073 1.23
WT TLEELDW
(hPDE4A5)
64.563.2 0.89 24418 4.6
doi:10.1371/journal.pone.0053339.t002
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hydrophobic pocket also allows the longer C-terminal glutamate
side-chain of TOMM20 to be accommodated.
Analysis of the mutations that occur in AIP in the context of the
structure (residues visible were Asp 172 to Arg 325) has allowed us
to define their effects on the structural integrity of the AIP protein.
Most mutations affect the structural integrity of the TPR domain
(Table 3). However, no single mutation of the TPR domain
prevents chaperone binding alone. In contrast, a subset of disease-
associated mutations of conserved residues of the Ca-7h that affect
client-protein binding alone was identified. Our structures and
ITC data show that for the R304A/Q mutations chaperone
binding is unaffected. For Gln 307 and Arg 325 these residues are
further away from the TPR domain binding-site and are not
involved in domain packing interactions. Consequently, they are
not part of the chaperone-binding site of the TPR-domain.
Interestingly, the R325Q mutation is one residue short of the 5-
residue deletion that disrupts AhR binding [5,48,52]. Of these five
residues only two are conserved, Ile 327 and Phe 328 (Fig. 6),
which alone are unlikely to represent the complete interaction site
of AhR as this would be very weak. Consequently, the extensive
conservation of the Ca-7h is likely to represent an interaction site
for at least AhR. However, the R304Q mutation is also known to
slightly destabilize the PDE4A5 interaction [52], providing clear
evidence that the conservation in the Ca-7h represents a binding
site for client proteins (Fig. 6D). Our results therefore suggest that
the primary change in a subset of AIP mutant of the Ca-7h is loss
of association with, at least some, client proteins. Whether in vivo
this also leads to a breakdown in the association of HSP90 and
AIP is currently unknown and warrants further investigation.
However, it appears that AIP acts as a co-chaperone that delivers
client protein to HSP90, in common with other co-chaperones of
HSP90 such as HOP and CDC37 [14].
The destabilization of AhR would naturally imbalance assembly
of AhR/ARNT complex and it has been shown that levels of
either ARNT or ARNT2, but not both, are devoid in AIP-
deficient mouse pituitary tumors [55]. Furthermore, PDE2A,
which is AIP dependent, inhibits nuclear translocation of AhR by
lowering cAMP levels. Consequently, elevated and aberrant
cAMP signalling, often seen in pituitary tumors, may imbalance
AhR/ARNT and ARNT/Hif-1e signalling. Disruption of AhR
binding to AIP might also have profound effects on ERa-
dependent transcription. Loss of AIP binding to AhR causes
degradation of AhR [56]. Thus, a model can be proposed (Fig. 7),
which results in the destabilization of AhR, which could then
upregulate expression from ERa dependant promoters by
affecting several different mechanisms. Thus, AhR would not
compete for ERa cofactors and transcription factors, would fail to
promote the proteasomal degradation of ERa and would not be
available for binding to inhibitory xenobiotic response elements
(iXRE), that downregulate specific ERa-directed expression [57].
However, the exact effects on ERa levels and ERa-directed
transcription are currently unknown. Certainly work by Cai et al.,
[58] shows that AIP acts as a negative regular of ERa. Although,
the same authors show that ERa is still able to associate with AIP
Table 3. Classification of the effect TPR-AIP mutations on its structure.
Mutation Mutation type AIP domain Probable effect of the mutation
Q184* Nonsense TPR domain Non-functional
K201* Nonsense TPR domain Non-functional
E216* Nonsense TPR domain Non-functional
Q217* Nonsense TPR domain Non-functional
E222* Nonsense TPR domain Non-functional
C238Y Missense TPR domain Disrupts packing of hydrophobic core
Q239* Nonsense TPR domain Non-functional
C240R Missense TPR domain Disrupts packing of hydrophobic core
K241E Missense TPR domain Disrupts hydrogen bonding to Glu246
K241* Nonsense TPR domain Non-functional
I257V Missense TPR domain Disrupts packing of hydrophobic core
Y261* Nonsense TPR domain Ligand binding
K266A Missense TPR domain Ligand binding
Y268C Missense TPR domain Disrupts packing of hydrophobic core
Y268* Nonsense TPR domain Non-functional
R271W Missense TPR domain Disrupts hydrogen bonding to Asp287 and Ser255
A277P Missense TPR domain Disrupts hydrophobic packing against Tyr 247
A291M/E Missense TPR domain Disrupts packing of hydrophobic core. (Forms base of hydrophobic pocket
interacting with bound peptide)
A299V Missense TPR domain At start of Ca-7h and may disrupt some small degree of packing with Leu292
R304* Nonsense TPR domain Weakens PDE4A5 binding (see E304Q and [52]) and would disrupt AhR
binding
R304Q Missense TPR domain Weakens PDE4A5 binding (see [52])
Q307* Nonsense TPR domain Would disrupt AhR binding
R325Q Missense TPR domain Potentially client-protein binding. One residue short of the 5-residue deletion
that disrupts AhR binding
doi:10.1371/journal.pone.0053339.t003
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Figure 6. Sequence conservation of the Ca-7h of AIP. (A), sequence alignment showing conservation of amino acid residues. Ss, Salmo salar
(NM_001140060.1); Dr, Danio rerio (NM_214712.1); Rn, Rattus norvegicus (NM_172327.2); Mm, Macaca mulatta (NM_001194313); Ca, Chlorocebus
aethiops (O97628); Hs, Homo sapiens (FJ514478.1); Bt, Bos taurus (NM_183082.1), Xt, Xenopus (Silurana) tropicalis (NM_001102749.1) and Cc, Caligus
clemensi (BT080130.1). (I313+), Ile 313 represents the last residue in the sequence that is involved in packing interactions of the TPR domain.
Mutations associated with disease are indicated above the sequence. (* below the sequence), Amino acids at these positions are identical; (:), highly
conserved (.) or conserved. Arg 304 of Human AIP is shown in red type face. Numbers above the sequence (positions 1 to 15) represent residue
numbers of the helical wheel shown in panel B. (B), Helical wheel showing the position of identical and conserved residues form the alignment in
panel A for the Ca-7h of AIP. Orange, non-polar; green, polar uncharged; pink, acidic and blue, basic amino-acid residues. (C), PyMol cartoon showing
a hypothetical helix (residues beyond Arg 325) with the identical and highly conserved amino acid residues shown in panels A and B. Conserved
residues on one side of the helix are shown in green and on the other in yellow. Residue numbers shown are those in panel B, while those in brackets
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R304* mutant. Furthermore, these experiments used overex-
pressed AIP mutant and therefore do not address whether the
mutation fails to provide the normal negative regulatory effect on
ERa under normal AIP levels. Interestingly, other mutations, such
as Q217*, that disrupt the TPR domain were seen to activate ERa
directed transcriptional activity. Furthermore, it is also known that
tumor suppressor levels of PLAGL1 decline in the absence of
functional AIP, but the mechanism leading to this is poorly
understood. None-the-less the loss of an important tumor
suppressor is likely to have some role in the formation of pituitary
adenomas. However, it is evident that because of AIP’s
promiscuity a variety of biochemical changes in pituitary cells
occur under conditions when AIP is non functional. Consequently,
pituitary tumor predisposition is likely to be a result of these
biochemical changes that may all contribute to a varying degree in
the process.
In conclusion, our results show that Arg 304 does not play any
significant role in mediating AIP binding to HSP90, HSP70 or
are actual residue numbers in panel A. (D), The TPR-domain of the R304* mutant of AIP. Deletion of the terminal region of AIP (transparent helical
region) allows chaperone binding but disrupts association with PDE4A5 and AhR.
doi:10.1371/journal.pone.0053339.g006
Figure 7. Model showing the affect of mutant AIP on cellular signaling pathways. (A), Wild type AIP stabilizes AhR, which in turn
downregulates ERa dependent transcription by promoting the ubiquitination and proteasomal destruction of ERa, by competing for specific
cofactors required for ERa dependent transcription and by binding to iXRE sites that block ERa dependent transcription. AIP downregulates
transcription by ERa at ERE sites. AIP is also known to maintain cellular levels of PLAGL1 and PDE4A5. Small triangles represent ligand bound to their
appropriate receptor. (B), Mutant AIP fails to bind AhR, PDE4A5 and possibly ERa, resulting in unstable AhR and PDE4A5 and perhaps upregulation of
transcription at ERE sites. A decline in levels of PLAGL1 and changes in cAMP concentration also result. The question mark emphasizes that AIP may
or may not interact with ERa at ERE sites, but if it does it may fail to provide appropriate negative regulation.
doi:10.1371/journal.pone.0053339.g007
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TOMM20. Taken together with the highly conserved C-terminus
of AIP, and specific mutations that occur on the Ca-7h, our results
support the idea that this helix is involved in client protein
interactions, at least with AhR and PDE4A5, and that loss of such
interactions leads to a variety of biochemical changes in pituitary
cells that predisposes to pituitary adenoma. Consequently,
understanding the role AIP plays in maintaining and activating
Ca-7h interacting client proteins will help towards understanding
the cellular events that lead to pituitary tumor predisposition. This
study forms the springboard for more detailed investigations in
isolating AIP client-proteins that when deregulated predispose to
pituitary tumors.
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Introduction
Despite their relative rarity, familial pituitary 
tumors represent a very interesting group of condi-
tions, with a heterogeneous genetic background 
and a widely variable phenotype within affected 
families (Figure 10.1). Previously, around 4–5% of 
the cases were suggested to occur in a family 
setting, either isolated or as part of an endocrine 
tumor syndrome [1], but current data suggest a 
higher proportion of familial cases [2], and the 
recent establishment of familial isolated pituitary 
adenoma (FIPA) as a separate clinical entity is 
expected to increase this prevalence [2]. There is a 
higher proportion of genetic forms of pituitary ade-
nomas within young patients (both hereditary and 
nonhereditary) [3]. In fact, up to 20% of children 
with a hormone-secreting pituitary adenoma have 
a germline mutation in a known predisposing gene 
[4,5]. A better understanding of the causative genes 
and the pathogenic mechanisms of this particular 
group of tumors is needed to improve the diagnosis 
and management of these patients, which, hope-
fully, will lead to a better prognosis.
The inherited conditions that, to date, are known 
to predispose to pituitary adenomas are multiple 
endocrine neoplasia type 1 (MEN1), multiple endo-
crine neoplasia type 4 (MEN4), Carney complex 
(CNC), FIPA and, possibly, mutations in DICER1 
[6] and succinate dehydrogenase (SDH) genes [7–
9]. Previous data suggest that approximately 2.7% 
of all pituitary tumors occur in the context of 
CHAPTER 10
MEN1 [10] and that FIPA accounts for another 
2.5% [11]. CNC explains a few hundred cases 
worldwide [11], while MEN4 and SDH-related 
familial pituitary adenomas have only been 
described in a few individuals [7,12–18]. Neverthe-
less, the genetic basis for these conditions has not 
been identified for all cases: in 5–10% of MEN1 
patients [19], 27% of CNC patients [20], and 
70–85% of FIPA patients [21] the causative gene 
or genes have not been identified as yet.
An important aspect of the study of these rare 
genetic syndromes is the potential role of the caus-
ative genes in the more common sporadic pituitary 
adenomas. Therefore, somatic mutations have 
been studied in sporadic pituitary adenomas: MEN1 
mutations have very rarely been identified [19], 
but no mutations have been described in other 
genes associated with familial pituitary adenomas 
(PRKAR1A and AIP) [22–25].
Multiple Endocrine 
Neoplasia Type 1
In 1954, Wermer reported the first clinical descrip-
tion of a family with an association of pituitary 
tumors, hypercalcemia and pancreatic adenomas 
[26]. MEN1 (OMIM #131100) is a syndrome char-
acterized by the development of tumors mainly 
in endocrine but also nonendocrine organs. The 
three main components of the syndrome are 
hyperparathyroidism, enteropancreatic endocrine 
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tumors, and pituitary adenomas [26]. The diag-
nosis of MEN1 is established when two of these 
features are present or when one feature is present 
together with a first-degree relative with estab-
lished MEN1 [27]. Other endocrine components of 
the syndrome are foregut carcinoids, adrenal cortex 
nonfunctioning tumors, and, rarely, pheochromo-
cytomas, while lipomas, facial angiofibromas, col-
lagenomas, and ependymomas are nonendocrine 
tumors associated with MEN1 [27].
The observation of loss of heterozygosity (LOH) 
of chromosome 11q13 in tumors from MEN1 
patients led to the mapping, in 1988 [28], and later 
cloning, in 1997 [29,30], of MEN1. This gene spans 
7.2 kb of genomic sequence, contains a 1830-bp 
coding region with 10 exons (the first is not trans-
lated) and encodes a 610-amino-acid protein, 
menin [29]. MEN1 mutations are detected in 
90–95% of MEN1 patients [19].
To date, more than 1300 MEN1 mutations are 
known, distributed through the whole gene, al -
though there are mutational ‘hot spots’ in exons 2, 
3, 9, and 10 and intron 4 [19,31]. Until 2008, 1133 
germline and 203 somatic mutations had been 
described: 23% were nonsense, 9% splice-site, 
41% frameshift deletions or insertions, 6% in-frame 
deletions or insertions, 20% missense, and 1% 
whole or partial gene deletions [19].
LOH in 11q13 occurs in around 90% of tumors 
from MEN1 patients but LOH can also be found at 
this region in 5–50% of sporadic endocrine tumors 
[19]. Somatic MEN1 mutations are common in 
sporadic parathyroid (9.5–21% of cases) and pan-
creatic islet cell tumors (19–44%), but they occur 
only very rarely (0–3.67%, only 10 mutations 
described) in sporadic pituitary tumors [19]. Non-
sense, frameshift, splice-site, and missense muta-
tions have been identified and characterized by 
several excellent publications.
Menin
MEN1 is considered a tumor suppressor gene 
because heterozygous inactivating mutations pre-
dispose to neoplasia, MEN1 knockout mice repro-
duce the human phenotype, and the majority of 
MEN1-related tumors show LOH at 11q13 [28, 
32–35]. In tumors without LOH, it is speculated 
that other mechanisms of gene inactivation (hyper-
methylation, mutations of the promoter or non-
coding regions microRNA regulation) may occur 
[32]. By transcriptional regulation, MEN1 produces 
two transcripts: a ubiquitously expressed 2.9-kb 
transcript with several alternatively spliced iso-
forms, and a 4.2-kb transcript, present in the pan-
creas and thymus [30]. Menin is a 67-kDa protein 
without homology to any other protein [29,36] 
(Figure 10.2). It is highly conserved within species: 
murine menin shows 97% identity/98% similarity 
to human menin [37].
Menin controls the promoter activity of various 
genes involved in transcriptional regulation, 
genome stability, cell division, and proliferation. It 
interacts with numerous partners:
• Menin activates the transcription of CDKN1B 
(encoding the cyclin-dependent kinase inhibitor 
p27Kip1) and CDKN2C (encoding the cyclin-
dependent kinase inhibitor 2C, also known as 
p18Ink4c) by recruiting the histone methyltrans-
ferase mixed lineage leukemia protein (MLL) to the 
promoters and coding regions of these genes, where 
MLL catalyzes histone H3 lysine 4 (H3K4) methyla-
tion. Although menin expression does not differ 
between endocrine and nonendocrine organs, 
MLL, p27Kip1, and p18Ink4c are predominantly ex -
pressed in endocrine organs and this expression 
profile could partially explain the selectivity of 
tumorigenesis in patients with MEN1 [38]. Through 
interaction with MLL, menin also regulates the 
transcription of homeobox (HOX) genes (particu-
larly Hoxa9), important for cell proliferation, dif-
ferentiation and morphogenesis [39]. In a similar 
way, menin recruits polycomb group (PcG) pro-
teins to enhance H3K27 methylation at the pleio-
tropin (PTN) gene, silencing the expression of this 
pro-proliferative gene.
• In the normal pituitary, menin interacts with 
activin, negatively regulating cell proliferation and 
the secretion of prolactin (PRL), growth hormone 
(GH), and adrenocorticotropin (ACTH), through 
inhibition of POU1F1.
• The transforming growth factor-β (TGF-β) sign-
aling pathway exerts inhibition of proliferation and 
transcriptional activity through Smad2 and Smad3 
90   Section 2: Disorders
Figure 10.2. Functional domains of the main proteins implicated in familial pituitary adenomas: menin, p27Kip1, AIP, 
and PRKAR1A. Menin has three nuclear localization signals (NLS) at its C-terminal domain, two phosphorylation 
sites at Ser 543 and 583, and five putative guanosine triphosphatase (GTPase) motifs [19,142]. p27Kip1 has a nuclear 
export signal (NES) and a NLS, as well as multiple phosphorylable residues, important for its regulation by other 
proteins [73,143]. The N-terminal half of AIP contains the so-called immunophilin-like domain (PPIase, FKBP-type), 
while its C-terminal region has three TPR domains and an α-7 helix [85,144,145]. The most important regions of 
PRKAR1A are those necessary for cAMP binding, in its C-terminal half [146].
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Clinical Features
MEN1 has an autosomal dominant pattern of 
inheritance. Eighty-five percent of the cases are 
familial and 15% are sporadic, but the frequency 
of MEN1 mutations is apparently not different 
between these two groups. Penetrance is variable 
and age and organ-specific [27]. Female gender 
slightly predominates (52–57% of patients) [53]. 
Within MEN1 patients, pituitary tumors are 
more common in females, while gastrinomas and 
thymic carcinomas are more common in males 
[53]. There is no clear genotype–phenotype cor-
relation [54].
Hyperparathyroidism is the most constant feature 
of the syndrome: it is present in 90–100% of the 
patients by the age of 50 years [27]. Parathyroid 
adenomas are usually the first manifestation of 
the syndrome (72–87% of patients). These tumors 
are usually multiple, and require extensive surgical 
treatment [27].
Thirty to 80% of MEN1 patients develop entero-
pancreatic islet cell tumors [27]. In the setting of 
MEN1, these tumors are multicentric and hormone-
secreting, and may become invasive or metastasic 
(especially gastrinomas and glucagonomas) [27, 
55]. They are the first manifestation of the disease 
in around 25% of patients [56]. Tumors arise in 
any part of the pancreas or the duodenal mucosa. 
The most common subtype is gastrinoma (in 
40–63% of patients), causing the Zollinger–Ellison 
syndrome (ZES) [57,58]. Surgery is usually cura-
tive only for insulinoma, but other enteropancre-
atic islet cell tumors respond well to medical 
treatment with proton pump inhibitors (gastrino-
mas) or somatostatin analogs (SA) [27]. Carci -
noids related to MEN1 arise in thymus and gastric 
mucosa and rarely hypersecrete hormones [27], 
but they may cause the ectopic ACTH syndrome or 
increased GH-releasing hormone (GHRH) secretion 
and acromegaly [59]. Metastasic neuroendocrine 
tumors represent the main MEN1-related cause of 
death [60].
Adrenal cortical tumors are present in 20–40% 
of MEN1 patients, and most often are bilateral, 
hyperplastic, and nonfunctional lesions; adrenal 
carcinomas are rare [27]. Up to one-third of the 
proteins [39]. Menin interacts with Smad3 and the 
loss of this function prevents Smad3 to bind DNA, 
blocking TGF-β effects [40].
• Other menin effects over transcriptional activity 
are the inhibition of JunD-mediated and en -
hancement of c-Jun-mediated transactivation of 
the activating protein-1 (AP-1) [41], as well as its 
interaction with members of the nuclear factor-
kappa B (NF-κB) family, modulating their tran-
scriptional activity [42].
• Menin interacts with the nuclear receptors per-
oxisome proliferator-activated receptor γ (PPAR-γ) 
and the vitamin D receptor (VDR), enhancing the 
expression of their target genes [43].
• The expression of insulin-like growth factor 
binding protein 2 (IGFBP-2) [44], insulin-like 
growth factor 2 (IGF-2) and parathyroid hormone-
related protein (PTHrp) [45], important prolifera-
tive factors in endocrine tumors, is negatively 
modulated by menin.
• Menin directly interacts with β-catenin and 
carries it out of the nucleus, thus inhibiting tran-
scriptional activity and cell proliferation by the 
wingless-type MMTV integration site family 
(WNT)/β-catenin signaling pathway [46].
• Menin interacts with the 32 kDa subunit of rep-
lication protein A (RPA2) [47] as well as with 
FANCD2 [48]; both are proteins involved in DNA 
repair. Through its interaction with the promoter 
of the human telomerase reverse transcriptase 
(hTERT), menin apparently acts as a repressor of 
telomerase activity [49].
• Other menin interactors are proteins involved in 
cell division, such as non-muscle myosin II-A 
heavy chain (NMHC II-A) [50], glial fibrillary acidic 
protein (GFAP) and vimentin [51].
In mice, homozygous deletion of MEN1 is lethal 
in utero due to multiple developmental delay and 
craniofacial, cardiac, neural, and hepatic abnor-
malities [19,33,52]. Heterozygous mice for partial 
deletions of MEN1 develop a syndrome similar to 
human MEN1 [33,52]. In another model, the same 
deletion, conditionally restricted to the pancreas, 
showed that heterozygous loss of menin expression 
caused hyperplasia, but LOH was necessary for pro-
gression to a tumor [34].
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new components of the syndrome can arise at any 
age [27]. An annual biochemical screening, includ-
ing calcium, parathyroid hormone, gastrin, fasting 
glucose, insulin, chromogranin-A, glucagon, proin-
sulin, PRL, and IGF-1 is recommended [27]. 
Imaging studies (CT, MRI, and, rarely, 111In-DTPA 
octreotide scan) should be done at regular inter-
vals [27].
Multiple Endocrine 
Neoplasia Type 4
The absence of MEN1 mutations in a minority 
(5–10%) of patients with MEN1 clinical features 
drove a search for additional loci implicated in 
this phenotype. Spontaneous mutations were 
found in Cdkn1b in association with a multiple 
endocrine neoplasia syndrome (called MENX) 
showing features of both human MEN1 and MEN2 
syndromes, occurring spontaneously in a labora-
tory rat strain [12]. Following this discovery, muta-
tions in CDKN1B were identified in a small group 
of human patients with multiple endocrine tumors 
typical of MEN1 but not MEN2 or other clinical 
features, but without germline mutations in MEN1 
or RET (the gene associated with MEN2 syndrome) 
[66]. This infrequent MEN1-like syndrome was 
named MEN4 (OMIM #610755) [67].
CDKN1B, a gene located at 12p13.1, encodes the 
cyclin-dependent kinase inhibitor (CDKI) p27Kip1. 
Since the first report, mutations in CDKN1B have 
been sought in many patients with MEN1 features, 
negative for MEN1 mutations, but they have rarely 
been found [68–71]. These patients might have a 
different genetic background, not yet identified. A 
large screening study of MEN1-like patients identi-
fied mutations in genes encoding CDKN1B as well 
as other CDKIs, p15, p18, and p21; however, these 
mutations appear to be uncommon [14].
p27Kip1
p27Kip1 is a highly conserved 27-kDa protein (Figure 
10.2). CDKN1B is a tumor suppressor gene. Subcel-
lular localization of p27Kip1 determines its functions. 
In G0 and early G1, p27Kip1 expression is maximal 
patients develop lipomas, both cutaneous and 
visceral [27]. Multiple facial angiofibromas are 
found in 40–80% of cases [27].
Approximately 40% of MEN1 patients develop 
pituitary adenomas [61]. A pituitary adenoma is 
the first manifestation of MEN1 in around 17% of 
patients [61] (ranging from 10 to 25% [27]). Pitui-
tary adenomas in the context of MEN1 arise at a 
younger age (35.1 ± 14.8 years) than in patients 
with sporadic pituitary adenomas [61]. The earliest 
age of presentation reported is 5 years [62]. Prol-
actinomas predominate (62%), but nonfunctioning 
pituitary adenomas (NFPAs) (15%), somatotropi-
nomas (9%), corticotropinomas (4%), and rarely 
thyrotropinomas can also arise [61,63]. One case 
of gonadotroph cells carcinoma in a MEN1 patient 
has been reported [63]. Ten to 39% of tumors 
secrete more than one hormone, usually PRL/GH 
[61,64]. The majority of these tumors are macroad-
enomas (76–85%) and around half of them are 
invasive [61,64]. Four percent of patients present 
multiple adenomas [64].
Pituitary adenomas in MEN1 patients are signifi-
cantly larger and more invasive than in sporadic 
patients, but the Ki-67 index and the mitotic activ-
ity are not different [64]. Hyperplasia of soma-
totroph or mammosomatotroph cells has been 
described, but it is not common and in some cases 
it is due to an ectopic GHRH-secreting tumor 
[64,65]. In an invasive tumor from a very young 
MEN1 patient, overexpression of genes related to 
tumorigenesis (TPD52, FOS, and SHC1), and cell 
growth (GNAS, FOSB, and SRF) as well as loss of 
E-cadherin function were detected [62].
In general, the response of secretory pituitary 
adenomas to medical and/or surgical treatment is 
suboptimal; normalization of hormone secretion is 
achieved in only 42% of patients [61]. Medical 
treatment of prolactinomas in MEN1 patients is 
complicated because they show a poor response to 
dopamine agonists [61].
Sequence analysis of MEN1 in index cases and 
their relatives is important in order to determine 
which individuals require follow-up, as well as to 
identify phenocopies (they are present in ∼5% 
of families). MEN1 mutation carriers and MEN1 
patients should have long-term follow-up, because 
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in multiple human cancers, correlating with aggres-
sive behavior [73], as well as in some endocrine 
malignant and benign tumors (pheochromocyto-
mas, parathyroid adenomas and pancreatic and 
digestive endocrine tumors) [66,78].
Germline mutations in CDKN1B are extremely 
rare: they explain only 1.5–2.8% of MEN1 
phenotype/MEN1-mutation negative cases [13,14], 
therefore, only ∼0.1–0.2% of all MEN1 cases. The 
first CDKN1B germline mutation identified in a 
MEN4 patient was a nonsense mutation that had 
been previously identified as a somatic change in 
an adult patient with leukemia [12,66]. To date, 
eight CDKN1B germline mutations have been 
described in MEN4 patients, including a frameshift, 
a nonsense mutation, a nonstop mutation, a dele-
tion in the 5′ untranslated region (UTR), a muta-
tion in the Kozak sequence, and three missense 
mutations [12,14–17]. The functional effect of 
these mutations is the production of a low-
expressing and/or unstable and nonfunctional 
protein [12,14–16,66,71]. To better define the role 
of CDKN1B mutations as a cause of pituitary ade-
nomas, 124 affected subjects from 88 FIPA families, 
negative for AIP mutations, were recently studied 
[18]. None of the identified variants was found to 
be causing the disease; thus, systematic screening 
for these mutations in FIPA patients is currently 
unjustified [18].
Pituitary Adenomas
Under physiologic conditions, p27Kip1 is especially 
highly expressed in the human pituitary [38] in all 
types of cells except normal corticotroph cells, 
which show a lower expression [79]. Expression 
of p27Kip1 is significantly reduced in all pituitary 
adenoma types, but the protein is practically absent 
in corticotropinomas and pituitary carcinomas [79], 
however, no somatic CDKN1B mutations, nor LOH 
of 12p13, have been found in corticotropinomas 
[76,80]. Out of the eight cases with germline 
CDKN1B mutations reported to date, only three 
pituitary adenomas have been reported among 
MEN4 patients (somatotropinoma, corticotropi-
noma, and NFPA) [71]. Because of the scarcity of 
cases, data about the specific histological features 
of pituitary adenomas in MEN4 cases are lacking.
and is localized in the nucleus, where it binds and 
inhibits the cyclin E-CDK2 complex. In proliferat-
ing cells, p27Kip1 is sequestered in the cytoplasm, 
with a substan tial proportion bound to cyclin 
D-CDK4. As cells progress through phase G1, 
p27Kip1 expression decreases, allowing cyclin 
E-CDK2 and cyclin A-CDK2 to activate the tran-
scription of genes necessary for G1-S transition and 
the initiation of DNA replication. On the other 
hand, p27Kip1 can act as a substrate for the cyclin 
E–CDK2 complex, resulting in tyrosine phosphor-
ylation which triggers ubiquination and proteaso-
mal degradation of p27Kip1 [72]. Many other 
proteins and also microRNAs modulate p27Kip1 
transcription and proteolysis [73]. Regarding cyclin 
D-CDK4 and cyclin D-CDK6 complexes, p27Kip1 
exerts a dual role. Under adverse conditions for 
replication, p27Kip1 inhibits type D cyclins, while in 
early G1 to mid-G1 phase it promotes cyclin 
D-CDK4 assembly and nuclear import [73].
In tumoral cells, cytoplasmic sequestration of 
p27Kip1 (via AKT-dependent phosphorylation on 
residue Thr157) inhibits its activity, leading to 
enhanced tumor invasiveness. p27Kip1 activity can 
also be reduced via SKP2, the E3 ubiquitin ligase 
of p27Kip1, which promotes its degradation [66,67]. 
p27Kip is a downstream element of the tumor sup-
pressor gene MEN1 signaling pathway. Menin, 
through its interaction with histone methyltrans-
ferases, enhances the activity of the CDKN1B 
promoter [66]. Paradoxically, p27Kip1 can display 
oncogenic activity through a CDK-independent 
mechanism in experiments using knock-in mice 
with a mutated p27Kip1 unable to bind CDKs [74].
Homozygous knockout mice for p27Kip1 have 
increased body size and develop multiorgan hyper-
plasia, retinal dysplasia, ovulatory defects, female 
sterility and, in 100% of cases, hyperplasia or ade-
nomas of the pituitary pars intermedia, secreting 
ACTH [75]. p27Kip1 somatic mutations or LOH at its 
locus have only rarely been described in human 
tumors [12,66,76]. Decreased p27Kip1 expression, 
either due to heterozygous mutation or because 
of changes in extragenic pathways that regulate 
protein levels, is enough for tumor development 
in p27Kip1+/− mice [77]. Furthermore, an important 
reduction in CDKN1B expression has been described 
94   Section 2: Disorders
Since the late 1990s, linkage analysis and LOH 
for 11q13 has been demonstrated in tumors from 
patients with a familial history of isolated pituitary 
adenomas. In 2006, linkage analysis identified a 
truncating germline mutation in AIP as the cause 
of multiple cases of pituitary adenomas (somatotro-
pinomas and prolactinomas) in one large Finnish 
family [81]. Further studies identified many other 
novel mutations in AIP in individuals from familial 
acromegaly and prolactinoma families and also in 
patients with apparently sporadic pituitary adeno-
mas [24,81,82]. Germline AIP mutations have been 
identified in only 20–25% of FIPA families (40% 
when only somatotrophinoma families are consid-
ered) [21], while the causative gene(s) in the rest 
of the families remain unknown.
The prevalence of FIPA is currently unknown, 
but is probably similar to or higher than MEN1. AIP 
mutations have been found only in 2–3.6% of 
patients with apparently sporadic pituitary adeno-
mas [21,83]. On the other hand, in patients younger 
than 30 years with apparently sporadic pituitary 
macroadenomas, AIP mutations are present in 
11.7% of the whole group and in 20.5% of pedi-
atric patients [5], and thus many of these patients 
represent previously unsuspected FIPA cases.
AIP
Also known as X-associated protein 2 (XAP2), Ah 
receptor-activated 9 (ARA9), and FK506-binding 
protein 37 (FKBP37), AIP was first described in 
1996 as an inhibitor of hepatitis B virus X protein-
mediated transactivation. It shows homology with 
members of the FK506-binding protein family 
(FKBP). AIP is ubiquitously expressed in human 
and murine tissues, and present in lower organisms 
such as Drosophila rerio, D. melanogaster and 
Caenorhabditis elegans, but its tissue-specific func-
tions remain elusive.
The AIP locus is on chromosomal region 11q13.2, 
just 2.6 Mb downstream from MEN1 [84]. AIP has 
six exons, coding for a 37-kDa protein, AIP. AIP is 
a co-chaperone protein, made up of 330 amino 
acids, and is member of the tetratricopeptide repeat 
(TPR) domain-containing protein family that 
includes proteins important for cell cycle control 
Clinical Features
As only a few MEN4 patients have been reported, 
penetrance of the syndrome, frequency of familial 
and sporadic cases, and possible phenotype–
genotype correlations cannot be determined at this 
moment. Nevertheless, as in MEN1, the most 
common component of the syndrome is parathy-
roid involvement. Three CDKN1B mutations have 
been described in familial and five in sporadic 
MEN4 patients. In two of the familial cases not 
only CDKN1B mutation carriers but also clinically 
affected relatives were identified [12,14]. The 
patients described to date have presented 1–4 
endocrine tumors concomitantly. Apart from par-
athyroid and pituitary adenomas, other benign and 
malignant tumors described as part of MEN4 are 
renal angiomyolipoma, an adrenal nonfunctional 
tumor, uterine fibroids, and a gastrinoma, as well 
as a neuroendocrine cervical carcinoma, bronchial 
carcinoid, papillary thyroid carcinoma, and gastric 
carcinoma [12–17].
Due to the lack of a specific MEN4 phenotype, it 
is not possible to establish this diagnosis only by 
clinical data [71]. Because of the low prevalence of 
MEN4, screening for CDKN1B mutations in patients 
with MEN1 diagnosis and negative MEN1 muta-
tions is currently not done routinely in the United 
Kingdom; however, patients previously considered 
as MEN1 phenocopies could be tested for CDKN1B 
mutations in a research setting [71].
Familial Isolated Pituitary 
Adenoma
FIPA (OMIM #102200) is characterized by the 
presence of pituitary adenomas in two or more 
members of a family without associated clinical or 
genetic abnormalities of the classic syndromes (e.g., 
related to MEN1, CNC, or pheochromocytomas/
paragangliomas). FIPA includes families previously 
identified as isolated familial somatotropinoma and 
also the subgroup of FIPA patients with pituitary 
adenoma predisposition (PAP) due to mutations in 
the aryl-hydrocarbon receptor interacting protein 
gene (AIP) [21,81].
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Despite the ubiquitous expression of AIP, no 
other tumor types have been consistently associ-
ated with AIP mutations. Screening in a large series 
of samples from different types of endocrine and 
nonendocrine cancer (colorectal, breast, and pros-
tate), revealed that neither germline nor somatic 
AIP mutations are associated with these neoplasms 
[93]. Somatic mutations have not been found in 
pituitary adenomas either [23,24].
AIP Partners
Direct and indirect associations of AIP with a 
number of proteins, such as aryl-hydrocarbon 
receptor (AhR), heat shock protein 90 (Hsp90), 
phosphodiesterases 4A5 (PDE4A5) [94] and 2A 
(PDE2A), heat shock cognate 70 (Hsc70), survivin, 
PPAR-α, thyroid hormone receptor β-1 (TRβ1), 
estrogen receptor (ER)-α, Epstein–Barr virus-
encoded nuclear protein 3 (EBNA-3), hepatitis B 
virus X protein, translocase of the outer membrane 
of mitochondria 20 (TOMM20), rearranged during 
transfection tyrosine-kinase receptor (RET), and 
G-protein α-13 (Gα13) have been described (see 
review [85]). The most studied associations are 
with AhR, but these may not be the ones involved 
in the pituitary tumorigenesis pathway.
AhR is a transcription factor whose best known 
function is as a mediator in the toxic effects 
(immune, hepatic, cardiac, dermal, teratogenic, 
endocrine, and carcinogenic) of the environmental 
toxin 2,3,7,8-tetrachloro-p-dioxin (TCDD, dioxin) 
[95]. Endogenous ligands have been described, 
such as indigo, indirubin, equilenin, 2-(1′-H-indole-
3′-carbonyl)-thiazole-4-carboxylic acid methyl ester, 
lipoxin 4A, prostaglandin G2, tryptamine, indole 
acetic acid, 6-formylindolo-[7] carbazole, bilirubin 
[96], and, most recently, kynurenine [97]. The 
physiological role of AhR is, apparently, ligand, 
tissue, and species-specific and includes a wide 
variety of effects, such as regulation of the activity 
of nuclear receptors, transcription factors and 
protein kinases, and modulation of cell cycle, cell 
adhesion, and migration as well as alteration of 
multiple intracellular signaling pathways [95]. 
AhR-dependent transcription is regulated by inter-
actions with multiple partners, thus AhR integrates 
[21,85,86]. AIP contains three TPR motifs, and a 
final α-helix, located in its C-terminal half, essen-
tial for interactions with other proteins [85] (Figure 
10.2). Since the identification of AIP as the gene 
related with FIPA, around 60 mutations have been 
described.
AIP mutations in FIPA patients include deletions, 
insertions, segmental duplications, nonsense, mis-
sense, splice-site, and promoter mutations, as well 
as large deletions of whole exons or the entire gene 
[21]. A de-novo mutation has been described in a 
single patient [4]. There are three mutational 
hotspots in AIP, corresponding to CpG islands: 
mutation of both members of the c.910–911 CpG 
site have been described (c.910C > T, p.R304X and 
c.911G > A, p.R304Q), c.811C > T (p.R271W), and 
c.241C > T (p.R81X) [87]. The c.40C > T, p.Q14X 
mutation has been described only in Finnish fami-
lies, suggesting a founder effect. Loss of the 
C-terminal end of AIP occurs in 78% of the 
mutants, due to stop codons or frameshifts result-
ing in stop codons. The missense variants and the 
in-frame segmental duplication mostly affect the 
TPR domains or the C-terminal α-helix. It is impor-
tant that a technique able to analyze a large segment 
of DNA, such as multiplex ligation-dependent 
probe amplification (MLPA), should be used in AIP 
mutation screening, because approximately 10% of 
families that are negative for AIP mutations by 
conventional methods do indeed have large AIP 
deletions [21].
The role of AIP as a tumor suppressor is supported 
by the association of multiple loss-of-function muta-
tions in this gene with the development of pituitary 
adenomas and the presence of LOH in 11q13 in 
pituitary adenomas from AIP mutation-positive 
FIPA patients [24,84,88,89]. Mutations in AIP lead 
to loss of function of the protein. Furthermore, AIP, 
like most tumor suppressor genes, is evolutionarily 
conserved among species [85], and its overexpres-
sion slows down cell proliferation in vitro [24] while 
AIP knockdown leads to increased proliferation 
[90]. As often occurs with other tumor suppressor 
genes, AIP plays a role in early development: AIP-
null mice die during embryonic development due to 
congenital cardiovascular abnormalities [91,92].
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rases and AhR, as both are involved in the cAMP 
pathway. The cAMP pathway is known to be 
important for somatotroph function, as it is the 
second-messenger pathway for GHRH receptor 
and also as disruption of this pathway via muta-
tions in GNAS (somatic GNAS mutations, so-called 
‘gsp’ mutations, and mosaic mutations in McCune–
Albright syndrome) result in pituitary adenomas. 
Loss of the AIP–PDE4A5 interaction has been dem-
onstrated in vitro with multiple missense and non-
sense mutations [24,84]. More functional studies 
are needed to explain the role of AIP mutations in 
pituitary tumorigenesis, determining if it involves 
only an absence of tumor suppression activity or 
if, additionally, mutant proteins acquire oncogenic 
abilities.
AIP in the Pituitary
AIP is expressed in the normal pituitary, predomi-
nantly in somatotroph and lactotroph cells [24,103]. 
Interestingly, AIP is associated with GH- and PRL-
containing vesicles in normal somatotroph and 
lactotroph cells [24]. Unexpectedly, AIP has been 
detected in corticotropinomas and it is especially 
increased in NFPAs (usually of gonadotroph cell 
origin), while it is absent in normal corticotroph 
and gonadotroph cells. In addition, in these adeno-
mas AIP is not located in the secretory vesicles but 
is free in the cytoplasm [24].
In somatotropinomas from FIPA patients, sparsely 
granulated tumors are more frequent than in spo-
radic patients; this histological characteristic is as -
sociated with increased invasive potential and a 
poor response to SA [24]. In AIP mutation-positive 
patients, AIP expression is reduced at the level of 
both mRNA and protein, correlating with invasive-
ness [103].
The role of AIP in patients with no germline 
mutations has been studied. Although no somatic 
AIP mutations have been found in pituitary adeno-
mas to date, there is reduced expression of AIP in 
aggressive somatotroph adenomas compared to less 
aggressive ones [103,104].
Clinical Features
More than 400 FIPA families have been identified 
to date. FIPA appears to be more common than 
signals from diverse ligands and molecular path-
ways [98]. Although there are some earlier contro-
versial data, more recent studies suggest that AIP 
inhibits the transcriptional effects of AhR in 
humans. Some data indicate that AIP modulates 
AhR levels; this effect is also apparently tissue-
specific [85] and potentially relevant for pituitary 
tumorigenesis.
Ligand-free AhR is localized in the cytoplasm, 
attached to a heterotetramer composed of a dimer 
of the chaperone Hsp90 and one unit of each of the 
co-chaperone proteins p23 [99] and AIP. AIP binds 
to both Hsp90 and AhR, but Hsp90 is required to 
model AhR to a ligand-binding configuration. The 
co-chaperone p23 binds to Hsp90, stabilizing the 
complex and favoring its nuclear import. After 
binding dioxin or other exogenous or endogenous 
ligands, AhR undergoes a conformational change, 
allowing protein complex translocation to nucleus. 
In the nucleus, aryl-hydrocarbon receptor nuclear 
translocator 1 (ARNT, also known as HIF-1β) binds 
to ligand-bound AhR [100], dissociating it from the 
rest of the complex. Thus, the ligand:AhR:ARNT 
complex is able to bind a dioxin-responsive element 
(DRE), also known as xenobiotic or Ah-responsive 
element (XRE or AhRE), leading to the activation 
of AhR-responsive genes [95].
Disruptions in the cyclic adenosine monophos-
phate (cAMP) molecular pathway are important 
in pituitary tumorigenesis, and therefore phos-
phodiesterases, which degrade cAMP, are poten-
tially important AIP interactors. AIP interacts with 
PDE4A5, causing reversible inhibition of the enzy-
matic activity of PDE4A5, and attenuation of the 
ability of cAMP-dependent protein kinase to phos-
phorylate PDE4A5 [94]. PDE2A is another phos-
phodiesterase that binds to AIP. This interaction 
inhibits dioxin and cAMP-induced nuclear translo-
cation of AhR, attenuating AhR-dependent gene 
transcription [101].
Survivin, a protein involved in cell survival, 
interacts with AIP. AIP mediates the import of sur-
vivin to mitochondria (via TOMM20), thus ena-
bling its anti-apoptotic function [102].
As AIP has numerous partners, it is not clear 
which one is relevant for pituitary tumorigenesis. 
The most promising candidates are phosphodieste-
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Tumors in AIP mutation-positive patients show 
a considerably reduced response to the treatment 
with SA and dopamine agonists, regarding both 
tumor size and hormone secretion [5]. Recent data 
suggest that AIP is a mediator of the response of 
somatotropinomas to treatment with SA. AIP is 
upregulated in sporadic somatotropinomas with 
preoperative SA treatment, compared to patients 
with no pretreatment [108]. Similar AIP upregula-
tion was shown in vitro in GH3 cells treated with 
SA. In addition, AIP overexpression upregulated 
ZAC1 [108], an antiproliferative target of somato-
statin [109]. Another set of data suggest that AIP 
expression in somatotropinomas is a positive pre-
dictor of responsiveness to treatment with SA 
[110]. These data need to be confirmed in larger 
studies.
Though AIP mutation-negative patients repre-
sent the wide majority of FIPA cases, their clinical 
features have been less accurately described, 
perhaps because they represent a genetically het-
erogeneous population [24]. These patients are 
12–16 years older at diagnosis than AIP mutation-
positive patients and their tumors are smaller 
[107,111]. Somatotropinomas predominate (55%), 
but less markedly than in AIP mutation-positive 
patients [107]. Although their response to treat-
ment is poor, it is not as bad as in AIP mutation-
positive patients [111]. Childhood-onset disease is 
present in 11% of AIP mutation-negative families, 
while it is demonstrated in 80% of AIP mutation-
positive families [107].
Genetic screening is now available for selected 
patients with pituitary adenomas (Figure 10.3). 
Follow-up of AIP mutation-positive FIPA families 
includes genetic testing for all at-risk subjects. For 
children we suggest genetic screening and, if posi-
tive, then follow-up from 4 years of age. Yearly 
measurement of height and weight, surveillance 
of height velocity and puberty development with 
biochemical tests as necessary, and baseline MRI 
around the age of 10 years are suggested. For 
adults, follow-up includes baseline clinical assess-
ment, pituitary function tests, and pituitary MRI, 
followed by yearly pituitary function tests. The 
likelihood of the development of a pituitary 
adenoma after the age of 50 years is low.
initially thought, but exact prevalence data are not 
currently available.
FIPA shows an autosomal dominant pattern of 
inheritance, with incomplete penetrance, around 
15–30%, but with a wide variation among families 
[81,103,105]. The observed earlier diagnosis in the 
consequent generations is due to patient education 
regarding the symptoms in other family members 
[21,106]. Two-thirds of AIP mutation-positive 
patients are male, but the reason for this remains 
unclear [106].
Most of FIPA families are composed of 2–5 
affected members. Somatotropinomas, prolactino-
mas, and somatomammotropinomas are the most 
common tumors [84,106], but NFPA, corticotropi-
nomas, gonadotropinomas, and a thyrotropinoma 
have also been diagnosed. Families can be catego-
rized as homogeneous, when patients within the 
same family exhibit the same pituitary tumor type, 
or heterogeneous, when two or more different 
tumor types are found within a family [11]. Patients 
from FIPA kindreds are on average 13–16 years 
younger at diagnosis than patients with sporadic 
pituitary adenomas, with a mean age of 33 years 
[107], but this large difference is due to AIP 
mutation-positive families.
The phenotype is better defined in AIP mutation-
positive patients: most tumors (93.3%) are mac-
roadenomas, commonly invasive [106]. Symptoms 
start during childhood or young adulthood and 
the diagnosis is established at a mean age of 18–24 
years [106,107]. In more than one-half of patients, 
the tumors are aggressive [58]. Gigantism is diag-
nosed in one-third of AIP mutation-positive patients 
with somatotropinomas, while this condition is 
rare in sporadic cases [106]. Around 76–78% of AIP 
mutation-positive patients present with somatotro-
pinomas, almost always macroadenomas [106,107]. 
Nevertheless, in AIP-mutation-positive patients de -
tected as apparent sporadic cases, somatotropino-
mas account for only 37.5% of tumors [83]. More 
than one-half cosecrete PRL, while macroprolac-
tinomas arise in 11–13% of patients [106]. The 
majority of AIP mutation-positive patients require 
more than one surgical intervention for their treat-
ment and, usually, require a combination of mul-
tiple modalities of treatment [106].
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first-degree relative with CNC [114,115]. Other 
clinical manifestations have been associated to 
CNC, though with a lower frequency: intense 
freckling, multiple blue nevi, café-au-lait spots, 
elevated IGF-1 levels, paradoxical GH response 
to thyrotropin releasing hormone (TRH) or oral 
glucose tolerance test (OGTT), cardiomyopathy, 
pilonidal sinus, a history of Cushing’s syndrome, 
acromegaly or sudden death in extended family, 
multiple skin tags or other lesions, lipomas, colonic 
polyps, hyperprolactinemia, a single benign thyroid 
nodule in a young patient or multiple nodules in 
older patients, and a family history of carcinoma or 
other benign or malignant tumors [115].
The genetic basis of CNC is heterogeneous, 
involving at least two loci, as demonstrated by 
linkage analysis [116]. The CNC1 gene is located at 
17q24.2 and encodes the regulatory subunit 1-α of 
the protein kinase A (PRKAR1A) [113,117]. 
PRKAR1A is 21 kb in length, contains 11 exons and 
has a coding region of 1143 bp [54]. Seventy-three 
percent of patients with CNC present germline 
mutations in this gene [20]. The CNC2 gene, 
located at 2p16, is still unknown [118]. This locus 
frequently presents amplification in tumors of CNC 
patients, including some with known mutations in 
PRKAR1A, and thus it is suspected that an onco-
gene may be implicated [119].
PRKAR1A
Protein kinase A (PKA) acts as a main mediator of 
cAMP signaling. PKA is a tetramer composed of a 
regulatory subunit dimer and two catalytic subu-
nits. When four molecules of cAMP bind to the 
regulatory subunit dimer, catalytic subunits are 
released to phosphorylate serine or threonine resi-
dues in the target protein. The regulatory subunit 
has four isoforms: Iα, Iβ, IIα, and IIβ, which can 
pair up as homodimers or type I or type II het-
erodimers, composing holoenzyme complexes of 
PKA with a number of combinatorial configura-
tions, including RIα2C2, RIβ2C2, RIIα2C2, RIIβ2C2, 
and RIαRIβC2 (Figure 10.2).
Experimental downregulation of PRKAR1A with 
antisense oligonucleotides inhibits growth in human 
cancer cell lines, while overexpression of type I 
PKA stimulates cell growth and proliferation, via 
Screening of AIP mutation-negative patients is 
more problematic, as carrier status cannot be estab-
lished and the penetrance is lower. We suggest edu-
cation regarding symptoms for all potential carrier 
subjects and we offer yearly screening for family 
members who wish to undergo these tests.
Carney Complex
In 1985, Carney and collaborators described the 
clinical features and reported the first series of 
patients with myxomas, spotty skin pigmentation 
and endocrine overactivity [112]. CNC (OMIM 
#160980 and %605244) is a syndrome character-
ized by the association of multiple endocrine neo-
plasia and cardiocutaneous manifestations [113]. A 
few patients with some components of the complex 
have previously been described as NAME (nevi, 
atrial myxomas, and ephelides, i.e., light-brown 
dermal maculas) or LAMB (lentigines, atrial 
myxomas, and blue nevi); currently all these cases 
are grouped as CNC [113,114].
CNC is an infrequent clinical entity: until 2006, 
around 500 cases had been registered [113]. 
Patients are from diverse ethnicity and are distrib-
uted worldwide [115]. Diagnostic criteria are [114]:
• Spotty skin pigmentation with a typical 
distribution
• Myxoma (cutaneous and mucosal)
• Cardiac myxoma
• Breast myxomatosis or MRI suggestive image
• Paradoxical positive response of urinary gluco-
corticoids to dexamethasone (PPNAD)
• Acromegaly
• Large-cell calcifying Sertoli cell tumors (LCCSCT) 
or characteristic calcification on testicular 
ultrasonography
• Thyroid carcinoma or multiple hypoechoic 
thyroid nodules in a young patient
• Psammomatous melanotic schwannoma
• Blue nevus or epithelioid blue nevus (multiple)
• Breast ductal adenoma (multiple)
• Osteochondromyxoma
The diagnosis is established if two major criteria 
are present or in the presence of one major crite-
rion plus an inactivating PRKAR1A mutation or a 
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viding a link between these tumor suppressor genes 
[125,127]. PRKAR1A haploinsufficiency causes 
an increase in cAMP levels, leading to increased 
MAPK activity, while complete PRKAR1A defi-
ciency causes constitutive activation of PKA and 
immortalization of mouse embryonic fibroblasts 
(MEF) through upregulation of cyclin D1 in vitro 
[125]. Multiple elements of the Wnt signaling 
pathway are over expressed in different tumors from 
PRKAR1A+/−, PRKAR1A+/−/Trp53+/−, PRKAR1A+/−/
Rb1+/− and PRKAR1A+/−/Prkaca+/− mice, suggesting 
its implication in PRKAR1A-derived tumorigenesis 
[125,126,128]. A microarray analysis of tumors 
from 3 mouse models of PRKAR1A haploinsuffi-
ciency (PRKAR1A+/−, PRKAR1A+/−/Trp53+/− and 
PRKAR1A+/−/Rb1+/−) identified Wnt signaling as the 
main pathway activated by abnormal cAMP signal-
ing, along with the mentioned cell cycle abnormali-
ties [125]. In human tissue from PPNAD, PKA 
activates the expression of WISP2, a component of 
the WNT signaling pathway, via microRNA regula-
tion [129].
Twenty percent of patients present PRKAR1A 
mutations in intronic sequences that affect splicing 
[20]. At least some of these mutations escape from 
NMD, leading to expression of the truncated protein 
[130]. LOH is not a universal finding in CNC tumors 
[20], and in vitro the expression of an abnormal 
PRKAR1A without concomitant loss of the normal 
allele causes increased PKA activity [130]. The con-
tribution of possible PKA-independent effects due 
to different protein interactions cannot be dis-
counted [20].
Clinical Features
CNC is inherited as an autosomal dominant trait 
[114]. Penetrance for CNC due to PRKAR1A is 
almost complete for some of the manifestations 
[20,131]. Clinical manifestations are variable, even 
within members of the same family. Thirty-two 
percent of cases present as simplex (sporadic) disease 
[20]. More than 85% of simplex cases with a 
PRKAR1A mutation have a de-novo mutation [20].
Lentiginosis is the most common feature of CNC 
(70% of patients) [20] and is present in half of 
patients before other components of the complex 
arise [120]. It consists of 2–10 mm brown to black 
interactions with the epidermal growth factor 
receptor (EGF-R) [120]. Tumors in CNC often 
present LOH at 17q22–24, supporting the role or 
PRKAR1A as a tumor suppressor gene [117].
Mutations in PRKAR1A are distributed through-
out the gene, with higher frequency in exons 2, 3, 
5, 7, and 8 [20]. Almost 80% of PRKAR1A muta-
tions originate in a premature stop codon, but trun-
cated proteins are not expressed [20,121]. The 
abnormal mRNA transcribed from the affected 
allele is destroyed by a mechanism called nonsense 
mediated decay (NMD), in which the cells degrade 
mRNA containing a deleterious premature stop 
codon mutation prior to its translation [120]. This 
loss of expression of PRKAR1A in CNC tumors 
leads to a reduced regulatory activity over PKA, but 
also to compensatory increases in the other PKA 
subunits [117]. These alterations derive in an 
increased response of PKA to cAMP, with upregula-
tion of this important signaling pathway [120].
There is no clear genotype–phenotype correla-
tion for most of the mutations in CNC [122], 
although the intronic deletion exon7 IVS del(−7→
−2) is related to isolated PPNAD [123]. Differences 
in presentation of molecular defects and clinical 
features may be due to disease-modifying genes 
located at other loci [116,122]. In a cohort of CNC 
patients, variants of the phosphodiesterase type 
11A gene (PDE11A) showed association with a 
higher incidence of PPNAD and LCCSCT, suggest-
ing that PDE11A can modify the phenotype [124]. 
No association was found with other components 
of the complex.
PRKAR1A−/− mice are not viable. Lethality occurs 
during embryogenesis, due to a failure in mesoderm-
derived structures [25]. Pituitary-conditional 
PRKAR1A−/− mice develop pituitary adenomas with 
a higher frequency than their littermates. These 
tumors are sometimes multiple and immunohisto-
chemistry is positive for GH, PRL, and thyroid-
stimulating hormone (TSH) [25]. PRKAR1A+/− mice 
are prone to develop tumors in some cAMP-
responsive tissues, such as bone, Schwann cells, 
and thyroid, but not myxomas or pituitary adeno-
mas [125,126]. E2f, a downstream effector of 
Rb, mediates the proliferative effects of defective 
PRKAR1A, and E2f activity is regulated by p53, pro-
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06:00 hours; then the dosage is increased to 2 mg 
every 6 hours for 2 days more. The 6-day Liddle 
test is considered positive if there is an increase of 
50% or more in urinary free cortisol levels on day 
6 (sensitivity 69.2%) [133]. Bilateral adrenalec-
tomy is the treatment of choice for PPNAD; 
however, some patients respond to ketoconazole or 
mitotane [115,132].
LCCSCT is a common (41% of male patients) 
[20] and almost always benign tumor in CNC; it 
usually appears in the first decade of life, most 
often detected by ultrasonography as microcalcifi-
cations [115]. This tumor can rarely lead to gyne-
comastia and precocious puberty, but impairment 
of fertility (due to obstruction of seminiferous 
tubules or inappropriate hormone production or 
aromatization) is common. Adrenal rests and 
Leydig cell tumors can exist concomitantly with 
LCCSCT. Ovarian cysts and cystadenoma have been 
found in some patients [115].
Thyroid nodules are present in 25% of patients 
and usually correspond to nontoxic adenomas of 
follicular type [20,113,114]. Thyroid cancer (fol-
licular or papillary) develop in up to 10% of CNC 
patients with previous thyroid nodules [115].
Psammomatous melanotic schwannoma (PMS) 
is a very rare tumor that can arise in any peripheral 
nerve, usually in the gastrointestinal tract and par-
aspinal sympathetic chain; it is pigmented, multi-
centric, and frequently calcified [114]. It is found 
in 8% of CNC patients [20] and in 10% of cases 
is malignant and metastasizes to lungs, liver, or 
brain [115].
The possible association between CNC and pan-
creatic neoplasms has recently been proposed. 
There is an unexpectedly high prevalence (2.5%) 
of pancreatic neoplasms within CNC patients, 
some of them of a very uncommon histological 
type (acinar cell carcinoma) [134]. Most of the 
ana lyzed cases presented LOH at chromosome 17 
and loss of PRKAR1A immunostaining [134]. The 
main CNC-related cause of death is metastasic 
cancer (56% of deaths) and pancreatic cancer 
accounts for one-third of cancer-related deaths in 
CNC patients [20].
Osteochondromyxomas of the bone and tetral-
ogy of Fallot have been found in some CNC patients 
macules, distributed on the lips, eyelids, ears, and 
genital area [113]. Lesions can be present at birth, 
but do not acquire their clinical characteristics until 
puberty [114]. Half of patients present others skin 
lesions, such as blue, Spitz, and compound nevi 
and café-au-lait spots [20]. Skin myxomas are 
found in 20% of patients in eyelids, external ear 
canal, nipple, oropharynx, female genital tract, and 
female pelvis [20,114]. Twenty percent of female 
patients present breast myxomas [20], and a few 
cases of breast ductal adenoma have also been 
reported [114].
Cardiac myxomas are detected in 32% of cases 
[20]. In the setting of CNC, these tumors occur at 
any age, are multicentric, can be present in any 
cardiac chamber, tend to recur, and can grow 
aggressively [113]. Surgical resection is necessary 
to avoid complications such as embolism, strokes, 
and cardiac failure.
ACTH-independent Cushing′s syndrome due to 
PPNAD is the main endocrine manifestation of 
CNC (60% of patients) [20,114]. PPNAD almost 
always occurs in the context of CNC, but a very 
infrequent sporadic form also exists [127]. It has a 
bimodal age distribution: most cases are diagnosed 
during the second and third decades of life but a 
minority present at 2–3 years of age [114]. Adrenal 
histology in PPNAD is characterized by small pig-
mented micronodules, with minimal atrophy or 
hyperplastic perinodular cortex, positive for synap-
tophysin and multiple steroidogenic enzymes by 
immunohistochemistry [120]. The disease is usually 
bilateral [113]. The adrenal glands do not always 
show an obvious enlargement on imaging studies 
as nodules can be very small [113]. Hypercortiso-
lism generally progresses subtly over years or 
follows a cyclic pattern, but the circadian cycle of 
cortisol is completely abolished, sometimes even in 
periods of inactive disease [115,132]. Pseudo-
precocious puberty or hirsutism can appear [132]. 
Diagnosis is better established with the 6-day Liddle 
test, showing a paradoxical increase in the 24-hour 
urinary free cortisol and/or 17-hydroxysteroids 
[132,133]. This test is performed as follows: after 2 
days of baseline measurements of urinary steroid 
excretion, 0.5 mg of dexamethasone are adminis-
tered orally every 6 hours for 2 days, starting at 
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not been found in sporadic pituitary tumors [22], 
but low levels of PRKAR1A have been detected in 
sporadic functioning and nonfunctioning pituitary 
adenomas, despite adequate mRNA [137].
Clinically evident acromegaly is a relatively 
infrequent manifestation of CNC; the incidence of 
GH-producing pituitary tumors in CNC is 12% 
[20]. Nevertheless, paradoxical GH responses to 
TRH or nonsuppressible GH during a glucose chal-
lenge and/or IGF-1 elevation are present in up to 
80% of patients, even in the absence of detectable 
tumors [114]. Acromegaly in CNC patients shows 
a slow progressive course [135]. In some patients 
it only becomes apparent after the patient under-
goes bilateral adrenalectomy for Cushing’s syn-
drome [67]. Pituitary tumors in CNC are almost 
exclusively GH or GH/PRL-secreting tumors. 
Around two-thirds of CNC patients have a mild 
hyperprolactinemia (generally <100 ng/mL), but 
there are few cases of frank prolactinomas [25].
Regular screening for the manifestations of the 
disease is recommended for patients with CNC and 
known carriers of PRKAR1A mutations. Screening 
for cardiac myxomas by echocardiography must 
start at diagnosis or during the first 6 months of 
life, and be done yearly thereafter [114]. If a cardiac 
myxoma was excised in the past, echocardiography 
is necessary every 6 months [115]. During child-
hood, screening for the other manifestations should 
be performed only by clinical examination, because, 
although possible, it is rare to detect endocrine 
tumors in CNC before the second decade of life 
[115]. Pubertal staging and growth rate must be 
monitored [113]. Additionally, for postpubertal 
patients the following annual studies are recom-
mended: urinary free cortisol determination (plus 
diurnal cortisol or overnight 1 mg dexamethasone 
test), serum IGF-1 and testicular ultrasonography 
in male patients [114]. Brain and spine MRI should 
be obtained at diagnosis and repeated only if clini-
cal signs suggest the possibility of a schwannoma 
[115]. Pelvic ultrasonography in women is recom-
mended at diagnosis and then as needed [114]. 
Thyroid ultrasonography is indicated at diagnosis 
and then as clinically indicated [114]. There are 
no specific recommendations regarding pancreatic 
cancer.
and are possible components of the syndrome 
[114].
Pituitary Adenomas
In the pituitary, GHRH requires the cAMP/PKA 
pathway to stimulate GH synthesis and release 
[25]. Other hormones are mainly regulated by dif-
ferent pathways, thus they are not affected by 
PRKAR1A mutations. Pituitary tumorigenesis in 
the context of CNC is a slow-developing process 
that requires mutation accumulation (“multiple 
hits”) [135]. Apparently, in CNC patients, germline 
mutations cause a predisposition, but other molec-
ular events are necessary for pituitary adenoma 
development [135].
Histologically, pituitaries of CNC patients show 
zones of mammosomatotroph hyperplasia, that 
only occasionally progress to adenomatous tissue 
[135]. This “pro-acromegalic state” is a common 
characteristic shared by CNC and McCune–Albright 
syndrome, in which the same molecular pathway 
is disturbed, but at a different level [136]. By 
immunohistochemistry, almost all somatotropino-
mas also stain for PRL and most tumors stain 
for multiple hormones, but, although staining for 
glycoprotein α-subunit, TSH-β, luteinizing hor-
mone (LH)-β and occasionally follicle-stimulating 
hormone (FSH)-β has been described, staining 
for ACTH has not been reported [25,136]. Micro-
adenomas are much more common than macroad-
enomas; they are frequently multiple, sometimes 
microscopic, and commonly grow surrounded by 
hyperplastic tissue [135,136]. Electron microscopy 
features are highly variable: from mammosoma-
totroph cells with abundant rough endoplasmic 
reticulum, immature secretory granules, and a 
small percentage (1%) of densely granulated cells, 
to sparsely granulated cells with poorly developed 
endoplasmic reticulum, and fibrous bodies, or 
a mixture of both types of cells [136]. Aggressive 
pituitary adenomas in CNC show genetic instabil-
ity, whereas cytogenetic abnormalities are absent 
in hyperplasia or microadenomas [135]. Though 
LOH of 17q is expected in pituitary adenomas 
of CNC patients with PRKAR1A mutations, it is not 
always detected [25]. PRKAR1A mutations have 
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[7,141]. A germline missense mutation in SDHB 
has been described in association with familial par-
agangliomas, together with a prolactinoma in one 
individual [9]. A germline frameshift mutation in 
SDHD was related to multiple paragangliomas and 
bilateral pheocromocytomas together with a soma-
totropinoma in a member of a kindred with familial 
paragangliomas [7]. A germline missense mutation 
in SDHC was described in a family with paragang-
liomas and prolactinomas. In the families with the 
SDHB and SDHD mutation, LOH at the respective 
loci was demonstrated in a prolactinoma and a 
somatotropinoma, respectively, in the index cases. 
Though still scarce, these data support the possibil-
ity of a new association between paraganglioma 
and pituitary adenoma.
Recommendations for Genetic 
Screening of Patients with 
Pituitary Adenomas
With the technical advancement of DNA sequenc-
ing, block screening of several or all of the candi-
date genes might overtake gene-by-gene screening 
in the future. However, careful assessment of clini-
cal features of the patient and family history 
remains crucially important and should be able to 
distinguish most, although not all, cases of MEN1, 
MEN4, FIPA, CNC, SDH-related or pituitary blast-
oma phenotypes, allowing for targeted gene screen-
ing (Figure 10.3):
• If clinical features of MEN1 are present, then 
MEN1 screening is recommended. Screening for 
CDKNB1 mutations can be performed on special 
request.
• In patients with pituitary adenomas and clinical 
findings compatible with CNC, PRKAR1A muta-
tions can be searched for.
• In patients with pituitary adenomas and 
pheochromocytoma/paraganglioma, SDH muta-
tions could be looked for.
• Patients with a family history of pituitary 
adenoma and no other syndromic features should 
be screened for AIP mutations.
• Screening for AIP mutations is suggested in iso-
lated cases of macro or microadenoma, without 
Other Possible Familial Pituitary 
Adenoma Syndromes
Pituitary Blastoma
Pituitary blastoma is a very rare and aggressive, 
apparently congenital, pituitary tumor. Only two 
cases have been reported to date, both in infants 
with Cushing’s disease [6,138]. Nevertheless, a 
recent review considered the possibility of this 
diagnosis in three further cases (two corticotropi-
nomas and one nonsecretory tumor), reported 
in the literature as adenomas [139]. The most 
recent case was reported by Wildi-Runge and 
colleagues in a 9-month-old boy with Cushing’s 
syndrome and a familial history of pleuropulmo-
nary blastoma in a second cousin and renal cysts 
and an ovarian tumor in a grandmother [6]. 
Genetic analysis showed a mutation in the RNase 
endonuclease gene DICER1 as the possible cause 
[6]. The genetic cause was not assessed in the 
remaining cases.
CDKIs
A mutation in the gene encoding the CDKI p21 
(CDKN1A) was described in two sisters with a 
MEN1-like syndrome of primary hyperparathy-
roidism and macroprolactinoma [14]. Mutations 
in the genes encoding the CDKIs p15 and p18 
(CDKN2B and CDKN2C, respectively) have also 
been detected in the context of multiple endocrine 
neoplasia, but these cases have not included pitui-
tary tumors as part of the syndrome [14].
Pheochromocytoma/Paraganglioma 
and Pituitary Adenoma
Although it was not considered as a syndrome until 
recently, coexistence of pheochromocytoma/para-
ganglioma and a pituitary adenoma (usually a 
somatotropinoma) has been previously reported in 
the literature [140]. Mutations in the genes encod-
ing subunits A, B, C, and D of the SDH mitochon-
drial complex II are known to be associated with 
the development of pheochromocytomas, paragan-
gliomas, gastrointestinal stromal tumors, renal and 
papillary thyroid cancer, neuroblastoma, adrenal 
medullary hyperplasia, and testicular seminoma 
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• Data supports the recommendation for patients 
with pituitary macroadenomas diagnosed before 
the age of 30 years to be screened for AIP muta-
tions, even in the absence of relevant family his -
tory [5].
• For young patients with prolactinomas and 
somatotropinomas and no AIP mutation, genetic 
testing for MEN1 mutations can be considered [4].
• Cushing’s disease diagnosed during infancy 
might be an indication for DICER1 mutation 
screening, though the scarcity of data precludes the 
establishment of a firm recommendation.
Genetic counseling is essential for these patients 
and their relatives. Follow-up of mutation carriers, 
by clinical, biochemical, and imaging studies, can 
lead to earlier pituitary tumor detection, allowing 
more efficient treatment [21]. For family studies, 
the high prevalence of pituitary incidentalomas 
must be kept in mind. FIPA patients, with or 
without AIP mutations, and their families should 
be informed about the low penetrance of the 
disease in order to avoid unnecessary concern.
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 Abstract 
 Pituitary adenomas are common tumors of the adenohypophysis which can cause considerable 
morbidity, due to excessive hormonal secretion or compression and local invasion of surrounding 
structures. The vast majority of pituitary adenomas occur sporadically. Altered gene expression is 
commonly detected but somatic mutations, epigenetic changes and abnormal microRNAs have also 
been described. Occurrence of  GNAS mutations at a postzygotic stage lead to McCune-Albright 
syndrome (MAS), a disease causing endocrine hyperfunction and tumors in several organs, includ-
ing the pituitary. Familial pituitary adenomas occur as part of a syndrome affecting other organs, 
such as in MEN1 or Carney complex, or occur with pituitary adenomas only as in familial isolated 
pituitary adenoma (FIPA). FIPA, an autosomal-dominant disease with variable penetrance, is ex-
plained in 20% of patients by germline mutations in the tumor suppressor  aryl hydrocarbon receptor 
interacting protein  (AIP) , while no gene abnormality has been identified to date in the majority of the 
FIPA families. AIP mutation-positive patients have a characteristic clinical phenotype with usually 
young- or childhood-onset growth hormone (GH) and/or prolactin (PRL)-secreting adenomas and 
can be seen in cases with no apparent family history as well. Understanding the tumorigenic process 
in  AIP -positive and  AIP -negative FIPA patients could result in better diagnostic and treatment op-
tions for both familial and sporadic cases.  Copyright © 2013 S. Karger AG, Basel 
 Pituitary adenomas are common tumors of the adenohypophysis. They can cause 
considerable morbidity due to excessive hormonal secretion or lack of appropriate 
hormone release and due to compression and local invasion of important 
 surrounding structures. The prevalence of pituitary adenomas is high (14–22%) in 
autopsy and MRI studies  [1] , but many of these lesions remain clinically silent 
and  represent incidentalomas. Clinically relevant adenomas diagnosed due to 
symptoms are significantly less common,  ∼ 1: 1,100 patients have been identified 
with pituitary adenomas in the general population in population-based studies 
 [2, 3] . 
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 The vast majority of pituitary adenomas are sporadic tumors. Genetic alterations 
are commonly seen in the tumor tissue, such as  GNAS gene mutations in 40% of so-
matotroph adenomas. On the other hand, increasing proportion of familial cases have 
been reported  [4] , and the recent establishment of a novel clinical entity, familial iso-
lated pituitary adenoma (FIPA), is expected to increase awareness and lead to an im-
proved recognition of familial cases.
 Despite their relative rarity, familial pituitary tumors represent an important 
group of conditions as often they have a more aggressive course and show younger 
age of onset, such as in patients with mutations in the multiple endocrine neoplasia 1 
(MEN1 , MIM * 613733 )  or aryl hydrocarbon receptor interacting protein (AIP , 
 MIM * 605555 ) genes. The genetic background of familial pituitary tumors is hetero-
geneous and the phenotype of the families varies quite widely. A better understanding 
of the causative genes and the pathogenic mechanisms of this particular group of tu-
mors is needed to improve the diagnosis and management of these patients, which, 
hopefully, will lead to a better prognosis, and may help to understand the pathogen-
esis of sporadic adenomas as well.
 The inherited conditions that, to date, are known to predispose to pituitary adeno-
mas are multiple endocrine neoplasia type 1 (MEN1, MIM#131100, see chapter by 
Agarwal, this vol.) and type 4 (MEN4, MIM#610755, see chapter by Lee and Pelle-
gata, this vol.), Carney complex (MIM#160980, see chapter by Espiard and Bertherat, 
this vol.) and FIPA (MIM#102200, this chapter). More recently case reports raised the 
possibility that mutations in the  DICER1  [5] and  succinate dehydrogenase (SDH) genes 
 [6–9] can also predispose to pituitary tumors. Genetic conditions associated with pi-
tuitary neoplasms have been summarized on  figure 1 . In the current chapter, we will 
discuss experimental and clinical data regarding FIPA and McCune-Albright syn-
drome. In addition, genes and microRNAs implicated in sporadic adenoma develop-
ment will be discussed.
 Familial Isolated Pituitary Adenomas 
 Clinical Characteristics 
 Approximately 5% of the pituitary adenomas occur with familial aggregation (MEN1, 
MEN4, Carney complex and FIPA). FIPA syndrome is defined as the occurrence of at 
least two cases of pituitary adenomas in a family that does not exhibit any other syn-
dromic features, such as MEN1, MEN4 or Carney complex. Somatotroph, lactotroph 
and somatolactotroph adenomas are the most common subtypes, but other subtypes 
have also been reported. FIPA is an autosomal dominant disease with a variable pen-
etrance. Germline  AIP  mutations are identified in 20% (range 15–40%) of patients 
with FIPA syndrome, while the causative gene in the majority of the families is un-
known. The penetrance in  AIP -positive FIPA families is usually 15–30% (range 10–
80%)  [12–14] , while it is somewhat lower in AIP-negative families  [13] . 
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 There is a phenotypic difference between  AIP -positive and  AIP -negative families. 
The mean age at diagnosis (24 years) in  AIP -positive families is approximately 13 years 
lower than in  AIP -negative families and the majority of  AIP -positive families harbor a 
childhood-onset case  [15] . Two-thirds of  AIP -positive patients are males, while there is 
no gender predominance in  AIP -negative familial cases and in sporadic pituitary adeno-
mas  [16] . In addition, families with members harboring  AIP mutations are mainly com-
posed of patients with either pure somatotroph adenomas or with mixed somatotroph 
and lactotroph adenomas  [12, 15] . Actually,  AIP mutations are found in 50% of homo-
geneous somatotroph FIPA families  [15, 17] .  AIP -positive cases that presented clinically 
as nonfunctioning pituitary adenomas (NFPAs) can also exhibit positive growth hor-
mone (GH)/prolactin (PRL) staining  [15] . Rarely, ACTH-, LH/FSH- and TSH-secreting 
adenomas or true null cell adenomas were also identified. The  AIP -negative families can 
have a more varied phenotype, with families composed of homologous prolactinoma, 
NFPA or rarely Cushing’s disease or comprising heterogeneous families.  AIP -positive 
acromegalic patients often exhibit sparsely granulated somatotroph adenomas  [18] . 
Consistent with this, the tumors of  AIP -positive patients usually have an aggressive 
clinical behavior, being large, with frequent invasion of nearby structures and, as a con-
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 Fig. 1. Pituitary tumors due to genetic origin. A somatic activating mutation in the  GNAS gene can be 
found in 30–40% of sporadic somatotroph adenomas. Theoretically, somatic mutations in other genes 
could also lead to pituitary adenoma development. Mosaic post-zygotic activating mutation of the 
 GNAS gene leads to the McCune-Albright syndrome; some of these patients develop somatotroph hy-
perplasia or adenoma. Germline mutation in the  MEN1 gene or rarely in the  CDKN1B (coding for cell 
cycle regulator protein p27) gene cause MEN1 or MEN4; in a small proportion other cell cycle regulators 
have been implicated (p18 ( CDKN2C ) and p21 ( CDKN1A ))  [11] or no gene abnormality can be found. A 
mutation in the type 1A regulatory subunit of the cAMP-dependent protein kinase A  (PRKAR1A) is 
found in the majority (60%) of patients with Carney complex; in the remainder patients, data suggest 
a putative causative gene in the 2q16 chromosome region. Patients have been described with  SDH 
 mutation-related familial paraganglioma/pheochromocytoma and familial pituitary adenomas  [6–9] . 
A mutation in the  DICER1 gene, a gene which regulates microRNAs, may cause an ACTH-secreting pi-
tuitary blastoma of infant onset  [5] . A fifth of FIPA cases show a mutation in the  AIP gene; in the major-
ity of families the causative gene has not yet been identified. Adapted from Korbonits et al.  [10] . 
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sequence, these patients are submitted to more surgical interventions  [16] . Regarding the 
response to medical therapy, Leontiou et al.  [18] observed that  AIP -positive patients 
showed a poorer response to somatostatin analogues (SSAs). Indeed, Daly et al. [16] 
compared 38  AIP -positive acromegaly patients and 160 matched acromegaly controls 
(without AIP mutations). They observed that patients harboring  AIP mutations pre-
sented less GH and insulin-like growth factor type 1 (IGF-1) reductions than controls 
with SSAs therapy (40.0 and 75.0% for GH and 47.4 and 56.0% for IGF-1, respectively). 
They also observed that the median magnitude of tumor shrinkage achieved with SSAs 
was significantly higher in the control group (median 41.1 vs. 0.0% in the AIP- mutated 
 patients; p < 0.001). This poor response to SSAs therapy is not due to a different expres-
sion profile of somatostatin receptor (SSTR) in these tumors, as there is no significant 
reduction of the SSTR subtypes in  AIP -positive samples compared to sporadic somato-
troph adenomas; actually, SSTR5 staining was shown to be slightly higher in  AIP -posi-
tive FIPA samples compared to sporadic adenoma samples  [19] .
 Interestingly, AIP protein expression is reduced in a subset of acromegalic patients 
with sporadic disease without  AIP mutation, especially in more invasive cases  [20] . 
Indeed, low AIP expression has been shown to be a better predictor of tumor invasion 
in somatotrophinomas than Ki-67 or p53  [20] . The mechanism involved in this low 
AIP expression is currently under investigation. Kasuki et al.  [21] reported that spo-
radic patients with acromegaly harboring somatotrophinomas with low AIP expres-
sion are more prone to exhibit resistance to SSAs therapy. The authors compared the 
AIP protein expression in somatotroph tumors from 35 sporadic patients with acro-
megaly treated with octreotide LAR after surgery. Of the 18 patients whose tumors 
exhibited low AIP expression, only 4 (22%) achieved disease control with octreotide 
therapy, in contrast with 11 of 17 patients (65%) whose tumors presented high AIP 
expression (p = 0.013). In the same study, the authors evaluated SSTR2 expression and 
observed that there was no difference in SSTR2 expression between patients with low 
or high AIP expression, in agreement with data on  AIP mutant tissues  [19, 21] .
 Assessment for FIPA 
 If a patient with pituitary adenoma has a relative presenting also with pituitary ade-
noma and no other known associated syndromes then we consider the diagnosis of 
FIPA. Genetic testing can be offered for  AIP . According to our current practice, we 
screen all FIPA cases, all childhood-onset pituitary adenomas and all young-onset 
(<30 years) macroadenomas even without known family history. We summarized our 
current strategy in  figure 2  [22] . 
 If an  AIP mutation is identified, genetic screening can be offered to family members. 
Based on the youngest known affected  AIP -positive case, we currently suggest screening 
at age 4 years or earlier  [12] . Unaffected carrier family members should undergo regular 
clinical assessment. For pediatric cases yearly measurements of height and weight with 
calculation of height velocity and documentation of development of puberty together 
with pituitary function tests are recommended. Baseline pituitary MRI is advised 
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around the age of 10 years and repeat MRI scanning of the pituitary every 5 years can 
be considered if clinical and pituitary function tests remain normal. Adult patients are 
suggested to have a baseline clinical assessment with pituitary function tests and MRI 
followed by yearly pituitary function tests. Although there is no long-term experience, 
repeat MRI of the pituitary every 5 years could be considered until the age of 30 years if 
clinical and pituitary function tests remain normal. Currently, we follow-up all patients, 
but in the future monitoring frequency may be reduced above the age of 30–50 years. 
Surveillance data from  AIP  mutation-positive families in the last few years have revealed 
a number of  AIP mutation carrier patients with abnormal biochemical and MRI find-
ings who either underwent treatment or are followed closely  [12, 17, 23] . Clinical, labora-
tory and MRI screening for family members of  AIP -negative FIPA patients could be 
performed upon patients request and/or under a research protocol.
 AIP Function, Mutations and Animal Models 
 The human  AIP gene is located at the 11q13 chromosome region, 2.7 Mb down-
stream of the  MEN1 gene.  AIP consists of 6 exons, encoding a 330 amino acid (37 
kDa) cytoplasmic co-chaperone phosphoprotein  [24] , also known as X-associated 
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 Fig. 2. Suggested approach for genetic testing in patients with pituitary adenomas.  *  Weak evi-
dence for these suggestions. Adapted from Hernández-Ramírez and Korbonits  [22] . 
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protein-2 (XAP2), Ah receptor-activated 9 (ARA9) or FK506-binding protein 37 
(FKBP37).  AIP is located on a conserved synthenic block in human, mouse and rat 
and the AIP protein sequence is evolutionarily conserved among species. The N-
terminal AIP protein consists of a peptidyl-prolyl cis-trans isomerase (PPIase)-like 
domain, whose 3D structure has now been resolved  [25] . The C-terminal protein 
consists of three tetratricopeptide repeat (TPR) motifs and a final α-7 helix and its 
structure has also been resolved [Prodromou and Korbonits, unpubl. data]. TPR do-
mains are 34 amino acid sequences, often arranged in tandem repeats, formed by 
two α-helices forming an antiparallel structure that mediates intra- and intermo-
lecular interactions  [26] . Other TPR protein family members are aryl hydrocarbon 
receptor-interacting protein-like 1 (AIPL1), protein phosphatase 5 (PP5), FKBP51, 
FKBP52, cyclophilin 40 (Cyp40), carboxyl-terminus of hsc70-interacting protein 
(CHIP), and heat shock protein 70 (hsp70)/hsp90 organizing protein (Hop)  [26] . 
 Numerous proteins have been identified to interact with AIP directly (viral pro-
teins (HBV X and EBNA-3), chaperone proteins (hsp90 and hsc70), phosphodiester-
ases (PDE4A5 and PDE2A3), nuclear receptors (AhR, PPARα and TRβ1), transmem-
brane receptors (RET and possibly EGFR), G proteins (Gα13 and Gαq), an inhibitor 
of apoptosis protein (survivin) and a mitochondrial import receptor (TOMM20)) or 
indirectly (glucocorticoid receptor and the co-chaperone protein p23)  [26] . The po-
tential for AIP to interact with several other steroid hormone receptors, such as the 
androgen and progesterone receptors, has recently been reported  [27] . The multiplic-
ity of AIP interactions suggests that AIP is involved in various cellular pathways; 
however, at the moment it is uncertain which of them play a role in pituitary tumori-
genesis. The AhR-cAMP-PDE pathway seems to be a very attractive candidate as AhR 
activation has well-known tumorigenic effects and phosphodiesterases are involved 
in the tight control of cellular cAMP levels, which are known to be involved in Gsα 
mutation-related as well as Carney complex-related somatotroph tumorigenesis  [26] .
 AIP is widely expressed in the human body, but its expression levels vary consid-
erably among tissues. For instance, high expression levels have been observed in 
spleen and thymus, whereas low AIP expression was detected in liver, kidney and 
lung  [28] .
 In the normal pituitary gland AIP is expressed only in somatotroph and lactotroph 
cells, where it associates with secretory vesicles, whereas in sporadic pituitary tumors 
AIP is expressed in all cell types and shows lack of colocalization with secretory ves-
icles in prolactinomas, corticotrophinomas and NFPAs  [18] . High AIP expression 
levels are usually observed in NFPAs  [18, 29] , whereas a low expression was described 
in invasive GH-secreting adenomas  [20] . These observations suggest that the regula-
tion of AIP is different in somatotroph compared to other pituitary cell types.
 Although AIP was originally identified in 1996, its clinical relevance was only es-
tablished 10 years later when heterozygous germline mutations were found in pitu-
itary adenomas  [30] . No genotype-phenotype correlation for age of onset, tumor type 
or level of penetrance has been established to date.
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 The presence of somatic  AIP mutations has been studied in both endocrine and 
nonendocrine tumors, but no mutations have been reported so far  [10] .
 To date, 112 different  AIP variants have been reported in the literature. In addition 
to single nucleotide polymorphisms, various missense, nonsense, splice-site and pro-
moter mutations, as well as small deletions and insertions (in-frame or leading to 
frame-shift), and large genomic deletions have been described. The latter constitutes 
about 10% of mutations in  AIP -positive FIPA families and can only be detected with 
specific techniques, such as MLPA (multiplex ligation-dependent probe amplifica-
tion). About 65% of  AIP mutations result in a truncated/lost protein, while missense 
variants and the in-frame changes mostly affect the TPR domain or the C-terminal 
α-helix. All known mutations are predicted to lead to loss of function of the protein. 
There are a few hotspot mutations described in  AIP , mostly affecting CpG sites, such 
as codons 81, 271 and 304. Founder mutations have also been described in Finland, 
Northern Ireland and Italy  [12, 14, 30] .
 The loss-of-function mutations, together with LOH and functional data, suggest 
that  AIP functions as a tumor suppressor gene in the pituitary gland  [13, 18, 30, 31] . 
Homozygous  Aip loss in mice was shown to cause embryonic lethality due to con-
genital defects in heart development and inability to maintain productive erythropoi-
esis  [32, 33] , whereas heterozygous  Aip ( Aip +/–) mice were shown to be prone to de-
velop pituitary adenomas, especially somatotrophinomas  [34] . Interestingly, unlike 
in humans, Aip+/– mice display complete penetrance of pituitary tumors  [34] pos-
sibly due to homogenous genetic background.
 GNAS Mutations and McCune-Albright Syndrome 
 Definition and Epidemiology 
 Originally described in the 1930s (first by McCune  [35] and then by Albright et al. 
 [36] ) as the triad of polyostotic fibrous dysplasia,  café-au-lait spots and precocious 
puberty. McCune-Albright syndrome (MAS, MIM#174800) is a complex genetic syn-
drome encompassing other diseases due to endocrine hyperfunction. According to 
the current definition of MAS, this diagnosis is established in the presence of (1) 
monostotic or polyostotic fibrous dysplasia, and (2) at least one manifestation of en-
docrine hyperfunction and/or café-au-lait spots  [37] . The original clinical triad is 
known as classic MAS, while the presence of only 2 manifestations is known as non-
classic MAS. Even though the presence of only one manifestation is not included in 
this definition, Lumbroso et al.  [38] found that there is a subgroup of girls with iso-
lated precocious puberty bearing GNAS mutations. This manifestation can appear 
isolated and remain like that, but it could also be the first manifestation in patients 
who will develop other components of the disease in the future. Café-au-lait spots are 
the commonest component of the syndrome (53–95% of patients)  [39] . In the largest 
available series (113 patients with MAS-related abnormalities), the classic triad was 
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present in only 24% of patients, one third had 2 components of the triad and the rest 
of them had only one (usually precocious puberty)  [38] . 
 MAS is a very rare disease with a prevalence around 1/100,000–1/1,000,000 in the 
general population, but fibrous dysplasia (especially the monostotic variant) is much 
more common  [37] . There is a gender imbalance with a predominance of female pa-
tients  [38] ; the reason for this is unknown.
 Genetic Issues 
 The genetic basis of MAS is a postzygotic (i.e. somatic) mutation in the  GNAS  (also 
known as  GNAS1 ) gene; the patients are somatic mosaics for  GNAS mutations  [40] . 
The clinical manifestations are widely variable due to the variable mutation status of 
the various tissues  [40, 41] . Germline  GNAS mutations are never inherited, they are 
probably embryonically lethal  [41, 42] . Theoretically, severe MAS cases are related to 
a mutational event at an early developmental stage  [42] . In agreement with this hy-
pothesis, in MAS patients with involvement of several tissues, the same  GNAS muta-
tion is found in all the tissues analyzed  [38] . Apparently, somatic mosaicism is a sine 
qua non condition for the development of MAS: cells bearing the mutation can only 
survive if they are interspersed with normal cells in the affected tissues  [41] , as has 
been proved for fibrous dysplasia lesions  [43] . 
 The GNAS locus displays complex genomic imprinting, generating multiple alter-
native products from the paternal and maternal alleles, driven by the activation of 
alternative promoters (4 sense and 1 antisense), differently imprinted  [44, 45] .
 Gsα is the best known product coded by  GNAS.  Gsα is transcribed from the exons 
1–13, resulting in four alternatively spliced products (two long, Gsα-1 and Gsα-2, and 
two short, Gsα-3 and Gsα-4), that might have variable biological roles  [46] . Exons 
2–13 are common to the other  GNAS gene products: NESP55 and XLαs.
 Gsα constitutive activation at multiple tissues is the accepted pathogenic basis of 
MAS, whereas there is not a clear contribution of the other  GNAS locus products to 
the clinical features  [40] . A tissue-specific imprinting pattern in some organs has been 
proposed  [47] and supported by data from inactivating  GNAS mutations.
 In humans, tissue-specific imprinting has been demonstrated in the pituitary, 
where Gsα is exclusively expressed from the maternal allele  [48] . Somatotrophinomas 
(both those with and without  GNAS mutations) often show a relaxation of Gsα mono-
allelic expression, but retain the normal imprinting of NESP55 and XLαs, implying a 
possible role for loss of Gsα imprinting in somatotroph cells tumorigenesis  [48] . In 
 GNAS mutation-positive somatotrophinomas, both sporadic and MAS-related, mu-
tations are almost always located in the maternal allele, in agreement with the pitu-
itary-specific imprinting of this gene  [49] . In thyroid and gonads, the expression of 
Gsα is mainly dependent on the maternal allele, but the paternal contribution is not 
negligible, indicating that genetic imprinting is not necessarily an all-or-nothing phe-
nomenon  [50] . Therefore, acromegaly occurs only in those MAS patients with an af-
fected maternal allele, but there is not an apparent relationship between the origin of 
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the mutated allele and the rest of MAS components  [49] , each individual showing a 
particular distribution of abnormal cells in the affected tissues.
 GNAS  mutations in MAS patients always occur at codon 201 and usually result 
in the substitution of the residue arginine by a histidine or cysteine  [46] , or, infre-
quently, by a serine, glycine or leucine. On the other hand, in isolated endocrine 
tumors  GNAS mutations can occur both at the 201 or 227 positions  [51] . Indeed, 
40% of sporadic somatotrophinomas bear a heterozygous activating  GNAS muta-
tion either at the position 201 or 227 ( gsp oncogene)  [52, 53] . Detection of  GNAS 
mutations in affected tissues is high (90%), while peripheral blood lymphocytes 
show 21–27% positivity in MAS patients  [38] . MAS is a clinical diagnosis but detec-
tion of  GNAS mutations in affected tissues could be important in certain non-clas-
sical cases  [38] .
 Pituitary Involvement 
 Pituitary disease in MAS is characterized by elevated GH and often (92%) accompa-
nying high prolactin levels  [54] . Excessive GH production is part of MAS in 21% of 
patients  [54] , but only 33–65% of these bear a pituitary adenoma detectable by imag-
ing studies  [54, 55] . The current concept is that pituitary involvement in MAS is wide-
spread and diffuse, including areas of normal gland, somatotroph hyperplasia (most 
common), somatotroph neoplasia, lactotroph neoplasia and mammosomatotroph 
neoplasia  [55] . Interestingly,  GNAS mutation-related acromegaly patients (both MAS 
(100%) and sporadic acromegaly (78%)) respond positively to a TRH test while gsp 
negative cases only in 50%  [54] . 
 Surgical treatment in MAS-related acromegaly can be difficult due to the presence 
of craniofacial bone lesions, complicating surgical approaches  [54, 55] . Visual and/or 
auditive compromise due to cranial nerve compression is more severe in patients with 
high GH and IGF-1 levels  [54] . Medical treatment with cabergoline and octreotide 
can lead to disease control, although often partial. Combined treatment with pegvi-
somant and radiotherapy achieved total disease control in a series of 5 out of 6 acro-
megalic SSA-resistant MAS patients  [56] .
 Other features of MAS include  peripheral (primary) precocious puberty in girls 
(30–50%  [57] ), hyperthyroidism (50%), Cushing’s syndrome (7%), renal phosphate 
wasting (50%) (explained by the production of the phosphaturic factor fibroblast 
growth factor 23 (FGF-23) by the fibrous dysplasia lesions  [58] ). Nonendocrine man-
ifestations include fibrous dysplasia, irregular café-au-lait spots (‘cost of Maine’ pat-
tern), rarely gastrointestinal reflux, gastrointestinal polyps, pancreatitis, neonatal 
cholestasis, sudden death, tachycardia, aortic root dilatation and platelet dysfunction 
 [37, 38, 59] . Hyperparathyroidism in MAS is secondary to the abnormalities in min-
eral metabolism and not caused by  GNAS mutations  [37] . A few cases of thyroid and 
breast cancer have been reported in association with MAS; nevertheless, a causative 
association has not been established  [59] .
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Table 1 .  Genes potentially involved in the pathogenesis of sporadic pituitary adenomas
Gene name MIM 
number
Location 
(Chr)
Function TSG/
oncogene
Defect
AIP 605555 11q13.2 Co-chaperone protein Tumor suppres-
sor gene (TSG)
Decreased expression in 
invasive somatotrophi-
nomas
AKT1 164730 14q32.33 Regulates many processes including metabolism, 
proliferation, cell survival, growth and angiogenesis
Oncogene Increased expression, 
especially in NFPAs
AKT2 164731 19q13.2 Regulates many processes including metabolism, 
proliferation, cell survival, growth and angiogenesis
Oncogene Increased expression, 
especially in NFPAs
BAG1 601497 9p13.3 Inhibits the chaperone activity
of HSP70/HSC70 and the pro-apoptotic function of 
PPP1R15A
– Increased expression
BMI1
(BMI-1)
164831 10p12.2 Component of the polycomb repressive complex 1, 
which is required to maintain the transcriptionally 
repressive state of many genes
Oncogene Increased expression, 
genetic amplification in 
one adenoma
BMP4 112262 14q22.2 Plays a crucial role in the control of the differentia-
tion and proliferation of the different cell types in 
the anterior pituitary
TSG Increased expression
CCNA1
(cyclin A1)
604036 13q13.3 Involved in the control of the G1/S and G2/M phas-
es of the cell cycle
Oncogene Increased expression, 
especially in recurrent 
adenomas
CCNB1
(cyclin B1)
123836 5q13.2 Involved in G2-M transition Oncogene Increased expression
CCNB2
(cyclin B2)
602755 15q22.2 Involved in G2-M transition Oncogene Increased expression 
that correlates with 
HMGA1 and HMGA2 
expression
CCND1
(cyclin D1)
168461 11q13.3 Promotes progression through the G1-S phase of 
the cell cycle
Oncogene Increased expression, 
allelic imbalance
CCNE1
(cyclin E1)
123837 19q12 Promotes progression through the G1-S phase of 
the cell cycle
Oncogene Increased expression
CDKN1A
 (p21CIP1)
116899 6p21.2 Regulator of cell cycle progression at G1 TSG Decreased expression in 
NFPAs, increased ex-
pression in hormone 
producing adenomas, 
especially somatotro-
phinomas
CDKN1B
 (p27KIP1)
600778 12p13.1 Blocks the cell cycle in the G0/G1 phase. Also in-
volved in cell migration, proliferation, neuronal 
differentiation and apoptosis
TSG or onco-
gene depending 
on cellular 
context
Decreased expression, 
especially in recurrent 
adenomas
CDKN2A
 (p16INK4)
600160 9p21.3 Induces cell cycle arrest in G1 and G2 phases TSG Decreased expression 
mostly by promoter 
methylation
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Tumor types Animal models References
Invasive somatotrophi-
nomas
Aip +/– mice develop pituitary tumors with 
complete penetrance
Kasuki et al. [20], 2011; Kasuki et al. [21], 2012
Various tumor types No pituitary tumors Musat et al. [75], 2005
Various tumor types No pituitary tumors Musat et al. [75], 2005
Somatotrophinomas, 
prolactinomas, NFPAs
No pituitary tumors Morris et al. [76], 2005
Various tumor types Conditional, neural and glial-specific transgen-
ic expression of Bmi1 in mice lead to develop-
ment of intermediate and anterior lobe ACTH-
secreting pituitary adenomas
Sanchez-Beato et al. [77], 2006; Palumbo et al. 
[74], 2012; Westerman et al. [78], 2012
Prolactinomas No pituitary tumors Paez-Pereda et al. [79], 2003
Various tumor types No pituitary tumors Turner et al. [80] 2000; Nakabayashi et al. [81], 
2001
Various tumor types Homozygous Ccnb1 KO is embryonic lethal in 
mice
Turner et al. [80], 2000; Wierinckx et al. [82], 2007
All tumor types Ccnb2-KO mice, although develop normally, 
are smaller than normal mice and have re-
duced litter sizes
De Martino et al. [83], 2009
Aggressive and non-
functioning adenomas, 
somatotrophinomas
No pituitary tumors Hibberts et al. [84], 1999; Jordan et al. [85], 2000; 
Turner et al. [80] 2000; Simpson et al. [86], 2001; 
Elston et al. [87], 2008
Mainly corticotropino-
mas
No pituitary tumors Jordan et al. [85], 2000; Turner et al. [80] 2000
All tumor types Cdkn1a KO mice do not develop pituitary 
adenomas, but both double Cdkn1a and Rb1, 
and Cdkn1a and Cdkn2c KO mice develop 
pituitary adenomas with a shorter latency than 
single Rb1 and Cdkn2c mutants, respectively. 
Double Cdkn1a and Cdkn1b KO mice show 
higher incidence of pituitary adenomas than 
Cdkn1b mutants
Neto et al. [88], 2005
All tumor types, espe-
cially corticotropinomas 
and pituitary carcino-
mas
Cdkn1b KO mice develop intermediate lobe 
hyperplasia leading to corticotropinomas
Qian et al. [89], 1996; Lloyd et al. [90], 1997; Bam-
berger et al. [91], 1999; Jin et al. [92], 1997; Lidhar 
et al. [93], 1999; Komatsubara et al. [94], 2001; 
Nakabayashi et al. [81], 2001; Korbonits et al. [95], 
2002; Musat et al. [75], 2005
All tumor types, but 
especially NFPAs
Cdkn2a KO mice do not show pituitary adeno-
mas, but double Cdkn2a and Cdkn2c KO mice 
develop intermediate lobe tumors with a 
shorter latency than single Cdkn2c mutants
Woloschak et al. [96], 1996; Jaffrain-Rea et al. [97], 
1999; Simpson et al. [98], 1999; Ruebel et al. [99], 
2001; Seemann et al. [100], 2001; Ogino et al. 
[101], 2005; Yoshino et al. [102], 2006; Machiavelli 
et al. [103], 2008; Kirsch et al. [104], 2009
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Table 1 . Continued
Gene name MIM 
number
Location 
(Chr)
Function TSG/
oncogene
Defect
CDKN2B 
(p15INK4B)
600431 9p21.3 Inhibits progression of cell cycle at G1 TSG Decreased expression 
partly by promoter 
 methylation, homozy-
gous deletion
CDKN2C 
(p18INK4C)
603369 1p32.3 Regulator of cell cycle progression at G1 TSG Decreased expression 
mostly by promoter 
methylation
COPS5
(JAB1)
604850 8q13.1 Probable protease subunit of the COP9 signalo-
some complex, which is involved in various 
cellular and developmental processes
– Increased expression
CREB1
(CREB)
123810 2q33.3 Phosphorylation-dependent transcriptional 
activator of cAMP response elements (CREs), that 
regulates mitogenesis, metabolism, differentia-
tion, and proliferation
Oncogene Constitutive activation by 
phosphorylation
DAPK1 600831 9q21.33 Positive mediator of the programmed cell death 
induced by gamma-interferon
TSG Decreased expression 
either by promoter 
methylation or by homo-
zygous deletion of the 
promoter CpG island
DKC1 300126 Xq28 Pseudouridine synthase that modifies rRNA and 
regulates telomerase activity
TSG Loss-of-function somatic 
mutation
DRD2 
(D2R)
126450 11q23.2 G protein-coupled receptor for dopamine – Decreased expression
EGFR 131550 7p11.2 Transmembrane glycoprotein required for 
 normal cellular proliferation, survival, adhesion, 
migration and differentiation
Oncogene Increased expression
FGF2
 (bFGF)
134920 4q27-28 Plays an important role in the regulation of 
cell survival, cell division, angiogenesis, cell 
 differentiation
and cell migration
– Increased expression, 
decreased mRNA expres-
sion in TSH-secreting 
adenomas
FGFR1 136350 8p11.23-
p11.22
Receptor for fibroblast growth factor Oncogene Increased expression 
especially in NFPAs, 
decreased mRNA expres-
sion in TSH-secreting 
adenomas
FGFR2 176943 10q26.13 Receptor for fibroblast growth factor Oncogene Decreased expression by 
promoter methylation
FGFR4 134935 5q35.2 Membrane-anchored receptor for fibroblast 
growth factor (preferentially binds acidic 
 fibroblast growth factors)
Oncogene Increased expression of a 
N-terminally truncated 
cytoplasmic isoform 
(ptd-FGFR4) by alterna-
tive transcription initia-
tion
FOLR1 (FR) 136430 11q13.4 Binds to folate and reduces folic acid derivatives 
and mediates delivery of 5-methyltetrahydrofo-
late to the interior of cells
Oncogene? Increased expression in 
NFPAs, decreased expres-
sion in PRL- and GH-se-
creting adenomas
GADD45B 
(GADD45-β)
604948 19p13.3 Regulation of growth and apoptosis TSG Decreased expression
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Tumor types Animal models References
Various tumor types No pituitary tumors Ogino et al. [101], 2005; Yoshino et al. [102], 2006
All tumor types Cdkn2c KO mice display intermediated lobe 
and anterior pituitary adenomas
Morris et al. [76], 2005; Hossain et al. [105], 2009; 
Kirsch et al. [104], 2009
Pituitary carcinomas No pituitary tumors Korbonits et al. [95], 2002
Somatotrophinomas A transcriptionally inactive Creb transgene in 
somatotrophs leads to dwarfism and somato-
troph hypoplasia in mice
Bertherat et al. [106], 1995
Various tumor types, 
preferentially invasive 
adenomas
No pituitary tumors Simpson et al. [107], 2002
1 NFPA No pituitary tumors Bellodi et al. [108], 2010
Resistant prolactinomas 
compared to non-resis-
tant tumors
Drd2 KO mice develop lactotroph hyperplasia 
which leads to PRL-secreting adenomas
Caccavelli et al. [109], 1994
NFPAs No pituitary tumors Chaidarun et al. [110], 1994
All tumor types Transgenic Fgfr2 mice show lactotroph 
 hyperplasia
McCabe et al. [111], 2003
All tumor types No pituitary tumors McCabe et al. [111], 2003
Various tumor types Transgenic Fgfr2 mice die shortly after birth 
(no pituitary abnormalities)
Zhu et al. [112], 2007
ptd-FGFR4 in all tumor 
types
Transgenic Fgfr4 mice develop lactotroph 
adenomas
Ezzat et al. [113], 2002
NFPAs, PRL- and GH-se-
creting adenomas
No pituitary tumors Evans et al. [114], 2001
Gonadotroph adeno-
mas
No pituitary tumors Michaelis et al. [115], 2011
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Table 1 .  Continued
Gene name MIM 
number
Location 
(Chr)
Function TSG/
oncogene
Defect
GADD45G 
(GADD45-γ)
604949 9q22.2 Growth suppression and apoptosis TSG Decreased expression 
mainly due to promoter 
methylation
GHR 600946 5p13-p12 Transmembrane receptor that mediates GH 
action
– Loss-of-function somatic 
mutation
GHRH 139190 20q11.23 Stimulates growth hormone secretion – Increased expression
GHRHR 139191 7p14.3 Transmembrane receptor that mediates GHRH 
action
– Truncated alternatively 
spliced nonfunctioning 
receptor
GNAI2
 (Gi2α)
139360 3p21.31 Inhibition of adenylate cyclase and calcium influx Oncogene Gain-of-function somatic 
mutations
GNAS
(GNAS1)
139320 20q13.32 Alpha subunit of the stimulatory G protein that 
activates adenylate cyclase
Oncogene Gain-of-function somatic 
mutations, loss of im-
printing, increased ex-
pression in some so-
matotrophinomas
HDAC2 605164 6q21 Enzyme that deacetylates of lysine residues on 
the N-terminal region of the core histones
Oncogene Decreased expression
HMGA1 600701 6p21.31 Variety of biological functions. Key role in growth 
and development
Oncogene Overexpression
HMGA2 600698 12q14.3 Variety of biological functions. Key role in growth 
and development
Oncogene Amplification and over-
expression
HRAS
(Ras)
190020 11p15.5 GDP/GTP binding protein that regulates cell 
division in response to growth factor stimulation
Oncogene Gain-of-function somatic 
mutations
IKZF1 603023 7p12.2 DNA-binding protein with crucial functions in the 
hematopoietic system and in the development of 
the immune system
Oncogene Dominant-negative 
truncated isoform (Ik6)
LAPTM4B 8q22.1 613296 Required for lysosome homeostasis, acidification 
and function
Oncogene Increased expression
MAGEA3 300174 Xq28 Unknown function, but may play a role in 
 embryonal development and tumor 
 transformation or progression
Oncogene Increased expression by 
promoter hypomethyl-
ation and histone acety-
lation in association with 
FGFR2 down-regulation
MEG3 605636 14q32.3 long non-coding RNA. Induces apoptosis and 
inhibits proliferation of tumor cells
TSG Decreased expression
MEN1 613733 11q13.1 Transcriptional regulator TSG Loss-of-function somatic 
mutations and deletions, 
decreased expression
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Tumor types Animal models References
NFPAs, somatotrophi-
nomas, prolactinomas
No pituitary tumors Zhang et al. [116], 2002; Bahar et al. [117], 2004
Somatotrophinomas Homozygous Ghr KO mice exhibit retarded 
postnatal growth, proportionate dwarfism, 
decreased IGF1 levels, small pituitaries
Asa et al. [118], 2007
Somatotrophinomas Transgenic Ghrh–expressing mice develop 
somatotroph hyperplasia which leads to 
GH-secreting adenomas
Thapar et al. [119], 1997
Somatotrophinomas Homozygous mice for a spontaneous null 
mutation exhibit reduced growth, impaired 
GH synthesis and release
Hashimoto et al. [120], 1995
NFPAs, 1 corticotropi-
noma
Gnai2 KO mice display growth retardation and 
die prematurely
Williamson et al. [121], 1994; Williamson et al. 
[122], 1995
Mainly somatotrophino-
mas (about 40%), some 
NFPAs, corticotropino-
mas
Cholera toxin-transgenic mice develop so-
matotroph hyperplasia
Vallar et al. [123], 1987; Landis et al. [52],1989; 
Tordjman et al. [124], 1993; Williamson et al. 
[121], 1994; Williamson et al. [122], 1995; Ham-
acher et al. [125], 1998; Hayward et al. [48], 2001; 
Riminucci et al. [126], 2002; Picard et al. [127], 
2007
Corticotropinomas Hdac2 –/– mice show partially penetrant 
embryonic lethality
Bilodeau et al. [128], 2006
All tumor types Hmga1 transgenic mice develop pituitary 
adenomas secreting PRL and GH
De Martino et al. [83], 2009
Prolactinomas, NFPAs Hmga2 transgenic mice develop GH- and 
PRL-secreting adenomas
Finelli et al. [129], 2002; Pierantoni et al. [130], 
2005
Pituitary carcinomas
metastases, 1 aggressive 
prolactinoma, invasive 
adenomas
No pituitary tumors Karga et al. [131], 1992; Cai et al. [132], 1994; Pei 
et al. [133], 1994; Lin et al. [134], 2009
Subset of adenomas Ikaros-null mice had contraction of the pitu-
itary corticomelanotroph population, reduced 
circulating adrenocorticotrophic hormone 
levels, and adrenal glucocorticoid insufficiency
Ezzat et al. [135], 2003
NFPAs and corticotropi-
nomas
No animal models available Morris et al. [76], 2005
Various tumor types No animal models available Zhu et al. [136], 2008
NFPAs 2 Meg3 KO mouse models available. Meg3 
deletion results in perinatal death
Zhang et al. [116], 2002; Zhang et al. [137], 2003; 
Zhao et al. [138], 2005; Gejman et al. [139], 2008; 
Cheunsuchon et al. [140], 2011; Mezzomo et al. 
[141], 2012
All tumor types Heterozygous Men1 KO mice develop, among 
others, pituitary tumors
Zhuang et al. [142], 1997; Tanaka et al. [143], 
1998; Wenbin et al. [144], 1999; Schmidt et al. 
[145],1999; McCabe et al. [146],1999
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Table 1 .  Continued
Gene name MIM 
number
Location 
(Chr)
Function TSG/
oncogene
Defect
MERTK 
(CMP-tk)
604705 2q13 Receptor tyrosine kinase that transduces signals 
from the extracellular matrix into the cytoplasm 
by binding to several ligands
Oncogene Increased expression in 
corticotropinomas, 
decreased expression in 
prolactinomas
NR3C1
(GR, GCR)
138040 5q31.3 Nuclear receptor for glucocorticoids – Loss-of-function somatic 
mutation, LOH
ODC1
(ODC)
165640 2p25.1 Catalyzes the decarboxylation of ornithine to 
form putrescine
Oncogene Increased expression in 
somatotrophinomas, 
decreased expression in 
corticotropinomas
PIK3CA 171834 3q26.32 Catalytic subunit of phosphatidylinositol 3-kinase, 
which coordinates a diverse range of cell func-
tions such as proliferation, cell survival, degranu-
lation, vesicular trafficking and cell migration
Oncogene Gain-of-function somatic 
mutations and genetic 
amplification
PITX2 601542 4q25 Member of the bicoid-like homeobox transcrip-
tion factor family, which is involved in the Wnt/
Dvl/β-catenin pathway
– Increased expression
PLAGL1 
(ZAC1)
603044 6q24.2 Zinc finger transcription factor that plays a role in 
pituitary development, differentiation, matura-
tion and tumorigenesis
TSG Decreased expression
POU1F1 
(PIT1)
173110 3p11.2 Transcription factor with a key role in specifica-
tion, expansion and survival of different pituitary 
cell types during anterior pituitary development
– Increased expression
PRKCA
(PKC α)
176960 17q24.2 Kinase that participates in growth factor- and 
hormone-mediated transmembrane signaling 
and cell proliferation
Oncogene Increased expression, 
gain-of-function somatic 
mutations in invasive 
tumors
PTTG1 (PTTG, 
Securin)
604147 5q33.3 Cell cycle regulation and cell senescence Oncogene Increased expression, 
especially in corticotropi-
nomas
PTTG1IP 
(PBF)
603784 21q22.3 Facilitates the nuclear translocation of PTTG1 and 
potentiates the transcriptional activation of FGF2 
by PTTG1
Oncogene Increased expression, 
especially in NFPAs
RB1
(pRB)
614041 13q14.2 Key regulator of entry into cell division TSG Decreased expression 
partly by promoter meth-
ylation
RHBDD3 
(PTAG)
– 22q12.2 Pro-apoptotic mediator TSG Decreased expression 
partly due to promoter 
methylation
SMARCA4 
(Brg1)
603254 19p13.2 Member of the SWI/SNF protein family with 
helicase and ATPase activities. Regulates gene 
transcription by altering chromatin structure
TSG Decreased expression, 
altered subcellular local-
ization
SSTR2 182452 17q25.1 G protein-coupled receptor for somatostatin – Decreased expression
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Tumor types Animal models References
Corticotropinomas, pro-
lactinomas
No pituitary tumors Evans et al. [114], 2001
Corticotropinomas Homozygous null mutants die at birth Karl et al. [147], 1996; Huizenga et al. [148], 1998
Somatotrophinomas, 
corticotropinomas
Homozygous null embryos die prior to 
 gastrulation
Evans et al. [114], 2001
Mutations in invasive 
corticotroph, lactotroph, 
plurihormonal and non-
functioning adenomas, 
amplifications in all types 
of adenomas, both inva-
sive and non-invasive
Homozygous KO or knock-in mutations of 
Pik3ca lead to embryonic death associated 
with growth retardation
Lin et al. [134], 2009
NFPAs Transgenic overexpression of Pitx2 in mouse 
pituitary increases gonadotroph population
Acunzo et al. [149], 2011
NFPAs Zac1 KO results in neonatal lethality in mice Pagotto et al. [150], 2000; Noh et al. [151], 2009
GH-, PRL- and TSH-secret-
ing adenomas
Homozygous Pou1f1 KO mice for spontaneous 
mutations exhibit hypoplasia of the anterior 
pituitary cells resulting in deficiencies in GH, 
PRL, and TSH, dwarfism
Palmieri et al. [152], 2012
NFPAs No pituitary tumors Alvaro et al. [153], 1993
All tumor types Targeted Pttg overexpression in mice results in 
focal pituitary hyperplasia with hormone 
hypersecretion; transgenic zebrafish overex-
pressing zPttg targeted to POMC cells show 
hypercortisolism and pituitary corticotroph 
expansion
Zhang et al. [154], 1999; McCabe et al. [111], 
2003; Morris et al. [76], 2005; Salehi et al. [155], 
2010
All tumor types No animal models available McCabe et al. [111], 2003
Aggressive adenomas pRB+/- mice develop intermediate lobe 
 hyperplasia which leads to ACTH-secreting 
adenomas
Simpson et al. [156], 2000; Ogino et al. [101], 
2005; Yoshino et al. [102], 2006
Various tumor types No animal models available Bahar et al. [157], 2004
Corticotropinomas Brg1 -/- mice died during the periimplantation 
stage. Brg1 +/- mice are predisposed to exen-
cephaly and various tumors (no pituitary)
Bilodeau et al. [128], 2006
Resistant somatotrophi-
nomas compared to 
non-resistant tumors
No pituitary tumors Corbetta et al. [158], 2001
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 Somatic Alterations in Pituitary Adenomas 
 Pituitary adenomas are monoclonal in origin, expanding from molecular abnormal-
ities in a single somatic cell  [60] . These alterations, which include activation of proto-
oncogenes, inactivation of tumor suppressor genes, and epimutations, confer the cell 
a growth advantage. The resulting genomic instability facilitates subsequent mutation 
accumulation  [61] . 
 The majority (about 95%) of pituitary adenomas occur sporadically. The most 
common somatic mutation is in the  GNAS gene (gsp mutation), which occurs in 
around 40% of GH-secreting adenomas. Alterations in classical tumor suppressor 
genes such as  TP53 and  RB1 or oncogenes such as  HRAS and  MYC are only rarely 
identified, and exclusively in aggressive tumors or pituitary carcinomas  [62] ( table 1 ).
 Numerous genes show altered expression in pituitary tumors ( table 1 ), but it is 
still unknown whether they initiate the tumorigenic process or if they represent a 
later event. A number of alterations have been found to alter the expression of genes 
implicated in the regulation of the cell cycle, apoptosis, growth factors and their 
receptors, signal transduction pathways (in particular, the cAMP, MAPK and PI3K/
Akt pathways  [63] ), specific hormonal factors, or other molecules with still unclear 
Table 1 .  Continued
Gene name MIM 
number
Location 
(Chr)
Function TSG/
oncogene
Defect
THRB
(TRβ)
190160 3p24.2 Nuclear receptor that mediates gene regulation by 
thyroid hormone
TSG Loss-of-function 
somatic mutation 
and aberrant alterna-
tively spliced variant
TP53 (P53) 191170 17p13.1 Involved in cell cycle regulation as a trans-activator 
that acts to negatively regulate cell division by 
 controlling a set of genes required for this process
TSG Loss-of-function 
somatic mutations
WIF1 605186 12q14.3 Secreted protein that binds WNT proteins and inhib-
its their activities
TSG Decreased expres-
sion by promoter 
methylation
 White background = Abnormal gene expression; light grey background = genetic defects; dark grey background = both 
genetic defects and abnormal expression. Gene names are shown accordingly to the HGNC (HUGO Gene Nomenclature 
Committee) approved gene symbol. Commonly used alternative symbols are shown in brackets. Data from nonvalidated 
microarray experiments are not reported in the table. MIM = Mendelian inheritance in man database; Chr = chromosome; 
TSG = tumor suppressor gene; SNP = single nucleotide polymorphism; KO = knock-out; LOH = loss of heterozygosity; 
NFPAs = nonfunctioning pituitary adenomas.
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functions. Different mechanisms leading to abnormal gene expression have been 
described, such as allelic loss, gene amplification, and epigenetic changes  [64] . Sev-
eral tumor suppressor genes, in particular the inhibitors of cyclin-dependent ki-
nase complexes, were shown to be frequently downregulated in pituitary tumors 
without presenting somatic mutations but as a consequence of epigenetic altera-
tions like promoter hypermethylation or histone modifications  [65, 66] . Moreover, 
abnormal miRNA expression profiles have been reported in recent years in pitu-
itary adenomas  [67] ( table 2 ). Several animal models have been generated, which 
usually confirmed the functional role of these genes in the pathogenesis of pituitary 
tumors  [62, 66] .
 To explain the predominance of benign versus malignant pituitary tumors, the oc-
currence of cellular senescence has been proposed  [68] . Cellular senescence is an an-
tiproliferative response triggered by DNA damage, chromosomal instability and an-
euploidy, loss of tumor-suppressive signaling or oncogene activation, which leads to 
irreversible cell cycle arrest via activation of inhibitors of cell cycle progression, such 
as p16 INK4 , p19 ARF , and p21 CIP1 . Pituitary adenoma cells may undergo premature se-
nescence in order to escape from the deleterious consequences that proliferative pres-
sure of oncogenes, hormones and transformation factors could exert on their crucial 
Tumor types Animal models References
Thyrotropinomas No pituitary tumors Ando et al. [159], 2001; Ando et al. [160], 2001
1 atypical ACTH-secret-
ing adenoma, 1 aggres-
sive ACTH-secreting 
adenoma after radio-
therapy, 1 atypical 
PRL-secreting adenoma 
and 1 pituitary carcino-
ma from the same 
patient, 2 ACTH-secret-
ing carcinomas
Tp53 KO mice are predisposed to develop 
pituitary adenomas, double Tp53 and Rb1 KO 
mice develop pituitary adenomas with a 
shorter latency than single Tp53 and Rb1 
mutants
Tanizaki et al. [161], 2007; Kawashima et al. [162], 
2009; Pinto et al. [163], 2011; Murakami et al. 
[164], 2011
Reduction of mRNA 
common to all tumor 
subtypes, reduction of 
protein levels predomi-
nantly limited to NFPAs
No pituitary tumors Elston et al. [87], 2008
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physiological function on homeostasis control. More than 70% of GH-secreting ad-
enomas overexpress the  PTTG gene, which leads to aneuploidy and induction of se-
nescence markers, including p21 CIP1 and senescence-associated β-galactosidase. In 
contrast, p21 CIP1 is weakly expressed in normal pituitary tissue and undetectable in 
pituitary carcinomas  [69] .
 MicroRNAs in Pituitary Adenomas 
 MicroRNAs (miRNAs) are small (approximately 22 nucleotides) noncoding RNA 
molecules involved in posttranscriptional regulation of gene expression  [70] . They 
regulate about 30% of human genes, constituting a major class of molecular regula-
tors. The mature miRNA, as part of a complex called RNA-induced silencing com-
plex (RISC), either binds to a perfectly complementary sequence in the mRNA strand 
resulting in degradation of the mRNA by RISC, or binds to a partially complemen-
tary mRNA sequence and this induces translational repression of the target mRNA 
 [71] . 
 miRNAs have been implicated in the regulation of many cellular processes, in-
cluding cell proliferation, apoptosis, cell adhesion and metabolism. Thus, alterations 
in miRNA expression can potentially be involved in the development of many 
 diseases, including human neoplasias. miRNAs can act either as activators or in-
hibitors of carcinogenesis, being called oncomiRs and tumor suppressor miRNAs, 
respectively.
 miRNA expression has been associated with pituitary tumor type, characteristics 
(size, invasion) and response to therapy. miRNAs have also been involved in the regula-
tion of some genes associated with the pathogenesis of pituitary adenomas ( table 2 )  [67] .
 Several different miRNAs have been shown to be differently expressed in the var-
ious subtypes of pituitary adenomas in comparison with normal pituitary and also in 
adenomas in comparison with carcinomas ( table 2 )  [67, 72] . Degli Uberti’s group ob-
served that miR-15a and miR-16–1 were downregulated in GH- and PRL-producing 
adenomas in comparison with normal pituitary and the expression of these miRNAs 
was inversely correlated with tumor size  [72] . Moreover, some miRNAs targets were 
evaluated individually in different studies:
 • miR-16–1 predicted target arginyl-tRNA synthetase (RARS) mRNA levels inverse-
ly correlated with miR-16-1 expression and tumor size in both somatotrophinomas 
and prolactinomas  [67, 72] . 
 • The expression of miR let-7 inversely correlated with mRNA levels of  high-mobil-
ity group A protein 2  (HMGA2) , a gene known to cause pituitary adenomas in 
transgenic mice, suggesting that the reduction of this miRNA may be responsible 
for the higher expression of HMGA2 in more invasive tumors  [67] . Moreover, 
functional studies showed that transfection of this miRNA reduced the prolifera-
tion of GH3 cells, indicating that it might act as a tumor suppressor miRNA. 
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 • Several miRNAs (miR-135a, miR-140–5p, miR-582–3p, miR-582–2p and miR-
938), known to inhibit Smad3, a protein underexpressed in NFPAs, were shown to 
be significantly overexpressed in NFPAs  [67] . 
 • Another group of miRNAs were suggested to influence the expression of cell cycle 
inhibitor  Wee1.  miR-155, miR-20a, miR-93, miR-128a and miR-516–3p were sig-
nificantly overexpressed in NFPAs and GH-secreting adenomas compared to NP. 
Table 2.  Studies addressing microRNAs expression in pituitary adenomas
Study Tumor type Aberrant microRNAs expression Affected
gene(s)
Clinical correlation
Bottoni et al.
[165], 2005
10 GH and 10 PRL Underexpression of miR-15a and miR-16-1 
in adenomas × NP
RARS Inverse correlation with tumor size
Bottoni et al.
[166], 2007
17 NFPA, 5 PRL,
4 ACTH and 6 GH
30 miRNAs differently expressed between 
adenomas and NP. 29 miRNAs predict 
tumor type
– 6 miRNAs correlated with tumor size in 
NFPA. 3 miRNAs up- and 3 down-regu-
lated in NFPA treated with DA in com-
parison with non-treated ones
Qian et al.
[167], 2009
98 adenomas of all
types
Let-7 overexpression in tumors with low 
HMGA2 expression
HMGA2
Amaral et al.
[168], 2009
14 ACTH Underexpression of miR-145, miR-21, miR-
141, miR-150, miR-15a, miR-16, miR-143 
and let-7a in adenomas × NP
– miR-141 levels directly correlated with 
chance of disease recurrence
Stilling et al.
[169], 2010
8 ACTH
2 ACTH carcinomas
188 miRNAs over- and 160 under-expressed 
in ACTH × NP
98 miRNAs differently expressed in adeno-
ma × carcinoma
– –
Butz et al.
[170], 2010*
27 NFPA and 15 GH miR-20a, miR-128a and miR-516-3p overex-
pressed in NFPA. miR-93 and miR-155 over-
expressed in GH and NFPA
WEE1 –
Mao et al.
[171], 2010
21 GH 23 miRNAs over- and 29 under-expressed in 
GH × NP
– 9 miRNAs differently expressed in micro 
× macroadenomas
13 differently expressed in lanreotide 
treated × surgery alone
7 differently expressed in lanreotide 
responders × non responders
Butz et al.
[172], 2011
8 NFPA 70 miRNAs over- and 92 under-expressed in 
NFPA × NP
– 18 miRNAs inversely correlated with 
tumor size
Palmieri et al.
[173], 2011*
14 PRL, 9 GH and
18 NFPA
miR-15, miR-16, miR26a, miR-196ab and 
Let-7a underexpressed in adenomas × NP
HMGA1
and
HMGA2
–
D’Ángelo et al.
[174], 2012*
18 GH miR34b, miR-326, miR-374b, miR-432, miR-
548c-3p, miR-570, miR-603 and miR-633 
under-expressed, and miR-320 
over-expressed in adenomas × NP
HMGA1,
HMGA2
and E2F1
–
Palumbo et al.
[74], 2012*
12 GH 5 miRNAs over- and 12 underexpressed in 
GH × NP
PTEN and
BMI1
–
Trivellin et al.
[73], 2012*
10 GH and 7 NFPA miR-107 overexpressed in tumors × NP
AIP expression inhibited by miR-107
AIP –
 GH = Somatotrophinoma; PRL = prolactinoma; NFPA = nonfunctioning pituitary adenoma; ACTH = corticotropinoma; NP = normal pitu-
itary tissue; DA = dopamine agonist; × = versus. * Studies where functional validation was done.
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Functional studies proved that overexpression of miR-128a, miR-516–3p and miR-
155 was associated with the reduced expression of Wee1 kinase, thereby indicating 
a role of these miRNAs in pituitary tumorigenesis  [67] . 
 • miR-107 is an interesting miRNA as it has been shown to have both tumor suppres-
sor miR and oncomiR properties, depending on the tissue type. In pituitary adeno-
mas it is upregulated in comparison with normal pituitary  [73] , however, it inhibits 
cell proliferation in human neuroblastoma SH-SY5Y and rat pituitary GH3 cell 
lines.  AIP  is a functional target of miR-107 as miR-107 inhibits human AIP expres-
sion  [73] ; therefore, miR-107 unlikely exerts its tumor suppressor role via  AIP. 
 • A recent study using somatotroph hyperplasia samples showed that miR-26b was 
overexpressed and miR-128 was underexpressed compared to normal pituitary 
 [74] . Molecular analysis revealed that these miRNAs regulate the expression levels 
of  PTEN and  BMI1,  genes known to be involved in the regulation of cell prolifera-
tion. 
 Conclusion 
 Tumorigenesis is influenced by inherited and acquired mutations as well as epigen-
etic changes. An important feature of pituitary adenomas is that they are relatively 
common but rarely cause clinically relevant disease and exceedingly rarely develop 
into a metastatic carcinoma. One of the suggested mechanisms of lack of malignant 
transformation is the development of cellular senescence. However, the regulating 
factors influencing these processes in the vast majority of sporadic adenoma cases are 
unknown. On the other hand, understanding the tumorigenic process in the rare fa-
milial adenomas could result in better diagnostic and treatment options for both fa-
milial and sporadic cases. 
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Abstract
Objective: The pathogenetic mechanisms of sporadic somatotroph adenomas are not well understood, but derangements
of the cAMP pathway have been implicated. Recent studies have identified L206R mutations in the alpha catalytic subunit
of protein kinase A (PRKACA) in cortisol-producing adrenocortical adenomas and amplification of the beta catalytic subunit
of protein kinase A PRKACB in acromegaly associated with Carney complex. Given that both adrenocortical adenomas and
somatotroph adenomas are known to be reliant on the cAMP signalling pathway, we sought to determine the relevance
of the L206R mutation in both PRKACA and PRKACB for the pathogenesis of sporadic somatotroph adenomas.
Design: Somatotroph adenoma specimens, both frozen and formalin-fixed, from patients who underwent surgery for
their acromegaly between 1995 and 2012, were used in the study.
Methods: The DNA sequence at codon 206 of PRKACA and PRKACB was determined by PCR amplification and sequencing.
The results were compared with patient characteristics, the mutational status of the GNAS complex locus and the tumour
granulation pattern.
Results: No mutations at codon 206 of PRKACA or PRKACB were found in a total of 92 specimens, comprising both WT
and mutant GNAS cases, and densely, sparsely and mixed granulation patterns.
Conclusions: It is unlikely that mutation at this locus is involved in the pathogenesis of sporadic somatotroph adenoma;
however, gene amplification or mutations at other loci or in other components of the cAMP signalling pathway, while
unlikely, cannot be ruled out.
European Journal of
Endocrinology
(2014) 171, 705–710
Introduction
Genetic studies of the pathogenesis of sporadic somato-
troph adenomas have identified a role for the cAMP
signalling pathway, and conversely syndromes that
feature a germline mutation in the components of this
pathway can be associated with the formation of
somatotroph adenomas. Thus, sporadic somatotroph
adenomas are often associated with mutations at the
GNAS complex locus, encoding the GSP oncogene. These
mutations implicate the cAMP pathway in the patho-
genesis of sporadic somatotroph adenomas in 15–58% of
cases (1, 2, 3), although the tumourigenic mechanism
is unclear. The McCune–Albright syndrome results from
post-zygotic germline mutations in GNAS and is often
characterised by endocrine neoplasia: it is associated with
somatotroph adenomas and acromegaly in 10–20% of
cases (4). Carney complex is an autosomal dominant
syndrome characterised by multiple, often endocrine
tumours, including somatotroph adenomas, in w10% of
cases (5). In over 60% of cases of Carney complex, a
mutation is found in the regulatory subunit 1A of protein
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kinase A (PRKAR1A), an intrinsic part of cAMP signalling,
although such mutations are not found in sporadic
pituitary adenomas (6, 7, 8). Recently, whole-exome
sequencing studies have identified a mutation in the
active-site cleft of catalytic subunit A of PKA (PRKACA) in
cortisol-producing adrenocortical adenomas, most com-
monly R206 (9, 10, 11). This mutation was observed in
37–66% of cases and resulted in constitutive activation of
PKA that was neither suppressed by the PKA regulatory
subunit nor increased by addition of cAMP (either directly
or indirectly by forskolin treatment) (10, 11). A recent
report of a patient with Carney complex with acromegaly,
spotty pigmentation and myxomas, but without Cush-
ing’s syndrome, has shown the presence of a triplication
of chromosome 1p31.1 (containing PRKACB), leading
to increased expression of PRKACB (12). The authors
propose that amplification of PRKACBmay be responsible
for non-adrenal manifestations of Carney complex. Given
the involvement of the cAMP pathway in sporadic
somatotroph adenoma pathogenesis, we sought to
determine whether mutations in the catalytic subunit of
PKA might also occur in these lesions and be involved
in the pathogenesis of these tumours. We therefore
amplified and sequenced the region of PRKACA and
PRKACB containing codon 206 in a large series of sporadic
somatotroph adenomas. The findings were compared with
patient characteristics, the mutational status of GNAS in a
sub-group and the granulation pattern of the specimens.
Subjects and methods
Patients (nZ92) with a diagnosis of acromegaly were
included. None of the patients had a clinical history of
FIPA, MEN1 or SDH-associated acromegaly, but germline
mutations inMEN1 and SDH were not sought routinely in
all individuals. The tumour samples, either formalin fixed
and paraffin embedded (FFPE; nZ43) or frozen (nZ49),
were retrieved from the surgical neuropathology archive
of the Oxford Brain Bank and the Tissue Bank of the
Department of Endocrinology at Barts and the London
School of Medicine. The specimens were excluded if the
samples were too small or the DNA was of insufficient
quality to enable successful amplification of the regions
containing codon 206 of PRKACA and PRKACB. The
specimens were preferentially included if previous analysis
had shown them to be GNAS WT. The findings of Sato
et al. (11) demonstrate that mutations in PRKACA and
GNAS are mutually exclusive in adrenocortical adenomas
and so we speculated that any PRKACA mutations
identified might only be present in GNAS-mutation
negative specimens. All studies were conducted on
linked-anonymised samples under multi-site and local
Research Ethics Committee (REC) approval.
DNA was extracted from either 5!10 mm sections
of FFPE tissue (QiaAmp FFPE DNA Kit, Qiagen) or from
homogenised fresh-frozen specimens (QiaAmp DNA Mini
Kit or DNeasy Blood and Tissue Kit (Qiagen)) according
to manufacturer’s instructions. PCR was carried out to
generate amplicons including codon 206 of PRKACA and
PRKACB. The primers were designed using Primer-Blast
(www.ncbi.nlm.nih.gov/tools/primer-blast). For FFPE
specimens primers were as follows: PRKACA sense
(5 0-GGTGACAGACTTCGGTTTCGC-3 0) and antisense
(5 0-CCTTGTTGTAGCCCTGGAGCA-3 0); PRKACB sense
(5 0-TGGTTTTATTTCTTTGCAGTGAGC-3 0) and antisense
(5 0-CCTGGATATAGCCTTGATGGTCA-3 0). The primers
for gDNA from frozen specimens were as follows: PRKACA
sense (5 0-CAACTGCCTGTTCTTGTGCC-3 0) and antisense
(5 0-AGTCCACGGCCTTGTTGTAG-3 0); PRKACB sense
(5 0-AAACTTTCAACGTAGGTGCAAT-3 0) and antisense
(5 0-CAAAAGTCCATAGGGATGCATGT-3 0). The primers
for cDNA from frozen specimens were as follows: PRKACA
sense (5 0-CTGCACTCGCTGGATCTCAT-3 0) and antisense
(5 0-CAGAGCTGAAGTGGGAAGGG-3 0) and PRKACB sense
(5 0-GCAGCTCAGATAGTGCTAACATTC-3 0) and antisense
(5 0-GGTCTGCAAAGAATGGGGGATA-3 0).
For FFPE specimens, DNA template (100 ng) was
added to 10! PCR buffer solution (10% v/v; Qiagen),
MgCl2 (final concentration 4 mmol/l, for PRKACB only),
dNTPs (200 mmol/l) (Promega), 0.5 U of Taq polymerase
(HotStarTaq Plus, Qiagen) and 400 nmol/l each of forward
and reverse primers. The cycling conditions were as
follows: 95 8C for 5 min, followed by 35 cycles of 95 8C
for 30 s; annealing temperature for 30 s (61 8C for PRKACA
and 57 8C for PRKACB) and 72 8C for 40 s, followed by a
single 1 min extension. Total reaction volume was 20 ml.
For frozen specimens, gDNA template ((100 ng) was added
to 10! Taq reaction buffer (10% v/v; (New England
Biolabs (NEB), Hitchin, UK)), dNTPs (200 mmol/l) (New
England Biolabs), 0.12 U of Taq polymerase (New England
Biolabs) and 200 nmol/l each of forward and reverse
primers. The cycling conditions were as follows: 95 8C
for 2 min, followed by 35 cycles at 95 8C for 30 s, annealing
temperature for 30 s (67.6 8C for PRKACA and 62.5 8C for
PRKACB) and 68 8C for 30 s, followed by a single 5 min
extension. Total reaction volume was 25 ml.
RNA was extracted from frozen specimens using the
RNeasy Kit (Qiagen), according to manufacturer’s instruc-
tions. RT was performed using 500 ng RNA, random
hexamer primers (0.5 mg/l, Promega) and M-MLV reverse
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Table 1 Cases included in the study. Cases 1–21 have previously been reported (13).
Case Sex Age Material Preservation Size Granulation GNAS PRKACA PRKACB
1 F 39 gDNA FFPE Macro S WT WT WT
2 F 64 gDNA FFPE Micro D WT WT WT
3 F 54 gDNA FFPE Macro D WT WT WT
4 F 41 gDNA FFPE Micro D WT WT WT
5 F 57 gDNA FFPE Macro D WT WT WT
6 M 49 gDNA FFPE Macro D WT WT WT
7 F 56 gDNA FFPE Micro M WT WT WT
8 M 35 gDNA FFPE Macro ND R201C WT WT
9 F 66 gDNA FFPE Macro S ND WT WT
10 F 23 gDNA FFPE Macro S ND WT WT
11 F 47 gDNA FFPE Macro S WT WT WT
12 M 43 gDNA FFPE Micro D WT WT WT
13 F 44 gDNA FFPE Macro S WT WT WT
14 F 62 gDNA FFPE Macro M WT WT WT
15 M 52 gDNA FFPE Macro S R102C WT WT
16 F 54 gDNA FFPE Macro M WT WT WT
17 F 26 gDNA FFPE Macro S ND WT WT
18 F 33 gDNA FFPE Macro ND WT WT WT
19 F 53 gDNA FFPE Macro ND WT WT WT
20 F 59 gDNA FFPE Micro D WT WT WT
21 M 56 gDNA Frozen Macro D R201C WT WT
22 F 49 gDNA FFPE ND S ND WT WT
23 M 31 gDNA FFPE ND S ND WT WT
24 F 45 gDNA FFPE ND ND ND WT WT
25 F 49 gDNA FFPE ND ND ND WT WT
26 M 34 gDNA FFPE Micro S ND WT WT
27 M 55 gDNA FFPE Micro S ND WT WT
28 M 43 gDNA FFPE Micro ND ND WT WT
29 F 46 gDNA FFPE Macro ND ND WT WT
30 F 61 gDNA FFPE Macro S ND WT WT
31 F 19 gDNA FFPE Macro ND ND WT WT
32 F 41 gDNA FFPE Macro D ND WT WT
33 M 52 gDNA FFPE ND ND ND WT WT
34 F 29 gDNA FFPE Micro ND ND WT WT
35 M 40 gDNA FFPE ND ND ND WT WT
36 M 69 gDNA FFPE ND ND ND WT WT
37 M 18 gDNA FFPE Macro ND ND WT WT
38 F 41 gDNA FFPE Micro D ND WT WT
39 F 25 gDNA FFPE Macro S ND WT WT
40 F 29 gDNA FFPE Macro S ND WT WT
41 F 67 gDNA FFPE Macro D ND WT WT
42 M 53 gDNA FFPE Macro ND WT WT WT
43 F 30 gDNA FFPE Macro S WT WT WT
44 F 36 gDNA FFPE Macro S WT WT WT
45 F 57 gDNA Frozen Macro ND ND WT WT
46 M 48 gDNA Frozen Micro ND ND WT WT
47 F 42 gDNA Frozen Macro ND ND WT WT
48 M 50 gDNA Frozen Micro ND WT WT WT
49 M 80 gDNA Frozen Macro ND ND WT WT
50 F 66 gDNA Frozen Macro ND ND WT WT
51 F 37 gDNA Frozen Macro ND ND WT WT
52 M 32 gDNA Frozen Macro ND ND WT WT
53 M 71 gDNA Frozen Macro ND ND WT WT
54 F 53 gDNA Frozen ND ND ND WT WT
55 M 42 gDNA Frozen Macro ND ND WT WT
56 F 33 gDNA Frozen Macro ND ND WT WT
57 M 44 gDNA Frozen Macro ND ND WT WT
58 F 38 gDNA Frozen Macro ND ND WT WT
59 M 48 gDNA Frozen ND ND ND WT WT
60 F 28 gDNA Frozen Macro ND ND WT WT
61 M 40 gDNA Frozen ND ND ND WT WT
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transcriptase (100 U) (Life Technologies). For amplifi-
cation of PRKACA, cDNA template (100 ng) was added to
5! Q5 reaction buffer (20% v/v; (New England Biolabs)),
0.25 ml DNA polymerase (Q5 High-Fidelity DNA poly-
merase, New England Biolabs) 5! Q5 High GC Enhancer
(20% v/v, New England Biolabs) dNTPs (200 mmol/l) and
500 nmol/l each of forward and reverse primers. The
cycling conditions were as follows: 98 8C, 30 s, followed
by 35 cycles of 98 8C for 10 s, 60 8C for 20 s, 72 8C for 20 s
followed by a single extension for 2 min. Total reaction
volume was 25 ml. For amplification of PRKACB, reaction
and cycling conditions were identical to those for gDNA
except that 400 mmol/l dNTPs were added and the
annealing temperature was 62 8C.
The products were examined by agarose gel separation
and purified (MinElute PCR Purification Kit (Qiagen)).
Bidirectional sequencing of amplicons was carried out
using BigDye Terminator chemistry (v3.1) and anABI-3730
capillary sequencer (Applied Biosystems). The sequences
were compared with the WT sequence (RefSeq
NM_002730.3 (PRKACA) and NM_182948.2 (PRKACB)).
The tumours were categorised as sparsely granulated
(SG), densely granulated (DG) or of mixed granulation
pattern (MG). A mixed phenotype was assigned when
more than 30% of tumour cells deviated from the
dominant Cam5.2 pattern. The immunohistochemical
methods for determination of granulation pattern and the
sequencing of GNAS have been previously described (13).
Results
In this study, a total of 92 sporadic somatotroph adenoma
specimens (54 from females) were used. Age at diagnosis
varied between 10 and 80 years, and 77% of samples were
obtained from patients with macroadenomas (where
tumour size was known; nZ77). There were mutations
at the GNAS complex locus, G-protein a subunit codon
201 (R201C), in four of 26 cases for which sequences
Table 1 Continued
Case Sex Age Material Preservation Size Granulation GNAS PRKACA PRKACB
62 F 33 gDNA Frozen Micro ND ND WT WT
63 F 43 gDNA Frozen Macro ND ND WT WT
64 F 26 gDNA Frozen Micro ND ND WT WT
65 M 63 gDNA Frozen Macro ND ND WT WT
66 F 57 gDNA Frozen Macro ND ND WT WT
67 M 48 gDNA Frozen Micro ND ND WT WT
68 F 46 gDNA Frozen ND ND ND WT WT
69 F 32 gDNA Frozen Macro ND ND WT WT
70 F 25 gDNA Frozen Macro ND ND WT WT
71 M 25 gDNA Frozen Macro ND ND WT WT
72 M 10 gDNA Frozen Macro ND ND WT WT
73 F 14 gDNA Frozen Macro ND ND WT WT
74 M 62 gDNA Frozen Macro ND ND WT WT
75 F 48 gDNA Frozen Micro ND ND WT WT
76 F 63 gDNA Frozen Macro ND ND WT WT
77 F 57 gDNA Frozen ND ND ND WT WT
78 M 34 gDNA Frozen Macro ND ND WT WT
79 M 26 gDNA Frozen Macro ND ND WT WT
80 F 28 gDNA Frozen ND ND ND WT WT
81 F 40 gDNA Frozen Macro ND ND WT WT
82 F 78 gDNA Frozen Micro ND ND WT WT
83 M 39 gDNA Frozen Macro ND ND WT WT
84 M 53 gDNA Frozen Macro ND ND WT WT
85 M 53 cDNA Frozen Macro ND WT WT WT
86 M ND cDNA Frozen Macro ND WT WT WT
87 M 69 cDNA Frozen Macro ND WT WT WT
88 M 62 cDNA Frozen Micro ND R201C WT WT
89 M 40 cDNA Frozen Macro ND ND WT WT
90 M 52 cDNA Frozen Macro ND ND WT WT
91 F 41 cDNA Frozen Macro ND ND WT WT
92 F 64 cDNA Frozen Macro ND ND WT WT
ND, not determined; DG, densely granulated; MG, mixed granulation pattern; SG, sparsely granulated; FFPE, formalin fixed, paraffin embedded; macro,
macroadenoma; micro, microadenoma.
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were available (20 from FFPE specimens and six from
frozen specimens) (Table 1). In the remaining FFPE
specimens (nZ23), DNA quality was not sufficient to
allow amplification of codons 201 and 227 of G-protein
a subunit, so such data for these cases were not available.
We did not find a mutation at codon 206 of PRKACA
or PRKACB in either the gDNA or cDNA of any of
the sporadic somatotroph adenomas. Although infor-
mation regarding the mutational status of GNAS and
the granulation pattern was not available for all cases,
we did not find a mutation in either GNAS mutant
or WT cases (mutational status was established in
26 of 92 specimens) or in tumours with any type of
granulation pattern.
Discussion
The lack of a mutation in either PRKACA or PRKACB in
our series suggests that constitutive activation of PRKACA
or PRKACB by mutation of codon 206 is unlikely to be
involved in the pathogenesis of sporadic somatotroph
adenomas. However, as we did not sequence all exons
of PRKACA or PRKACB, we cannot rule out mutations at
other loci, although this seems unlikely.
Both adrenal adenomas and pituitary somatotroph
adenomas are known to contain mutations in com-
ponents of the cAMP signalling pathway in a proportion
of cases, and mutations in PRKAR1A can underlie the
development of both of these lesions. However, while
mutation of PRKACA appears to be important for the
development of up to two-thirds of cortisol-producing
adrenal adenomas (9, 10), it does not appear to be the case
for somatotroph adenomas, even though mutation of the
cAMP signalling pathway has been shown to be involved
in the pathogenesis of this tumour type (1, 2, 13, 14, 15,
16, 17, 18, 19). We did not determine whether there was
amplification of either the PRKACA or PRKACB gene in
this series. Amplification of chromosome 19p (containing
PRKACA) and 1p31.1 has been shown to underlie impaired
inhibition of the catalytic subunit by the PKA regulatory
subunit and increased basal PKA activity (9, 12). In the
absence of a PRKACA or PRKACB mutation, amplification
could lead to increased cAMP signalling that might result
in somatotroph tumourigenesis.
In adrenocortical adenomas, mutations in PRKACA
have been found to be mutually exclusive with mutations
in GNAS (11). In this series, we found no mutation in
codon 206 of PRKACA or PRKACB in 22 specimens
which were GNAS WT and four specimens that had
GNAS R201C mutations. Where GNAS status was known,
we preferentially included WT specimens in this series.
However, there is a lack of information concerning the
mutational status of GNAS in the remaining cases (nZ66).
Given the reported prevalence of GNAS mutations in
somatotroph adenomas (1, 2, 3), we could expect 15–58%
of them (between ten and 38 specimens) to harbour aGNAS
mutation; this suggests that although themajoritywould be
negative for GNAS mutation, GNAS mutation in a subset
maypreclude thefindingof aPRKACAorPRKACBmutation.
Previously, we and others have suggested that DG and
SG somatotroph adenomas may have differing clinical
characteristics and responses to treatment (1, 18, 20,
21, 22). The genetic basis for this difference has yet to be
determined, and so a series containing representative
samples from all granulation subtypes was chosen for
this study.
The findings of several groups (9, 10, 11, 12) support
a central role for the cAMP signalling pathway in the
pathogenesis of adrenocortical adenomas and somatotroph
adenomas. Although we did not demonstrate the presence
of a recurring mutation in either PRKACA or PRKACB,
mutations in other components of this pathway cannot
be ruled out and warrant further investigation. At present,
any mutational event pathogenetic in the majority of
sporadic somatotroph tumours remains elusive.
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Context: Familial isolated pituitary adenoma (FIPA) due to aryl hydrocarbon receptor interacting protein (AIP)
genemutations is an autosomal dominant diseasewith incomplete penetrance. Clinical screeningof apparently
unaffected AIP mutation (AIPmut) carriers could identify previously unrecognized disease.
Objective: To determine the AIP mutational status of FIPA and young pituitary adenoma patients, analyzing
their clinical characteristics, and to perform clinical screening of apparently unaffected AIPmut carrier family
members.
Design: This was an observational, longitudinal study conducted in over 7 years.
Setting: International collaborative study conducted at referral centers for pituitary diseases.
Participants: FIPA families (n  216) and sporadic young-onset (30 y) pituitary adenoma patients (n  404)
participated in the study.
Interventions: We performed genetic screening of patients for AIPmuts, clinical assessment of their family
members, and genetic screening for somatic GNAS1 mutations and the germline FGFR4 p.G388R variant.
Main Outcome Measure(s): We assessed clinical disease in mutation carriers, comparison of characteristics of
AIPmut positive and negative patients, results of GNAS1, and FGFR4 analysis.
Results: Thirty-seven FIPA families and 34 sporadic patients hadAIPmuts. Patients with truncatingAIPmuts had
a younger age at disease onset and diagnosis, compared with patients with nontruncating AIPmuts. Somatic
GNAS1 mutations were absent in tumors from AIPmut-positive patients, and the studied FGFR4 variant did not
modify thediseasebehaviororpenetrance inAIPmut-positive individuals.A totalof164AIPmut-positiveunaffected
family members were identified; pituitary disease was detected in 18 of those who underwent clinical screening.
Conclusions: A quarter of the AIPmut carriers screened were diagnosed with pituitary disease, justifying this
screening and suggesting a variable clinical course for AIPmut-positive pituitary adenomas. (J Clin Endocrinol
Metab 100: 0000–0000, 2015)
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Familial isolated pituitary adenoma (FIPA) is character-ized by the presence of pituitary adenomas in two or
more members of the same family in the absence of other
syndromic clinical features, such as those characteristic of
multiple endocrine neoplasia (MEN) type 1 and MEN4,
Carney complex or tumors related to mutations in the
succinate dehydrogenase genes. FIPA is a heterogeneous
condition, encompassing cases with unknown genetic
cause and patients with mutations in the aryl-hydrocar-
bon receptor interacting protein gene (AIP), with distinc-
tive clinical characteristics. GermlineAIPmutations (AIP-
muts) play a role not only in a subset of FIPA families (1–4)
but also in sporadically diagnosed pituitary adenomas (5–
9), and in the setting of somatostatin analog (SSA)-resis-
tant acromegaly (10). Another form of FIPA, X-linked
acrogigantism, due to microduplications in the Xq26.3
region, has been recently identified in patients with very
young-onset gigantism and pituitary adenoma/hyperpla-
sia (11).
The phenotype of AIPmut-associated pituitary adeno-
mas has been described before (2–4, 12), but a systematic
follow-up of cases and families is lacking due to the rela-
tive novelty of this pathogenic association (1), the variable
disease penetrance (4, 12–14), and the rarity of this clinical
entity. We present the clinical and genetic characteristics
of a large cohort of FIPA and simplex (patients with germ-
line mutation and no family history) AIPmut-positive pa-
tients, aiming for the following: 1) to perform a systematic
follow-up of families to identify and characterizeAIPmut-
positive carriers, 2) to seek the role of disease-modifying
genes on the variable phenotype and penetrance of the
disease, and 3) to confirm and extend the description of the
phenotype of AIPmut-positive patients, providing a com-
parison with AIPmut-negative cases. We establish that
genetic screening followed by clinical assessment identifies
a large percentage of family members with pituitary ab-
normalities, supporting the facilitation of genetic diagno-
sis and follow-up of these patients and their families.
Patients and Methods
Our study population (1725 subjects, Table 1) was re-
cruited via the collaborative research network of the In-
ternational FIPA Consortium (15). Pituitary adenoma pa-
tients were grouped into 11 clinical diagnostic categories
(Supplemental Table 1). The diagnoses of acromegaly, ac-
romegaly/prolactinoma, gigantism, gigantism/prolacti-
noma, and mild acromegaly (16) were grouped together
under the category of GH excess for some analyses.
Between January 2007 and January 2014, we recruited
patients from 35 countries from two different groups: ei-
ther members of FIPA families, defined by the presence of
pituitary adenomas in two or more members of a family
without other associated clinical features (1–3, 17) (fa-
milial cohort), or sporadically diagnosed pituitary ade-
noma patients with disease onset at 30 years of age or
younger (sporadic cohort). As an exception to these in-
clusion criteria, one AIPmut-positive sporadic patient
older than 30 years was found thanks to AIP screening in
Table 1. Study Population: Demographics and General Description
Familial Cohort Sporadic Cohort Combined
Total individuals, n, % 1231 (71.4) 494 (28.6) 1725 (100)
Females, n, % 668 (54.3) 250 (50.6) 918 (53.2)
Current age, median (range [IQR]) 46.2 (2–97 [32–62]) 35 (3–77 [26–42]) 42.6 (2–97 [29–56])
Clinical status, n, %
Affected 502 (40.8) 404 (81.8) 906 (52.5)
Unaffected 729 (59.2) 90 (18.2) 819 (47.5)
Affected males, n, % 219 (43.6) 203 (50.2) 422 (46.6)
Affected females, n, % 283 (56.4) 201 (49.8) 484 (53.4)
Diagnoses, n, %
Acromegaly 170 (33.9) 203 (50.2) 373 (41.2)
Acromegaly/prolactinoma 17 (3.4) 12 (3) 29 (3.2)
Cushing’s disease 24 (4.8) 21 (5.2) 45 (5)
FSHoma 2 (0.4) 1 (0.2) 3 (0.3)
Gigantism 44 (8.8) 65 (16.1) 109 (12)
Gigantism/prolactinoma 1 (0.2) 10 (2.5) 11 (1.2)
Mild acromegaly 2 (0.4) – 2 (0.2)
NFPA 91 (18.1) 21 (5.2) 112 (12.4)
Pituitary tumor 17 (3.4) 2 (0.5) 19 (2.1)
Prolactinoma 134 (26.7) 67 (16.6) 201 (22.2)
TSHoma — 2 (0.5) 2 (0.2)
GH excess patients, n, % 234 (46.6) 290 (71.8) 524 (57.8)
Abbreviations: FSHoma, FSH secreting adenoma. TSHoma, thyrotropinoma.
Dash indicates no patients in this category.
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the setting of a research study, and the screening of his
relatives detected a second AIPmut-positive pituitary ad-
enoma case; this family was included in the familial co-
hort. The first patient reported in each FIPA family and all
the sporadic patients were considered probands. All the
patients received treatment and were followed up in ac-
cordance with the guidelines and clinical criteria of their
respective centers. Relevant clinical and family structure
data were received from clinicians and/or patients, and
genetic screening was performed in the families of all the
AIPmut-positive probands, selecting individuals accord-
ing to their risk of inheriting the mutation, based on their
position in the family tree, and extending the screening to
as many generations as possible. In both familial and spo-
radic cases, other causes of familial pituitary adenomas,
such as MEN1 and MEN4, Carney complex, pheochro-
mocytoma/paraganglioma and pituitary adenoma syn-
drome, and X-linked acrogigantism were ruled out by clin-
ical, biochemical and, in some cases, genetic tests, as
appropriate.
The study population included a great majority of new
cases but also previously diagnosed patients being fol-
lowed up by the participating centers and a few historical
cases, corresponding to deceased members of FIPA fam-
ilies (further details in Supplemental Results). Four AIP-
mut-positive patients (two with diagnosis of acromegaly
and two with gigantism) died in the postrecruitment pe-
riod.Threeof thedeathsweredue tocardiovascular causes
(stroke, chronic heart failure, and acute coronary syn-
drome), whereas the exact cause of death is unknown in
the fourth, a patient with long-standing untreated familial
acromegaly.
All the patients and family members included agreed to
take part by providing signed informed consent forms ap-
proved by the local ethics committee. Further details on
the study population and the procedures for genetic/clin-
ical screening and search for disease-modifying genes are
described in the Supplemental Material.
Statistical analysis
The qualitative, categorical variables were expressed as per-
centages and compared using the2 test or the Fisher’s exact test,
as appropriate. The normal distribution of the quantitative vari-
ables was verified using the Shapiro-Wilk and the Kolmogorov-
Smirnov tests for normality. Means and SDs were used to report
parametric data, and nonparametric data were expressed as me-
dian and interquartile ranges. Parametric data were analyzed
with the unpaired t test, with a 95% confidence interval (CI),
whereas the Mann-Whitney U test was used for the nonpara-
metric data. Statistical significance was considered when the
P value was  .05. All the statistical analyses were carried out
using the GraphPad Prism 6 (GraphPad Software Inc) and Stata
12 (StataCorp LP) statistical software.
Results
Study population
The familial cohort was composed of 216 FIPA fami-
lies, including 156 new families (989 subjects: 337 patients
and 652 unaffected family members) and 60 previously
described families (3, 12), in which 46 new subjects (15
patients and 31 unaffected family members) were added to
the previously reported 196 individuals (150 patients and
46 unaffected family members). The sporadic cohort orig-
inally included 409 pituitary adenoma patients 30 years
old or younger at disease onset, with no known family
history of pituitary adenoma, but we excluded five pa-
tients from further analysis due to harboring an Xq26.3
microduplication. Of the remaining 404 sporadic pa-
tients, six were reported previously (3). In addition to the
AIPmut screening, a subset ofAIPmut-negative FIPA (n
55) and sporadic (n  45) patients underwent genetic
screening for other endocrine neoplasia-associated genes
(Supplemental Table 2). All of these tests were negative for
pathogenic variants. After the genetic screening and fol-
low-up of the patients and carriers, 60 individuals in the
familial cohort and seven in the sporadic cohort were
classified as not at risk of inheriting an AIPmut and
were excluded from further analysis. Twenty-three in-
dividuals initially thought to be unaffected were iden-
tified with pituitary abnormalities (see details in Pro-
spective diagnosis).
Genetic screening results
Thirty-seven of 216 FIPA families screened (17.1%)
and 34 of 404 sporadic patients (8.4%) were positive for
pathogenic or likely pathogenic AIPmuts, accounting for
a total of 71 AIPmut-positive kindreds and 144 AIPmut-
positive patients (76.4% familial and 23.6% simplex, Ta-
ble 2). We also identified 164AIPmut-positive apparently
unaffected family members (see Follow-up and prospec-
tive diagnosis). Samples were not available from family
members of 25AIPmut-positive simplex cases to establish
the presence or lack of de novo mutations. We identified
three pituitary adenoma patients (two with clinically non-
functioning pituitary adenoma [NFPA] and one with a
microprolactinoma) belonging to AIPmut-positive FIPA
families and being at risk of inheriting but not carrying an
AIPmut; therefore, they were considered as phenocopies.
Thirty-one different AIPmuts (10 not previously re-
ported) were identified in our study population: 12 exclu-
sively in familial cases, 12 in simplex cases only, and seven
in both settings (Table 3 and Supplemental Figure 1). Of
the total mutations, 70.8% (22/31) predicted a truncated
or missing protein and were termed as truncatingAIPmuts
(Supplemental Figure 2). We also identified 11 apparently
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nonpathogenic AIP variants (three of them novel) in our
population (Supplemental Table 3).
A multiple regression analysis was performed to deter-
mine which clinical features could more accurately predict
the likelihood of a patient to carry an AIPmut. An age at
diagnosis of 10 years or older and younger than 20 years
conferred an odds ratio (OR) of 5.8 (P  .000, 95% CI
3.1–10.8) of having an AIPmut, whereas the OR was 2.8
if the age at diagnosis was 20 years or older and younger
than 30 years (P .000, 95% CI 1.3–5.7); thus, an age at
diagnosis between 10 and 30 years is the best predictor of
AIPmuts. Inversely, a diagnosis of prolactinoma resulted
in an OR of 0.2 (P .000, 95% CI 0.1–0.5).
Genotype-phenotype correlation within the
AIPmut-positive cohort
Truncating mutations accounted for 78.9% of theAIP-
muts found in the familial cohort (15 of 19) and for 57.9%
of those detected in the sporadic cohort (11 of 19). To
study a possible difference in disease penetrance between
truncating and nontruncating mutations, we compared
the number of affected individuals with truncating AIP-
muts in the familial (85 of 110 [77.3%]) and simplex co-
horts (21 of 34 [61.8%]), finding no significant difference,
although a trend was observed (P  .0729, analysis in-
cluded prospectively diagnosed patients). No significant
differences were found regarding the proportion of GH
excess cases, number of patients per family, maximum
tumoral diameter, frequency of macroadenomas, extra-
sellar invasion, or number of treatments received between
the patients with truncating and nontruncating mutations.
However, patients with truncating mutations were signif-
icantly younger at disease onset (median 16 [interquartile
range (IQR) 15–25] vs 22 [IQR 17.3–27.8] y, P .0046,
Figure 1A) and at diagnosis (median 21 [IQR 16–30] vs 27
[IQR 20.8–37] y, P  .0028, Figure 1B), and the occur-
rence of pediatric cases was more common in this group
(60% [57 of 95], Figure 1C), compared with the patients
with nontruncating AIPmuts (33.3% [12 of 36], P 
.0064). In concordance with these differences, gigantism
accounted for a significantly higher proportion of the GH
excess cases in the patients with truncating AIPmuts
(54.7% [47 of 86]), compared with those with nontrun-
cating AIPmuts (30% [9 of 30], P  .0200). Because
p.R304* was the most commonAIPmut in our study pop-
Table 2. Screening for AIPmuts
Familial Cohort Sporadic Cohort Combined
AIPmut-
Positive
Familial
AIPmut-
Negative
Familial
Total
Familial
AIPmut-
Positive
Simplex
AIPmut-
Negative
Sporadic
Total
Sporadic
AIPmut-
Positive
Familial
and
Simplex
AIPmut-
Negative
Familial
and
Sporadic Total
Total number of kindreds, n, % 37 (17.1%
of
familial)
179 (82.9%
of
familial)
216 (34.8%
of total)
34 (8.4%
of
sporadic)
370 (91.6%
of
sporadic)
404 (65.2%
of total)
71 (11.5%
of total)
549 (88.5%
of total)
620 (100)
Total individuals, n, % 475 (38.6%
of
familial)
756 (61.4%
of
familial)
1231 (71.4%
of total)
82 (16.6%
of
sporadic)
412 (83.4%
of
sporadic)
494 (28.6%
of total)
557 (32.3%
of total)
1168 (67.7%
of total)
1725 (100)
Genetic status, n, %
AIPmut-negative patients 3 (0.6) 389 (51.5)a 392 (31.8) — 370 (89.8) 370 (74.9) 3 (0.5) 759 (65) 762 (44.2)
AIPmut-positive tested
patients
95 (20) — 95 (7.7) 34 (41.5) — 34 (6.9) 129 (23.2) — 129 (7.5)
At risk but not tested 33 (6.9) — 33 (2.7) 8 (9.8) — 8 (1.6) 41 (7.4) — 41 (2.4)
Not at risk 48 (10.1) 12 (1.6) 60 (4.9) 7 (8.5) — 7 (1.4) 55 (9.9) 12 (1) 67 (3.9)
Obligate unaffected carriers,
not tested
8 (1.7) — 8 (0.6) 2 (2.4) — 2 (0.4) 10 (1.8) — 10 (0.6)
Predicted AIPmut-positive
patients
15 (3.2) — 15 (1.2) — — - 15 (2.7) — 15 (0.9)
Unaffected AIPmut tested
carriers
120 (25.3) — 120 (9.7) 16 (19.5) — 16 (3.2) 136 (24.4) — 136 (7.9)
Unaffected and AIPmut
negative
153 (32.2) — 153 (12.4) 15 (18.3) — 15 (3) 168 (30.2) — 168 (9.7)
Unaffected relatives of
AIPmut-negative patients
— 355 (47) 355 (28.8) — 42 (10.2) 42 (8.5) — 397 (34) 397 (23)
Summary of AIPmut-positive individuals, n, %
Total AIPmut-positive
patientsb
110 (23.2) — 110 (8.9) 34 (41.5) — 34 (6.9) 144 (25.9) — 144 (8.3)
Total unaffected AIPmut
carriersc
128 (26.9) — 128 (10.4) 18 (22) — 18 (3.6) 146 (26.2) — 146 (8.5)
Dash indicates no individuals in this category.
a In AIPmut-negative FIPA families, 199 patients were tested for AIPmuts; the rest (n  190) were assumed to be negative.
b This is equal to the sum of tested AIPmut-positive patients plus the predicted AIPmut-positive patients.
c Sum of tested unaffected carriers plus obligate unaffected carriers.
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ulation (20 kindreds), we analyzed whether these patients
behaved differently from other patients with truncating
mutations. We found more affected individuals per family
(median 4 [IQR 2.5–5]) among families carrying the
p.R304* AIPmut, compared with families with other
AIPmuts (median 2 [IQR 2–3], P  .0133). When con-
Table 3. AIP Pathogenic or Likely Pathogenic Mutations in the Familial and Sporadic Cohorts
Mutation (DNA Level
[Protein Level]) Mutation Type Pathogenic
Location in
Protein
Familial
Cohort
(n  238)a
Simplex
Cohort
(n  52)a
Combined
(n  290)a References/SRb
g.4856_4857CGAA Promoter Yesc Not in protein (5
UTR)
3 (1.3) — 3 (1) (3, 12)/(SR30)
c.3GA (p.?) Start codon Likelyc N terminus 2 (0.8) — 2 (0.7) This paper
c.40CT (p.Q14*) Nonsense Yesc N terminus 2 (0.8) — 2 (0.7) (1)/(SR31, 32)
c.70GT (p.E24*) Nonsense Yesc N terminus 9 (3.8) — 9 (3.1) (3)/(SR33)
c.74_81delins7 (p.L25Pfs*130) Frameshift Yesc PPIase domain 10 (4.2) — 10 (3.4) (12)/(SR34)
c.100–1025_279  357del
(ex2del) (p.A34_K93del)
Large genomic
deletion
Yesc PPIase domain 12 (5) 2 (4) 14 (4.8) (SR35)
c.100–18CT Intronic Likely Not in
protein (intron
1)
— 3 (6) 3 (1) (3, 7, 10)/(SR31)
c.241CT (p.R81*) Nonsense Yesc PPIase domain 12 (5) 4 (8) 16 (5.5) (3)/(SR30, 36–38)
c.249GT (p.G83Afs*15) Splice site (cryptic
splice site)
Yesc PPIase domain 4 (1.7) — 4 (1.4) (12)
c.338_341dup (p.L115Pfs*16) Frameshift Yesc PPIase domain — 2 (4) 2 (0.7) (6)
c.427CT (p.Q143*) Nonsense Yesc Between PPIase
and TPR1
domains
— 1 (2) 1 (0.3) This paper
c.469–2AG (p.E158_Q184del) Splice site Likely TPR1 domain — 1 (2) 1 (0.3) (5)/(SR39, 40)
c.490CT (p.Q164*) Nonsense Yesc Between PPIase
and TPR1
domains
3 (1.3) — 3 (1) (12)
c.570CG (p.Y190*) Nonsense Yesc TPR1 domain 9 (3.8) — 9 (3.1) This paper
c.662dupC (p.E222*) Nonsense Yesc Between TPR1
and 2 domains
3 (1.3) — 3 (1) (12)
c.713GA (p.C238Y) Missense Yes TPR2 domain 4 (1.7) — 4 (1.4) (3)/(SR33)
c.783CG (p.Y261*) Nonsense Yesc TPR2 domain 4 (1.7) — 4 (1.4) (9)/(SR39, 41, 42)
c.787  9CT Intronic Uncertain Not in
protein (intron
5)
— 1 (2) 1 (0.3) This paper
c.804CA (p.Y268*) Nonsense Yesc TPR3 domain 19 (8) 3 (6) 22 (7.6) (SR43, 44)
c.805_825dup
(p.F269_H275dup)
In-frame insertion Yes TPR3 domain 16 (6.7) 2 (4) 18 (6.2) (3)/(SR30, 39, 45)
c.807CT (p.()) Splice site
(reduced
transcript level)
Yes TPR3 domain 7 (2.9) 4 (8) 11 (3.8) (3, 5, 7, 10, 12)/
(SR46, 47)
c.811CT (p.R271W) Missense Yes TPR3 domain — 1 (2) 1 (0.3) (2, 7, 12)/(SR48)
c.816delC (p.K273Rfs*30) Frameshift Yesc TPR3 domain — 1 (2) 1 (0.3) This paper
c.868AT (p.K290*) Nonsense Yesc TPR3 domain — 1 (2) 1 (0.3) This paper
c.872_877delTGCTGG
(p.V291_L292del)
In-frame deletion Yes TPR3 domain — 1 (2) 1 (0.3) This paper
c.910CT (p.R304*) Nonsense Yesc C-terminal -
helix
88 (37) 16 (31) 104 (35.9) (1–3, 5, 7, 9, 12,
14)/ (SR39, 49–
51)
c.911GA (p.R304Q) Missense Yes C-terminal -
helix
20 (8.4) 3 (6) 23 (7.9) (3, 5, 7, 9, 12)/
(SR31, 39, 52,
53)
c.967delC (p.R323Gfs*39) Frameshift Yesc C-terminal -
helix
— 4 (8) 4 (1.4) This paper
c.976_977insC (p.G326Afs*?) Frameshift Yesc C-terminal -
helix
— 1 (2) 1 (0.3) This paper
c.978dupG (p.I327Dfs*?) Frameshift Yesc C-terminal -
helix
— 1 (2) 1 (0.3) This paper
c.1-?_993?del (whole gene
deletion)
Large genomic
deletion
Yesc Absence of the
whole protein
11 (4.6) — 11 (3.8) (12)
Abbreviations: PPIase, peptidylprolyl isomerase; SR, supplemental references; TPR, tetratricopeptide repeat; UTR, untranslated region.
Dash indicates no individuals in this category.
a Number of positive individuals for each mutation, considering the AIPmut-positive tested individuals, the obligate carriers, and the predicted
AIPmut patients.
b For supplemental references, see Supplemental Material.
c Truncating mutation.
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sidering all theAIPmut-positive patients together (familial
and sporadic), we found a higher proportion of pediatric
patients among those with the AIP p.R304* mutation
(65.8% [25 of 38] vs 46.5% [40 of 86], P  .0475).
Clinical and histopathological features
Findings regarding gender distribution, age at onset/
diagnosis, distribution of clinical diagnoses, tumor size/
extension, pituitary apoplexy, histopathological features,
extrapituitary tumors, and specific analyses of patients
with GH excess and with gigantism are detailed in the
Supplemental Material and depicted in Supplemental Ta-
bles 4 and 5 and Supplemental Figures 3–7.
Disease penetrance
To calculate the penetrance of pituitary adenomas
among AIPmut positive families, complete data are
needed both for phenotype and genotype. Therefore, we
have selected three families (two with p.R304* and one
with p.A34_K39del mutations) in which complete data
were available in three or more generations for consenting
at-risk individuals. The AIP genotype was known in
76.6% (range 68.4%–94.7%) of the individuals at risk; of
them, 16.8% were patients and 83.2% were unaffected
carriers. The gender distribution was similar between pa-
tients and unaffected carriers. The
mean penetrance in these three fam-
ilies was 28.6% (19%–38.1%), and
it decreased to 22.7% (18.2%–
26.7%) when 50% of the individu-
als at risk with unknown genotype
were considered as unaffected car-
riers. When the prospectively diag-
nosed patients were omitted from
this calculation, the total pen-
etrance of pituitary adenomas was
12.5%, highlighting the impor-
tance of the follow-up of appar-
ently unaffected carriers for the
correct calculation of the disease
penetrance.
Because penetrance cannot be ap-
propriately calculated for AIPmut-
negative families, we assessed the
number of affected family members.
The AIPmut-positive families had
more affected individuals per family
than the AIPmut-negative families
(P  .0001, Supplemental Figure
7E). Whereas 84.9% of theAIPmut-
negative families (152 of 179) had
only two affected members, 48.6%
of the AIPmut-positive families (18
of 37) had three or more pituitary adenoma patients per
family. The maximum number of affected individuals
within the same family was eight (six of them prospectively
diagnosed) in a family carrying the p.R304*AIPmut, and
the maximum number of cases of gigantism in the same
family was five, in a FIPA family with the p.E24*AIPmut.
Follow-up and prospective diagnosis
Of the 164 originally identified AIPmut carriers, 160
were available and advised to undergo biochemical and
clinical screening. Prospective diagnosis of a pituitary ad-
enoma was established in 11.3% (18 subjects, 11 males) of
the individuals originally considered as unaffected AIP-
mut carriers.
Six of the prospectively diagnosed patients had acro-
megaly (one of them with prolactin [PRL] cosecretion),
one patient had gigantism, two patients were diagnosed
with mild acromegaly (16), and nine patients harbored
NFPAs. Of the 142 individuals remaining as apparently
unaffected AIPmut carriers, 79 (55.6%) underwent clin-
ical assessment and one or more biochemical or imaging
tests, whereas 63 subjects (44.4%) had only clinical
evaluation.
Figure 1. Patients with truncating vs nontruncating AIPmuts. Patients with truncating AIPmuts
present with a more aggressive phenotype, characterized by an earlier age at onset (A) (P 
.005) and (B) at diagnosis (P  .003). C, This earlier disease onset results in a higher frequency of
pediatric cases (n [total]  131); in fact, most of the patients with truncating mutations present
in childhood and adolescence. **, P  .01.
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The prospective cases were diagnosed at an older age
than the rest of the patients (median 30 [IQR 22.8–39.5]
vs 23 [IQR 16–33] y, P .025). At diagnosis, seven of the
prospectively diagnosed patients were symptomatic
(headaches, arthralgias, acral growth, facial changes,
weight gain, or hyperhidrosis). Five of the 18 prospectively
diagnosed tumors were macroadenomas, in contrast with
a predominance of macroadenomas (89.9%, 71 of 79) in
the rest of theAIPmut-positive FIPA patients (P .0001).
The maximum diameter was significantly smaller for pro-
spective cases (median 5.8 [IQR 4.7–14.4] vs 16.5 [IQR
10–29] mm, P  .0002). Four of the patients with mac-
roadenomas had surgery, and the histopathological study
confirmed GH- or GH/PRL-positive adenomas. The fifth
macroadenoma was identified in a 68-year-old male pa-
tient with high IGF-1, well-controlled hypertension and
diabetes mellitus and no other comorbidities or symp-
toms, who did not want to receive any treatment. In ad-
dition, one AIPmut-negative pituitary adenoma patient,
harboring a 25-mm NFPA, was prospectively diagnosed
as part of an AIPmut-positive family (brother of the AIP-
mut positive proband).
A further seven subjects had abnormalities in their
screening tests, but a pituitary disease was not confirmed:
five individuals had slightly elevated IGF-1 levels for their
age/gender, one patient displayed acromegaloid features
but normal pituitary magnetic resonance imaging (MRI)
and biochemistry, and a 17-year-old female had repeat-
edly borderline high IGF-1 and incompletely suppressed
GH on oral glucose tolerance test, but her bulky pituitary
gland (11 mm in height), normal at this age group, is not
changing during follow-up and her biochemical results are
now within the normal range, after 3 years of follow-up.
The global penetrance of pituitary adenomas among
the individuals initially considered as unaffected AIPmut
carriers was 11.3% (18 of 160). However, the penetrance
was higher in the group of carriers who underwent bio-
chemical and imaging investigations, varying between
18.6% and 28.1%, depending on the depth of screening
(Figure 2). Overall, these data suggest that approximately
20%–25% of the apparently unaffected AIPmut carriers
screened with biochemical or imaging tests will be iden-
tified with a pituitary adenoma at some point in their lives.
Clinical screening was not systematically performed in
the AIPmut-negative FIPA unaffected family members.
Nevertheless, due to the increased disease awareness given
by the existence of previous pituitary adenoma cases
within their families, four individuals (three females and
one male) from three different AIPmut-negative FIPA
families were prospectively diagnosed. Three of them har-
bored NFPAs, but we lack complete information about the
fourth patient. The mean age at diagnosis in the three
NFPA cases was 37 years, and only one patient referred
symptoms at diagnosis (galactorrhea, not clearly associ-
ated to stalk compression, and lethargy). All of them had
microadenomas, with a mean diameter of 6.5 mm and did
not require any therapeutic intervention other than hor-
monal replacement in one case. The characteristics of
these cases resemble those of incidentalomas; however, the
occurrence of two prospective cases in the same family
supports an apparent inherited component.
Disease-modifying genes
We have studied the role of two possible disease-mod-
ifying genes: GNAS1 (somatic) (18) and FGFR4 (germ-
line) (19).GNAS1mutations were absent in all the studied
AIPmut-positive somatotropinomas (n  23) but were
detected in 50% of the AIPmut-negative familial soma-
totropinomas (5 of 10), 16.7% of the AIPmut-negative,
young-onset cases (1 of 6), and 26.3% of the unselected
acromegaly cases studied (5 of 19). The distribution of the
FGFR4 p.G388R single-nucleotide polymorphism (SNP)
conserved the Hardy-Weinberg equilibrium (20), and the
genotype distribution was similar between patients (n 
98) and AIPmut carriers (n 108) (P .523). The age at
onset and at diagnosis, tumor size, and frequency of ex-
trasellar invasion were not significantly different between
the GG (wild type) and GR/RR patients.
Discussion
AIPmuts are prevalent in young-onset, GH excess patients
(24%) and FIPA (17.1%), with more than double fre-
quency in patients with gigantism (46.7%) in our cohort,
Figure 2. Penetrance in screened AIPmut-positive carriers (n [total] 
160). The probability of detecting new cases of pituitary adenomas
within apparently unaffected AIPmut carriers depends on the clinical
assessment and the type of complementary biochemical/imaging
studies included in the screening protocol (see text).
doi: 10.1210/jc.2015-1869 press.endocrine.org/journal/jcem 7
in concordance with other studies (7, 9, 21, 22). However,
in contrast to previous reports, in this large and exten-
sively studied cohort, there was no predominance of male
patients among the AIPmut-positive familial cases, and
equal numbers of male and female unaffected carriers
were identified. Earlier studies (3, 4, 12, 23) may have had
an ascertainment bias for families with cases of gigantism,
a disease that is more prevalent in males, at least partly due
to the physiologically later puberty and therefore later
cessation of growth in boys.
We have demonstrated that approximately a quarter of
the individuals initially identified as unaffected AIPmut
carriers who underwent clinical screening tests were di-
agnosed with pituitary abnormalities. Full clinical screen-
ing identified 28.1% of the carriers, with fewer tests un-
derstandably resulting in fewer positive cases. Our data
suggest that not all the AIPmut-associated pituitary ade-
nomas have a rapidly growing, aggressive phenotype. The
follow-up of these patients allowed us to observe some
probably very early cases of acromegaly, in which the cur-
rent clinical scenario had not indicated intervention at
data closure. We cannot rule out that some of the small
NFPAs are indeed incidentalomas, similar to those fre-
quently observed in AIPmut-negative subjects of the gen-
eral population.
This frequency of prospective diagnosis may justify the
clinical screening and, possibly, follow-up of all the AIP-
mut-positive unaffected carriers. Our data would support
the assessment of all the newly identified AIPmut carriers
(clinical examination/history, PRL, and IGF-1, as a min-
imum, up to a full screening, also including an oral glucose
tolerance test and contrast enhanced pituitary MRI). Fol-
low-up of the younger family members should continue
until at least 30 years of age, preferably annually, with
clinical assessment and basal pituitary hormonal levels,
leaving stimulation tests for cases with suspicion of pitu-
itary disease and a follow-up MRI if necessary (24, 25).
The cost-effectiveness and the possible psychological bur-
den of this approach will need future study. Stopping the
follow-up should be considered in older patients, given the
low possibility of detecting new pituitary adenoma pa-
tients in these individuals after the fifth decade of life (24,
25). Once a case has been prospectively diagnosed, the
treatment and follow-up should proceed as for the general
population of pituitary adenoma patients because there
are no data to suggest a different type of treatment in
AIPmut-positive patients (26) although reduced SSA re-
sponsiveness has been described.
The genetic and clinical screening of AIPmut-negative
FIPA families is uncertain at this point. Baseline screening
and follow-up of obligate carriers could be considered,
keeping in mind that the age of onset is considerably older
in these families. Education on possible signs and symp-
toms of family members is a viable option in the routine
setting. We expect that the identification of further genes
implicated in the pathogenesis of FIPA in the next years
will allow us to tailor these recommendations in accor-
dance with the clinical behavior of each genetic entity.
Patients with GH excess starting before the age of 5
years should be tested for the recently identified Xq26.3
chromosomal microduplications (11). The genetic screen-
ing of other sporadic, young-onset pituitary adenoma pa-
tients with no evidence of other endocrine tumors should
be focused on AIPmuts in first instance in cases of GH
excess (with or without PRL cosecretion) and on MEN1
mutations, especially in cases of prolactinoma (9) because
this can be the first manifestation of MEN1 (27). Whether
it would be advisable to continue screening young patients
with other diagnoses for AIPmuts out of the setting of
research studies needs longer follow-up.
To explain the variable clinical phenotype in our AIP-
mut-positive patients, we evaluated the possible influence
of two disease-modifying genes, GNAS1 and FGFR4.
Whereas somatic GNAS1 mutations are common in un-
selected somatotropinomas (4.4%–59% of the cases)
(28–35), we have not identified any in adenomas from
AIPmut-positive patients, suggesting that germline AIP-
muts and somatic GNAS1 mutations are mutually exclu-
sive in somatotropinomas.GNAS1mutations have rarely
been studied in pediatric patients with acromegaly and
gigantism, and they seem to be an extremely infrequent
finding in this age group (36, 37). A recent study has
shown no change in the AIP immunostaining in sporadic
somatotropinomas in the presence of GNAS1 mutations
(38). The characteristic phenotype of adenomas contain-
ing the GNAS1 mutations (small [32, 39], highly respon-
sive to the treatment with SSAs, and more often densely
granulated according to some [40], but not all studies
[41]), seems to be in contrast with the typical AIPmut-
positive tumor phenotype. On the other hand, in soma-
totroph adenomas of AIPmut-negative FIPA patients,
half of the tested samples had GNAS1 mutations. This
suggests that in AIPmut-negative FIPA, the somatic
GNAS1 mutations could exist in a similar frequency as
to in unselected somatotropinomas and possibly, in ad-
dition to a germline predisposing mutation, may play a
role in their pathogenesis.
The FGFR4 gene SNP rs351855 (c.1162GA,
p.G388R), with a minor allele frequency of 0.3, is a pre-
dictor of progression and poor prognosis in a variety of
human neoplasms (42). A role for rs351855 as a facilitator
of somatotroph cell tumorigenesis has been recently pro-
posed (19), and we hypothesized that this variant could
increase the penetrance and/or size and extension of AIP-
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mut-positive pituitary adenomas. The screening for this
SNP in our AIPmut-positive patients failed to show in-
crease in size, extension, or apoplexy, even though this
association had previously been suggested in sporadic
acromegaly patients (19), and no earlier onset or higher
penetrance was observed. The lack of association with
these two potentially disease-modifying genes suggests
that AIPmut-related pituitary adenomas are regulated
by different pathogenic mechanisms than unselected
somatotropinomas.
We recognize the numerous limitations of our study.
We chose an arbitrary age cutoff (30 y), in concordance
with previousAIP-related publications, but our data show
that only 13.2% of the AIPmut-positive patients had dis-
ease onset after the age of 30 years. Our patients were
recruited from different genetic backgrounds, and this
could have influenced the disease penetrance and presen-
tation. On the other hand, 19.7% of the AIPmut-positive
kindreds (24.3% of the AIPmut positive patients) belong
to a cohort with a founder AIPmut (p.R304*), originally
from Northern Ireland (14). The larger number of subjects
screened in these families provided a higher number of
carriers and chance for detection of affected individuals.
Additional genetic traits possibly cosegregating with this
founder mutation could modify the phenotype and thus
introduce a bias into our results. Full genotype and phe-
notype data were not available for all the families; there-
fore, we limited our penetrance calculations to three large,
well-characterized families. A better assessment of the
prevalence of pituitary apoplexy and extrapituitary ade-
nomas in AIPmut-positive patients would require a large
control group, screened ad hoc, which was beyond the
scope of this study. Finally, the data about therapeutic
modalities were limited, hampering the analysis of the re-
sponse to different treatments.
Conclusions
The analysis of this large cohort of FIPA patients allowed
us to establish a number of novel aspects of FIPA. A phe-
notype-genotype correlation was found with younger on-
set of disease in patients with truncating AIPmuts. We
identified a surprisingly high percentage of somatic
GNAS1 mutations in the AIPmut-negative somatotropi-
nomas and their absence in AIPmut-positive tumors. The
lack of influence of the germline FGFR4 p.G388R variant
on disease penetrance/severity suggests that currently un-
known factors drive penetrance and variable phenotype in
AIPmut-positive pituitary adenomas. The presence of
milder, more indolent disease in some AIPmut-positive
subjects has been established. Genetic and clinical screen-
ing leads to the prospective identification of an unexpect-
edly high proportion of affected patients in the originally
apparently unaffected carrier group, resulting in earlier
diagnosis and treatment and, possibly, better long-term
outcome (25). The recruitment of a large study population
with this uncommon disease has only been possible thanks
to worldwide collaboration.
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SUPPLEMENTAL MATERIAL 
 
SUPPLEMENTAL METHODS 
Study population 
At recruitment, relevant clinical and biochemical data were collected at each participating center 
using a standard datasheet designed for this study (available on request) and all the information was 
entered into our central database. Data about the follow-up, treatments and current status of the 
patients were prospectively requested and collected from the collaborating centers and directly from 
the patients. Data about the historical cases were collected from family members and from hospital 
archives, when available. With a few exceptions, genetic screening results were directly sent to our 
center and entered in the database. The available data did not allow a comprehensive analysis of the 
response to specific therapeutic modalities.    
 
We identified subjects ‘at risk’ (those with the possibility of inheriting an AIPmut), ‘obligate carriers’ 
(based on their position in family tree, AIPmuts were verified when possible) and ‘unaffected 
carriers’. Therefore, in our analysis the term ‘unaffected carrier’ includes all the relatives of AIPmut-
positive patients without clinical manifestations of a pituitary adenoma and with either a genetic 
screening positive for the AIPmut present in the proband or with a position in the family tree defining 
them as ‘obligate carriers’. Additionally, the analysis of the family trees led to the identification of 
some affected individuals as ‘predicted AIPmut-positive patients’, defined as individuals with an 
established clinical diagnosis of pituitary adenoma in whom the genetic screening could not be carried 
out due to unavailability of a DNA sample, but in whom the presence of the mutation was assumed 
based on both the phenotype and the position in the family tree. Therefore, the term ‘AIPmut-positive 
patient’ will refer to both ‘predicted AIPmut-positive patients’ and ‘AIPmut-positive patients’ in 
whom the presence of the mutation was verified. Subjects ‘not at risk’ of inheriting an AIPmut were 
defined based on their position in the family tree. In the sporadic cohort, the AIPmut-positive patients 
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with no apparent familial history of pituitary disease were also referred as ‘simplex’ cases as they can 
be considered the first case of a potentially hereditary disease.  
 
Genetic and clinical screening 
Pituitary adenoma patients and their apparently unaffected relatives were screened for AIPmuts using 
Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA), as described in 
Supplemental Material. We have divided the AIP variants into five classes according to the likelihood 
of pathogenicity, as recommended by Plon et al. (SR1): definitely pathogenic, likely pathogenic, 
uncertain, unlikely pathogenic and not pathogenic. All the unaffected individuals with positive genetic 
screening for AIPmuts were advised to undergo clinical, biochemical and image screening tests for the 
early diagnosis of possible pituitary disease, on an annual basis or as appropriate. The 
recommendations for screening were based on the published experience of our group (24) and others 
(26). Additional genetic tests were performed in subjects with no pituitary adenomas, but with other 
clinical features indicative of such tests (screening for mutations in BRCA1 and 2 and TP53 was 
performed in members of a family with breast cancer, osteosarcoma and a neuroendocrine tumor of 
the colon), as well as and in a randomly selected cohort of AIPmut-negative FIPA probands, searching 
for mutations in other genes via direct sequencing and MLPA (BRCA1 and 2, CDKN1B, MEN1, 
TP53, PRKAR1A) or via a next-generation sequencing panel (MAX, RET, SDHA, SDHAF2, SDHB, 
SDHC, SDHD, TMEM127, and VHL) (SR2).  
 
Genomic DNA was obtained from blood (Ilustra DNA Extraction Kit BACC2, GE Healthcare, Little 
Chalfont, UK) or saliva (Oragene-DNA [collection] and prepIT-L2P [extraction] kits, DNA Genotek, 
Ontario, Canada) samples. The detection of the AIP gene variants and dosage was performed at the 
Molecular Genetics Laboratory, Royal Devon and Exeter, NHS Foundation Trust for the great 
majority of the samples, as previously described (3;12). Although the genetic tests were performed in 
one of the largest Genetics laboratories in the world, with appropriate quality controls, we cannot rule 
out that mutations were not identified in a small number of cases, due to either technical problems or 
due to location of mutations in areas not analyzed (such as intronic regions). The pathogenicity of the 
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detected variants was assessed using the Pathogenic Or Not-Pipeline (PON-P) and Alamut 2.2.1 in 
silico prediction programs, as well as considering the scientific literature concerning clinical and 
experimental data on the previously reported variants. Only those variants considered as definitely or 
likely pathogenic (SR1) were included in the study. Additionally, we included one novel intronic 
variant with no experimental data available, for which the prediction software could not exclude 
pathogenicity. The variants described in this paper are listed by their position in the DNA, with the 
corresponding change at the protein level in parentheses, according to the nomenclature guidelines of 
the Human Genome Variation Society (HGVS) version 1.0 (SR3) and the changes proposed for the 
version 2.0 (http://www.hgvs.org/mutnomen/). The nomenclature was verified using the Mutalyzer 
2.0.beta-21 software (http://www.lovd.nl/mutalyzer/). The positions in the DNA are based on the 
GRCh37/hg19 assembly of the human genome and the human AIP reference sequence (Locus 
Reference Genomic code LRG_460 (SR4), based on NG_008969.1 and NM_003977.2). Array 
comparative genomic hybridization analysis was performed in a group of patients with gigantism, and 
patients positive for Xq26 microduplications (11) were excluded from further analysis.  
 
Disease-modifying genes 
Genomic DNA (gDNA) samples from 98 AIPmut-positive patients (55 males/43 females) and 108 
unaffected AIPmut carriers (56 males/52 females) were subjected to PCR, using previously described 
primers (SR5) and screened for the FGFR4 p.G388R (rs351855) single nucleotide polymorphism 
(SNP). Additionally, gDNA was extracted from paraffin-embedded somatotropinomas for 23 AIPmut-
positive patients (familial and simplex), ten AIPmut-negative FIPA patients and six AIPmut-negative 
sporadic patients and cDNA was obtained from 19 frozen somatotropinomas from unselected 
acromegaly cases (control group, 13 males and six females, age at diagnosis 37-77 years).  All these 
samples were screened for mutations in the GNAS1 codons 201 and 227 using previously described 
primers for gDNA (SR6), and the primers  5’-CAAGCAGGCTGACTATGTGC-3’ and 5’-
ACCACGAAGATGATGGCAGT-3’ for cDNA. The sequence analysis of the FGFR4 and GNAS1 
PCR products was carried out by Sanger sequencing (BigDye Terminator v 3.1 kit in and ABI 3730 
capillary sequencer, Applied Biosystems, Foster City, CA, USA).   
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SUPPLEMENTAL RESULTS AND DISCUSSION 
 
Clinical and histopathological features 
Gender distribution  
Among the familial patients, there was a significantly different gender distribution of the affected 
individuals between the AIPmut-positive and negative subgroups (P=0.0015, Supplemental Figure 
3a), showing a predominance of females in the AIPmut-negative families. This difference is unlikely 
to be due to a selection bias, as the gender distribution was not significantly different between affected 
and unaffected individuals in the whole study population (P=0.8581), or, in the familial cohort, 
between unaffected AIPmut-positive and negative individuals (P=0.4421, Supplemental Figure 3b), 
or between AIPmut-positive affected and unaffected individuals (P=0.1367). We did not see a 
difference in gender distribution between the AIPmut-positive and negative sporadic patients either 
(P=0.1605, Supplemental Figure 3c). 
 
Age 
Familial patients 
FIPA AIPmut-positive patients were younger at disease onset (Supplemental Figure 4a) compared 
with AIPmut-negative FIPA patients. In the AIPmut-positive subgroup, the earliest age at onset was 
three years, while in the AIPmut-negative families a female patient with Cushing’s disease had the 
earliest disease onset at seven years. Most of the AIPmut-positive FIPA patients (71.7% [71/99]) 
developed their pituitary adenomas during the second and third decades of life (10-29 years), whereas 
only 39.2% (121/309) of the AIPmut-negative FIPA patients had their first signs/symptoms of 
pituitary adenoma during the same stage of life (P<0.0001, Supplemental Figure 4a and b). The age at 
diagnosis was also significantly different (P<0.0001): 68.2% (75/110) of the AIPmut-positive FIPA 
patients were diagnosed at ≤30 years of age, whereas the diagnosis was established in only 36.7% 
(116/316) of the AIPmut-negative patients by that age. The earlier disease presentation was also 
reflected in a much higher frequency of pediatric cases (disease onset at ≤18 years of age, 
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Supplemental Figure 4c) in the AIPmut-positive FIPA families, compared with the AIPmut-negative 
FIPA families (44.1 vs. 11.8%, P<0.0001). These distributions were calculated taking into 
consideration the prospectively diagnosed AIPmut-positive patients; however, the statistical analysis 
results were not significantly different when those patients were excluded.  
 
Sporadic patients 
Even though our sporadic cohort included only young-onset pituitary adenoma patients, a significant 
younger age at onset was still found within this young group in the AIPmut-positive simplex patients 
in comparison with the AIPmut-negative ones (median 16 [IQR 14.8-22.3] vs. 22 [IQR 16-26] years, 
P=0.0054, Supplemental Figure 4d), and there was a higher proportion of pediatric cases within the 
AIPmut-positive subgroup (58.8% vs. 35.9%, P=0.0085). Nevertheless, while the youngest age at 
onset in the AIPmut-positive simplex patients was nine years, 3% (11/369) of the AIPmut-negative 
patients had disease onset before the nine years of age, with a minimum age of three years.  
 
Clinical diagnoses 
GH excess patients accounted for 57.8% (524/906) of the total affected individuals in the entire 
cohort: 46.6% (234/502) of the familial and 71.8% (290/404) of the sporadic cases. Patients with GH 
excess, prolactinomas and NFPAs were present in both AIPmut-positive and negative subgroups, but 
Cushing’s disease, functioning gonadotropinomas and TSHomas were not found in patients bearing 
AIPmuts.  
 
Familial patients 
We classified the FIPA families as ‘homogeneous’, when all the affected individuals within the family 
had the same diagnosis (GH excess was considered as a single category), or ‘heterogeneous’, when 
different diagnoses were found in the same family (17). Around one half of the families in our cohort 
were homogeneous FIPA families (families with only one pituitary adenoma type) in both the 
AIPmut-positive (48.6%) and negative (52.5%) subgroups (Supplemental Table 4). The most common 
family type in both subgroups (according to the diagnostic categories found in the affected members) 
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was the pure GH excess family, but it was significantly more frequent within the AIPmut-positive 
FIPA families (P=0.0249). The most common diagnoses in AIPmut-positive and negative families 
were the different categories of GH excess; nevertheless, these cases were significantly more frequent 
in the AIPmut-positive subgroup, with at least one case of GH excess in 91.9% (34/37) of the AIPmut-
positive and in 53.1% (95/179) of the AIPmut-negative FIPA families (P<0.0001, Supplemental 
Figure 4e). There was a higher frequency of PRL co-secretion among the AIPmut-positive patients 
with acromegaly or gigantism, compared with the AIPmut-negative ones (P=0.0158, Supplemental 
Figure 4f). In the AIPmut-negative FIPA patients the most frequent diagnosis was acromegaly, in 
35.3% (137/389) of the patients, with prolactinoma in the second place of frequency (30.9%, 
120/389). In sharp contrast to AIPmut-positive families, where 31% (35/113) of the patients had 
gigantism, only 2.1% (8/389) of the AIPmut-negative FIPA patients had this diagnosis. 
 
Sporadic patients 
In the sporadic cohort, all the AIPmut-positive simplex patients harbored GH-secreting adenomas (vs. 
69.2% of the AIPmut-negative cases), as proven by the clinical diagnosis and immunohistochemistry 
(IHC) report. The predominance of GH excess cases in both groups could be due to a selection bias, 
as the previously reported association between AIPmuts and acromegaly/gigantism could have 
influenced the referral of these patients for the study.  
 
Histopathology 
Familial patients 
The IHC analysis of the operated pituitary adenomas confirmed the clinical/biochemical picture in the 
vast majority of the cases, reporting a predominance of somatotropinomas and mammosomatotroph 
adenomas in FIPA patients, more evident in the AIPmut-positive subgroup (P= 0.0304, Supplemental 
Figure 5a and b).  There was a unique case of a double adenoma (one tumor positive for GH and 
another one for PRL) and one unusual case of somatotroph hyperplasia in a patient with gigantism 
within the AIPmut-positive patients. None of the few AIPmut-positive clinically NFPA cases were 
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gonadotroph or null cell adenomas. In contrast, in the AIPmut-negative FIPA families, 48.3% of the 
NFPAs analyzed were reported as gonadotropinomas and 31% were null cell adenomas (based on 
negative immunostaining for GH, ACTH, PRL, TSH, LH and FSH). There was a similar prevalence 
of plurihormonal tumors in both subgroups (17.4% in the AIPmut-positive and 10.5% in the AIPmut-
negative families, P=0.2763). Seventy five percent of all the plurihormonal tumors in both subgroups 
had positive GH staining. There was a significant difference among the AIPmut-positive and negative 
FIPA patients involving the granulation pattern in GH positive adenomas. All the AIPmut-positive 
FIPA patients for whom this parameter was available (22/22) had sparsely granulated adenomas, 
while 43.8% (7/16) of the AIPmut-negative patients harbored densely granulated adenomas 
(P<0.0001, Supplemental Figure 5c); this difference could correspond to the response to the treatment 
with SSA, as suggested by previous reports (SR7). We found no difference in the proportion of 
patients with Ki-67 index 3% between the two subgroups (global 28.1%, P=1.0000).  
 
The presence of two different types of pituitary adenomas in the same gland is infrequent (2.3% of all 
the cases and 3.3% of the cases of Cushing’s disease) (SR8). Multiple pituitary adenomas have been 
previously described in a few cases of MEN1 and FIPA (not screened for AIPmuts) patients (SR9-13). 
Although somatotroph hyperplasia has been described before in the setting of AIPmuts (10;SR14), 
this finding does not seem to be particularly frequent, as in our cohort it was found only in one patient 
with acromegaly and PRL co-secretion.  
 
There was a marked predominance of sparsely granulated GH-secreting adenomas among the 
AIPmut-positive patients, compared with the AIPmut-negative ones. Patients with sparsely granulated 
tumors are usually younger at diagnosis than those with a densely granulated pattern (SR15;SR16), 
have increased invasiveness (SR7;SR15-17) and reduced response to the treatment with SSA 
(SR7;SR17), though the strength of these associations has been variable among different studies. The 
mechanism proposed for this effect in sporadic adenomas implies a reduced expression of the 
somatostatin receptor subtype 2 (SSTR2) (SR18;SR19). Since the expression of the SSTR2 and other 
somatostatin receptor subtypes is not reduced in somatotropinomas from AIPmut-positive patients, 
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other molecular mechanisms must be involved in the association of these mutations with decreased 
responsiveness to SSAs and a sparsely granulated pattern, such as ZAC1 activation (SR20;SR21) or 
an impaired inhibitory G protein subunit function in these tumors (SR22).  
 
Sporadic patients 
All the AIPmut-positive patients with available histopathology results (n=14) had GH positive 
pituitary adenomas by IHC, 28.6% of them (n=4) were mammosomatotroph adenomas (Supplemental 
Figure 5d). In contrast, the AIPmut-negative subgroup (n=89) included corticotropinomas (7.9%), null 
cell adenomas (3.4%), plurihormonal tumors (13.5%), prolactinomas (12.4%), somatotropinomas 
(32.6%), mammosomatotroph adenomas (29.2%), as well as a TSHoma (1.1%, Supplemental Figure 
5e). In the AIPmut-positive subgroup, one third (2/6) of the somatotroph adenomas with available 
cytokeratin staining had a densely granulated pattern and the rest were sparsely granulated. The 
distribution was similar in the AIPmut-negative subgroup, where 31.6% of the GH adenomas 
presented a densely granulated pattern (6/19) and 68.4% were sparsely granulated. Additionally, one 
AIPmut-negative patient had a somatotropinoma with a mixed granulation pattern.  
 
Pituitary adenoma size and extension  
Familial patients 
We compared size and extension of pituitary adenomas between AIPmut-positive and negative FIPA 
patients (Supplemental Figure 6), and for this purpose, the prospectively diagnosed AIPmut-positive 
patients were excluded from the analysis. Despite macroadenomas being predominant in both FIPA 
patient groups, the AIPmut-positive FIPA patients had larger tumors, demonstrated by a larger 
maximum diameter (P=0.0404, Supplemental Figure 6a) and a higher prevalence of macroadenomas 
(P<0.0001, Supplemental Figure 6b). The proportion of giant (maximum diameter ≥40mm) adenomas 
(6.3% in AIPmut-positive and 3% in AIPmut-negative patients) was not significantly different 
(P=0.1766). There was a higher frequency of extrasellar extension in AIPmut-positive FIPA patients 
with pituitary adenomas (P=0.004, Supplemental Figure 6c). Three of the AIPmut-negative, but none 
of the AIPmut-positive patients, harbored tumors with extensive invasion (defined as involvement of 
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intracranial areas beyond the perisellar region); two of them had somatotropinomas and the third one 
harbored a gonadotropinoma. None of the patients in our cohort had evidence of metastases to justify 
a diagnosis of pituitary carcinoma.  
 
Sporadic patients 
In the sporadic cohort, the maximum diameter of the tumors and the proportion of giant adenomas 
were similar between AIPmut-positive and negative sporadic cases (P=0.6965 and 0.7859, 
respectively). All the AIPmut-positive patients had macroadenomas (29/29) vs. 86.3% (283/328) of 
the AIPmut-negative subgroup, and the presence of extrasellar extension was more common in the 
former group (95% vs. 58.9%, P=0.0011).  
 
Apoplexy of the pituitary adenoma 
Excluding the prospectively diagnosed patients, symptomatic apoplexy of the pituitary adenoma 
occurred in 8.3% of the AIPmut-positive cases (9.1% of the familial cases, including three families 
with two cases per family, and 5.9% of the sporadic patients) and in only 1.3% of the patients in the 
AIPmut-negative subgroup (P<0.0001) and this difference remained significant when only the 
familial cases were analyzed (10.6% of the AIPmut-positive vs. 2.3% of the AIPmut-negative patients, 
P=0.0002, Supplemental Figure 6d). Eight (72.7%) of the AIPmut-positive patients with a history of 
pituitary apoplexy had a diagnosis of gigantism, and in three of them (27.2%) apoplexy was the 
manifestation that led to the diagnosis of pituitary disease (Supplemental Figure 6e). There were no 
significant differences in the age at onset/diagnosis or in the tumoral size between the AIPmut-
positive patients that developed pituitary apoplexy and those who did not have this complication. Out 
of ten AIPmut-negative pituitary adenoma patients with a history of apoplexy, six had NFPA, two had 
acromegaly, one had gigantism and the specific diagnosis was unknown in the last patient.  
 
The original description of multiple cases of pituitary adenoma apoplexy in AIPmut-positive patients 
(3) was later confirmed in other studies (4;12;25;SR14;SR23;SR24) as well as now in this larger 
cohort. Although the prevalence of 8.3% does not seem to be higher than the prevalence reported in 
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populations of unselected pituitary adenomas (7.9%) (SR25), in the latter study patients were older 
(mean age 60.5 years) and harbored NFPAs, while in our cohort the majority had gigantism and the 
rest, acromegaly or  prolactinoma, with a mean age at diagnosis of 23.4 years. Our three familial 
apoplexy families, together with a recently reported family with three apoplexy cases (SR24) provide 
support for the phenotype of young-onset, familial apoplexy in AIPmut-positive patients. To our 
knowledge, there are no previously known genetic causes of familial pituitary adenoma apoplexy, and 
this remains an uncommon finding. The mechanism why AIPmut-positive cases are more prone to 
apoplexy needs further study. 
 
GH excess patients 
With the purpose of analyzing a relatively homogeneous population of patients, we compared the 
main clinical features of the AIPmut-positive and negative GH excess patients from both cohorts, 
excluding the prospectively diagnosed patients. Similar to the whole study population, the GH excess 
AIPmut-positive patients had an earlier disease onset and diagnosis, had significantly more apoplexy 
cases (8.4 vs. 1.2%, P<0.0001) and a higher frequency of sparsely granulated tumors (91.7 vs. 57.1%, 
P=0.0073). In the AIPmut-positive subgroup there is a preponderance of males (60.7% [65/107]), in 
contrast with the gender distribution found in patients with all the diagnostic categories. PRL co-
secretion was more common in AIPmut-positive patients (14 vs. 5.9%, P=0.0046). There were no 
differences in tumor size, frequency of extrasellar extension, or giant tumors, though most of the 
tumors in both subgroups (89.5%) were macroadenomas. There was no significant difference in the 
number of therapeutic modalities employed between the two subgroups, but there were fewer patients 
cured or controlled in the AIPmut-negative subgroup (41/66 vs. 86/192, P=0.0151). Given that the 
AIPmut-positive patients had a significantly longer follow-up duration, we decided to evaluate the 
current status (i.e. effect of the therapies) only in patients with zero to five years of follow-up. In this 
subset of patients, there was no significant difference in the percentage of cured or controlled patients 
between the AIPmut-positive (57.1%) and the AIPmut-negative (41.7%) subgroups.  
 
Gigantism 
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This study included 120 patients with gigantism, 45 of them, (37.5%) were part of FIPA families and 
75 (62.5%) presented as sporadic patients. Overall, 46.7% (56/120) of the patients with gigantism 
were AIPmut-positive. Males were predominant among AIPmut-positive and negative patients (global 
67.5%), as expected for gigantism cases. Childhood-onset GH excess resulting in gigantism was more 
prevalent among the AIPmut-positive patients (48.3% [56/116]) than GH excess with no pathological 
body height, while the opposite pattern was observed in the AIPmut-negative subgroup (only 16.7% 
[64/408] had gigantism, P<0.0001). Sixty percent of the AIPmut-positive families had at least one 
patient with gigantism. The frequency of AIPmuts was much higher in the gigantism cases occurring 
in a familial setting (Supplemental Figure 7a), where 82.2% (37/45) of the patients were AIPmut-
positive, in comparison with the sporadic cohort, where AIPmut-positive patients accounted for only 
25.3% (19/75) of the patients (P<0.0001). Familial gigantism, defined as the occurrence of two or 
more gigantism cases due to pituitary adenoma in the same family, occurred only in AIPmut-positive 
FIPA families (9/37 families, 24.3%, Supplemental Figure 7b). Four of these families harbored the 
p.R304* AIPmut, and the AIPmuts g.4856_4857CG>AA, p.Q164*, p.269_H275dup, p.E24* and a 
whole gene deletion accounted for one family each. AIPmut-positive gigantism patients were taller 
than their AIPmut-negative counterparts if we considered the criterion of height >3SD over percentile 
50 but not when considering >2SD over midparental height (Supplemental Figure 7c and d). 
 
There was no difference in the age at diagnosis (global median 18 [IQR 15-23]) between the AIPmut-
positive and negative gigantism subgroups. Differences in the frequency of disease onset and 
diagnosis during the first decade of life did not reach statistical significance (onset: AIPmut-positive 
9.1% vs. AIPmut-negative 9.5%; diagnosis: 3.6% vs. 1.6%). There were no significant differences in 
the parameters of tumor size and extension either (maximum diameter, frequency of giant adenomas 
and extrasellar invasion). However, it is worth noting that the vast majority of the tumors in both 
subgroups were macroadenomas (global 91.5%), and most of them displayed extrasellar invasion 
(77.6%). A small percentage of the patients had PRL co-secretion at diagnosis (9.2% global, not 
significantly different between AIPmut-positive and negative patients). There were no significant 
differences in the number of treatments received or the frequency of controlled patients between the 
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two subgroups. Overall, 43.2% of all the patients with gigantism have currently active or only 
partially controlled disease. 
 
Extra-pituitary neoplasms in AIPmut-positive individuals 
To explore the possibility of a syndromic presentation, we looked for additional neoplasms in the 
affected and unaffected AIPmut-positive individuals (n=290). We found a total of ten cases of eight 
different extra-pituitary neoplasms (osteosarcoma, breast cancer, neuroendocrine tumor of the colon, 
gastrointestinal stromal tumor [GIST], glioma, meningioma, non-Hodgkin’s lymphoma and spinal 
ependymoma) in nine subjects (four patients and five unaffected AIPmut carriers, Supplemental Table 
5), accounting for 3.1% of the AIPmut-positive individuals studied. AIPmut-positive GH excess 
patients accounted for 44.4% (4/9) of the individuals with extra-pituitary neoplasms, while the rest 
were unaffected AIPmut-positive carriers. We note that the association of these tumors with AIPmuts 
could be coincidental.  
 
An increased risk of malignancy among unselected pituitary adenoma patients has been previously 
reported (SR26;SR27). We have also found neoplasms within the AIPmut-positive individuals with no 
pituitary adenomas, where hormonal excess, especially GH, does not play a role. Further analyses are 
needed to establish whether there is a possible association between AIPmuts and these neoplasms. 
Recently, germline AIPmuts have been associated with three cases of parathyroid adenomas (two 
middle aged women in the setting of non-familial, isolated hyperparathyroidism and a young male 
with acromegaly) (SR28;SR29). An MEN-1 like phenotype was an exclusion criterion in our study, 
therefore, it was not possible to assess this novel pathogenic association, and none of our patients or 
carriers developed hyperparathyroidism during the follow-up. 
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SUPPLEMENTAL FIGURES AND TABLES 
 
Supplemental Table 1. Definition of the clinical diagnostic categories used in our study. 
Diagnosis Criteria 
Cushing’s disease 
Evidence of ACTH-depending hypercortisolemia with proven pituitary adenoma, in 
accordance to the diagnostic protocol of each institution 
Clinically functioning FSH-secreting 
pituitary adenoma (FSHoma) 
Raised serum FSH levels for age and gender and evidence of gonadal stimulation in a patient 
with a pituitary adenoma 
GH excess 
Acromegaly 
Raised IGF-1 levels and unsuppressed GH during an oral glucose tolerance test (OGTT), 
with cut-offs according to the protocol of each institution 
Acromegaly/prolactinoma Diagnosis of acromegaly with concurrent hyperprolactinemia 
Mild acromegaly* 
Mild clinical features attributed to acromegaly, fulfilling the criterion of raised IGF-1 levels 
but not the lack of suppression of GH during an OGTT, or normal IGF-1 but lack of 
suppression of GH during an OGTT (16) 
Gigantism 
Any of the following categories in a patient with a pituitary adenoma: (i) abnormally high 
growth velocity in children or teenagers with abnormal IGF-1 and OGTT, (ii) height >3SD 
above the mean height for age, (iii)  >2SD over the calculated midparental height, using 
country-specific growth charts when possible 
Gigantism/prolactinoma Diagnosis of gigantism with concurrent hyperprolactinemia 
Clinically nonfunctioning pituitary 
adenoma (NFPA) 
Pituitary adenoma in the absence of clinical or biochemical evidence of pituitary 
hypersecretion 
Pituitary tumor 
Cases of pituitary tumor where the diagnosis could not be specified, due to unavailability of 
histopathological specimens, clinical and/or biochemical data 
Prolactinoma 
Hyperprolactinemia in the presence of a pituitary adenoma and unlikely to be purely due to a 
stalk effect, based on either histopathology results or the relation between PRL levels and 
tumor size 
Thyrotropinoma (TSHoma) 
Hyperthyrotropinemia in a patient with a pituitary adenoma, with clinical and/or biochemical 
hyperthyroidism and no other demonstrable causes of raised TSH 
* This category is important in our study, as we detected acromegaly via biochemical screening of AIPmut-positive carriers, often not 
presented (yet) clinically. 
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Supplemental Table 2. Other genes tested. 
 
 Familial cohort Sporadic cohort 
Combined, 
no. (%)  
AIPmut-
positive, 
no. (%) 
AIPmut-
negative, 
no. (%) 
Total 
familial,          
no. (%) 
AIPmut-
positive, 
no. (%) 
AIPmut-
negative, 
no. (%) 
Total 
sporadic,       
no. (%) 
BRCA1 1 (14.3) 2 (0.7) 3 (1) - - - 3 (0.8) 
BRCA2 1 (14.3) 2 (0.7) 3 (1) - - - 3 (0.8) 
CDKN1B - 20 (6.5) 20 (6.4) - 1 (2.4) 1 (2.4) 21 (5.9) 
GPR101 - - - - 8 (19) 8 (19) 8 (2.2) 
MAX - 23 (7.5) 23 (7.3) - - - 23 (6.5) 
MEN1 3 (42.9) 51 (16.6) 54 (17.2) - 33 (78.6) 33 (78.6) 87 (24.4) 
PRKAR1A - 23 (7.5) 23 (7.3) - - - 23 (6.5) 
RET - 23 (7.5) 23 (7.3) - - - 23 (6.5) 
SDHA - 23 (7.5) 23 (7.3) - - - 23 (6.5) 
SDHAF2 - 23 (7.5) 23 (7.3) - - - 23 (6.5) 
SDHB - 23 (7.5) 23 (7.3) - - - 23 (6.5) 
SDHC - 23 (7.5) 23 (7.3) - - - 23 (6.5) 
SDHD - 25 (8.1) 25 (8) - - - 25 (7) 
TMEM127 - 23 (7.5) 23 (7.3) - - - 23 (6.5) 
TP53 2 (28.6) - 2 (0.6) - - - 2 (0.6) 
VHL - 23 (7.5) 23 (7.3) - - - 23 (6.5) 
Total 7 307 314 0 42 42 712 
-, no individuals in this category. 
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Supplemental Table 3. AIP nonpathogenic mutations in the familial and sporadic cohorts. 
 
Variant (DNA level 
[protein level]) 
Variant type Pathogenic 
Location in 
protein 
Familial 
cohort* 
(N=19) 
Sporadic 
cohort* 
(N=37) 
Combined* 
(N=56) 
References/ 
SR‡ 
c.47G>A (p.R16H) Missense No N-terminus 0 2 2 
(2;5;7)/ 
(SR31;39;54-58) 
c.132C>T (p.(=)) Synonymous No 
PPIase 
domain 
0 3 3 (5)/(SR59) 
c.144C>T (p.(=)) Synonymous No 
PPIase 
domain 
0 1 1 (SR53;59-61) 
c.516C>T (p.(=)) Synonymous No 
Between 
PPIase and 
TPR1 
domains 
8 13 21 
(5;12)/(SR56;58;
59;61-63) 
c.573C>T (p.(=)) Synonymous No 
TPR1 
domain 
0 0 0 This paper 
c.579G>T (p.(=)) Synonymous No 
TPR1 
domain 
1 0 1 This paper 
c.682A>C (p.K228Q) † Missense No 
Between 
TPR1 and 2 
domains 
2 16 18 (5)/(SR58;59;63) 
c.831C>T (p.(=)) Synonymous Unlikely 
TPR3 
domain 
1 0 1 This paper 
c.891C>A (p.(=)) Synonymous No 
TPR3 
domain 
0 2 2 (5)/(SR59) 
C.896C>T (p.A299V) Missense Unlikely 
TPR3 
domain 
5 0 5 (12)/(SR31) 
c.906G>A (p.(=)) Synonymous No 
C-terminal 
α-helix 
2 0 2 (SR31;59) 
* Number of positive individuals for each mutation, considering the AIPmut-positive tested individuals, the obligate carriers and the 
predicted AIPmut patients. 
†There is a Q at this position in the AIP reference sequence, but we consider K as the wild type amino acid, due to its higher 
prevalence in the population screened so far (Stals K., unpublished data). 
PPIase, peptidylprolyl isomerase, TPR, tetratricopeptide repeat. 
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Supplemental Table 4. Classification of FIPA families by diagnoses 
  
AIPmut-
positive 
AIPmut-
negative 
Total 
Total families, no.: 37 179 216 
Diagnoses:    
Cushing's disease only, no. (%) - 3 (1.7) 3 (1.4) 
Cushing's disease + FSHoma, no. (%) - 1 (0.6) 1 (0.5) 
Cushing's disease + NFPA, no. (%) - 1 (0.6) 1 (0.5) 
Cushing's disease + NFPA + pituitary tumor, no. (%) - 1 (0.6) 1 (0.5) 
Cushing's disease +  prolactinoma, no. (%) - 5 (2.8) 5 (2.3) 
FSHoma +  prolactinoma, no. (%) - 1 (0.6) 1 (0.5) 
Cushing's disease+ GH excess, no. (%) - 7 (3.9) 7 (3.2) 
GH excess only, no. (%) 16 (43.2) 44 (24.6) 60 (27.8) 
GH excess + NFPA, no. (%) 8 (21.6) 12 (6.7) 20 (9.3) 
GH excess + NFPA + prolactinoma, no. (%) 1 (2.7%) 3 (1.7) 4 (1.9) 
GH excess + pituitary tumor, no. (%) - 5 (2.8) 5 (2.3) 
GH excess + pituitary tumor +  prolactinoma, no. (%) - 1 (0.6) 1 (0.5) 
GH excess +  prolactinoma, no. (%) 9 (24.3) 30 (16.8) 39 (18.1) 
NFPA only, no. (%) 2 (5.4) 17 (9.5) 19 (8.8) 
NFPA + pituitary tumor, no. (%) - 7 (3.9) 7 (3.2) 
NFPA +  prolactinoma, no. (%) 1 (2.7) 10 (5.6) 11 (5.1) 
Pituitary tumor +  prolactinoma, no. (%) - 1 (0.6) 1 (0.5) 
 Prolactinoma, no. (%) - 30 (16.8) 30 (13.9) 
* The category "GH excess" includes the following diagnoses: acromegaly, acromegaly/ prolactinoma, 
gigantism, gigantism/ prolactinoma and mild acromegaly. 
-, no families in this category. 
FSHoma, FSH secreting adenoma. NFPA, nonfunctioning pituitary adenoma.  
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Supplemental Table 5. Extrapituitary neoplasms in AIPmut-positive individuals. 
 
Pituitary 
diagnosis 
Cohort Gender AIPmut Extrapituitary neoplasm 
Unaffected Familial Male c.910C>T (p.R304*) 
Osteosarcoma and neuroendocrine 
tumor of the colon † 
Unaffected Familial Female c.910C>T (p.R304*) Breast cancer† 
Unaffected Familial Female c.910C>T (p.R304*) Breast cancer† 
Acromegaly Familial Male c.805_825dup (p.F269_H275dup) GIST 
Acromegaly Familial Male c.241C>T (p.R81*) GIST* 
Unaffected Sporadic Male c.910C>T (p.R304*) Glioma 
Acromegaly Familial Female c.241C>T (p.R81*) Meningioma* 
Gigantism Familial Male c.74_81delins7 (p.L25Pfs*130) Non-Hodgkin’s lymphoma 
Unaffected Familial Female c.100-1025_279+357del (ex2del) (p.A34_K93del) Spinal ependymoma 
* Brother and sister. † Brother and 2 sisters.  
GIST, gastrointestinal stromal tumor. 
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Supplemental Figure 1. AIPmut types and frequency according to age at disease onset in the familial and 
sporadic cohorts (whole study population). a) Number of AIPmuts per mutation type, note the predominance of 
nonsense mutations. b) The probability of finding an AIPmut was higher when testing patients with disease onset 
during the second decade of life; c) in concordance, three quarters of all the AIPmut-positive patients had disease 
onset during the second and third decades of life.  
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Supplemental Figure 2.  AIPmuts detected in the study population and their position in the AIP gene. Shadowed areas indicate the protein domains codified by each 
region of the gene. Mutations producing a truncated or missing protein are shown at the bottom of the scheme, and nontruncating mutations are at the top. Even though we 
identified variants throughout the whole AIP gene, mutations tended to cluster in the genomic regions encoding the tetratricopeptide repeat (TPR) domains and the C-terminal 
α-helix of the protein. Furthermore, the mutations located at the N-terminal extreme and inside the peptidylprolyl isomerase (PPIase) domain were essentially truncating 
mutations, resulting in short and unstable proteins, lacking the TPR domains. As expected based on previous data (26;SR64), the commonest mutation in both cohorts was 
c.910C>T (p.R304*), found in 33.3% of the AIPmut patients and in 35.9% of all the AIPmut-positive individuals (affected plus unaffected carriers). There were no exclusive 
associations of specific AIPmuts with particular diagnoses. However, 77.4% of all the mutations (24/31) were found in cases of gigantism (with or without prolactin (PRL) 
co-secretion), being this the diagnosis with the highest number of associated AIPmuts. Furthermore, all the mutations were found in at least one patient with GH excess, 
supporting this diagnostic category as the most frequent AIPmut pathogenic association. Patients with diagnosis of NFPA harbored 29% (9/31) of the AIPmuts found in the 
study, and 22.6% of them (7/31) were detected in prolactinoma cases.  
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Supplemental Figure 3. Gender distribution in FIPA families and sporadic patients: a) Gender distribution was 
different between the AIPmut-positive and negative FIPA patients, due to a predominance of female patients within 
the AIPmut-negative families. b) This difference cannot be explained by a selection bias towards one specific gender, 
as there were similar numbers of males and females within the unaffected family members (excluding ‘not at risk’ 
individuals) of AIPmut-positive and negative FIPA families. c) The gender distribution was not significantly different 
between AIPmut-positive and negative patients, despite a slight prevalence of males in the AIPmut-positive subgroup. 
ns, not significant, **, P<0.01.  
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Supplemental Figure 4. Clinical features in FIPA families and sporadic patients: a) AIPmut-positive familial 
patients were younger at disease onset (P<0.0001), b) as most of them developed symptoms after the age of 10 and 
before the age of 40. c) There was a higher frequency of pediatric cases (n [total]=425) in the AIPmut-positive FIPA 
families, compared with the AIPmut-negative FIPA families. d) In the sporadic group, although all these patients were 
≤30 years at disease onset, AIPmut-positive individuals were significantly younger at disease onset than the AIPmut-
negative ones. e) GH excess and f) presence of GH and PRL co-secretion were significantly more frequent in AIPmut-
positive familial patients. *, P<0.05, **, P<0.01, ****, P<0.0001.  
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Supplemental Figure 5. Histopathological diagnoses in FIPA families and sporadic patients. The distribution of the IHC 
diagnoses was different between AIPmut-positive (a) and negative (b) familial patients, though GH positive tumors 
predominated in both subgroups. c) The analysis of the granulation pattern reported sparsely granulated tumors in all the 
AIPmut-positive and in 43.8% of the AIPmut-negative familial adenomas (P<0.0001). d) AIPmut simplex patients had GH 
positive adenomas (with or without positive PRL staining), while e) the AIPmut-negative sporadic patients had a variety of 
other tumor types. PRLoma, prolactinoma; GH/PRLoma, mammosomatotroph adenoma; ns, not significant; ****, P<0.0001. 
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Supplemental Figure 6. Tumor size and and pituitary apoplexy in FIPA families (excluding prospectively 
diagnosed AIPmut-positive patients): AIPmut-positive vs. AIPmut-negative patients. a) Pituitary adenomas were 
larger in AIPmut-positive familial patients (P=0.040), b) what was reflected in a higher frequency of macroadenomas 
(P=0.0001). c) In concordance with this, there was a higher frequency of extrasellar extension within AIPmut-positive 
patients (P=0.004). d) The occurrence of symptomatic apoplexy of the pituitary adenoma was significantly more 
common among the AIPmut-positive families, occurring in 10.6% of these patients (vs. 2.3% of the AIPmut-negative 
FIPA patients, (P=0.0002), including one phenocopy NFPA patient. e) Apoplexy was the first sign of pituitary disease 
in 4.3% of the AIPmut-positive familial patients, but only in 1% of the AIPmut-negative ones. * P<0.05, **, P<0.01, 
***, P<0.001, ****, P<0.0001.   
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Supplemental Figure 7. Characteristics of gigantism cases (familial n=45, sporadic n=75) and penetrance.  a) 
The great majority of the gigantism cases occurring in a familial setting were AIPmut-positive vs. only one quarter of 
those cases presenting sporadically (P<0.0001). b) In our study population, all the kindreds including more than one 
case of gigantism carried AIPmuts (this graph includes all the AIPmut-positive kindreds, FIPA and simplex patients, 
and the AIPmut-negative FIPA families). c) Considering only those patients fulfilling the criterion of height >3SD 
over percentile 50, AIPmut-positive patients were taller at diagnosis than the AIPmut-negative ones (P=0.0164); 
however, d) there was no significant difference in height when the comparison was done among patients fulfilling the 
criterion of >2SD over midparental height. e) In average, there were more affected individuals per family in the 
AIPmut-positive families (P<0.0001). ns, not significant, * P<0.05, ** P<0.01, ****, P<0.0001. 
